chr10	122454931	122454932	rs10490924	0.0	Age-related macular degeneration
chr1	196710324	196710325	rs10737680	0.0	Age-related macular degeneration
chr16	56959411	56959412	rs3764261	0.0	HDL cholesterol
chr16	56959411	56959412	rs3764261	0.0	HDL cholesterol
chr4	9942427	9942428	rs12498742	0.0	Urate levels
chr6	43957788	43957789	rs4513773	0.0	Vascular endothelial growth factor levels
chr2	233763992	233763993	rs6742078	5e-324	Bilirubin levels
chr10	122454931	122454932	rs10490924	4e-322	Age-related macular degeneration
chr12	120722811	120722812	rs2066938	3.9999999999999975e-305	Metabolic traits
chr6	31368322	31368323	rs7743761	4.999999999999997e-304	Ankylosing spondylitis
chr7	95308944	95308945	rs2057681	9.999999999999993e-304	Paraoxonase activity 
chr15	28120471	28120472	rs12913832	9.999999999999994e-301	Eye color
chr15	28120471	28120472	rs12913832	9.999999999999994e-301	Eye color traits
chr6	32315076	32315077	rs6910071	9.999999999999996e-300	Rheumatoid arthritis
chr19	44892361	44892362	rs2075650	9.999999999999994e-296	Alzheimer's disease
chr19	5841344	5841345	rs3760775	2.999999999999998e-290	Tumor biomarkers
chr11	61790330	61790331	rs102275	3.999999999999998e-264	Metabolite levels
chr19	11091629	11091630	rs6511720	3.999999999999998e-262	LDL cholesterol
chr3	165773491	165773492	rs1803274	5.999999999999997e-262	Butyrylcholinesterase levels
chr11	61803310	61803311	rs174547	7.999999999999996e-262	Lipid metabolism phenotypes
chr1	196690106	196690107	rs1061170	9.999999999999995e-262	Age-related macular degeneration
chr2	73591808	73591809	rs13391552	4.999999999999998e-252	Metabolic traits
chr4	9925342	9925343	rs13129697	1.999999999999999e-242	Urate levels
chr15	28285035	28285036	rs1667394	9.999999999999996e-242	Blue vs. brown eyes
chr1	109275683	109275684	rs629301	4.999999999999998e-241	LDL cholesterol
chr11	116778200	116778201	rs964184	6.999999999999997e-240	Triglycerides
chr2	27508072	27508073	rs1260326	1.999999999999999e-239	Triglycerides
chr6	32445273	32445274	rs3135388	3.9999999999999986e-225	Multiple sclerosis
chr11	116778200	116778201	rs964184	6.9999999999999975e-224	Triglycerides
chr2	168906637	168906638	rs560887	8.999999999999997e-218	Fasting glucose-related traits
chr12	112379978	112379979	rs11066280	2.9999999999999987e-215	Drinking behavior
chr6	31306777	31306778	rs10484554	3.999999999999998e-214	Psoriasis
chr12	111803961	111803962	rs671	3.999999999999999e-211	Drinking behavior
chr19	48703373	48703374	rs1047781	5.999999999999998e-209	Tumor biomarkers
chr16	50729866	50729867	rs2066847	5.999999999999998e-209	Crohn's disease
chr6	32445767	32445768	rs3129889	9.999999999999996e-207	Multiple sclerosis
chr11	61790330	61790331	rs102275	9.999999999999998e-204	Phospholipid levels (plasma)
chr3	186742137	186742138	rs710446	1.9999999999999995e-203	Activated partial thromboplastin time
chr19	11091629	11091630	rs6511720	4.999999999999998e-202	Cholesterol, total
chr6	31398009	31398010	rs4349859	9.999999999999995e-201	Ankylosing spondylitis
chr20	35176750	35176751	rs867186	1.999999999999999e-200	Protein C levels
chr7	73568543	73568544	rs17145738	8.999999999999999e-99	Triglycerides
chr8	19986710	19986711	rs12678919	9.999999999999999e-98	HDL cholesterol
chr6	31810751	31810752	rs2075799	5.999999999999998e-97	Complement C3 and C4 levels
chr19	11091629	11091630	rs6511720	6.999999999999998e-97	Cholesterol, total
chr16	89919708	89919709	rs1805007	9.999999999999997e-97	Freckles
chr15	58391166	58391167	rs1532085	2.9999999999999997e-96	HDL cholesterol
chr2	21041027	21041028	rs1367117	3.999999999999999e-96	Cholesterol, total
chr12	120737720	120737721	rs2014355	4.999999999999998e-96	Metabolite levels
chr2	102316101	102316102	rs950880	6.999999999999999e-94	Serum protein levels (sST2)
chr16	56971566	56971567	rs1532624	8.999999999999999e-94	HDL cholesterol
chr16	56961323	56961324	rs1800775	2.9999999999999993e-93	Lipid metabolism phenotypes
chr16	56961323	56961324	rs1800775	4e-93	HDL cholesterol
chr6	32638106	32638107	rs2187668	8e-93	Nephropathy (idiopathic membranous)
chr3	165773491	165773492	rs1803274	5.999999999999998e-92	Cardiovascular disease risk factors
chr7	44196068	44196069	rs4607517	6.999999999999998e-92	Fasting glucose-related traits
chr6	396320	396321	rs12203592	1.9999999999999998e-91	Freckling
chr10	98387302	98387303	rs4345897	1.9999999999999998e-91	Metabolite levels
chr23	67343175	67343176	rs2497938	1.9999999999999998e-91	Male-pattern baldness
chr6	31090562	31090563	rs3130544	1.9999999999999996e-90	Myasthenia gravis 
chr4	154586437	154586438	rs6050	8.999999999999998e-90	Fibrinogen
chr2	233763992	233763993	rs6742078	9.999999999999999e-90	Bilirubin levels
chr6	31962684	31962685	rs429608	3.9999999999999995e-89	Age-related macular degeneration
chr19	44892008	44892009	rs157580	7.999999999999999e-89	Alzheimer's disease
chr11	47272247	47272248	rs10501320	1e-88	Proinsulin levels
chr5	177414337	177414338	rs2545801	5.999999999999998e-88	Activated partial thromboplastin time
chr15	28120471	28120472	rs12913832	8.999999999999998e-88	Hair color
chr16	89752323	89752324	rs12931267	4.999999999999999e-87	Hair color
chr16	56961323	56961324	rs1800775	4.999999999999999e-87	Lipid metabolism phenotypes
chr11	116783718	116783719	rs603446	1.9999999999999995e-86	Triglycerides
chr3	141386727	141386728	rs724016	2.9999999999999994e-86	Height
chr6	135105434	135105435	rs4895441	7e-86	Mean corpuscular volume
chr3	122284909	122284910	rs1801725	8.999999999999998e-86	Calcium levels
chr1	113834945	113834946	rs2476601	8.999999999999999e-85	Type 1 diabetes
chr1	162064099	162064100	rs12143842	9.999999999999999e-84	QT interval
chr16	82617111	82617112	rs3865188	2.9999999999999994e-83	Adiponectin levels
chr6	32836292	32836293	rs241428	8.999999999999998e-83	Complement C3 and C4 levels
chr9	133278430	133278431	rs651007	2e-82	E-selectin levels
chr5	40410481	40410482	rs11742570	2e-82	Inflammatory bowel disease
chr16	56961323	56961324	rs1800775	1e-81	Lipid metabolism phenotypes
chr16	53769661	53769662	rs1558902	2e-81	Obesity
chr6	32445273	32445274	rs3135388	8.999999999999999e-81	Multiple sclerosis
chr4	9921379	9921380	rs734553	9.999999999999998e-81	Serum uric acid levels
chr1	113834945	113834946	rs2476601	1.9999999999999995e-80	Type 1 diabetes
chr1	169522316	169522317	rs2420371	3.999999999999999e-80	Hemostatic factors and hematological phenotypes
chr1	62560270	62560271	rs2131925	3.999999999999999e-80	Cholesterol, total
chr17	7618596	7618597	rs12150660	3.999999999999999e-80	Sex hormone-binding globulin levels
chr16	53788738	53788739	rs7185735	9.999999999999997e-80	Obesity
chr10	94981295	94981296	rs1057910	2.9999999999999994e-79	Warfarin maintenance dose
chr1	162064099	162064100	rs12143842	1.9999999999999998e-78	QT interval
chr1	162064099	162064100	rs12143842	1.9999999999999998e-78	QT interval
chr2	233763992	233763993	rs6742078	1.9999999999999998e-78	Bilirubin levels
chr5	75360713	75360714	rs12916	7.999999999999999e-78	LDL cholesterol
chr16	56961323	56961324	rs1800775	7.999999999999999e-78	Lipid metabolism phenotypes
chr15	28120471	28120472	rs12913832	1e-77	Black vs. red hair color
chr19	19296908	19296909	rs10401969	4e-77	Cholesterol, total
chr10	121592802	121592803	rs2981582	1.9999999999999995e-76	Breast cancer
chr1	196710324	196710325	rs10737680	1.9999999999999995e-76	Age-related macular degeneration
chr15	58388443	58388444	rs35853021	6.999999999999999e-76	Lipid metabolism phenotypes
chr20	3213246	3213247	rs7270101	8.999999999999998e-76	Chronic Hepatitis C infection
chr16	56954131	56954132	rs173539	4e-75	HDL cholesterol
chr6	32696073	32696074	rs6457617	5e-75	Rheumatoid arthritis
chr3	187008098	187008099	rs11710456	5.999999999999999e-75	IgG glycosylation
chr10	112998589	112998590	rs7903146	9e-75	Type 2 diabetes
chr4	110784611	110784612	rs6817105	2e-74	Atrial fibrillation
chr3	38733340	38733341	rs6800541	2e-74	PR interval
chr1	62560270	62560271	rs2131925	2.9999999999999993e-74	Triglycerides
chr2	233759923	233759924	rs887829	2.9999999999999993e-74	Metabolic traits
chr5	75360713	75360714	rs12916	4.999999999999999e-74	Cholesterol, total
chr1	113834945	113834946	rs2476601	8.999999999999998e-74	Rheumatoid arthritis
chr16	56961323	56961324	rs1800775	9.999999999999998e-74	HDL cholesterol
chr20	5967580	5967581	rs16991615	9.999999999999998e-74	Menopause (age at onset)
chr15	78601996	78601997	rs1051730	2.9999999999999995e-73	Smoking behavior
chr2	43845436	43845437	rs4299376	2.9999999999999995e-73	Cholesterol, total
chr1	159679909	159679910	rs16827466	3.9999999999999994e-73	C-reactive protein
chr6	31273331	31273332	rs13191343	1.9999999999999997e-72	Psoriatic arthritis
chr10	122454931	122454932	rs10490924	2.999999999999999e-72	Age-related macular degeneration
chr2	43845436	43845437	rs4299376	3.9999999999999994e-72	LDL cholesterol
chr6	32197666	32197667	rs2071278	3.9999999999999994e-72	Complement C3 and C4 levels
chr6	33102115	33102116	rs3117242	9.999999999999997e-72	Antineutrophil cytoplasmic antibody-associated vasculitis 
chr1	75640989	75640990	rs211718	1.9999999999999994e-71	Metabolic traits
chr4	10054751	10054752	rs7671266	8.999999999999999e-71	Cardiovascular disease risk factors
chr6	32619076	32619077	rs9271366	1.9999999999999997e-70	Inflammatory bowel disease
chr16	56954131	56954132	rs173539	2.9999999999999995e-70	Metabolite levels
chr4	9964755	9964756	rs7442295	2.9999999999999995e-70	Urate levels
chr2	233264856	233264857	rs12994997	3.9999999999999993e-70	Crohn's disease
chr6	25821387	25821388	rs1165151	7e-70	Urate levels
chr22	37066895	37066896	rs855791	1e-69	Red blood cell traits
chr2	233759923	233759924	rs887829	1e-69	Bilirubin levels
chr19	19296908	19296909	rs10401969	1e-69	Triglycerides
chr15	78601996	78601997	rs1051730	2e-69	Smoking behavior
chr3	56815720	56815721	rs1354034	2.9999999999999994e-69	Mean platelet volume
chr16	50722969	50722970	rs2076756	4e-69	Crohn's disease
chr2	233760497	233760498	rs4148323	4.999999999999999e-69	Bilirubin levels
chr6	135097777	135097778	rs7776054	6.999999999999998e-69	Mean corpuscular hemoglobin
chr3	38736062	38736063	rs10428132	9.999999999999999e-69	Brugada syndrome
chr1	19845366	19845367	rs6426833	1.9999999999999997e-68	Ulcerative colitis
chr13	42377312	42377313	rs9533090	4.999999999999999e-68	Bone mineral density
chr5	177415472	177415473	rs2731672	9.999999999999998e-68	Circulating vasoactive peptide levels 
chr6	31143578	31143579	rs9263739	3.999999999999999e-67	Ulcerative colitis
chr6	29938913	29938914	rs2860580	4.999999999999999e-67	Nasopharyngeal carcinoma
chr1	196690106	196690107	rs1061170	4.999999999999999e-67	Age-related macular degeneration (GA)
chr6	25842722	25842723	rs1408272	4.999999999999999e-67	Red blood cell traits
chr16	56971566	56971567	rs1532624	9.999999999999998e-67	Lipid metabolism phenotypes
chr15	78601996	78601997	rs1051730	1.9999999999999997e-66	Smoking behavior
chr2	168906637	168906638	rs560887	1.9999999999999997e-66	Fasting glucose-related traits
chr6	135097496	135097497	rs7775698	2.999999999999999e-66	Mean corpuscular hemoglobin
chr14	63768837	63768838	rs7157785	8.999999999999998e-66	Sphingolipid levels
chr6	32409010	32409011	rs3763317	8.999999999999998e-66	Complement C3 and C4 levels
chr16	89919708	89919709	rs1805007	1e-65	Tanning
chr9	104902019	104902020	rs1883025	2e-65	HDL cholesterol
chr8	125478729	125478730	rs2954029	2e-65	Cholesterol, total
chr6	33092340	33092341	rs2281388	2e-65	Graves' disease
chr6	31382926	31382927	rs1521	2e-65	Graves' disease
chr4	9993557	9993558	rs3775948	2e-65	Renal function-related traits (urea)
chr12	65958045	65958046	rs1351394	2e-65	Height
chr16	56954131	56954132	rs173539	2.9999999999999996e-65	Cardiovascular disease risk factors
chr4	89716449	89716450	rs356219	5.999999999999999e-65	Parkinson's disease
chr1	67240274	67240275	rs11209026	9.999999999999998e-65	Crohn's disease
chr11	61803310	61803311	rs174547	2.9999999999999994e-64	Phospholipid levels (plasma)
chr1	196733679	196733680	rs1329428	2.9999999999999994e-64	Age-related macular degeneration
chr2	21008651	21008652	rs676210	3.999999999999999e-64	Lipid metabolism phenotypes
chr11	61790330	61790331	rs102275	6.999999999999999e-64	Phospholipid levels (plasma)
chr1	75640989	75640990	rs211718	9.999999999999998e-64	Metabolite levels
chr11	61784454	61784455	rs174536	9.999999999999998e-64	Phospholipid levels (plasma)
chr11	69513995	69513996	rs614367	1.9999999999999996e-63	Breast cancer
chr11	61830499	61830500	rs1535	3e-63	Phospholipid levels (plasma)
chr11	64696612	64696613	rs504915	3e-63	Renal function-related traits (urea)
chr12	112379978	112379979	rs11066280	3e-63	Metabolite levels
chr4	110787130	110787131	rs17042171	3.999999999999999e-63	Atrial fibrillation
chr1	67236842	67236843	rs11465804	6.999999999999999e-63	Crohn's disease
chr2	233760497	233760498	rs4148323	2e-62	Bilirubin levels
chr7	141972803	141972804	rs10246939	2e-62	Bitter taste perception
chr1	65695777	65695778	rs4420065	4e-62	C-reactive protein
chr11	116778200	116778201	rs964184	4e-62	Triglycerides
chr16	134390	134391	rs7203560	5e-62	Mean corpuscular hemoglobin
chr2	233764662	233764663	rs4148325	5e-62	Bilirubin levels
chr16	89752323	89752324	rs12931267	8e-62	Freckling
chr6	33065244	33065245	rs3077	2e-61	Hepatitis B
chr1	169594712	169594713	rs6136	4e-61	Soluble levels of adhesion molecules
chr5	89080243	89080244	rs1366594	4e-61	Bone mineral density
chr10	122454931	122454932	rs10490924	1e-60	Age-related macular degeneration
chr19	44919688	44919689	rs4420638	1e-60	LDL cholesterol
chr2	210195325	210195326	rs2286963	2.9999999999999996e-60	Metabolite levels
chr11	61872100	61872101	rs174448	2.9999999999999996e-60	Phospholipid levels (plasma)
chr4	88131170	88131171	rs2231142	2.9999999999999996e-60	Urate levels
chr10	122459758	122459759	rs3793917	4e-60	Age-related macular degeneration
chr6	104931078	104931079	rs7759938	5e-60	Menarche (age at onset)
chr16	56956803	56956804	rs247617	8.999999999999999e-60	Metabolic syndrome
chr11	61796826	61796827	rs4246215	8.999999999999999e-60	Phospholipid levels (plasma)
chr19	55322295	55322296	rs11668344	1e-59	Menopause (age at onset)
chr16	56961323	56961324	rs1800775	2e-59	Lipid metabolism phenotypes
chr8	144084618	144084619	rs6558295	2e-59	Metabolic traits
chr9	133279293	133279294	rs495828	4e-59	Hematological and biochemical traits
chr16	72074193	72074194	rs2000999	8e-59	Haptoglobin levels
chr12	112207596	112207597	rs2074356	9.000000000000002e-59	Alcohol consumption
chr6	32713150	32713151	rs7765379	9.000000000000002e-59	Crohn's disease
chr7	73568543	73568544	rs17145738	9.000000000000002e-59	Triglycerides
chr3	38725183	38725184	rs6795970	1e-58	Electrocardiographic traits
chr20	35437975	35437976	rs143384	1e-58	Height
chr20	3213195	3213196	rs1127354	2e-58	Chronic Hepatitis C infection
chr6	32703325	32703326	rs13192471	2e-58	Rheumatoid arthritis
chr19	44908821	44908822	rs7412	3e-58	Lipid metabolism phenotypes
chr11	121927188	121927189	rs1219414	5e-58	Rheumatoid arthritis
chr11	61792608	61792609	rs174538	5e-58	Phospholipid levels (plasma)
chr11	61783883	61783884	rs174535	6e-58	Phospholipid levels (plasma)
chr9	22125503	22125504	rs1333049	7e-58	Coronary heart disease
chr12	110976656	110976657	rs12229654	8.999999999999999e-58	Gamma glutamyl transpeptidase
chr2	168906637	168906638	rs560887	1e-57	Fasting plasma glucose
chr11	61804005	61804006	rs174550	1e-57	Phospholipid levels (plasma)
chr2	217041108	217041109	rs13387042	2e-57	Breast cancer
chr16	56959411	56959412	rs3764261	2e-57	HDL cholesterol
chr1	154453787	154453788	rs4129267	2e-57	Protein quantitative trait loci
chr10	100315721	100315722	rs603424	2.9999999999999994e-57	Metabolic traits
chr14	63765667	63765668	rs17101394	2.9999999999999994e-57	Sphingolipid levels
chr9	133273812	133273813	rs505922	5e-57	End-stage coagulation
chr11	116778200	116778201	rs964184	5.999999999999999e-57	Cholesterol, total
chr1	22384979	22384980	rs6426749	6.999999999999999e-57	Bone mineral density
chr7	106731772	106731773	rs342293	6.999999999999999e-57	Mean platelet volume
chr19	44912382	44912383	rs445925	1e-56	Lipoprotein-associated phospholipase A2 activity and mass
chr9	133278430	133278431	rs651007	1e-56	Serum alkaline phosphatase levels
chr19	5839734	5839735	rs3760776	2e-56	Tumor biomarkers
chr6	135097496	135097497	rs7775698	2.9999999999999994e-56	Mean corpuscular volume
chr13	113105719	113105720	rs561241	4e-56	Prothrombin time
chr9	136371952	136371953	rs10781499	4e-56	Inflammatory bowel disease
chr7	44196068	44196069	rs4607517	8e-56	Fasting glucose-related traits (interaction with BMI)
chr2	21008651	21008652	rs676210	8.999999999999998e-56	Lipid metabolism phenotypes
chr6	32461865	32461866	rs9268853	1e-55	Ulcerative colitis
chr16	89919708	89919709	rs1805007	2e-55	Skin sensitivity to sun
chr17	7618596	7618597	rs12150660	2e-55	Sex hormone-binding globulin levels
chr11	116778200	116778201	rs964184	2.9999999999999998e-55	Cholesterol, total
chr16	56971566	56971567	rs1532624	2.9999999999999998e-55	Lipid metabolism phenotypes
chr8	125478729	125478730	rs2954029	2.9999999999999998e-55	Triglycerides
chr11	61832869	61832870	rs174574	4e-55	Phospholipid levels (plasma)
chr11	61796826	61796827	rs4246215	5.9999999999999996e-55	Phospholipid levels (plasma)
chr1	159204892	159204893	rs2814778	6.999999999999999e-55	White blood cell count
chr10	99524479	99524480	rs4409764	9.999999999999999e-55	Inflammatory bowel disease
chr6	31590013	31590014	rs11575839	9.999999999999999e-55	Complement C3 and C4 levels
chr10	69333635	69333636	rs16926246	2.9999999999999995e-54	Glycated hemoglobin levels
chr19	19296908	19296909	rs10401969	2.9999999999999995e-54	LDL cholesterol
chr3	56815720	56815721	rs1354034	2.9999999999999995e-54	Platelet counts
chr6	32701378	32701379	rs9275390	2.9999999999999995e-54	Systemic sclerosis
chr6	33087083	33087084	rs9277535	2.9999999999999995e-54	Hepatitis B
chr13	43883788	43883789	rs3764147	3.9999999999999995e-54	Leprosy
chr10	61961416	61961417	rs7090445	5e-54	Acute lymphoblastic leukemia (B-cell precursor)
chr16	67894138	67894139	rs16942887	7.999999999999999e-54	HDL cholesterol
chr7	74711702	74711703	rs117026326	1e-53	Sjögren's syndrome
chr16	56961323	56961324	rs1800775	1e-53	Lipid metabolism phenotypes
chr1	109275907	109275908	rs646776	2e-53	Lipid metabolism phenotypes
chr15	28285035	28285036	rs1667394	2e-53	Blue vs. green eyes
chr11	18264226	18264227	rs4638289	2.9999999999999997e-53	Amyloid A serum levels
chr19	44908821	44908822	rs7412	2.9999999999999997e-53	Lipid traits
chr2	27518369	27518370	rs780094	5.9999999999999995e-53	Metabolic traits
chr9	104902019	104902020	rs1883025	5.9999999999999995e-53	Cholesterol, total
chr22	24594245	24594246	rs4820599	6.999999999999999e-53	Gamma glutamyl transpeptidase
chr5	132435112	132435113	rs2188962	1e-52	Inflammatory bowel disease
chr9	133261661	133261662	rs687621	2e-52	Venous thromboembolism
chr6	31753255	31753256	rs3131379	2e-52	Systemic lupus erythematosus
chr2	20703254	20703255	rs4971516	2e-52	LDL cholesterol
chr4	10329669	10329670	rs4698036	2e-52	Cardiovascular disease risk factors
chr15	28120471	28120472	rs12913832	2.9999999999999997e-52	Eye color
chr4	186227232	186227233	rs4253238	4e-52	Circulating vasoactive peptide levels 
chr1	94587796	94587797	rs12029080	5.999999999999999e-52	D-dimer levels
chr6	32533366	32533367	rs2157337	9e-52	Rheumatoid arthritis
chr19	11091629	11091630	rs6511720	1.9999999999999997e-51	LDL cholesterol
chr15	78601996	78601997	rs1051730	1.9999999999999997e-51	Lung adenocarcinoma
chr16	53785980	53785981	rs11075990	1.9999999999999997e-51	Body mass index
chr10	112998589	112998590	rs7903146	1.9999999999999997e-51	Type 2 diabetes
chr11	18301969	18301970	rs4353250	1.9999999999999997e-51	Amyloid A serum levels
chr19	44744369	44744370	rs4803750	3e-51	Lipid metabolism phenotypes
chr7	121334710	121334711	rs3801387	3e-51	Bone mineral density
chr6	31090400	31090401	rs4947296	3.9999999999999994e-51	Graves' disease
chr1	159205563	159205564	rs12075	3.9999999999999994e-51	Inflammatory biomarkers
chr1	169511984	169511985	rs6427196	3.9999999999999994e-51	Venous thromboembolism
chr16	53786614	53786615	rs9939609	3.9999999999999994e-51	Body mass index
chr4	144647199	144647200	rs7689420	6e-51	Height
chr5	23542601	23542602	rs2914276	1e-50	Recombination (males)
chr15	48099967	48099968	rs1834640	1e-50	Skin pigmentation
chr6	32638106	32638107	rs2187668	1e-50	Celiac disease
chr8	125478729	125478730	rs2954029	2e-50	LDL cholesterol
chr2	43847291	43847292	rs4245791	2e-50	Phytosterol levels
chr6	33087760	33087761	rs9277554	2e-50	Wegener's granulomatosis
chr12	88496893	88496894	rs995030	2e-50	Testicular germ cell tumor
chr1	21439959	21439960	rs1976403	2e-50	Liver enzyme levels (alkaline phosphatase)
chr11	92975543	92975544	rs10830963	3e-50	Fasting plasma glucose
chr1	55038976	55038977	rs2479409	3e-50	LDL cholesterol
chr2	210678330	210678331	rs715	3e-50	Metabolite levels
chr6	32460507	32460508	rs6903608	3e-50	Hodgkin's lymphoma
chr11	116715566	116715567	rs7350481	1e-49	Triglycerides
chr9	133266941	133266942	rs643434	1e-49	End-stage coagulation
chr16	88298033	88298034	rs9938149	2e-49	Corneal structure
chr4	71742665	71742666	rs2282679	2e-49	Vitamin D levels
chr9	4744742	4744743	rs409801	3e-49	Platelet counts
chr2	66554320	66554321	rs2300478	3e-49	Restless legs syndrome
chr20	45925375	45925376	rs6065906	3e-49	Lipid metabolism phenotypes
chr18	49634582	49634583	rs7241918	3e-49	HDL cholesterol
chr2	622826	622827	rs2867125	3e-49	Body mass index
chr14	22533735	22533736	rs1154155	5e-49	Narcolepsy
chr10	112994328	112994329	rs7901695	1e-48	Type 2 diabetes
chr14	92307318	92307319	rs12896399	1e-48	Blond vs. brown hair color
chr16	56959411	56959412	rs3764261	1e-48	Metabolic syndrome
chr6	31869288	31869289	rs11966200	1e-48	Vitiligo
chr5	132433481	132433482	rs2106854	2e-48	Fibrinogen
chr1	154453787	154453788	rs4129267	2e-48	C-reactive protein
chr6	30908374	30908375	rs1052693	3e-48	Complement C3 and C4 levels
chr11	2191935	2191936	rs7111341	4e-48	Type 1 diabetes
chr14	94378505	94378506	rs1303	5e-48	Metabolite levels
chr21	39093607	39093608	rs2836878	5e-48	Inflammatory bowel disease
chr11	116778200	116778201	rs964184	6e-48	HDL cholesterol
chr16	82629682	82629683	rs12051272	6e-48	Adiponectin levels
chr12	121927676	121927677	rs7961894	7e-48	Mean platelet volume
chr6	135097496	135097497	rs7775698	7e-48	Red blood cell count
chr7	96491362	96491363	rs4727338	8e-48	Bone mineral density
chr16	260380	260381	rs13335629	9e-48	Red blood cell traits
chr16	53782362	53782363	rs8050136	9.999999999999999e-48	Body mass index
chr3	49684098	49684099	rs3197999	9.999999999999999e-48	Inflammatory bowel disease
chr6	135114362	135114363	rs9483788	9.999999999999999e-48	Other erythrocyte phenotypes
chr4	89716449	89716450	rs356219	1.9999999999999997e-47	Parkinson's disease
chr2	43845436	43845437	rs4299376	1.9999999999999997e-47	LDL cholesterol
chr1	196691130	196691131	rs10801555	1.9999999999999997e-47	Age-related macular degeneration
chr13	113098516	113098517	rs10665	1.9999999999999997e-47	End-stage coagulation
chr19	44908821	44908822	rs7412	1.9999999999999997e-47	Response to statin therapy (LDL-C)
chr2	21008651	21008652	rs676210	2.9999999999999997e-47	LDL (oxidized)
chr3	133765184	133765185	rs3811647	2.9999999999999997e-47	Iron levels
chr2	20983310	20983311	rs6754295	3.9999999999999994e-47	Lipid metabolism phenotypes
chr3	141414607	141414608	rs1991431	3.9999999999999994e-47	Height
chr9	133266803	133266804	rs644234	3.9999999999999994e-47	Protein biomarker
chr6	135097879	135097880	rs9399137	5e-47	Platelet counts
chr1	159001295	159001296	rs4657616	5e-47	Hematology traits
chr11	116778200	116778201	rs964184	5e-47	HDL cholesterol
chr10	122454931	122454932	rs10490924	6.999999999999999e-47	Age-related macular degeneration (GA)
chr15	58391166	58391167	rs1532085	6.999999999999999e-47	Cholesterol, total
chr7	92618761	92618762	rs42235	7.999999999999999e-47	Height
chr5	75360713	75360714	rs12916	9e-47	Cholesterol, total
chr12	121957870	121957871	rs830124	1e-46	Urinary metabolites
chr13	113098849	113098850	rs2181540	1e-46	End-stage coagulation
chr6	26092912	26092913	rs1800562	1e-46	Mean corpuscular volume
chr17	7631359	7631360	rs6258	2.9999999999999995e-46	Sex hormone-binding globulin levels
chr19	50858500	50858501	rs17632542	2.9999999999999995e-46	Serum prostate-specific antigen levels
chr9	114783385	114783386	rs6478106	5e-46	Crohn's disease
chr10	62685803	62685804	rs10761659	5.999999999999999e-46	Inflammatory bowel disease
chr10	61963817	61963818	rs10821936	5.999999999999999e-46	Acute lymphoblastic leukemia (childhood)
chr4	18031864	18031865	rs6449353	7e-46	Height
chr13	50531197	50531198	rs3118905	1e-45	Height
chr15	45360504	45360505	rs1153858	1e-45	Homoarginine levels
chr20	45925375	45925376	rs6065906	1e-45	Lipid metabolism phenotypes
chr2	21002408	21002409	rs1042034	1e-45	Triglycerides
chr22	43928846	43928847	rs738409	1e-45	Liver enzyme levels (alanine transaminase)
chr6	32634491	32634492	rs9272219	1e-45	Rheumatoid arthritis
chr13	113118392	113118393	rs6041	2e-45	End-stage coagulation
chr3	187008098	187008099	rs11710456	2e-45	IgG glycosylation
chr1	68182032	68182033	rs12407028	2.9999999999999995e-45	Bone mineral density
chr1	162163326	162163327	rs12029454	2.9999999999999995e-45	QT interval
chr2	43845436	43845437	rs4299376	4e-45	Cholesterol, total
chr6	33065244	33065245	rs3077	4e-45	Hepatitis B (viral clearance)
chr14	23392601	23392602	rs365990	5e-45	Heart rate
chr5	75360713	75360714	rs12916	5e-45	LDL cholesterol
chr12	120987057	120987058	rs7310409	6.999999999999999e-45	Liver enzyme levels (gamma-glutamyl transferase)
chr9	22096055	22096056	rs10757274	8e-45	Coronary heart disease
chr9	4981601	4981602	rs10758669	8e-45	Inflammatory bowel disease
chr16	56956803	56956804	rs247617	1e-44	HDL cholesterol
chr18	49634582	49634583	rs7241918	1e-44	HDL cholesterol
chr2	27508072	27508073	rs1260326	1e-44	Urate levels
chr19	44919688	44919689	rs4420638	2e-44	Alzheimer's disease
chr10	63290898	63290899	rs7075195	2e-44	Mean platelet volume
chr1	55039973	55039974	rs11591147	2e-44	LDL cholesterol
chr12	121927676	121927677	rs7961894	2.9999999999999997e-44	Mean platelet volume
chr7	15024683	15024684	rs2191349	2.9999999999999997e-44	Fasting glucose-related traits
chr9	22098574	22098575	rs4977574	2.9999999999999997e-44	Myocardial infarction (early onset)
chr20	3213195	3213196	rs1127354	4e-44	Ribavirin-induced anemia
chr3	186842992	186842993	rs182052	5e-44	Adiponectin levels
chr3	187008098	187008099	rs11710456	5e-44	IgG glycosylation
chr12	112927815	112927816	rs11066453	5.999999999999999e-44	Gamma glutamyl transpeptidase
chr2	127135233	127135234	rs6733839	7e-44	Alzheimer's disease (late onset)
chr1	159728758	159728759	rs7553007	8e-44	C-reactive protein
chr20	44436387	44436388	rs6017342	1e-43	Ulcerative colitis
chr6	10982739	10982740	rs3734398	1e-43	Phospholipid levels (plasma)
chr15	28268217	28268218	rs916977	1e-43	Iris color
chr16	89641687	89641688	rs154657	2e-43	Homocysteine levels
chr19	44919688	44919689	rs4420638	2.9999999999999996e-43	LDL cholesterol
chr11	92975543	92975544	rs10830963	2.9999999999999996e-43	Fasting glucose-related traits
chr3	133775509	133775510	rs1049296	5e-43	Alcohol consumption (transferrin glycosylation)
chr3	38582761	38582762	rs3922844	5e-43	PR interval
chr4	186286226	186286227	rs2289252	5.999999999999999e-43	Activated partial thromboplastin time
chr15	58386312	58386313	rs10468017	6.999999999999998e-43	Phospholipid levels (plasma)
chr16	134390	134391	rs7203560	8e-43	Mean corpuscular volume
chr8	19990178	19990179	rs10503669	8e-43	HDL cholesterol
chr1	62560270	62560271	rs2131925	9e-43	Triglycerides
chr5	159399783	159399784	rs6871626	1e-42	Inflammatory bowel disease
chr3	186830775	186830776	rs6810075	2e-42	Adiponectin levels
chr1	152090290	152090291	rs17646946	2e-42	Common traits (Other)
chr20	45916408	45916409	rs4810479	2e-42	Metabolite levels
chr1	109274967	109274968	rs12740374	2e-42	LDL cholesterol
chr11	2818520	2818521	rs2237892	2e-42	Type 2 diabetes
chr2	27508072	27508073	rs1260326	2.9999999999999996e-42	Cholesterol, total
chr19	40857859	40857860	rs8102683	4e-42	Smoking behavior
chr2	191099906	191099907	rs7574865	5e-42	Systemic lupus erythematosus
chr2	21014671	21014672	rs673548	5e-42	Lipid metabolism phenotypes
chr1	113761185	113761186	rs6679677	5.999999999999999e-42	Rheumatoid arthritis
chr18	60172535	60172536	rs571312	5.999999999999999e-42	Body mass index
chr19	44912382	44912383	rs445925	5.999999999999999e-42	Metabolite levels
chr1	206766558	206766559	rs3024505	7e-42	Inflammatory bowel disease
chr6	135106678	135106679	rs9402686	7e-42	Hematological parameters
chr4	9921379	9921380	rs734553	1e-41	Uric acid levels
chr3	186852663	186852664	rs17366568	1e-41	Adiponectin levels
chr17	7618596	7618597	rs12150660	1e-41	Testosterone levels
chr19	6718375	6718376	rs2230199	1e-41	Age-related macular degeneration
chr2	233730663	233730664	rs11891311	1e-41	Bilirubin levels
chr8	19986710	19986711	rs12678919	2e-41	Triglycerides
chr8	9325847	9325848	rs9987289	2e-41	HDL cholesterol
chr9	133278723	133278724	rs579459	2e-41	Soluble levels of adhesion molecules
chr9	133279426	133279427	rs9411489	2e-41	LDL cholesterol
chr22	37074183	37074184	rs2413450	3e-41	Mean corpuscular volume
chr4	110789012	110789013	rs2200733	3e-41	Atrial fibrillation/atrial flutter
chr14	94546046	94546047	rs11160190	4e-41	Vaspin levels
chr16	72074193	72074194	rs2000999	4e-41	LDL cholesterol
chr1	230159943	230159944	rs4846914	4e-41	HDL cholesterol
chr1	196673102	196673103	rs800292	5e-41	Circulating myeloperoxidase levels (serum) 
chr1	62560270	62560271	rs2131925	5e-41	Cholesterol, total
chr5	156963285	156963286	rs6882076	5e-41	Cholesterol, total
chr16	72074193	72074194	rs2000999	7e-41	Cholesterol, total
chr2	233275770	233275771	rs3792109	7e-41	Crohn's disease
chr1	113761185	113761186	rs6679677	1e-40	Type 1 diabetes
chr1	85331426	85331427	rs28489187	1e-40	Serum dimethylarginine levels (asymmetric)
chr19	44892008	44892009	rs157580	1e-40	Alzheimer's disease
chr5	35037009	35037010	rs37369	1e-40	Serum dimethylarginine levels (symmetric)
chr8	18415789	18415790	rs1495743	2e-40	Metabolic traits
chr6	41946639	41946640	rs9349204	2e-40	Red blood cell traits
chr10	112998589	112998590	rs7903146	2e-40	Type 2 diabetes
chr19	44919688	44919689	rs4420638	2e-40	LDL cholesterol
chr2	20703254	20703255	rs4971516	2e-40	LDL cholesterol
chr3	187005155	187005156	rs7652995	2.9999999999999994e-40	IgG glycosylation
chr3	188394765	188394766	rs1464510	2.9999999999999994e-40	Celiac disease
chr5	1287078	1287079	rs2853677	2.9999999999999994e-40	Lung adenocarcinoma
chr16	50685191	50685192	rs9302752	4e-40	Leprosy
chr20	45906011	45906012	rs6065904	4e-40	Lipid metabolism phenotypes
chr6	33087083	33087084	rs9277535	4e-40	Chronic hepatitis B infection
chr3	128597591	128597592	rs4328821	5e-40	White blood cell types
chr2	27508072	27508073	rs1260326	5e-40	C-reactive protein
chr16	82629682	82629683	rs12051272	5e-40	Adiponectin levels
chr20	45925375	45925376	rs6065906	5e-40	HDL cholesterol
chr2	233763992	233763993	rs6742078	5.999999999999999e-40	Bilirubin levels
chr9	133273812	133273813	rs505922	7e-40	Protein quantitative trait loci
chr7	99891947	99891948	rs17277546	9e-40	Metabolic traits
chr9	133268029	133268030	rs612169	9e-40	Metabolic traits
chr9	2691185	2691186	rs10738760	1e-39	Vascular endothelial growth factor levels
chr6	26200448	26200449	rs806794	1e-39	Height
chr20	7125641	7125642	rs1884302	1e-39	Sagittal craniosynostosis
chr4	154562761	154562762	rs1800788	1e-39	Fibrinogen
chr19	44919688	44919689	rs4420638	1e-39	Alzheimer's disease
chr16	56971566	56971567	rs1532624	1e-39	Lipid metabolism phenotypes
chr19	44919688	44919689	rs4420638	1e-39	Alzheimer's disease (late onset)
chr11	61802357	61802358	rs174546	2e-39	LDL cholesterol
chr1	55038976	55038977	rs2479409	2e-39	Cholesterol, total
chr20	22056936	22056937	rs6047844	2e-39	Male-pattern baldness
chr2	102340830	102340831	rs13029918	2e-39	Serum protein levels (sST2)
chr22	43930115	43930116	rs12483959	2e-39	Metabolite levels
chr6	31306777	31306778	rs10484554	2e-39	Psoriasis
chr4	54528856	54528857	rs218238	2.9999999999999996e-39	Red blood cell traits
chr8	118995180	118995181	rs2062377	2.9999999999999996e-39	Bone mineral density
chr6	25842722	25842723	rs1408272	4e-39	Mean corpuscular hemoglobin
chr1	109275907	109275908	rs646776	4e-39	Lipid metabolism phenotypes
chr11	123490688	123490689	rs735665	4e-39	Chronic lymphocytic leukemia
chr19	44873026	44873027	rs519113	5e-39	Alzheimer's disease (late onset)
chr6	160589085	160589086	rs10455872	5e-39	Lp (a) levels
chr6	33065244	33065245	rs3077	5e-39	Chronic hepatitis B infection
chr16	53767041	53767042	rs1421085	5.999999999999999e-39	Obesity
chr6	33087083	33087084	rs9277535	5.999999999999999e-39	Hepatitis B
chr7	37949492	37949493	rs16879765	5.999999999999999e-39	Dupuytren's disease
chr8	19990178	19990179	rs10503669	6.999999999999999e-39	Triglycerides
chr16	56963320	56963321	rs1864163	6.999999999999999e-39	HDL cholesterol
chr4	154567668	154567669	rs6056	8e-39	Fibrinogen
chr6	11075792	11075793	rs1321535	1e-38	Phospholipid levels (plasma)
chr10	6055319	6055320	rs12722495	1e-38	Type 1 diabetes autoantibodies
chr10	112998589	112998590	rs7903146	2e-38	Type 2 diabetes
chr1	161509954	161509955	rs1801274	2e-38	Inflammatory bowel disease
chr12	111446803	111446804	rs3184504	2e-38	Type 1 diabetes autoantibodies
chr6	32251211	32251212	rs9296015	2e-38	Rheumatoid arthritis
chr19	19296908	19296909	rs10401969	3e-38	Cholesterol, total
chr5	77234523	77234524	rs6885099	3e-38	Thyroid hormone levels
chr8	127705822	127705823	rs9642880	4e-38	Bladder cancer
chr3	157080985	157080986	rs900400	4e-38	Birth weight
chr7	38088723	38088724	rs6959212	4e-38	Bone mineral density
chr14	92307318	92307319	rs12896399	4e-38	Blue vs. green eyes
chr10	13113725	13113726	rs1561570	4e-38	Paget's disease
chr17	39756123	39756124	rs12946510	4e-38	Inflammatory bowel disease
chr17	29387568	29387569	rs8076739	5e-38	Mean platelet volume
chr12	121927676	121927677	rs7961894	6e-38	Mean platelet volume
chr2	27518369	27518370	rs780094	6e-38	Fasting glucose-related traits
chr11	61802357	61802358	rs174546	7e-38	Triglycerides
chr11	64566641	64566642	rs2078267	9e-38	Urate levels
chr2	27508072	27508073	rs1260326	1e-37	Lipid metabolism phenotypes
chr1	159728758	159728759	rs7553007	1e-37	C-reactive protein
chr16	50722969	50722970	rs2076756	1e-37	Crohn's disease
chr19	44744369	44744370	rs4803750	1e-37	Lipid metabolism phenotypes
chr6	32696073	32696074	rs6457617	2e-37	Systemic sclerosis
chr5	44706395	44706396	rs10941679	2e-37	Breast cancer
chr11	61802357	61802358	rs174546	2.9999999999999996e-37	Cholesterol, total
chr3	187008098	187008099	rs11710456	2.9999999999999996e-37	IgG glycosylation
chr5	150898346	150898347	rs11741861	2.9999999999999996e-37	Inflammatory bowel disease
chr6	32702477	32702478	rs2856718	4e-37	Hepatitis B
chr6	32762234	32762235	rs7453920	5e-37	Hepatitis B
chr19	50861366	50861367	rs2735839	5.999999999999999e-37	Prostate-specific antigen levels
chr20	35176750	35176751	rs867186	5.999999999999999e-37	Coagulation factor levels
chr3	122284909	122284910	rs1801725	5.999999999999999e-37	Calcium levels
chr12	112207596	112207597	rs2074356	6.9999999999999994e-37	HDL cholesterol
chr20	35142583	35142584	rs6120849	6.9999999999999994e-37	Protein C levels
chr20	45925375	45925376	rs6065906	8e-37	Lipid metabolism phenotypes
chr20	35436181	35436182	rs224333	8e-37	Height
chr3	187008098	187008099	rs11710456	9e-37	IgG glycosylation
chr6	32623175	32623176	rs9271588	9e-37	Sjögren's syndrome
chr10	62518922	62518923	rs10995190	1e-36	Breast cancer
chr16	52552428	52552429	rs3803662	1e-36	Breast cancer
chr16	56959411	56959412	rs3764261	1e-36	Lipid metabolism phenotypes
chr16	72080102	72080103	rs217181	1e-36	Metabolite levels
chr9	136372043	136372044	rs4077515	1e-36	Crohn's disease
chr8	9325847	9325848	rs9987289	2e-36	Cholesterol, total
chr4	154530606	154530607	rs12511469	2e-36	Fibrinogen
chr18	60183188	60183189	rs538656	2e-36	Obesity
chr11	92940661	92940662	rs1387153	2e-36	Fasting plasma glucose
chr1	155192275	155192276	rs4072037	2e-36	Magnesium levels
chr14	92307318	92307319	rs12896399	2e-36	Hair color
chr5	56736056	56736057	rs889312	2.9999999999999995e-36	Breast cancer
chr6	10968907	10968908	rs4713103	2.9999999999999995e-36	Phospholipid levels (plasma)
chr6	135097879	135097880	rs9399137	2.9999999999999995e-36	F-cell distribution
chr7	99521177	99521178	rs11761528	2.9999999999999995e-36	Dehydroepiandrosterone sulphate levels
chr2	127419800	127419801	rs1158867	4e-36	Protein C levels
chr19	48703373	48703374	rs1047781	4e-36	Vitamin B12 levels
chr1	231681095	231681096	rs12042938	4e-36	Neuranatomic and neurocognitive phenotypes
chr11	76588149	76588150	rs2155219	4e-36	Inflammatory bowel disease
chr16	53782362	53782363	rs8050136	5e-36	Weight
chr19	44892361	44892362	rs2075650	5e-36	Alzheimer's disease (late onset)
chr6	139523291	139523292	rs590856	5e-36	Red blood cell traits
chr8	125478729	125478730	rs2954029	5e-36	Cholesterol, total
chr5	40410481	40410482	rs11742570	7e-36	Crohn's disease
chr6	33572431	33572432	rs210134	7e-36	Platelet counts
chr16	264780	264781	rs9924561	8e-36	Red blood cell traits
chr3	133765184	133765185	rs3811647	1e-35	Alcohol consumption (transferrin glycosylation)
chr6	32711221	32711222	rs9275572	1e-35	Alopecia areata
chr2	102332171	102332172	rs1420103	1e-35	Serum protein levels (sST2)
chr19	5841344	5841345	rs3760775	1e-35	Tumor biomarkers
chr15	58391166	58391167	rs1532085	1e-35	HDL cholesterol
chr12	112379978	112379979	rs11066280	1e-35	Blood pressure
chr10	112998589	112998590	rs7903146	1e-35	Type 2 diabetes
chr12	56471271	56471272	rs2638315	2e-35	Metabolite levels
chr15	83911829	83911830	rs11259936	2e-35	Height
chr3	157080985	157080986	rs900400	2e-35	Birth weight
chr9	133279426	133279427	rs9411489	3e-35	Cholesterol, total
chr2	27508072	27508073	rs1260326	3e-35	Lipid metabolism phenotypes
chr2	55884173	55884174	rs3791675	3e-35	Height
chr10	68241123	68241124	rs1900004	3e-35	Optic disc parameters
chr10	112998589	112998590	rs7903146	3e-35	Type 2 diabetes
chr11	61896218	61896219	rs174468	3e-35	Phospholipid levels (plasma)
chr1	19845366	19845367	rs6426833	4e-35	Ulcerative colitis
chr12	110976656	110976657	rs12229654	4e-35	Alcohol consumption
chr6	151586612	151586613	rs4869742	4e-35	Bone mineral density
chr11	116778200	116778201	rs964184	5e-35	Hypertriglyceridemia
chr8	128933907	128933908	rs987525	5e-35	Orofacial clefts
chr10	63379149	63379150	rs7910927	6e-35	Sex hormone-binding globulin levels
chr15	28285035	28285036	rs1667394	6e-35	Blond vs. brown hair color
chr1	109809854	109809855	rs10494112	6.999999999999999e-35	Paget's disease
chr2	60493110	60493111	rs11886868	6.999999999999999e-35	Fetal hemoglobin levels
chr4	89720188	89720189	rs356220	8e-35	Parkinson's disease
chr1	11796320	11796321	rs1801133	8e-35	Homocysteine levels
chr17	40000458	40000459	rs4794822	9e-35	White blood cell count
chr9	133273812	133273813	rs505922	1e-34	Venous thromboembolism
chr9	108126197	108126198	rs865686	1e-34	Breast cancer
chr19	8206836	8206837	rs7258249	1e-34	Sphingolipid levels
chr12	93584727	93584728	rs11107116	1e-34	Height
chr1	162143119	162143120	rs16857031	1e-34	QT interval
chr10	112998589	112998590	rs7903146	2e-34	Type 2 diabetes
chr12	111803961	111803962	rs671	2e-34	Coronary heart disease
chr16	248588	248589	rs13339636	2e-34	Red blood cell traits
chr16	56959411	56959412	rs3764261	2e-34	LDL cholesterol
chr20	44413723	44413724	rs1800961	2e-34	HDL cholesterol
chr20	45925375	45925376	rs6065906	2e-34	Triglycerides
chr3	156689207	156689208	rs7651446	2e-34	Ovarian cancer
chr8	19986710	19986711	rs12678919	2e-34	HDL cholesterol
chr4	45180509	45180510	rs10938397	2.9999999999999996e-34	Obesity
chr11	116746523	116746524	rs11216126	2.9999999999999996e-34	HDL cholesterol
chr2	164656580	164656581	rs10195252	4e-34	Waist-hip ratio
chr22	43928846	43928847	rs738409	4e-34	Nonalcoholic fatty liver disease
chr6	32689800	32689801	rs7774434	4e-34	Primary biliary cirrhosis
chr9	133260147	133260148	rs8176704	4e-34	Coagulation factor levels
chr16	31036757	31036758	rs10871454	5e-34	Warfarin maintenance dose
chr11	102824376	102824377	rs495366	5.999999999999999e-34	Matrix metalloproteinase levels
chr4	9954454	9954455	rs4481233	5.999999999999999e-34	Metabolic traits
chr11	1100036	1100037	rs7934606	7.0000000000000006e-34	Interstitial lung disease 
chr2	62324336	62324337	rs10865331	7.0000000000000006e-34	Ankylosing spondylitis
chr17	70189444	70189445	rs8080944	8e-34	Primary tooth development (time to first tooth eruption)
chr3	56815720	56815721	rs1354034	8.999999999999999e-34	Mean platelet volume
chr22	37074183	37074184	rs2413450	8.999999999999999e-34	Mean corpuscular hemoglobin
chr1	109279543	109279544	rs599839	1e-33	LDL cholesterol
chr16	134390	134391	rs7203560	1e-33	Mean corpuscular hemoglobin concentration
chr6	121810338	121810339	rs1015451	1e-33	Heart rate
chr6	142476151	142476152	rs7763064	1e-33	Height
chr9	104902019	104902020	rs1883025	2e-33	HDL cholesterol
chr9	106204806	106204807	rs2090409	2e-33	Menarche (age at onset)
chr7	2762168	2762169	rs798489	2e-33	Height
chr8	142680512	142680513	rs2294008	2e-33	Duodenal ulcer 
chr6	32638106	32638107	rs2187668	2e-33	Immunoglobulin A 
chr6	31291059	31291060	rs9468925	2e-33	Vitiligo
chr23	79241620	79241621	rs5912838	2e-33	Graves' disease
chr7	106731772	106731773	rs342293	2e-33	Mean platelet volume
chr11	2212343	2212344	rs7127900	2.9999999999999998e-33	Prostate cancer
chr2	102532640	102532641	rs1014286	2.9999999999999998e-33	Serum protein levels (sST2)
chr22	46025961	46025962	rs6519955	2.9999999999999998e-33	Dupuytren's disease
chr6	31295973	31295974	rs2894207	2.9999999999999998e-33	Nasopharyngeal carcinoma
chr6	32619076	32619077	rs9271366	2.9999999999999998e-33	Immunoglobulin A 
chr7	50402282	50402283	rs11980379	2.9999999999999998e-33	Acute lymphoblastic leukemia (B-cell precursor)
chr11	116778200	116778201	rs964184	4e-33	Triglycerides
chr22	39263767	39263768	rs2413583	4e-33	Inflammatory bowel disease
chr1	219577374	219577375	rs4846567	4.9999999999999996e-33	Waist-hip ratio
chr1	113834945	113834946	rs2476601	4.9999999999999996e-33	Rheumatoid arthritis
chr1	109279543	109279544	rs599839	5.9999999999999997e-33	LDL cholesterol
chr6	32696073	32696074	rs6457617	7e-33	Graves' disease
chr1	162240819	162240820	rs4657178	7e-33	QT interval
chr16	67894138	67894139	rs16942887	8e-33	HDL cholesterol
chr6	31464002	31464003	rs2395029	9e-33	Drug-induced liver injury (flucloxacillin)
chr11	15688537	15688538	rs7108738	9.999999999999999e-33	Bone mineral density
chr1	200908433	200908434	rs7554511	9.999999999999999e-33	Inflammatory bowel disease
chr16	56951226	56951227	rs9989419	9.999999999999999e-33	HDL cholesterol
chr6	26092912	26092913	rs1800562	1.9999999999999998e-32	Alcohol consumption (transferrin glycosylation)
chr6	127131493	127131494	rs9491696	1.9999999999999998e-32	Waist-hip ratio
chr4	88117929	88117930	rs1481012	1.9999999999999998e-32	Gout
chr5	35037009	35037010	rs37369	1.9999999999999998e-32	Serum dimethylarginine levels (asymmetric/symetric ratio)
chr15	58431475	58431476	rs1800588	1.9999999999999998e-32	HDL cholesterol
chr11	61790330	61790331	rs102275 	1.9999999999999998e-32	Oleic acid (18:1n-9) plasma levels
chr11	112214592	112214593	rs2250417	1.9999999999999998e-32	Inflammatory biomarkers
chr2	233271763	233271764	rs3828309	1.9999999999999998e-32	Crohn's disease
chr1	173222335	173222336	rs2205960	3e-32	Systemic lupus erythematosus
chr1	62560270	62560271	rs2131925	3e-32	LDL cholesterol
chr19	39252524	39252525	rs8099917	3e-32	Response to hepatitis C treatment
chr9	114790968	114790969	rs4246905	3e-32	Inflammatory bowel disease
chr2	27508072	27508073	rs1260326	3.9999999999999997e-32	Lipid metabolism phenotypes
chr6	31285147	31285148	rs12191877	3.9999999999999997e-32	Psoriasis
chr9	16915022	16915023	rs3814113	3.9999999999999997e-32	Ovarian cancer
chr1	149920978	149920979	rs11205277	4.999999999999999e-32	Height
chr1	46938513	46938514	rs9332998	4.999999999999999e-32	Metabolic traits
chr2	27518369	27518370	rs780094	6e-32	Triglycerides
chr12	124777046	124777047	rs838880	6e-32	HDL cholesterol
chr1	196685193	196685194	rs1061147	7e-32	Age-related macular degeneration
chr12	65958045	65958046	rs1351394	7e-32	Height
chr1	53909896	53909897	rs2235544	7.999999999999999e-32	Thyroid hormone levels
chr12	68106294	68106295	rs7134599	8.999999999999999e-32	Inflammatory bowel disease
chr2	60977720	60977721	rs7608910	8.999999999999999e-32	Inflammatory bowel disease
chr5	176951572	176951573	rs365132	8.999999999999999e-32	Menopause (age at onset)
chr12	88496893	88496894	rs995030	9.999999999999999e-32	Testicular germ cell tumor
chr10	94942289	94942290	rs1799853	9.999999999999999e-32	Warfarin maintenance dose
chr11	59456670	59456671	rs7943953	9.999999999999999e-32	Odorant perception (ß-ionone)
chr1	196704862	196704863	rs1831282	9.999999999999999e-32	Age-related macular degeneration
chr6	41957420	41957421	rs9349205	9.999999999999999e-32	Mean corpuscular volume
chr20	45906011	45906012	rs6065904	1.9999999999999997e-31	Lipid metabolism phenotypes
chr19	11091629	11091630	rs6511720	1.9999999999999997e-31	Lipid metabolism phenotypes
chr17	40010625	40010626	rs8078723	1.9999999999999997e-31	White blood cell count
chr12	112207596	112207597	rs2074356	1.9999999999999997e-31	Esophageal cancer
chr2	27508072	27508073	rs1260326	1.9999999999999997e-31	Triglycerides
chr1	184054394	184054395	rs1046934	1.9999999999999997e-31	Height
chr11	64673447	64673448	rs506338	1.9999999999999997e-31	Urate levels
chr10	112998589	112998590	rs7903146	1.9999999999999997e-31	Type 2 diabetes
chr1	196677045	196677046	rs1329424	1.9999999999999997e-31	Age-related macular degeneration
chr5	156963285	156963286	rs6882076	3e-31	LDL cholesterol
chr5	142302222	142302223	rs4624820	3e-31	Testicular germ cell tumor
chr6	32619076	32619077	rs9271366	3e-31	Inflammatory bowel disease
chr3	169774312	169774313	rs10936599	3e-31	Telomere length
chr1	152110848	152110849	rs11803731	3e-31	Hair morphology
chr16	56951226	56951227	rs9989419	3e-31	HDL cholesterol
chr11	116778200	116778201	rs964184	3e-31	Metabolic syndrome
chr2	21174309	21174310	rs506585	3e-31	Lipid metabolism phenotypes
chr10	121577820	121577821	rs2981579	3.9999999999999995e-31	Breast cancer
chr16	56959411	56959412	rs3764261	3.9999999999999995e-31	Cholesterol, total
chr3	187008098	187008099	rs11710456	3.9999999999999995e-31	IgG glycosylation
chr4	45180509	45180510	rs10938397	3.9999999999999995e-31	Body mass index
chr6	32465389	32465390	rs2395185	3.9999999999999995e-31	Hodgkin's lymphoma
chr2	60490907	60490908	rs1427407	6e-31	F-cell distribution
chr3	56831747	56831748	rs12485738	6e-31	Mean platelet volume
chr6	31946402	31946403	rs641153	6e-31	Age-related macular degeneration
chr1	230159943	230159944	rs4846914	7e-31	Triglycerides
chr15	51232094	51232095	rs2414095	7e-31	Hormone measurements
chr12	112379978	112379979	rs11066280	7.999999999999999e-31	Blood pressure
chr12	28002146	28002147	rs10771399	7.999999999999999e-31	Breast cancer
chr6	104931078	104931079	rs7759938	7.999999999999999e-31	Height
chr16	31096367	31096368	rs9923231	9e-31	Warfarin maintenance dose
chr19	44911193	44911194	rs439401	1e-30	Triglycerides
chr12	120983003	120983004	rs1183910	1e-30	C-reactive protein
chr2	21002408	21002409	rs1042034	1e-30	HDL cholesterol
chr10	121586675	121586676	rs1219648	1e-30	Breast cancer
chr10	112998589	112998590	rs7903146	1e-30	Type 2 diabetes and other traits
chr10	79300559	79300560	rs1250550	1e-30	Crohn's disease
chr5	177415472	177415473	rs2731672	2e-30	Activated partial thromboplastin time
chr4	154561590	154561591	rs1800789	2e-30	Fibrinogen
chr3	27374521	27374522	rs4973768	2e-30	Breast cancer
chr2	102336983	102336984	rs17639215	2e-30	Serum protein levels (sST2)
chr9	133263861	133263862	rs657152	2e-30	Liver enzyme levels
chr19	39248146	39248147	rs12979860	2e-30	Chronic Hepatitis C infection
chr19	44908821	44908822	rs7412	2e-30	Lipid traits
chr1	109275907	109275908	rs646776	2e-30	Progranulin levels
chr11	61803909	61803910	rs174549	2e-30	Metabolite levels
chr1	197101645	197101646	rs10922162	2e-30	End-stage coagulation
chr12	88496893	88496894	rs995030	3e-30	Testicular germ cell tumor
chr8	23668949	23668950	rs1512268	3e-30	Prostate cancer
chr11	69078930	69078931	rs35264875	4e-30	Blond vs. brown hair color
chr16	82617111	82617112	rs3865188	4e-30	Adiponectin levels
chr18	23147646	23147647	rs4800452	4e-30	Height
chr2	165744535	165744536	rs1346004	4e-30	Bone mineral density
chr4	88038769	88038770	rs2725220	4e-30	Renal function-related traits (urea)
chr12	88934557	88934558	rs12821256	4e-30	Blond vs. brown hair color
chr1	197004052	197004053	rs12116643	5.0000000000000004e-30	End-stage coagulation
chr19	44919688	44919689	rs4420638	5.0000000000000004e-30	Lipoprotein-associated phospholipase A2 activity and mass
chr17	7618596	7618597	rs12150660	6e-30	Sex hormone-binding globulin levels
chr12	56469985	56469986	rs2657880	7e-30	Metabolite levels
chr2	233760497	233760498	rs4148323	7e-30	Bilirubin levels
chr12	120986152	120986153	rs2393791	7e-30	Gamma glutamyl transpeptidase
chr1	152577541	152577542	rs4085613	7e-30	Psoriasis
chr10	112998589	112998590	rs7903146	9.000000000000001e-30	Type 2 diabetes
chr21	15445618	15445619	rs2823286	9.000000000000001e-30	Inflammatory bowel disease
chr3	187995929	187995930	rs10937329	9.000000000000001e-30	Renal function-related traits (BUN)
chr9	133278723	133278724	rs579459	1.0000000000000001e-29	Soluble E-selectin levels
chr7	129055928	129055929	rs13239597	1.0000000000000001e-29	Systemic lupus erythematosus and Systemic sclerosis
chr6	32697642	32697643	rs10484561	1.0000000000000001e-29	Follicular lymphoma
chr9	4814947	4814948	rs13300663	1.0000000000000001e-29	Platelet counts
chr11	5008472	5008473	rs2445284	1.0000000000000001e-29	Sickle cell anemia (haemolysis)
chr1	145711326	145711327	rs1471633	1.0000000000000001e-29	Urate levels
chr2	60492834	60492835	rs766432	1.0000000000000001e-29	Fetal hemoglobin levels
chr19	19296908	19296909	rs10401969	2.0000000000000002e-29	Triglycerides
chr3	156689207	156689208	rs7651446	2.0000000000000002e-29	Ovarian cancer
chr4	54528004	54528005	rs218237	2.0000000000000002e-29	Mean corpuscular volume
chr6	118346358	118346359	rs11153730	2.0000000000000002e-29	QT interval
chr7	50405552	50405553	rs6964969	2.0000000000000002e-29	Acute lymphoblastic leukemia (childhood)
chr8	127091691	127091692	rs1456315	2.0000000000000002e-29	Prostate cancer
chr9	22132076	22132077	rs2383208	2.0000000000000002e-29	Type 2 diabetes
chr8	125478729	125478730	rs2954029	2.9999999999999997e-29	HDL cholesterol
chr8	125478729	125478730	rs2954029	2.9999999999999997e-29	LDL cholesterol
chr6	30049293	30049294	rs6917603	2.9999999999999997e-29	Lipid metabolism phenotypes
chr2	27508072	27508073	rs1260326	2.9999999999999997e-29	Lipid metabolism phenotypes
chr11	117661015	117661016	rs10892151	2.9999999999999997e-29	Triglycerides
chr1	109275907	109275908	rs646776	2.9999999999999997e-29	LDL cholesterol
chr10	122455798	122455799	rs3750848	2.9999999999999997e-29	Age-related macular degeneration (extreme sampling)
chr11	2818520	2818521	rs2237892	4.0000000000000003e-29	Type 2 diabetes
chr1	16980179	16980180	rs2284746	4.0000000000000003e-29	Height
chr2	210210184	210210185	rs3764913	4.0000000000000003e-29	Metabolite levels
chr6	25870313	25870314	rs1165205	4.0000000000000003e-29	Urate levels
chr9	16915022	16915023	rs3814113	4.0000000000000003e-29	Ovarian cancer
chr2	21063184	21063185	rs515135	5e-29	LDL cholesterol
chr20	38215635	38215636	rs6127471	5e-29	Heart rate
chr19	6718375	6718376	rs2230199	5e-29	Age-related macular degeneration
chr16	56959411	56959412	rs3764261	5e-29	Hematological and biochemical traits
chr16	264780	264781	rs9924561	5e-29	Red blood cell traits
chr12	40398497	40398498	rs11564258	5.999999999999999e-29	Inflammatory bowel disease
chr14	103106477	103106478	rs944002	5.999999999999999e-29	Liver enzyme levels (gamma-glutamyl transferase)
chr22	43104205	43104206	rs5759167	5.999999999999999e-29	Prostate cancer
chr3	142930267	142930268	rs9832727	5.999999999999999e-29	Phospholipid levels (plasma)
chr6	32082980	32082981	rs1150754	5.999999999999999e-29	Systemic lupus erythematosus
chr11	46721696	46721697	rs3136441	7e-29	HDL cholesterol
chr11	46721696	46721697	rs3136441	7e-29	HDL cholesterol
chr16	56959411	56959412	rs3764261	7e-29	HDL cholesterol
chr5	40791781	40791782	rs13361707	8.000000000000001e-29	Gastric cancer
chr6	31412751	31412752	rs2256183	8.000000000000001e-29	Height
chr2	160060985	160060986	rs4664308	9.000000000000001e-29	Nephropathy (idiopathic membranous)
chr11	102820750	102820751	rs11225434	9.000000000000001e-29	Matrix metalloproteinase levels
chr10	46046325	46046326	rs10993994	9.000000000000001e-29	Prostate cancer
chr1	109274967	109274968	rs12740374	9.000000000000001e-29	Coronary heart disease
chr10	88263275	88263276	rs10509540	1e-28	Type 1 diabetes
chr16	52565275	52565276	rs4784227	1e-28	Breast cancer
chr16	53767041	53767042	rs1421085	1e-28	Obesity
chr17	45637483	45637484	rs2942168	1e-28	Parkinson's disease
chr19	39248146	39248147	rs12979860	1e-28	Response to hepatitis C treatment
chr3	38725823	38725824	rs6801957	1e-28	QRS duration
chr6	396320	396321	rs12203592	1e-28	Hair color
chr7	92618761	92618762	rs42235	1e-28	Height
chr8	18414927	18414928	rs4921914	1e-28	Urinary metabolites
chr8	19962212	19962213	rs328	2e-28	Triglycerides
chr8	129713418	129713419	rs6470764	2e-28	Height
chr6	396320	396321	rs12203592	2e-28	Hair color
chr6	31284618	31284619	rs2524054	2e-28	CD4:CD8 lymphocyte ratio
chr5	159290780	159290781	rs2082412	2e-28	Psoriasis
chr10	59709779	59709780	rs1171614	2e-28	Urate levels
chr1	55038976	55038977	rs2479409	2e-28	LDL cholesterol
chr12	40340399	40340400	rs34637584	2e-28	Parkinson's disease
chr1	207630249	207630250	rs12034383	2e-28	Erythrocyte sedimentation rate
chr16	56978466	56978467	rs12708980	2e-28	HDL cholesterol
chr4	110796910	110796911	rs6843082	2.9999999999999996e-28	Atrial fibrillation
chr2	27508072	27508073	rs1260326	2.9999999999999996e-28	Lipid metabolism phenotypes
chr2	66554320	66554321	rs2300478	2.9999999999999996e-28	Restless legs syndrome
chr16	53767041	53767042	rs1421085	2.9999999999999996e-28	Obesity (early onset extreme)
chr1	91611539	91611540	rs1192415	2.9999999999999996e-28	Optic disc parameters
chr3	159947261	159947262	rs17810546	4e-28	Celiac disease
chr4	45173673	45173674	rs13130484	4e-28	Obesity
chr7	116546186	116546187	rs3807989	4e-28	PR interval
chr1	67240274	67240275	rs11209026	5e-28	Ulcerative colitis
chr6	31306602	31306603	rs9264942	5e-28	Crohn's disease
chr6	32638106	32638107	rs2187668	5.999999999999999e-28	Systemic lupus erythematosus
chr1	159714874	159714875	rs3091244	5.999999999999999e-28	C-reactive protein
chr6	32762234	32762235	rs7453920	5.999999999999999e-28	Hepatitis B
chr17	29376330	29376331	rs2138852	7e-28	Mean platelet volume
chr5	156963285	156963286	rs6882076	7e-28	Cholesterol, total
chr11	61872100	61872101	rs174448	7e-28	Phospholipid levels (plasma)
chr6	34231314	34231315	rs2780226	8e-28	Height
chr11	61802357	61802358	rs174546	8e-28	HDL cholesterol
chr15	51325510	51325511	rs2445762	8e-28	Hormone measurements
chr18	48927092	48927093	rs4939827	8e-28	Colorectal cancer
chr5	79020652	79020653	rs921943	9e-28	Blood trace element (Se levels)
chr6	396320	396321	rs12203592	9e-28	Black vs. red hair color
chr4	81228851	81228852	rs788867	9e-28	Height
chr8	127343371	127343372	rs13281615	1e-27	Breast cancer
chr7	121378524	121378525	rs917727	1e-27	Bone mineral density
chr6	12296021	12296022	rs5370	1e-27	Circulating vasoactive peptide levels 
chr5	1286400	1286401	rs2736100	1e-27	Lung cancer
chr4	87852696	87852697	rs6532023	1e-27	Bone mineral density
chr3	141383990	141383991	rs6763931	1e-27	Height
chr19	44744369	44744370	rs4803750	1e-27	Lipid metabolism phenotypes
chr16	56959411	56959412	rs3764261	1e-27	Waist circumference and related phenotypes
chr1	21496798	21496799	rs1697421	1e-27	Phosphorus levels
chr11	117220892	117220893	rs236918	1e-27	Iron status biomarkers
chr4	54541594	54541595	rs172629	1e-27	Mean corpuscular volume
chr9	97793826	97793827	rs965513	2e-27	Thyroid cancer
chr9	22031005	22031006	rs7865618	2e-27	Coronary heart disease
chr6	32441752	32441753	rs3129882	2e-27	Systemic sclerosis
chr5	96788626	96788627	rs30187	2e-27	Ankylosing spondylitis
chr4	122194346	122194347	rs13151961	2e-27	Celiac disease
chr2	210752169	210752170	rs2216405	2e-27	Metabolic traits
chr2	102348931	102348932	rs12999542	2e-27	Serum protein levels (sST2)
chr19	8206836	8206837	rs7258249	2e-27	Sphingolipid levels
chr18	60184529	60184530	rs10871777	2e-27	Obesity
chr11	71456402	71456403	rs12785878	2e-27	Vitamin D insufficiency
chr1	109275907	109275908	rs646776	2e-27	Lipid metabolism phenotypes
chr10	79976224	79976225	rs3923564	2e-27	Chronic obstructive pulmonary disease-related biomarkers
chr9	133290773	133290774	rs7025162	3e-27	Serum alkaline phosphatase levels
chr9	104902019	104902020	rs1883025	3e-27	Cholesterol, total
chr6	36655601	36655602	rs9470361	3e-27	QRS duration
chr5	77239985	77239986	rs2046045	3e-27	Thyroid function
chr4	145873468	145873469	rs4547811	3e-27	Liver enzyme levels (gamma-glutamyl transferase)
chr12	111446803	111446804	rs3184504	3e-27	Type 1 diabetes
chr16	89689494	89689495	rs258322	3e-27	Melanoma
chr15	58179779	58179780	rs16939881	3e-27	Metabolite levels
chr12	56088395	56088396	rs2292239	3e-27	Type 1 diabetes autoantibodies
chr16	89689494	89689495	rs258322	3e-27	Melanoma
chr1	205275824	205275825	rs1172130	4e-27	Mean platelet volume
chr15	88845673	88845674	rs16942341	4e-27	Height
chr19	44919688	44919689	rs4420638	4e-27	Cognitive decline
chr19	44919688	44919689	rs4420638	4e-27	LDL cholesterol
chr3	56831747	56831748	rs12485738	4e-27	Mean platelet volume
chr5	1286400	1286401	rs2736100	4e-27	Lung cancer
chr6	41937536	41937537	rs3218097	4e-27	Mean corpuscular volume
chr6	33104394	33104395	rs4282438	5e-27	Cervical cancer
chr6	32460507	32460508	rs6903608	5e-27	Hodgkin's lymphoma
chr3	38725183	38725184	rs6795970	5e-27	Electrocardiographic conduction measures
chr2	210675782	210675783	rs7422339	5e-27	Homocysteine levels
chr19	44919688	44919689	rs4420638	5e-27	C-reactive protein
chr2	27520286	27520287	rs780092	5e-27	Triglycerides
chr1	154453787	154453788	rs4129267	6e-27	Fibrinogen
chr19	32873721	32873722	rs8101881	6e-27	Urinary metabolites
chr15	63130572	63130573	rs2652822	6.999999999999999e-27	Metabolic traits
chr2	27508072	27508073	rs1260326	6.999999999999999e-27	Cholesterol, total
chr5	40392625	40392626	rs4613763	6.999999999999999e-27	Crohn's disease
chr8	56281603	56281604	rs7460090	8e-27	Height
chr7	100899510	100899511	rs13245899	8e-27	Heart rate
chr10	122454931	122454932	rs10490924	8e-27	Age-related macular degeneration
chr6	32606393	32606394	rs615672	8e-27	Rheumatoid arthritis
chr16	56951226	56951227	rs9989419	9.000000000000002e-27	HDL cholesterol
chr22	39263767	39263768	rs2413583	1e-26	Crohn's disease
chr1	109275215	109275216	rs660240	1e-26	LDL cholesterol
chr11	116778200	116778201	rs964184	1e-26	LDL cholesterol
chr11	116781490	116781491	rs12286037	1e-26	Triglycerides
chr11	2818520	2818521	rs2237892	1e-26	Type 2 diabetes
chr11	62419069	62419070	rs3741240	1e-26	Chronic obstructive pulmonary disease-related biomarkers
chr12	111446803	111446804	rs3184504	1e-26	Platelet counts
chr16	62066306	62066307	rs8050940	1e-26	Myopia (pathological)
chr17	34266954	34266955	rs3091316	1e-26	Inflammatory bowel disease
chr5	96393193	96393194	rs6235	1e-26	Proinsulin levels
chr8	128933907	128933908	rs987525	1e-26	Orofacial clefts
chr5	77234523	77234524	rs6885099	2e-26	Thyroid hormone levels
chr6	31464002	31464003	rs2395029	2e-26	Psoriasis
chr11	64566641	64566642	rs2078267	2e-26	Urate levels
chr6	43791135	43791136	rs6905288	2e-26	Waist-hip ratio
chr6	43929989	43929990	rs9472155	2e-26	Vascular endothelial growth factor levels
chr21	44195857	44195858	rs7282490	2e-26	Inflammatory bowel disease
chr6	32713853	32713854	rs9275596	2e-26	Nephropathy
chr2	113074755	113074756	rs6743376	2e-26	Inflammatory biomarkers
chr1	121538814	121538815	rs11249433	2e-26	Breast cancer
chr17	82727656	82727657	rs1046896	2e-26	Glycated hemoglobin levels
chr12	88559783	88559784	rs3782181	2e-26	Testicular germ cell cancer
chr1	169544767	169544768	rs1018827	2e-26	Venous thromboembolism
chr11	68433826	68433827	rs3736228	2e-26	Bone mineral density
chr7	107839869	107839870	rs4380874	2e-26	Ulcerative colitis
chr11	116778200	116778201	rs964184	2e-26	LDL cholesterol
chr11	116736720	116736721	rs1558861	2e-26	Triglycerides
chr19	11091629	11091630	rs6511720	2e-26	LDL cholesterol
chr9	863634	863635	rs755383	2e-26	Testicular germ cell tumor
chr6	32689800	32689801	rs7774434	3e-26	Primary biliary cirrhosis
chr5	159323760	159323761	rs3213094	3e-26	Psoriasis
chr18	12809340	12809341	rs1893217	3e-26	Inflammatory bowel disease
chr4	24576473	24576474	rs6841898	3e-26	Myopia (pathological)
chr15	78513680	78513681	rs8034191	3e-26	Lung cancer
chr16	53782362	53782363	rs8050136	3e-26	Adiposity
chr15	74785025	74785026	rs1378942	3e-26	Diastolic blood pressure
chr12	7538537	7538538	rs7136716	3e-26	Hematological and biochemical traits
chr1	207767507	207767508	rs11118555	4e-26	Heart rate
chr19	11091629	11091630	rs6511720	4e-26	LDL cholesterol
chr2	178856318	178856319	rs17362588	4e-26	Heart rate
chr4	9945031	9945032	rs4475146	4e-26	Gout
chr8	19970336	19970337	rs10105606	4e-26	Triglycerides
chr1	113761185	113761186	rs6679677	5e-26	Type 1 diabetes
chr11	27704438	27704439	rs10767664	5e-26	Body mass index
chr1	159302269	159302270	rs2251746	5e-26	IgE levels 
chr12	111803961	111803962	rs671	5e-26	Response to alcohol consumption (flushing response)
chr19	55322295	55322296	rs11668344	5e-26	Menopause (age at onset)
chr2	168906637	168906638	rs560887	5e-26	Metabolic syndrome
chr6	24491246	24491247	rs1883415	6e-26	Liver enzyme levels (alkaline phosphatase)
chr9	104858553	104858554	rs9282541	6e-26	HDL cholesterol
chr3	38592431	38592432	rs11708996	6e-26	PR interval
chr6	109305761	109305762	rs1008084	6e-26	Red blood cell traits
chr10	103086420	103086421	rs11191548	7.000000000000001e-26	Systolic blood pressure
chr3	189638471	189638472	rs4488809	7.000000000000001e-26	Lung cancer
chr6	32762234	32762235	rs7453920	7.000000000000001e-26	Chronic hepatitis B infection
chr8	19961816	19961817	rs325	8e-26	HDL cholesterol
chr8	127412546	127412547	rs7014346	9e-26	Colorectal cancer
chr6	12903724	12903725	rs9349379	9e-26	Coronary heart disease
chr6	12903724	12903725	rs9349379	9e-26	Coronary heart disease
chr11	86156832	86156833	rs10792832	9e-26	Alzheimer's disease (late onset)
chr11	116791862	116791863	rs651821	9e-26	Triglycerides
chr12	55996851	55996852	rs705702	9e-26	Polycystic ovary syndrome
chr10	122459758	122459759	rs3793917	1e-25	Age-related macular degeneration
chr10	63379149	63379150	rs7910927	1e-25	Sex hormone-binding globulin levels
chr19	11091629	11091630	rs6511720	1e-25	Lipid metabolism phenotypes
chr2	21174309	21174310	rs506585	1e-25	Lipid metabolism phenotypes
chr6	26200448	26200449	rs806794	1e-25	Height
chr7	44196068	44196069	rs4607517	1e-25	Fasting plasma glucose
chr8	127527114	127527115	rs7837688	1e-25	Prostate cancer
chr23	5266660	5266661	rs6638512	2e-25	Antineutrophil cytoplasmic antibody-associated vasculitis 
chr9	133278430	133278431	rs651007	2e-25	End-stage coagulation
chr20	3207086	3207087	rs6139030	2e-25	Response to hepatitis C treatment
chr9	4981601	4981602	rs10758669	2e-25	Ulcerative colitis
chr9	22098574	22098575	rs4977574	2e-25	Coronary heart disease
chr19	48725014	48725015	rs2287921	2e-25	Retinal vascular caliber
chr6	32433439	32433440	rs3135338	2e-25	Multiple sclerosis
chr12	57450265	57450266	rs3741414	2e-25	Urate levels
chr12	56088395	56088396	rs2292239	2e-25	Type 1 diabetes
chr11	128441163	128441164	rs6590330	2e-25	Systemic lupus erythematosus
chr10	69340156	69340157	rs7072268	2e-25	Glycated hemoglobin levels
chr10	35006502	35006503	rs11010067	2e-25	Inflammatory bowel disease
chr16	56959411	56959412	rs3764261	2e-25	Triglycerides
chr16	56963320	56963321	rs1864163	3e-25	Lipid metabolism phenotypes
chr16	58533333	58533334	rs37062	3e-25	QT interval
chr17	63488669	63488670	rs4343	3e-25	Angiotensin-converting enzyme activity
chr22	37066895	37066896	rs855791	3e-25	Hemoglobin
chr4	54528004	54528005	rs218237	3e-25	Mean corpuscular hemoglobin
chr8	27610168	27610169	rs9331896	3e-25	Alzheimer's disease (late onset)
chr3	41087072	41087073	rs430727	4e-25	Bone mineral density
chr12	111446803	111446804	rs3184504	4e-25	Diastolic blood pressure
chr11	116851324	116851325	rs10047462	4e-25	Iron status biomarkers
chr11	61872100	61872101	rs174448	4e-25	Phospholipid levels (plasma)
chr13	42377312	42377313	rs9533090	5.0000000000000005e-25	Bone mineral density (spine)
chr17	63889104	63889105	rs2665838	5.0000000000000005e-25	Height
chr19	11091629	11091630	rs6511720	5.0000000000000005e-25	Lipid metabolism phenotypes
chr2	233759923	233759924	rs887829	5.0000000000000005e-25	Cholelithiasis-related traits in sickle cell anemia
chr22	37066895	37066896	rs855791	5.0000000000000005e-25	Mean corpuscular hemoglobin
chr6	139518285	139518286	rs643381	5.0000000000000005e-25	Mean corpuscular volume
chr6	25812921	25812922	rs1165196	5.0000000000000005e-25	Urate levels
chr6	36651043	36651044	rs1321313	5.0000000000000005e-25	Electrocardiographic conduction measures
chr8	9325847	9325848	rs9987289	6e-25	HDL cholesterol
chr7	28150326	28150327	rs1708299	6e-25	Height
chr7	106718769	106718770	rs342275	6e-25	Platelet counts
chr2	43846516	43846517	rs41360247	6e-25	Phytosterol levels
chr2	21041027	21041028	rs1367117	6e-25	Lipid metabolism phenotypes
chr1	113761185	113761186	rs6679677	6e-25	Rheumatoid arthritis
chr11	243267	243268	rs505404	6.9999999999999995e-25	Platelet counts
chr16	58588273	58588274	rs7188697	6.9999999999999995e-25	QT interval
chr4	1732511	1732512	rs798766	6.9999999999999995e-25	Bladder cancer
chr6	160143443	160143444	rs662138	6.9999999999999995e-25	Metabolic traits
chr6	32338201	32338202	rs3129900	6.9999999999999995e-25	Lumiracoxib-related liver injury
chr9	133266941	133266942	rs643434	9e-25	Inflammatory biomarkers
chr6	33104394	33104395	rs4282438	9e-25	Sjögren's syndrome
chr4	80243568	80243569	rs1458038	9e-25	Diastolic blood pressure
chr18	49433129	49433130	rs9967417	9e-25	Height
chr20	3204476	3204477	rs11697186	9e-25	Response to hepatitis C treatment
chr1	118961219	118961220	rs984222	9e-25	Waist-hip ratio
chr2	233759923	233759924	rs887829	9e-25	Metabolite levels
chr7	25831488	25831489	rs1055144	1.0000000000000001e-24	Waist-hip ratio
chr7	106731772	106731773	rs342293	1.0000000000000001e-24	Mean platelet volume
chr6	165632994	165632995	rs753760	1.0000000000000001e-24	Thyroid hormone levels
chr22	39463163	39463164	rs909674	1.0000000000000001e-24	IgG glycosylation
chr23	120733620	120733621	rs1972809	1.0000000000000001e-24	Antineutrophil cytoplasmic antibody-associated vasculitis 
chr17	7642402	7642403	rs1641537	1.0000000000000001e-24	Sex hormone-binding globulin levels
chr16	56971566	56971567	rs1532624	1.0000000000000001e-24	HDL cholesterol
chr15	58401820	58401821	rs16940212	1.0000000000000001e-24	HDL cholesterol
chr1	171980609	171980610	rs10914144	1.0000000000000001e-24	Mean platelet volume
chr20	44413723	44413724	rs1800961	1.0000000000000001e-24	Cholesterol, total
chr6	118359210	118359211	rs11970286	2.0000000000000002e-24	QT interval
chr8	127506308	127506309	rs4242384	2.0000000000000002e-24	Prostate cancer
chr8	11482671	11482672	rs7812879	2.0000000000000002e-24	Systemic lupus erythematosus
chr6	33574760	33574761	rs210138	2.0000000000000002e-24	Testicular germ cell tumor
chr6	32702477	32702478	rs2856718	2.0000000000000002e-24	Chronic hepatitis B infection
chr20	6645570	6645571	rs2145272	2.0000000000000002e-24	Height
chr13	50532651	50532652	rs3118906	2.0000000000000002e-24	Height
chr17	61419287	61419288	rs2079795	2.0000000000000002e-24	Height
chr16	81230991	81230992	rs6564851	2.0000000000000002e-24	Carotenoid and tocopherol levels
chr15	28090673	28090674	rs11855019	2.0000000000000002e-24	Black vs. blond hair color
chr3	141375366	141375367	rs6440003	2.0000000000000002e-24	Height
chr10	63267849	63267850	rs10761731	2.0000000000000002e-24	Platelet counts
chr9	22125503	22125504	rs1333049	2.9999999999999996e-24	Coronary artery calcification
chr8	128933907	128933908	rs987525	2.9999999999999996e-24	Orofacial clefts
chr5	1279912	1279913	rs2242652	2.9999999999999996e-24	Prostate cancer
chr4	1101492	1101493	rs3796619	2.9999999999999996e-24	Recombination rate (males)
chr2	27518369	27518370	rs780094	2.9999999999999996e-24	Fasting insulin-related traits
chr17	44148178	44148179	rs227584	2.9999999999999996e-24	Bone mineral density
chr16	72074193	72074194	rs2000999	2.9999999999999996e-24	Cholesterol, total
chr16	50729866	50729867	rs2066847	2.9999999999999996e-24	Crohn's disease
chr13	18737100	18737101	rs9552416	2.9999999999999996e-24	Fasting insulin-related traits (interaction with BMI)
chr12	111803961	111803962	rs671	2.9999999999999996e-24	Esophageal cancer
chr2	27518369	27518370	rs780094	2.9999999999999996e-24	Fasting glucose-related traits
chr2	27518369	27518370	rs780094	4.0000000000000004e-24	Fasting glucose-related traits (interaction with BMI)
chr4	158709664	158709665	rs8396	4.0000000000000004e-24	Metabolite levels
chr2	27508072	27508073	rs1260326	4.0000000000000004e-24	Lipid metabolism phenotypes
chr10	122459758	122459759	rs3793917	4.0000000000000004e-24	Age-related macular degeneration
chr1	55038976	55038977	rs2479409	4.0000000000000004e-24	Cholesterol, total
chr11	123490688	123490689	rs735665	4.0000000000000004e-24	Chronic lymphocytic leukemia
chr21	43066853	43066854	rs234709	4.0000000000000004e-24	Homocysteine levels
chr1	109823460	109823461	rs484959	5e-24	Paget's disease
chr11	116778200	116778201	rs964184	5e-24	Hypertriglyceridemia
chr1	159205563	159205564	rs12075	5e-24	White blood cell count
chr11	61802357	61802358	rs174546	5e-24	Triglycerides
chr15	58391166	58391167	rs1532085	5e-24	Metabolic syndrome
chr5	1308436	1308437	rs4635969	5e-24	Testicular germ cell tumor
chr6	32606213	32606214	rs9270984	5e-24	Systemic lupus erythematosus
chr3	56815720	56815721	rs1354034	5.999999999999999e-24	Platelet counts
chr5	77234523	77234524	rs6885099	5.999999999999999e-24	Thyroid hormone levels
chr5	177415472	177415473	rs2731672	5.999999999999999e-24	Circulating vasoactive peptide levels 
chr12	33424054	33424055	rs7980799	5.999999999999999e-24	Heart rate
chr1	207518703	207518704	rs6656401	5.999999999999999e-24	Alzheimer's disease (late onset)
chr11	116792990	116792991	rs662799	5.999999999999999e-24	Lipid traits
chr19	44919688	44919689	rs4420638	5.999999999999999e-24	Lipoprotein-associated phospholipase A2 activity and mass
chr4	9914116	9914117	rs11722228	7.000000000000001e-24	Urate levels
chr17	16960323	16960324	rs4985726	7.000000000000001e-24	Non-albumin protein levels 
chr16	260380	260381	rs13335629	7.000000000000001e-24	Red blood cell traits
chr10	103086420	103086421	rs11191548	7.000000000000001e-24	Systolic blood pressure
chr1	248333560	248333561	rs4481887	7.000000000000001e-24	Common traits (Other)
chr14	80984884	80984885	rs12101261	7.000000000000001e-24	Graves' disease
chr1	113761185	113761186	rs6679677	8.000000000000001e-24	Type 1 diabetes
chr17	16945435	16945436	rs4561508	8.000000000000001e-24	Hematology traits
chr4	99318161	99318162	rs1229984	8.000000000000001e-24	Esophageal cancer
chr1	196704862	196704863	rs1831282	9e-24	Age-related macular degeneration (extreme sampling)
chr19	11100235	11100236	rs2228671	9e-24	Cholesterol, total
chr19	15879620	15879621	rs2108622	9e-24	Metabolite levels
chr22	39463163	39463164	rs909674	9e-24	IgG glycosylation
chr8	9325847	9325848	rs9987289	9e-24	Cholesterol, total
chr8	9325847	9325848	rs9987289	9e-24	LDL cholesterol
chr9	863634	863635	rs755383	1e-23	Testicular germ cell cancer
chr9	136968180	136968181	rs57024841	1e-23	Beta-trace protein levels
chr6	7101850	7101851	rs675209	1e-23	Urate levels
chr6	26092912	26092913	rs1800562	1e-23	Hematological parameters
chr5	1308436	1308437	rs4635969	1e-23	Testicular germ cell cancer
chr6	7725526	7725527	rs3812163	1e-23	Height
chr16	56955677	56955678	rs247616	1e-23	Cardiovascular disease risk factors
chr15	74785025	74785026	rs1378942	1e-23	Diastolic blood pressure
chr12	110895817	110895818	rs10849915	1e-23	Alcohol consumption
chr1	172084146	172084147	rs17346452	1e-23	Height
chr20	63717554	63717555	rs6062504	1e-23	Inflammatory bowel disease
chr6	46716484	46716485	rs1805017	2e-23	Lipoprotein-associated phospholipase A2 activity and mass
chr6	31936026	31936027	rs9332739	2e-23	Age-related macular degeneration
chr6	31270540	31270541	rs9264638	2e-23	Beta-2 microglubulin plasma levels
chr6	147650437	147650438	rs1302019	2e-23	Myopia (pathological)
chr4	80243568	80243569	rs1458038	2e-23	Systolic blood pressure
chr4	105767746	105767747	rs10516526	2e-23	Pulmonary function
chr2	43411698	43411699	rs13429458	2e-23	Polycystic ovary syndrome
chr16	89689494	89689495	rs258322	2e-23	Black vs. red hair color
chr16	31301931	31301932	rs9888739	2e-23	Systemic lupus erythematosus
chr16	134390	134391	rs7203560	2e-23	Hematology traits
chr14	92307318	92307319	rs12896399	2e-23	Eye color
chr1	161976936	161976937	rs2340727	2e-23	Hematology traits
chr2	233763992	233763993	rs6742078	2e-23	Circulating cell-free DNA
chr3	38582761	38582762	rs3922844	3e-23	PR interval
chr6	396320	396321	rs12203592	3e-23	Tanning
chr6	160157827	160157828	rs1564348	3e-23	Cholesterol, total
chr7	50266266	50266267	rs4917014	3e-23	Systemic lupus erythematosus
chr2	43494368	43494369	rs12478601	3e-23	Polycystic ovary syndrome
chr12	110976656	110976657	rs12229654	3e-23	HDL cholesterol
chr19	54288906	54288907	rs386000	3e-23	HDL cholesterol
chr16	260380	260381	rs13335629	3e-23	Red blood cell traits
chr11	2148912	2148913	rs1004446	3e-23	Type 1 diabetes autoantibodies
chr10	112998589	112998590	rs7903146	3e-23	Type 2 diabetes
chr2	181454573	181454574	rs1449263	3e-23	White blood cell count
chr1	149934519	149934520	rs11205303	4e-23	Height
chr1	177920344	177920345	rs543874	4e-23	Body mass index
chr16	53766841	53766842	rs9940128	4e-23	Body mass index
chr19	10286726	10286727	rs3093030	4e-23	Soluble levels of adhesion molecules
chr20	59176061	59176062	rs6015450	4e-23	Systolic blood pressure
chr2	168906637	168906638	rs560887	4e-23	Fasting plasma glucose
chr6	32216567	32216568	rs404860	4e-23	Asthma
chr6	32463369	32463370	rs9268877	4e-23	Ulcerative colitis
chr7	2720160	2720161	rs798554	4e-23	Height
chr6	32713150	32713151	rs7765379	4.9999999999999997e-23	Rheumatoid arthritis
chr8	105569299	105569300	rs6993770	4.9999999999999997e-23	Vascular endothelial growth factor levels
chr22	50532836	50532837	rs140522	4.9999999999999997e-23	Red blood cell traits
chr10	63374061	63374062	rs7923609	6e-23	Liver enzyme levels (alkaline phosphatase)
chr1	118312963	118312964	rs9428104	6e-23	Height
chr1	222098424	222098425	rs873549	6e-23	Keloid
chr15	74785025	74785026	rs1378942	6e-23	Systolic blood pressure
chr16	113598	113599	rs11248850	6e-23	Red blood cell traits
chr16	15046353	15046354	rs4500751	6e-23	Phospholipid levels (plasma)
chr20	59176061	59176062	rs6015450	6e-23	Diastolic blood pressure
chr2	233790143	233790144	rs2361502	7e-23	Bilirubin levels
chr1	109275907	109275908	rs646776	8e-23	LDL cholesterol
chr15	58386312	58386313	rs10468017	8e-23	HDL cholesterol
chr7	92635095	92635096	rs2282978	8e-23	Height
chr6	29974305	29974306	rs3823355	9.000000000000001e-23	Vitiligo
chr2	21009322	21009323	rs693	9.000000000000001e-23	Cholesterol, total
chr8	19962212	19962213	rs328	9.000000000000001e-23	HDL cholesterol
chr1	177883444	177883445	rs633715	9.000000000000001e-23	Obesity
chr2	172446824	172446825	rs12621278	9.000000000000001e-23	Prostate cancer
chr6	147359222	147359223	rs9390459	9.999999999999999e-23	Coagulation factor levels
chr2	230226507	230226508	rs13397985	9.999999999999999e-23	Chronic lymphocytic leukemia
chr9	22098574	22098575	rs4977574	9.999999999999999e-23	Coronary heart disease
chr6	32051968	32051969	rs2857009	9.999999999999999e-23	Complement C3 and C4 levels
chr17	29376330	29376331	rs2138852	9.999999999999999e-23	Mean platelet volume
chr15	67744513	67744514	rs12593813	9.999999999999999e-23	Restless legs syndrome
chr14	65308976	65308977	rs11847263	9.999999999999999e-23	IgG glycosylation
chr11	72722052	72722053	rs1552224	9.999999999999999e-23	Type 2 diabetes
chr11	61803909	61803910	rs174549	9.999999999999999e-23	Heart rate
chr11	102199907	102199908	rs1894116	9.999999999999999e-23	Polycystic ovary syndrome
chr10	69223184	69223185	rs4746822	9.999999999999999e-23	Glycemic traits (pregnancy)
chr15	28120471	28120472	rs12913832	9.999999999999999e-23	Tanning
chr9	22083404	22083405	rs1333040	1.9999999999999999e-22	Intracranial aneurysm
chr22	28719077	28719078	rs4822983	1.9999999999999999e-22	Esophageal cancer (squamous cell)
chr22	18984936	18984937	rs2023634	1.9999999999999999e-22	Metabolic traits
chr23	107001536	107001537	rs12688220	1.9999999999999999e-22	Pancreatitis
chr3	122274399	122274400	rs17251221	1.9999999999999999e-22	Calcium levels
chr3	186831905	186831906	rs10937273	1.9999999999999999e-22	Adiponectin levels
chr6	20687889	20687890	rs10440833	1.9999999999999999e-22	Type 2 diabetes
chr5	156963285	156963286	rs6882076	1.9999999999999999e-22	LDL cholesterol
chr6	29952554	29952555	rs9260489	1.9999999999999999e-22	Beta-2 microglubulin plasma levels
chr6	32369852	32369853	rs2273017	1.9999999999999999e-22	Graves' disease
chr9	111153624	111153625	rs10980800	1.9999999999999999e-22	White blood cell count
chr5	1286400	1286401	rs2736100	1.9999999999999999e-22	Lung adenocarcinoma
chr2	21174309	21174310	rs506585	1.9999999999999999e-22	Lipid metabolism phenotypes
chr2	233759923	233759924	rs887829	1.9999999999999999e-22	Bilirubin levels
chr20	45925375	45925376	rs6065906	1.9999999999999999e-22	HDL cholesterol
chr21	39093607	39093608	rs2836878	1.9999999999999999e-22	Ulcerative colitis
chr1	109274967	109274968	rs12740374	1.9999999999999999e-22	Lipoprotein-associated phospholipase A2 activity and mass
chr1	109275215	109275216	rs660240	1.9999999999999999e-22	Cardiovascular disease risk factors
chr11	61802357	61802358	rs174546	1.9999999999999999e-22	HDL cholesterol
chr1	169549810	169549811	rs6025	1.9999999999999999e-22	Venous thromboembolism
chr11	7946811	7946812	rs878860	1.9999999999999999e-22	Atopic dermatitis
chr11	61802357	61802358	rs174546	1.9999999999999999e-22	Cholesterol, total
chr16	50987891	50987892	rs1566045	1.9999999999999999e-22	Bone mineral density
chr16	72074193	72074194	rs2000999	1.9999999999999999e-22	LDL cholesterol
chr16	88774053	88774054	rs10445033	1.9999999999999999e-22	Red blood cell traits
chr1	72346756	72346757	rs2815752	1.9999999999999999e-22	Body mass index
chr17	7631359	7631360	rs6258	1.9999999999999999e-22	Testosterone levels
chr12	95633982	95633983	rs17356907	1.9999999999999999e-22	Breast cancer
chr2	64993775	64993776	rs2160387	3e-22	Metabolite levels
chr9	134548681	134548682	rs1536482	3e-22	Corneal structure
chr9	130603439	130603440	rs7851693	3e-22	Bone mineral density
chr6	32768917	32768918	rs9276606	3e-22	Complement C3 and C4 levels
chr6	32762308	32762309	rs2051549	3e-22	Systemic lupus erythematosus
chr4	17950584	17950585	rs6845078	3e-22	Height
chr23	69578859	69578860	rs11796357	3e-22	Primary tooth development (time to first tooth eruption)
chr6	32633025	32633026	rs9272143	3e-22	Cervical cancer
chr21	41326979	41326980	rs441810	3e-22	Tumor biomarkers
chr18	60185714	60185715	rs11152213	3e-22	Obesity
chr23	67343175	67343176	rs2497938	3e-22	Male-pattern baldness
chr14	22533735	22533736	rs1154155	3e-22	Narcolepsy
chr12	21225086	21225087	rs4149081	3e-22	Metabolic traits
chr1	159709025	159709026	rs2794520	3e-22	Metabolic traits
chr11	27706991	27706992	rs2030323	3e-22	Obesity
chr8	19990178	19990179	rs10503669	3.9999999999999997e-22	Triglycerides
chr6	12903724	12903725	rs9349379	3.9999999999999997e-22	Coronary artery calcification
chr17	70194684	70194685	rs8079702	3.9999999999999997e-22	Primary tooth development (time to first tooth eruption)
chr11	18398258	18398259	rs2896526	3.9999999999999997e-22	Amyloid A serum levels
chr10	62685803	62685804	rs10761659	3.9999999999999997e-22	Crohn's disease
chr16	260380	260381	rs13335629	3.9999999999999997e-22	Red blood cell traits
chr6	32632221	32632222	rs9272105	5.0000000000000005e-22	Hepatocellular carcinoma
chr7	106731772	106731773	rs342293	5.0000000000000005e-22	Mean platelet volume
chr6	50830812	50830813	rs2206277	5.0000000000000005e-22	Obesity
chr6	32465389	32465390	rs2395185	5.0000000000000005e-22	Ulcerative colitis
chr1	162115894	162115895	rs10494366	5.0000000000000005e-22	Electrocardiographic traits
chr16	53808995	53808996	rs12149832	5.0000000000000005e-22	Body mass index
chr15	58434544	58434545	rs261334	5.0000000000000005e-22	HDL cholesterol
chr15	45349026	45349027	rs2453533	5.0000000000000005e-22	Chronic kidney disease
chr6	118672468	118672469	rs11756438	5.0000000000000005e-22	QT interval
chr2	21065448	21065449	rs562338	6e-22	LDL cholesterol
chr3	38616407	38616408	rs11710077	6e-22	QRS duration
chr2	24935138	24935139	rs713586	6e-22	Body mass index
chr2	231933255	231933256	rs2580816	6e-22	Height
chr20	33745374	33745375	rs7274811	6e-22	Height
chr16	90000527	90000528	rs4785763	6e-22	Melanoma
chr16	88264517	88264518	rs12447690	6e-22	Central corneal thickness
chr1	172893093	172893094	rs9286879	6e-22	Crohn's disease
chr10	112998589	112998590	rs7903146	6e-22	Type 2 diabetes
chr17	42375525	42375526	rs12942547	6e-22	Inflammatory bowel disease
chr3	170412313	170412314	rs10936632	7.000000000000001e-22	Prostate cancer
chr10	79081390	79081391	rs704010	7.000000000000001e-22	Breast cancer
chr16	56963320	56963321	rs1864163	7.000000000000001e-22	Lipid metabolism phenotypes
chr19	19296908	19296909	rs10401969	7.000000000000001e-22	LDL cholesterol
chr3	123346930	123346931	rs11708067	7.000000000000001e-22	Fasting glucose-related traits
chr6	32421870	32421871	rs3135363	7.000000000000001e-22	Hepatitis B vaccine response
chr7	73568543	73568544	rs17145738	7.000000000000001e-22	Triglycerides
chr6	38398096	38398097	rs9357271	7.999999999999999e-22	Restless legs syndrome
chr3	141386727	141386728	rs724016	7.999999999999999e-22	Height
chr21	34985563	34985564	rs2014300	7.999999999999999e-22	Esophageal cancer
chr12	112379978	112379979	rs11066280	7.999999999999999e-22	Metabolite levels
chr9	133279426	133279427	rs635634	7.999999999999999e-22	LDL cholesterol
chr19	1124031	1124032	rs2024092	7.999999999999999e-22	Crohn's disease
chr12	115398716	115398717	rs1292011	9e-22	Breast cancer
chr1	19901229	19901230	rs4654925	9e-22	Ulcerative colitis
chr10	63402392	63402393	rs7896783	9e-22	Fibrinogen
chr1	109275907	109275908	rs646776	9e-22	Cholesterol, total
chr6	32444657	32444658	rs3177928	1.0000000000000001e-21	Cholesterol, total
chr6	32183665	32183666	rs2070600	1.0000000000000001e-21	Pulmonary function (interaction)
chr4	80263186	80263187	rs16998073	1.0000000000000001e-21	Diastolic blood pressure
chr6	137685366	137685367	rs6920220	1.0000000000000001e-21	Inflammatory bowel disease
chr6	130027973	130027974	rs6569648	1.0000000000000001e-21	Height
chr5	159399783	159399784	rs6871626	1.0000000000000001e-21	Ulcerative colitis
chr3	186742137	186742138	rs710446	1.0000000000000001e-21	Activated partial thromboplastin time
chr1	159205563	159205564	rs12075	1.0000000000000001e-21	Obesity-related traits
chr2	191099906	191099907	rs7574865	1.0000000000000001e-21	Systemic lupus erythematosus
chr20	5967580	5967581	rs16991615	1.0000000000000001e-21	Menarche and menopause (age at onset)
chr16	50722969	50722970	rs2076756	1.0000000000000001e-21	Crohn's disease
chr16	28506387	28506388	rs26528	1.0000000000000001e-21	Inflammatory bowel disease
chr11	61802357	61802358	rs174546	1.0000000000000001e-21	LDL cholesterol
chr11	5285278	5285279	rs4910742	1.0000000000000001e-21	Fetal hemoglobin levels
chr2	21009322	21009323	rs693	1.0000000000000001e-21	LDL cholesterol
chr20	4699604	4699605	rs1799990	2.0000000000000002e-21	Creutzfeldt-Jakob disease
chr19	44919688	44919689	rs4420638	2.0000000000000002e-21	HDL cholesterol
chr5	132420365	132420366	rs11242111	2.0000000000000002e-21	Fibrinogen
chr19	44900154	44900155	rs1160985	2.0000000000000002e-21	LDL cholesterol
chr6	151592977	151592978	rs3757318	2.0000000000000002e-21	Breast cancer
chr6	32696680	32696681	rs2647012	2.0000000000000002e-21	Follicular lymphoma
chr6	33087083	33087084	rs9277535	2.0000000000000002e-21	Hepatitis B (viral clearance)
chr5	32830414	32830415	rs1173727	2.0000000000000002e-21	Height
chr19	44892361	44892362	rs2075650	2.0000000000000002e-21	C-reactive protein
chr12	6180052	6180053	rs1558324	2.0000000000000002e-21	Mean platelet volume
chr17	30837004	30837005	rs3764419	2.0000000000000002e-21	Height
chr13	43883788	43883789	rs3764147	2.0000000000000002e-21	Crohn's disease
chr13	42458456	42458457	rs9594759	2.0000000000000002e-21	Bone mineral density (spine)
chr12	65830680	65830681	rs2272046	2.0000000000000002e-21	Polycystic ovary syndrome
chr17	7674796	7674797	rs1625895	2.0000000000000002e-21	Sex hormone-binding globulin levels
chr1	19845366	19845367	rs6426833	2.0000000000000002e-21	Ulcerative colitis
chr1	154841876	154841877	rs13376333	2.0000000000000002e-21	Atrial fibrillation
chr1	113834945	113834946	rs2476601	2.0000000000000002e-21	Rheumatoid arthritis
chr4	188199756	188199757	rs6857559	3e-21	Myopia (pathological)
chr4	99318161	99318162	rs1229984	3e-21	Alcohol dependence
chr6	160157827	160157828	rs1564348	3e-21	LDL cholesterol
chr6	31962684	31962685	rs429608	3e-21	Age-related macular degeneration
chr9	133257485	133257486	rs8176720	3e-21	Serum alkaline phosphatase levels
chr7	15024683	15024684	rs2191349	3e-21	Fasting glucose-related traits (interaction with BMI)
chr9	114796422	114796423	rs6478108	3e-21	Leprosy
chr3	187999751	187999752	rs4686914	3e-21	Metabolite levels
chr6	32638106	32638107	rs2187668	3e-21	Systemic lupus erythematosus
chr3	152112519	152112520	rs11712066	3e-21	Infantile hypertrophic pyloric stenosis
chr23	50439185	50439186	rs1934179	3e-21	Hypospadias
chr2	240630274	240630275	rs3749171	3e-21	Inflammatory bowel disease
chr16	81501184	81501185	rs2925979	3e-21	Adiponectin levels
chr16	19922277	19922278	rs12444979	3e-21	Body mass index
chr15	98651666	98651667	rs2871865	3e-21	Height
chr15	73927240	73927241	rs3825942	3e-21	Glaucoma (exfoliation)
chr14	65308976	65308977	rs11847263	3e-21	IgG glycosylation
chr12	40363525	40363526	rs34778348	3e-21	Parkinson's disease
chr1	11778588	11778589	rs12134663	3e-21	Homocysteine levels
chr10	63373395	63373396	rs2393967	3e-21	Mean platelet volume
chr7	46713954	46713955	rs700752	4.0000000000000004e-21	Insulin-like growth factors
chr9	133257520	133257521	rs8176719	4.0000000000000004e-21	Malaria
chr4	144647199	144647200	rs7689420	4.0000000000000004e-21	Height
chr3	186748462	186748463	rs1656966	4.0000000000000004e-21	Myopia (pathological)
chr19	44919688	44919689	rs4420638	4.0000000000000004e-21	HDL cholesterol
chr18	60191595	60191596	rs8089364	4.0000000000000004e-21	Body mass index
chr17	36463348	36463349	rs4796217	4.0000000000000004e-21	Protein quantitative trait loci
chr6	126530013	126530014	rs1490384	4.0000000000000004e-21	Height
chr15	71352780	71352781	rs12899618	4.0000000000000004e-21	Pulmonary function (interaction)
chr1	230159943	230159944	rs4846914	4.0000000000000004e-21	HDL cholesterol
chr1	19514679	19514680	rs10799824	4.0000000000000004e-21	Thyroid hormone levels
chr1	159715345	159715346	rs3093059	4.0000000000000004e-21	C-reactive protein
chr1	159706380	159706381	rs16842559	4.0000000000000004e-21	C-reactive protein
chr11	116714270	116714271	rs4938303	4.0000000000000004e-21	Triglycerides
chr10	112998589	112998590	rs7903146	4.0000000000000004e-21	Type 2 diabetes
chr1	67240274	67240275	rs11209026	4.0000000000000004e-21	Crohn's disease
chr8	129673210	129673211	rs4295627	5.0000000000000005e-21	Glioma
chr6	32240546	32240547	rs424232	5.0000000000000005e-21	Celiac disease
chr4	38809929	38809930	rs2101521	5.0000000000000005e-21	Self-reported allergy
chr11	89284792	89284793	rs1126809	5.0000000000000005e-21	Tanning
chr12	120978846	120978847	rs1169288	6e-21	LDL cholesterol
chr12	21224624	21224625	rs4149080	6e-21	Methotrexate clearance (acute lymphoblastic leukemia)
chr12	40398497	40398498	rs11564258	6e-21	Crohn's disease
chr3	157080683	157080684	rs1482853	6e-21	Adiposity in newborns
chr3	33023846	33023847	rs7613051	6e-21	Atopic dermatitis
chr6	31284618	31284619	rs2524054	6e-21	CD4:CD8 lymphocyte ratio
chr16	56959411	56959412	rs3764261	6.999999999999999e-21	Lipoprotein-associated phospholipase A2 activity and mass
chr1	65640260	65640261	rs1892534	6.999999999999999e-21	C-reactive protein
chr6	166960058	166960059	rs1819333	6.999999999999999e-21	Inflammatory bowel disease
chr12	111569951	111569952	rs653178	6.999999999999999e-21	Celiac disease
chr11	126374056	126374057	rs11220462	6.999999999999999e-21	LDL cholesterol
chr12	111730204	111730205	rs11066015	6.999999999999999e-21	Esophageal cancer
chr10	99530543	99530544	rs6584283	8.000000000000001e-21	Ulcerative colitis
chr14	92297046	92297047	rs4900109	8.000000000000001e-21	Iris characteristics
chr14	92307318	92307319	rs12896399	8.000000000000001e-21	Black vs. blond hair color
chr18	62414859	62414860	rs3018362	8.000000000000001e-21	Paget's disease
chr2	48751019	48751020	rs13405728	8.000000000000001e-21	Polycystic ovary syndrome
chr6	118346358	118346359	rs11153730	8.000000000000001e-21	Heart rate
chr8	11486170	11486171	rs2254546	8.000000000000001e-21	Kawasaki disease
chr9	133458631	133458632	rs4962153	8.000000000000001e-21	Liver enzyme levels
chr6	32222628	32222629	rs443198	9.000000000000001e-21	Systemic sclerosis
chr9	133279426	133279427	rs635634	9.000000000000001e-21	Cholesterol, total
chr19	44906744	44906745	rs769449	9.000000000000001e-21	C-reactive protein
chr5	132448700	132448701	rs12521868	1.0000000000000001e-20	Crohn's disease
chr8	19967051	19967052	rs1059611	1.0000000000000001e-20	Lipid metabolism phenotypes
chr9	22124477	22124478	rs10757278	1.0000000000000001e-20	Myocardial infarction
chr8	125465735	125465736	rs2001945	1.0000000000000001e-20	Triglycerides
chr7	44189468	44189469	rs1799884	1.0000000000000001e-20	Glycated hemoglobin levels
chr6	32635229	32635230	rs2040406	1.0000000000000001e-20	Multiple sclerosis
chr6	142334663	142334664	rs7741741	1.0000000000000001e-20	Height
chr6	111592058	111592059	rs33980500	1.0000000000000001e-20	Psoriatic arthritis
chr5	75352777	75352778	rs12654264	1.0000000000000001e-20	Metabolite levels
chr5	75352777	75352778	rs12654264	1.0000000000000001e-20	LDL cholesterol
chr5	159332891	159332892	rs2546890	1.0000000000000001e-20	Psoriasis
chr5	151098756	151098757	rs17728338	1.0000000000000001e-20	Psoriasis
chr4	99318161	99318162	rs1229984	1.0000000000000001e-20	Upper aerodigestive tract cancers
chr11	18303598	18303599	rs2403254	1.0000000000000001e-20	Metabolic traits
chr20	44436387	44436388	rs6017342	1.0000000000000001e-20	Ulcerative colitis
chr20	49286481	49286482	rs237743	1.0000000000000001e-20	Height
chr1	10986797	10986798	rs9430161	1.0000000000000001e-20	Ewing sarcoma
chr1	205266861	205266862	rs1668873	1.0000000000000001e-20	Mean platelet volume
chr12	49853684	49853685	rs7138803	1.0000000000000001e-20	Obesity
chr16	20356367	20356368	rs12917707	1.0000000000000001e-20	Chronic kidney disease
chr11	61790330	61790331	rs102275	1.0000000000000001e-20	Stearic acid (18:0) plasma levels
chr16	56972677	56972678	rs7499892	1.0000000000000001e-20	Lipid metabolism phenotypes
chr1	85331426	85331427	rs28489187	1.0000000000000001e-20	Serum dimethylarginine levels (asymmetric/symetric ratio)
chr19	39252524	39252525	rs8099917	1.0000000000000001e-20	Response to hepatitis C treatment
chr19	44919688	44919689	rs4420638	1.0000000000000001e-20	LDL cholesterol
chr16	53786614	53786615	rs9939609	1.0000000000000001e-20	Type 2 diabetes
chr5	111131800	111131801	rs1438673	2.0000000000000002e-20	Self-reported allergy
chr2	43846741	43846742	rs6544713	2.0000000000000002e-20	LDL cholesterol
chr3	187005155	187005156	rs7652995	2.0000000000000002e-20	IgG glycosylation
chr3	38678443	38678444	rs9851724	2.0000000000000002e-20	QRS duration
chr4	1316112	1316113	rs6815464	2.0000000000000002e-20	Type 2 diabetes
chr4	88131170	88131171	rs2231142	2.0000000000000002e-20	Serum uric acid levels
chr5	77222616	77222617	rs4704397	2.0000000000000002e-20	Thyroid stimulating hormone
chr6	411063	411064	rs872071	2.0000000000000002e-20	Chronic lymphocytic leukemia
chr6	31131799	31131800	rs4959053	2.0000000000000002e-20	Behcet's disease
chr6	32624422	32624423	rs9271640	2.0000000000000002e-20	Multiple sclerosis (OCB status)
chr6	33075102	33075103	rs987870	2.0000000000000002e-20	Systemic sclerosis
chr22	43937813	43937814	rs2896019	2.0000000000000002e-20	Non-alcoholic fatty liver disease
chr6	41937536	41937537	rs3218097	2.0000000000000002e-20	Mean corpuscular hemoglobin
chr7	100642672	100642673	rs2075672	2.0000000000000002e-20	Red blood cell traits
chr6	29967472	29967473	rs3893464	2.0000000000000002e-20	Graves' disease
chr2	21063184	21063185	rs515135	2.0000000000000002e-20	LDL cholesterol
chr6	31946402	31946403	rs641153	2.0000000000000002e-20	Age-related macular degeneration
chr19	44919688	44919689	rs4420638	2.0000000000000002e-20	Age-related macular degeneration
chr10	112998589	112998590	rs7903146	2.0000000000000002e-20	Proinsulin levels
chr10	99524479	99524480	rs4409764	2.0000000000000002e-20	Crohn's disease
chr1	109275907	109275908	rs646776	2.0000000000000002e-20	Lipid metabolism phenotypes
chr1	159721768	159721769	rs1341665	2.0000000000000002e-20	Inflammatory biomarkers
chr1	161509954	161509955	rs1801274	2.0000000000000002e-20	Ulcerative colitis
chr11	89415203	89415204	rs7130284	2.0000000000000002e-20	Homocysteine levels
chr1	159302269	159302270	rs2251746	2.0000000000000002e-20	IgE levels 
chr12	69433877	69433878	rs10748128	2.0000000000000002e-20	Height
chr15	28285035	28285036	rs1667394	2.0000000000000002e-20	Eye color
chr16	28874337	28874338	rs7359397	2.0000000000000002e-20	Body mass index
chr16	50069822	50069823	rs4785204	2.0000000000000002e-20	Esophageal cancer (squamous cell)
chr16	53786614	53786615	rs9939609	2.0000000000000002e-20	Body mass index
chr17	7668433	7668434	rs78378222	2.0000000000000002e-20	Basal cell carcinoma 
chr12	56088395	56088396	rs2292239	2.0000000000000002e-20	Type 1 diabetes
chr2	191099906	191099907	rs7574865	2.0000000000000002e-20	Systemic lupus erythematosus
chr2	27518369	27518370	rs780094	2.9999999999999997e-20	Triglycerides
chr9	4856876	4856877	rs10758658	2.9999999999999997e-20	Mean corpuscular volume
chr8	129601367	129601368	rs10098310	2.9999999999999997e-20	White blood cell count
chr8	117173493	117173494	rs11558471	2.9999999999999997e-20	Fasting glucose-related traits (interaction with BMI)
chr6	50835336	50835337	rs987237	2.9999999999999997e-20	Body mass index
chr6	26092912	26092913	rs1800562	2.9999999999999997e-20	Glycated hemoglobin levels
chr4	144564585	144564586	rs1980057	2.9999999999999997e-20	Pulmonary function
chr3	38550914	38550915	rs1805126	2.9999999999999997e-20	Electrocardiographic conduction measures
chr2	102454107	102454108	rs917997	2.9999999999999997e-20	Inflammatory bowel disease
chr16	56971566	56971567	rs1532624	2.9999999999999997e-20	Cholesterol
chr15	58382495	58382496	rs4775041	2.9999999999999997e-20	HDL cholesterol
chr12	65964566	65964567	rs1042725	2.9999999999999997e-20	Height
chr12	53334170	53334171	rs2016266	2.9999999999999997e-20	Bone mineral density
chr12	24617943	24617944	rs17287293	2.9999999999999997e-20	Heart rate
chr1	21494496	21494497	rs10799701	2.9999999999999997e-20	Metabolic traits
chr1	151372264	151372265	rs2769264	2.9999999999999997e-20	Blood trace element (Cu levels)
chr11	14893331	14893332	rs10741657	2.9999999999999997e-20	Vitamin D insufficiency
chr19	48703727	48703728	rs602662	2.9999999999999997e-20	Folate pathway vitamin levels
chr9	5070830	5070831	rs10974944	4.0000000000000004e-20	Myeloproliferative neoplasms
chr6	32609602	32609603	rs660895	4.0000000000000004e-20	IgA nephropathy
chr6	29950321	29950322	rs2517713	4.0000000000000004e-20	Nasopharyngeal carcinoma
chr5	33951587	33951588	rs16891982	4.0000000000000004e-20	Hair color
chr5	33951587	33951588	rs16891982	4.0000000000000004e-20	Hair color
chr2	27518369	27518370	rs780094	4.0000000000000004e-20	Fasting insulin-related traits
chr2	27518369	27518370	rs780094	4.0000000000000004e-20	Fasting glucose-related traits
chr15	62090955	62090956	rs4502156	4.0000000000000004e-20	Proinsulin levels
chr19	48705752	48705753	rs503279	4.0000000000000004e-20	Metabolic traits
chr15	73373164	73373165	rs4489968	4.0000000000000004e-20	Heart rate
chr10	94306583	94306584	rs2274223	4.0000000000000004e-20	Esophageal cancer
chr10	69340131	69340132	rs10159477	4.0000000000000004e-20	Red blood cell traits
chr10	62678725	62678726	rs10995271	4.0000000000000004e-20	Crohn's disease
chr2	164694690	164694691	rs7607980	4.0000000000000004e-20	Fasting insulin-related traits (interaction with BMI)
chr6	111352510	111352511	rs240993	5e-20	Psoriasis
chr22	37185444	37185445	rs229527	5e-20	Graves' disease
chr2	226155936	226155937	rs7578326	5e-20	Type 2 diabetes
chr1	182199749	182199750	rs1689800	5e-20	HDL cholesterol
chr13	74168184	74168185	rs12429889	5e-20	Sudden cardiac arrest
chr10	6068865	6068866	rs7090512	5e-20	Multiple sclerosis
chr15	78513680	78513681	rs8034191	5e-20	Lung cancer
chr7	33216426	33216427	rs10262453	5.999999999999999e-20	Sagittal craniosynostosis
chr6	411063	411064	rs872071	5.999999999999999e-20	Chronic lymphocytic leukemia
chr4	85719995	85719996	rs7692808	5.999999999999999e-20	PR interval
chr3	123377972	123377973	rs9883204	5.999999999999999e-20	Birth weight
chr2	27518369	27518370	rs780094	5.999999999999999e-20	Metabolic syndrome
chr6	165632994	165632995	rs753760	5.999999999999999e-20	Thyroid hormone levels
chr19	50889861	50889862	rs1354774	5.999999999999999e-20	Prostate-specific antigen levels
chr15	78601996	78601997	rs1051730	5.999999999999999e-20	Nicotine dependence
chr15	28090673	28090674	rs11855019	5.999999999999999e-20	Black vs. red hair color
chr10	62638705	62638706	rs10995251	5.999999999999999e-20	Atopic dermatitis
chr2	102159741	102159742	rs13019803	5.999999999999999e-20	Serum protein levels (sST2)
chr1	177883444	177883445	rs633715	7e-20	Obesity
chr12	111569951	111569952	rs653178	7e-20	Blood pressure
chr15	60591081	60591082	rs339969	7e-20	Liver enzyme levels (gamma-glutamyl transferase)
chr5	56736056	56736057	rs889312	7e-20	Breast cancer
chr6	20657332	20657333	rs4712523	7e-20	Type 2 diabetes
chr6	105987149	105987150	rs6568421	8.000000000000001e-20	Inflammatory bowel disease
chr8	125522428	125522429	rs921720	8.000000000000001e-20	Inflammatory bowel disease
chr6	41957420	41957421	rs9349205	8.000000000000001e-20	Mean corpuscular hemoglobin
chr6	32190541	32190542	rs176095	8.000000000000001e-20	Atopic dermatitis
chr21	39093251	39093252	rs2242944	8.000000000000001e-20	Ankylosing spondylitis
chr22	24600662	24600663	rs5751902	8.000000000000001e-20	Hematological and biochemical traits
chr17	63486096	63486097	rs4329	8.000000000000001e-20	Metabolic traits
chr14	65308976	65308977	rs11847263	8.000000000000001e-20	IgG glycosylation
chr12	89666808	89666809	rs17249754	8.000000000000001e-20	Blood pressure
chr11	116791862	116791863	rs651821	8.000000000000001e-20	Lipid metabolism phenotypes
chr11	116778200	116778201	rs964184	8.000000000000001e-20	Metabolite levels
chr19	12913435	12913436	rs741702	8.000000000000001e-20	Red blood cell traits
chr15	58391166	58391167	rs1532085	9e-20	Cholesterol, total
chr2	233759923	233759924	rs887829	9e-20	Bilirubin levels
chr5	63290473	63290474	rs7445832	1e-09	Alcohol and nictotine co-dependence
chr5	62778890	62778891	rs16891077	1e-09	Homeostasis model assessment of insulin resistance (interaction)
chr5	583326	583327	rs4957048	1e-09	Ulcerative colitis
chr5	135107915	135107916	rs254560	1e-09	Ulcerative colitis
chr5	31020413	31020414	rs6888304	1e-09	Liver enzyme levels (gamma-glutamyl transferase)
chr5	76751113	76751114	rs17568628	1e-09	Platelet counts
chr4	9993557	9993558	rs3775948	1e-09	Uric acid levels
chr5	40437845	40437846	rs9292777	1e-09	Multiple sclerosis
chr5	88856299	88856300	rs700585	1e-09	Platelet counts
chr6	12927311	12927312	rs12526453	1e-09	Myocardial infarction (early onset)
chr6	118256879	118256880	rs89107	1e-09	Cardiac structure and function
chr6	12927311	12927312	rs12526453	1e-09	Coronary heart disease
chr6	139512874	139512875	rs632057	1e-09	Mean corpuscular volume
chr6	134452415	134452416	rs9321453	1e-09	Urate levels
chr6	135097879	135097880	rs9399137	1e-09	Hematology traits
chr6	137681499	137681500	rs10499194	1e-09	Rheumatoid arthritis
chr6	139512874	139512875	rs632057	1e-09	Mean corpuscular hemoglobin
chr4	9925342	9925343	rs13129697	1e-09	Biochemical measures
chr6	115991729	115991730	rs9488822	1e-09	Cholesterol, total
chr4	78667890	78667891	rs10007186	1e-09	Non-albumin protein levels 
chr2	43505683	43505684	rs7578597	1e-09	Type 2 diabetes
chr4	144653691	144653692	rs1812175	1e-09	Height
chr6	142429378	142429379	rs3817928	1e-09	Pulmonary function
chr2	27519735	27519736	rs780093 	1e-09	Palmitoleic acid (16:1n-7) plasma levels
chr2	27629050	27629051	rs3749147	1e-09	Waist Circumference - Triglycerides (WC-TG)
chr23	17680276	17680277	rs5955543	1e-09	Wilms tumor
chr2	42023408	42023409	rs7584262	1e-09	Bone mineral density
chr2	43847291	43847292	rs4245791	1e-09	LDL cholesterol
chr2	62324336	62324337	rs10865331	1e-09	Crohn's disease
chr3	110070722	110070723	rs10934011	1e-09	DNA methylation (parent-of-origin)
chr3	133756967	133756968	rs1799899	1e-09	Alcohol consumption (transferrin glycosylation)
chr3	133789619	133789620	rs1830084	1e-09	Iron status biomarkers
chr3	159947261	159947262	rs17810546	1e-09	Celiac disease
chr3	172067377	172067378	rs9647379	1e-09	Heart rate
chr3	185812501	185812502	rs6769511	1e-09	Type 2 diabetes
chr3	185911779	185911780	rs2002675	1e-09	Menarche (age at onset)
chr3	188411190	188411191	rs9860547	1e-09	Self-reported allergy
chr3	27747288	27747289	rs11129295	1e-09	Multiple sclerosis
chr3	30420910	30420911	rs7640543	1e-09	Migraine
chr3	32900359	32900360	rs7648704:rs4868644	1e-09	Venous thromboembolism (gene x gene interaction)
chr3	41744516	41744517	rs6599175	1e-09	Multiple myeloma (hyperdiploidy)
chr4	54226458	54226459	rs2114039	1e-09	Corneal curvature
chr6	151574320	151574321	rs6909279	1e-09	Bone mineral density
chr2	27518369	27518370	rs780094	1e-09	Uric acid levels
chr6	31216418	31216419	rs3869109	1e-09	Coronary heart disease
chr8	125469232	125469233	rs2980879	1e-09	Adiponectin levels
chr8	143946998	143946999	rs7464572	1e-09	Fibrinogen
chr8	19962212	19962213	rs328	1e-09	Triglycerides
chr8	56183248	56183249	rs10958476	1e-09	Height
chr8	56188231	56188232	rs13273123	1e-09	Height
chr8	94948282	94948283	rs896854	1e-09	Type 2 diabetes
chr9	101460950	101460951	rs10819937	1e-09	Liver enzyme levels (alkaline phosphatase)
chr9	104902019	104902020	rs1883025	1e-09	HDL cholesterol
chr8	125467072	125467073	rs6982636	1e-09	Lipid metabolism phenotypes
chr9	111044801	111044802	rs1468758	1e-09	Height
chr9	117530055	117530056	rs1985317:rs827637	1e-09	Venous thromboembolism (gene x gene interaction)
chr9	22103813	22103814	rs1333042	1e-09	Coronary heart disease
chr9	33128022	33128023	rs10813951	1e-09	IgG glycosylation
chr9	4792338	4792339	rs423955	1e-09	Platelet counts
chr9	70383415	70383416	rs11142387	1e-09	Body mass index
chr9	93953745	93953746	rs11789015	1e-09	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined)
chr9	94131662	94131663	rs1257763	1e-09	Height
chr9	97787745	97787746	rs1443438	1e-09	Obesity-related traits
chr9	116490349	116490350	rs6478241	1e-09	Migraine - clinic-based
chr7	98187014	98187015	rs6465657	1e-09	Prostate cancer
chr7	73568543	73568544	rs17145738	1e-09	HDL cholesterol
chr7	72664688	72664689	rs13238203	1e-09	Triglycerides
chr6	31344548	31344549	rs3134792	1e-09	Psoriasis
chr6	31472891	31472892	rs3828890	1e-09	Renal function-related traits (eGRFcrea)
chr6	32251065	32251066	rs3115573	1e-09	Nephropathy
chr6	32433301	32433302	rs3129860	1e-09	Hepatitis C induced liver cirrhosis
chr6	32696073	32696074	rs6457617	1e-09	Rheumatoid arthritis
chr6	33065244	33065245	rs3077	1e-09	Hepatitis B (viral clearance)
chr6	475488	475489	rs12210050	1e-09	Basal cell carcinoma 
chr6	7101850	7101851	rs675209	1e-09	Urate levels
chr6	94446699	94446700	rs2224003	1e-09	Brain connectivity
chr7	100747482	100747483	rs2075671	1e-09	Other erythrocyte phenotypes
chr7	128928905	128928906	rs729302	1e-09	Systemic lupus erythematosus
chr7	128954128	128954129	rs10488631	1e-09	Systemic sclerosis
chr7	151217984	151217985	rs1122979	1e-09	IgG glycosylation
chr7	21898621	21898622	rs4487645	1e-09	Multiple myeloma (hyperdiploidy)
chr7	25862018	25862019	rs12700667	1e-09	Endometriosis
chr7	38096674	38096675	rs1524058	1e-09	Bone mineral density (spine)
chr7	40426600	40426601	rs4379368	1e-09	Migraine
chr7	46580546	46580547	rs7784776	1e-09	QRS duration
chr7	50310670	50310671	rs6583437	1e-09	IgG glycosylation
chr6	160589085	160589086	rs10455872	1e-09	Response to statin therapy
chr22	39274845	39274846	rs968451	1e-09	Primary biliary cirrhosis
chr6	32107026	32107027	rs12153855	1e-09	Age-related macular degeneration
chr2	233770737	233770738	rs11563251	1e-09	Cholesterol, total
chr1	176823112	176823113	rs1325598	1e-09	Height
chr11	86157597	86157598	rs3851179	1e-09	Alzheimer's disease
chr1	196727802	196727803	rs1410996	1e-09	End-stage coagulation
chr1	205945628	205945629	rs4077468	1e-09	Cystic fibrosis-related diabetes
chr12	102518779	102518780	rs35747	1e-09	Fasting insulin-related traits (interaction with BMI)
chr12	10408357	10408358	rs2617170	1e-09	Behcet's disease
chr12	106973446	106973447	rs1053051	1e-09	Bone mineral density
chr1	221872103	221872104	rs6691170	1e-09	Colorectal cancer
chr11	76590271	76590272	rs7927894	1e-09	Crohn's disease
chr1	222650186	222650187	rs17465637	1e-09	Myocardial infarction (early onset)
chr1	230160041	230160042	rs10127775	1e-09	Metabolite levels
chr1	248874236	248874237	rs12032643	1e-09	Myopia (pathological)
chr12	56344188	56344189	rs2066808	1e-09	Psoriasis
chr12	674317	674318	rs12425791	1e-09	Stroke
chr1	26811901	26811902	rs12748152	1e-09	Triglycerides
chr22	37071351	37071352	rs5756506	1e-09	Hematological parameters
chr12	69377292	69377293	rs315122:rs884483	1e-09	Venous thromboembolism (gene x gene interaction)
chr12	71269321	71269322	rs7961581	1e-09	Type 2 diabetes
chr12	240131	240132	rs10774021	1e-09	Chronic kidney disease
chr1	169581724	169581725	rs6703865	1e-09	Hippocampal atrophy
chr11	62432344	62432345	rs17157266	1e-09	Chronic obstructive pulmonary disease-related biomarkers
chr1	162225947	162225948	rs4657175	1e-09	QT interval
chr10	102959338	102959339	rs12413409	1e-09	Coronary heart disease
chr10	102959338	102959339	rs12413409	1e-09	Intracranial aneurysm
chr10	35246766	35246767	rs12242110	1e-09	Crohn's disease
chr10	46046325	46046326	rs10993994	1e-09	PCA3 expression level
chr10	61764832	61764833	rs1530440	1e-09	Diastolic blood pressure
chr10	62518922	62518923	rs10995190	1e-09	Mammographic density
chr11	116813311	116813312	rs7396835	1e-09	Quantitative traits
chr1	112673920	112673921	rs2932538	1e-09	Diastolic blood pressure
chr1	112673920	112673921	rs2932538	1e-09	Systolic blood pressure
chr11	129591275	129591276	rs11820646	1e-09	Breast cancer
chr11	17388024	17388025	rs5219	1e-09	Type 2 diabetes
chr11	2835963	2835964	rs2237895	1e-09	Type 2 diabetes
chr11	30727542	30727543	rs963837	1e-09	Renal function-related traits (eGRFcrea)
chr11	34812656	34812657	rs12793173	1e-09	Cystic fibrosis severity
chr11	47253512	47253513	rs10838681	1e-09	Metabolic syndrome
chr1	159705142	159705143	rs876537	1e-09	C-reactive protein
chr1	15972816	15972817	rs10927875	1e-09	Dilated cardiomyopathy
chr1	160882255	160882256	rs2274910	1e-09	Crohn's disease
chr11	61026178	61026179	rs4939490	1e-09	Multiple sclerosis
chr12	84170288	84170289	rs1545843	1e-09	Major depressive disorder
chr12	89615181	89615182	rs2681472	1e-09	Diastolic blood pressure
chr1	159728758	159728759	rs7553007	1e-09	C-reactive protein
chr13	49989310	49989311	rs9596219	1e-09	Height
chr1	99058490	99058491	rs10747502	1e-09	Myopia (pathological)
chr20	32788475	32788476	rs4911259	1e-09	Inflammatory bowel disease
chr20	3400901	3400902	rs965469	1e-09	IFN-related cytopenia
chr20	59012715	59012716	rs4812048	1e-09	Mean platelet volume
chr2	102338621	102338622	rs13408661	1e-09	Asthma
chr2	112013192	112013193	rs4374383	1e-09	Hepatitis C induced liver fibrosis
chr2	135045854	135045855	rs4954218	1e-09	Corneal structure
chr21	42416076	42416077	rs11203203	1e-09	Vitiligo
chr19	11052924	11052925	rs1122608	1e-09	Coronary heart disease
chr21	44195677	44195678	rs762421	1e-09	Crohn's disease
chr2	191145761	191145762	rs7574070	1e-09	Behcet's disease
chr2	202881161	202881162	rs6725887	1e-09	Coronary heart disease
chr2	21065448	21065449	rs562338	1e-09	LDL cholesterol
chr2	217445616	217445617	rs966423	1e-09	Thyroid cancer
chr2	223072840	223072841	rs960246	1e-09	C-reactive protein and white blood cell count
chr2	227270463	227270464	rs7606754	1e-09	Corneal structure
chr2	232648464	232648465	rs2140773	1e-09	Liver enzyme levels (gamma-glutamyl transferase)
chr13	34032048	34032049	rs2321744:rs6497540	1e-09	Venous thromboembolism (gene x gene interaction)
chr2	156240263	156240264	rs17188434	1e-09	Menarche (age at onset)
chr18	69864405	69864406	rs763361	1e-09	Type 1 diabetes autoantibodies
chr21	46270153	46270154	rs2839186	1e-09	Testicular germ cell tumor
chr18	49640843	49640844	rs4939883	1e-09	Lipid metabolism phenotypes
chr14	69899206	69899207	rs11627546	1e-09	Red blood cell traits
chr18	49640843	49640844	rs4939883	1e-09	Lipid metabolism phenotypes
chr15	73685995	73685996	rs8038465	1e-09	Liver enzyme levels (gamma-glutamyl transferase)
chr15	77671544	77671545	rs9652490	1e-09	Essential tremor
chr16	23853268	23853269	rs7404095	1e-09	Inflammatory bowel disease
chr16	28871919	28871920	rs7498665	1e-09	Weight
chr16	53767041	53767042	rs1421085	1e-09	Dietary macronutrient intake
chr16	79612091	79612092	rs889472	1e-09	Renal function-related traits (urea)
chr16	83730598	83730599	rs3096277	1e-09	Blood pressure
chr16	85922064	85922065	rs1044873	1e-09	Chronic lymphocytic leukemia
chr16	52552428	52552429	rs3803662	1e-09	Breast cancer
chr17	16945435	16945436	rs4561508	1e-09	Serum total protein level
chr17	2223209	2223210	rs216172	1e-09	Coronary heart disease
chr17	37738048	37738049	rs4430796	1e-09	Prostate cancer
chr17	40614033	40614034	rs7221109	1e-09	Type 1 diabetes
chr17	4779739	4779740	rs12051548	1e-09	Sphingolipid levels
chr17	50614720	50614721	rs117964204	1e-09	Alzheimer's disease (cognitive decline)
chr16	85977730	85977731	rs10521318	1e-09	Inflammatory bowel disease
chr17	72102019	72102020	rs9913711	1e-09	Liver enzyme levels (gamma-glutamyl transferase)
chr18	48868650	48868651	rs7240004	1e-09	Inflammatory bowel disease
chr2	58606357	58606358	rs6731302	2e-09	Obesity
chr3	169774312	169774313	rs10936599	2e-09	Chronic lymphocytic leukemia
chr3	158391589	158391590	rs2362965	2e-09	Height
chr3	153466866	153466867	rs6778194	2e-09	Immune reponse to smallpox (secreted IFN-alpha)
chr3	132444355	132444356	rs17404153	2e-09	LDL cholesterol
chr2	73673772	73673773	rs10206899	2e-09	Glomerular filtration rate
chr3	114643916	114643917	rs9841504	2e-09	Gastric cancer
chr2	68343639	68343640	rs9309413	2e-09	Metabolite levels
chr2	57706919	57706920	rs13026414	2e-09	Epilepsy (generalized)
chr3	185793898	185793899	rs4402960	2e-09	Type 2 diabetes
chr3	12587420	12587421	rs2290159	2e-09	Cholesterol, total
chr3	185811291	185811292	rs1470579	2e-09	Type 2 diabetes
chr4	144721926	144721927	rs6854783	2e-09	Height
chr3	3013562	3013563	rs17024684	2e-09	Brain connectivity
chr3	3638167	3638168	rs17034687	2e-09	Disc degeneration (lumbar)
chr3	41954643	41954644	rs2272007	2e-09	Multiple myeloma (hyperdiploidy)
chr3	52550770	52550771	rs2251219	2e-09	Major mood disorders
chr3	52810517	52810518	rs17331151	2e-09	Immune reponse to smallpox (secreted IL-2)
chr3	67365897	67365898	rs17806888	2e-09	Height
chr4	144601605	144601606	rs2353398	2e-09	Height
chr4	17944808	17944809	rs2724475	2e-09	Height
chr4	76489164	76489165	rs4859682	2e-09	Glomerular filtration rate
chr2	55885304	55885305	rs1367228:rs3905075	2e-09	Venous thromboembolism (gene x gene interaction)
chr4	88954757	88954758	rs1964516	2e-09	Chronic obstructive pulmonary disease
chr3	186715309	186715310	rs11924390	2e-09	Adiponectin levels
chr2	55884173	55884174	rs3791675	2e-09	Height
chr2	168984063	168984064	rs16856332	2e-09	Liver enzyme levels (alkaline phosphatase)
chr23	51498819	51498820	rs5945619	2e-09	Prostate cancer
chr5	105618626	105618627	rs10479334	2e-09	Personality dimensions
chr2	127137038	127137039	rs744373	2e-09	Alzheimer's disease
chr21	42416076	42416077	rs11203203	2e-09	Type 1 diabetes
chr21	44227537	44227538	rs4819388	2e-09	Celiac disease
chr2	152100896	152100897	rs3820706	2e-09	Adverse response to chemotherapy in breast cancer (alopecia)
chr2	167302840	167302841	rs10497324	2e-09	DNA methylation (parent-of-origin)
chr2	202667580	202667581	rs11694172	2e-09	Cholesterol, total
chr2	21008651	21008652	rs676210	2e-09	Lipid metabolism phenotypes
chr22	23953098	23953099	rs2739330	2e-09	Liver enzyme levels (gamma-glutamyl transferase)
chr22	24186072	24186073	rs8141797	2e-09	Amyotrophic lateral sclerosis
chr2	226235981	226235982	rs2972146	2e-09	HDL cholesterol
chr2	46310464	46310465	rs7579899	2e-09	Renal cell carcinoma
chr2	228646212	228646213	rs1435867	2e-09	Pulmonary function (interaction)
chr22	30133641	30133642	rs2412973	2e-09	Inflammatory bowel disease (early onset)
chr22	37066895	37066896	rs855791	2e-09	Mean corpuscular volume
chr22	38148290	38148291	rs2284063	2e-09	Melanoma
chr22	39123190	39123191	rs139371	2e-09	Multiple myeloma (hyperdiploidy)
chr2	240624321	240624322	rs4676410	2e-09	Sclerosing cholangitis and ulcerative colitis (combined)
chr2	241357033	241357034	rs1476698	2e-09	Fibrinogen
chr2	24190428	24190429	rs2288073:rs10771022	2e-09	Venous thromboembolism (gene x gene interaction)
chr2	27520286	27520287	rs780092	2e-09	Lipid traits
chr2	27578891	27578892	rs1919128	2e-09	Waist Circumference - Triglycerides (WC-TG)
chr23	153597179	153597180	rs12010175	2e-09	Type 2 diabetes
chr2	33136357	33136358	rs6714546	2e-09	Height
chr22	30098381	30098382	rs2412971	2e-09	Nephropathy
chr5	123519721	123519722	rs4530754	2e-09	Cholesterol, total
chr8	19968861	19968862	rs2197089	2e-09	Metabolic syndrome (bivariate traits)
chr5	126582455	126582456	rs13182402	2e-09	Osteoporosis
chr7	151217984	151217985	rs1122979	2e-09	IgG glycosylation
chr7	1881189	1881190	rs10275045	2e-09	Schizophrenia or bipolar disorder
chr7	1964785	1964786	rs12666575	2e-09	Schizophrenia
chr7	27298247	27298248	rs17428471	2e-09	Blood pressure
chr7	38088723	38088724	rs6959212	2e-09	Height
chr7	50310670	50310671	rs6583437	2e-09	IgG glycosylation
chr7	69146972	69146973	rs6945541	2e-09	Male-pattern baldness
chr7	77787121	77787122	rs6465825	2e-09	Chronic kidney disease
chr8	120598197	120598198	rs6469937	2e-09	Myopia (severe)
chr8	129611858	129611859	rs1991866	2e-09	Inflammatory bowel disease
chr8	18415370	18415371	rs1495741	2e-09	Cholesterol, total
chr7	132345251	132345252	rs1364505:rs1204660	2e-09	Venous thromboembolism (gene x gene interaction)
chr8	19958726	19958727	rs295	2e-09	Metabolic syndrome
chr8	24258790	24258791	rs1013209	2e-09	Height
chr8	32574850	32574851	rs2439302	2e-09	Thyroid cancer
chr8	54524963	54524964	rs9298506	2e-09	Intracranial aneurysm
chr8	6465756	6465757	rs2916733	2e-09	Epirubicin-induced leukopenia 
chr8	75703427	75703428	rs4735692	2e-09	Obesity
chr8	9326085	9326086	rs4841132	2e-09	Metabolite levels
chr9	106204806	106204807	rs2090409	2e-09	Menarche (age at onset)
chr9	22169700	22169701	rs1537377	2e-09	Endometriosis
chr9	2640758	2640759	rs3780181	2e-09	LDL cholesterol
chr9	33153528	33153529	rs10813957	2e-09	IgG glycosylation
chr9	6172379	6172380	rs7032572	2e-09	Self-reported allergy
chr2	111742457	111742458	rs17040773	2e-09	Bone mineral density
chr6	5071257	5071258	rs9392653:rs7780976	2e-09	Venous thromboembolism (gene x gene interaction)
chr6	44978768	44978769	rs9472414	2e-09	Height
chr6	33236496	33236497	rs9277952	2e-09	Cervical cancer
chr5	142099499	142099500	rs11167764	2e-09	Crohn's disease
chr5	151078584	151078585	rs10036748	2e-09	Systemic lupus erythematosus
chr5	173935454	173935455	rs6861681	2e-09	Waist-hip ratio
chr5	180304013	180304014	rs6879260	2e-09	Height
chr5	56027066	56027067	rs17348299	2e-09	IgG glycosylation
chr5	5792393	5792394	rs32566	2e-09	Morbidity-free survival
chr5	62689025	62689026	rs1423386:rs6491679	2e-09	Venous thromboembolism (gene x gene interaction)
chr5	6324179	6324180	rs12518614	2e-09	End-stage coagulation
chr5	73776528	73776529	rs7714670:rs12880735	2e-09	Venous thromboembolism (gene x gene interaction)
chr5	79045473	79045474	rs17823642	2e-09	Metabolite levels
chr5	88804133	88804134	rs4521516	2e-09	Mean platelet volume
chr6	121837123	121837124	rs12110693	2e-09	Biomedical quantitative traits
chr6	12903724	12903725	rs9349379	2e-09	Coronary heart disease
chr6	135097496	135097497	rs7775698	2e-09	Mean corpuscular volume
chr6	135105434	135105435	rs4895441	2e-09	White blood cell count
chr6	137685366	137685367	rs6920220	2e-09	Rheumatoid arthritis
chr6	137811378	137811379	rs10499197	2e-09	Systemic lupus erythematosus and Systemic sclerosis
chr6	158508409	158508410	rs9456307	2e-09	Height
chr6	160160341	160160342	rs651164	2e-09	Prostate cancer
chr6	26092912	26092913	rs1800562	2e-09	Hematocrit
chr6	27742385	27742386	rs17693963	2e-09	Schizophrenia, schizoaffective disorder or bipolar disorder
chr6	31440050	31440051	rs9469003	2e-09	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)
chr6	31946402	31946403	rs641153	2e-09	Age-related macular degeneration (GA)
chr6	32690301	32690302	rs7775228	2e-09	IgE grass sensitization
chr6	32774090	32774091	rs2621416	2e-09	Lymphoma
chr5	124996409	124996410	rs4836133	2e-09	Body mass index
chr20	63686866	63686867	rs4809324	2e-09	Glioma (high-grade)
chr19	51224705	51224706	rs3865444	2e-09	Alzheimer's disease (late onset)
chr20	53830763	53830764	rs6022786	2e-09	Polycystic ovary syndrome
chr1	168649402	168649403	rs1412337	2e-09	Morbidity-free survival
chr11	69227199	69227200	rs10896449	2e-09	Prostate cancer
chr1	172893093	172893094	rs9286879	2e-09	Crohn's disease
chr11	75565132	75565133	rs606452	2e-09	Height
chr1	18098516	18098517	rs9804128:rs4784379	2e-09	Venous thromboembolism (gene x gene interaction)
chr11	90142268	90142269	rs11018874	2e-09	White blood cell types
chr11	92940661	92940662	rs1387153	2e-09	Metabolic syndrome (bivariate traits)
chr11	92958365	92958366	rs2166706	2e-09	Fasting plasma glucose
chr11	93051036	93051037	rs7931462	2e-09	DNA methylation (parent-of-origin)
chr1	200912466	200912467	rs7522462	2e-09	Multiple sclerosis
chr1	206766558	206766559	rs3024505	2e-09	Type 1 diabetes
chr11	66127694	66127695	rs564343	2e-09	Obesity (early onset extreme)
chr1	207698944	207698945	rs7527798	2e-09	Erythrocyte sedimentation rate
chr12	102481790	102481791	rs35767	2e-09	Fasting insulin-related traits
chr12	106755643	106755644	rs2067615	2e-09	Heart rate
chr12	111634619	111634620	rs11065987	2e-09	LDL cholesterol
chr12	112207596	112207597	rs2074356	2e-09	Renal function-related traits (BUN)
chr1	212064455	212064456	rs10863936	2e-09	Height
chr12	14434366	14434367	rs3213764	2e-09	Prostate-specific antigen levels
chr12	21178614	21178615	rs4149056	2e-09	Response to statin therapy
chr1	221991605	221991606	rs6687758	2e-09	Colorectal cancer
chr12	24031609	24031610	rs10842262	2e-09	Non-obstructive azoospermia
chr1	240433913	240433914	rs9287237	2e-09	Bone mineral density
chr12	49853684	49853685	rs7138803	2e-09	Body mass index
chr12	102481790	102481791	rs35767	2e-09	Fasting glucose-related traits
chr11	64589599	64589600	rs505802	2e-09	Uric acid levels
chr11	61944002	61944003	rs2521572	2e-09	Phospholipid levels (plasma)
chr11	61804005	61804006	rs174550	2e-09	Fasting glucose-related traits (interaction with BMI)
chr10	103016150	103016151	rs7914558	2e-09	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr10	103146453	103146454	rs11191580	2e-09	Schizophrenia
chr10	112174127	112174128	rs2255141	2e-09	LDL cholesterol
chr10	114021767	114021768	rs2782980	2e-09	Blood pressure
chr10	18153552	18153553	rs10740993	2e-09	Primary tooth development (number of teeth)
chr10	22550698	22550699	rs10828317	2e-09	Acute lymphoblastic leukemia (B-cell precursor)
chr10	34998721	34998722	rs17582416	2e-09	Crohn's disease
chr10	48491913	48491914	rs4838605	2e-09	Diabetic retinopathy 
chr10	79171723	79171724	rs780151	2e-09	Height
chr10	92705801	92705802	rs5015480	2e-09	Type 2 diabetes
chr10	94298540	94298541	rs3765524	2e-09	Esophageal cancer and gastric cancer
chr11	103789838	103789839	rs974819	2e-09	Coronary heart disease
chr11	116782579	116782580	rs2075290	2e-09	Metabolic syndrome
chr11	116789969	116789970	rs2266788	2e-09	Metabolic syndrome
chr11	118827827	118827828	rs638893	2e-09	Vitiligo
chr11	121564877	121564878	rs11218343	2e-09	Alzheimer's disease (late onset)
chr11	124736388	124736389	rs12807809	2e-09	Schizophrenia
chr20	63678485	63678486	rs6010620	2e-09	Glioma
chr11	130947683	130947684	rs7940866	2e-09	Schizophrenia
chr11	16880720	16880721	rs381815	2e-09	Systolic blood pressure
chr11	31189223	31189224	rs16921914	2e-09	Bone mineral density (spine)
chr11	35259304	35259305	rs10768122	2e-09	Vitiligo
chr11	47419961	47419962	rs10838708	2e-09	Height
chr11	5285278	5285279	rs4910742	2e-09	Inflammatory biomarkers
chr11	61803310	61803311	rs174547	2e-09	Resting heart rate
chr12	51857487	51857488	rs7976059	2e-09	Urate levels
chr1	25243589	25243590	rs1043879	2e-09	Erythrocyte sedimentation rate
chr11	126413889	126413890	rs2236653	2e-09	Liver enzyme levels (alkaline phosphatase)
chr12	57739472	57739473	rs12368653	2e-09	Multiple sclerosis
chr1	65636573	65636574	rs1805096	2e-09	C-reactive protein
chr16	79701089	79701090	rs7188445	2e-09	Urate levels
chr17	19900933	19900934	rs397969	2e-09	Platelet counts
chr17	30920696	30920697	rs3760318	2e-09	Height
chr17	39820215	39820216	rs9303277	2e-09	Primary biliary cirrhosis
chr17	39884509	39884510	rs2872507	2e-09	Crohn's disease
chr17	49267823	49267824	rs11650494	2e-09	Prostate cancer
chr17	58631696	58631697	rs412000	2e-09	Primary tooth development (time to first tooth eruption)
chr17	61161859	61161860	rs11868441	2e-09	Renal function-related traits (BUN)
chr17	72645558	72645559	rs7210086	2e-09	Ulcerative colitis
chr18	60217516	60217517	rs12970134	2e-09	Waist circumference and related phenotypes
chr1	65513596	65513597	rs11208659	2e-09	Obesity (early onset extreme)
chr18	79013972	79013973	rs7241993	2e-09	Prostate cancer
chr19	11052924	11052925	rs1122608	2e-09	Myocardial infarction (early onset)
chr19	11232026	11232027	rs12979813	2e-09	HDL cholesterol
chr19	17278894	17278895	rs8170	2e-09	Breast cancer
chr19	44908821	44908822	rs7412	2e-09	LDL cholesterol
chr19	44911193	44911194	rs439401	2e-09	Triglycerides
chr19	46620525	46620526	rs1126510	2e-09	Ulcerative colitis
chr19	6690759	6690760	rs3745567	2e-09	Complement C3 and C4 levels
chr20	16074336	16074337	rs16997087	2e-09	Brain connectivity
chr20	1778943	1778944	rs6080550	2e-09	Non-obstructive azoospermia
chr20	44413723	44413724	rs1800961	2e-09	C-reactive protein
chr12	54293447	54293448	rs10506328	2e-09	Mean platelet volume
chr19	1050420	1050421	rs115550680	2e-09	Alzheimer's disease (late onset)
chr16	53766841	53766842	rs9940128	2e-09	Metabolic syndrome
chr19	19250925	19250926	rs1064395	2e-09	Bipolar disorder
chr16	28826193	28826194	rs8049439	2e-09	Inflammatory bowel disease (early onset)
chr12	6330842	6330843	rs1800693	2e-09	Primary biliary cirrhosis
chr12	65368277	65368278	rs12229918	2e-09	Primary tooth development (number of teeth)
chr12	66000883	66000884	rs4026608	2e-09	Aortic root size
chr12	8929984	8929985	rs4883201	2e-09	Cholesterol, total
chr13	23631055	23631056	rs9510787	2e-09	Nasopharyngeal carcinoma
chr13	43196337	43196338	rs9533425	2e-09	End-stage coagulation
chr13	53490845	53490846	rs9568856	2e-09	Obesity
chr13	53533216	53533217	rs9568867	2e-09	Obesity
chr1	63661796	63661797	rs2749097	2e-09	Alcohol consumption (transferrin glycosylation)
chr14	36180039	36180040	rs944289	2e-09	Thyroid cancer
chr1	45513002	45513003	rs4660306	2e-09	Homocysteine levels
chr14	93129245	93129246	rs11624776	2e-09	Thyroid hormone levels
chr13	72985843	72985844	rs8002688	2e-09	Blood pressure measurement (low sodium intervention)
chr15	101241728	101241729	rs752092	2e-09	Corneal structure
chr1	62652524	62652525	rs10889353	2e-09	Triglycerides
chr16	134390	134391	rs7203560	2e-09	Sickle cell anemia (haemolysis)
chr15	93598603	93598604	rs12437854	2e-09	Type 1 diabetes nephropathy
chr14	94397298	94397299	rs7151526	2e-09	Antineutrophil cytoplasmic antibody-associated vasculitis 
chr15	80139879	80139880	rs11634397	2e-09	Type 2 diabetes
chr15	88854873	88854874	rs2351491	2e-09	Height
chr15	67788547	67788548	rs4776970	2e-09	Body mass index
chr15	51238297	51238298	rs16964211	2e-09	Height
chr15	51223857	51223858	rs2899472	2e-09	AB1-42
chr15	43953732	43953733	rs2929282	2e-09	Triglycerides
chr15	79159526	79159527	rs939658	2e-09	Refractive error
chr3	86801467	86801468	rs7628864	3e-09	Pubertal anthropometrics
chr3	41871158	41871159	rs9815354	3e-09	Diastolic blood pressure
chr3	87446399	87446400	rs9834692	3e-09	Brain connectivity
chr3	87476298	87476299	rs9883474	3e-09	Brain connectivity
chr4	113762687	113762688	rs6858698	3e-09	Chronic lymphocytic leukemia
chr4	15395739	15395740	rs16891867	3e-09	Conduct disorder (symptom count)
chr4	15736313	15736314	rs4538475	3e-09	Parkinson's disease
chr4	9933119	9933120	rs737267	3e-09	Urate levels
chr4	72779633	72779634	rs12507628	3e-09	Metabolite levels
chr4	85762406	85762407	rs11732231	3e-09	PR interval
chr4	864543	864544	rs11248051	3e-09	Parkinson's disease
chr4	87292655	87292656	rs6834314	3e-09	Liver enzyme levels (alanine transaminase)
chr4	970570	970571	rs11248060	3e-09	Parkinson's disease
chr3	32973976	32973977	rs13314993	3e-09	Celiac disease
chr5	111069976	111069977	rs3806932	3e-09	Eosinophilic esophagitis (pediatric)
chr4	165951383	165951384	rs6812849	3e-09	Post-traumatic stress disorder
chr3	186106214	186106215	rs1516725	3e-09	Obesity
chr2	229359314	229359315	rs7594321	3e-09	Pulmonary function (interaction)
chr3	119501086	119501087	rs2293370	3e-09	Primary biliary cirrhosis
chr5	1315544	1315545	rs4975616	3e-09	Lung cancer
chr2	166122239	166122240	rs7587026	3e-09	Mesial temporal lobe epilepsy with hippocampal sclerosis
chr2	191038031	191038032	rs3821236	3e-09	Systemic sclerosis
chr2	201246656	201246657	rs3769825	3e-09	Chronic lymphocytic leukemia
chr2	205453868	205453869	rs11884476	3e-09	AIDS progression
chr2	22074130	22074131	rs7600502	3e-09	C-reactive protein and white blood cell count
chr22	29225487	29225488	rs132390	3e-09	Breast cancer
chr3	185793898	185793899	rs4402960	3e-09	Type 2 diabetes
chr2	232290399	232290400	rs6717918	3e-09	Height
chr22	39463163	39463164	rs909674	3e-09	IgG glycosylation
chr22	39463163	39463164	rs909674	3e-09	IgG glycosylation
chr2	27508072	27508073	rs1260326	3e-09	Non-albumin protein levels 
chr2	45419684	45419685	rs3213787	3e-09	Glaucoma
chr2	61649829	61649830	rs2421332	3e-09	Homeostasis model assessment of beta-cell function (interaction)
chr2	75192587	75192588	rs3771863	3e-09	Brain connectivity
chr3	119501086	119501087	rs2293370	3e-09	Multiple sclerosis
chr2	237478584	237478585	rs7584330	3e-09	Prostate cancer
chr5	135107915	135107916	rs254560	3e-09	Ulcerative colitis
chr8	33808161	33808162	rs10503951	3e-09	Immune response to smallpox vaccine (IL-6)
chr5	40410832	40410833	rs6451493	3e-09	Ulcerative colitis
chr8	128252342	128252343	rs9792269	3e-09	Celiac disease
chr8	128531702	128531703	rs10088218	3e-09	Ovarian cancer
chr8	13121890	13121891	rs12541254:rs305009	3e-09	Venous thromboembolism (gene x gene interaction)
chr8	32558755	32558756	rs7825175	3e-09	Thyroid hormone levels
chr8	51974980	51974981	rs1015213	3e-09	Glaucoma (primary open-angle)
chr8	56296686	56296687	rs4075154	3e-09	Height
chr8	77181600	77181601	rs7821178	3e-09	Menarche (age at onset)
chr8	80549738	80549739	rs440837	3e-09	Sex hormone-binding globulin levels
chr8	81239511	81239512	rs12216812	3e-09	Myopia (pathological)
chr9	106174392	106174393	rs7861820	3e-09	Menarche and menopause (age at onset)
chr9	15305379	15305380	rs581080	3e-09	Cholesterol, total
chr9	33153528	33153529	rs10813957	3e-09	IgG glycosylation
chr9	3929423	3929424	rs514716	3e-09	Alzheimer's disease biomarkers
chr9	4981601	4981602	rs10758669	3e-09	Crohn's disease
chr21	41374153	41374154	rs45430	3e-09	Melanoma
chr8	125492483	125492484	rs6987702	3e-09	Cholesterol, total
chr7	80606697	80606698	rs13236689	3e-09	Mean platelet volume
chr7	73612047	73612048	rs17145750	3e-09	Liver enzyme levels (gamma-glutamyl transferase)
chr7	44189468	44189469	rs1799884	3e-09	Glycemic traits
chr6	115991729	115991730	rs9488822	3e-09	LDL cholesterol
chr6	135090089	135090090	rs9376090	3e-09	Cholesterol, total
chr6	135093865	135093866	rs7745098	3e-09	Hodgkin's lymphoma
chr6	135111413	135111414	rs9494145	3e-09	Mean platelet volume
chr6	16127175	16127176	rs3757354	3e-09	Cholesterol, total
chr6	26090950	26090951	rs1799945	3e-09	Iron levels
chr6	26092912	26092913	rs1800562	3e-09	Red blood cell traits
chr5	153274918	153274919	rs17504622	3e-09	Schizophrenia
chr6	26092912	26092913	rs1800562	3e-09	Red blood cell traits
chr6	31472891	31472892	rs3828890	3e-09	Renal function-related traits (sCR)
chr6	32142201	32142202	rs204999	3e-09	Serum total protein level
chr6	54059898	54059899	rs9296736	3e-09	Liver enzyme levels (gamma-glutamyl transferase)
chr6	80136271	80136272	rs2322633	3e-09	Height
chr7	153227807	153227808	rs2710201:rs3780293	3e-09	Venous thromboembolism (gene x gene interaction)
chr7	28156602	28156603	rs849134	3e-09	Type 2 diabetes
chr7	2830350	2830351	rs1182188	3e-09	Height
chr6	27742385	27742386	rs17693963	3e-09	Schizophrenia or bipolar disorder
chr2	102369761	102369762	rs3771166	3e-09	Asthma
chr2	227051207	227051208	rs2272205	3e-09	Immune reponse to smallpox (secreted IFN-alpha)
chr20	46119307	46119308	rs4810485	3e-09	Rheumatoid arthritis
chr11	61855667	61855668	rs174601	3e-09	Liver enzyme levels (alkaline phosphatase)
chr1	167451187	167451188	rs2056626	3e-09	Systemic sclerosis
chr1	169582443	169582444	rs6028	3e-09	Activated partial thromboplastin time
chr1	177886381	177886382	rs516636	3e-09	Body mass index
chr11	8583045	8583046	rs4929949	3e-09	Body mass index
chr11	86076781	86076782	rs536841	3e-09	Alzheimer's disease
chr11	89277877	89277878	rs1393350	3e-09	Eye color
chr1	207851474	207851475	rs12731740	3e-09	Biomedical quantitative traits
chr1	211744901	211744902	rs11119805 	3e-09	Stearic acid (18:0) plasma levels
chr12	120986152	120986153	rs2393791	3e-09	C-reactive protein and white blood cell count
chr1	219483820	219483821	rs11118316	3e-09	Visceral adipose tissue/subcutaneous adipose tissue ratio
chr1	22123993	22123994	rs2235529	3e-09	Endometriosis
chr1	22371953	22371954	rs7524102	3e-09	Dupuytren's disease
chr12	2414188	2414189	rs7312105	3e-09	Red blood cell traits
chr1	239882607	239882608	rs536477:rs1937920	3e-09	Venous thromboembolism (gene x gene interaction)
chr11	61798435	61798436	rs174541	3e-09	Metabolite levels
chr11	61723013	61723014	rs198426	3e-09	Phospholipid levels (plasma)
chr1	161502367	161502368	rs10800309	3e-09	Ulcerative colitis
chr1	158615624	158615625	rs2779116	3e-09	Glycated hemoglobin levels
chr20	63678485	63678486	rs6010620	3e-09	Glioma (high-grade)
chr10	12876763	12876764	rs7909670	3e-09	Height
chr10	17114151	17114152	rs1801222	3e-09	Folate pathway vitamin levels
chr10	37219521	37219522	rs1148259	3e-09	Metabolite levels
chr10	60462348	60462349	rs10994359	3e-09	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr10	6056860	6056861	rs706779	3e-09	Vitiligo
chr10	6060048	6060049	rs12722489	3e-09	Crohn's disease
chr12	56286960	56286961	rs3816804	3e-09	Height
chr10	62427804	62427805	rs7089814	3e-09	Breast size
chr11	108412433	108412434	rs11212617	3e-09	Response to metformin in type 2 diabetes (glycemic)
chr11	116755541	116755542	rs11825181	3e-09	Triglycerides-Blood Pressure (TG-BP)
chr11	116778418	116778419	rs11823543	3e-09	Triglycerides-Blood Pressure (TG-BP)
chr11	1887775	1887776	rs3817198	3e-09	Breast cancer
chr11	30727542	30727543	rs963837	3e-09	Renal function-related traits (sCR)
chr1	145709376	145709377	rs12129861	3e-09	Uric acid levels
chr1	156285664	156285665	rs6684514	3e-09	mean corpuscular hemoglobin concentration
chr11	108412433	108412434	rs11212617	3e-09	Response to metformin
chr1	2581776	2581777	rs734999	3e-09	Ulcerative colitis
chr11	108304734	108304735	rs1801516	3e-09	Melanoma
chr13	33119699	33119700	rs9315204	3e-09	Intracranial aneurysm
chr17	59772889	59772890	rs11650106	3e-09	Lipoprotein-associated phospholipase A2 activity and mass
chr1	78157941	78157942	rs17391694	3e-09	Crohn's disease
chr18	45220182	45220183	rs10502861	3e-09	Male-pattern baldness
chr18	58716959	58716960	rs7238078	3e-09	Multiple sclerosis
chr19	11236816	11236817	rs737337	3e-09	HDL cholesterol
chr19	11239811	11239812	rs2278426	3e-09	HDL cholesterol
chr19	16074748	16074749	rs8109288	3e-09	Mean platelet volume
chr19	19362635	19362636	rs2905424	3e-09	Schizophrenia
chr19	19547662	19547663	rs16996148	3e-09	LDL cholesterol
chr19	19547662	19547663	rs16996148	3e-09	Triglycerides
chr19	33408158	33408159	rs731839	3e-09	Triglycerides
chr19	33818626	33818627	rs29941	3e-09	Body mass index
chr19	40796800	40796801	rs7937	3e-09	Chronic obstructive pulmonary disease
chr20	4121152	4121153	rs1741344	3e-09	Height
chr1	2595306	2595307	rs3748816	3e-09	Celiac disease
chr17	58555181	58555182	rs9905704	3e-09	Testicular germ cell tumor
chr17	40010625	40010626	rs8078723	3e-09	C-reactive protein and white blood cell count
chr19	33408158	33408159	rs731839	3e-09	HDL cholesterol
chr17	2312963	2312964	rs391300	3e-09	Type 2 diabetes
chr17	2359408	2359409	rs4790333	3e-09	Proinsulin levels
chr13	92336069	92336070	rs7982677	3e-09	Tetralogy of Fallot
chr1	41223265	41223266	rs11209718	3e-09	Height
chr14	78319733	78319734	rs11624704	3e-09	Obesity
chr13	73154001	73154002	rs9600079	3e-09	Prostate cancer
chr15	65759006	65759007	rs6494537	3e-09	Mean corpuscular hemoglobin
chr15	65778354	65778355	rs2572207	3e-09	Red blood cell traits
chr15	71404546	71404547	rs12441227	3e-09	Pulmonary function
chr14	79437032	79437033	rs2370983	3e-09	Obesity
chr16	175653	175654	rs2858942	3e-09	Mean corpuscular hemoglobin
chr16	56961323	56961324	rs1800775	3e-09	Lipid traits
chr16	80463703	80463704	rs4581712	3e-09	Liver enzyme levels (gamma-glutamyl transferase)
chr16	85910832	85910833	rs391525	3e-09	Chronic lymphocytic leukemia
chr16	85980634	85980635	rs16940202	3e-09	Ulcerative colitis
chr16	89919708	89919709	rs1805007	3e-09	Hair color
chr15	78523714	78523715	rs8031948	3e-09	Airflow obstruction 
chr16	90018152	90018153	rs11648785	3e-09	Tanning
chr5	171724226	171724227	rs10516089:rs11072930	4e-09	Venous thromboembolism (gene x gene interaction)
chr3	136255373	136255374	rs9844666	4e-09	Height
chr3	185811291	185811292	rs1470579	4e-09	Type 2 diabetes
chr3	186116500	186116501	rs7647305	4e-09	Weight
chr3	189638471	189638472	rs4488809	4e-09	Lung cancer
chr3	27496417	27496418	rs13082711	4e-09	Diastolic blood pressure
chr3	56815720	56815721	rs1354034	4e-09	Platelet counts
chr3	47019692	47019693	rs2290547	4e-09	HDL cholesterol
chr3	49684098	49684099	rs3197999	4e-09	Ulcerative colitis
chr5	1286400	1286401	rs2736100	4e-09	Glioma
chr5	148466251	148466252	rs3995090	4e-09	Pulmonary function
chr5	148476769	148476770	rs7733088	4e-09	Airflow obstruction 
chr3	38725183	38725184	rs6795970	4e-09	Electrocardiographic traits
chr3	12587420	12587421	rs2290159	4e-09	Cholesterol, total
chr2	27508072	27508073	rs1260326	4e-09	Hematological and biochemical traits
chr3	122329796	122329797	rs17265703	4e-09	Phosphorus levels
chr2	60854406	60854407	rs702873	4e-09	Psoriasis
chr2	5523875	5523876	rs11894081	4e-09	Crohn's disease
chr2	48751019	48751020	rs13405728	4e-09	Polycystic ovary syndrome
chr2	46128708	46128709	rs13008603	4e-09	Red blood cell traits
chr2	44253810	44253811	rs4953076	4e-09	Height
chr2	25078885	25078886	rs478222	4e-09	Type 1 diabetes
chr22	37066895	37066896	rs855791	4e-09	Hepcidin levels
chr22	23828808	23828809	rs2186369	4e-09	IgG glycosylation
chr22	23828808	23828809	rs2186369	4e-09	IgG glycosylation
chr5	32814921	32814922	rs1173771	4e-09	Blood pressure
chr2	198032170	198032171	rs6738825	4e-09	Crohn's disease
chr21	44289269	44289270	rs2075876	4e-09	Rheumatoid arthritis
chr3	123121028	123121029	rs3792366	4e-09	Platelet counts
chr5	75719416	75719417	rs2112347	4e-09	Obesity
chr7	129365005	129365006	rs11766298	4e-09	Response to fenofibrate
chr6	11040189	11040190	rs3798722	4e-09	Metabolite levels
chr2	102355404	102355405	rs13015714	4e-09	Celiac disease
chr9	97786730	97786731	rs7850258	4e-09	Hypothyroidism
chr9	121189638	121189639	rs9408928	4e-09	Immune reponse to smallpox (secreted IFN-alpha)
chr9	117525429	117525430	rs2771051:rs827637	4e-09	Venous thromboembolism (gene x gene interaction)
chr8	58476005	58476006	rs2081687	4e-09	LDL cholesterol
chr8	51844532	51844533	rs10504130:rs2847351	4e-09	Venous thromboembolism (gene x gene interaction)
chr8	119423571	119423572	rs2071518	4e-09	Blood pressure
chr7	73556900	73556901	rs13233571	4e-09	C-reactive protein
chr7	65861833	65861834	rs11763147	4e-09	Corneal structure
chr7	28140936	28140937	rs864745	4e-09	Crohn's disease
chr7	25862018	25862019	rs12700667	4e-09	Endometriosis
chr7	151708918	151708919	rs10480300	4e-09	Urate levels
chr7	150815083	150815084	rs10231759	4e-09	Height
chr6	104931078	104931079	rs7759938	4e-09	Pubertal anthropometrics
chr7	128775140	128775141	rs1799922	4e-09	Primary tooth development (number of teeth)
chr7	108141754	108141755	rs382140	4e-09	Coffee consumption
chr7	102878583	102878584	rs17135875	4e-09	Blood pressure measurement (cold pressor test)
chr6	78846448	78846449	rs16890334	4e-09	Blood pressure measurement (high sodium intervention)
chr6	72933565	72933566	rs7744813	4e-09	Refractive error
chr6	34585019	34585020	rs2814944	4e-09	HDL cholesterol
chr6	32993583	32993584	rs9500927	4e-09	Asthma
chr6	32712798	32712799	rs7764819	4e-09	Pulmonary function (interaction)
chr6	32712798	32712799	rs7764819	4e-09	Pulmonary function (interaction)
chr6	29388553	29388554	rs9257809	4e-09	Barrett's esophagus
chr6	26092912	26092913	rs1800562	4e-09	Hepcidin levels
chr6	25776720	25776721	rs11754288	4e-09	Cardiovascular disease risk factors
chr6	160320589	160320590	rs3120139	4e-09	Lp (a) levels
chr6	152469437	152469438	rs9371601	4e-09	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr7	1234208	1234209	rs10275044	4e-09	Renal function-related traits (BUN)
chr20	45947862	45947863	rs7679	4e-09	HDL cholesterol
chr9	91166133	91166134	rs4743820	4e-09	Inflammatory bowel disease
chr20	35176750	35176751	rs867186	4e-09	Anticoagulant levels
chr12	57133499	57133500	rs11172113	4e-09	Migraine
chr12	5687934	5687935	rs12579350	4e-09	Panic disorder
chr12	4497001	4497002	rs2970818	4e-09	Phosphorus levels
chr1	243445664	243445665	rs6703335	4e-09	Schizophrenia, schizoaffective disorder or bipolar disorder
chr12	38712928	38712929	rs826838	4e-09	Heart rate
chr1	230169241	230169242	rs10489615	4e-09	HDL cholesterol
chr1	213985912	213985913	rs340874	4e-09	Fasting glucose-related traits (interaction with BMI)
chr1	200923008	200923009	rs296547	4e-09	Celiac disease
chr1	176715295	176715296	rs4507975:rs9914518	4e-09	Venous thromboembolism (gene x gene interaction)
chr11	65481673	65481674	rs17146964	4e-09	Vertical cup-disc ratio
chr11	60993139	60993140	rs17824933	4e-09	Multiple sclerosis
chr11	60173125	60173126	rs1019670	4e-09	Fibrinogen
chr1	158962764	158962765	rs1101999	4e-09	Asthma
chr12	65781113	65781114	rs1531343	4e-09	Type 2 diabetes
chr11	46700670	46700671	rs7932354	4e-09	Bone mineral density (hip)
chr11	2148912	2148913	rs1004446	4e-09	Type 1 diabetes
chr1	113834945	113834946	rs2476601	4e-09	Crohn's disease
chr11	123490688	123490689	rs735665	4e-09	Follicular lymphoma
chr11	113120895	113120896	rs1436109	4e-09	Cardiac muscle measurement
chr11	111042515	111042516	rs4938174	4e-09	Corneal structure
chr1	109279543	109279544	rs599839	4e-09	Coronary heart disease
chr10	94310617	94310618	rs3781264	4e-09	Esophageal cancer and gastric cancer
chr10	73661449	73661450	rs10824026	4e-09	Atrial fibrillation
chr10	6348487	6348488	rs947474	4e-09	Type 1 diabetes
chr10	25629949	25629950	rs12775535	4e-09	Immune response to smallpox vaccine (IL-6)
chr10	114045296	114045297	rs1801253	4e-09	Birth weight
chr10	100035603	100035604	rs10883437	4e-09	Liver enzyme levels (alanine transaminase)
chr20	40600143	40600144	rs6102059	4e-09	LDL cholesterol
chr11	27645654	27645655	rs925946	4e-09	Weight
chr12	97507491	97507492	rs11109072	4e-09	Obesity (early onset extreme)
chr10	79081390	79081391	rs704010	4e-09	Breast cancer
chr1	3167147	3167148	rs2651899	4e-09	Migraine
chr20	34141637	34141638	rs4911414	4e-09	Tanning
chr13	110308364	110308365	rs4773144	4e-09	Coronary heart disease
chr19	46704396	46704397	rs11083846	4e-09	Chronic lymphocytic leukemia
chr19	19547662	19547663	rs16996148	4e-09	Triglycerides
chr19	11091629	11091630	rs6511720	4e-09	Metabolite levels
chr19	10362256	10362257	rs280519	4e-09	Psoriasis
chr18	62458878	62458879	rs694419	4e-09	Serum albumin level
chr18	55487770	55487771	rs9960767	4e-09	Schizophrenia
chr18	23144363	23144364	rs4800148	4e-09	Height
chr17	7559237	7559238	rs11552708	4e-09	IgM levels
chr17	58292487	58292488	rs12940923	4e-09	Circulating myeloperoxidase levels (plasma)
chr17	48592067	48592068	rs9299	4e-09	Obesity
chr17	47347748	47347749	rs7206971	4e-09	LDL cholesterol
chr17	39820215	39820216	rs9303277	4e-09	Primary biliary cirrhosis
chr19	10364975	10364976	rs2304256	4e-09	Type 1 diabetes
chr16	7409345	7409346	rs10500355	4e-09	Refractive error
chr13	22654551	22654552	rs1034200	4e-09	Central corneal thickness
chr16	85984056	85984057	rs17445836	4e-09	Multiple sclerosis
chr13	42554440	42554441	rs9525638	4e-09	Cortical thickness
chr15	38530703	38530704	rs7403531	4e-09	Type 2 diabetes
chr15	38606988	38606989	rs16967103	4e-09	Crohn's disease
chr15	60602765	60602766	rs340029	4e-09	C-reactive protein
chr14	98032613	98032614	rs4900384	4e-09	Type 1 diabetes
chr13	22654551	22654552	rs1034200	4e-09	Corneal structure
chr15	78818750	78818751	rs4380028	4e-09	Coronary heart disease
chr16	14294447	14294448	rs1659127	4e-09	Menarche (age at onset)
chr16	19933040	19933041	rs11639988	4e-09	Obesity
chr16	50109032	50109033	rs8046148	4e-09	Testicular germ cell tumor
chr15	67154446	67154447	rs744910	4e-09	Asthma
chr1	62465960	62465961	rs1167998	4e-09	Lipid metabolism phenotypes
chr3	52687288	52687289	rs11177	5e-09	Osteoarthritis
chr3	64719688	64719689	rs6795735	5e-09	Age-related macular degeneration
chr3	72091380	72091381	rs6771316:rs10986432	5e-09	Venous thromboembolism (gene x gene interaction)
chr5	149524528	149524529	rs10058728	5e-09	Esophageal cancer
chr4	170132367	170132368	rs11726248	5e-09	Thyroid hormone levels
chr4	18016106	18016107	rs6830062	5e-09	Height
chr3	27496417	27496418	rs13082711	5e-09	Blood pressure
chr4	31395995	31395996	rs6448771	5e-09	Lipid traits
chr3	87103018	87103019	rs9284813	5e-09	Prostate cancer
chr4	156798971	156798972	rs4691380	5e-09	Fasting insulin-related traits (interaction with BMI)
chr23	142272784	142272785	rs5954596	5e-09	Antineutrophil cytoplasmic antibody-associated vasculitis 
chr3	188394765	188394766	rs1464510	5e-09	Celiac disease
chr3	169774312	169774313	rs10936599	5e-09	Bladder cancer
chr3	132444355	132444356	rs17404153	5e-09	HDL cholesterol
chr2	60959693	60959694	rs13003464	5e-09	Crohn's disease
chr2	27592642	27592643	rs13022873	5e-09	Waist Circumference - Triglycerides (WC-TG)
chr2	241443448	241443449	rs3771570	5e-09	Prostate cancer
chr22	37073550	37073551	rs4820268	5e-09	Iron levels
chr22	37066895	37066896	rs855791	5e-09	Red blood cell traits
chr5	151060535	151060536	rs2233287	5e-09	Systemic sclerosis
chr2	236196874	236196875	rs13401104	5e-09	Educational attainment
chr3	190951728	190951729	rs9877502	5e-09	Alzheimer's disease biomarkers
chr5	173910849	173910850	rs17695092	5e-09	Crohn's disease
chr6	94446735	94446736	rs10485022	5e-09	Brain connectivity
chr5	56736056	56736057	rs889312	5e-09	Breast cancer
chr2	233275770	233275771	rs3792109	5e-09	Crohn's disease
chr8	55686988	55686989	rs4737395	5e-09	Myopia (pathological)
chr8	128180024	128180025	rs2019960	5e-09	Multiple sclerosis
chr8	125527808	125527809	rs1551398	5e-09	Crohn's disease
chr8	125469834	125469835	rs2954021	5e-09	Liver enzyme levels (alanine transaminase)
chr7	50310670	50310671	rs6583437	5e-09	IgG glycosylation
chr7	50230075	50230076	rs1456893	5e-09	Crohn's disease
chr7	46713954	46713955	rs700752	5e-09	Insulin-like growth factors
chr7	37801931	37801932	rs2718058	5e-09	Alzheimer's disease (late onset)
chr7	26852045	26852046	rs7804356	5e-09	Type 1 diabetes
chr7	149592372	149592373	rs354033	5e-09	Multiple sclerosis
chr6	90263439	90263440	rs1847472	5e-09	Crohn's disease
chr6	40568388	40568389	rs2494938	5e-09	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)
chr6	33118670	33118671	rs1883414	5e-09	Nephropathy
chr6	32405534	32405535	rs10947262	5e-09	Knee osteoarthritis
chr6	32224553	32224554	rs3096702	5e-09	Prostate cancer
chr6	2912042	2912043	rs318497:rs7019259	5e-09	Venous thromboembolism (gene x gene interaction)
chr6	25821541	25821542	rs17342717	5e-09	Iron levels
chr6	165632994	165632995	rs753760	5e-09	Thyroid hormone levels
chr6	151627230	151627231	rs2046210	5e-09	Breast Cancer in BRCA1 mutation carriers
chr6	151612039	151612040	rs1038304	5e-09	Bone mineral density (hip)
chr6	135097879	135097880	rs9399137	5e-09	HbA2 levels
chr5	96514545	96514546	rs261967	5e-09	Body mass index
chr5	32814921	32814922	rs1173771	5e-09	Blood pressure
chr22	21776835	21776836	rs2283792	5e-09	Multiple sclerosis
chr3	70879778	70879779	rs2687201	5e-09	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined)
chr2	121261186	121261187	rs17006292	5e-09	Behcet's disease
chr12	111803961	111803962	rs671	5e-09	Hematological and biochemical traits
chr12	111752633	111752634	rs6490294	5e-09	Mean platelet volume
chr12	111672684	111672685	rs3782886	5e-09	Hematological and biochemical traits
chr12	111446803	111446804	rs3184504	5e-09	Systolic blood pressure
chr11	88824822	88824823	rs10831496	5e-09	Tanning
chr11	61955172	61955173	rs1109748	5e-09	Phospholipid levels (plasma)
chr11	5209676	5209677	rs7120391	5e-09	Red blood cell traits
chr1	150986359	150986360	rs267733	5e-09	LDL cholesterol
chr11	47641496	47641497	rs10838738	5e-09	Body mass index
chr11	2810310	2810311	rs8181588	5e-09	Type 2 diabetes
chr12	112927815	112927816	rs11066453	5e-09	Glycemic traits
chr11	17294481	17294482	rs1330	5e-09	Height
chr10	9286687	9286688	rs10491003	5e-09	Calcium levels
chr10	92725453	92725454	rs2497306	5e-09	Dehydroepiandrosterone sulphate levels
chr10	92722159	92722160	rs7923837	5e-09	Multiple sclerosis
chr10	79945676	79945677	rs7078012	5e-09	Chronic obstructive pulmonary disease-related biomarkers
chr10	79935193	79935194	rs1923539	5e-09	Chronic obstructive pulmonary disease-related biomarkers
chr10	62198352	62198353	rs3125734	5e-09	Rheumatoid arthritis
chr10	6052733	6052734	rs61839660	5e-09	Type 1 diabetes
chr10	5995762	5995763	rs7911500	5e-09	Inflammatory biomarkers
chr10	113475354	113475355	rs1472750	5e-09	Myopia (pathological)
chr2	210675782	210675783	rs7422339	5e-09	Homocysteine levels
chr10	94135419	94135420	rs9663362	5e-09	Blood pressure
chr12	2236128	2236129	rs1006737	5e-09	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr11	116768387	116768388	rs10790162	5e-09	Metabolic syndrome
chr12	52880119	52880120	rs902774	5e-09	Prostate cancer
chr2	111039880	111039881	rs17483466	5e-09	Chronic lymphocytic leukemia
chr1	227610248	227610249	rs1390401	5e-09	Height
chr20	58833370	58833371	rs965808	5e-09	DNA methylation (variation)
chr19	49365793	49365794	rs2303759	5e-09	Multiple sclerosis
chr19	33818626	33818627	rs29941	5e-09	Weight
chr19	33041393	33041394	rs10411210	5e-09	Colorectal cancer
chr1	88657759	88657760	rs6699417	5e-09	Height
chr1	85066027	85066028	rs6695223:rs1763510	5e-09	Venous thromboembolism (gene x gene interaction)
chr18	49433129	49433130	rs9967417	5e-09	Height
chr1	7961912	7961913	rs35675666	5e-09	Ulcerative colitis
chr17	78407902	78407903	rs4129767	5e-09	HDL cholesterol
chr18	69863202	69863203	rs727088	5e-09	Inflammatory bowel disease
chr14	98021669	98021670	rs1456988	5e-09	Graves' disease
chr1	74525717	74525718	rs1514177	5e-09	Obesity
chr17	39965739	39965740	rs3894194	5e-09	Asthma
chr17	39884509	39884510	rs2872507	5e-09	Crohn's disease
chr16	72186473	72186474	rs7186908	5e-09	Liver enzyme levels (alkaline phosphatase)
chr12	70856215	70856216	rs12229663	5e-09	Refractive error
chr16	51424378	51424379	rs1362756	5e-09	Optic disc parameters
chr1	55039973	55039974	rs11591147	5e-09	Response to statin therapy (LDL-C)
chr13	42180385	42180386	rs4142110	5e-09	Nephrolithiasis
chr13	112677553	112677554	rs7998202	5e-09	Glycated hemoglobin levels
chr13	102312652	102312653	rs1336708:rs1423386	5e-09	Venous thromboembolism (gene x gene interaction)
chr17	49363103	49363104	rs16948048	5e-09	Diastolic blood pressure
chr3	141418192	141418193	rs9825379	6e-09	Height
chr2	191153044	191153045	rs897200	6e-09	Behcet's disease
chr2	73673772	73673773	rs10206899	6e-09	Glomerular filtration rate
chr4	45173673	45173674	rs13130484	6e-09	Body mass index
chr4	109737910	109737911	rs10033900	6e-09	Age-related macular degeneration (CNV)
chr2	62922421	62922422	rs2710642	6e-09	LDL cholesterol
chr2	203937854	203937855	rs4675374	6e-09	Celiac disease
chr2	55869756	55869757	rs3791679	6e-09	Height
chr2	231454042	231454043	rs16828074	6e-09	Attention deficit hyperactivity disorder
chr2	203829152	203829153	rs231735	6e-09	Rheumatoid arthritis
chr4	76439277	76439278	rs9992101	6e-09	Creatinine levels
chr2	59075741	59075742	rs887912	6e-09	Obesity
chr6	127957652	127957653	rs802734	6e-09	Multiple sclerosis
chr9	133278430	133278431	rs651007	6e-09	Metabolite levels
chr6	31139409	31139410	rs1265093	6e-09	Chronic obstructive pulmonary disease-related biomarkers
chr6	32711221	32711222	rs9275572	6e-09	Hepatocellular carcinoma
chr7	128977411	128977412	rs12531711	6e-09	Systemic lupus erythematosus
chr7	1929316	1929317	rs12699477	6e-09	Testicular germ cell tumor
chr7	21567733	21567734	rs12670798	6e-09	LDL cholesterol
chr8	11486463	11486464	rs2736340	6e-09	Rheumatoid arthritis
chr8	143969374	143969375	rs11136341	6e-09	Cholesterol, total
chr8	81741408	81741409	rs11782652	6e-09	Ovarian cancer
chr9	118597007	118597008	rs11789399	6e-09	Bipolar disorder and schizophrenia
chr9	1202370	1202371	rs10809650	6e-09	Dupuytren's disease
chr9	135637875	135637876	rs1537415	6e-09	Periodontitis
chr9	8846954	8846955	rs1975197	6e-09	Restless legs syndrome
chr2	140963572	140963573	rs12474609	6e-09	Aging
chr6	135131013	135131014	rs6569992	6e-09	Red blood cell traits
chr2	11587380	11587381	rs13394619	6e-09	Endometriosis
chr19	18707092	18707093	rs10423674	6e-09	Menarche (age at onset)
chr20	46113424	46113425	rs1569723	6e-09	Kawasaki disease
chr20	5607802	5607803	rs238295	6e-09	Cortical structure
chr10	100542699	100542700	rs11190604 	6e-09	Palmitoleic acid (16:1n-7) plasma levels
chr10	62492217	62492218	rs10822013	6e-09	Breast cancer
chr10	79300559	79300560	rs1250550	6e-09	Inflammatory bowel disease (early onset)
chr10	79300559	79300560	rs1250550	6e-09	Multiple sclerosis
chr11	116763145	116763146	rs11820589	6e-09	Metabolic syndrome (bivariate traits)
chr11	117166644	117166645	rs7112513	6e-09	Protein quantitative trait loci
chr1	116561592	116561593	rs2300747	6e-09	Multiple sclerosis
chr11	17138600	17138601	rs4356203	6e-09	Schizophrenia or bipolar disorder
chr1	182579883	182579884	rs533259	6e-09	Multiple sclerosis
chr1	210362680	210362681	rs7527939	6e-09	Schizophrenia
chr12	112207596	112207597	rs2074356	6e-09	Glycemic traits
chr1	23439739	23439740	rs1077514	6e-09	Cholesterol, total
chr11	105685871	105685872	rs11601239	6e-09	Refractive error
chr1	247876148	247876149	rs3811444	6e-09	Platelet counts
chr20	40640433	40640434	rs13041247	6e-09	Orofacial clefts
chr12	4224752	4224753	rs11611647	6e-09	Red blood cell count
chr20	17865276	17865277	rs2328223	6e-09	LDL cholesterol
chr19	49496751	49496752	rs2280401	6e-09	Serum albumin level
chr19	19678718	19678719	rs2304130	6e-09	Sphingolipid levels
chr17	55680425	55680426	rs1549519	6e-09	Height
chr19	39252524	39252525	rs8099917	6e-09	Chronic Hepatitis C infection
chr15	62088059	62088060	rs7178424	6e-09	Height
chr15	25649510	25649511	rs6576443	6e-09	Immune reponse to smallpox (secreted IFN-alpha)
chr14	92460607	92460608	rs10498633	6e-09	Alzheimer's disease (late onset)
chr13	80143020	80143021	rs1359790	6e-09	Type 2 diabetes
chr12	65389597	65389598	rs10506525	6e-09	Primary tooth development (time to first tooth eruption)
chr17	48334137	48334138	rs9303542	6e-09	Ovarian cancer
chr3	67309	67310	rs9841287	7e-09	Fasting insulin-related traits (interaction with BMI)
chr2	62486397	62486398	rs6545946	7e-09	Crohn's disease
chr3	58384449	58384450	rs6445975	7e-09	Systemic lupus erythematosus
chr3	49664549	49664550	rs9858542	7e-09	Ulcerative colitis
chr3	46240899	46240900	rs12636651	7e-09	Obesity-related traits
chr3	18665365	18665366	rs13073817	7e-09	Crohn's disease
chr3	127755186	127755187	rs664910:rs877228	7e-09	Venous thromboembolism (gene x gene interaction)
chr2	60997123	60997124	rs10181042	7e-09	Crohn's disease
chr2	162267540	162267541	rs1990760	7e-09	Type 1 diabetes
chr2	37365484	37365485	rs2373000	7e-09	Schizophrenia
chr2	27518369	27518370	rs780094	7e-09	Triglycerides
chr2	27508072	27508073	rs1260326	7e-09	Hypertriglyceridemia
chr22	30285267	30285268	rs1043099	7e-09	Rheumatoid arthritis
chr2	150781421	150781422	rs7560163	7e-09	Type 2 diabetes
chr2	134834810	134834811	rs6710823	7e-09	Parkinson's disease
chr5	1279674	1279675	rs10069690	7e-09	Breast cancer
chr2	60959693	60959694	rs13003464	7e-09	Ulcerative colitis
chr5	1286400	1286401	rs2736100	7e-09	Glioma
chr8	19990568	19990569	rs17410962	7e-09	Triglycerides
chr6	104931078	104931079	rs7759938	7e-09	Menarche (age at onset)
chr21	15432900	15432901	rs1736135	7e-09	Crohn's disease
chr9	27536398	27536399	rs2814707	7e-09	Amyotrophic lateral sclerosis
chr9	21816528	21816529	rs7023329	7e-09	Melanoma
chr9	15296035	15296036	rs643531	7e-09	HDL cholesterol
chr8	9329731	9329732	rs1461729	7e-09	HDL cholesterol
chr8	125469232	125469233	rs2980879	7e-09	Adiponectin levels
chr8	119000460	119000461	rs11995824	7e-09	Bone mineral density (hip)
chr9	69151676	69151677	rs11145465	7e-09	Refractive error
chr7	25952205	25952206	rs4722551	7e-09	Cholesterol, total
chr7	151222742	151222743	rs7812088	7e-09	Bone mineral density
chr6	89948063	89948064	rs404256	7e-09	IgG glycosylation
chr6	3433083	3433084	rs17309827	7e-09	Crohn's disease
chr6	32610304	32610305	rs674313	7e-09	Chronic lymphocytic leukemia
chr6	26092912	26092913	rs1800562	7e-09	Mean corpuscular hemoglobin
chr6	1318642	1318643	rs11242675	7e-09	Breast cancer
chr6	109313624	109313625	rs11966072	7e-09	Red blood cell count
chr7	22816986	22816987	rs2286503	7e-09	Fibrinogen
chr20	7831702	7831703	rs2423279	7e-09	Colorectal cancer
chr5	23907463	23907464	rs1910358:rs9981595	7e-09	Venous thromboembolism (gene x gene interaction)
chr19	8679119	8679120	rs2164983	7e-09	Atopic dermatitis
chr1	178546176	178546177	rs4650994	7e-09	HDL cholesterol
chr11	73152651	73152652	rs11235667	7e-09	Crohn's disease
chr1	160887173	160887174	rs4656958	7e-09	Inflammatory bowel disease
chr11	34784301	34784302	rs7929679	7e-09	Chronic obstructive pulmonary disease-related biomarkers
chr11	21543532	21543533	rs12279250	7e-09	Thiazide-induced adverse metabolic effects in hypertensive patients
chr11	127891770	127891771	rs7927044	7e-09	Asthma (childhood onset)
chr11	118883643	118883644	rs630923	7e-09	Inflammatory bowel disease
chr1	18653379	18653380	rs742071	7e-09	Orofacial clefts
chr1	111141653	111141654	rs1335645	7e-09	Liver enzyme levels (gamma-glutamyl transferase)
chr10	62655423	62655424	rs7076156	7e-09	Crohn's disease
chr10	60519365	60519366	rs10994397	7e-09	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr10	44280375	44280376	rs1746048	7e-09	Myocardial infarction (early onset)
chr10	12265894	12265895	rs11257655	7e-09	Type 2 diabetes
chr10	119389890	119389891	rs10886471	7e-09	Type 2 diabetes
chr10	109975991	109975992	rs17095355	7e-09	Biliary atresia
chr20	51524724	51524725	rs6021270	7e-09	Self-reported allergy
chr1	106293320	106293321	rs1330225	7e-09	Blood pressure measurement (low sodium intervention)
chr1	19816372	19816373	rs3806308	7e-09	Ulcerative colitis
chr10	46002467	46002468	rs7085433	7e-09	Mean corpuscular volume
chr1	219519877	219519878	rs2820464	7e-09	Waist-hip ratio
chr1	19874496	19874497	rs4654903	7e-09	Ulcerative colitis
chr19	48756271	48756272	rs838133	7e-09	Homocysteine levels
chr19	44893407	44893408	rs59007384	7e-09	Alzheimer's disease biomarkers
chr18	74121440	74121441	rs9945428:rs4823535	7e-09	Venous thromboembolism (gene x gene interaction)
chr18	22610831	22610832	rs4331426	7e-09	Tuberculosis
chr1	7819002	7819003	rs2797685	7e-09	Crohn's disease
chr17	29590752	29590753	rs3110496	7e-09	Height
chr1	67294456	67294457	rs924080	7e-09	Behcet's disease
chr18	60181789	60181790	rs12967135	7e-09	HDL cholesterol
chr16	53775334	53775335	rs1121980	7e-09	HDL cholesterol
chr16	28910487	28910488	rs7184597	7e-09	Obesity
chr15	74833303	74833304	rs6495122	7e-09	Coffee consumption
chr15	73934423	73934424	rs4337252	7e-09	Height
chr15	40047292	40047293	rs4924410	7e-09	Ewing sarcoma
chr14	50936812	50936813	rs7142143	7e-09	Acute lymphoblastic leukemia (childhood)
chr13	50537218	50537219	rs3116602	7e-09	Height
chr16	56959411	56959412	rs3764261	7e-09	Age-related macular degeneration
chr13	112882312	112882313	rs1278769	7e-09	Interstitial lung disease 
chr6	20679477	20679478	rs7756992	8e-09	Type 2 diabetes
chr6	170063800	170063801	rs924043	8e-09	Type 1 diabetes
chr6	160419219	160419220	rs7758229	8e-09	Colorectal cancer
chr6	137874585	137874586	rs5029939	8e-09	Sjögren's syndrome
chr6	13722290	13722291	rs204247	8e-09	Breast cancer
chr4	87037242	87037243	rs340630	8e-09	Systemic lupus erythematosus
chr6	108946846	108946847	rs2798641	8e-09	Pulmonary function
chr5	1321971	1321972	rs401681	8e-09	Lung cancer
chr4	54258292	54258293	rs7677751	8e-09	Corneal astigmatism
chr6	30064744	30064745	rs8321	8e-09	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr3	119399948	119399949	rs11712165	8e-09	Celiac disease
chr6	108963985	108963986	rs2273669	8e-09	Prostate cancer
chr6	31129523	31129524	rs3130559	8e-09	Chronic obstructive pulmonary disease-related biomarkers
chr8	133133267	133133268	rs2294025	8e-09	Graves' disease
chr6	34068668	34068669	rs1906953	8e-09	Osteosarcoma
chr6	81483391	81483392	rs17530068	8e-09	Breast cancer
chr7	3089154	3089155	rs4722404	8e-09	Atopic dermatitis
chr7	50315610	50315611	rs6421315	8e-09	IgG glycosylation
chr7	65806209	65806210	rs17711722	8e-09	Calcium levels
chr8	125472283	125472284	rs2954026	8e-09	HDL Cholesterol - Triglycerides (HDLC-TG)
chr8	127802782	127802783	rs4410871	8e-09	Multiple sclerosis
chr8	9326085	9326086	rs4841132	8e-09	Fasting glucose-related traits (interaction with BMI)
chr9	12521825	12521826	rs16929097	8e-09	Asthma (childhood onset)
chr9	133266789	133266790	rs514659	8e-09	Coronary heart disease
chr9	13557491	13557492	rs1324183	8e-09	Corneal structure
chr2	68371822	68371823	rs17035378	8e-09	Celiac disease
chr6	32658352	32658353	rs7744020	8e-09	Narcolepsy (age of onset)
chr2	62904595	62904596	rs721048	8e-09	Prostate cancer
chr18	2946292	2946293	rs643507	8e-09	Body mass index (asthmatics)
chr2	217818430	217818431	rs2571445	8e-09	Pulmonary function (interaction)
chr23	154717326	154717327	rs2664170	8e-09	Type 1 diabetes
chr10	116638459	116638460	rs10885997	8e-09	Phospholipid levels (plasma)
chr10	45517828	45517829	rs970548	8e-09	Cholesterol, total
chr10	48834905	48834906	rs877819	8e-09	Systemic lupus erythematosus
chr10	58238164	58238165	rs2790216	8e-09	Inflammatory bowel disease
chr1	145707382	145707383	rs1797052	8e-09	Contrast sensitivity
chr11	57435535	57435536	rs11229030	8e-09	Crohn's disease
chr11	78384326	78384327	rs10899489	8e-09	Menarche (age at onset)
chr11	92940661	92940662	rs1387153	8e-09	Metabolic syndrome (bivariate traits)
chr11	96262283	96262284	rs11021504	8e-09	Height
chr1	199038078	199038079	rs7529925	8e-09	Red blood cell traits
chr12	123311690	123311691	rs4759375	8e-09	HDL cholesterol
chr12	123338163	123338164	rs7980687	8e-09	Head circumference (infant)
chr1	184051810	184051811	rs2274432	8e-09	Height
chr12	47814584	47814585	rs11168249	8e-09	Inflammatory bowel disease
chr12	124822506	124822507	rs11057830	8e-09	Vitamin E levels
chr19	48756271	48756272	rs838133	8e-09	Dietary macronutrient intake
chr18	7068462	7068463	rs8090011	8e-09	Type 2 diabetes
chr1	78772329	78772330	rs4650608	8e-09	Schizophrenia or bipolar disorder
chr1	78772329	78772330	rs4650608	8e-09	Bipolar disorder
chr17	31006497	31006498	rs17826255	8e-09	Myopia (pathological)
chr20	46119307	46119308	rs4810485	8e-09	Rheumatoid arthritis
chr17	14390703	14390704	rs3848445	8e-09	Protein quantitative trait loci
chr14	68346397	68346398	rs1570106	8e-09	Height
chr14	52933910	52933911	rs17125944	8e-09	Alzheimer's disease (late onset)
chr13	40983973	40983974	rs7329174	8e-09	Crohn's disease
chr17	16945824	16945825	rs4273077	8e-09	Multiple myeloma
chr4	110460481	110460482	rs6825911	9e-09	Blood pressure
chr4	109737910	109737911	rs10033900	9e-09	Age-related macular degeneration
chr3	38725823	38725824	rs6801957	9e-09	PR interval
chr3	189683986	189683987	rs17505102	9e-09	Acute lymphoblastic leukemia (childhood)
chr3	175357319	175357320	rs6771725:rs10507246	9e-09	Venous thromboembolism (gene x gene interaction)
chr3	141744455	141744456	rs16851720	9e-09	Hepatitis C induced liver fibrosis
chr23	22129933	22129934	rs1540283	9e-09	Immune reponse to smallpox (secreted IFN-alpha)
chr2	6892486	6892487	rs16865717:rs2009579	9e-09	Venous thromboembolism (gene x gene interaction)
chr23	154536001	154536002	rs1050828	9e-09	Red blood cell traits
chr23	154326057	154326058	rs766420	9e-09	Bilirubin levels
chr2	27518369	27518370	rs780094	9e-09	Phospholipid levels (plasma)
chr2	232212353	232212354	rs7571816	9e-09	Height
chr3	102029793	102029794	rs771767	9e-09	Multiple sclerosis
chr5	102434021	102434022	rs6878284	9e-09	Schizophrenia
chr9	36969207	36969208	rs16933812	9e-09	Obesity and blood pressure
chr5	88842913	88842914	rs11951031	9e-09	Bone mineral density
chr6	139514551	139514552	rs668459	9e-09	Mean corpuscular hemoglobin
chr6	25533305	25533306	rs12526480	9e-09	Mean platelet volume
chr6	25607342	25607343	rs742132	9e-09	Uric acid levels
chr6	25842722	25842723	rs1408272	9e-09	Iron status biomarkers
chr6	31354781	31354782	rs2523608	9e-09	Beta-2 microglubulin plasma levels
chr6	43860844	43860845	rs4711751	9e-09	Age-related macular degeneration
chr6	47485641	47485642	rs9349407	9e-09	Alzheimer's disease (late onset)
chr8	10002569	10002570	rs7826222	9e-09	Adiposity
chr8	125481503	125481504	rs2954033	9e-09	Triglycerides-Blood Pressure (TG-BP)
chr8	70474668	70474669	rs10091374	9e-09	Cardiac Troponin-T levels
chr9	22072264	22072265	rs10757269	9e-09	Ankle-brachial index 
chr2	210675782	210675783	rs7422339	9e-09	Fibrinogen
chr5	175547572	175547573	rs10476160:rs1707420	9e-09	Venous thromboembolism (gene x gene interaction)
chr2	144602341	144602342	rs10496964	9e-09	Epilepsy (generalized)
chr4	87265356	87265357	rs7694379	9e-09	Platelet counts
chr20	59038946	59038947	rs151361	9e-09	Mean platelet volume
chr2	120551911	120551912	rs2030746	9e-09	LDL cholesterol
chr10	30623100	30623101	rs399593	9e-09	Dental caries
chr10	60420053	60420054	rs10994336	9e-09	Bipolar disorder
chr10	94136182	94136183	rs932764	9e-09	Hypertension
chr11	100302804	100302805	rs11223581	9e-09	Immune reponse to smallpox (secreted IL-2)
chr11	69228490	69228491	rs7130881	9e-09	Prostate cancer
chr1	184099373	184099374	rs971572:rs10828151	9e-09	Venous thromboembolism (gene x gene interaction)
chr1	197758511	197758512	rs1998598	9e-09	Crohn's disease
chr1	22371953	22371954	rs7524102	9e-09	Bone mineral density (spine)
chr12	96423643	96423644	rs2028385:rs2038227	9e-09	Venous thromboembolism (gene x gene interaction)
chr14	70035332	70035333	rs17175227	9e-09	Tuberculosis
chr15	101325266	101325267	rs7182874	9e-09	Relative hand skill in reading disability
chr15	63104667	63104668	rs2652834	9e-09	HDL cholesterol
chr16	23622704	23622705	rs420259	9e-09	Bipolar disorder
chr1	65620510	65620511	rs10889569	9e-09	C-reactive protein
chr10	20304157	20304158	rs12219125	9e-09	Diabetic retinopathy 
chr16	56954131	56954132	rs173539	9e-09	Metabolic syndrome
chr20	58894017	58894018	rs6026584	9e-09	Renal function-related traits (BUN)
chr20	23597551	23597552	rs1158167	9e-09	Cystatin C
chr19	52780881	52780882	rs10404486	9e-09	Phospholipid levels (plasma)
chr19	39252524	39252525	rs8099917	9e-09	Response to hepatitis C treatment
chr18	62387623	62387624	rs884205	9e-09	Bone mineral density (spine)
chr18	51186669	51186670	rs8096445	9e-09	Immune response to smallpox vaccine (IL-6)
chr19	33266155	33266156	rs736289	9e-09	Crohn's disease
chr17	63930137	63930138	rs2070776	9e-09	Height
chr17	48045641	48045642	rs72823592	9e-09	Epilepsy (generalized)
chr17	39954435	39954436	rs17609240	9e-09	Hematological parameters
chr17	39917777	39917778	rs9303280	9e-09	Self-reported allergy
chr17	28283225	28283226	rs34517613	9e-09	Amyotrophic lateral sclerosis (sporadic)
chr18	45737000	45737001	rs7238033	9e-09	Bladder cancer
chr4	1260746	1260747	rs7656416	1e-08	Type 2 diabetes
chr4	53933077	53933078	rs871606	1e-08	Blood pressure
chr4	174894977	174894978	rs6858430:rs4800250	1e-08	Venous thromboembolism (gene x gene interaction)
chr4	147479666	147479667	rs6842241	1e-08	Intracranial aneurysm
chr3	66381177	66381178	rs2242285	1e-08	QRS duration
chr3	186933000	186933001	rs10937275	1e-08	Drug-induced liver injury (flucloxacillin)
chr3	53028644	53028645	rs9847710	1e-08	Ulcerative colitis
chr3	52804385	52804386	rs4687552	1e-08	Schizophrenia
chr3	39514088	39514089	rs864643	1e-08	Attention deficit hyperactivity disorder
chr3	32491517	32491518	rs7640978	1e-08	LDL cholesterol
chr3	187008098	187008099	rs11710456	1e-08	IgG glycosylation
chr4	6268328	6268329	rs4689388	1e-08	Type 2 diabetes and other traits
chr3	64726227	64726228	rs4607103	1e-08	Type 2 diabetes
chr4	76476861	76476862	rs10032549	1e-08	Glomerular filtration rate
chr5	110810745	110810746	rs17513503	1e-08	IgE grass sensitization
chr4	83453326	83453327	rs1494961	1e-08	Upper aerodigestive tract cancers
chr4	94303660	94303661	rs17021463	1e-08	Testicular germ cell tumor
chr4	99329261	99329262	rs1789891	1e-08	Alcohol dependence
chr5	10695413	10695414	rs2930047	1e-08	Inflammatory bowel disease
chr5	95899086	95899087	rs3777200	1e-08	Serum total protein level
chr5	132503925	132503926	rs4705952	1e-08	C-reactive protein
chr5	132660271	132660272	rs20541	1e-08	Hodgkin's lymphoma
chr5	154457545	154457546	rs148763909	1e-08	Alzheimer's disease (cognitive decline)
chr5	56214828	56214829	rs4700060	1e-08	Alzheimer's disease (cognitive decline)
chr5	6821800	6821801	rs1566039	1e-08	Sphingolipid levels
chr5	75329661	75329662	rs7703051	1e-08	LDL cholesterol
chr5	75719416	75719417	rs2112347	1e-08	Obesity
chr3	177586509	177586510	rs7620503	1e-08	Corneal structure
chr4	79609516	79609517	rs9307551	1e-08	Refractive error
chr3	169779796	169779797	rs1317082	1e-08	Telomere length
chr2	43312985	43312986	rs7590268	1e-08	Orofacial clefts
chr3	169364844	169364845	rs6774494	1e-08	Nasopharyngeal carcinoma
chr2	202881161	202881162	rs6725887	1e-08	Myocardial infarction (early onset)
chr2	203874195	203874196	rs3087243	1e-08	Rheumatoid arthritis
chr2	216033934	216033935	rs7590720	1e-08	Alcohol dependence
chr22	21577778	21577779	rs181362	1e-08	HDL cholesterol
chr22	21610471	21610472	rs4821112	1e-08	Mean corpuscular volume
chr22	28704722	28704723	rs1547014	1e-08	Vertical cup-disc ratio
chr22	28734023	28734024	rs738722	1e-08	Esophageal cancer and gastric cancer
chr22	29982713	29982714	rs5763662	1e-08	LDL cholesterol
chr2	233919015	233919016	rs6741751	1e-08	Migraine - clinic-based
chr22	37137993	37137994	rs2284033	1e-08	Asthma
chr2	241323570	241323571	rs12694997	1e-08	Height
chr22	46231705	46231706	rs4253772	1e-08	Cholesterol, total
chr2	24946330	24946331	rs1172294	1e-08	Pubertal anthropometrics
chr2	27375229	27375230	rs4665972	1e-08	Triglycerides
chr2	30222159	30222160	rs7579944	1e-08	Celiac disease and Rheumatoid arthritis
chr23	67801707	67801708	rs5919432	1e-08	Prostate cancer
chr5	98633748	98633749	rs467650:rs7153749	1e-08	Venous thromboembolism (gene x gene interaction)
chr2	60937195	60937196	rs13017599	1e-08	Psoriatic arthritis
chr2	62225525	62225526	rs11900673	1e-08	Rheumatoid arthritis
chr2	6321288	6321289	rs7591996	1e-08	Osteosarcoma
chr2	69060810	69060811	rs4315565	1e-08	Height
chr2	80054046	80054047	rs6738962	1e-08	Alzheimer's disease (cognitive decline)
chr2	81441683	81441684	rs10496265	1e-08	Aging traits
chr2	86817192	86817193	rs6547705	1e-08	Progressive supranuclear palsy
chr2	99844191	99844192	rs7583877	1e-08	Type 1 diabetes nephropathy
chr3	119841758	119841759	rs6805251	1e-08	HDL cholesterol
chr3	132891907	132891908	rs6439371	1e-08	Menarche (age at onset)
chr3	13701632	13701633	rs9846232	1e-08	Personality dimensions
chr3	16583540	16583541	rs10510452	1e-08	Testicular germ cell tumor
chr3	169383110	169383111	rs448378	1e-08	Magnesium levels
chr6	104958398	104958399	rs17065417	1e-08	Neuroblastoma
chr6	26107234	26107235	rs198846	1e-08	Hemoglobin
chr6	106074151	106074152	rs6911490	1e-08	Ulcerative colitis
chr7	50310670	50310671	rs6583437	1e-08	IgG glycosylation
chr7	50315610	50315611	rs6421315	1e-08	IgG glycosylation
chr7	8112436	8112437	rs59072263	1e-08	Intraocular pressure
chr7	92635095	92635096	rs2282978	1e-08	Height
chr7	92635095	92635096	rs2282978	1e-08	Height
chr7	99995722	99995723	rs4727443	1e-08	Interstitial lung disease 
chr8	10826418	10826419	rs11776767	1e-08	Triglycerides
chr8	11486463	11486464	rs2736340	1e-08	Systemic lupus erythematosus and Systemic sclerosis
chr8	117172785	117172786	rs3802177	1e-08	Type 2 diabetes
chr8	122960827	122960828	rs10108684	1e-08	Immune response to smallpox vaccine (IL-6)
chr8	19961927	19961928	rs326	1e-08	HDL cholesterol
chr8	19961927	19961928	rs326	1e-08	Triglycerides
chr8	23893637	23893638	rs10109414	1e-08	Chronic kidney disease
chr7	50295635	50295636	rs4917017	1e-08	IgG glycosylation
chr8	23919492	23919493	rs17786744	1e-08	Urate levels
chr8	41691675	41691676	rs6474359	1e-08	Glycated hemoglobin levels
chr8	42695354	42695355	rs6474412	1e-08	Smoking behavior
chr8	88535702	88535703	rs10504861	1e-08	Migraine without aura
chr8	89863689	89863690	rs7015630	1e-08	Crohn's disease
chr8	9325847	9325848	rs9987289	1e-08	HDL Cholesterol - Triglycerides (HDLC-TG)
chr8	9327180	9327181	rs6601299	1e-08	Coronary heart disease
chr9	107543833	107543834	rs10759243	1e-08	Breast cancer
chr9	22068652	22068653	rs4977756	1e-08	Glioma
chr9	22206987	22206988	rs1679013	1e-08	Chronic lymphocytic leukemia
chr9	27543282	27543283	rs3849942	1e-08	Amyotrophic lateral sclerosis
chr9	27543282	27543283	rs3849942	1e-08	Amyotrophic lateral sclerosis (sporadic)
chr9	3929423	3929424	rs514716	1e-08	Alzheimer's disease biomarkers
chr2	199850664	199850665	rs2949006	1e-08	Schizophrenia
chr8	41661943	41661944	rs515071	1e-08	Type 2 diabetes
chr7	50266266	50266267	rs4917014	1e-08	HDL cholesterol
chr7	50264864	50264865	rs1456896	1e-08	Crohn's disease
chr7	117252791	117252792	rs38904	1e-08	Inflammatory bowel disease
chr6	109287293	109287294	rs9386791	1e-08	Red blood cell traits
chr6	109313624	109313625	rs11966072	1e-08	Mean corpuscular hemoglobin
chr6	116065970	116065971	rs1999930	1e-08	Age-related macular degeneration
chr6	121409575	121409576	rs17083533	1e-08	Heart rate
chr6	127172465	127172466	rs6569474	1e-08	Metabolite levels
chr6	129498892	129498893	rs12193446	1e-08	Axial length
chr6	135131013	135131014	rs6569992	1e-08	Red blood cell traits
chr6	136046866	136046867	rs11154851	1e-08	Alzheimer's disease (cognitive decline)
chr6	137646076	137646077	rs13192841	1e-08	Multiple sclerosis
chr6	20660802	20660803	rs10946398	1e-08	Type 2 diabetes
chr6	20728499	20728500	rs6908425	1e-08	Crohn's disease
chr6	25869142	25869143	rs548987	1e-08	Homocysteine levels
chr6	27069300	27069301	rs13194491	1e-08	Iron status biomarkers
chr6	27176103	27176104	rs13194053	1e-08	Schizophrenia
chr6	27176103	27176104	rs13194053	1e-08	Schizophrenia
chr6	31050629	31050630	rs2517532	1e-08	Hypothyroidism
chr6	31150241	31150242	rs1265112	1e-08	Nevirapine-induced rash
chr6	31359923	31359924	rs9378249	1e-08	Bipolar disorder
chr6	31394532	31394533	rs16899524	1e-08	Beta-2 microglubulin plasma levels
chr6	32222842	32222843	rs3134931	1e-08	Circulating myeloperoxidase levels (serum) 
chr6	32251211	32251212	rs9296015	1e-08	Systemic sclerosis
chr6	32400309	32400310	rs3817963	1e-08	Hepatitis C induced liver cirrhosis
chr6	32411711	32411712	rs9268516	1e-08	Asthma
chr6	32601913	32601914	rs477515	1e-08	Inflammatory bowel disease
chr6	32713499	32713500	rs2858331	1e-08	IgE levels 
chr6	33796255	33796256	rs751728	1e-08	Crohn's disease
chr6	34227233	34227234	rs1776897	1e-08	Height
chr6	35067022	35067023	rs17609940	1e-08	Coronary heart disease
chr7	107951752	107951753	rs2072209	1e-08	IgG glycosylation
chr6	104959786	104959787	rs314277	1e-08	Height
chr2	173462116	173462117	rs10930597	1e-08	Blood pressure measurement (high sodium and potassium intervention)
chr2	122468046	122468047	rs17007761	1e-08	Immune reponse to smallpox (secreted IFN-alpha)
chr2	164645338	164645339	rs3923113	1e-08	Type 2 diabetes
chr11	96290262	96290263	rs483905	1e-08	Ulcerative colitis
chr1	200857640	200857641	rs2292096	1e-08	Epilepsy
chr1	202218047	202218048	rs6678914	1e-08	Breast cancer
chr1	206766558	206766559	rs3024505	1e-08	Ulcerative colitis
chr12	112663188	112663189	rs17824620	1e-08	Platelet counts
chr12	114430332	114430333	rs1265507	1e-08	Mammographic density
chr12	118950112	118950113	rs1997111	1e-08	T-tau
chr12	120965128	120965129	rs7305618	1e-08	C-reactive protein
chr12	123975619	123975620	rs4765127	1e-08	Triglycerides
chr12	124827878	124827879	rs10846744	1e-08	Lipoprotein-associated phospholipase A2 activity and mass
chr12	12504578	12504579	rs11612508	1e-08	Inflammatory bowel disease
chr12	13719109	13719110	rs2268118	1e-08	Immune reponse to smallpox (secreted IL-2)
chr12	15582507	15582508	rs2300290	1e-08	Cognitive function
chr1	19514679	19514680	rs10799824	1e-08	Thyroid hormone levels
chr1	218686725	218686726	rs993925	1e-08	Pulmonary function
chr1	222650186	222650187	rs17465637	1e-08	Coronary heart disease
chr12	28003147	28003148	rs12371778	1e-08	Breast size
chr1	247436998	247436999	rs1539019	1e-08	Fibrinogen
chr12	53334170	53334171	rs2016266	1e-08	Bone mineral density (spine)
chr12	57133499	57133500	rs11172113	1e-08	Pulmonary function
chr12	9723494	9723495	rs10466829	1e-08	Multiple sclerosis
chr13	23553070	23553071	rs1572072	1e-08	Nasopharyngeal carcinoma
chr13	36078479	36078480	rs1926320	1e-08	Vertical cup-disc ratio
chr13	40535291	40535292	rs2755237	1e-08	Central corneal thickness
chr13	40983973	40983974	rs7329174	1e-08	Systemic lupus erythematosus
chr13	73946048	73946049	rs1886512	1e-08	QRS duration
chr13	74553976	74553977	rs17718828	1e-08	Phospholipid levels (plasma)
chr13	78836438	78836439	rs11838918	1e-08	Conduct disorder (symptom count)
chr12	20320823	20320824	rs7134375	1e-08	HDL cholesterol
chr11	92917835	92917836	rs7950811	1e-08	Conduct disorder (symptom count)
chr11	8617652	8617653	rs4929923	1e-08	Menarche (age at onset)
chr1	177944383	177944384	rs10913469	1e-08	Weight
chr2	172108242	172108243	rs2016394	1e-08	Breast cancer
chr10	102900246	102900247	rs11191454	1e-08	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr10	103146453	103146454	rs11191580	1e-08	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr10	1110224	1110225	rs10794720	1e-08	Chronic kidney disease
chr10	112996281	112996282	rs4506565	1e-08	Fasting glucose-related traits
chr10	112998589	112998590	rs7903146	1e-08	Type 2 diabetes
chr10	121586601	121586602	rs2981575	1e-08	Breast cancer in BRCA2 mutation carriers
chr10	12272997	12272998	rs10906115	1e-08	Type 2 diabetes
chr10	129627757	129627758	rs477692	1e-08	Response to temozolomide
chr10	18419868	18419869	rs11014166	1e-08	Diastolic blood pressure
chr10	59653594	59653595	rs12356193	1e-08	Uric acid levels
chr10	63577392	63577393	rs10822184	1e-08	Androgen levels
chr10	99531835	99531836	rs11190140	1e-08	Ulcerative colitis
chr1	10506157	10506158	rs616488	1e-08	Breast cancer
chr1	106293320	106293321	rs1330225	1e-08	Blood pressure measurement (low sodium intervention)
chr11	116781490	116781491	rs12286037	1e-08	Metabolic syndrome (bivariate traits)
chr11	118606651	118606652	rs498872	1e-08	Glioma
chr11	118615351	118615352	rs11603023	1e-08	Cholesterol, total
chr1	112648184	112648185	rs17030613	1e-08	Blood pressure
chr1	113834945	113834946	rs2476601	1e-08	Crohn's disease
chr1	113834945	113834946	rs2476601	1e-08	Rheumatoid arthritis
chr1	11986005	11986006	rs2336384	1e-08	Platelet counts
chr11	47536318	47536319	rs10838725	1e-08	Alzheimer's disease (late onset)
chr1	156476449	156476450	rs2274316	1e-08	Migraine
chr1	159204892	159204893	rs2814778	1e-08	Neutrophil count
chr11	61649999	61650000	rs1692120	1e-08	Phospholipid levels (plasma)
chr1	167933840	167933841	rs10489202	1e-08	Schizophrenia
chr11	68164293	68164294	rs4930561	1e-08	IgG glycosylation
chr11	76588149	76588150	rs2155219	1e-08	IgE grass sensitization
chr13	93756252	93756253	rs7995215	1e-08	Attention deficit hyperactivity disorder
chr13	96365293	96365294	rs7989336	1e-08	Obesity
chr11	75743975	75743976	rs499974	1e-08	HDL cholesterol
chr14	104810871	104810872	rs4983559	1e-08	HDL cholesterol
chr17	61388335	61388336	rs2079742	1e-08	Urate levels
chr17	71129464	71129465	rs11654749	1e-08	Pulmonary function (interaction)
chr17	74703693	74703694	rs10512597	1e-08	Fibrinogen
chr17	7583789	7583790	rs2075230	1e-08	Hormone measurements
chr18	21681451	21681452	rs11662721	1e-08	Phospholipid levels (plasma)
chr18	55085468	55085469	rs4801131	1e-08	Schizophrenia
chr18	62458878	62458879	rs694419	1e-08	Serum albumin level
chr18	69864405	69864406	rs763361	1e-08	Type 1 diabetes
chr19	10981462	10981463	rs11669133	1e-08	Coronary heart disease
chr19	18193889	18193890	rs874628	1e-08	Multiple sclerosis
chr19	22176637	22176638	rs412658	1e-08	Telomere length
chr19	33402101	33402102	rs3786897	1e-08	Type 2 diabetes
chr19	40804665	40804666	rs3733829	1e-08	Smoking behavior
chr17	56695876	56695877	rs227731	1e-08	Orofacial clefts
chr19	44892961	44892962	rs157582	1e-08	Metabolic syndrome
chr19	50871710	50871711	rs10424878	1e-08	PCA3 expression level
chr19	6718375	6718376	rs2230199	1e-08	Age-related macular degeneration
chr19	7166097	7166098	rs2059807	1e-08	Polycystic ovary syndrome
chr19	8404853	8404854	rs2967605	1e-08	HDL cholesterol
chr20	34000288	34000289	rs2284378	1e-08	Breast cancer
chr20	40462846	40462847	rs2902940	1e-08	LDL cholesterol
chr20	49905792	49905793	rs495337	1e-08	Psoriasis
chr20	57416638	57416639	rs6092477	1e-08	Mean corpuscular volume
chr2	111907623	111907624	rs17174870	1e-08	Multiple sclerosis
chr2	135080335	135080336	rs7570971	1e-08	Cholesterol, total
chr21	42416076	42416077	rs11203203	1e-08	Celiac disease and Rheumatoid arthritis
chr14	100565879	100565880	rs6575793	1e-08	Menarche (age at onset)
chr2	144383973	144383974	rs12991836	1e-08	Schizophrenia
chr19	44911193	44911194	rs439401	1e-08	HDL Cholesterol - Triglycerides (HDLC-TG)
chr17	47347748	47347749	rs7206971	1e-08	Cholesterol, total
chr19	41479678	41479679	rs11672691	1e-08	Prostate cancer
chr17	45439035	45439036	rs17631303	1e-08	Ovarian cancer in BRCA1 mutation carriers 
chr14	25034592	25034593	rs10147992	1e-08	White blood cell types
chr14	36104811	36104812	rs1537424	1e-08	Thyroid hormone levels
chr17	45727827	45727828	rs9303521	1e-08	Bone mineral density (spine)
chr14	60437038	60437039	rs1254319	1e-08	Refractive error
chr14	65448148	65448149	rs10483776	1e-08	N-glycan levels
chr14	68847341	68847342	rs434943	1e-08	Fibrinogen
chr15	26032397	26032398	rs4906844	1e-08	Cortical thickness
chr15	37057600	37057601	rs1568679	1e-08	Response to antipsychotic treatment
chr1	55030365	55030366	rs11206510	1e-08	Myocardial infarction (early onset)
chr15	58388754	58388755	rs2043085	1e-08	Metabolic syndrome (bivariate traits)
chr15	63445725	63445726	rs10519210	1e-08	Heart failure
chr15	67157966	67157967	rs17228058	1e-08	Self-reported allergy
chr15	77454847	77454848	rs7178572	1e-08	Type 2 diabetes
chr15	78513680	78513681	rs8034191	1e-08	Lung cancer
chr15	85282335	85282336	rs6496932	1e-08	Central corneal thickness
chr15	58386312	58386313	rs10468017	1e-08	Age-related macular degeneration
chr16	20246544	20246545	rs12597579	1e-08	Body mass index
chr17	45439035	45439036	rs17631303	1e-08	Ovarian cancer in BRCA1 mutation carriers 
chr17	45130753	45130754	rs12946454	1e-08	Systolic blood pressure
chr17	43800797	43800798	rs8077889	1e-08	Triglycerides
chr17	39933090	39933091	rs4794820	1e-08	Asthma
chr1	74527378	74527379	rs1514174	1e-08	Obesity
chr16	85977426	85977427	rs13333054	1e-08	Multiple sclerosis
chr17	10130361	10130362	rs11656696	1e-08	Intraocular pressure
chr1	67240274	67240275	rs11209026	1e-08	Ulcerative colitis
chr16	68787042	68787043	rs9929218	1e-08	Colorectal cancer
chr16	5535850	5535851	rs870288	1e-08	Phospholipid levels (plasma)
chr16	28528526	28528527	rs4788084	1e-08	Type 1 diabetes autoantibodies
chr16	259155	259156	rs1122794	1e-08	Red blood cell traits
chr1	67259436	67259437	rs10889677	1e-08	Ulcerative colitis
chr3	50055775	50055776	rs6762477	2e-08	Menarche (age at onset)
chr3	41883905	41883906	rs1052501	2e-08	Multiple myeloma
chr3	37474335	37474336	rs197770	2e-08	Phospholipid levels (plasma)
chr3	3573202	3573203	rs9815663	2e-08	Asthma (childhood onset)
chr3	32491517	32491518	rs7640978	2e-08	Cholesterol, total
chr3	30641446	30641447	rs12493607	2e-08	Breast cancer
chr3	195137644	195137645	rs2131877	2e-08	Non-small cell lung cancer
chr3	28037593	28037594	rs170934	2e-08	Multiple sclerosis
chr3	27374521	27374522	rs4973768	2e-08	Breast cancer
chr3	196180781	196180782	rs4916483	2e-08	Mean corpuscular volume
chr3	141383990	141383991	rs6763931	2e-08	Prostate cancer
chr3	16913766	16913767	rs1372072	2e-08	Primary biliary cirrhosis
chr3	189683986	189683987	rs17505102	2e-08	Acute lymphoblastic leukemia (childhood)
chr3	53813380	53813381	rs14165	2e-08	Refractive error
chr3	30438592	30438593	rs6790925	2e-08	Migraine - clinic-based
chr4	105213158	105213159	rs6855629	2e-08	Height
chr5	116423792	116423793	rs26595	2e-08	Wegener's granulomatosis
chr4	136605428	136605429	rs10012307	2e-08	DNA methylation (parent-of-origin)
chr5	159391736	159391737	rs6556416	2e-08	Ankylosing spondylitis
chr3	12288911	12288912	rs17036170	2e-08	Drug-induced liver injury 
chr5	151081487	151081488	rs960709	2e-08	Systemic lupus erythematosus and Systemic sclerosis
chr5	135030509	135030510	rs3805663	2e-08	Testicular germ cell tumor
chr5	114463288	114463289	rs17136627	2e-08	Coronary arterial lesions in patients with Kawasaki disease
chr5	102611093	102611094	rs7705924	2e-08	Crohn's disease
chr4	99318161	99318162	rs1229984	2e-08	Alcohol consumption
chr4	87854090	87854091	rs1471403	2e-08	Bone mineral density (spine)
chr4	81228676	81228677	rs710841	2e-08	Height
chr4	58347678	58347679	rs17218161	2e-08	Asthma (childhood onset)
chr4	56920283	56920284	rs1713985	2e-08	Age-related macular degeneration
chr4	48361965	48361966	rs6837335	2e-08	Crohn's disease
chr4	3471411	3471412	rs6831256	2e-08	LDL cholesterol
chr4	3447924	3447925	rs16844401	2e-08	Fibrinogen
chr4	165334551	165334552	rs17046216	2e-08	Insulin-related traits
chr4	10725228	10725229	rs16872571	2e-08	Vitiligo
chr3	121941816	121941817	rs4285028	2e-08	Multiple sclerosis
chr2	199812202	199812203	rs7605378	2e-08	Osteoporosis
chr2	88360068	88360069	rs1659258	2e-08	Visceral fat
chr2	231513519	231513520	rs6750795	2e-08	Height
chr2	226314913	226314914	rs925735	2e-08	Adiponectin levels
chr2	226235981	226235982	rs2972146	2e-08	Triglycerides
chr22	23828808	23828809	rs2186369	2e-08	IgG glycosylation
chr22	23828808	23828809	rs2186369	2e-08	IgG glycosylation
chr22	23828808	23828809	rs2186369	2e-08	IgG glycosylation
chr2	219079123	219079124	rs6724465	2e-08	Height
chr2	217041108	217041109	rs13387042	2e-08	Breast cancer
chr2	21014671	21014672	rs673548	2e-08	Metabolic traits
chr2	190120953	190120954	rs13034723	2e-08	Body mass index
chr2	173432930	173432931	rs10497394	2e-08	Otitis media (chronic/recurrent)
chr2	164058697	164058698	rs13002573	2e-08	Blood pressure
chr2	162254025	162254026	rs2111485	2e-08	Inflammatory bowel disease
chr2	147958858	147958859	rs2307394	2e-08	Urate levels
chr5	16812528	16812529	rs17651119	2e-08	Major depressive disorder
chr2	232878398	232878399	rs778371	2e-08	Schizophrenia
chr3	120866467	120866468	rs322458	2e-08	Aging (facial)
chr2	234394165	234394166	rs11887188	2e-08	Blood pressure measurement (high sodium and potassium intervention)
chr2	238186780	238186781	rs12472274	2e-08	Phospholipid levels (plasma)
chr2	65440137	65440138	rs6740462	2e-08	Inflammatory bowel disease
chr2	65381774	65381775	rs1876518	2e-08	Celiac disease and Rheumatoid arthritis
chr2	60839530	60839531	rs1432295	2e-08	Hodgkin's lymphoma
chr2	55289186	55289187	rs2589113	2e-08	Height
chr2	54457419	54457420	rs11898505	2e-08	Bone mineral density (spine)
chr2	43845436	43845437	rs4299376	2e-08	Lipid metabolism phenotypes
chr2	43326809	43326810	rs1465618	2e-08	Prostate cancer
chr23	8945784	8945785	rs5934505	2e-08	Androgen levels
chr2	37733469	37733470	rs17511102	2e-08	Height
chr23	147961253	147961254	rs5904818	2e-08	Antineutrophil cytoplasmic antibody-associated vasculitis 
chr2	27508072	27508073	rs1260326	2e-08	Serum albumin level
chr2	27508072	27508073	rs1260326	2e-08	Cardiovascular disease risk factors
chr22	50532836	50532837	rs140522	2e-08	Multiple sclerosis
chr22	45566023	45566024	rs1985671	2e-08	Temperament (bipolar disorder)
chr22	37195277	37195278	rs229541	2e-08	Type 1 diabetes
chr5	177367189	177367190	rs12654812	2e-08	Inflammatory bowel disease
chr9	106870071	106870072	rs4743034	2e-08	Height
chr5	35874472	35874473	rs6897932	2e-08	Multiple sclerosis
chr8	127401059	127401060	rs6983267	2e-08	Colorectal cancer
chr8	115636337	115636338	rs2737229	2e-08	Cholesterol, total
chr8	11495031	11495032	rs2618476	2e-08	Systemic lupus erythematosus
chr8	10813761	10813762	rs6601530	2e-08	Carotid intima media thickness
chr7	98187014	98187015	rs6465657	2e-08	Prostate cancer
chr7	92779055	92779056	rs445	2e-08	White blood cell count
chr8	128303767	128303768	rs975730	2e-08	Celiac disease and Rheumatoid arthritis
chr7	90348445	90348446	rs42648	2e-08	Homocysteine levels
chr7	68585425	68585426	rs1403155	2e-08	Immune reponse to smallpox (secreted IL-2)
chr7	51938718	51938719	rs406001	2e-08	Post-traumatic stress disorder (asjusted for relatedness)
chr7	28149791	28149792	rs1635852	2e-08	Systemic lupus erythematosus and Systemic sclerosis
chr7	27192142	27192143	rs4722672	2e-08	Ulcerative colitis
chr7	21544469	21544470	rs2285947	2e-08	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)
chr7	150832360	150832361	rs17173637	2e-08	HDL cholesterol
chr7	75543860	75543861	rs1167796	2e-08	Systemic lupus erythematosus
chr8	132917671	132917672	rs853308	2e-08	Vitiligo
chr8	17348067	17348068	rs4921542	2e-08	Creutzfeldt-Jakob disease (variant)
chr8	32553697	32553698	rs16879552	2e-08	Hirschsprung's disease
chr2	144450625	144450626	rs12105918	2e-08	Renal cell carcinoma
chr9	98361053	98361054	rs10986018	2e-08	Folate pathway vitamin levels
chr9	22115959	22115960	rs2383207	2e-08	Abdominal aortic aneurysm
chr9	21984661	21984662	rs3731217	2e-08	Acute lymphoblastic leukemia (B-cell precursor)
chr9	16368733	16368734	rs7864648	2e-08	Height
chr9	136229893	136229894	rs12338076	2e-08	Height
chr9	136197832	136197833	rs7860634	2e-08	Thyroid hormone levels
chr9	133263861	133263862	rs657152	2e-08	Obesity-related traits
chr9	124021567	124021568	rs2075064	2e-08	Waist circumference
chr9	114478625	114478626	rs79509430	2e-08	Obesity-related traits
chr8	87856111	87856112	rs12543318	2e-08	Orofacial clefts
chr8	73095111	73095112	rs12677663	2e-08	Crohn's disease
chr8	4323321	4323322	rs10503253	2e-08	Schizophrenia
chr8	40626719	40626720	rs2722425	2e-08	Fasting plasma glucose
chr8	32558755	32558756	rs7825175	2e-08	Thyroid hormone levels
chr7	128933912	128933913	rs4728142	2e-08	Ulcerative colitis
chr7	116717989	116717990	rs38855	2e-08	Triglycerides
chr7	106731772	106731773	rs342293	2e-08	Mean platelet volume
chr7	103886921	103886922	rs3914132	2e-08	Otosclerosis
chr6	26510335	26510336	rs1056667	2e-08	Educational attainment
chr6	26092912	26092913	rs1800562	2e-08	Iron status biomarkers
chr6	26092912	26092913	rs1800562	2e-08	Cholesterol, total
chr6	165741968	165741969	rs1039002	2e-08	Bipolar disorder
chr6	16196962	16196963	rs2142672	2e-08	LDL cholesterol
chr6	151747228	151747229	rs1999805	2e-08	Bone mineral density (spine)
chr6	148200155	148200156	rs9497965	2e-08	Thyroid hormone levels
chr6	143577756	143577757	rs12199775	2e-08	Inflammatory bowel disease
chr6	14096426	14096427	rs12529514	2e-08	Rheumatoid arthritis
chr6	126446453	126446454	rs1361108	2e-08	Menarche (age at onset)
chr6	117550672	117550673	rs9285425	2e-08	Height
chr6	116122571	116122572	rs3812111	2e-08	Age-related macular degeneration
chr5	95700995	95700996	rs153916	2e-08	Pulmonary function
chr5	593967	593968	rs11739663	2e-08	Ulcerative colitis
chr5	59264890	59264891	rs17444059	2e-08	Immune response to smallpox vaccine (IL-6)
chr6	28808339	28808340	rs4324798	2e-08	Lung adenocarcinoma
chr5	32804421	32804422	rs1173766	2e-08	Blood pressure
chr6	29466636	29466637	rs4713226	2e-08	Immune reponse to smallpox (secreted IFN-alpha)
chr6	31481198	31481199	rs3099844	2e-08	Metabolic syndrome
chr7	100889132	100889133	rs12666989	2e-08	Resting heart rate
chr6	99760561	99760562	rs4840086	2e-08	Menarche (age at onset)
chr6	39316273	39316274	rs1535500	2e-08	Type 2 diabetes
chr6	34270736	34270737	rs6918981	2e-08	Height
chr6	34246544	34246545	rs1150781	2e-08	Height
chr6	33572431	33572432	rs210134	2e-08	Platelet counts
chr6	32759025	32759026	rs1049110	2e-08	IgG glycosylation
chr6	32665935	32665936	rs9274477	2e-08	Narcolepsy (age of onset)
chr6	32636594	32636595	rs9272346	2e-08	Asthma
chr6	32614111	32614112	rs4530903	2e-08	Lymphoma
chr6	31973119	31973120	rs389884	2e-08	Hematology traits
chr6	31938232	31938233	rs9380272	2e-08	Age-related macular degeneration
chr6	31936026	31936027	rs9332739	2e-08	Age-related macular degeneration (CNV)
chr6	31605178	31605179	rs2844479	2e-08	Weight
chr6	31537702	31537703	rs2734583	2e-08	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)
chr6	31168675	31168676	rs3130501	2e-08	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)
chr21	42416280	42416281	rs9976767	2e-08	Type 1 diabetes
chr10	100101677	100101678	rs11597390	2e-08	Liver enzyme levels
chr2	111191749	111191750	rs6738028	2e-08	Dehydroepiandrosterone sulphate levels
chr12	121001629	121001630	rs1169310	2e-08	C-reactive protein
chr12	120965920	120965921	rs7953249	2e-08	N-glycan levels
chr12	120965128	120965129	rs7305618	2e-08	Type 2 diabetes
chr12	120951158	120951159	rs2650000	2e-08	LDL cholesterol
chr1	211981665	211981666	rs17018311	2e-08	Temperament (bipolar disorder)
chr12	112083643	112083644	rs4767364	2e-08	Upper aerodigestive tract cancers
chr12	121022882	121022883	rs7957197	2e-08	Type 2 diabetes
chr1	19534611	19534612	rs10917477	2e-08	Thyroid function
chr11	89468458	89468459	rs957140	2e-08	Homocysteine levels
chr11	89284792	89284793	rs1126809	2e-08	Sunburns
chr11	87414395	87414396	rs6592362	2e-08	Inflammatory bowel disease
chr11	85966427	85966428	rs17817600	2e-08	Alzheimer's disease
chr1	182112824	182112825	rs10911021	2e-08	Cardiovascular heart disease in diabetics
chr1	177883444	177883445	rs633715	2e-08	Menarche (age at onset)
chr1	192571890	192571891	rs1323292	2e-08	Multiple sclerosis
chr12	123246875	123246876	rs11532322	2e-08	Schizophrenia
chr12	123975619	123975620	rs4765127	2e-08	Triglycerides
chr12	12620586	12620587	rs12822507	2e-08	Systemic lupus erythematosus
chr13	23290517	23290518	rs9552911	2e-08	Type 2 diabetes
chr13	113040194	113040195	rs11842874	2e-08	Osteoarthritis
chr13	108821597	108821598	rs17393344	2e-08	Alzheimer's disease (cognitive decline)
chr13	100165837	100165838	rs2184971	2e-08	Refractive error
chr12	57398796	57398797	rs11613352	2e-08	HDL cholesterol
chr1	247882969	247882970	rs11204538	2e-08	Mean corpuscular volume
chr12	45381124	45381125	rs17095830	2e-08	Ankylosing spondylitis
chr12	43760022	43760023	rs4251424	2e-08	Immune reponse to smallpox (secreted TNF-alpha)
chr1	243500590	243500591	rs14403	2e-08	Schizophrenia
chr1	22376364	22376365	rs6696981	2e-08	Bone mineral density (spine)
chr12	2310729	2310730	rs4765913	2e-08	Bipolar disorder
chr12	21178614	21178615	rs4149056	2e-08	Sex hormone-binding globulin levels
chr12	20077704	20077705	rs10770612	2e-08	Aortic root size
chr1	219527176	219527177	rs2785980	2e-08	Fasting insulin-related traits (interaction with BMI)
chr1	2137732	2137733	rs425277	2e-08	Height
chr11	76559638	76559639	rs7130588	2e-08	Asthma
chr1	17348041	17348042	rs2240335	2e-08	Rheumatoid arthritis
chr1	17348041	17348042	rs2240335	2e-08	Rheumatoid arthritis
chr1	171980609	171980610	rs10914144	2e-08	Mean platelet volume
chr11	111404407	111404408	rs4938534	2e-08	Primary biliary cirrhosis
chr21	35477120	35477121	rs16993221	2e-08	C-reactive protein and white blood cell count
chr10	93079884	93079885	rs2068888	2e-08	Triglycerides
chr10	92703124	92703125	rs1111875	2e-08	Type 2 diabetes
chr10	9011168	9011169	rs962993	2e-08	Self-reported allergy
chr10	88990205	88990206	rs1800682	2e-08	Chronic lymphocytic leukemia
chr10	74536030	74536031	rs7924176	2e-08	Primary tooth development (time to first tooth eruption)
chr10	71376161	71376162	rs1417210	2e-08	Vitiligo
chr10	68241123	68241124	rs1900004	2e-08	Vertical cup-disc ratio
chr10	21626689	21626690	rs1243180	2e-08	Ovarian cancer
chr10	121334386	121334387	rs11199914	2e-08	Breast cancer
chr10	117068048	117068049	rs7078160	2e-08	Orofacial clefts
chr10	104086315	104086316	rs1320448	2e-08	Cardiac hypertrophy
chr10	103913083	103913084	rs11191865	2e-08	Interstitial lung disease 
chr10	103016150	103016151	rs7914558	2e-08	Schizophrenia
chr11	118703965	118703966	rs494459	2e-08	Height
chr13	31245187	31245188	rs9542236	2e-08	Age-related macular degeneration
chr11	128712661	128712662	rs665440	2e-08	Myopia (pathological)
chr1	113905766	113905767	rs11552449	2e-08	Breast cancer
chr1	170026660	170026661	rs1541160	2e-08	Amyotrophic lateral sclerosis
chr1	165904154	165904155	rs3790672	2e-08	Testicular germ cell tumor
chr1	165749741	165749742	rs7555523	2e-08	Intraocular pressure
chr11	62028113	62028114	rs11230874	2e-08	Phospholipid levels (plasma)
chr1	161514419	161514420	rs368433	2e-08	Helicobacter pylori serologic status
chr11	58705325	58705326	rs2507838	2e-08	Body mass (lean)
chr1	156730858	156730859	rs12145743	2e-08	HDL cholesterol
chr11	56094614	56094615	rs2945816	2e-08	Phospholipid levels (plasma)
chr1	154861706	154861707	rs1218582	2e-08	Prostate cancer
chr1	154454493	154454494	rs8192284	2e-08	C-reactive protein
chr1	154453787	154453788	rs4129267	2e-08	Asthma
chr1	151922616	151922617	rs10788819	2e-08	Hair morphology
chr11	49537619	49537620	rs1814175	2e-08	Height
chr11	48311807	48311808	rs1483121	2e-08	Fasting glucose-related traits (interaction with BMI)
chr11	27658368	27658369	rs6265	2e-08	Smoking behavior
chr11	13272357	13272358	rs900145	2e-08	Menarche (age at onset)
chr13	39543930	39543931	rs9315702	2e-08	Hippocampal atrophy
chr10	94991512	94991513	rs2185570	2e-08	Dehydroepiandrosterone sulphate levels
chr13	42378008	42378009	rs9594738	2e-08	Bone mineral density (hip)
chr18	48339225	48339226	rs11082671	2e-08	Height
chr18	23299252	23299253	rs9949617	2e-08	Hypertriglyceridemia
chr18	22610831	22610832	rs4331426	2e-08	Tuberculosis
chr18	12821593	12821594	rs2847281	2e-08	C-reactive protein
chr18	12797694	12797695	rs2847297	2e-08	Rheumatoid arthritis
chr17	8232773	8232774	rs3027234	2e-08	Telomere length
chr18	49640843	49640844	rs4939883	2e-08	Lipid metabolism phenotypes
chr17	80617310	80617311	rs7503807	2e-08	Obesity
chr17	70648047	70648048	rs17718586	2e-08	Sudden cardiac arrest
chr17	56762397	56762398	rs1401796	2e-08	Height
chr17	56695876	56695877	rs227731	2e-08	Orofacial clefts
chr17	49488949	49488950	rs16948200	2e-08	Immune reponse to smallpox (secreted IL-2)
chr17	49007348	49007349	rs9674544	2e-08	Primary tooth development (number of teeth)
chr17	48911234	48911235	rs46522	2e-08	Coronary heart disease
chr17	80374693	80374694	rs6565681	2e-08	Moyamoya disease
chr18	6939947	6939948	rs597503	2e-08	Sudden cardiac arrest
chr19	19296908	19296909	rs10401969	2e-08	LDL cholesterol
chr1	92543880	92543881	rs7515577	2e-08	Cholesterol, total
chr13	42079300	42079301	rs1012053	2e-08	Bipolar disorder
chr2	105840834	105840835	rs2377339	2e-08	Addiction
chr2	102438306	102438307	rs11465699	2e-08	Serum protein levels (sST2)
chr20	6781117	6781118	rs235770	2e-08	Refractive error
chr20	6640245	6640246	rs967417	2e-08	Height
chr20	54190681	54190682	rs16999165	2e-08	Atopic dermatitis
chr20	52476456	52476457	rs13041126	2e-08	Obesity
chr20	10988381	10988382	rs1327235	2e-08	Systolic blood pressure
chr19	8368311	8368312	rs7255436	2e-08	HDL cholesterol
chr19	6718375	6718376	rs2230199	2e-08	Age-related macular degeneration
chr19	48705607	48705608	rs504963	2e-08	Crohn's disease
chr19	44912382	44912383	rs445925	2e-08	Carotid intima media thickness
chr19	44892361	44892362	rs2075650	2e-08	Cognitive decline
chr19	33831231	33831232	rs11084753	2e-08	Body mass index
chr19	33415216	33415217	rs4805885	2e-08	Adiponectin levels
chr17	44364975	44364976	rs708382	2e-08	Platelet counts
chr17	44115816	44115817	rs228769	2e-08	Bone mineral density (hip)
chr20	35211476	35211477	rs6088765	2e-08	Ulcerative colitis
chr1	72299432	72299433	rs2568958	2e-08	Weight
chr15	58395680	58395681	rs493258	2e-08	Age-related macular degeneration
chr15	58382495	58382496	rs4775041	2e-08	Triglycerides
chr15	53648109	53648110	rs10518733	2e-08	Hematological and biochemical traits
chr15	43927408	43927409	rs16948098	2e-08	Serum albumin level
chr15	42391588	42391589	rs2412710	2e-08	Triglycerides
chr15	41271751	41271752	rs28374715	2e-08	Ulcerative colitis
chr15	32702554	32702555	rs4779584	2e-08	Colorectal cancer
chr15	101334917	101334918	rs11855415	2e-08	Handedness in dyslexia
chr14	95298226	95298227	rs115102486	2e-08	Alzheimer's disease (cognitive decline)
chr14	95254340	95254341	rs8014194	2e-08	Response to statin therapy
chr1	4608609	4608610	rs3896439	2e-08	Dental caries
chr14	35212965	35212966	rs12586317	2e-08	Psoriasis
chr1	41065198	41065199	rs6686842	2e-08	Height
chr17	43729962	43729963	rs1513670	2e-08	Bone mineral density (hip)
chr13	60939534	60939535	rs7337573	2e-08	Phospholipid levels (plasma)
chr15	60585830	60585831	rs340005	2e-08	Gamma gluatamyl transferase levels
chr15	63049796	63049797	rs11071720	2e-08	Mean platelet volume
chr14	75539213	75539214	rs2300603	2e-08	Multiple sclerosis
chr15	78559272	78559273	rs2036527	2e-08	Smoking behavior
chr15	78497145	78497146	rs13180	2e-08	Chronic obstructive pulmonary disease
chr1	72285501	72285502	rs3101336	2e-08	Obesity (early onset extreme)
chr1	70529878	70529879	rs2651244	2e-08	Inflammatory bowel disease
chr17	21380910	21380911	rs4640244	2e-08	Height
chr16	86677053	86677054	rs10048146	2e-08	Bone mineral density (spine)
chr16	84544634	84544635	rs371915	2e-08	Eosinophilic esophagitis (pediatric)
chr16	77393871	77393872	rs11864477	2e-08	Bone mineral density
chr16	9768698	9768699	rs11866328	2e-08	Hepatitis B
chr16	75356417	75356418	rs2865531	2e-08	Pulmonary function (interaction)
chr16	73034778	73034779	rs879324	2e-08	Stroke (ischemic)
chr16	69554668	69554669	rs1364063	2e-08	Menarche (age at onset)
chr1	62726105	62726106	rs12130333	2e-08	Triglycerides
chr16	15036082	15036083	rs3198697	2e-08	Triglycerides
chr16	134390	134391	rs7203560	2e-08	Hematology traits
chr16	76532259	76532260	rs4485401	2e-08	Sphingolipid levels
chr15	83899405	83899406	rs10906982	2e-08	Height
chr4	164987568	164987569	rs4691139	3e-08	Ovarian cancer in BRCA1 mutation carriers 
chr5	1286400	1286401	rs2736100	3e-08	Red blood cell count
chr5	1286400	1286401	rs2736100	3e-08	Idiopathic pulmonary fibrosis
chr5	108777642	108777643	rs13177718	3e-08	Height
chr4	91494377	91494378	rs11933531	3e-08	DNA methylation (variation)
chr4	6301294	6301295	rs1801214	3e-08	Type 2 diabetes
chr4	73991990	73991991	rs2472649	3e-08	Inflammatory bowel disease
chr4	68726063	68726064	rs293428	3e-08	Sex hormone-binding globulin levels
chr4	184718014	184718015	rs2130392	3e-08	Kawasaki disease
chr4	165334551	165334552	rs17046216	3e-08	Insulin-related traits
chr4	89720188	89720189	rs356220	3e-08	Parkinson's disease
chr5	1321971	1321972	rs401681	3e-08	Melanoma
chr5	60073966	60073967	rs1588265	3e-08	Asthma
chr5	54004831	54004832	rs4311394	3e-08	Adiponectin levels
chr5	58888233	58888234	rs10472076	3e-08	Breast cancer
chr5	59041653	59041654	rs1353747	3e-08	Breast cancer
chr5	59380222	59380223	rs1823068	3e-08	Sleepiness
chr5	593967	593968	rs11739663	3e-08	Ulcerative colitis
chr5	88927602	88927603	rs190982	3e-08	Alzheimer's disease (late onset)
chr5	91003405	91003406	rs1967256	3e-08	Response to antipsychotic treatment
chr6	109313624	109313625	rs11966072	3e-08	Mean corpuscular volume
chr6	109462737	109462738	rs1046943	3e-08	Height
chr6	10959924	10959925	rs6918936	3e-08	Phospholipid levels (plasma)
chr6	126845926	126845927	rs13204965	3e-08	Bone mineral density
chr3	87124173	87124174	rs17181170	3e-08	Prostate cancer
chr6	127279484	127279485	rs2180341	3e-08	Breast cancer
chr5	27611323	27611324	rs12054895	3e-08	Major depressive disorder
chr3	87061523	87061524	rs2660753	3e-08	Prostate cancer
chr22	38150025	38150026	rs5756931	3e-08	Triglycerides
chr3	49173298	49173299	rs7617480	3e-08	Menarche (age at onset)
chr6	12903724	12903725	rs9349379	3e-08	Migraine
chr2	20983310	20983311	rs6754295	3e-08	Triglycerides
chr2	215439660	215439661	rs1250229	3e-08	LDL cholesterol
chr2	216998757	216998758	rs10932688	3e-08	Primary tooth development (number of teeth)
chr22	19996753	19996754	rs1034566	3e-08	Platelet counts
chr22	23828808	23828809	rs2186369	3e-08	IgG glycosylation
chr2	232123871	232123872	rs3103267	3e-08	Height
chr2	233159829	233159830	rs35349669	3e-08	Alzheimer's disease (late onset)
chr2	233910223	233910224	rs7577262	3e-08	Blood pressure measurement (cold pressor test)
chr2	236149499	236149500	rs11687170	3e-08	Educational attainment
chr22	37066895	37066896	rs855791	3e-08	Hematology traits
chr22	38148290	38148291	rs2284063	3e-08	Cutaneous nevi
chr3	52781888	52781889	rs2710323	3e-08	Schizophrenia, schizoaffective disorder or bipolar disorder
chr22	39463163	39463164	rs909674	3e-08	IgG glycosylation
chr22	50663509	50663510	rs6010044	3e-08	Fibrinogen
chr2	43098431	43098432	rs6718520	3e-08	Multiple sclerosis
chr2	9977739	9977740	rs11902236	3e-08	Prostate cancer
chr3	136207779	136207780	rs645040	3e-08	Triglycerides
chr3	138401109	138401110	rs2306374	3e-08	Coronary heart disease
chr3	166296680	166296681	rs509208	3e-08	Alzheimer's disease biomarkers
chr3	169582430	169582431	rs1344555	3e-08	Pulmonary function
chr3	169774312	169774313	rs10936599	3e-08	Colorectal cancer
chr3	1856288	1856289	rs2727943	3e-08	Bipolar disorder
chr3	186948672	186948673	rs16861329	3e-08	Type 2 diabetes
chr3	24309319	24309320	rs9310736	3e-08	Mean corpuscular volume
chr3	47885993	47885994	rs319690	3e-08	Blood pressure
chr22	41035337	41035338	rs4820425	3e-08	Crohn's disease
chr6	135131013	135131014	rs6569992	3e-08	Red blood cell traits
chr7	51938718	51938719	rs406001	3e-08	Post-traumatic stress disorder (asjusted for relatedness)
chr6	139508528	139508529	rs605066	3e-08	HDL cholesterol
chr7	26852820	26852821	rs10486483	3e-08	Crohn's disease
chr7	35515177	35515178	rs343064	3e-08	Non-alcoholic fatty liver disease histology (other)
chr7	50310670	50310671	rs6583437	3e-08	IgG glycosylation
chr7	73490479	73490480	rs17145713	3e-08	Protein C levels
chr7	98364049	98364050	rs3779195	3e-08	Sex hormone-binding globulin levels
chr8	11187651	11187652	rs7819412	3e-08	Triglycerides
chr8	141094844	141094845	rs4961252	3e-08	Response to interferon beta therapy
chr8	18415370	18415371	rs1495741	3e-08	Cholesterol, total
chr8	20010874	20010875	rs1441756	3e-08	Metabolic syndrome (bivariate traits)
chr8	21963301	21963302	rs7843479	3e-08	Mean corpuscular volume
chr8	29502787	29502788	rs10091038	3e-08	Response to statin therapy
chr8	88579853	88579854	rs11995572	3e-08	Schizophrenia
chr7	148953541	148953542	rs822552	3e-08	Height
chr8	88748081	88748082	rs7004633	3e-08	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr9	114228790	114228791	rs7868992	3e-08	Tourette syndrome
chr9	114806485	114806486	rs6478109	3e-08	Inflammatory bowel disease
chr9	133279293	133279294	rs495828	3e-08	Angiotensin-converting enzyme activity
chr9	22062134	22062135	rs1011970	3e-08	Breast cancer
chr9	22137685	22137686	rs7018475	3e-08	Type 2 diabetes
chr9	28414340	28414341	rs10968576	3e-08	Obesity
chr9	34710262	34710263	rs2812378	3e-08	Rheumatoid arthritis
chr9	4267208	4267209	rs1571583	3e-08	Thyroid hormone levels
chr9	5893860	5893861	rs2150702	3e-08	Multiple sclerosis
chr9	79337212	79337213	rs13292136	3e-08	Type 2 diabetes
chr9	8045605	8045606	rs2146180	3e-08	Personality dimensions
chr2	198016943	198016944	rs1016883	3e-08	Ulcerative colitis
chr8	97269960	97269961	rs1864729	3e-08	Estradiol plasma levels (breast cancer)
chr7	135645229	135645230	rs12530845	3e-08	Red blood cell traits
chr7	124822606	124822607	rs17246404	3e-08	Chronic lymphocytic leukemia
chr7	117277063	117277064	rs4730775	3e-08	Dupuytren's disease
chr6	139508528	139508529	rs605066	3e-08	HDL cholesterol
chr6	148200155	148200156	rs9497965	3e-08	Thyroid hormone levels
chr6	150931848	150931849	rs6922269	3e-08	Coronary heart disease
chr6	160668784	160668785	rs1084651	3e-08	HDL cholesterol
chr6	161740586	161740587	rs926849	3e-08	Disc degeneration (lumbar)
chr6	26092912	26092913	rs1800562	3e-08	Iron status biomarkers
chr6	31150733	31150734	rs130067	3e-08	Prostate cancer
chr6	32082289	32082290	rs185819	3e-08	Height
chr6	32683762	32683763	rs17212223	3e-08	Narcolepsy (age of onset)
chr6	32732305	32732306	rs2858884	3e-08	Narcolepsy
chr6	32884869	32884870	rs2187689	3e-08	Disc degeneration (lumbar)
chr6	33691268	33691269	rs4711336	3e-08	Height
chr6	34270736	34270737	rs6918981	3e-08	Height
chr6	34335091	34335092	rs206936	3e-08	Body mass index
chr6	39283060	39283061	rs2758886	3e-08	Cholesterol, total
chr6	43790158	43790159	rs998584	3e-08	Adiponectin levels
chr6	50868565	50868566	rs734597	3e-08	Obesity (extreme)
chr6	52236940	52236941	rs763780	3e-08	Response to gemcitabine in pancreatic cancer 
chr6	70579485	70579486	rs1048886	3e-08	Type 2 diabetes
chr6	7217283	7217284	rs6931262	3e-08	Waist-hip ratio
chr6	87157344	87157345	rs1925690	3e-08	MRI atrophy measures
chr6	90247743	90247744	rs3757247	3e-08	Vitiligo
chr6	90248511	90248512	rs11755527	3e-08	Type 1 diabetes autoantibodies
chr7	100860470	100860471	rs7801190	3e-08	Coronary heart disease
chr7	101472712	101472713	rs17135437	3e-08	Response to citalopram treatment
chr7	107604099	107604100	rs10953541	3e-08	Coronary heart disease
chr7	107854988	107854989	rs886774	3e-08	Ulcerative colitis
chr6	137685366	137685367	rs6920220	3e-08	Rheumatoid arthritis
chr2	177819992	177819993	rs7567851	3e-08	Height
chr22	39463163	39463164	rs909674	3e-08	IgG glycosylation
chr2	164672365	164672366	rs13389219	3e-08	Waist-hip ratio
chr12	120987057	120987058	rs7310409	3e-08	C-reactive protein
chr12	122141444	122141445	rs7953704	3e-08	Urate levels
chr12	123311690	123311691	rs4759375	3e-08	HDL cholesterol
chr12	124836303	124836304	rs4765623	3e-08	Renal cell carcinoma
chr1	218821930	218821931	rs7552186	3e-08	Height
chr1	219470881	219470882	rs2605100	3e-08	Adiposity
chr12	2236128	2236129	rs1006737	3e-08	Bipolar disorder and major depressive disorder (combined)
chr12	40034758	40034759	rs1994090	3e-08	Parkinson's disease
chr12	4259185	4259186	rs10774214	3e-08	Colorectal cancer
chr1	243381524	243381525	rs1538774	3e-08	Schizophrenia
chr12	50740957	50740958	rs7968440	3e-08	Fibrinogen
chr12	56018702	56018703	rs1701704	3e-08	Alopecia areata
chr12	111446803	111446804	rs3184504	3e-08	Beta-2 microglubulin plasma levels
chr12	57133499	57133500	rs11172113	3e-08	Migraine
chr12	68567803	68567804	rs12313946	3e-08	White blood cell count
chr12	96464583	96464584	rs12423247	3e-08	Phospholipid levels (plasma)
chr13	111568949	111568950	rs7333181	3e-08	Menopause (age at onset)
chr1	31411077	31411078	rs4478858	3e-08	Alcohol dependence
chr13	50816461	50816462	rs9316505	3e-08	Primary tooth development (number of teeth)
chr13	99389483	99389484	rs7335046	3e-08	Basal cell carcinoma 
chr14	100693078	100693079	rs7149242	3e-08	Platelet counts
chr1	4122945	4122946	rs10915437	3e-08	Migraine - clinic-based
chr14	22995272	22995273	rs997154	3e-08	Primary tooth development (number of teeth)
chr14	23507800	23507801	rs223116	3e-08	Resting heart rate
chr14	24632953	24632954	rs8192917	3e-08	Vitiligo
chr14	65308976	65308977	rs11847263	3e-08	IgG glycosylation
chr1	26415052	26415053	rs7532866	3e-08	Height
chr14	68322206	68322207	rs1956529	3e-08	Primary tooth development (number of teeth)
chr12	109457362	109457363	rs2338104	3e-08	HDL cholesterol
chr12	102481790	102481791	rs35767	3e-08	Fasting glucose-related traits
chr10	103146453	103146454	rs11191580	3e-08	Schizophrenia
chr10	113014167	113014168	rs7904519	3e-08	Breast cancer
chr10	117774245	117774246	rs7088969	3e-08	Homeostasis model assessment of beta-cell function (interaction)
chr10	130949623	130949624	rs10829848	3e-08	Insulin-related traits
chr10	131373855	131373856	rs10734105	3e-08	Crohn's disease
chr10	46046325	46046326	rs10993994	3e-08	Prostate cancer
chr10	52464216	52464217	rs1733724	3e-08	QRS duration
chr10	6060048	6060049	rs12722489	3e-08	Multiple sclerosis
chr10	6564578	6564579	rs4748153	3e-08	Immune response to smallpox vaccine (IL-6)
chr10	92677093	92677094	rs7911264	3e-08	Inflammatory bowel disease
chr1	10226117	10226118	rs17396340	3e-08	Mean platelet volume
chr11	116786844	116786845	rs3741298	3e-08	Obesity-related traits
chr12	102481790	102481791	rs35767	3e-08	Fasting insulin-related traits
chr11	122651666	122651667	rs7941030	3e-08	HDL cholesterol
chr11	18611436	18611437	rs10128711	3e-08	Cholesterol, total
chr11	5352020	5352021	rs5006884	3e-08	Fetal hemoglobin levels
chr11	54705061	54705062	rs5017948	3e-08	Height
chr1	156199818	156199819	rs2072499	3e-08	Testicular germ cell tumor
chr11	56408194	56408195	rs1945213	3e-08	Acute lymphoblastic leukemia (childhood)
chr1	159709025	159709026	rs2794520	3e-08	Select biomarker traits
chr11	65623845	65623846	rs12801636	3e-08	HDL cholesterol
chr1	172220748	172220749	rs678962	3e-08	Height
chr11	7345863	7345864	rs10769780	3e-08	Phospholipid levels (plasma)
chr11	76198574	76198575	rs4944092	3e-08	PR interval
chr1	191590225	191590226	rs10801047	3e-08	Crohn's disease
chr1	209539543	209539544	rs6703183	3e-08	Amyotrophic lateral sclerosis
chr11	16880720	16880721	rs381815	3e-08	Blood pressure
chr14	75234517	75234518	rs4899554	3e-08	Inflammatory bowel disease
chr11	128441163	128441164	rs6590330	3e-08	Systemic lupus erythematosus
chr15	100246065	100246066	rs4533267	3e-08	Height
chr18	12779947	12779948	rs2542151	3e-08	Crohn's disease
chr18	26990702	26990703	rs1436904	3e-08	Breast cancer
chr18	55084785	55084786	rs12966547	3e-08	Schizophrenia
chr18	55539975	55539976	rs1452787	3e-08	Sclerosing cholangitis and ulcerative colitis (combined)
chr18	59836145	59836146	rs8093763	3e-08	Bleomycin sensitivity
chr18	59955054	59955055	rs4368253	3e-08	Chronic lymphocytic leukemia
chr18	73500516	73500517	rs7240777	3e-08	Thyroid hormone levels
chr19	15879620	15879621	rs2108622	3e-08	Warfarin maintenance dose
chr19	17172492	17172493	rs2279008	3e-08	Height
chr19	19547662	19547663	rs16996148	3e-08	LDL cholesterol
chr19	2170954	2170955	rs12986413	3e-08	Height
chr1	92543880	92543881	rs7515577	3e-08	Cholesterol, total
chr18	12606463	12606464	rs9959145	3e-08	Immune response to smallpox vaccine (IL-6)
chr2	173348165	173348166	rs1550623	3e-08	Breast cancer
chr19	49496751	49496752	rs2280401	3e-08	Hematological and biochemical traits
chr19	54193223	54193224	rs7595	3e-08	Obesity-related traits
chr19	8368311	8368312	rs7255436	3e-08	HDL cholesterol
chr20	17141947	17141948	rs852069	3e-08	Menarche (age at onset)
chr20	2404325	2404326	rs34972666	3e-08	Alzheimer's disease (cognitive decline)
chr20	56443203	56443204	rs7274581	3e-08	Alzheimer's disease (late onset)
chr2	102110200	102110201	rs12712127	3e-08	Fibrinogen
chr21	31545980	31545981	rs13048019	3e-08	Amyotrophic lateral sclerosis
chr21	34279938	34279939	rs9978142	3e-08	Pulmonary function
chr2	150869277	150869278	rs10195263	3e-08	Immune reponse to smallpox (secreted IFN-alpha)
chr2	152124820	152124821	rs16830728	3e-08	Adverse response to chemotherapy in breast cancer (alopecia)
chr14	87039903	87039904	rs11624056	3e-08	Sudden cardiac arrest
chr19	3797101	3797102	rs12104221	3e-08	Obesity-related traits
chr17	81261987	81261988	rs7224668	3e-08	IgG glycosylation
chr20	1960524	1960525	rs6045676	3e-08	Aortic root size
chr17	70722592	70722593	rs4793501	3e-08	Refractive error
chr15	33613208	33613209	rs2229116	3e-08	Carotid atherosclerosis in HIV infection
chr1	77582645	77582646	rs17381664	3e-08	Obesity
chr15	71869061	71869062	rs12902421	3e-08	Height
chr15	75132251	75132252	rs7172677	3e-08	Systemic lupus erythematosus and Systemic sclerosis
chr15	83913371	83913372	rs4842838	3e-08	Height
chr15	90894157	90894158	rs2521501	3e-08	Blood pressure
chr16	11310035	11310036	rs12928822	3e-08	Celiac disease
chr16	30631545	30631546	rs7197475	3e-08	Systemic lupus erythematosus
chr16	30907165	30907166	rs11649653	3e-08	Triglycerides
chr16	53786614	53786615	rs9939609	3e-08	Menarche (age at onset)
chr16	53796552	53796553	rs9930506	3e-08	Obesity-related traits
chr16	53811574	53811575	rs11642841	3e-08	Type 2 diabetes
chr16	56955677	56955678	rs247616	3e-08	Lipoprotein-associated phospholipase A2 activity and mass
chr15	94727237	94727238	rs7173947	3e-08	Hematological and biochemical traits
chr17	46710943	46710944	rs183211	3e-08	Ovarian cancer in BRCA1 mutation carriers 
chr17	66783311	66783312	rs3889237	3e-08	Height
chr17	51167385	51167386	rs4605213	3e-08	Height
chr17	46710943	46710944	rs183211	3e-08	Ovarian cancer in BRCA1 mutation carriers 
chr17	61209282	61209283	rs8068952	3e-08	Vertical cup-disc ratio
chr17	42418753	42418754	rs11871801	3e-08	Crohn's disease
chr17	32016262	32016263	rs17780086	3e-08	Height
chr17	39905942	39905943	rs2305480	3e-08	Ulcerative colitis
chr1	69869998	69869999	rs2226284	3e-08	Hypertension risk in short sleep duration
chr16	88710833	88710834	rs8052560	3e-08	Height
chr1	67228518	67228519	rs2201841	3e-08	Psoriasis
chr16	68557326	68557327	rs1728785	3e-08	Ulcerative colitis
chr16	67979567	67979568	rs255049	3e-08	HDL cholesterol
chr16	60280751	60280752	rs9932186	3e-08	Phospholipid levels (plasma)
chr3	89485226	89485227	rs7632427	4e-08	Orofacial clefts
chr4	105163620	105163621	rs9790517	4e-08	Breast cancer
chr4	122408206	122408207	rs17388568	4e-08	Self-reported allergy
chr5	153160793	153160794	rs2910032	4e-08	Schizophrenia
chr3	58395559	58395560	rs13315871	4e-08	Cholesterol, total
chr3	49664549	49664550	rs9858542	4e-08	Crohn's disease
chr3	186762416	186762417	rs822354	4e-08	Adiponectin levels
chr3	89485226	89485227	rs7632427	4e-08	Orofacial clefts
chr4	122602719	122602720	rs7682241	4e-08	Alopecia areata
chr5	113694466	113694467	rs4621553	4e-08	Sudden cardiac arrest
chr4	183294521	183294522	rs955748	4e-08	Height
chr4	945324	945325	rs6599389	4e-08	Parkinson's disease
chr5	103261018	103261019	rs26232	4e-08	Rheumatoid arthritis
chr5	109613235	109613236	rs367615	4e-08	Colorectal cancer
chr5	132067044	132067045	rs3091338	4e-08	Crohn's disease
chr5	132637484	132637485	rs2040704	4e-08	IgE levels 
chr5	132713334	132713335	rs2897442	4e-08	Atopic dermatitis
chr3	186106214	186106215	rs1516725	4e-08	Body mass index
chr5	145659267	145659268	rs10515552	4e-08	Vitamin B12 levels
chr4	148158345	148158346	rs3931397	4e-08	Corneal structure
chr3	169253442	169253443	rs784288	4e-08	Osteoporosis
chr22	38150025	38150026	rs5756931	4e-08	Triglycerides
chr2	55862404	55862405	rs1367226	4e-08	Height
chr2	173462116	173462117	rs10930597	4e-08	Blood pressure measurement (low sodium intervention)
chr5	159177954	159177955	rs10076782	4e-08	Mean platelet volume
chr2	173598125	173598126	rs4972593	4e-08	End-stage renal disease in Type 1 diabetics
chr2	191722477	191722478	rs11903757	4e-08	Colorectal cancer
chr2	197766989	197766990	rs700651	4e-08	Intracranial aneurysm
chr2	20923591	20923592	rs6711016	4e-08	Metabolic syndrome
chr2	20983310	20983311	rs6754295	4e-08	HDL cholesterol
chr2	21018632	21018633	rs12713956	4e-08	LDL cholesterol
chr2	237534582	237534583	rs2292884	4e-08	Prostate cancer
chr2	73673772	73673773	rs10206899	4e-08	Glomerular filtration rate
chr2	24894107	24894108	rs7586879	4e-08	Body mass index
chr22	50528484	50528485	rs470119	4e-08	Mean corpuscular hemoglobin
chr2	27508072	27508073	rs1260326	4e-08	Waist circumference and related phenotypes
chr23	153942091	153942092	rs2269372	4e-08	Schizophrenia
chr2	32896436	32896437	rs6728021	4e-08	Immune response to smallpox vaccine (IL-6)
chr23	91557718	91557719	rs6618677	4e-08	Antineutrophil cytoplasmic antibody-associated vasculitis 
chr2	41853483	41853484	rs4305317	4e-08	Rheumatoid arthritis
chr2	46126026	46126027	rs10495928	4e-08	Red blood cell count
chr2	54120612	54120613	rs1559040	4e-08	Sudden cardiac arrest
chr2	55616276	55616277	rs782590	4e-08	Metabolic syndrome
chr22	49997050	49997051	rs5771069	4e-08	Ulcerative colitis
chr5	171588618	171588619	rs6892884	4e-08	Height
chr7	70341036	70341037	rs6943555	4e-08	Alcohol consumption
chr5	35876171	35876172	rs3194051	4e-08	Ulcerative colitis
chr7	37964803	37964804	rs1668357	4e-08	Myopia (pathological)
chr7	50310670	50310671	rs6583437	4e-08	IgG glycosylation
chr7	50959496	50959497	rs4948088	4e-08	Type 1 diabetes
chr8	117172785	117172786	rs3802177	4e-08	Type 2 diabetes
chr8	26348560	26348561	rs1594829	4e-08	Height
chr8	27630272	27630273	rs569214	4e-08	Alzheimer's disease
chr8	4323321	4323322	rs10503253	4e-08	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr8	93210715	93210716	rs278541	4e-08	IgG glycosylation
chr8	93210715	93210716	rs278541	4e-08	IgG glycosylation
chr7	37334905	37334906	rs6974491	4e-08	Primary biliary cirrhosis
chr8	9325847	9325848	rs9987289	4e-08	Metabolic syndrome (bivariate traits)
chr9	120890619	120890620	rs881375	4e-08	Rheumatoid arthritis
chr9	121152595	121152596	rs9408926	4e-08	Immune reponse to smallpox (secreted IFN-alpha)
chr9	133255934	133255935	rs8176746	4e-08	mean corpuscular hemoglobin concentration
chr9	133263861	133263862	rs657152	4e-08	Serum alkaline phosphatase levels
chr9	133613232	133613233	rs3025343	4e-08	Smoking behavior
chr9	22081850	22081851	rs6475606	4e-08	Intracranial aneurysm
chr9	36099401	36099402	rs4878639	4e-08	IgG glycosylation
chr9	74534920	74534921	rs7042950	4e-08	Refractive error
chr2	173462116	173462117	rs10930597	4e-08	Blood pressure measurement (high sodium and potassium intervention)
chr9	116490349	116490350	rs6478241	4e-08	Migraine
chr5	35852208	35852209	rs6890853	4e-08	Primary biliary cirrhosis
chr7	149506570	149506571	rs855913	4e-08	Amyotrophic lateral sclerosis
chr7	128928905	128928906	rs729302	4e-08	Systemic lupus erythematosus
chr5	44365442	44365443	rs2121875	4e-08	Prostate cancer
chr5	59684119	59684120	rs17382202	4e-08	Response to antipsychotic treatment
chr5	61203303	61203304	rs171748	4e-08	Schizophrenia
chr5	61435630	61435631	rs7709645	4e-08	Schizophrenia
chr5	96783161	96783162	rs17482078	4e-08	Behcet's disease
chr6	105987149	105987150	rs6568421	4e-08	Crohn's disease
chr6	11729848	11729849	rs2294426	4e-08	Orofacial clefts (interaction)
chr6	139514551	139514552	rs668459	4e-08	Mean corpuscular volume
chr6	149008130	149008131	rs2500535	4e-08	Response to antidepressants
chr7	142357118	142357119	rs2854536	4e-08	Narcolepsy
chr6	156591877	156591878	rs2817461	4e-08	Sensory disturbances after bilateral sagittal split ramus osteotomy
chr6	31386404	31386405	rs6932730	4e-08	Allergic sensitization
chr6	32146737	32146738	rs9296009	4e-08	IgG glycosylation
chr6	32289788	32289789	rs926070	4e-08	Chronic lymphocytic leukemia
chr6	32759025	32759026	rs1049110	4e-08	IgG glycosylation
chr6	34877671	34877672	rs4646949	4e-08	Fasting insulin-related traits (interaction with BMI)
chr6	35435007	35435008	rs4713858	4e-08	Height
chr6	41368362	41368363	rs6922617	4e-08	Alzheimer's disease biomarkers
chr6	89022381	89022382	rs12201676	4e-08	Bipolar disorder and schizophrenia
chr6	90287049	90287050	rs12212193	4e-08	Multiple sclerosis
chr6	29881841	29881842	rs2523809	4e-08	IgE levels 
chr2	169348335	169348336	rs2544390	4e-08	Urate levels
chr17	29348207	29348208	rs11653144	4e-08	Mean platelet volume
chr2	162925276	162925277	rs1424760	4e-08	Phospholipid levels (plasma)
chr11	58292719	58292720	rs12289961	4e-08	Lymphoma
chr1	16178824	16178825	rs1497406	4e-08	Gamma gluatamyl transferase levels
chr11	61803875	61803876	rs174548	4e-08	Hematology traits
chr11	76588149	76588150	rs2155219	4e-08	Allergic rhinitis
chr11	79366148	79366149	rs12576775	4e-08	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr11	79366148	79366149	rs12576775	4e-08	Bipolar disorder
chr11	85306431	85306432	rs17148090	4e-08	Phospholipid levels (plasma)
chr11	92975543	92975544	rs10830963	4e-08	Obesity-related traits
chr1	196731920	196731921	rs380390	4e-08	Age-related macular degeneration
chr11	56408194	56408195	rs1945213	4e-08	Acute lymphoblastic leukemia (childhood)
chr1	205707134	205707135	rs12748961	4e-08	White blood cell types
chr12	114914925	114914926	rs2384550	4e-08	Diastolic blood pressure
chr12	121001040	121001041	rs735396	4e-08	N-glycan levels
chr12	131137216	131137217	rs885389	4e-08	RR interval (heart rate)
chr12	14260996	14260997	rs12422552	4e-08	Breast cancer
chr1	219554436	219554437	rs3001032	4e-08	Adiponectin levels
chr12	20320823	20320824	rs7134375	4e-08	HDL cholesterol
chr12	20345101	20345102	rs7955516	4e-08	Adiponectin levels
chr1	230159943	230159944	rs4846914	4e-08	HDL cholesterol
chr1	230171435	230171436	rs4846922	4e-08	Metabolic syndrome
chr12	102405819	102405820	rs5742692	4e-08	Height
chr1	239806796	239806797	rs12059546	4e-08	Epilepsy (generalized)
chr1	150755062	150755063	rs2230061	4e-08	Fat body mass
chr1	145711420	145711421	rs1967017	4e-08	Urate levels
chr10	113721258	113721259	rs3814231	4e-08	Vitiligo
chr10	124737578	124737579	rs2629540	4e-08	Cocaine dependence
chr10	126979125	126979126	rs9733352	4e-08	Apolipoprotein Levels
chr10	18312998	18312999	rs2799573	4e-08	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr10	30046192	30046193	rs2505083	4e-08	Coronary heart disease
chr10	6060048	6060049	rs12722489	4e-08	Multiple sclerosis
chr10	69171717	69171718	rs1802295	4e-08	Type 2 diabetes
chr10	72018508	72018509	rs1245582	4e-08	Disc degeneration (lumbar)
chr10	81806929	81806930	rs9787485	4e-08	Homeostasis model assessment of insulin resistance (interaction)
chr11	47264738	47264739	rs7120118	4e-08	HDL cholesterol
chr10	89243169	89243170	rs1412444	4e-08	Coronary heart disease
chr1	100865979	100865980	rs12048904	4e-08	Multiple sclerosis
chr1	100865979	100865980	rs12048904	4e-08	Multiple sclerosis
chr11	10369033	10369034	rs6484218	4e-08	Schizophrenia, bipolar disorder and depression (combined)
chr2	166122239	166122240	rs7587026	4e-08	Mesial temporal lobe epilepsy with hippocampal sclerosis
chr11	116781490	116781491	rs12286037	4e-08	Lipoprotein-associated phospholipase A2 activity and mass
chr11	116789969	116789970	rs2266788	4e-08	Triglycerides-Blood Pressure (TG-BP)
chr11	125956806	125956807	rs4937076	4e-08	Primary tooth development (time to first tooth eruption)
chr11	1852841	1852842	rs907611	4e-08	Bladder cancer
chr1	119975335	119975336	rs10923931	4e-08	Type 2 diabetes
chr10	94253947	94253948	rs9419788	4e-08	Personality dimensions
chr12	68385632	68385633	rs416350	4e-08	Temperament (bipolar disorder)
chr1	111649499	111649500	rs494453	4e-08	Osteoporosis
chr13	47588422	47588423	rs2478333	4e-08	QT interval
chr18	76471018	76471019	rs6565887	4e-08	Renal transplant outcome
chr19	17282084	17282085	rs8100241	4e-08	Breast cancer
chr19	19678718	19678719	rs2304130	4e-08	Triglycerides
chr19	44892361	44892362	rs2075650	4e-08	Cardiovascular disease risk factors
chr1	94586919	94586920	rs2022309	4e-08	End-stage coagulation
chr19	48993897	48993898	rs3764618	4e-08	Follicule stimulating hormone
chr20	10988381	10988382	rs1327235	4e-08	Blood pressure
chr20	14766824	14766825	rs4141463	4e-08	Autism
chr20	1478414	1478415	rs6042507	4e-08	Circulating myeloperoxidase levels (serum) 
chr18	71771836	71771837	rs17085106	4e-08	Orofacial clefts
chr20	57495448	57495449	rs6025590	4e-08	Obesity-related traits
chr20	62440554	62440555	rs2427345	4e-08	Prostate cancer
chr2	109018800	109018801	rs4676049	4e-08	Alzheimer's disease (late onset)
chr2	111231794	111231795	rs6720394	4e-08	Primary sclerosing cholangitis
chr21	21317023	21317024	rs11088859	4e-08	Obesity
chr2	133771519	133771520	rs6722456 	4e-08	Palmitoleic acid (16:1n-7) plasma levels
chr2	15722877	15722878	rs6431731	4e-08	Chronic kidney disease
chr2	160314942	160314943	rs7593730	4e-08	Type 2 diabetes
chr2	161236128	161236129	rs7309	4e-08	Educational attainment
chr12	7182216	7182217	rs7973719	4e-08	IgG glycosylation
chr20	61278881	61278882	rs1970546	4e-08	Volumetric brain MRI
chr18	60181789	60181790	rs12967135	4e-08	HDL cholesterol
chr2	100807868	100807869	rs7565981	4e-08	Creutzfeldt-Jakob disease (variant)
chr17	49312651	49312652	rs2072153	4e-08	Height
chr15	28111712	28111713	rs1129038	4e-08	Vitiligo
chr18	36114156	36114157	rs1050631	4e-08	Esophageal squamous cell cancer (length of survival)
chr15	46347609	46347610	rs4775302	4e-08	Prostate cancer
chr1	55030365	55030366	rs11206510	4e-08	LDL cholesterol
chr15	52987180	52987181	rs719714	4e-08	Cognitive function
chr15	78540880	78540881	rs12901682	4e-08	Response to tocilizumab in rheumatoid arthritis
chr15	86648745	86648746	rs2469184	4e-08	Activated partial thromboplastin time
chr16	24664267	24664268	rs8045064	4e-08	Alzheimer's disease (cognitive decline)
chr16	3963465	3963466	rs2531995	4e-08	Obesity
chr16	53775334	53775335	rs1121980	4e-08	Body mass index
chr15	62141762	62141763	rs11071657	4e-08	Fasting glucose-related traits
chr16	53821378	53821379	rs11075995	4e-08	Breast cancer
chr16	58041377	58041378	rs12447804	4e-08	Pulmonary function
chr16	58041377	58041378	rs12447804	4e-08	Pulmonary function (interaction)
chr16	66124832	66124833	rs8050896	4e-08	Response to antipsychotic treatment
chr16	68557326	68557327	rs1728785	4e-08	Ulcerative colitis
chr16	68640884	68640885	rs6499188	4e-08	Ulcerative colitis
chr17	42329510	42329511	rs2293152	4e-08	Multiple sclerosis
chr16	53782362	53782363	rs8050136	4e-08	Body mass in chronic obstructive pulmonary disease
chr17	34266954	34266955	rs3091316	4e-08	Crohn's disease
chr4	153943597	153943598	rs13135284	5e-08	DNA methylation (parent-of-origin)
chr4	156077388	156077389	rs4234898	5e-08	Speech perception in dyslexia
chr4	26061367	26061368	rs10019888	5e-08	HDL cholesterol
chr4	74577304	74577305	rs62314947	5e-08	Breast size
chr4	99093653	99093654	rs2602836	5e-08	HDL cholesterol
chr5	159580769	159580770	rs10065906	5e-08	Major depressive disorder
chr5	138371625	138371626	rs757647	5e-08	Menarche (age at onset)
chr5	173512422	173512423	rs6869841	5e-08	Prostate cancer
chr5	54002194	54002195	rs6450176	5e-08	HDL cholesterol
chr5	7649746	7649747	rs4702484	5e-08	Capecitabine sensitivity
chr4	101010668	101010669	rs1405687	5e-08	Response to antipsychotic treatment
chr5	57876250	57876251	rs4432842	5e-08	Birth weight
chr5	108580034	108580035	rs10447248	5e-08	Adiponectin levels
chr3	80816612	80816613	rs9850225	5e-08	Erectile dysfunction
chr2	81628600	81628601	rs6736587	5e-08	Orthostatic hypotension
chr3	49664549	49664550	rs9858542	5e-08	Crohn's disease
chr3	187005155	187005156	rs7652995	5e-08	IgG glycosylation
chr3	187005155	187005156	rs7652995	5e-08	IgG glycosylation
chr3	186855915	186855916	rs6773957	5e-08	Adiponectin levels
chr3	186502273	186502274	rs1868152	5e-08	Illicit drug use
chr3	139185142	139185143	rs7638110	5e-08	Obesity and blood pressure
chr3	12226147	12226148	rs7616006	5e-08	Platelet counts
chr3	11358774	11358775	rs2606736	5e-08	HDL cholesterol
chr2	75699438	75699439	rs2298948	5e-08	Hippocampal atrophy
chr2	53555421	53555422	rs13407662	5e-08	Stroke (ischemic)
chr2	48974188	48974189	rs2268363	5e-08	Erectile dysfunction and prostate cancer treatment
chr2	25146132	25146133	rs1561288	5e-08	Body mass index
chr6	10897254	10897255	rs2153157	5e-08	Menarche and menopause (age at onset)
chr22	39576156	39576157	rs3788556	5e-08	IgG glycosylation
chr3	58571113	58571114	rs13315591	5e-08	Rheumatoid arthritis
chr6	116792861	116792862	rs6901250	5e-08	C-reactive protein
chr8	70064269	70064270	rs7010162	5e-08	Testicular germ cell tumor
chr6	150683633	150683634	rs17080102	5e-08	Blood pressure
chr22	35315104	35315105	rs138777	5e-08	Cholesterol, total
chr9	83937289	83937290	rs7853377	5e-08	Height
chr9	33153528	33153529	rs10813957	5e-08	IgG glycosylation
chr9	33124873	33124874	rs12342831	5e-08	IgG glycosylation
chr9	22134094	22134095	rs10811661	5e-08	Type 2 diabetes
chr9	136372043	136372044	rs4077515	5e-08	Ulcerative colitis
chr9	136197832	136197833	rs7860634	5e-08	Thyroid hormone levels
chr9	134676204	134676205	rs7044529	5e-08	Central corneal thickness
chr9	133273812	133273813	rs505922	5e-08	Pancreatic cancer
chr8	77247942	77247943	rs7846385	5e-08	Height
chr8	4380616	4380617	rs6558872	5e-08	Schizophrenia, schizoaffective disorder or bipolar disorder
chr8	19973409	19973410	rs10096633	5e-08	Metabolic traits
chr8	15675075	15675076	rs4831760	5e-08	Pulmonary function decline
chr8	117172543	117172544	rs13266634	5e-08	Type 2 diabetes
chr8	117172543	117172544	rs13266634	5e-08	Type 2 diabetes
chr8	117172543	117172544	rs13266634	5e-08	Type 2 diabetes
chr8	117172543	117172544	rs13266634	5e-08	Glycated hemoglobin levels
chr8	102566645	102566646	rs2511714	5e-08	Chronic lymphocytic leukemia
chr7	154513712	154513713	rs10260404	5e-08	Amyotrophic lateral sclerosis
chr7	108332852	108332853	rs6975557	5e-08	Femoral neck bone geometry and menarche (age at onset)
chr6	90248511	90248512	rs11755527	5e-08	Type 1 diabetes
chr6	49441773	49441774	rs9473555	5e-08	Folate pathway vitamin levels
chr6	471135	471136	rs12202284	5e-08	Non-melanoma skin cancer
chr6	44626421	44626422	rs556621	5e-08	Stroke (ischemic)
chr6	33579059	33579060	rs210142	5e-08	Chronic lymphocytic leukemia
chr6	33176170	33176171	rs2254287	5e-08	LDL cholesterol
chr6	31386782	31386783	rs13437082	5e-08	Height
chr6	25821541	25821542	rs17342717	5e-08	Red blood cell traits
chr6	160489484	160489485	rs12214416	5e-08	Lp (a) levels
chr6	12903724	12903725	rs9349379	5e-08	Migraine
chr2	233770737	233770738	rs11563251	5e-08	LDL cholesterol
chr7	37397250	37397251	rs11984075	5e-08	Celiac disease and Rheumatoid arthritis
chr2	193119894	193119895	rs17662626	5e-08	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr12	21215787	21215788	rs4363657	5e-08	Bilirubin levels
chr12	131091645	131091646	rs1569019	5e-08	Height
chr12	113169696	113169697	rs2384207	5e-08	Response to fenofibrate (adiponectin levels)
chr12	111803961	111803962	rs671	5e-08	Alcohol dependence
chr1	201376358	201376359	rs12564445	5e-08	Cardiac Troponin-T levels
chr1	201376358	201376359	rs12564445	5e-08	Cardiac Troponin-T levels
chr1	201293303	201293304	rs860554	5e-08	Panic disorder
chr11	93058933	93058934	rs7120482	5e-08	Adverse response to radiation therapy
chr1	172272110	172272111	rs2421992	5e-08	Height
chr1	171122734	171122735	rs1795240	5e-08	Lentiform nucleus volume 
chr11	68424877	68424878	rs599083	5e-08	Bone mineral density (spine)
chr2	193119894	193119895	rs17662626	5e-08	Schizophrenia
chr11	64281439	64281440	rs477895	5e-08	Mean platelet volume
chr11	61803875	61803876	rs174548	5e-08	Metabolite levels
chr1	155135690	155135691	rs12726330	5e-08	Parkinson's disease
chr11	43706779	43706780	rs11037575	5e-08	Neuroblastoma
chr11	27484129	27484130	rs10835187	5e-08	Bone mineral density
chr1	115135324	115135325	rs12134493	5e-08	Migraine without aura
chr11	116861795	116861796	rs2075292	5e-08	Triglycerides
chr11	10367234	10367235	rs2923084	5e-08	HDL cholesterol
chr11	10367234	10367235	rs2923084	5e-08	HDL cholesterol
chr10	99095944	99095945	rs12570188	5e-08	Asthma (childhood onset)
chr10	81806929	81806930	rs9787485	5e-08	Fasting insulin (interaction)
chr10	76555465	76555466	rs11001819	5e-08	Pulmonary function (interaction)
chr10	725591	725592	rs877282	5e-08	Uric acid levels
chr10	66206815	66206816	rs12251332	5e-08	Metabolite levels (Pyroglutamine)
chr10	63501423	63501424	rs2893923	5e-08	Platelet aggregation
chr10	43260305	43260306	rs28461806	5e-08	Obesity-related traits
chr10	112998589	112998590	rs7903146	5e-08	Type 2 diabetes
chr1	243445664	243445665	rs6703335	5e-08	Schizophrenia
chr12	54342685	54342686	rs4326844	5e-08	Platelet counts
chr11	34533643	34533644	rs836132	5e-08	&beta;2-Glycoprotein I (&beta;2-GPI) plasma levels
chr12	9681031	9681032	rs3764021	5e-08	Type 1 diabetes
chr12	93841388	93841389	rs61144803	5e-08	Alzheimer's disease (cognitive decline)
chr2	19121041	19121042	rs12710696	5e-08	Breast cancer
chr2	187468336	187468337	rs4140885	5e-08	Heart rate
chr21	16110812	16110813	rs2823615	5e-08	Obesity-related traits
chr2	112495	112496	rs300774	5e-08	Suicide attempts in bipolar disorder
chr20	50338886	50338887	rs913678	5e-08	Inflammatory bowel disease
chr20	46134644	46134645	rs4813003	5e-08	Kawasaki disease
chr20	10658894	10658895	rs2273061	5e-08	Bone mineral density
chr19	48711016	48711017	rs281379	5e-08	Pubertal anthropometrics
chr19	44892008	44892009	rs157580	5e-08	LDL cholesterol
chr1	9348899	9348900	rs11121380	5e-08	Response to tocilizumab in rheumatoid arthritis
chr19	17641879	17641880	rs12608932	5e-08	Amyotrophic lateral sclerosis
chr18	13708574	13708575	rs4796995	5e-08	Bone mineral density
chr17	63899887	63899888	rs2854160	5e-08	Height
chr17	47691469	47691470	rs8070463	5e-08	Ankylosing spondylitis
chr1	95083979	95083980	rs9437689	5e-08	Phospholipid levels (plasma)
chr16	55570215	55570216	rs6499766	5e-08	Thyroid hormone levels
chr13	104386795	104386796	rs17450420	5e-08	Esophageal cancer  (alcohol interaction)
chr16	83678829	83678830	rs3784943	5e-08	Response to amphetamines
chr13	110166250	110166251	rs3742207	5e-08	Arterial stiffness
chr13	110276814	110276815	rs494558	5e-08	Obesity-related traits
chr13	32398488	32398489	rs11571833	5e-08	Breast cancer
chr14	38214055	38214056	rs11622412	5e-08	Metabolite levels (5-HIAA/ MHPG Ratio)
chr14	65008821	65008822	rs4466998	5e-08	Mean corpuscular volume
chr14	37607942	37607943	rs1998359	5e-08	Self-reported allergy
chr14	79478818	79478819	rs10146997	5e-08	Waist circumference
chr15	32635274	32635275	rs8037818	5e-08	Obesity-related traits
chr15	74013624	74013625	rs8039584	5e-08	Myopia (pathological)
chr1	60576202	60576203	rs12565755	5e-08	Response to tocilizumab in rheumatoid arthritis
chr16	11923061	11923062	rs10852344	5e-08	Menopause (age at onset)
chr14	67472765	67472766	rs17104363	5e-08	Obesity-related traits
chr6	167024499	167024500	rs2301436	6e-08	Crohn's disease
chr3	52821212	52821213	rs2239547	6e-08	Schizophrenia
chr6	12888771	12888772	rs1332844	6e-08	Coronary heart disease
chr5	5297086	5297087	rs16875288	6e-08	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia
chr6	26500334	26500335	rs13194984	6e-08	Iron status biomarkers
chr4	15396281	15396282	rs1861046	6e-08	Conduct disorder (case status)
chr3	87085649	87085650	rs17023900	6e-08	Prostate cancer
chr3	36822997	36822998	rs6550435	6e-08	Schizophrenia
chr3	122074339	122074340	rs4308217	6e-08	Multiple sclerosis
chr3	189928143	189928144	rs710521	6e-08	Urinary bladder cancer
chr3	184372477	184372478	rs6141	6e-08	Platelet counts
chr3	168180032	168180033	rs2686586	6e-08	Thiazide-induced adverse metabolic effects in hypertensive patients
chr3	123346930	123346931	rs11708067	6e-08	Type 2 diabetes
chr3	100757868	100757869	rs9823506	6e-08	Asthma (childhood onset)
chr6	31306777	31306778	rs10484554	6e-08	AIDS progression
chr23	12953404	12953405	rs5979785	6e-08	Celiac disease
chr3	35101018	35101019	rs11129640	6e-08	Entorhinal cortical thickness
chr6	32730007	32730008	rs2859113	6e-08	IgG glycosylation
chr8	88748081	88748082	rs7004633	6e-08	Schizophrenia
chr6	32891970	32891971	rs11969002	6e-08	Disc degeneration (lumbar)
chr2	27508072	27508073	rs1260326	6e-08	Serum total protein level
chr9	22062134	22062135	rs1011970	6e-08	Breast cancer
chr9	134548681	134548682	rs1536482	6e-08	Central corneal thickness
chr9	132742895	132742896	rs11243897	6e-08	Attention deficit hyperactivity disorder
chr8	88572818	88572819	rs7838490	6e-08	Body mass index and cholesterol (psychopharmacological treatment)
chr8	81115436	81115437	rs10097731	6e-08	Serum total protein level
chr8	79315212	79315213	rs1460163	6e-08	Creutzfeldt-Jakob disease
chr8	75661475	75661476	rs2922763	6e-08	Body mass index
chr8	24186787	24186788	rs11777116	6e-08	Migraine - clinic-based
chr8	117172543	117172544	rs13266634	6e-08	Type 2 diabetes
chr7	40426600	40426601	rs4379368	6e-08	Migraine without aura
chr7	107567249	107567250	rs4730250	6e-08	Osteoarthritis
chr7	107122772	107122773	rs13224682	6e-08	Response to antipsychotic treatment
chr6	96437009	96437010	rs11757063	6e-08	Migraine
chr6	542158	542159	rs6918152	6e-08	Black vs. blond hair color
chr6	383545	383546	rs1033180	6e-08	Celiac disease
chr6	33572431	33572432	rs210134	6e-08	Platelet counts
chr6	32891934	32891935	rs7744666	6e-08	Disc degeneration (lumbar)
chr22	50578923	50578924	rs5770917	6e-08	Narcolepsy
chr5	54002194	54002195	rs6450176	6e-08	Adiponectin levels
chr2	217258924	217258925	rs2553026	6e-08	Height
chr15	58386312	58386313	rs10468017	6e-08	Metabolic syndrome (bivariate traits)
chr14	54881399	54881400	rs3783637	6e-08	Obesity-related traits
chr14	23563860	23563861	rs2281680	6e-08	Sudden cardiac arrest
chr13	111529089	111529090	rs9555810	6e-08	Menarche (age at onset)
chr1	26194648	26194649	rs11809207	6e-08	Height
chr12	56124623	56124624	rs11171747	6e-08	Systemic sclerosis
chr12	4279104	4279105	rs3217810	6e-08	Colorectal cancer
chr1	221991605	221991606	rs6687758	6e-08	Progressive supranuclear palsy
chr1	220484891	220484892	rs12563333	6e-08	Bipolar disorder
chr11	92989594	92989595	rs1447352	6e-08	Metabolic traits
chr1	177944383	177944384	rs10913469	6e-08	Body mass index
chr11	46031023	46031024	rs16938437	6e-08	Menarche (age at onset)
chr11	10328990	10328991	rs7129220	6e-08	Diastolic blood pressure
chr10	99528006	99528007	rs10883365	6e-08	Crohn's disease
chr10	76397813	76397814	rs10509373	6e-08	Response to tamoxifen in breast cancer
chr10	18419868	18419869	rs11014166	6e-08	Hypertension
chr22	19703978	19703979	rs4819833	6e-08	DNA methylation (parent-of-origin)
chr1	56385013	56385014	rs11206801	6e-08	AB1-42
chr15	78618838	78618839	rs8040868	6e-08	Obesity-related traits
chr11	41893815	41893816	rs9300039	6e-08	Type 2 diabetes
chr16	23622704	23622705	rs420259	6e-08	Bipolar disorder
chr15	83617739	83617740	rs2562784	6e-08	Height
chr2	184947212	184947213	rs4380187	6e-08	Schizophrenia
chr2	150779317	150779318	rs6757804	6e-08	Endometriosis
chr2	102354739	102354740	rs9807989	6e-08	Asthma
chr20	58987046	58987047	rs2273359	6e-08	Response to diuretic therapy in hypertension
chr20	39672164	39672165	rs6016142	6e-08	Estradiol levels
chr19	18692361	18692362	rs10419226	6e-08	Barrett's esophagus
chr1	8699494	8699495	rs12025126	6e-08	Vertical cup-disc ratio
chr2	149290763	149290764	rs10432496	6e-08	Immune reponse to smallpox (secreted IL-2)
chr17	61419915	61419916	rs757608	6e-08	Height
chr17	45436074	45436075	rs11012	6e-08	Parkinson's disease
chr1	72346756	72346757	rs2815752	6e-08	Body mass index
chr17	2305604	2305605	rs4523957	6e-08	Schizophrenia
chr2	18953469	18953470	rs1876040	6e-08	Cognitive performance
chr17	17811786	17811787	rs11868035	6e-08	Parkinson's disease
chr16	53797858	53797859	rs9922619	6e-08	Subcutaneous adipose tissue
chr17	7648804	7648805	rs72829446	6e-08	Androgen levels
chr1	62531166	62531167	rs1168013	6e-08	Triglycerides
chr4	78359538	78359539	rs1268789	7e-08	Hair morphology
chr4	143436583	143436584	rs3805236	7e-08	Asthma
chr4	11628424	11628425	rs6448799	7e-08	Alzheimer's disease (late onset)
chr4	110460481	110460482	rs6825911	7e-08	Blood pressure
chr3	37477053	37477054	rs189897	7e-08	Nasopharyngeal carcinoma
chr3	157080683	157080684	rs1482853	7e-08	Adiposity in newborns
chr2	27519735	27519736	rs780093	7e-08	Sex hormone-binding globulin levels
chr2	44435335	44435336	rs13414205	7e-08	Immune reponse to smallpox (secreted TNF-alpha)
chr2	238440720	238440721	rs3769124	7e-08	Pulmonary function
chr2	229657681	229657682	rs1861612	7e-08	Type 2 diabetes
chr4	88143428	88143429	rs3114018	7e-08	Dental caries
chr2	134722409	134722410	rs6723108	7e-08	Type 2 diabetes
chr3	134514249	134514250	rs10935120	7e-08	Height
chr4	89757389	89757390	rs2736990	7e-08	Parkinson's disease
chr6	43791135	43791136	rs6905288	7e-08	Coronary heart disease
chr5	174587110	174587111	rs145848414	7e-08	Alzheimer's disease (late onset)
chr5	180743818	180743819	rs12517906	7e-08	Weight
chr5	8652757	8652758	rs200113	7e-08	Uric acid levels
chr6	121427395	121427396	rs11154022	7e-08	Resting heart rate
chr6	159044944	159044945	rs1738074	7e-08	Celiac disease
chr6	32634491	32634492	rs9272219	7e-08	Schizophrenia
chr6	33497704	33497705	rs9394152	7e-08	Chronic obstructive pulmonary disease
chr7	100638346	100638347	rs7385804	7e-08	Iron levels
chr7	24200545	24200546	rs886448	7e-08	Asthma (childhood onset)
chr7	55091655	55091656	rs11979158	7e-08	Glioma
chr8	56183248	56183249	rs10958476	7e-08	Height
chr8	80549738	80549739	rs440837	7e-08	Sex hormone-binding globulin levels
chr2	11618304	11618305	rs73175262	7e-08	Obesity-related traits
chr9	33128022	33128023	rs10813951	7e-08	IgG glycosylation
chr5	159387524	159387525	rs10045431	7e-08	Crohn's disease
chr21	14309672	14309673	rs2192161	7e-08	Non-word repetition
chr17	71129464	71129465	rs11654749	7e-08	Pulmonary function (interaction)
chr18	52991405	52991406	rs7504990	7e-08	Gallbladder cancer
chr19	49496751	49496752	rs2280401	7e-08	Serum total protein level
chr10	102831635	102831636	rs17115100	7e-08	Parkinson's disease
chr10	52464216	52464217	rs1733724	7e-08	Electrocardiographic traits
chr10	8051070	8051071	rs501764	7e-08	Hodgkin's lymphoma
chr10	92705801	92705802	rs5015480	7e-08	Type 2 diabetes
chr11	125309956	125309957	rs12284594	7e-08	Substance dependence
chr11	34633815	34633816	rs286913	7e-08	Response to antipsychotic treatment
chr1	205744249	205744250	rs823128	7e-08	Parkinson's disease
chr1	207955376	207955377	rs2745967	7e-08	Resting heart rate
chr1	212953222	212953223	rs3002288	7e-08	Eye color
chr12	21304499	21304500	rs11568563	7e-08	Progressive supranuclear palsy
chr12	2236128	2236129	rs1006737	7e-08	Bipolar disorder
chr12	2236128	2236129	rs1006737	7e-08	Schizophrenia or bipolar disorder
chr12	29960949	29960950	rs1463605	7e-08	Aging traits
chr11	56698622	56698623	rs1397048	7e-08	Hemostatic factors and hematological phenotypes
chr1	240441751	240441752	rs12091371	7e-08	Alzheimer's disease (cognitive decline)
chr17	17164867	17164868	rs61744862	7e-08	Obesity-related traits
chr1	236016568	236016569	rs3768080	7e-08	Cutaneous nevi
chr16	89600928	89600929	rs154659	7e-08	Tanning
chr16	88287829	88287830	rs6540223	7e-08	Axial length
chr1	53405412	53405413	rs114216682	7e-08	Chronic obstructive pulmonary disease
chr14	51843385	51843386	rs8015138	7e-08	Non-melanoma skin cancer
chr15	92387180	92387181	rs17702901	7e-08	Weight loss (gastric bypass surgery)
chr13	93293604	93293605	rs143258881	7e-08	Alzheimer's disease (cognitive decline)
chr13	80385071	80385072	rs534870	7e-08	Adiposity
chr13	26957129	26957130	rs17085007	7e-08	Ulcerative colitis
chr12	58865845	58865846	rs11172782	7e-08	Heart failure
chr1	24193429	24193430	rs4649203	7e-08	Psoriasis
chr1	43853700	43853701	rs3011225	7e-08	Amyotrophic lateral sclerosis (age of onset)
chr6	31600691	31600692	rs2857595	8e-08	Pulmonary function (interaction)
chr9	15335915	15335916	rs16933006	8e-08	Obesity-related traits
chr6	25771818	25771819	rs4712972	8e-08	Carotid intima media thickness
chr5	165337080	165337081	rs1145652	8e-08	Phospholipid levels (plasma)
chr5	159332891	159332892	rs2546890	8e-08	Multiple sclerosis
chr5	104734215	104734216	rs161645	8e-08	Depression (quantitative trait)
chr4	105536172	105536173	rs7669317	8e-08	Response to antipsychotic therapy (extrapyramidal side effects)
chr3	169448099	169448100	rs1918974	8e-08	Diastolic blood pressure
chr3	56701151	56701152	rs6773931	8e-08	Height
chr3	191804062	191804063	rs1516489	8e-08	Immune response to smallpox vaccine (IL-6)
chr3	188866890	188866891	rs13067593	8e-08	Immune reponse to smallpox (secreted IFN-alpha)
chr3	185793898	185793899	rs4402960	8e-08	Type 2 diabetes
chr3	141424587	141424588	rs10513137	8e-08	Height
chr6	39816588	39816589	rs2395730	8e-08	Pulmonary function
chr4	101639132	101639133	rs17031508	8e-08	Blood pressure
chr6	41411576	41411577	rs7762544	8e-08	Periodontitis
chr8	80355919	80355920	rs6473223	8e-08	Self-reported allergy
chr6	9450963	9450964	rs10484246	8e-08	Morbidity-free survival
chr2	34405964	34405965	rs6543833	8e-08	Ovarian reserve
chr8	95041771	95041772	rs7818382	8e-08	Alzheimer's disease (late onset)
chr8	89198870	89198871	rs2046315	8e-08	Smooth-surface caries 
chr8	27608797	27608798	rs1532278	8e-08	Alzheimer's disease (late onset)
chr8	23676504	23676505	rs10503733	8e-08	Prostate cancer
chr8	21110039	21110040	rs7015657	8e-08	Migraine with aura
chr8	18120140	18120141	rs17126232	8e-08	Obesity
chr8	117172543	117172544	rs13266634	8e-08	Type 2 diabetes and other traits
chr7	80657591	80657592	rs11574703	8e-08	Response to fenofibrate
chr7	54911230	54911231	rs2252586	8e-08	Glioma
chr7	50683392	50683393	rs10248619	8e-08	Fasting glucose-related traits (interaction with BMI)
chr7	21108058	21108059	rs11974269	8e-08	Obesity-related traits
chr7	155969462	155969463	rs6943029	8e-08	Platelet aggregation
chr7	107862995	107862996	rs4598195	8e-08	Ulcerative colitis
chr7	107297974	107297975	rs3815148	8e-08	Osteoarthritis
chr6	41568688	41568689	rs1983891	8e-08	Prostate cancer
chr2	33246124	33246125	rs3769528	8e-08	Height
chr16	78154598	78154599	rs8056446   	8e-08	Pulmonary function (interaction)
chr22	34493104	34493105	rs738968	8e-08	Immune reponse to smallpox (secreted TNF-alpha)
chr12	128816148	128816149	rs1385374	8e-08	Systemic lupus erythematosus
chr12	120979184	120979185	rs2244608	8e-08	Urate levels
chr12	116564852	116564853	rs2089222	8e-08	Acute lymphoblastic leukemia (childhood)
chr12	111569951	111569952	rs653178	8e-08	Celiac disease
chr1	206770622	206770623	rs3024493	8e-08	Ulcerative colitis
chr11	91151170	91151171	rs1528753	8e-08	Aging traits
chr12	442383	442384	rs1048466	8e-08	Obesity (early onset extreme)
chr1	189620208	189620209	rs10489759	8e-08	Immune response to smallpox vaccine (IL-6)
chr11	61978818	61978819	rs10792320	8e-08	Phospholipid levels (plasma)
chr11	47419206	47419207	rs2293579	8e-08	Serum albumin level
chr11	110870289	110870290	rs1469170	8e-08	Malaria
chr10	71831772	71831773	rs11000019	8e-08	Asthma (childhood onset)
chr10	121573062	121573063	rs3750817	8e-08	Breast cancer
chr2	235886698	235886699	rs13025591	8e-08	Schizophrenia
chr1	165767642	165767643	rs7518099	8e-08	Intraocular pressure
chr13	98458954	98458955	rs3783006	8e-08	Educational attainment
chr11	31883987	31883988	rs652722	8e-08	Body mass index
chr14	22013584	22013585	rs3811321	8e-08	Renal transplant outcome
chr14	20793573	20793574	rs10131141	8e-08	Obesity-related traits
chr2	233498008	233498009	rs6704644	8e-08	Bilirubin levels
chr2	232561815	232561816	rs1656402	8e-08	Non-small cell lung cancer (survival)
chr2	20688504	20688505	rs13385191	8e-08	Prostate cancer
chr2	163634018	163634019	rs982393	8e-08	Folate pathway vitamin levels
chr20	17455827	17455828	rs6044834	8e-08	Obesity-related traits
chr19	44892361	44892362	rs2075650	8e-08	Age-related macular degeneration
chr2	22964631	22964632	rs2681019	8e-08	Dialysis-related mortality
chr17	47853172	47853173	rs4794202	8e-08	Alzheimer's disease (cognitive decline)
chr16	1023551	1023552	rs2744148	8e-08	Multiple sclerosis
chr15	96165061	96165062	rs8023580	8e-08	Sex hormone-binding globulin levels
chr15	88816457	88816458	rs8041863	8e-08	Height
chr15	78943103	78943104	rs3825932	8e-08	Type 1 diabetes
chr15	75463125	75463126	rs4886707	8e-08	Height
chr17	50196929	50196930	rs2075555	8e-08	Breast cancer
chr14	53700753	53700754	rs210359	8e-08	Immune reponse to smallpox (secreted IFN-alpha)
chr3	150750020	150750021	rs6788895	9e-08	Breast cancer
chr2	67746754	67746755	rs13432159	9e-08	Response to antidepressant treatment
chr2	67637542	67637543	rs4141819	9e-08	Endometriosis
chr2	43312985	43312986	rs7590268	9e-08	Orofacial clefts
chr2	191038031	191038032	rs3821236	9e-08	Systemic sclerosis
chr19	55809296	55809297	rs12461110	9e-08	Menopause (age at onset)
chr2	101996550	101996551	rs4321386	9e-08	Hormone measurements
chr19	4830615	4830616	rs6510827	9e-08	Vitiligo
chr3	188369839	188369840	rs9851967	9e-08	Vitiligo
chr19	33418803	33418804	rs8182584	9e-08	Fasting insulin-related traits (interaction with BMI)
chr2	168926369	168926370	rs569805	9e-08	Metabolic syndrome (bivariate traits)
chr4	186236879	186236880	rs3733402	9e-08	Obesity-related traits
chr6	34796204	34796205	rs9469890	9e-08	Pubertal anthropometrics
chr5	127833519	127833520	rs245201	9e-08	Brain imaging in schizophrenia (interaction)
chr5	133686159	133686160	rs6596140	9e-08	Hypertension
chr6	168540943	168540944	rs13208776	9e-08	Vitiligo
chr6	32638978	32638979	rs9272535	9e-08	Chronic lymphocytic leukemia
chr6	32887939	32887940	rs6457690	9e-08	Disc degeneration (lumbar)
chr6	32888603	32888604	rs1029296	9e-08	Disc degeneration (lumbar)
chr6	41937536	41937537	rs3218097	9e-08	Mean corpuscular volume
chr6	51101003	51101004	rs7775861	9e-08	Body mass index (non-asthmatics)
chr8	100800927	100800928	rs3847153	9e-08	Premature ovarian failure
chr8	128933907	128933908	rs987525	9e-08	Orofacial clefts
chr18	12779947	12779948	rs2542151	9e-08	Type 1 diabetes
chr4	80025320	80025321	rs4389526	9e-08	Ankylosing spondylitis
chr1	7986611	7986612	rs12727642	9e-08	Celiac disease
chr4	80028674	80028675	rs4333130	9e-08	Ankylosing spondylitis
chr16	86647389	86647390	rs300032	9e-08	IgG glycosylation
chr17	59946913	59946914	rs180515	9e-08	Multiple sclerosis
chr10	111282334	111282335	rs10885122	9e-08	Fasting glucose-related traits (interaction with BMI)
chr10	17346143	17346144	rs359312	9e-08	Response to treatment for acute lymphoblastic leukemia
chr10	18131042	18131043	rs4373814	9e-08	Hypertension
chr10	44258418	44258419	rs501120	9e-08	Coronary heart disease
chr10	57429417	57429418	rs4462262	9e-08	Diabetic retinopathy 
chr10	6057081	6057082	rs2104286	9e-08	Multiple sclerosis
chr10	8912260	8912261	rs2388896	9e-08	Tetralogy of Fallot
chr11	103547429	103547430	rs716274	9e-08	Small-cell lung cancer (survival)
chr11	64757743	64757744	rs589691	9e-08	Urate levels
chr1	183112058	183112059	rs10911251	9e-08	Colorectal cancer
chr1	18995000	18995001	rs16862426	9e-08	Methotrexate phramacokinetics (acute lymphoblastic leukemia)
chr10	8677305	8677306	rs827382	9e-08	Migraine
chr14	96637469	96637470	rs17094273	9e-08	Tanning
chr1	22384979	22384980	rs6426749	9e-08	Bone mineral density (hip)
chr1	226376989	226376990	rs3219090	9e-08	Melanoma
chr12	57574931	57574932	rs1678542	9e-08	Rheumatoid arthritis
chr12	73207351	73207352	rs11615274	9e-08	Body mass index and cholesterol (psychopharmacological treatment)
chr16	85942052	85942053	rs305061	9e-08	Chronic lymphocytic leukemia
chr13	49732084	49732085	rs3736830	9e-08	Menopause (age at onset)
chr14	60606156	60606157	rs10483727	9e-08	Glaucoma (primary open-angle)
chr1	55030365	55030366	rs11206510	9e-08	Coronary heart disease
chr15	78618838	78618839	rs8040868   	9e-08	Pulmonary function (interaction)
chr16	3988385	3988386	rs2444217	9e-08	Body mass index
chr1	203682798	203682799	rs1541252	9e-08	Mean corpuscular hemoglobin concentration
chr3	180832913	180832914	rs6782299	1e-07	Schizophrenia
chr2	8302117	8302118	rs10174949	1e-07	Self-reported allergy
chr3	169383110	169383111	rs448378	1e-07	Systolic blood pressure
chr3	18742930	18742931	rs6809854	1e-07	Psoriasis
chr3	185813872	185813873	rs1374910	1e-07	Type 2 diabetes
chr3	128176382	128176383	rs2687729	1e-07	Menarche (age at onset)
chr2	85478553	85478554	rs11688246	1e-07	Estradiol plasma levels (breast cancer)
chr3	119508399	119508400	rs4688011	1e-07	Arthritis (juvenile idiopathic)
chr3	111514391	111514392	rs56238310	1e-07	Chronic obstructive pulmonary disease
chr3	111482937	111482938	rs76884941	1e-07	Chronic obstructive pulmonary disease
chr3	10494086	10494087	rs6807064	1e-07	Metabolite levels
chr3	189928143	189928144	rs710521	1e-07	Urinary bladder cancer
chr3	123012062	123012063	rs9868873	1e-07	Esophageal cancer
chr3	36814538	36814539	rs9834970	1e-07	Bipolar disorder (mood-incongruent)
chr4	34892232	34892233	rs17390445	1e-07	Response to antipsychotic treatment
chr3	39471786	39471787	rs538867	1e-07	Alzheimer's disease (cognitive decline)
chr3	40055126	40055127	rs6599077	1e-07	Sleep duration
chr3	87192346	87192347	rs7629490	1e-07	Prostate cancer
chr4	102657479	102657480	rs228614	1e-07	Multiple sclerosis
chr4	105657596	105657597	rs1982346	1e-07	Lung function (forced expiratory volume in 1 second)
chr4	122557560	122557561	rs6852535	1e-07	Progressive supranuclear palsy
chr4	141084418	141084419	rs10007052	1e-07	Chronic obstructive pulmonary disease-related biomarkers
chr4	144559627	144559628	rs1828591	1e-07	Chronic obstructive pulmonary disease
chr4	165951383	165951384	rs6812849	1e-07	Post-traumatic stress disorder (asjusted for relatedness)
chr4	20619059	20619060	rs1379659	1e-07	Echocardiographic traits
chr2	78971041	78971042	rs11683503	1e-07	Contrast sensitivity
chr4	41054698	41054699	rs114070671	1e-07	Opioid sensitivity
chr4	81223771	81223772	rs1662853	1e-07	Pubertal anthropometrics
chr4	88948180	88948181	rs2869967	1e-07	Pulmonary function
chr3	38551901	38551902	rs12053903	1e-07	Electrocardiographic traits
chr2	76148584	76148585	rs10204325	1e-07	Economic and political preferences (fairness)
chr23	11030571	11030572	rs5934953	1e-07	Cognitive performance
chr4	89876149	89876150	rs6532197	1e-07	Parkinson's disease
chr2	133508429	133508430	rs16826005	1e-07	Hypersomnia (HLA-DQB1*06:02 negative)
chr2	136218684	136218685	rs882300	1e-07	Multiple sclerosis
chr2	138521351	138521352	rs10170310	1e-07	Response to antipsychotic treatment
chr21	42421218	42421219	rs3788013	1e-07	Type 1 diabetes autoantibodies
chr2	158121281	158121282	rs2074955	1e-07	P-tau181p
chr2	161038151	161038152	rs197273	1e-07	Dietary macronutrient intake
chr2	1773377	1773378	rs6735179	1e-07	Response to antipsychotic treatment
chr2	18653384	18653385	rs1445130	1e-07	Bulimia nervosa
chr2	20901017	20901018	rs7569328	1e-07	Coronary heart disease
chr2	216689489	216689490	rs2241193	1e-07	Visceral fat
chr2	226697422	226697423	rs7558386	1e-07	P-tau181p
chr2	233656636	233656637	rs11892031	1e-07	Bladder cancer
chr2	233656636	233656637	rs11892031	1e-07	Bladder cancer
chr2	64276760	64276761	rs2698530	1e-07	Iron status biomarkers
chr2	233919015	233919016	rs6741751	1e-07	Migraine with aura
chr2	238955451	238955452	rs12477314	1e-07	Pulmonary function
chr22	39445694	39445695	rs5757676	1e-07	IgG glycosylation
chr2	241431685	241431686	rs757978	1e-07	Chronic lymphocytic leukemia
chr2	242084343	242084344	rs749924	1e-07	Coronary artery calcification
chr2	31153787	31153788	rs6543610	1e-07	Methotrexate phramacokinetics (acute lymphoblastic leukemia)
chr23	119433738	119433739	rs5910578	1e-07	Paget's disease
chr2	12828773	12828774	rs10180496	1e-07	Dental caries
chr23	124939812	124939813	rs7060947	1e-07	Immune reponse to smallpox (secreted IFN-alpha)
chr23	23365326	23365327	rs5925760	1e-07	Immune reponse to smallpox (secreted IFN-alpha)
chr23	29622700	29622701	rs7890572	1e-07	Cardiovascular disease risk factors
chr2	33076879	33076880	rs542631	1e-07	Immune reponse to smallpox (secreted IFN-alpha)
chr2	43360364	43360365	rs6732426	1e-07	Hair morphology
chr2	48419259	48419260	rs10454142	1e-07	Sex hormone-binding globulin levels
chr2	60492834	60492835	rs766432	1e-07	Fetal hemoglobin levels
chr2	23675446	23675447	rs4665630	1e-07	Coronary heart disease
chr4	98875632	98875633	rs7665590	1e-07	Primary biliary cirrhosis
chr7	15024207	15024208	rs10244051	1e-07	Metabolic traits
chr5	132435112	132435113	rs2188962	1e-07	Crohn's disease
chr6	83516875	83516876	rs1171113	1e-07	Bipolar disorder (mood-incongruent)
chr6	86445535	86445536	rs13202860	1e-07	Sexual dysfunction (female)
chr6	94712899	94712900	rs4145130	1e-07	Methotrexate phramacokinetics (acute lymphoblastic leukemia)
chr7	107812657	107812658	rs2108225	1e-07	Ulcerative colitis
chr7	112037850	112037851	rs10428959	1e-07	Response to fenofibrate
chr7	131768765	131768766	rs1106683	1e-07	Body mass index
chr7	139806780	139806781	rs10277664	1e-07	Gray matter volume (schizophrenia interaction)
chr7	156255954	156255955	rs10949808	1e-07	Bipolar disorder and schizophrenia
chr7	44196068	44196069	rs4607517	1e-07	Fasting plasma glucose
chr7	46352968	46352969	rs17513961	1e-07	Treatment response for severe sepsis 
chr8	118995180	118995181	rs2062377	1e-07	Bone mineral density
chr8	125469834	125469835	rs2954021	1e-07	LDL cholesterol
chr8	127081051	127081052	rs1016343	1e-07	Prostate cancer
chr8	128063585	128063586	rs2608053	1e-07	Hodgkin's lymphoma
chr6	50830812	50830813	rs2206277	1e-07	Metabolic syndrome (bivariate traits)
chr8	38120213	38120214	rs2517388	1e-07	Menopause (age at onset)
chr8	57876521	57876522	rs10504249	1e-07	Blood pressure measurement (low sodium intervention)
chr8	58411602	58411603	rs2859998	1e-07	Narcolepsy with cataplexy
chr8	58476005	58476006	rs2081687	1e-07	LDL cholesterol
chr8	65711996	65711997	rs10504390	1e-07	IgG glycosylation
chr8	65909794	65909795	rs6472235	1e-07	Myopia (pathological)
chr8	72324574	72324575	rs7006742	1e-07	Pulmonary function decline
chr9	116487059	116487060	rs7852872	1e-07	Hippocampal volume
chr9	116490349	116490350	rs6478241	1e-07	Migraine without aura
chr9	116571403	116571404	rs10983238	1e-07	Attention deficit hyperactivity disorder
chr9	126703045	126703046	rs867559	1e-07	Body mass index
chr9	32556381	32556382	rs17290760	1e-07	Immune response to smallpox vaccine (IL-6)
chr9	79730965	79730966	rs2151145	1e-07	Menopause (age at onset)
chr9	8196510	8196511	rs7044355	1e-07	Platelet aggregation
chr2	101052394	101052395	rs2278729	1e-07	Osteoporosis
chr8	4760287	4760288	rs1379326	1e-07	Interstitial lung disease 
chr5	128380873	128380874	rs17608902	1e-07	Migraine - clinic-based
chr6	39561205	39561206	rs9380880	1e-07	Immune response to smallpox vaccine (IL-6)
chr6	32894829	32894830	rs3749982	1e-07	Disc degeneration (lumbar)
chr5	132660150	132660151	rs1295686	1e-07	Asthma
chr5	21749238	21749239	rs12109285	1e-07	Response to tocilizumab in rheumatoid arthritis
chr5	32804421	32804422	rs1173766	1e-07	Blood pressure
chr5	35039380	35039381	rs37370	1e-07	Serum dimethylarginine levels (asymmetric)
chr5	36308994	36308995	rs16902947	1e-07	Serum tamsulosin hydrochloride concentration
chr5	39397029	39397030	rs11959928	1e-07	Chronic kidney disease
chr5	56558325	56558326	rs6867983	1e-07	Waist circumference
chr5	81110746	81110747	rs138206701	1e-07	Eating disorders (purging via substances) 
chr5	89080243	89080244	rs1366594	1e-07	Bone mineral density
chr5	94818882	94818883	rs17418283	1e-07	Bipolar disorder
chr6	101226413	101226414	rs2797369	1e-07	Renal function-related traits (eGRFcrea)
chr6	132321977	132321978	rs589756	1e-07	Obesity-related traits
chr6	132321977	132321978	rs589756	1e-07	Obesity-related traits
chr6	13270712	13270713	rs1223397	1e-07	Blood pressure
chr6	33121845	33121846	rs3117027	1e-07	Cervical cancer
chr6	134577317	134577318	rs228437	1e-07	Melanoma
chr6	142190998	142190999	rs225675	1e-07	Thiazide-induced adverse metabolic effects in hypertensive patients
chr6	142206004	142206005	rs225694	1e-07	Height
chr6	150330763	150330764	rs1591830	1e-07	Metabolite levels
chr6	151618214	151618215	rs3734805	1e-07	Breast cancer
chr6	161580403	161580404	rs992037	1e-07	Metabolite levels
chr6	166763933	166763934	rs635808	1e-07	Dental caries
chr6	29387424	29387425	rs3094548	1e-07	Pulmonary function
chr6	29945520	29945521	rs1061235	1e-07	Adverse response to carbamapezine
chr6	32276849	32276850	rs3130340	1e-07	Bone mineral density (spine)
chr6	32445681	32445682	rs2227139	1e-07	Hematological parameters
chr6	32464299	32464300	rs9268905	1e-07	Cystic fibrosis severity
chr6	32701378	32701379	rs9275390	1e-07	Systemic sclerosis
chr6	32889156	32889157	rs6936004	1e-07	Disc degeneration (lumbar)
chr6	32892974	32892975	rs9469300	1e-07	Disc degeneration (lumbar)
chr6	137685366	137685367	rs6920220	1e-07	Rheumatoid arthritis
chr20	7405310	7405311	rs6054973	1e-07	Asthma (childhood onset)
chr1	19242477	19242478	rs710865	1e-07	Brain structure
chr20	61933123	61933124	rs6061910	1e-07	Obesity-related traits
chr11	61802357	61802358	rs174546	1e-07	LDL cholesterol
chr11	65739350	65739351	rs4014195	1e-07	Chronic kidney disease
chr1	173340573	173340574	rs10798269	1e-07	Systemic lupus erythematosus
chr11	9090010	9090011	rs963167	1e-07	&beta;2-Glycoprotein I (&beta;2-GPI) plasma levels
chr1	204546896	204546897	rs2290854	1e-07	Breast Cancer in BRCA1 mutation carriers
chr1	205795511	205795512	rs823156	1e-07	Parkinson's disease
chr1	205927106	205927107	rs11240594	1e-07	Response to antipsychotic treatment
chr12	103518727	103518728	rs10861032	1e-07	Coronary restenosis
chr12	104028029	104028030	rs2629751	1e-07	Hepatitis C induced liver fibrosis
chr12	110266681	110266682	rs11065611	1e-07	Protein quantitative trait loci
chr12	114357637	114357638	rs3825214	1e-07	Electrocardiographic traits
chr12	123915002	123915003	rs1316952	1e-07	Visceral adipose tissue/subcutaneous adipose tissue ratio
chr1	216543194	216543195	rs12757165	1e-07	Cardiac hypertrophy
chr12	2240417	2240418	rs4765905	1e-07	Schizophrenia
chr12	23793211	23793212	rs11047102	1e-07	Systemic sclerosis
chr12	24236725	24236726	rs1464500	1e-07	Response to antipsychotic treatment
chr1	243671883	243671884	rs320320	1e-07	Menarche (age at onset)
chr1	244013121	244013122	rs476141	1e-07	Diabetic retinopathy 
chr12	48539449	48539450	rs11168618	1e-07	Adiponectin levels
chr12	49853684	49853685	rs7138803	1e-07	Body mass index
chr12	53338106	53338107	rs10876432	1e-07	Bone mineral density (spine)
chr12	57574931	57574932	rs1678542	1e-07	Rheumatoid arthritis
chr1	2622184	2622185	rs3890745	1e-07	Rheumatoid arthritis
chr12	89666808	89666809	rs17249754	1e-07	Biomedical quantitative traits
chr12	95877649	95877650	rs1036429	1e-07	Pulmonary function (interaction)
chr13	105999311	105999312	rs4996815	1e-07	Bipolar disorder and schizophrenia
chr13	21913485	21913486	rs17369571	1e-07	Protein quantitative trait loci
chr13	27346473	27346474	rs9512637	1e-07	Alcoholism (heaviness of drinking)
chr13	64372565	64372566	rs2220327	1e-07	Rheumatoid arthritis
chr11	58292719	58292720	rs12289961	1e-07	Lymphoma
chr1	156476449	156476450	rs2274316	1e-07	Migraine - clinic-based
chr1	150977585	150977586	rs4970988	1e-07	Urate levels
chr1	150968148	150968149	rs267738	1e-07	Rhegmatogenous retinal detachment
chr20	63778359	63778360	rs6062314	1e-07	Multiple sclerosis
chr10	112998589	112998590	rs7903146	1e-07	Glycated hemoglobin levels
chr10	113029055	113029056	rs12243326	1e-07	Two-hour glucose challenge
chr10	117620144	117620145	rs181654	1e-07	Airflow obstruction 
chr10	123228636	123228637	rs11597068	1e-07	Menopause (age at onset)
chr10	130369800	130369801	rs11017221	1e-07	Migraine
chr10	130949623	130949624	rs10829848	1e-07	Insulin-related traits
chr10	13319975	13319976	rs1747683	1e-07	IgG glycosylation
chr10	14903406	14903407	rs11594111	1e-07	Migraine
chr10	21626689	21626690	rs1243180	1e-07	Ovarian cancer
chr10	23569281	23569282	rs16923476	1e-07	Obesity (early onset extreme)
chr10	44029226	44029227	rs17154929	1e-07	HIV-associated dementia 
chr10	572744	572745	rs17221323	1e-07	Immune reponse to smallpox (secreted IFN-alpha)
chr10	62518922	62518923	rs10995190	1e-07	Breast cancer
chr13	65637887	65637888	rs11619878	1e-07	IgG glycosylation
chr10	63107151	63107152	rs10995439	1e-07	IgG glycosylation
chr1	109279543	109279544	rs599839	1e-07	LDL cholesterol
chr1	109457215	109457216	rs1933182	1e-07	Chronic kidney disease
chr11	103256335	103256336	rs12294076	1e-07	Tuberculosis
chr11	11482680	11482681	rs7940423	1e-07	Response to tocilizumab in rheumatoid arthritis
chr11	116912257	116912258	rs11216185	1e-07	Infantile hypertrophic pyloric stenosis
chr1	113834945	113834946	rs2476601	1e-07	Type 1 diabetes
chr1	116495664	116495665	rs12025416	1e-07	Multiple sclerosis
chr1	116558334	116558335	rs1335532	1e-07	Multiple sclerosis
chr11	17138600	17138601	rs4356203	1e-07	Schizophrenia
chr11	17388024	17388025	rs5219	1e-07	Type 2 diabetes
chr11	2818520	2818521	rs2237892	1e-07	Type 2 diabetes
chr11	2915721	2915722	rs16928809	1e-07	Bilirubin levels
chr11	35308067	35308068	rs3794087	1e-07	Essential tremor
chr11	47419206	47419207	rs2293579	1e-07	Serum albumin level
chr10	6430928	6430929	rs11258747	1e-07	Type 1 diabetes
chr13	88052450	88052451	rs7323893	1e-07	Coronary heart disease
chr1	113834945	113834946	rs2476601	1e-07	Vitiligo
chr13	93358915	93358916	rs9561329	1e-07	Neuroticism
chr17	22180453	22180454	rs1975974	1e-07	Psoriasis
chr17	3761680	3761681	rs220470	1e-07	Attention deficit hyperactivity disorder
chr17	39895094	39895095	rs8067378	1e-07	Ulcerative colitis
chr17	39905942	39905943	rs2305480	1e-07	Asthma
chr17	47347748	47347749	rs7206971	1e-07	Cholesterol, total
chr17	47691469	47691470	rs8070463	1e-07	Multiple sclerosis
chr17	48763178	48763179	rs7219021	1e-07	Schizophrenia or bipolar disorder
chr17	56772967	56772968	rs4794665	1e-07	Height
chr17	72131394	72131395	rs9915657	1e-07	Thyroid hormone levels
chr17	7581493	7581494	rs9901675	1e-07	Sex hormone-binding globulin levels
chr18	31756627	31756628	rs10502575	1e-07	Coronary artery calcification
chr18	36527488	36527489	rs17651157	1e-07	Response to antipsychotic treatment
chr18	42857685	42857686	rs16977065	1e-07	Response to tocilizumab in rheumatoid arthritis
chr18	47059048	47059049	rs2576037	1e-07	Personality dimensions
chr16	86334919	86334920	rs4083242	1e-07	Obesity-related traits
chr18	48927092	48927093	rs4939827	1e-07	Colorectal cancer
chr18	64751207	64751208	rs17073641	1e-07	Age-related macular degeneration (smoking status interaction)
chr18	73391386	73391387	rs1943816	1e-07	P-tau181p
chr19	17283314	17283315	rs2363956	1e-07	Ovarian cancer
chr19	41559908	41559909	rs4803480	1e-07	Schizophrenia
chr19	44878776	44878777	rs6859	1e-07	Alzheimer's disease (late onset)
chr19	44892361	44892362	rs2075650	1e-07	C-reactive protein
chr19	49834978	49834979	rs2017698	1e-07	Blood trace element (Se levels)
chr19	58480633	58480634	rs58632700	1e-07	Obesity-related traits
chr19	7199791	7199792	rs1035942	1e-07	Urate levels
chr19	7674290	7674291	rs1423096	1e-07	Resistin levels 
chr1	99584228	99584229	rs7543130	1e-07	Aortic root size
chr20	45352085	45352086	rs1008953	1e-07	Psoriasis
chr20	46111556	46111557	rs6074022	1e-07	Multiple sclerosis
chr13	92670892	92670893	rs17267292	1e-07	Metabolite levels
chr18	55391006	55391007	rs17594526	1e-07	Schizophrenia
chr16	82424127	82424128	rs7187223	1e-07	Non-word repetition
chr19	11091629	11091630	rs6511720	1e-07	Carotid intima media thickness
chr16	78154005	78154006	rs12716850   	1e-07	Pulmonary function (interaction)
chr14	100159564	100159565	rs7157599	1e-07	Sudden cardiac arrest
chr16	82293199	82293200	rs11863065	1e-07	Obesity-related traits
chr1	43130712	43130713	rs16830359	1e-07	Cardiac hypertrophy
chr14	48994280	48994281	rs11845208	1e-07	Immune reponse to smallpox (secreted IL-2)
chr14	62501676	62501677	rs4902141	1e-07	Estradiol plasma levels (breast cancer)
chr14	65006477	65006478	rs7148590	1e-07	Blood trace element (Zn levels)
chr14	68283209	68283210	rs3784099	1e-07	Breast cancer (survival)
chr14	75159338	75159339	rs910316	1e-07	Height
chr14	75663247	75663248	rs724743	1e-07	Height
chr15	27951674	27951675	rs7173419	1e-07	Eye color
chr15	48747599	48747600	rs784411	1e-07	Prostate cancer (gene x gene interaction)
chr1	55047321	55047322	rs2495478	1e-07	Wilms tumor
chr15	58382495	58382496	rs4775041	1e-07	Metabolite levels
chr15	59136458	59136459	rs4218	1e-07	Social communication problems
chr15	60777788	60777789	rs11071559	1e-07	Asthma
chr14	75494192	75494193	rs7155603	1e-07	Rheumatoid arthritis
chr15	68422692	68422693	rs7164335	1e-07	Attention deficit hyperactivity disorder
chr16	67991091	67991092	rs255052	1e-07	HDL cholesterol
chr16	58532399	58532400	rs37060	1e-07	QT interval
chr15	62040780	62040781	rs17271305	1e-07	Two-hour glucose challenge
chr16	53769661	53769662	rs1558902	1e-07	Obesity
chr16	28826193	28826194	rs8049439	1e-07	Educational attainment
chr16	27363078	27363079	rs1801275	1e-07	IgE levels 
chr1	61914625	61914626	rs1056513	1e-07	Obesity-related traits
chr16	53775334	53775335	rs1121980	1e-07	Obesity (early onset extreme)
chr1	61326190	61326191	rs6691768	1e-07	Celiac disease
chr15	83913371	83913372	rs4842838	1e-07	Height
chr15	78535288	78535289	rs28675338	1e-07	Chronic obstructive pulmonary disease
chr15	68600649	68600650	rs11856323	1e-07	Cognitive performance
chr15	71387619	71387620	rs2044029	1e-07	Airflow obstruction 
chr3	107746969	107746970	rs6437740	2e-07	Smoking behavior
chr3	39805580	39805581	rs17079534	2e-07	Acute lymphoblastic leukemia (childhood)
chr3	36821488	36821489	rs4624519	2e-07	Schizophrenia
chr3	35940637	35940638	rs6799705	2e-07	Cognitive performance
chr3	32978542	32978543	rs4678680	2e-07	Hepatocellular carcinoma
chr3	30668750	30668751	rs3773643	2e-07	Tonometry
chr3	196024758	196024759	rs4927850	2e-07	Pancreatic cancer
chr3	185811291	185811292	rs1470579	2e-07	Diabetes (gestational)
chr3	16354160	16354161	rs690037	2e-07	Optic disc size (cup)
chr3	12351625	12351626	rs1801282	2e-07	Fasting insulin-related traits (interaction with BMI)
chr3	132095055	132095056	rs6775745	2e-07	Neutrophil count
chr3	42261581	42261582	rs4377469	2e-07	Body mass index
chr3	122662075	122662076	rs790116	2e-07	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy)
chr3	12248300	12248301	rs13081389	2e-07	Type 2 diabetes
chr3	120706483	120706484	rs13077101	2e-07	Obesity-related traits
chr3	12236344	12236345	rs17036101	2e-07	Type 2 diabetes
chr3	122050674	122050675	rs2681424	2e-07	Multiple sclerosis
chr3	12075119	12075120	rs308971	2e-07	Fasting insulin-related traits (interaction with BMI)
chr2	8808939	8808940	rs7587928	2e-07	Neutrophil count
chr3	146170669	146170670	rs1913185	2e-07	Obesity-related traits
chr3	42864623	42864624	rs2228467	2e-07	Monocyte count
chr4	129810128	129810129	rs4864201	2e-07	Obesity
chr3	43426402	43426403	rs7650267	2e-07	Obesity-related traits
chr4	59883110	59883111	rs10517480	2e-07	Metabolite levels
chr4	42451235	42451236	rs10517025	2e-07	Immune reponse to smallpox (secreted IFN-alpha)
chr2	8294054	8294055	rs3102947	2e-07	IgE levels 
chr4	33623079	33623080	rs10517287	2e-07	Response to antidepressant treatment
chr4	25941128	25941129	rs7654585	2e-07	Obesity-related traits
chr4	187424213	187424214	rs1431005	2e-07	Response to statin therapy
chr4	147361189	147361190	rs1429138	2e-07	Dental caries
chr4	1316112	1316113	rs6815464	2e-07	Type 2 diabetes
chr4	113940143	113940144	rs4460079b	2e-07	Blood pressure measurement (high sodium and potassium intervention)
chr4	110796910	110796911	rs6843082	2e-07	Stroke (ischemic)
chr4	103216632	103216633	rs4699052	2e-07	Testicular germ cell tumor
chr4	102536260	102536261	rs230529	2e-07	Schizophrenia (treatment refractory) 
chr3	98315681	98315682	rs1497546	2e-07	Drug-induced liver injury (flucloxacillin)
chr3	88475024	88475025	rs2880961	2e-07	Response to acetaminophen (hepatotoxicity)
chr3	69203747	69203748	rs6806528	2e-07	Celiac disease
chr3	64741409	64741410	rs7433808	2e-07	Visceral adipose tissue/subcutaneous adipose tissue ratio
chr3	64741409	64741410	rs7433808	2e-07	Visceral adipose tissue/subcutaneous adipose tissue ratio
chr3	52786994	52786995	rs1042779	2e-07	Bipolar disorder
chr3	45775925	45775926	rs758386	2e-07	Immune reponse to smallpox (secreted TNF-alpha)
chr3	42867667	42867668	rs3919627	2e-07	Obesity-related traits
chr2	70905883	70905884	rs3771395	2e-07	Corneal astigmatism
chr22	23135782	23135783	rs4820539	2e-07	Bone mineral density
chr2	68419650	68419651	rs7592330	2e-07	Multiple sclerosis
chr2	226222567	226222568	rs2943636	2e-07	Sexual dimorphism in anthropometric traits
chr2	226203363	226203364	rs2943634	2e-07	Coronary heart disease
chr2	22514114	22514115	rs17043947	2e-07	Self-rated health
chr22	24596298	24596299	rs5751901	2e-07	Protein quantitative trait loci
chr22	23828808	23828809	rs2186369	2e-07	IgG glycosylation
chr22	23828808	23828809	rs2186369	2e-07	IgG glycosylation
chr22	21628602	21628603	rs2298428	2e-07	Celiac disease
chr22	19902301	19902302	rs3788317	2e-07	Glaucoma (primary open-angle)
chr2	219833403	219833404	rs10498070	2e-07	Systemic lupus erythematosus and Systemic sclerosis
chr2	218650035	218650036	rs10187066	2e-07	Height
chr2	216760799	216760800	rs13015993	2e-07	Thyroid hormone levels
chr2	212304042	212304043	rs7588550	2e-07	Type 1 diabetes nephropathy
chr2	21166786	21166787	rs4635554	2e-07	Hypertriglyceridemia
chr2	21009322	21009323	rs693	2e-07	Triglycerides
chr2	20981152	20981153	rs6544366	2e-07	Triglycerides
chr2	203225006	203225007	rs16839626	2e-07	Obesity-related traits
chr2	203225006	203225007	rs16839626	2e-07	Obesity-related traits
chr4	69106744	69106745	rs4356975	2e-07	Obesity-related traits
chr2	198520996	198520997	rs2054125	2e-07	Educational attainment
chr2	226257499	226257500	rs1515110	2e-07	Adiponectin levels
chr2	7007841	7007842	rs6741819	2e-07	Response to antipsychotic treatment
chr22	29533249	29533250	rs8135828	2e-07	Lipid traits
chr2	236247905	236247906	rs13390159	2e-07	Response to statin therapy
chr2	64276760	64276761	rs2698530	2e-07	Iron status biomarkers
chr2	60854406	60854407	rs702873	2e-07	Psoriatic arthritis
chr2	5767747	5767748	rs16864170	2e-07	Chronic kidney disease
chr2	51509855	51509856	rs1406428	2e-07	Response to tocilizumab in rheumatoid arthritis
chr2	46795403	46795404	rs76351433	2e-07	Chronic obstructive pulmonary disease
chr2	40351418	40351419	rs17025867	2e-07	Obesity (early onset extreme)
chr23	92147220	92147221	rs2573905	2e-07	Alzheimer's disease
chr23	67722782	67722783	rs5031002	2e-07	LDL cholesterol
chr23	48047087	48047088	rs142513793	2e-07	Tuberculosis
chr23	40026376	40026377	rs17145638	2e-07	Pit-and-Fissure caries 
chr23	139035246	139035247	rs10521792 	2e-07	Response to taxane treatment (placlitaxel)
chr2	28124814	28124815	rs7601155	2e-07	Waist circumference
chr22	49997050	49997051	rs5771069	2e-07	Ulcerative colitis
chr22	49824962	49824963	rs138880	2e-07	Schizophrenia
chr22	40301576	40301577	rs139909	2e-07	Height
chr2	238955451	238955452	rs12477314	2e-07	Pulmonary function (interaction)
chr22	37195277	37195278	rs229541	2e-07	Type 1 diabetes
chr22	37148445	37148446	rs3218255	2e-07	Tuberculosis
chr2	230226507	230226508	rs13397985	2e-07	Chronic lymphocytic leukemia
chr4	77215779	77215780	rs11937061	2e-07	Response to tocilizumab in rheumatoid arthritis
chr8	119941632	119941633	rs7005380	2e-07	Interstitial lung disease 
chr4	9921379	9921380	rs734553	2e-07	Gout
chr8	18120140	18120141	rs17126232	2e-07	Obesity
chr8	130021249	130021250	rs16904191	2e-07	Migraine
chr2	19799584	19799585	rs6728440	2e-07	Inflammatory biomarkers
chr8	115801678	115801679	rs800586	2e-07	Response to tocilizumab in rheumatoid arthritis
chr7	93612327	93612328	rs7780752	2e-07	Birth weight
chr7	93135668	93135669	rs1133906	2e-07	Systemic lupus erythematosus and Systemic sclerosis
chr7	77109273	77109274	rs3864639	2e-07	Obesity-related traits
chr7	50315610	50315611	rs6421315	2e-07	IgG glycosylation
chr7	50295635	50295636	rs4917017	2e-07	IgG glycosylation
chr7	37334905	37334906	rs6974491	2e-07	Celiac disease
chr7	32307722	32307723	rs215614	2e-07	Smoking behavior
chr7	29178542	29178543	rs245914	2e-07	Psychosis (atypical)
chr7	25121982	25121983	rs1861525	2e-07	Alzheimer's disease (cognitive decline)
chr7	22716843	22716844	rs10155981	2e-07	Bilirubin levels
chr7	16822224	16822225	rs10253216	2e-07	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin)
chr7	146262150	146262151	rs802568	2e-07	Bipolar disorder and schizophrenia
chr7	141805286	141805287	rs145241704	2e-07	Anorexia nervosa
chr7	135816720	135816721	rs13237474	2e-07	Periodontitis (CDC/AAP)
chr7	128954128	128954129	rs10488631	2e-07	Systemic sclerosis
chr8	19682126	19682127	rs7816924	2e-07	Response to antidepressant treatment (citalopram)
chr8	20019234	20019235	rs7016880	2e-07	Hypertriglyceridemia
chr8	30125001	30125002	rs12681963	2e-07	Migraine
chr8	31775930	31775931	rs10503887	2e-07	Hip geometry
chr9	95666983	95666984	rs11790994	2e-07	Inattentive symptoms
chr9	93953745	93953746	rs11789015	2e-07	Esophageal adenocarcinoma
chr9	68856995	68856996	rs6560397	2e-07	Pit-and-Fissure caries 
chr9	27610658	27610659	rs2889829	2e-07	PCA3 expression level
chr9	22129579	22129580	rs7020996	2e-07	Type 2 diabetes
chr9	22088260	22088261	rs10757272	2e-07	Intracranial aneurysm
chr9	18930223	18930224	rs1571228	2e-07	Non-small cell lung cancer
chr9	126166743	126166744	rs888219	2e-07	Response to antipsychotic treatment
chr7	128954128	128954129	rs10488631	2e-07	Primary biliary cirrhosis
chr9	123684498	123684499	rs10818854	2e-07	Body mass index (non-asthmatics)
chr9	114287610	114287611	rs946053	2e-07	Height
chr9	111531353	111531354	rs10980926	2e-07	Pubertal anthropometrics
chr8	88748081	88748082	rs7004633	2e-07	Schizophrenia
chr8	80119586	80119587	rs10957961	2e-07	Metabolite levels (Pyroglutamine)
chr8	78488802	78488803	rs1520333	2e-07	Multiple sclerosis
chr8	74382739	74382740	rs4471028	2e-07	Waist circumference
chr8	70678967	70678968	rs7017914	2e-07	Bone mineral density
chr8	65711996	65711997	rs10504390	2e-07	IgG glycosylation
chr8	57928364	57928365	rs1992045	2e-07	Bipolar disorder and schizophrenia
chr9	120927960	120927961	rs3761847	2e-07	Rheumatoid arthritis
chr4	87010251	87010252	rs340635	2e-07	Alzheimer's disease (cognitive decline)
chr7	113271354	113271355	rs10953730	2e-07	Metabolite levels
chr7	106954439	106954440	rs7779057	2e-07	Serum tamsulosin hydrochloride concentration
chr6	115991729	115991730	rs9488822	2e-07	LDL cholesterol
chr6	108946846	108946847	rs2798641	2e-07	Pulmonary function (interaction)
chr6	104916545	104916546	rs11156429	2e-07	Pubertal anthropometrics
chr6	103351170	103351171	rs994988 	2e-07	Palmitic acid (16:0) plasma levels
chr5	91128461	91128462	rs10514345	2e-07	Hip geometry
chr5	77485645	77485646	rs163030	2e-07	Caudate nucleus volume
chr5	56027066	56027067	rs17348299	2e-07	IgG glycosylation
chr5	52883957	52883958	rs2456203   	2e-07	Pulmonary function (interaction)
chr5	40424323	40424324	rs6896969	2e-07	Multiple sclerosis
chr5	33955220	33955221	rs35390	2e-07	Melanoma
chr5	28747215	28747216	rs2548003	2e-07	Hip geometry
chr5	28340065	28340066	rs11949289	2e-07	Response to antidepressant treatment
chr5	177367189	177367190	rs12654812	2e-07	Renal function-related traits (eGRFcrea)
chr5	170813418	170813419	rs11134654	2e-07	Smooth-surface caries 
chr5	158418393	158418394	rs11953630	2e-07	Hypertension
chr5	1344342	1344343	rs31490	2e-07	Chronic lymphocytic leukemia
chr5	132387595	132387596	rs2073643	2e-07	Asthma
chr5	107646858	107646859	rs10074258	2e-07	Hippocampal atrophy
chr4	9992590	9992591	rs6449213	2e-07	Uric acid levels
chr6	127700657	127700658	rs17299841	2e-07	Immune response to smallpox vaccine (IL-6)
chr6	130935223	130935224	rs7769153	2e-07	Response to statin therapy (LDL-C)
chr6	133875535	133875536	rs12524865	2e-07	Coronary heart disease
chr6	142358434	142358435	rs6570507	2e-07	Height
chr7	105117802	105117803	rs6968355	2e-07	Myopia (pathological)
chr6	78846448	78846449	rs16890334	2e-07	Blood pressure measurement (low sodium intervention)
chr6	56085575	56085576	rs12196860	2e-07	Psychosis (atypical)
chr6	52971096	52971097	rs492146	2e-07	Epilepsy (remission after treatment)
chr6	50818294	50818295	rs2206271	2e-07	Renal function-related traits (BUN)
chr6	44801499	44801500	rs7770848	2e-07	Asthma (childhood onset)
chr6	3359102	3359103	rs4959235	2e-07	Antipsychotic-induced QTc interval prolongation
chr6	32889641	32889642	rs10214886	2e-07	Disc degeneration (lumbar)
chr6	32707331	32707332	rs9275524	2e-07	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr7	107951752	107951753	rs2072209	2e-07	IgG glycosylation
chr6	32690532	32690533	rs9469220	2e-07	IgE levels 
chr6	31171674	31171675	rs879882	2e-07	Height
chr6	30945680	30945681	rs3132581	2e-07	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr6	30125586	30125587	rs10947055	2e-07	Cardiac hypertrophy
chr6	28162010	28162011	rs1150668	2e-07	Pubertal anthropometrics
chr6	22017508	22017509	rs1928168   	2e-07	Pulmonary function (interaction)
chr6	22017508	22017509	rs1928168	2e-07	Pulmonary function
chr6	21996630	21996631	rs2078543   	2e-07	Pulmonary function (interaction)
chr6	19803536	19803537	rs6907340	2e-07	Endometriosis
chr6	151580273	151580274	rs4870044	2e-07	Bone mineral density (hip)
chr6	31504942	31504943	rs2855812	2e-07	Pulmonary function
chr2	19429542	19429543	rs13398721	2e-07	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer
chr2	21008719	21008720	rs6413458	2e-07	Lipoprotein-associated phospholipase A2 activity and mass
chr2	178873541	178873542	rs11693319	2e-07	Blood pressure measurement (cold pressor test)
chr1	237826821	237826822	rs2819742	2e-07	Response to cerivastatin
chr12	3055756	3055757	rs12425451	2e-07	Narcolepsy with cataplexy
chr1	228515587	228515588	rs1925714	2e-07	Tuberculosis
chr12	2240417	2240418	rs4765905	2e-07	Schizophrenia
chr1	22047130	22047131	rs2501276	2e-07	Immune response to smallpox vaccine (IL-6)
chr12	128297476	128297477	rs11059635	2e-07	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel)
chr12	124006981	124006982	rs1187415	2e-07	Adiponectin levels
chr12	106556208	106556209	rs4964469	2e-07	Parkinson's disease
chr12	105058663	105058664	rs10861337	2e-07	IgG glycosylation
chr1	207701829	207701830	rs4844614	2e-07	LDL cholesterol
chr1	205720678	205720679	rs823094	2e-07	Pubertal anthropometrics
chr1	200966737	200966738	rs11584383	2e-07	Ulcerative colitis
chr1	200908433	200908434	rs7554511	2e-07	Crohn's disease
chr11	9951514	9951515	rs10500715	2e-07	Pancreatic cancer
chr11	98254675	98254676	rs2509843	2e-07	Bipolar disorder and schizophrenia
chr1	197660211	197660212	rs1775453	2e-07	Serum protein levels (sST2)
chr11	96375263	96375264	rs7118648	2e-07	Parkinson's disease
chr1	19005581	19005582	rs7523455	2e-07	Methotrexate phramacokinetics (acute lymphoblastic leukemia)
chr11	8222250	8222251	rs11041816	2e-07	Fasting glucose-related traits (interaction with BMI)
chr1	240542806	240542807	rs10495471	2e-07	Immune response to smallpox vaccine (IL-6)
chr11	80347434	80347435	rs7395555	2e-07	Response to antipsychotic treatment
chr1	24299683	24299684	rs10794657	2e-07	Adiponectin levels
chr12	49853684	49853685	rs7138803	2e-07	Weight
chr14	81168978	81168979	rs10131728	2e-07	IgG glycosylation
chr14	68567964	68567965	rs999737	2e-07	Breast cancer
chr14	54409465	54409466	rs4251631	2e-07	Dental caries
chr14	47405353	47405354	rs17118552	2e-07	Response to tocilizumab in rheumatoid arthritis
chr14	47394631	47394632	rs7159841	2e-07	Hemostatic factors and hematological phenotypes
chr14	45560483	45560484	rs7140958	2e-07	Bilirubin levels
chr14	26019260	26019261	rs862946	2e-07	Liver enzyme levels (aspartate transaminase)
chr13	95123177	95123178	rs16950650	2e-07	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer
chr13	63060216	63060217	rs9317284	2e-07	Bone mineral density
chr13	43642927	43642928	rs4942242	2e-07	Response to tocilizumab in rheumatoid arthritis
chr13	21730959	21730960	rs518590	2e-07	Response to antipsychotic treatment
chr13	101575143	101575144	rs9557704	2e-07	Waist-to-hip circumference ratio (interaction)
chr12	95096471	95096472	rs12310399	2e-07	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin)
chr12	93583177	93583178	rs3825199	2e-07	Height
chr12	83802749	83802750	rs11116045	2e-07	Obesity-related traits
chr12	80103142	80103143	rs10506821	2e-07	Hip geometry
chr12	65996187	65996188	rs10400419	2e-07	Axial length
chr12	56344188	56344189	rs2066808	2e-07	Psoriasis
chr12	54705211	54705212	rs1153188	2e-07	Type 2 diabetes
chr12	4414289	4414290	rs10849061	2e-07	Migraine
chr1	175150942	175150943	rs6701037	2e-07	Alcohol dependence
chr1	172929236	172929237	rs12035082	2e-07	Crohn's disease
chr1	17005180	17005181	rs3738814	2e-07	Height
chr2	184913700	184913701	rs1344706	2e-07	Schizophrenia
chr10	68252080	68252081	rs3858145	2e-07	Optic disc size (cup)
chr10	68207689	68207690	rs6480314	2e-07	Optic disc size (disc)
chr10	6747500	6747501	rs12570744	2e-07	Response to anti-TNF treatment in rheumatoid arthritis
chr10	63246695	63246696	rs6479891	2e-07	Arthritis (juvenile idiopathic)
chr10	62800709	62800710	rs1444418	2e-07	Atopic dermatitis
chr10	56579480	56579481	rs1907926	2e-07	Nicotine use
chr10	48777064	48777065	rs10857636	2e-07	Response to antidepressant treatment
chr10	43318600	43318601	rs2503875	2e-07	Multiple sclerosis
chr10	4198677	4198678	rs11252394	2e-07	Asthma (bronchodilator response)
chr10	33186353	33186354	rs2228638	2e-07	Tetralogy of Fallot
chr10	18153552	18153553	rs10740993	2e-07	Primary tooth development (time to first tooth eruption)
chr10	16257951	16257952	rs10508503	2e-07	Obesity
chr10	13319975	13319976	rs1747683	2e-07	IgG glycosylation
chr10	125008302	125008303	rs4962416	2e-07	Prostate cancer
chr10	122153814	122153815	rs17103138	2e-07	Myopia (pathological)
chr10	10958375	10958376	rs62209	2e-07	Alzheimer's disease (late onset)
chr10	103498028	103498029	rs7071247	2e-07	Platelet aggregation
chr10	100315721	100315722	rs603424 	2e-07	Palmitic acid (16:0) plasma levels
chr10	95007176	95007177	rs2860975	2e-07	Immune response to smallpox vaccine (IL-6)
chr10	99530543	99530544	rs6584283	2e-07	Ulcerative colitis
chr1	107003752	107003753	rs17496332	2e-07	Sex hormone-binding globulin levels
chr1	109896857	109896858	rs333960	2e-07	Obesity-related traits
chr11	66783530	66783531	rs10896135	2e-07	Bipolar disorder
chr11	65811200	65811201	rs11227306	2e-07	DNA methylation (variation)
chr11	61803310	61803311	rs174547	2e-07	Comprehensive strength and appendicular lean mass
chr11	61726854	61726855	rs4963243	2e-07	Immune reponse to smallpox (secreted IL-2)
chr11	60824802	60824803	rs595018	2e-07	Wegener's granulomatosis
chr1	160776285	160776286	rs576523	2e-07	Capecitabine sensitivity
chr1	160660352	160660353	rs11265461	2e-07	Schizophrenia (treatment refractory) 
chr1	160108063	160108064	rs6688363	2e-07	Response to antipsychotic treatment
chr1	159484146	159484147	rs4133289	2e-07	Hemostatic factors and hematological phenotypes
chr14	89760906	89760907	rs2093746	2e-07	IgG glycosylation
chr11	56474784	56474785	rs7939886	2e-07	Myopia (pathological)
chr1	15222139	15222140	rs10737909	2e-07	Migraine
chr1	147383113	147383114	rs4950322	2e-07	Protein quantitative trait loci
chr11	35071522	35071523	rs2785197	2e-07	Systemic lupus erythematosus
chr11	27658368	27658369	rs6265	2e-07	Weight
chr11	2148543	2148544	rs3741208	2e-07	Type 1 diabetes
chr11	122159481	122159482	rs577948	2e-07	Myopia (pathological)
chr11	116810291	116810292	rs1263173	2e-07	Coronary heart disease
chr11	10652191	10652192	rs4909945	2e-07	Migraine
chr1	110491186	110491187	rs4839431	2e-07	Immune reponse to smallpox (secreted IFN-alpha)
chr11	56128268	56128269	rs2220004	2e-07	Odorant perception (ß-damascenone)
chr14	95205533	95205534	rs1187614	2e-07	Response to antipsychotic treatment
chr10	69828747	69828748	rs1227756	2e-07	Non-alcoholic fatty liver disease histology (lobular)
chr14	98020207	98020208	rs10142119	2e-07	IgE levels in asthmatics (D.f. specific) 
chr20	40192164	40192165	rs6028945	2e-07	Response to TNF antagonist treatment
chr20	371299	371300	rs6051520	2e-07	Information processing speed
chr20	35326404	35326405	rs6060373	2e-07	Spine bone size
chr19	9889645	9889646	rs1862471	2e-07	Menarche (age at onset)
chr1	98711696	98711697	rs9727115	2e-07	Proinsulin levels
chr19	44919688	44919689	rs4420638	2e-07	LDL cholesterol
chr19	28544648	28544649	rs4141232	2e-07	Femoral neck bone geometry and menarche (age at onset)
chr19	21773333	21773334	rs8101143	2e-07	Capecitabine sensitivity
chr19	17278894	17278895	rs8170	2e-07	Ovarian cancer
chr19	16437563	16437564	rs10411936	2e-07	Multiple sclerosis
chr19	15879620	15879621	rs2108622	2e-07	Response to Vitamin E supplementation
chr19	11084353	11084354	rs11668477	2e-07	LDL cholesterol
chr18	74506787	74506788	rs12971120	2e-07	Refractive error
chr18	67618041	67618042	rs17077540	2e-07	Major depressive disorder
chr18	60708700	60708701	rs2168303	2e-07	Gout
chr18	55399096	55399097	rs11152369	2e-07	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr18	50997790	50997791	rs9807334	2e-07	Immune reponse to smallpox (secreted IFN-alpha)
chr18	49655297	49655298	rs2156552	2e-07	HDL cholesterol
chr18	4773110	4773111	rs7237848	2e-07	White blood cell types
chr20	47796831	47796832	rs13038095	2e-07	Atrial fibrillation
chr18	46108609	46108610	rs11874712	2e-07	Migraine - clinic-based
chr20	49905792	49905793	rs495337	2e-07	Psoriasis
chr20	59183664	59183665	rs16982520	2e-07	Hypertension
chr14	95425936	95425937	rs12895389	2e-07	Follicule stimulating hormone
chr2	168184875	168184876	rs6749447	2e-07	Blood pressure
chr2	165034222	165034223	rs776488	2e-07	Common traits (Other)
chr2	15786043	15786044	rs2544527   	2e-07	Pulmonary function (interaction)
chr2	149707969	149707970	rs17801127	2e-07	Liver enzyme levels (alanine transaminase)
chr21	45745514	45745515	rs8127571	2e-07	Immune reponse to smallpox (secreted IFN-alpha)
chr21	43984456	43984457	rs7435	2e-07	Phospholipid levels (plasma)
chr21	43025181	43025182	rs234720	2e-07	Cognitive performance
chr21	41923400	41923401	rs451390	2e-07	Tuberculosis
chr2	141470939	141470940	rs12472911	2e-07	Menarche (age at onset)
chr2	13889622	13889623	rs1598106	2e-07	IgG glycosylation
chr21	35044034	35044035	rs9983044	2e-07	Phospholipid levels (plasma)
chr2	134782396	134782397	rs6430538	2e-07	Parkinson's disease
chr2	134311222	134311223	rs4953911	2e-07	Multiple sclerosis (severity)
chr21	26773869	26773870	rs2830487	2e-07	Metabolite levels (HVA)
chr2	120437604	120437605	rs7581710	2e-07	Obesity
chr21	20405417	20405418	rs1888414	2e-07	Hippocampal atrophy
chr21	15432900	15432901	rs1736135	2e-07	Ulcerative colitis
chr20	7831702	7831703	rs2423279	2e-07	Colorectal cancer
chr20	57853648	57853649	rs12481680	2e-07	Response to fenofibrate (adiponectin levels)
chr18	43098269	43098270	rs4130047	2e-07	Parkinson's disease
chr21	39093607	39093608	rs2836878	2e-07	C-reactive protein
chr18	12779947	12779948	rs2542151	2e-07	Crohn's disease
chr1	61914625	61914626	rs1056513	2e-07	Obesity-related traits
chr1	61914625	61914626	rs1056513	2e-07	Obesity-related traits
chr1	61154823	61154824	rs334699	2e-07	Thyroid hormone levels
chr16	11136845	11136846	rs7203459	2e-07	Self-reported allergy
chr16	11072830	11072831	rs11865121	2e-07	Multiple sclerosis
chr16	10987391	10987392	rs6498142	2e-07	Immunoglobulin A 
chr1	60739796	60739797	rs1514178	2e-07	Phospholipid levels (plasma)
chr1	60629885	60629886	rs472913	2e-07	Bipolar disorder
chr15	91174121	91174122	rs886144	2e-07	Metabolite levels
chr15	81334383	81334384	rs3935740	2e-07	Parkinson's disease
chr15	78575139	78575140	rs17486278	2e-07	Airflow obstruction 
chr15	78571129	78571130	rs667282	2e-07	Smoking behavior
chr15	72790024	72790025	rs4777542	2e-07	Urate levels
chr1	56500677	56500678	rs17114046	2e-07	Coronary heart disease
chr15	38614839	38614840	rs7171171	2e-07	Type 1 diabetes autoantibodies
chr15	36057644	36057645	rs1898036	2e-07	Response to tocilizumab in rheumatoid arthritis
chr15	29901264	29901265	rs711355	2e-07	Response to antipsychotic treatment
chr18	24169650	24169651	rs9635963	2e-07	Protein quantitative trait loci
chr15	25667191	25667192	rs17636733	2e-07	Cardiac hypertrophy
chr16	20331249	20331250	rs12444268	2e-07	Type 1 diabetes
chr16	30907165	30907166	rs11649653	2e-07	Triglycerides
chr15	67166300	67166301	rs17228212	2e-07	Coronary heart disease
chr16	53786614	53786615	rs9939609	2e-07	Type 2 diabetes
chr17	76287587	76287588	rs164009	2e-07	Urate levels
chr16	53786614	53786615	rs9939609	2e-07	Biomedical quantitative traits
chr17	9040611	9040612	rs8076457	2e-07	Orofacial clefts
chr17	7608755	7608756	rs11653545	2e-07	IgM levels
chr17	73339120	73339121	rs3816995	2e-07	Panic disorder
chr1	76433778	76433779	rs4949718	2e-07	Liver enzyme levels (alanine transaminase)
chr17	6238356	6238357	rs7503953	2e-07	Wegener's granulomatosis
chr17	49325444	49325445	rs12940887	2e-07	Blood pressure
chr17	46935904	46935905	rs17608766	2e-07	Blood pressure
chr17	2525213	2525214	rs9891572	2e-07	HDL cholesterol
chr17	72131394	72131395	rs9915657	2e-07	Thyroid hormone levels
chr17	17239581	17239582	rs12600635	2e-07	IgG glycosylation
chr16	6649259	6649260	rs11643447	2e-07	Visceral adipose tissue adjusted for BMI
chr16	6767373	6767374	rs6500818	2e-07	Dengue shock syndrome 
chr16	67937476	67937477	rs11574514	2e-07	Crohn's disease
chr16	6846126	6846127	rs11645781	2e-07	Heart rate
chr16	67674993	67674994	rs12449157	2e-07	HDL cholesterol
chr16	86677053	86677054	rs10048146	2e-07	Bone mineral density (hip)
chr16	87957444	87957445	rs4843747	2e-07	Menopause (age at onset)
chr16	78154840	78154841	rs12716852	2e-07	Pulmonary function
chr16	73679783	73679784	rs764255	2e-07	Word reading
chr4	179734471	179734472	rs17746001	3e-07	Bipolar disorder
chr4	177397036	177397037	rs1395479	3e-07	Serum selenium levels
chr4	15735724	15735725	rs4698412	3e-07	Parkinson's disease
chr4	155724360	155724361	rs13139571	3e-07	Blood pressure
chr4	144585303	144585304	rs13141641	3e-07	Chronic obstructive pulmonary disease
chr4	113942549	113942550	rs7658266b	3e-07	Blood pressure measurement (high sodium intervention)
chr4	179734471	179734472	rs17746001	3e-07	Bipolar disorder and schizophrenia
chr4	10060701	10060702	rs6834555	3e-07	Alzheimer's disease
chr3	192100852	192100853	rs4585146	3e-07	Major depressive disorder
chr3	97449895	97449896	rs1458303	3e-07	Blood trace element (Cu levels)
chr3	46310892	46310893	rs6441961	3e-07	Celiac disease
chr3	39013825	39013826	rs883565	3e-07	Handedness
chr3	32447041	32447042	rs12638540	3e-07	Mortality in heart failure
chr4	109717653	109717654	rs2285714	3e-07	Age-related macular degeneration
chr4	179734471	179734472	rs17746001	3e-07	Bipolar disorder and schizophrenia
chr4	99353128	99353129	rs1789924	3e-07	Upper aerodigestive tract cancers
chr4	55802264	55802265	rs753129	3e-07	Alzheimer's disease
chr5	159176562	159176563	rs1473247	3e-07	Mean platelet volume
chr3	189395471	189395472	rs6789327	3e-07	Axial length
chr5	150860513	150860514	rs1000113	3e-07	Crohn's disease
chr5	149762503	149762504	rs9285640	3e-07	Response to fenofibrate
chr5	139569776	139569777	rs261532	3e-07	Immune reponse to smallpox (secreted IFN-alpha)
chr5	138084299	138084300	rs2040862	3e-07	Atrial fibrillation
chr5	137859072	137859073	rs7722600	3e-07	Heart rate
chr5	132565532	132565533	rs2244012	3e-07	Asthma
chr4	99307308	99307309	rs1042026	3e-07	Esophageal cancer  (alcohol interaction)
chr4	93965879	93965880	rs13130787	3e-07	Colorectal cancer
chr4	87834675	87834676	rs7698623	3e-07	Cardiovascular disease risk factors
chr4	77684214	77684215	rs958617	3e-07	Tuberculosis
chr4	74090654	74090655	rs546829	3e-07	White blood cell types
chr4	72551806	72551807	rs1383934	3e-07	Dental caries
chr4	64304696	64304697	rs7656244	3e-07	Kawasaki disease
chr4	39086720	39086721	rs35141484	3e-07	Asthma (childhood onset)
chr3	184292259	184292260	rs3914188	3e-07	Menarche (age at onset)
chr2	162053712	162053713	rs6741949	3e-07	Hippocampal volume
chr3	158796570	158796571	rs6802315	3e-07	Periodontitis (CDC/AAP)
chr21	41421863	41421864	rs459482	3e-07	IgG glycosylation
chr2	140604488	140604489	rs491391	3e-07	Optic disc size (disc)
chr21	38801603	38801604	rs1209950	3e-07	Non-small cell lung cancer (survival)
chr2	136218684	136218685	rs882300	3e-07	Electrocardiographic traits
chr2	135787728	135787729	rs16832011	3e-07	Phospholipid levels (plasma)
chr21	33424578	33424579	rs2834215	3e-07	Crohn's disease
chr2	177815703	177815704	rs13413635	3e-07	Heart rate
chr2	129710792	129710793	rs10928927	3e-07	Chronic obstructive pulmonary disease
chr2	119087740	119087741	rs17189298	3e-07	T-tau
chr2	111246289	111246290	rs2271404	3e-07	Atopic dermatitis
chr20	40842786	40842787	rs6072161	3e-07	IgG glycosylation
chr20	39500358	39500359	rs6028466	3e-07	Telomere length
chr20	33894825	33894826	rs742614 	3e-07	Stearic acid (18:0) plasma levels
chr5	175751871	175751872	rs10039217	3e-07	Obesity-related traits
chr2	119564240	119564241	rs2587695	3e-07	Attention deficit hyperactivity disorder
chr2	178431543	178431544	rs9283487	3e-07	Multiple sclerosis (OCB status)
chr2	191099906	191099907	rs7574865	3e-07	Rheumatoid arthritis
chr2	21617220	21617221	rs1117324	3e-07	Response to antipsychotic treatment
chr3	156679959	156679960	rs2665390	3e-07	Ovarian cancer
chr3	109132943	109132944	rs4441659	3e-07	Homeostasis model assessment of beta-cell function (interaction)
chr3	10835925	10835926	rs1809529	3e-07	Response to tocilizumab in rheumatoid arthritis
chr2	99844191	99844192	rs7583877	3e-07	Type 1 diabetes nephropathy
chr2	81523999	81524000	rs10496262	3e-07	Aging traits
chr2	57995792	57995793	rs2312147	3e-07	Schizophrenia
chr2	55884173	55884174	rs3791675	3e-07	Height
chr2	54491043	54491044	rs4557020	3e-07	Myopia (pathological)
chr2	51440600	51440601	rs1206397	3e-07	Cognitive performance
chr2	46598886	46598887	rs17818399	3e-07	Height
chr2	40168937	40168938	rs404005	3e-07	HIV-associated dementia 
chr2	241114130	241114131	rs17382723	3e-07	Height
chr22	33990483	33990484	rs7286472	3e-07	Blood pressure measurement (cold pressor test)
chr2	227850658	227850659	rs7591163	3e-07	Blood pressure
chr2	225360906	225360907	rs1473307	3e-07	Menopause (age at onset)
chr3	175929376	175929377	rs6772209	3e-07	Esophageal cancer
chr5	1895714	1895715	rs12653946	3e-07	Prostate cancer
chr6	98014624	98014625	rs12529874 	3e-07	Oleic acid (18:1n-9) plasma levels
chr5	32888711	32888712	rs10472828	3e-07	Height
chr7	42286025	42286026	rs12532960	3e-07	Inflammatory biomarkers
chr7	31115732	31115733	rs1558477	3e-07	Major depressive disorder
chr7	25968431	25968432	rs745580	3e-07	Obesity-related traits
chr7	158932097	158932098	rs2730245	3e-07	Height
chr7	15296310	15296311	rs12531027	3e-07	Obesity-related traits
chr7	128940625	128940626	rs3807306	3e-07	Rheumatoid arthritis
chr7	73450538	73450539	rs714052	3e-07	Triglycerides
chr7	11251772	11251773	rs4720952	3e-07	IgG glycosylation
chr6	90497631	90497632	rs806276	3e-07	Attention deficit hyperactivity disorder (time to onset)
chr6	81483391	81483392	rs17530068	3e-07	Breast cancer
chr6	79855118	79855119	rs346291	3e-07	Partial epilepsies
chr6	7240343	7240344	rs2714337	3e-07	Fasting glucose-related traits (interaction with BMI)
chr6	65855459	65855460	rs9354308	3e-07	Metabolite levels
chr6	6283432	6283433	rs749005	3e-07	MRI atrophy measures
chr7	108908602	108908603	rs848353	3e-07	Smoking behavior
chr8	104980467	104980468	rs977396	3e-07	Response to antipsychotic treatment
chr8	11486463	11486464	rs2736340	3e-07	Systemic lupus erythematosus
chr8	11552482	11552483	rs2255327	3e-07	Immune response to smallpox vaccine (IL-6)
chr20	2774841	2774842	rs6138892	3e-07	Response to tocilizumab in rheumatoid arthritis
chr9	130890268	130890269	rs10901296	3e-07	Bilirubin levels
chr9	117164146	117164147	rs4838255	3e-07	Response to antipsychotic treatment
chr9	10505223	10505224	rs72700966	3e-07	Epilepsy (remission after treatment)
chr9	104031444	104031445	rs1536895	3e-07	Orofacial clefts (interaction)
chr8	9141508	9141509	rs3748140	3e-07	Alzheimer's disease
chr8	6971562	6971563	rs2738113	3e-07	Endometriosis
chr8	68651459	68651460	rs7825271	3e-07	Obesity-related traits
chr8	52772300	52772301	rs7822058	3e-07	Obesity-related traits
chr8	48899641	48899642	rs12155623	3e-07	Sudden cardiac arrest
chr8	37829230	37829231	rs6468442	3e-07	Menopause (age at onset)
chr8	36601935	36601936	rs7814403	3e-07	Obesity-related traits
chr8	2923433	2923434	rs2627282	3e-07	Blood pressure measurement (high sodium intervention)
chr8	127492251	127492252	rs17766217	3e-07	Response to antidepressant treatment
chr8	125478729	125478730	rs2954029	3e-07	Triglycerides
chr6	61987840	61987841	rs6455128	3e-07	Protein quantitative trait loci
chr5	32888711	32888712	rs10472828	3e-07	Height
chr6	55608495	55608496	rs11754509	3e-07	Obesity-related traits
chr6	43937042	43937043	rs11755845 	3e-07	Thyroid hormone levels
chr6	14586771	14586772	rs12213875	3e-07	Ovarian reserve
chr6	141535996	141535997	rs7742587	3e-07	Methotrexate phramacokinetics (acute lymphoblastic leukemia)
chr6	140848687	140848688	rs11155133	3e-07	Acute lymphoblastic leukemia (childhood)
chr6	1339953	1339954	rs9502893	3e-07	Pancreatic cancer
chr6	131488779	131488780	rs2807278	3e-07	Obesity
chr6	124370090	124370091	rs9491140	3e-07	Neuroticism
chr6	149441400	149441401	rs2179367	3e-07	Dupuytren's disease
chr6	121495732	121495733	rs9490306	3e-07	Migraine without aura
chr5	9623509	9623510	rs10513025	3e-07	Autism
chr5	66856429	66856430	rs39861	3e-07	Epilepsy (generalized)
chr5	6635477	6635478	rs472402	3e-07	Response to amphetamines
chr5	56264199	56264200	rs1020388	3e-07	Celiac disease and Rheumatoid arthritis
chr5	40490687	40490688	rs10440635	3e-07	Ankylosing spondylitis
chr5	35874472	35874473	rs6897932	3e-07	Multiple sclerosis
chr6	104775988	104775989	rs733724	3e-07	Multiple sclerosis
chr6	159650126	159650127	rs2842992	3e-07	Age-related macular degeneration (GA)
chr6	163765644	163765645	rs10945919	3e-07	Response to TNF antagonist treatment
chr6	168110335	168110336	rs1473500	3e-07	Immune reponse to smallpox (secreted IL-2)
chr6	34959502	34959503	rs1535001	3e-07	Systemic lupus erythematosus and Systemic sclerosis
chr6	33694517	33694518	rs3227	3e-07	Educational attainment
chr6	33574760	33574761	rs210138	3e-07	Testicular germ cell tumor
chr9	4015369	4015370	rs564816	3e-07	Methotrexate phramacokinetics (acute lymphoblastic leukemia)
chr6	32706959	32706960	rs1794265	3e-07	IgG glycosylation
chr6	32237332	32237333	rs9267911	3e-07	Crohn's disease
chr6	32203297	32203298	rs3132935	3e-07	Schizophrenia
chr6	31952139	31952140	rs522162	3e-07	Age-related macular degeneration (extreme sampling)
chr6	31834687	31834688	rs4711279	3e-07	IgG glycosylation
chr6	31125809	31125810	rs3815087	3e-07	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)
chr6	31039077	31039078	rs2844665	3e-07	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)
chr6	29212943	29212944	rs9257616	3e-07	Social communication problems
chr6	26092912	26092913	rs1800562	3e-07	Hepcidin levels
chr6	25488354	25488355	rs2274089	3e-07	Iron status biomarkers
chr6	20717023	20717024	rs9465871	3e-07	Type 2 diabetes
chr6	4874524	4874525	rs73717741	3e-07	Chronic obstructive pulmonary disease
chr20	19590936	19590937	rs3790268	3e-07	Matrix metalloproteinase levels
chr6	32886919	32886920	rs10046257	3e-07	Disc degeneration (lumbar)
chr19	51581582	51581583	rs1543922	3e-07	Response to tocilizumab in rheumatoid arthritis
chr12	55676883	55676884	rs55874825	3e-07	Response to amphetamines
chr12	53720373	53720374	rs941184	3e-07	Panic disorder
chr12	51484975	51484976	rs147845115	3e-07	Alzheimer's disease (cognitive decline)
chr12	50819649	50819650	rs17291650	3e-07	Sudden cardiac arrest
chr12	47245742	47245743	rs11610206	3e-07	Alzheimer's disease
chr1	244369911	244369912	rs3101457	3e-07	Smoking behavior
chr12	6332834	6332835	rs4149639	3e-07	Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin)
chr12	43573873	43573874	rs7295246	3e-07	Alzheimer's disease (late onset)
chr1	237435115	237435116	rs7529251	3e-07	IgG glycosylation
chr1	235436813	235436814	rs6429082	3e-07	Adiposity
chr1	233584237	233584238	rs11800854	3e-07	Periodontal microbiota
chr12	32283474	32283475	rs708224	3e-07	Pancreatic cancer
chr1	22371953	22371954	rs7524102	3e-07	Ulcerative colitis
chr1	220803990	220803991	rs6693017	3e-07	Monocyte early outgrowth colony forming units
chr12	4296222	4296223	rs3217901	3e-07	Colorectal cancer
chr12	132769222	132769223	rs12282	3e-07	Immune response to smallpox vaccine (IL-6)
chr12	6356914	6356915	rs3782724	3e-07	Obesity (early onset extreme)
chr12	95566011	95566012	rs7136572	3e-07	Response to antidepressant treatment
chr1	36696750	36696751	rs589249	3e-07	Schizophrenia
chr13	64376289	64376290	rs1340319	3e-07	Rheumatoid arthritis
chr13	64371041	64371042	rs9598783	3e-07	Rheumatoid arthritis
chr13	64366134	64366135	rs12873872	3e-07	Rheumatoid arthritis
chr13	64362110	64362111	rs9571178	3e-07	Rheumatoid arthritis
chr13	64356862	64356863	rs1340317	3e-07	Rheumatoid arthritis
chr12	65767190	65767191	rs10784496	3e-07	AB1-42
chr13	49611067	49611068	rs9568281	3e-07	Multiple sclerosis
chr1	33463156	33463157	rs12565140	3e-07	Estradiol plasma levels (breast cancer)
chr13	26957129	26957130	rs17085007	3e-07	Ulcerative colitis
chr13	110817690	110817691	rs767210	3e-07	Cognitive performance
chr13	105154671	105154672	rs16965962	3e-07	Response to citalopram treatment
chr13	105154671	105154672	rs16965962	3e-07	Response to citalopram treatment
chr12	99423063	99423064	rs7968606	3e-07	Response to antipsychotic treatment
chr13	39931372	39931373	rs9548988	3e-07	Ulcerative colitis
chr12	115064912	115064913	rs2194980	3e-07	Metabolite levels
chr1	202500594	202500595	rs12734338	3e-07	Celiac disease
chr1	193656102	193656103	rs6678275	3e-07	Alzheimer's disease (late onset)
chr10	62463623	62463624	rs10995170	3e-07	Intelligence
chr10	60519365	60519366	rs10994397	3e-07	Bipolar disorder
chr10	6011199	6011200	rs12722605	3e-07	Inflammatory biomarkers
chr10	54444530	54444531	rs7476422	3e-07	Adverse response to chemotherapy in breast cancer (alopecia)
chr10	51029594	51029595	rs6479874	3e-07	Migraine
chr10	42845656	42845657	rs2142991	3e-07	Progressive supranuclear palsy
chr10	63555636	63555637	rs12411988	3e-07	Arthritis (juvenile idiopathic)
chr10	3496601	3496602	rs7092929	3e-07	Coronary artery calcification
chr10	24206656	24206657	rs11013962	3e-07	Common traits (Other)
chr10	20253704	20253705	rs1571942	3e-07	Diabetic retinopathy 
chr10	13319975	13319976	rs1747683	3e-07	IgG glycosylation
chr10	11678308	11678309	rs7920721	3e-07	Alzheimer's disease (late onset)
chr10	102902700	102902701	rs7897654	3e-07	Schizophrenia
chr19	950379	950380	rs2159128	3e-07	Vertical cup-disc ratio
chr10	31077341	31077342	rs2994684	3e-07	Response to antipsychotic treatment
chr10	89612775	89612776	rs11185790	3e-07	Metabolic traits
chr10	94787705	94787706	rs12767583	3e-07	Acenocoumarol maintenance dosage
chr11	112585497	112585498	rs7105881	3e-07	Response to antipsychotic treatment
chr11	9087739	9087740	rs2647528	3e-07	&beta;2-Glycoprotein I (&beta;2-GPI) plasma levels
chr11	73601206	73601207	rs10751226   	3e-07	Pulmonary function (interaction)
chr1	169639678	169639679	rs1569476	3e-07	Total ventricular volume
chr11	69072691	69072692	rs3750965	3e-07	Hair color
chr11	58580291	58580292	rs948562	3e-07	Lymphoma
chr11	45206015	45206016	rs17723470	3e-07	Thyroid hormone levels
chr11	44356605	44356606	rs11037965	3e-07	Blood pressure measurement (high sodium intervention)
chr11	24657272	24657273	rs4561213	3e-07	Magnesium levels
chr11	133697089	133697090	rs4397868	3e-07	Menopause (age at onset)
chr11	130960852	130960853	rs10894294	3e-07	Schizophrenia
chr11	129603794	129603795	rs7107217	3e-07	Type 2 diabetes
chr1	112673920	112673921	rs2932538	3e-07	Hypertension
chr11	118883643	118883644	rs630923	3e-07	Multiple sclerosis
chr11	116748356	116748357	rs28927680	3e-07	Lipid traits
chr11	113120895	113120896	rs1436109	3e-07	Cardiac muscle measurement
chr13	74421522	74421523	rs17714988	3e-07	Immune reponse to smallpox (secreted IFN-alpha)
chr13	80094738	80094739	rs9574565	3e-07	Orofacial clefts
chr10	26445657	26445658	rs2992257	3e-07	Response to angiotensin II receptor blocker therapy
chr13	94811137	94811138	rs9302001	3e-07	Panic disorder
chr1	80445428	80445429	rs12118390	3e-07	Estradiol plasma levels (breast cancer)
chr17	81244913	81244914	rs2659005	3e-07	IgG glycosylation
chr17	7559651	7559652	rs3803800	3e-07	IgA levels
chr17	7514345	7514346	rs6761	3e-07	Protein quantitative trait loci
chr17	69854759	69854760	rs2366017 	3e-07	Palmitoleic acid (16:1n-7) plasma levels
chr17	66231244	66231245	rs11867410	3e-07	Blood pressure measurement (high sodium and potassium intervention)
chr18	10078073	10078074	rs8089099   	3e-07	Pulmonary function (interaction)
chr17	66231244	66231245	rs11867410	3e-07	Blood pressure measurement (high sodium and potassium intervention)
chr17	47347748	47347749	rs7206971	3e-07	LDL cholesterol
chr17	46710943	46710944	rs183211	3e-07	Parkinson's disease
chr17	36031259	36031260	rs712046	3e-07	Pulmonary function
chr17	16342701	16342702	rs7477	3e-07	Amyotrophic lateral sclerosis
chr17	15289738	15289739	rs1380181	3e-07	QT interval
chr17	14007231	14007232	rs17608059	3e-07	Temperament
chr17	48643202	48643203	rs2326017	3e-07	Cognitive performance
chr18	11064409	11064410	rs12455924	3e-07	Thiazide-induced adverse metabolic effects in hypertensive patients
chr18	22074175	22074176	rs4800353	3e-07	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined)
chr18	23560467	23560468	rs1805081	3e-07	Obesity
chr13	91551558	91551559	rs16946160	3e-07	Nephrotic syndrome (acquired)
chr19	48745472	48745473	rs838145	3e-07	Dietary macronutrient intake
chr19	44919688	44919689	rs4420638	3e-07	Quantitative traits
chr19	44919688	44919689	rs4420638	3e-07	C-reactive protein
chr19	33829948	33829949	rs2546057	3e-07	Major depressive disorder
chr19	22431319	22431320	rs931608	3e-07	Response to statin therapy (LDL-C)
chr1	91611539	91611540	rs1192415	3e-07	Optic disc size (disc)
chr19	15613391	15613392	rs3764563	3e-07	Inflammatory biomarkers
chr18	79632378	79632379	rs7233060	3e-07	Schizophrenia
chr18	75338378	75338379	rs62090893	3e-07	Anorexia nervosa
chr18	71698063	71698064	rs11665307	3e-07	IgG glycosylation
chr18	62412878	62412879	rs2980976	3e-07	Response to antipsychotic treatment
chr18	49464789	49464790	rs8099594	3e-07	Height
chr18	45376706	45376707	rs2243803	3e-07	Menarche (age at onset)
chr18	25677221	25677222	rs1840440	3e-07	Weight
chr17	12874084	12874085	rs11651483	3e-07	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)
chr16	86647389	86647390	rs300032	3e-07	IgG glycosylation
chr19	44892361	44892362	rs2075650	3e-07	AB1-42
chr16	84180077	84180078	rs4150167	3e-07	Autism
chr15	61578743	61578744	rs12592967	3e-07	Schizophrenia
chr15	50748600	50748601	rs8035452	3e-07	Alzheimer's disease (late onset)
chr15	27467497	27467498	rs74006954	3e-07	Alzheimer's disease (cognitive decline)
chr14	95476109	95476110	rs11622887	3e-07	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer
chr14	92307318	92307319	rs12896399	3e-07	Eye color
chr14	89760906	89760907	rs2093746	3e-07	IgG glycosylation
chr15	62395139	62395140	rs2456930	3e-07	Brain structure (temporal lobe volume)
chr14	85497511	85497512	rs8014131	3e-07	Menarche (age at onset)
chr14	68283209	68283210	rs3784099	3e-07	Breast cancer (survival)
chr14	50617516	50617517	rs17122693	3e-07	Cognitive performance
chr14	103018487	103018488	rs751837	3e-07	Large B-cell lymphoma
chr14	23119847	23119848	rs2239633	3e-07	Acute lymphoblastic leukemia (childhood)
chr14	106772331	106772332	rs2337406	3e-07	Alzheimer's disease (late onset)
chr16	86070535	86070536	rs8050326	3e-07	Major depressive disorder
chr14	74085266	74085267	rs2239557	3e-07	Common traits (Other)
chr1	56500677	56500678	rs17114046	3e-07	Coronary heart disease
chr14	46985782	46985783	rs11627056	3e-07	Obesity-related traits
chr15	74751896	74751897	rs2472304	3e-07	Caffeine consumption
chr15	68304788	68304789	rs7174755	3e-07	Major depressive disorder
chr16	81455767	81455768	rs16955379	3e-07	Type 2 diabetes
chr1	65349975	65349976	rs1413885	3e-07	Anticoagulant levels
chr16	52288063	52288064	rs16951021	3e-07	Methotrexate phramacokinetics (acute lymphoblastic leukemia)
chr16	30624337	30624338	rs7186852	3e-07	Systemic lupus erythematosus
chr16	27399507	27399508	rs2107357	3e-07	Self-reported allergy
chr16	27045133	27045134	rs2203512	3e-07	Cognitive performance
chr1	67639769	67639770	rs344924	3e-07	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer
chr1	61914625	61914626	rs1056513	3e-07	Obesity-related traits
chr1	58696475	58696476	rs2811893	3e-07	Diabetic retinopathy 
chr1	62652524	62652525	rs10889353	3e-07	Triglycerides
chr15	92501108	92501109	rs8040009	3e-07	Alcoholism (heaviness of drinking)
chr1	61350126	61350127	rs41350144	3e-07	Bipolar disorder
chr16	82344175	82344176	rs4087296	3e-07	Bone mineral density
chr16	14989007	14989008	rs4985167	3e-07	Phospholipid levels (plasma)
chr1	61914625	61914626	rs1056513	3e-07	Obesity-related traits
chr4	105376355	105376356	rs2636697	4e-07	Response to antipsychotic treatment
chr3	176312307	176312308	rs6799767	4e-07	Eosinophilic esophagitis (pediatric)
chr3	185811291	185811292	rs1470579	4e-07	Type 2 diabetes
chr3	192376185	192376186	rs4453795	4e-07	Metabolite levels
chr3	23156992	23156993	rs6780569	4e-07	Type 2 diabetes
chr3	35598333	35598334	rs17033506	4e-07	Asthma (childhood onset)
chr3	152817575	152817576	rs10513432	4e-07	Immune reponse to smallpox (secreted IL-2)
chr3	36814538	36814539	rs9834970	4e-07	Schizophrenia or bipolar disorder
chr3	46298320	46298321	rs9990343	4e-07	Brain structure
chr3	66717939	66717940	rs17045031	4e-07	Carotid intima media thickness
chr3	94524868	94524869	rs13067306	4e-07	Blood pressure measurement (high sodium intervention)
chr3	96134787	96134788	rs111325002	4e-07	Cocaine dependence
chr3	171936112	171936113	rs3913363	4e-07	Response to angiotensin II receptor blocker therapy
chr3	187005155	187005156	rs7652995	4e-07	IgG glycosylation
chr4	54368657	54368658	rs17690232	4e-07	Height
chr4	116333132	116333133	rs2389202	4e-07	Sudden cardiac arrest
chr4	130216605	130216606	rs1024020	4e-07	RR interval (heart rate)
chr4	161329779	161329780	rs4470583	4e-07	Diabetic retinopathy 
chr4	170132367	170132368	rs11726248	4e-07	Thyroid hormone levels
chr4	26106574	26106575	rs874040	4e-07	Rheumatoid arthritis
chr4	4717766	4717767	rs1000579	4e-07	Alcohol dependence
chr4	76277832	76277833	rs6812193	4e-07	Parkinson's disease
chr5	128046609	128046610	rs146579248	4e-07	Alzheimer's disease (cognitive decline)
chr5	153790813	153790814	rs4958351	4e-07	Asparaginase hypersensitivity in acute lymphoblastic leukemia
chr5	155967219	155967220	rs17053082	4e-07	Type 2 diabetes
chr5	155967219	155967220	rs17053082	4e-07	Type 2 diabetes
chr5	160393923	160393924	rs10515808	4e-07	Weight loss (gastric bypass surgery)
chr5	35803474	35803475	rs931555	4e-07	Multiple sclerosis
chr5	40414964	40414965	rs1992660	4e-07	Crohn's disease
chr4	109976428	109976429	rs11568995	4e-07	IgG glycosylation
chr3	15253856	15253857	rs1318937	4e-07	Alcohol and nictotine co-dependence
chr22	37074183	37074184	rs2413450	4e-07	Red blood cell traits
chr3	11915123	11915124	rs6777876	4e-07	Alcohol dependence
chr2	133605460	133605461	rs7588567	4e-07	Glaucoma (primary open-angle)
chr5	67898640	67898641	rs10940138	4e-07	Menarche (age at onset)
chr21	38911808	38911809	rs9979250	4e-07	Periodontitis (Mean PAL)
chr21	42082651	42082652	rs220299	4e-07	Obesity-related traits
chr21	43359799	43359800	rs496300	4e-07	Metabolic syndrome
chr2	168917560	168917561	rs563694	4e-07	Fasting plasma glucose
chr2	170462383	170462384	rs2118674	4e-07	Palmitoleic acid (16:1n-7) plasma levels
chr2	203225006	203225007	rs16839626	4e-07	Obesity-related traits
chr2	203407366	203407367	rs1376877	4e-07	Subclinical atherosclerosis traits (other)
chr2	205221446	205221447	rs4675502	4e-07	Autism
chr2	20976027	20976028	rs11902417	4e-07	HDL cholesterol
chr2	217013485	217013486	rs6435957	4e-07	Primary tooth development (number of teeth)
chr2	22599286	22599287	rs13015955	4e-07	Coronary heart disease
chr2	227616702	227616703	rs11889798	4e-07	Immune reponse to smallpox (secreted TNF-alpha)
chr3	140528334	140528335	rs4683505	4e-07	Myopia (pathological)
chr22	28765018	28765019	rs4820792	4e-07	Breast size
chr22	40040968	40040969	rs11704416	4e-07	Prostate cancer
chr22	43183042	43183043	rs13058467	4e-07	Molar-incisor hypomineralization
chr22	45272130	45272131	rs58667	4e-07	Pulmonary function in asthmatics
chr2	25436374	25436375	rs6746082	4e-07	Multiple myeloma
chr23	155005498	155005499	rs17281398	4e-07	Antineutrophil cytoplasmic antibody-associated vasculitis 
chr23	47314876	47314877	rs6611365	4e-07	Optic disc size (disc)
chr23	53947620	53947621	rs7065696	4e-07	Bipolar disorder and schizophrenia
chr2	49957255	49957256	rs11681792	4e-07	Behavioural disinhibition (generation interaction)
chr2	57867737	57867738	rs2717068	4e-07	Epilepsy (generalized)
chr2	67749655	67749656	rs6724422	4e-07	Response to antidepressant treatment
chr2	76996811	76996812	rs1470506	4e-07	IgG glycosylation
chr2	99259780	99259781	rs2200578	4e-07	IgG glycosylation
chr3	103640373	103640374	rs10937540	4e-07	Economic and political preferences (environmentalism)
chr3	113711751	113711752	rs11711311	4e-07	IgG glycosylation
chr22	37066895	37066896	rs855791	4e-07	Mean corpuscular hemoglobin concentration
chr5	76625146	76625147	rs457717	4e-07	Hearing impairment
chr7	7843691	7843692	rs7780564	4e-07	Insulin-like growth factors
chr6	117450113	117450114	rs17635492	4e-07	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer
chr7	92779055	92779056	rs445	4e-07	White blood cell count
chr8	105130104	105130105	rs9297357	4e-07	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr8	11246601	11246602	rs7824557	4e-07	Retinal vascular caliber
chr8	116618443	116618444	rs16892766	4e-07	Colorectal cancer
chr8	118965097	118965098	rs12679857	4e-07	Type 1 diabetes
chr8	123819593	123819594	rs10481151	4e-07	Cognitive performance
chr8	126889757	126889758	rs4871750	4e-07	Obesity-related traits
chr8	128415271	128415272	rs7815944	4e-07	Atopic dermatitis
chr8	141726332	141726333	rs4072286	4e-07	Obesity-related traits
chr8	18120140	18120141	rs17126232	4e-07	Obesity
chr8	27559283	27559284	rs17057381	4e-07	Dental caries
chr8	4427169	4427170	rs4875102	4e-07	Disc degeneration (lumbar)
chr8	56243038	56243039	rs9650315	4e-07	Height
chr8	57876521	57876522	rs10504249	4e-07	Blood pressure measurement (low sodium intervention)
chr8	60049261	60049262	rs569688	4e-07	Myopia (pathological)
chr8	74461712	74461713	rs16938910	4e-07	Response to tocilizumab in rheumatoid arthritis
chr8	95114801	95114802	rs7000734	4e-07	Radiation response
chr9	102182472	102182473	rs320209	4e-07	Response to antipsychotic treatment
chr9	116419514	116419515	rs17303101	4e-07	Migraine
chr9	21816528	21816529	rs7023329	4e-07	Melanoma
chr9	27543282	27543283	rs3849942	4e-07	Amyotrophic lateral sclerosis
chr9	33128022	33128023	rs10813951	4e-07	IgG glycosylation
chr9	33180363	33180364	rs10813960	4e-07	Urate levels
chr9	4774014	4774015	rs296859 	4e-07	Handedness
chr9	7925380	7925381	rs1535480	4e-07	Common traits (Other)
chr9	80192587	80192588	rs12554086	4e-07	RR interval (heart rate)
chr9	863634	863635	rs755383	4e-07	Testicular germ cell tumor
chr9	99961409	99961410	rs10760706	4e-07	Alopecia areata
chr2	132386818	132386819	rs16831128	4e-07	Conduct disorder (case status)
chr7	92627590	92627591	rs2040494	4e-07	Height
chr7	70422098	70422099	rs11766624	4e-07	Obesity-related traits
chr7	66631040	66631041	rs10263935	4e-07	Aortic root size
chr7	51470189	51470190	rs1949829	4e-07	Wegener's granulomatosis
chr6	119544975	119544976	rs1392089	4e-07	Immune reponse to smallpox (secreted IL-2)
chr6	12903724	12903725	rs9349379	4e-07	Coronary heart disease
chr6	129540246	129540247	rs2275215	4e-07	Body mass index
chr6	134255372	134255373	rs9493873	4e-07	Immune reponse to smallpox (secreted IFN-alpha)
chr6	139519555	139519556	rs592423	4e-07	Adiponectin levels
chr6	141535456	141535457	rs6570465	4e-07	Methotrexate phramacokinetics (acute lymphoblastic leukemia)
chr6	147438397	147438398	rs9403856	4e-07	IgG glycosylation
chr6	150249730	150249731	rs3734729   	4e-07	Pulmonary function (interaction)
chr6	159044944	159044945	rs1738074	4e-07	Multiple sclerosis
chr6	2565517	2565518	rs12195826	4e-07	Obesity-related traits
chr6	27310240	27310241	rs16897515	4e-07	Schizophrenia
chr6	29658543	29658544	rs2252711   	4e-07	Pulmonary function (interaction)
chr6	32396177	32396178	rs2076529	4e-07	Waist-hip ratio
chr6	396320	396321	rs12203592	4e-07	Hair color
chr5	80151080	80151081	rs73772260	4e-07	Borderline personality disorder features
chr6	41655294	41655295	rs2143678	4e-07	Cardiovascular disease risk factors
chr6	7743429	7743430	rs9505270	4e-07	Myopia (pathological)
chr6	96617335	96617336	rs11759769	4e-07	Migraine - clinic-based
chr7	106855363	106855364	rs17153527	4e-07	Menopause (age at onset)
chr7	11251772	11251773	rs4720952	4e-07	IgG glycosylation
chr7	118351840	118351841	rs41997	4e-07	Response to platinum-based chemotherapy in non-small-cell lung cancer
chr7	1249002	1249003	rs13241427	4e-07	Fat distribution (HIV)
chr7	128954128	128954129	rs10488631	4e-07	Systemic sclerosis
chr7	131685279	131685280	rs11761231	4e-07	Rheumatoid arthritis
chr7	153928757	153928758	rs6464375	4e-07	Pancreatic cancer
chr7	157087703	157087704	rs6966038	4e-07	Response to citalopram treatment
chr7	16287020	16287021	rs35681285	4e-07	Serum tamsulosin hydrochloride concentration
chr7	17521958	17521959	rs10499504	4e-07	Response to antipsychotic treatment
chr7	19066915	19066916	rs430	4e-07	Obesity-related traits
chr7	24338420	24338421	rs2521634	4e-07	Periodontitis
chr6	54400597	54400598	rs16885294	4e-07	Radiation response
chr21	23770801	23770802	rs2828520	4e-07	Major depressive disorder
chr1	88186087	88186088	rs10923038	4e-07	Serum protein levels (sST2)
chr2	110842128	110842129	rs4849121	4e-07	IgA nephropathy
chr11	16368047	16368048	rs297325	4e-07	Obesity and osteoporosis
chr11	17387082	17387083	rs5215	4e-07	Type 2 diabetes
chr11	19030324	19030325	rs7111562	4e-07	IgG glycosylation
chr11	2631426	2631427	rs10832417	4e-07	Blood pressure measurement (high sodium intervention)
chr11	5242622	5242623	rs16912210	4e-07	Obesity-related traits
chr1	155192275	155192276	rs4072037	4e-07	Esophageal cancer and gastric cancer
chr11	61830499	61830500	rs1535	4e-07	Metabolic syndrome
chr11	64329760	64329761	rs694739	4e-07	Alopecia areata
chr1	165434665	165434666	rs285480	4e-07	Personality dimensions
chr1	167442146	167442147	rs864537	4e-07	Celiac disease
chr1	17265183	17265184	rs3003429   	4e-07	Pulmonary function (interaction)
chr11	72959854	72959855	rs72981516	4e-07	Crohn's disease
chr1	173257055	173257056	rs704840	4e-07	Systemic lupus erythematosus and Systemic sclerosis
chr11	73325435	73325436	rs2027760   	4e-07	Pulmonary function (interaction)
chr11	73601206	73601207	rs10751226   	4e-07	Pulmonary function (interaction)
chr11	79281640	79281641	rs1151200	4e-07	Obesity-related traits
chr11	83012029	83012030	rs11233413	4e-07	Economic and political preferences (feminism/equality)
chr12	100827460	100827461	rs1399439	4e-07	Alzheimer's disease (cognitive decline)
chr12	109960339	109960340	rs4766646	4e-07	Metabolite levels (MHPG)
chr12	114678546	114678547	rs59336	4e-07	Colorectal cancer
chr1	213737150	213737151	rs1704198	4e-07	Obesity
chr1	227480088	227480089	rs12410462	4e-07	Major depressive disorder
chr1	231134889	231134890	rs12023396	4e-07	Obesity-related traits
chr1	233204407	233204408	rs12027542	4e-07	Type 2 diabetes
chr12	56421496	56421497	rs2291738	4e-07	Axial length
chr12	65965971	65965972	rs8756	4e-07	Height
chr1	29959371	29959372	rs4949526	4e-07	Bipolar disorder and schizophrenia
chr12	99872334	99872335	rs11110077	4e-07	Response to antipsychotic treatment in schizophrenia (working memory)
chr13	103407736	103407737	rs9586179	4e-07	Phospholipid levels (plasma)
chr1	116197827	116197828	rs4839516	4e-07	Word reading
chr1	1143817	1143818	rs11260603	4e-07	IgG glycosylation
chr11	13598624	13598625	rs9630182	4e-07	Bone mineral density
chr11	132771850	132771851	rs10894604	4e-07	Waist-hip ratio
chr10	102988960	102988961	rs1890185	4e-07	Migraine
chr10	11182701	11182702	rs596406	4e-07	Liver enzyme levels (aspartate transaminase)
chr10	128571225	128571226	rs749141	4e-07	Serum dimethylarginine levels (symmetric)
chr10	13319975	13319976	rs1747683	4e-07	IgG glycosylation
chr2	111078960	111078961	rs7578982	4e-07	White blood cell types
chr10	1429569	1429570	rs2820651	4e-07	Migraine with aura
chr10	16706610	16706611	rs7916663	4e-07	Obesity-related traits
chr10	18661625	18661626	rs10829156	4e-07	Sudden cardiac arrest
chr10	24346026	24346027	rs2484873	4e-07	Cognitive performance
chr10	25873836	25873837	rs4749080	4e-07	Obesity-related traits
chr10	44046116	44046117	rs10508881	4e-07	Endometriosis
chr10	61589008	61589009	rs1350172 	4e-07	Response to taxane treatment (placlitaxel)
chr10	79274912	79274913	rs1250542	4e-07	Multiple sclerosis
chr10	79379705	79379706	rs941873	4e-07	Height
chr13	106132915	106132916	rs1372791	4e-07	Immune reponse to smallpox (secreted IL-2)
chr10	85193570	85193571	rs12098564 	4e-07	Stearic acid (18:0) plasma levels
chr10	94298878	94298879	rs117607728	4e-07	Chronic obstructive pulmonary disease
chr10	94974581	94974582	rs10509680	4e-07	Warfarin maintenance dose
chr10	98410625	98410626	rs6584202	4e-07	Obesity-related traits
chr1	10521600	10521601	rs2056417	4e-07	Self-reported allergy
chr1	110227600	110227601	rs958798	4e-07	Self-rated health
chr11	10328990	10328991	rs7129220	4e-07	Blood pressure
chr11	111300983	111300984	rs3802842	4e-07	Colorectal cancer
chr11	111300983	111300984	rs3802842	4e-07	Colorectal cancer
chr11	116778200	116778201	rs964184	4e-07	Response to Vitamin E supplementation
chr11	120156039	120156040	rs2084898	4e-07	Stroke (pediatric)
chr11	120169733	120169734	rs2444240	4e-07	Corneal curvature
chr11	123725218	123725219	rs2126709	4e-07	Response to antipsychotic therapy (extrapyramidal side effects)
chr11	125434112	125434113	rs1783925	4e-07	Formal thought disorder in schizophrenia
chr11	126426693	126426694	rs4935969	4e-07	Hair color
chr10	94276222	94276223	rs11187837	4e-07	Sudden cardiac arrest
chr13	43260133	43260134	rs17538444	4e-07	Major depressive disorder
chr10	13319975	13319976	rs1747683	4e-07	IgG glycosylation
chr1	38158456	38158457	rs12131057	4e-07	Rheumatoid arthritis
chr1	70455489	70455490	rs10458561	4e-07	Antipsychotic-induced QTc interval prolongation
chr17	17239581	17239582	rs12600635	4e-07	IgG glycosylation
chr17	3284717	3284718	rs2005290	4e-07	Cocaine dependence
chr17	47273751	47273752	rs7209700	4e-07	IgG glycosylation
chr17	48046569	48046570	rs3764400	4e-07	Body mass index
chr17	5233751	5233752	rs7225151	4e-07	Alzheimer's disease (late onset)
chr17	60889176	60889177	rs7224438	4e-07	Immune reponse to smallpox (secreted IL-2)
chr17	62701570	62701571	rs2251393	4e-07	Sudden cardiac arrest
chr17	72717399	72717400	rs891684	4e-07	Serum selenium levels
chr17	7565911	7565912	rs11078697	4e-07	IgM levels
chr17	81194467	81194468	rs2279913	4e-07	IgG glycosylation
chr17	81244913	81244914	rs2659005	4e-07	IgG glycosylation
chr17	82450938	82450939	rs9303029	4e-07	Protein quantitative trait loci
chr1	79043423	79043424	rs6687262	4e-07	IgG glycosylation
chr18	10078073	10078074	rs8089099   	4e-07	Pulmonary function (interaction)
chr18	24358693	24358694	rs7227401	4e-07	Osteoporosis
chr18	26312707	26312708	rs1791780	4e-07	Visceral adipose tissue adjusted for BMI
chr18	35977502	35977503	rs2276314	4e-07	Drug-induced torsades de pointes
chr18	60215553	60215554	rs489693	4e-07	Waist circumference
chr18	77147087	77147088	rs1789110	4e-07	Age-related macular degeneration (GA)
chr1	90410330	90410331	rs2136093	4e-07	Response to antidepressants
chr19	10102477	10102478	rs8109578	4e-07	Protein quantitative trait loci
chr19	44007236	44007237	rs2191566	4e-07	Acute lymphoblastic leukemia (childhood)
chr19	44892008	44892009	rs157580	4e-07	HDL cholesterol
chr19	45192479	45192480	rs2159324	4e-07	Quantitative traits
chr20	14407568	14407569	rs6110278	4e-07	Mean platelet volume
chr20	19871858	19871859	rs6046396	4e-07	Bipolar disorder and schizophrenia
chr20	6780864	6780865	rs6054512	4e-07	Axial length
chr13	69512197	69512198	rs9572182	4e-07	Homeostasis model assessment of beta-cell function (interaction)
chr16	82612727	82612728	rs3844412	4e-07	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel)
chr16	82560777	82560778	rs4783227	4e-07	Response to antipsychotic treatment
chr20	16330664	16330665	rs2208059	4e-07	Ileal carcinoids
chr16	81927352	81927353	rs3813009	4e-07	IgG glycosylation
chr16	82293199	82293200	rs11863065	4e-07	Obesity-related traits
chr13	93580875	93580876	rs7998314	4e-07	Obesity-related traits
chr14	25660359	25660360	rs12586774	4e-07	Obesity-related traits
chr14	61441613	61441614	rs1957895	4e-07	Rheumatoid arthritis
chr14	65138009	65138010	rs17102423	4e-07	Obesity-related traits
chr14	68811486	68811487	rs4899260	4e-07	Celiac disease
chr1	47453148	47453149	rs527430	4e-07	Response to antidepressant treatment
chr14	94944191	94944192	rs10133840	4e-07	Body mass index (interaction)
chr15	26043246	26043247	rs6576507	4e-07	Insulin resistance/response
chr15	38703289	38703290	rs12899449	4e-07	Bipolar disorder
chr15	38856447	38856448	rs2624265	4e-07	Metabolic traits
chr15	51253256	51253257	rs12907866	4e-07	Menarche (age at onset)
chr15	56090096	56090097	rs16976734	4e-07	Chronic lymphocytic leukemia
chr15	57960907	57960908	rs3784262	4e-07	Barrett's esophagus
chr13	93580875	93580876	rs7998314	4e-07	Obesity-related traits
chr15	64433290	64433291	rs74615166	4e-07	Alzheimer's disease (late onset)
chr16	77842865	77842866	rs9934540	4e-07	Alzheimer's disease (cognitive decline)
chr15	58391166	58391167	rs1532085	4e-07	Cholesterol, total
chr16	74438797	74438798	rs10871290	4e-07	Breast cancer
chr1	65703995	65703996	rs12753193	4e-07	Metabolic traits
chr16	52552428	52552429	rs3803662	4e-07	Breast cancer
chr1	63643099	63643100	rs2269241	4e-07	Type 1 diabetes
chr16	31083849	31083850	rs11865038	4e-07	Parkinson's disease
chr13	91849409	91849410	rs7328464	4e-07	Obesity-related traits
chr16	13061020	13061021	rs4465599 	4e-07	Palmitoleic acid (16:1n-7) plasma levels
chr16	16864057	16864058	rs7186128	4e-07	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer
chr15	78633675	78633676	rs950776	4e-07	Sudden cardiac arrest
chr15	83904288	83904289	rs7183263	4e-07	Height
chr1	56661245	56661246	rs2746347	4e-07	Lymphocyte counts
chr15	86893513	86893514	rs17647114	4e-07	Response to antidepressant treatment
chr15	92340609	92340610	rs12905014	4e-07	Airflow obstruction 
chr4	36077971	36077972	rs12651329	5e-07	Amyotrophic lateral sclerosis (age of onset)
chr4	5235425	5235426	rs78647349	5e-07	Alzheimer's disease (cognitive decline)
chr4	94694617	94694618	rs4699587	5e-07	Estradiol plasma levels (breast cancer)
chr5	158997382	158997383	rs10040979	5e-07	Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs)
chr5	10169710	10169711	rs13361160	5e-07	Pain
chr5	105011947	105011948	rs13178964	5e-07	Blood pressure measurement (low sodium intervention)
chr5	118002057	118002058	rs13166814	5e-07	Subcutaneous adipose tissue
chr5	1321971	1321972	rs401681	5e-07	Bladder cancer
chr5	143624039	143624040	rs17100498	5e-07	Response to antipsychotic treatment
chr5	150243801	150243802	rs4958456	5e-07	Obesity-related traits
chr4	165951383	165951384	rs6812849	5e-07	Post-traumatic stress disorder (asjusted for relatedness)
chr4	180047277	180047278	rs1994816	5e-07	Multiple myeloma (IgH translocation)
chr4	95238665	95238666	rs12643654	5e-07	P-tau181p
chr5	177357510	177357511	rs4075958	5e-07	Multiple sclerosis
chr5	167783466	167783467	rs2973662	5e-07	Immune response to smallpox vaccine (IL-6)
chr5	177367189	177367190	rs12654812	5e-07	Renal function-related traits (sCR)
chr5	56727255	56727256	rs16886165	5e-07	Breast cancer
chr5	65151949	65151950	rs17206779	5e-07	Osteosarcoma
chr5	92818871	92818872	rs17668565	5e-07	Obesity-related traits
chr5	9474833	9474834	rs433755	5e-07	Obesity-related traits
chr6	104995313	104995314	rs364663	5e-07	Menarche (age at onset)
chr6	106237319	106237320	rs3827644	5e-07	Systemic lupus erythematosus and Systemic sclerosis
chr6	108666980	108666981	rs2153960	5e-07	Insulin-like growth factors
chr6	150592824	150592825	rs9372078	5e-07	Panic disorder
chr4	154426240	154426241	rs1466662	5e-07	Alzheimer's disease (age of onset)
chr6	16161193	16161194	rs6924995	5e-07	Response to statin therapy (LDL-C)
chr6	25820210	25820211	rs17270561	5e-07	Iron status biomarkers
chr5	164462273	164462274	rs6556756	5e-07	Breast cancer
chr5	88887833	88887834	rs17560407	5e-07	Thiazide-induced adverse metabolic effects in hypertensive patients
chr3	169774312	169774313	rs10936599	5e-07	Celiac disease
chr4	12497262	12497263	rs7665957	5e-07	Obesity-related traits
chr2	27518369	27518370	rs780094	5e-07	LDL cholesterol
chr6	26092912	26092913	rs1800562	5e-07	Iron status biomarkers
chr2	31251375	31251376	rs597800	5e-07	Estradiol levels
chr23	14932408	14932409	rs5980075	5e-07	Waist-to-hip circumference ratio (interaction)
chr2	46133767	46133768	rs10168349	5e-07	Hematological and biochemical traits
chr2	47012872	47012873	rs10194115	5e-07	Erectile dysfunction and prostate cancer treatment
chr2	63074028	63074029	rs6545977	5e-07	Prostate cancer
chr2	6554386	6554387	rs10495537	5e-07	Visceral adipose tissue adjusted for BMI
chr2	74236438	74236439	rs13006863	5e-07	Immune reponse to smallpox (secreted TNF-alpha)
chr2	79460125	79460126	rs399885	5e-07	Response to antipsychotic treatment
chr2	79695675	79695676	rs11695685	5e-07	Protein quantitative trait loci
chr2	88016273	88016274	rs12714207	5e-07	Bilirubin levels
chr3	100872080	100872081	rs9833094	5e-07	Acute urticaria and angiodema (non-steroidal anti-inflammatory drug-induced)
chr3	102055198	102055199	rs991258	5e-07	Hip geometry
chr3	137389639	137389640	rs1382269	5e-07	Metabolite levels
chr3	187825553	187825554	rs10513821   	5e-07	Pulmonary function (interaction)
chr3	187970101	187970102	rs16862782	5e-07	Myopia (pathological)
chr3	31754077	31754078	rs1902341	5e-07	Peripheral artery disease
chr3	38733340	38733341	rs6800541	5e-07	Atrioventricular conduction
chr3	42865619	42865620	rs2228468	5e-07	Monocyte count
chr3	45689958	45689959	rs2742417	5e-07	Response to antidepressant treatment
chr3	50314768	50314769	rs11130248	5e-07	Keloid
chr3	52879262	52879263	rs3796352	5e-07	Immune reponse to smallpox (secreted IL-2)
chr3	64306960	64306961	rs741013	5e-07	Coronary artery calcification
chr4	102267551	102267552	rs13107325	5e-07	Hypertension
chr4	121686022	121686023	rs55645543	5e-07	Chronic obstructive pulmonary disease
chr4	122456824	122456825	rs2069762	5e-07	Type 1 diabetes autoantibodies
chr4	144565236	144565237	rs13118928	5e-07	Chronic obstructive pulmonary disease
chr6	29931899	29931900	rs2524005	5e-07	Bipolar disorder and schizophrenia
chr8	117172543	117172544	rs13266634	5e-07	Type 2 diabetes
chr6	30698891	30698892	rs9468811	5e-07	IgG glycosylation
chr8	12854353	12854354	rs4831837	5e-07	Morbidity-free survival
chr8	14659784	14659785	rs11203649	5e-07	Obesity-related traits
chr8	19962212	19962213	rs328	5e-07	Triglycerides
chr8	2882979	2882980	rs641525	5e-07	Emphysema-related traits
chr8	4442360	4442361	rs17070309	5e-07	Immune response to smallpox vaccine (IL-6)
chr8	495600	495601	rs17665859	5e-07	Bilirubin levels
chr8	52301704	52301705	rs7009219	5e-07	Alzheimer's disease (cognitive decline)
chr8	54398150	54398151	rs1504749	5e-07	Intracranial aneurysm
chr8	66062016	66062017	rs13279522	5e-07	Response to statin therapy
chr9	104832082	104832083	rs2515629	5e-07	Coronary heart disease
chr9	104885373	104885374	rs3890182	5e-07	HDL cholesterol
chr9	111586336	111586337	rs2273788	5e-07	Monocyte count
chr9	11257447	11257448	rs10959672	5e-07	Response to amphetamines
chr9	116551937	116551938	rs13290997   	5e-07	Pulmonary function (interaction)
chr9	117796732	117796733	rs10115586	5e-07	IgG glycosylation
chr9	121803540	121803541	rs10760187	5e-07	Periodontal microbiota
chr9	12672096	12672097	rs1408799	5e-07	Eye color
chr9	16034539	16034540	rs3008706	5e-07	Bilirubin levels
chr9	17731922	17731923	rs1536076	5e-07	Parkinson's disease
chr9	22043926	22043927	rs1412829	5e-07	Nasopharyngeal carcinoma
chr9	27490968	27490969	rs7046653	5e-07	Response to TNF antagonist treatment
chr9	33124873	33124874	rs12342831	5e-07	IgG glycosylation
chr9	87594221	87594222	rs3095748	5e-07	Immune reponse to smallpox (secreted IFN-alpha)
chr9	89421511	89421512	rs4132699	5e-07	Orofacial clefts
chr9	95468725	95468726	rs16909898	5e-07	Pulmonary function
chr9	97829180	97829181	rs7045138	5e-07	Thyroid hormone levels
chr22	44130224	44130225	rs75617873	5e-07	Alzheimer's disease (cognitive decline)
chr8	127310935	127310936	rs445114	5e-07	Prostate cancer
chr8	117537136	117537137	rs17667932	5e-07	Kawasaki disease
chr7	97600465	97600466	rs10486003	5e-07	Response to platinum-based agents
chr7	50315610	50315611	rs6421315	5e-07	IgG glycosylation
chr6	31090562	31090563	rs3130544	5e-07	Hematology traits
chr6	31870935	31870936	rs494620	5e-07	Menopause (age at onset)
chr6	32103239	32103240	rs3117181	5e-07	Phospholipid levels (plasma)
chr6	32203297	32203298	rs3132935	5e-07	Schizophrenia
chr6	32395437	32395438	rs1980493	5e-07	Anti-cyclic Citrullinated Peptide Antibody
chr6	32695853	32695854	rs3129720	5e-07	Hypothyroidism
chr6	32701595	32701596	rs11752643	5e-07	Coronary heart disease
chr6	32888704	32888705	rs1029295	5e-07	Disc degeneration (lumbar)
chr6	33080883	33080884	rs1042151	5e-07	Aspirin exacerbated respiratory disease in asthmatics
chr6	35395979	35395980	rs9658108	5e-07	Response to antipsychotic treatment
chr6	35436576	35436577	rs2206030   	5e-07	Pulmonary function (interaction)
chr6	35534424	35534425	rs9380516	5e-07	Hepatitis C induced liver fibrosis
chr6	39215693	39215694	rs10456100	5e-07	Migraine
chr6	30064744	30064745	rs8321	5e-07	AIDS progression
chr6	51778215	51778216	rs728996	5e-07	Weight loss (gastric bypass surgery)
chr6	5600204	5600205	rs9328321	5e-07	Obesity (early onset extreme)
chr6	78846448	78846449	rs16890334	5e-07	Blood pressure measurement (high sodium and potassium intervention)
chr6	90708032	90708033	rs713155	5e-07	Brain structure
chr6	99880321	99880322	rs4840097	5e-07	Age-related macular degeneration (smoking status interaction)
chr7	114101049	114101050	rs6466479	5e-07	IgG glycosylation
chr7	134063192	134063193	rs11770757	5e-07	Alzheimer's disease (cognitive decline)
chr7	153838603	153838604	rs2110267	5e-07	Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms)
chr7	157087703	157087704	rs6966038	5e-07	Response to citalopram treatment
chr7	20822682	20822683	rs2709736	5e-07	Bipolar I disorder
chr7	28189422	28189423	rs550448	5e-07	Type 1 diabetes
chr7	45864207	45864208	rs6956740	5e-07	Rheumatoid arthritis
chr7	46202984	46202985	rs6964415	5e-07	Sudden cardiac arrest
chr7	50306537	50306538	rs7781977	5e-07	IgG glycosylation
chr6	542158	542159	rs6918152	5e-07	Black vs. red hair color
chr22	40056114	40056115	rs9623117	5e-07	Prostate cancer
chr14	51544080	51544081	rs7140150	5e-07	Brain structure
chr22	37066895	37066896	rs855791	5e-07	Hepcidin levels
chr12	130012926	130012927	rs1624802	5e-07	Obesity-related traits
chr12	131840693	131840694	rs6598163	5e-07	Migraine
chr1	219502699	219502700	rs2791553	5e-07	Adiponectin levels
chr12	20368719	20368720	rs10841496	5e-07	Male infertility
chr1	229150110	229150111	rs9793739	5e-07	Dental caries
chr1	236149826	236149827	rs7520258	5e-07	Response to antipsychotic treatment in schizophrenia (working memory)
chr1	243320451	243320452	rs12145833	5e-07	Obesity (early onset extreme)
chr12	47377645	47377646	rs2074193	5e-07	Migraine with aura
chr12	49925302	49925303	rs297941	5e-07	Obsessive-compulsive disorder
chr12	54293447	54293448	rs10506328	5e-07	Mean platelet volume
chr12	56080358	56080359	rs34379766	5e-07	Obesity-related traits
chr12	61841051	61841052	rs2198776	5e-07	Obesity-related traits
chr12	68202880	68202881	rs2870946	5e-07	Ulcerative colitis
chr12	91080020	91080021	rs10777288   	5e-07	Pulmonary function (interaction)
chr13	101055957	101055958	rs2044117	5e-07	Bipolar disorder and schizophrenia
chr1	33894256	33894257	rs2281597	5e-07	Attention deficit hyperactivity disorder
chr13	50267186	50267187	rs806321	5e-07	Multiple sclerosis
chr13	62862666	62862667	rs2204037	5e-07	QT interval
chr13	64317064	64317065	rs11148643	5e-07	Rheumatoid arthritis
chr13	79314340	79314341	rs1155848	5e-07	Response to anti-TNF alpha therapy in inflammatory bowel disease
chr14	22533735	22533736	rs1154155	5e-07	Narcolepsy
chr14	28647488	28647489	rs12587311	5e-07	Phospholipid levels (plasma)
chr14	32738315	32738316	rs2300835	5e-07	Fasting insulin-related traits (interaction with BMI)
chr14	50704160	50704161	rs8020441	5e-07	Cognitive performance
chr14	95656070	95656071	rs8015016	5e-07	QT interval
chr15	32702554	32702555	rs4779584	5e-07	Colorectal cancer
chr15	32702554	32702555	rs4779584	5e-07	Colorectal cancer
chr12	127308068	127308069	rs1823172	5e-07	Sudden cardiac arrest
chr15	42692089	42692090	rs16957063	5e-07	Protein quantitative trait loci
chr12	124517776	124517777	rs150954431	5e-07	Cocaine dependence
chr12	108305254	108305255	rs1878022	5e-07	Response to platinum-based chemotherapy in non-small-cell lung cancer
chr22	37066895	37066896	rs855791	5e-07	Iron status biomarkers
chr10	107866307	107866308	rs1834180	5e-07	Social communication problems
chr10	26485764	26485765	rs786870	5e-07	Inflammatory biomarkers
chr10	29798429	29798430	rs2986961	5e-07	Migraine with aura
chr10	51733712	51733713	rs7922491	5e-07	Asthma
chr10	53647330	53647331	rs7077606	5e-07	Thiazide-induced adverse metabolic effects in hypertensive patients
chr10	55657200	55657201	rs1916521	5e-07	Cardiac hypertrophy
chr10	5844770	5844771	rs2380205	5e-07	Breast cancer
chr10	60421369	60421370	rs10994338	5e-07	Bipolar disorder and major depressive disorder (combined)
chr10	63112650	63112651	rs10822136	5e-07	IgG glycosylation
chr10	72089880	72089881	rs1245541	5e-07	Insulin-like growth factors
chr10	95037712	95037713	rs1934953	5e-07	Immune response to smallpox vaccine (IL-6)
chr10	99532632	99532633	rs11190141	5e-07	Crohn's disease
chr1	106889953	106889954	rs12726652	5e-07	Response to antipsychotic treatment in schizophrenia (working memory)
chr11	113439146	113439147	rs11214606	5e-07	Response to antipsychotic treatment in schizophrenia (working memory)
chr11	114519383	114519384	rs9326244	5e-07	IgG glycosylation
chr11	115528027	115528028	rs7483296	5e-07	Metabolite levels (HVA/MHPG ratio)
chr11	121373006	121373007	rs72991	5e-07	Response to tocilizumab in rheumatoid arthritis
chr11	128946325	128946326	rs11221522	5e-07	Metabolite levels (5-HIAA)
chr11	16381964	16381965	rs4756846	5e-07	Obesity and osteoporosis
chr11	17388024	17388025	rs5219	5e-07	Type 2 diabetes
chr11	17774563	17774564	rs60349741	5e-07	Opioid sensitivity
chr1	118325781	118325782	rs17038182	5e-07	Height
chr11	1963896	1963897	rs10769945	5e-07	DNA methylation (variation)
chr11	32874117	32874118	rs10767971	5e-07	Parkinson's disease (age of onset)
chr11	36990986	36990987	rs391317	5e-07	Inflammatory biomarkers
chr1	18813022	18813023	rs12063142	5e-07	Parkinson's disease
chr12	120997783	120997784	rs2259816	5e-07	Coronary heart disease
chr15	49647648	49647649	rs8039808	5e-07	Response to antidepressant treatment
chr11	129603794	129603795	rs7107217	5e-07	Breast cancer
chr1	55894139	55894140	rs6684428	5e-07	Airflow obstruction 
chr1	98087275	98087276	rs1198588	5e-07	Schizophrenia
chr1	99058490	99058491	rs10747502	5e-07	Obesity-related traits
chr20	39061820	39061821	rs926392	5e-07	Dialysis-related mortality
chr20	44742678	44742679	rs11696845	5e-07	Obesity-related traits
chr20	4717979	4717980	rs6116492	5e-07	Creutzfeldt-Jakob disease (variant)
chr20	51943112	51943113	rs6068020	5e-07	Male infertility
chr20	52940621	52940622	rs6097169	5e-07	Body mass index (non-asthmatics)
chr20	54650571	54650572	rs2023454	5e-07	Functional MRI
chr20	63264567	63264568	rs1406961	5e-07	Cardiovascular disease risk factors
chr2	102047166	102047167	rs2310173	5e-07	Ankylosing spondylitis
chr2	102959629	102959630	rs12105421	5e-07	Psychosis (atypical)
chr2	120525053	120525054	rs17050244	5e-07	Age-related macular degeneration
chr2	124524332	124524333	rs17727261	5e-07	Response to antipsychotic treatment
chr1	96648358	96648359	rs12071951	5e-07	Schizophrenia
chr21	26773869	26773870	rs2830487	5e-07	Metabolite levels (HVA-5-HIAA Factor score)
chr21	31912987	31912988	rs2833556	5e-07	Response to antipsychotic treatment in schizophrenia (reasoning)
chr21	34866209	34866210	rs2834655	5e-07	Immune response to smallpox vaccine (IL-6)
chr2	144594253	144594254	rs7355746	5e-07	Obesity-related traits
chr2	147720766	147720767	rs7584099	5e-07	Response to statin therapy
chr2	157923691	157923692	rs10183640	5e-07	Sudden cardiac arrest
chr2	173462116	173462117	rs10930597	5e-07	Blood pressure measurement (low sodium intervention)
chr2	176127050	176127051	rs2592394	5e-07	Magnesium levels
chr2	200783915	200783916	rs13430864	5e-07	Response to citalopram treatment
chr22	22158021	22158022	rs987710	5e-07	Iron status biomarkers
chr2	225373193	225373194	rs1517484	5e-07	Attention deficit hyperactivity disorder (time to onset)
chr22	31833662	31833663	rs5994434	5e-07	Intelligence
chr2	234302082	234302083	rs12151790	5e-07	Osteoporosis
chr15	51242349	51242350	rs727479	5e-07	Estradiol levels
chr21	27324156	27324157	rs239713	5e-07	AB1-42
chr19	55939682	55939683	rs2043599	5e-07	Immune reponse to smallpox (secreted IFN-alpha)
chr21	38919815	38919816	rs2836754	5e-07	Crohn's disease
chr19	44878776	44878777	rs6859	5e-07	Alzheimer's disease
chr1	56777780	56777781	rs17372114	5e-07	Resistin levels 
chr15	77485289	77485290	rs7119	5e-07	Type 2 diabetes
chr19	47158235	47158236	rs307896	5e-07	Multiple sclerosis
chr15	78606380	78606381	rs12914385	5e-07	Pulmonary function
chr15	83899405	83899406	rs10906982	5e-07	Height
chr1	5853560	5853561	rs548726 	5e-07	Response to taxane treatment (placlitaxel)
chr15	89904713	89904714	rs7178909	5e-07	Common traits (Other)
chr15	91668543	91668544	rs7164176	5e-07	Response to tocilizumab in rheumatoid arthritis
chr16	11086015	11086016	rs12708716	5e-07	Type 1 diabetes
chr16	11096030	11096031	rs12599402	5e-07	Systemic lupus erythematosus
chr16	12547257	12547258	rs1641895	5e-07	Visceral adipose tissue adjusted for BMI
chr16	55810696	55810697	rs2244613	5e-07	Response to dabigatran etexilate treatment
chr16	7454851	7454852	rs9924951	5e-07	Metabolite levels
chr16	81270153	81270154	rs4889294	5e-07	Protein quantitative trait loci
chr15	87152279	87152280	rs11636768	5e-07	Migraine
chr16	85059141	85059142	rs8056742	5e-07	Amyotrophic lateral sclerosis
chr16	83327169	83327170	rs9940464	5e-07	Malaria
chr1	9372330	9372331	rs9308447	5e-07	Dental caries
chr1	83788867	83788868	rs7552393	5e-07	Select biomarker traits
chr1	8362615	8362616	rs2252865	5e-07	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr18	52666025	52666026	rs4940203	5e-07	Obesity-related traits
chr1	79043423	79043424	rs6687262	5e-07	IgG glycosylation
chr18	6941662	6941663	rs3810046	5e-07	Response to citalopram treatment
chr17	58236542	58236543	rs8067912	5e-07	IgG glycosylation
chr17	57788925	57788926	rs12938916	5e-07	Bipolar disorder
chr17	39938920	39938921	rs6503525	5e-07	Asthma
chr17	36831826	36831827	rs17138064	5e-07	Orofacial clefts
chr17	7730373	7730374	rs16956936	5e-07	Type 1 diabetes
chr4	26942691	26942692	rs6844153	6e-07	Phospholipid levels (plasma)
chr4	182379460	182379461	rs4862046	6e-07	IgG glycosylation
chr4	168488806	168488807	rs2710833	6e-07	Non-alcoholic fatty liver disease histology (AST)
chr4	37645611	37645612	rs13144232	6e-07	IgG glycosylation
chr4	6889791	6889792	rs11734132	6e-07	Mean platelet volume
chr4	82578159	82578160	rs7658637	6e-07	Cognitive performance
chr4	99135846	99135847	rs3805322	6e-07	Esophageal cancer  (alcohol interaction)
chr4	35981488	35981489	rs6834483	6e-07	Obesity-related traits
chr5	178999317	178999318	rs11249608	6e-07	Pubertal anthropometrics
chr5	134110883	134110884	rs756699	6e-07	Multiple sclerosis
chr5	14071947	14071948	rs163818	6e-07	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel)
chr5	180044200	180044201	rs13161895	6e-07	Coronary heart disease
chr5	72421100	72421101	rs10515148	6e-07	Hip geometry
chr5	7649746	7649747	rs4702484	6e-07	Capecitabine sensitivity
chr5	77996115	77996116	rs12655917	6e-07	Insulin resistance/response
chr4	145954398	145954399	rs723794	6e-07	Smooth-surface caries 
chr6	105646181	105646182	rs9386463	6e-07	Primary tooth development (time to first tooth eruption)
chr5	97740843	97740844	rs10515260	6e-07	Estradiol plasma levels (breast cancer)
chr5	107775474	107775475	rs1422438	6e-07	Alzheimer's disease biomarkers
chr4	105127202	105127203	rs1541374	6e-07	Pulmonary function
chr3	118402487	118402488	rs488628	6e-07	White matter integrity (interaction)
chr3	72460119	72460120	rs11128271	6e-07	IgG glycosylation
chr2	241563540	241563541	rs12479254	6e-07	Brain structure
chr6	124005081	124005082	rs117780815	6e-07	Alzheimer's disease (cognitive decline)
chr22	40646086	40646087	rs12159200	6e-07	Treatment response for severe sepsis 
chr22	43995805	43995806	rs2143571	6e-07	Nonalcoholic fatty liver disease
chr23	106250702	106250703	rs379742	6e-07	Pancreatitis
chr23	76127598	76127599	rs5937496	6e-07	Amyotrophic lateral sclerosis
chr2	39888555	39888556	rs6721181	6e-07	Asthma (childhood onset)
chr2	79482227	79482228	rs7570469	6e-07	Response to antipsychotic treatment
chr3	73570409	73570410	rs11128347	6e-07	Dialysis-related mortality
chr3	103662007	103662008	rs6775909	6e-07	Economic and political preferences (environmentalism)
chr3	150324830	150324831	rs4301033	6e-07	Adiponectin levels
chr3	159947261	159947262	rs17810546	6e-07	Behcet's disease
chr3	170445685	170445686	rs6444931	6e-07	Bipolar disorder and schizophrenia
chr3	185811291	185811292	rs1470579	6e-07	Fasting glucose-related traits (interaction with BMI)
chr3	27374521	27374522	rs4973768	6e-07	Breast cancer
chr3	4395673	4395674	rs794185	6e-07	Multiple sclerosis--Brain Glutamate Levels
chr3	56496680	56496681	rs2054989	6e-07	Hip geometry
chr3	70879778	70879779	rs2687201	6e-07	Esophageal adenocarcinoma
chr3	141080370	141080371	rs16851055	6e-07	Stroke (ischemic)
chr6	126514508	126514509	rs1490388	6e-07	Height
chr8	23961173	23961174	rs7833268	6e-07	Subcutaneous adipose tissue
chr6	133837661	133837662	rs1208285	6e-07	Infantile hypertrophic pyloric stenosis
chr7	94380321	94380322	rs7792596	6e-07	Intelligence
chr8	108617673	108617674	rs2935776	6e-07	T-tau
chr8	127375605	127375606	rs1562430	6e-07	Breast cancer
chr8	1295963	1295964	rs17669535	6e-07	Menarche (age at onset)
chr8	2923433	2923434	rs2627282	6e-07	Blood pressure measurement (high sodium intervention)
chr8	50472426	50472427	rs13272236	6e-07	IgG glycosylation
chr8	62971033	62971034	rs7834588	6e-07	Response to Vitamin E supplementation
chr8	78044422	78044423	rs2219968	6e-07	Prostate cancer (gene x gene interaction)
chr7	94062431	94062432	rs9918668	6e-07	Aging
chr8	78122223	78122224	rs13272568	6e-07	Bone mineral density
chr8	98101458	98101459	rs10107366	6e-07	Obesity-related traits
chr9	121758980	121758981	rs3747851	6e-07	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel)
chr9	126432493	126432494	rs758970	6e-07	Obesity-related traits
chr9	36099401	36099402	rs4878639	6e-07	IgG glycosylation
chr9	38041144	38041145	rs7873102	6e-07	Brain structure
chr9	92060257	92060258	rs7872515	6e-07	Bipolar disorder and schizophrenia
chr2	23726082	23726083	rs7608623	6e-07	Obesity-related traits
chr9	94306643	94306644	rs10993160	6e-07	Body mass index
chr8	9133066	9133067	rs189798	6e-07	Myopia (pathological)
chr7	82153197	82153198	rs6942458	6e-07	Obesity-related traits
chr7	7219638	7219639	rs12702595	6e-07	Serum dimethylarginine levels (asymmetric/symetric ratio)
chr7	24652932	24652933	rs2721800	6e-07	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr6	14636731	14636732	rs707824	6e-07	Lymphoma
chr6	160368263	160368264	rs402219	6e-07	Monocyte early outgrowth colony forming units
chr6	17240922	17240923	rs1322846	6e-07	Immune response to smallpox vaccine (IL-6)
chr6	26092912	26092913	rs1800562	6e-07	Red blood cell traits
chr6	30698891	30698892	rs9468811	6e-07	IgG glycosylation
chr6	31200251	31200252	rs6903896	6e-07	Common traits (Other)
chr6	32945468	32945469	rs1480380	6e-07	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr6	32985502	32985503	rs3097645	6e-07	IgG glycosylation
chr6	33510718	33510719	rs9296092	6e-07	Chronic obstructive pulmonary disease
chr6	41186911	41186912	rs9381040	6e-07	Alzheimer's disease (late onset)
chr6	44809953	44809954	rs10948172	6e-07	Osteoarthritis
chr6	66939322	66939323	rs11970254	6e-07	Brain structure
chr6	68627894	68627895	rs2585617	6e-07	Phospholipid levels (plasma)
chr6	81510834	81510835	rs6924906	6e-07	Blood pressure
chr6	89988554	89988555	rs12204127	6e-07	Visceral adipose tissue/subcutaneous adipose tissue ratio
chr6	96632321	96632322	rs12200560	6e-07	Coronary heart disease
chr7	105633272	105633273	rs10242311	6e-07	Dental caries
chr7	122562538	122562539	rs2429582	6e-07	Brain structure
chr7	137519072	137519073	rs6467710	6e-07	AIDS progression
chr6	129710347	129710348	rs17057678	6e-07	Antineutrophil cytoplasmic antibody-associated vasculitis 
chr22	33165759	33165760	rs743793	6e-07	Visceral adipose tissue/subcutaneous adipose tissue ratio
chr1	96698786	96698787	rs7544736	6e-07	Schizophrenia
chr2	213683812	213683813	rs6707387	6e-07	Fasting insulin (interaction)
chr11	61790330	61790331	rs102275	6e-07	Metabolic syndrome
chr11	61802357	61802358	rs174546	6e-07	Metabolic syndrome
chr11	62048330	62048331	rs4963452	6e-07	Phospholipid levels (plasma)
chr1	165210851	165210852	rs1532815	6e-07	Response to acetaminophen (hepatotoxicity)
chr11	65745635	65745636	rs593982	6e-07	Atopic dermatitis
chr1	183207294	183207295	rs525410	6e-07	Systemic lupus erythematosus
chr11	941940	941941	rs10751667	6e-07	Alzheimer's disease (late onset)
chr11	95578257	95578258	rs4409785	6e-07	Multiple sclerosis
chr1	160860477	160860478	rs4656940	6e-07	Crohn's disease
chr12	110717725	110717726	rs11065706	6e-07	Heart rate
chr12	114276460	114276461	rs10744816	6e-07	Obesity-related traits
chr12	117873937	117873938	rs4767631	6e-07	Biochemical measures
chr12	119551840	119551841	rs7137869	6e-07	Aging traits
chr12	21998638	21998639	rs10743430	6e-07	Entorhinal cortical thickness
chr12	32227566	32227567	rs10844154	6e-07	Emphysema-related traits
chr12	7702674	7702675	rs12307997	6e-07	Thiazide-induced adverse metabolic effects in hypertensive patients
chr12	94289427	94289428	rs4761470	6e-07	Estradiol plasma levels (breast cancer)
chr12	955271	955272	rs10849605	6e-07	Lung cancer
chr12	114200042	114200043	rs4767234	6e-07	Airflow obstruction 
chr13	24673147	24673148	rs1530530	6e-07	Obesity-related traits
chr11	58580291	58580292	rs948562	6e-07	Lymphoma
chr11	40816162	40816163	rs4611189	6e-07	Response to antipsychotic treatment in schizophrenia (reasoning)
chr2	218680585	218680586	rs2303565	6e-07	Amyotrophic lateral sclerosis
chr10	117467830	117467831	rs4752066	6e-07	Pulmonary function in asthmatics
chr10	120519963	120519964	rs118048115	6e-07	Alzheimer's disease (cognitive decline)
chr10	12393379	12393380	rs4750211	6e-07	Obesity-related traits
chr10	13319975	13319976	rs1747683	6e-07	IgG glycosylation
chr10	23014323	23014324	rs1054052	6e-07	IgG glycosylation
chr10	44539223	44539224	rs7072122	6e-07	Estradiol plasma levels (breast cancer)
chr10	69503507	69503508	rs1227969 	6e-07	Response to taxane treatment (placlitaxel)
chr1	147611314	147611315	rs583583	6e-07	Schizophrenia (negative symptoms)
chr10	69820363	69820364	rs17497526	6e-07	Parkinson's disease
chr1	107035209	107035210	rs4118325	6e-07	AIDS
chr1	1070425	1070426	rs3934834	6e-07	Body mass index
chr11	103718365	103718366	rs1917445	6e-07	Neutrophil count
chr11	114360532	114360533	rs11214966	6e-07	Asthma
chr11	128316986	128316987	rs10893845	6e-07	Self-reported allergy
chr1	116927158	116927159	rs2806864	6e-07	Erectile dysfunction and prostate cancer treatment
chr1	11792458	11792459	rs17375901	6e-07	Atrial fibrillation
chr1	121458636	121458637	rs6600671	6e-07	Hip geometry
chr10	86456644	86456645	rs7075426	6e-07	Migraine without aura
chr13	28409925	28409926	rs9508025	6e-07	Coronary heart disease
chr1	147548684	147548685	rs594206	6e-07	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU)
chr1	34285334	34285335	rs771390	6e-07	Epilepsy (generalized)
chr17	56201353	56201354	rs1019238	6e-07	Cannabis dependence
chr17	66920915	66920916	rs17645023	6e-07	Bipolar disorder and schizophrenia
chr17	78885620	78885621	rs4789939	6e-07	Dupuytren's disease
chr18	13366862	13366863	rs12456874	6e-07	Pancreatic cancer
chr18	55153892	55153893	rs9951150	6e-07	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr18	72774832	72774833	rs41418949	6e-07	Economic and political preferences (time)
chr19	1056492	1056493	rs3752246	6e-07	Alzheimer's disease (late onset)
chr20	17848635	17848636	rs2745851	6e-07	IgG glycosylation
chr17	48539656	48539657	rs6504340	6e-07	Primary tooth development (number of teeth)
chr20	59602559	59602560	rs6026990	6e-07	Response to tocilizumab in rheumatoid arthritis
chr2	11370821	11370822	rs6716724	6e-07	Sudden cardiac arrest
chr21	14967967	14967968	rs2229741	6e-07	Cognitive performance
chr21	15542585	15542586	rs2823357	6e-07	Parkinson's disease
chr2	160925261	160925262	rs1722636	6e-07	Subcutaneous adipose tissue
chr2	175919409	175919410	rs1020410	6e-07	Obesity-related traits
chr2	17593764	17593765	rs4038131	6e-07	Alzheimer's disease
chr13	34080780	34080781	rs690705	6e-07	Alzheimer's disease
chr2	198814385	198814386	rs10189905	6e-07	Corneal astigmatism
chr20	61371987	61371988	rs4925189	6e-07	T-tau
chr16	7365550	7365551	rs4787008	6e-07	Diabetic retinopathy 
chr19	33677366	33677367	rs4805924	6e-07	Response to antipsychotic treatment in schizophrenia (working memory)
chr16	53779454	53779455	rs17817449	6e-07	Breast cancer
chr13	75202131	75202132	rs548097	6e-07	Heart failure
chr14	20489273	20489274	rs12147450	6e-07	Response to antipsychotic therapy (extrapyramidal side effects)
chr16	57013386	57013387	rs16965039	6e-07	Coronary heart disease
chr14	55866794	55866795	rs7350721	6e-07	Body mass index (interaction)
chr14	58899596	58899597	rs405460	6e-07	Obesity-related traits
chr14	63809093	63809094	rs7144584	6e-07	Pulmonary function decline
chr15	26178899	26178900	rs547843	6e-07	Smoking behavior
chr15	60974896	60974897	rs12912233	6e-07	Depression (quantitative trait)
chr15	74833303	74833304	rs6495122	6e-07	Caffeine consumption
chr15	75090200	75090201	rs12148488	6e-07	Caffeine consumption
chr1	53909896	53909897	rs2235544	6e-07	Multiple myeloma (hyperdiploidy)
chr1	63015058	63015059	rs17124318	6e-07	Body mass index
chr15	88575872	88575873	rs17776563	6e-07	Thyroid hormone levels
chr15	93493458	93493459	rs7175404	6e-07	Attention deficit hyperactivity disorder
chr15	95598637	95598638	rs10520789	6e-07	Response to TNF-alpha inhibitors in rheumatoid arthritis
chr16	11312945	11312946	rs7191700	6e-07	Multiple sclerosis
chr1	61154823	61154824	rs334699	6e-07	Thyroid hormone levels
chr16	24520396	24520397	rs11643520	6e-07	Brain structure
chr15	78606380	78606381	rs12914385	6e-07	Serum albumin level
chr16	48587490	48587491	rs6500395	6e-07	Response to tocilizumab in rheumatoid arthritis
chr4	173653254	173653255	rs11723864	7e-07	Type 1 diabetes nephropathy
chr3	60137794	60137795	rs10510829	7e-07	Adverse response to lamotrigine and phenytoin
chr4	148053450	148053451	rs6845865	7e-07	QT interval
chr4	147472511	147472512	rs1878406	7e-07	Carotid intima media thickness
chr3	84431916	84431917	rs10511089	7e-07	Brain structure
chr4	122297157	122297158	rs13119723	7e-07	Rheumatoid arthritis
chr3	95969998	95969999	rs9814870	7e-07	Male infertility
chr4	183356977	183356978	rs17074636	7e-07	Gout
chr4	147126397	147126398	rs1395821	7e-07	Coronary heart disease
chr4	189616908	189616909	rs13145041	7e-07	Periodontitis (CDC/AAP)
chr5	179811260	179811261	rs72807343	7e-07	Alzheimer's disease (late onset)
chr4	858524	858525	rs1564282	7e-07	Parkinson's disease (familial)
chr5	110810745	110810746	rs17513503	7e-07	Allergic rhinitis
chr5	116176654	116176655	rs1396485	7e-07	Inflammatory biomarkers
chr5	124235466	124235467	rs17501712	7e-07	Subcutaneous adipose tissue
chr5	1321971	1321972	rs401681	7e-07	Pancreatic cancer
chr5	159491885	159491886	rs10866713	7e-07	Multiple sclerosis
chr5	165950693	165950694	rs9313296	7e-07	Weight
chr5	3276581	3276582	rs61670327	7e-07	Epilepsy (remission after treatment)
chr3	4662252	4662253	rs7632000	7e-07	Obesity-related traits
chr5	44874902	44874903	rs7716600	7e-07	Breast cancer
chr4	80248757	80248758	rs11099098	7e-07	Urate levels
chr3	194606368	194606369	rs789852	7e-07	QT interval
chr2	192049635	192049636	rs10497721	7e-07	Diabetes (incident)
chr3	183152647	183152648	rs514636	7e-07	Bipolar disorder
chr5	89813932	89813933	rs10514317	7e-07	Sex hormone-binding globulin levels
chr2	14257927	14257928	rs16861531	7e-07	Response to antidepressant treatment
chr2	150269888	150269889	rs6716455	7e-07	Alcoholism (alcohol use disorder factor score)
chr2	187331741	187331742	rs840616	7e-07	Coronary heart disease
chr2	19758734	19758735	rs17564315	7e-07	Inflammatory biomarkers
chr2	21009322	21009323	rs693	7e-07	Triglycerides
chr2	217658438	217658439	rs6435999	7e-07	Height
chr22	27982483	27982484	rs5762430	7e-07	Obesity
chr2	231433364	231433365	rs12475512	7e-07	Eating disorders (purging via substances) 
chr2	233910223	233910224	rs7577262	7e-07	Blood pressure measurement (cold pressor test)
chr3	186783858	186783859	rs266719	7e-07	Adiponectin levels
chr2	235052248	235052249	rs10174126	7e-07	Orofacial clefts
chr2	47171924	47171925	rs815815	7e-07	Dialysis-related mortality
chr2	5113464	5113465	rs1075309	7e-07	Tuberculosis
chr2	60273008	60273009	rs10202231	7e-07	Response to antipsychotic treatment
chr3	103626594	103626595	rs9821642	7e-07	Economic and political preferences (environmentalism)
chr3	105292045	105292046	rs9810233	7e-07	Erectile dysfunction
chr3	12585016	12585017	rs3729931	7e-07	Cardiac hypertrophy
chr3	150979420	150979421	rs16863118	7e-07	IgG glycosylation
chr3	157136952	157136953	rs13064954	7e-07	Diabetic retinopathy 
chr3	169774312	169774313	rs10936599	7e-07	Multiple sclerosis
chr3	170776619	170776620	rs4955755	7e-07	Menopause (age at onset)
chr23	65147138	65147139	rs7064929	7e-07	Erectile dysfunction and prostate cancer treatment
chr5	90250291	90250292	rs12518099	7e-07	Type 2 diabetes and other traits
chr9	16512749	16512750	rs10124550	7e-07	Metabolite levels (Pyroglutamine)
chr6	115989123	115989124	rs1933737	7e-07	Urate levels
chr8	133449607	133449608	rs10106540	7e-07	Personality dimensions
chr8	133766098	133766099	rs74566133	7e-07	Eating disorders (purging via substances) 
chr8	20208537	20208538	rs1106634	7e-07	Major depressive disorder (broad)
chr8	20768809	20768810	rs2122469	7e-07	Serum tamsulosin hydrochloride concentration
chr8	27595329	27595330	rs17466684	7e-07	Panic disorder
chr8	3630815	3630816	rs2449215	7e-07	Obesity-related traits
chr8	69581738	69581739	rs13273088	7e-07	Fasting insulin-related traits (interaction with BMI)
chr9	88925143	88925144	rs1875620	7e-07	Response to statin therapy (LDL-C)
chr8	81532988	81532989	rs16909318	7e-07	Visceral fat
chr8	89198870	89198871	rs2046315	7e-07	Pit-and-Fissure caries 
chr9	110538554	110538555	rs1889321	7e-07	Pulmonary function decline
chr9	129681819	129681820	rs7866070	7e-07	Common traits (Other)
chr9	130177512	130177513	rs4836694	7e-07	Alzheimer's disease (cognitive decline)
chr9	134233654	134233655	rs10785877	7e-07	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin)
chr9	18109236	18109237	rs2210327	7e-07	Heart failure
chr9	22134094	22134095	rs10811661	7e-07	Type 2 diabetes
chr9	27488093	27488094	rs17779457	7e-07	Urinary symptoms in response to radiotherapy in prostate cancer
chr9	4289049	4289050	rs7034200	7e-07	Fasting glucose-related traits (interaction with BMI)
chr9	76793227	76793228	rs10781380	7e-07	Hippocampal atrophy
chr9	79424446	79424447	rs2378383	7e-07	Asthma (childhood onset)
chr2	134842305	134842306	rs10198552	7e-07	Obesity-related traits
chr8	129946704	129946705	rs16904179	7e-07	Post-traumatic stress disorder (asjusted for relatedness)
chr8	125855260	125855261	rs4006531	7e-07	Metabolite levels (Dihydroxy docosatrienoic acid)
chr8	122868978	122868979	rs6470120	7e-07	Nicotine use
chr8	11826953	11826954	rs2645424	7e-07	Non-alcoholic fatty liver disease histology (other)
chr6	137878279	137878280	rs610604	7e-07	Psoriasis
chr6	147438397	147438398	rs9403856	7e-07	IgG glycosylation
chr6	148383817	148383818	rs6930576	7e-07	Type 2 diabetes nephropathy
chr6	148949692	148949693	rs13219957	7e-07	Job-related exhaustion
chr6	150249730	150249731	rs3734729   	7e-07	Pulmonary function (interaction)
chr6	152469437	152469438	rs9371601	7e-07	Bipolar disorder
chr6	155876367	155876368	rs4269383	7e-07	Pancreatic cancer
chr6	17699090	17699091	rs12199222	7e-07	Height
chr6	19969406	19969407	rs16883019	7e-07	Response to statin therapy
chr6	20660802	20660803	rs10946398	7e-07	Type 2 diabetes
chr6	114226816	114226817	rs9488343	7e-07	Gray matter volume (schizophrenia interaction)
chr6	20766465	20766466	rs4510656	7e-07	Bladder cancer
chr6	31965383	31965384	rs406936	7e-07	Age-related macular degeneration
chr6	32371298	32371299	rs2050190	7e-07	Activated partial thromboplastin time
chr6	51757650	51757651	rs2025751	7e-07	Intraocular pressure
chr6	79547563	79547564	rs3747767	7e-07	Hoarding
chr7	104863365	104863366	rs10953454	7e-07	Obesity
chr7	11251772	11251773	rs4720952	7e-07	IgG glycosylation
chr7	15591245	15591246	rs11763353	7e-07	Blood trace element (Zn levels)
chr7	2756322	2756323	rs798497	7e-07	Height
chr7	40426600	40426601	rs4379368	7e-07	Migraine - clinic-based
chr7	49290083	49290084	rs7801534	7e-07	Thiazide-induced adverse metabolic effects in hypertensive patients
chr6	31174467	31174468	rs3094188	7e-07	Crohn's disease
chr2	133247996	133247997	rs10496702	7e-07	Bipolar disorder and schizophrenia
chr10	87578875	87578876	rs9664222	7e-07	Longevity
chr21	16455970	16455971	rs2823819	7e-07	Attention deficit hyperactivity disorder
chr1	159204096	159204097	rs3027009	7e-07	Lean body mass and age at menarche (combined)
chr1	159848722	159848723	rs6659742	7e-07	Multiple sclerosis (OCB status)
chr11	81217765	81217766	rs11232535	7e-07	Blood trace element (Zn levels)
chr11	8229263	8229264	rs4758317	7e-07	Alcohol consumption
chr11	85111276	85111277	rs1452928	7e-07	Hip geometry
chr12	101626667	101626668	rs10860757	7e-07	Lung function (forced expiratory volume in 1 second)
chr12	123172177	123172178	rs1790100	7e-07	Multiple sclerosis
chr12	15777870	15777871	rs17415853	7e-07	Protein quantitative trait loci
chr12	21176826	21176827	rs11045818	7e-07	Methotrexate phramacokinetics (acute lymphoblastic leukemia)
chr12	59455895	59455896	rs276000	7e-07	Methotrexate phramacokinetics (acute lymphoblastic leukemia)
chr12	73596056	73596057	rs1154865	7e-07	Breast cancer
chr12	9703361	9703362	rs11052552	7e-07	Type 1 diabetes
chr13	101348593	101348594	rs7996217	7e-07	HIV-associated dementia 
chr13	102027775	102027776	rs11617740	7e-07	Preeclampsia
chr13	108695310	108695311	rs7984522	7e-07	Blood pressure
chr13	110137884	110137885	rs641862	7e-07	Obesity-related traits
chr13	113919623	113919624	rs9604529	7e-07	Response to tocilizumab in rheumatoid arthritis
chr13	24508491	24508492	rs9581094	7e-07	Sudden cardiac arrest
chr13	35902309	35902310	rs6563210	7e-07	Height
chr13	42996664	42996665	rs17064002	7e-07	Obesity-related traits
chr13	50261578	50261579	rs2762051	7e-07	Celiac disease
chr1	154465419	154465420	rs2229238	7e-07	Coronary heart disease
chr13	50268303	50268304	rs9596270	7e-07	Multiple sclerosis
chr1	147383113	147383114	rs4950322	7e-07	Protein quantitative trait loci
chr11	23023045	23023046	rs10833905	7e-07	Sudden cardiac arrest
chr21	33170481	33170482	rs6517147	7e-07	Inflammatory biomarkers
chr10	112998589	112998590	rs7903146	7e-07	Metabolic syndrome
chr10	117854098	117854099	rs10886159	7e-07	Celiac disease
chr10	12009816	12009817	rs10795917	7e-07	Prostate cancer (gene x gene interaction)
chr10	127476238	127476239	rs4363506	7e-07	Amyotrophic lateral sclerosis
chr10	13061284	13061285	rs525455	7e-07	Platelet aggregation
chr10	13313130	13313131	rs1095368	7e-07	IgG glycosylation
chr10	18419868	18419869	rs11014166	7e-07	Systolic blood pressure
chr10	20521595	20521596	rs16920624	7e-07	Response to antidepressants
chr10	63112650	63112651	rs10822136	7e-07	IgG glycosylation
chr10	63203688	63203689	rs4379723	7e-07	Platelet counts
chr10	66838533	66838534	rs7902091	7e-07	Schizophrenia (cytomegalovirus infection interaction)
chr10	86087201	86087202	rs7910620	7e-07	Cardiac structure and function
chr10	89067021	89067022	rs1937332	7e-07	Atrioventricular conduction
chr1	10736808	10736809	rs880315	7e-07	Blood pressure
chr11	110628529	110628530	rs326946	7e-07	Alzheimer's disease (cognitive decline)
chr11	116733007	116733008	rs12272004	7e-07	Cholesterol, total
chr11	118274970	118274971	rs17122021	7e-07	Pain
chr11	125454068	125454069	rs11220082	7e-07	Schizophrenia
chr11	134756992	134756993	rs11223996	7e-07	Myopia (pathological)
chr11	1920715	1920716	rs909116	7e-07	Breast cancer
chr11	46827808	46827809	rs1007738	7e-07	Bone mineral density (hip)
chr13	66393489	66393490	rs17081231	7e-07	Obesity
chr10	60586879	60586880	rs16915157	7e-07	Schizophrenia
chr13	93580875	93580876	rs7998314	7e-07	Obesity-related traits
chr17	27240053	27240054	rs12602978	7e-07	Dental caries
chr17	46781777	46781778	rs415430	7e-07	Parkinson's disease
chr17	63635603	63635604	rs7209435	7e-07	Height
chr17	66137607	66137608	rs7209395	7e-07	&beta;2-Glycoprotein I (&beta;2-GPI) plasma levels
chr17	77215125	77215126	rs3744064	7e-07	Cognitive performance
chr18	11987272	11987273	rs7506045	7e-07	Stroke
chr18	23785888	23785889	rs11082762	7e-07	Amyotrophic lateral sclerosis
chr18	41185694	41185695	rs17697518	7e-07	Obesity
chr18	64209920	64209921	rs4534959	7e-07	Airflow obstruction 
chr1	86537788	86537789	rs11161841	7e-07	Serum dimethylarginine levels (asymmetric)
chr19	32598524	32598525	rs17692896	7e-07	Major depressive disorder
chr19	48743608	48743609	rs838147	7e-07	Dietary macronutrient intake
chr20	11007450	11007451	rs6104690	7e-07	Bladder cancer
chr20	11176362	11176363	rs6040399	7e-07	Response to citalopram treatment
chr20	16555768	16555769	rs6044112 	7e-07	Response to taxane treatment (docetaxel)
chr20	2014887	2014888	rs6081597	7e-07	Immune response to smallpox vaccine (IL-6)
chr20	20653461	20653462	rs6132333	7e-07	IgG glycosylation
chr20	4699604	4699605	rs1799990	7e-07	Prion diseases
chr20	60371430	60371431	rs55681231	7e-07	Metabolite levels (MHPG)
chr2	112771662	112771663	rs11677416	7e-07	Response to antipsychotic treatment in schizophrenia (working memory)
chr13	81501456	81501457	rs9545740	7e-07	Obesity-related traits
chr17	1730809	1730810	rs12150338	7e-07	Calcium levels
chr17	10670841	10670842	rs6503319	7e-07	Malaria
chr20	187378	187379	rs13036722	7e-07	Obesity-related traits
chr1	67240274	67240275	rs11209026	7e-07	Psoriasis
chr14	46934480	46934481	rs12883384	7e-07	Neuroticism
chr16	86288852	86288853	rs987052	7e-07	Obesity-related traits
chr14	73300505	73300506	rs2333194	7e-07	Bipolar disorder (mood-incongruent)
chr14	95709640	95709641	rs11849538	7e-07	Adverse response to aromatase inhibitors
chr14	97996819	97996820	rs7140601	7e-07	Immune response to smallpox vaccine (IL-6)
chr15	51277212	51277213	rs2305707	7e-07	Height
chr15	51360921	51360922	rs12148477	7e-07	Follicule stimulating hormone
chr1	55595277	55595278	rs10888935	7e-07	Inflammatory biomarkers
chr15	57960907	57960908	rs3784262	7e-07	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined)
chr15	60768507	60768508	rs12591650	7e-07	Subcutaneous adipose tissue
chr15	62112182	62112183	rs1436955	7e-07	Type 2 diabetes
chr15	38172672	38172673	rs16966389	7e-07	Hypersomnia (HLA-DQB1*06:02 negative)
chr15	77977129	77977130	rs12906542	7e-07	Breast cancer
chr15	76254591	76254592	rs1914816	7e-07	Response to tocilizumab in rheumatoid arthritis
chr16	10539307	10539308	rs11074889	7e-07	Attention deficit hyperactivity disorder
chr16	10465405	10465406	rs13335336	7e-07	Response to antipsychotic treatment
chr15	90894157	90894158	rs2521501	7e-07	Hypertension
chr15	98529675	98529676	rs12719740	7e-07	Arthritis (juvenile idiopathic)
chr15	85919620	85919621	rs4262906	7e-07	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel)
chr15	78618838	78618839	rs8040868   	7e-07	Pulmonary function (interaction)
chr15	78559272	78559273	rs2036527	7e-07	Pulmonary function
chr16	4596876	4596877	rs8050907	7e-07	Obesity-related traits
chr16	11597896	11597897	rs8049607	7e-07	QT interval
chr3	61808379	61808380	rs652889	8e-07	QT interval
chr4	167218228	167218229	rs9312517	8e-07	Obesity-related traits
chr3	7361958	7361959	rs13080594	8e-07	Personality dimensions
chr4	117411098	117411099	rs4318720	8e-07	QT interval
chr4	12109924	12109925	rs187075894	8e-07	Metabolite levels (MHPG)
chr4	137661556	137661557	rs17049741	8e-07	Obesity-related traits
chr3	43189230	43189231	rs17075286	8e-07	Bipolar disorder and schizophrenia
chr4	87854090	87854091	rs1471403	8e-07	Bone mineral density (hip)
chr4	8501631	8501632	rs1949733	8e-07	Response to antineoplastic agents
chr4	87811539	87811540	rs1054627	8e-07	Bone mineral density
chr5	111203693	111203694	rs1370967	8e-07	Periodontitis (PAL4Q3)
chr5	127393757	127393758	rs143954261	8e-07	Alzheimer's disease (cognitive decline)
chr5	142638294	142638295	rs152528	8e-07	Cardiac hypertrophy
chr3	41835921	41835922	rs3774372	8e-07	Blood pressure
chr5	157079640	157079641	rs193098517	8e-07	Serum dimethylarginine levels (asymmetric)
chr5	162656511	162656512	rs7711337	8e-07	Autism
chr4	61571599	61571600	rs6856328	8e-07	Response to antipsychotic treatment in schizophrenia (working memory)
chr3	3334099	3334100	rs9835812	8e-07	Immune response to smallpox vaccine (IL-6)
chr2	54457419	54457420	rs11898505	8e-07	Bone mineral density (spine)
chr3	187008098	187008099	rs11710456	8e-07	IgG glycosylation
chr2	16534139	16534140	rs4441471	8e-07	Orofacial clefts
chr5	174221434	174221435	rs10475598	8e-07	Information processing speed
chr2	207629509	207629510	rs2952768	8e-07	Opioid sensitivity
chr2	223072019	223072020	rs1440072	8e-07	Waist circumference
chr22	39291478	39291479	rs54211	8e-07	Sudden cardiac arrest
chr22	43998521	43998522	rs2073080	8e-07	Nonalcoholic fatty liver disease
chr2	25053414	25053415	rs6733301	8e-07	Height
chr2	28423933	28423934	rs6547853	8e-07	Type 1 diabetes
chr2	43590365	43590366	rs11897432	8e-07	DNA methylation (variation)
chr2	60908993	60908994	rs13031237	8e-07	Rheumatoid arthritis
chr2	63284299	63284300	rs2138798	8e-07	Obesity-related traits
chr2	76013234	76013235	rs436000	8e-07	Economic and political preferences (fairness)
chr2	9581766	9581767	rs6432018	8e-07	Heart rate variability traits
chr3	137728642	137728643	rs10935268	8e-07	Acenocoumarol maintenance dosage
chr3	140380850	140380851	rs17411949	8e-07	Multiple sclerosis (OCB status)
chr3	149363	149364	rs10510181	8e-07	Adolescent idiopathic scoliosis
chr3	159541501	159541502	rs2222328	8e-07	Quantitative traits
chr3	26501928	26501929	rs2202157	8e-07	Tuberculosis
chr5	1877165	1877166	rs4975709	8e-07	Cardiovascular disease risk factors
chr8	137897475	137897476	rs62531686	8e-07	PCA3 expression level
chr5	34628521	34628522	rs409045	8e-07	Left ventricular mass
chr8	139507273	139507274	rs2468677	8e-07	Adiponectin levels
chr8	141622214	141622215	rs13263959	8e-07	Hair color
chr8	18816220	18816221	rs2638663	8e-07	Lung function (forced expiratory volume in 1 second)
chr8	3230650	3230651	rs73660619	8e-07	Alzheimer's disease (cognitive decline)
chr8	71649506	71649507	rs7834018	8e-07	Autism
chr8	74600898	74600899	rs6472866	8e-07	Protein quantitative trait loci
chr8	97317536	97317537	rs6468544	8e-07	Antipsychotic-induced QTc interval prolongation
chr8	102040148	102040149	rs16868941	8e-07	Coffee consumption
chr8	9935151	9935152	rs2055729	8e-07	Multiple myeloma (hyperdiploidy)
chr9	105892814	105892815	rs4742971	8e-07	Protein quantitative trait loci
chr9	130588696	130588697	rs7466269	8e-07	Height
chr9	22770886	22770887	rs10811771	8e-07	Response to antipsychotic therapy (extrapyramidal side effects)
chr9	37037978	37037979	rs1329568	8e-07	Response to tocilizumab in rheumatoid arthritis
chr9	70542499	70542500	rs10780944	8e-07	Pubertal anthropometrics
chr9	72272786	72272787	rs11143230	8e-07	Suicidal ideation
chr2	162103237	162103238	rs2270447	8e-07	Common traits (Other)
chr9	102972912	102972913	rs1342899	8e-07	Response to antineoplastic agents
chr7	34657447	34657448	rs2530544	8e-07	IgG glycosylation
chr7	33633652	33633653	rs17170316	8e-07	Cytomegalovirus antibody response
chr7	28974578	28974579	rs2018683	8e-07	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer
chr5	38955693	38955694	rs2043112	8e-07	Obesity-related traits
chr5	56564124	56564125	rs11743303	8e-07	Sexual dimorphism in anthropometric traits
chr5	63737890	63737891	rs10042968	8e-07	Alcohol and nictotine co-dependence
chr5	84788957	84788958	rs113524839	8e-07	Alzheimer's disease biomarkers
chr6	104970102	104970103	rs314268	8e-07	Height
chr6	118359210	118359211	rs11970286	8e-07	Electrocardiographic traits
chr6	124238585	124238586	rs77490164	8e-07	Periodontitis (Mean PAL)
chr6	159225300	159225301	rs365302	8e-07	Coronary heart disease
chr6	24306158	24306159	rs16889038	8e-07	Airflow obstruction 
chr6	25488354	25488355	rs2274089	8e-07	Iron status biomarkers
chr6	26116753	26116754	rs12206204	8e-07	Bilirubin levels
chr6	32421870	32421871	rs3135363	8e-07	Hepatitis B vaccine response
chr6	49521194	49521195	rs9473582	8e-07	Brain structure
chr6	67471803	67471804	rs4710654	8e-07	Response to amphetamines
chr7	128954128	128954129	rs10488631	8e-07	Systemic sclerosis
chr7	156044600	156044601	rs10226930	8e-07	Corneal astigmatism
chr7	21464808	21464809	rs17144465	8e-07	Major depressive disorder (broad)
chr5	32000376	32000377	rs10054504	8e-07	Renal cell carcinoma
chr21	45427028	45427029	rs2838923	8e-07	Hippocampal atrophy
chr1	83024160	83024161	rs12742923	8e-07	HIV-associated dementia 
chr2	129276752	129276753	rs7567687	8e-07	Periodontitis (PAL4Q3)
chr1	230159168	230159169	rs2144300	8e-07	Triglycerides
chr12	3648381	3648382	rs887304	8e-07	Non-alcoholic fatty liver disease histology (lobular)
chr1	239273241	239273242	rs2820037	8e-07	Hypertension
chr1	242711582	242711583	rs6676375	8e-07	Tuberculosis
chr12	49853684	49853685	rs7138803	8e-07	Waist circumference
chr13	24221350	24221351	rs715921	8e-07	Airflow obstruction 
chr13	25433838	25433839	rs7322916	8e-07	Eating disorders
chr12	28075633	28075634	rs522958	8e-07	Hyperactive-impulsive symptoms
chr13	47324743	47324744	rs1417205	8e-07	Cannabis use (initiation)
chr13	69855960	69855961	rs2325244	8e-07	Response to amphetamines
chr13	97364161	97364162	rs9556711	8e-07	Alcoholism (alcohol dependence factor score)
chr14	23396675	23396676	rs452036	8e-07	Resting heart rate
chr14	50506913	50506914	rs17718580	8e-07	Cognitive performance
chr14	50980052	50980053	rs1959536	8e-07	Psychosis (atypical)
chr14	52522509	52522510	rs745080	8e-07	Orofacial clefts
chr14	56754420	56754421	rs878889	8e-07	Type 1 diabetes nephropathy
chr13	52920558	52920559	rs9536318	8e-07	Airflow obstruction 
chr12	14813669	14813670	rs4764124	8e-07	Pubertal anthropometrics
chr12	115114631	115114632	rs35444	8e-07	Blood pressure
chr12	108373555	108373556	rs10861905	8e-07	Erectile dysfunction and prostate cancer treatment
chr10	112974336	112974337	rs11196174	8e-07	Breast Cancer in BRCA1 mutation carriers
chr10	30230902	30230903	rs2995271	8e-07	Pancreatitis
chr10	33942346	33942347	rs7905537	8e-07	Emphysema-related traits
chr10	55089224	55089225	rs16906916	8e-07	Response to tocilizumab in rheumatoid arthritis
chr21	42286990	42286991	rs425215	8e-07	Common traits (Other)
chr10	72046529	72046530	rs1678618	8e-07	Smoking behavior
chr10	79256138	79256139	rs11593576	8e-07	Vitiligo
chr10	94136182	94136183	rs932764	8e-07	Diastolic blood pressure
chr10	98540424	98540425	rs10786436	8e-07	Type 1 diabetes
chr11	107610791	107610792	rs10431058	8e-07	Common traits (Other)
chr11	115528027	115528028	rs7483296	8e-07	Metabolite levels (5-HIAA/ MHPG Ratio)
chr11	117286176	117286177	rs1047964	8e-07	Cardiovascular disease risk factors
chr11	128622843	128622844	rs4937362	8e-07	Rheumatoid arthritis
chr11	24589583	24589584	rs12361953	8e-07	Alzheimer's disease (late onset)
chr1	159035858	159035859	rs1772408	8e-07	Celiac disease and Rheumatoid arthritis
chr11	61803909	61803910	rs174549	8e-07	Comprehensive strength and appendicular lean mass
chr1	178173072	178173073	rs316274	8e-07	Immune response to smallpox vaccine (IL-6)
chr14	64432336	64432337	rs10498514	8e-07	Cognitive performance
chr14	81128035	81128036	rs3783938	8e-07	Visceral fat
chr10	71362187	71362188	rs1084004	8e-07	Obesity-related traits
chr14	95702793	95702794	rs7158782	8e-07	Adverse response to aromatase inhibitors
chr17	39387195	39387196	rs7208487	8e-07	Primary biliary cirrhosis
chr17	40023238	40023239	rs2302777	8e-07	Multiple myeloma (hyperdiploidy)
chr17	49007348	49007349	rs9674544	8e-07	Primary tooth development (time to first tooth eruption)
chr18	12550747	12550748	rs1940973	8e-07	Immune response to smallpox vaccine (IL-6)
chr18	58342371	58342372	rs12454023	8e-07	Migraine with aura
chr19	18692361	18692362	rs10419226	8e-07	Esophageal adenocarcinoma
chr19	22558872	22558873	rs8111998	8e-07	Corneal structure
chr16	84954072	84954073	rs2326458	8e-07	Height
chr1	92936279	92936280	rs12745968	8e-07	Bipolar disorder and schizophrenia
chr19	31105871	31105872	rs12459897	8e-07	Phospholipid levels (plasma)
chr19	41345603	41345604	rs4803455	8e-07	Migraine
chr19	49496751	49496752	rs2280401	8e-07	Serum albumin level
chr19	6887724	6887725	rs3826782	8e-07	Periodontitis
chr20	13143085	13143086	rs17190927	8e-07	Personality dimensions
chr20	35321980	35321981	rs6088792	8e-07	Height
chr14	94329846	94329847	rs61280460	8e-07	Breast size
chr19	30608982	30608983	rs746961	8e-07	Select biomarker traits
chr16	84412777	84412778	rs10514604	8e-07	Attention deficit hyperactivity disorder
chr20	1225241	1225242	rs397020	8e-07	Multiple sclerosis
chr16	68723865	68723866	rs192253604	8e-07	Serum dimethylarginine levels (asymmetric)
chr16	78918541	78918542	rs9923451	8e-07	Obesity
chr1	54202604	54202605	rs1890566	8e-07	Migraine
chr15	54576469	54576470	rs2553218	8e-07	Immune response to smallpox vaccine (IL-6)
chr15	60489313	60489314	rs3743266	8e-07	Menarche (age at onset)
chr15	63020432	63020433	rs1873147	8e-07	Orofacial clefts
chr15	77872363	77872364	rs11857176	8e-07	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin)
chr15	86311358	86311359	rs10152811	8e-07	Thiazide-induced adverse metabolic effects in hypertensive patients
chr15	88702007	88702008	rs4932194	8e-07	Dupuytren's disease
chr15	45830737	45830738	rs35053544	8e-07	Serum dimethylarginine levels (asymmetric/symetric ratio)
chr15	98063083	98063084	rs1993976	8e-07	Fat distribution (HIV)
chr16	20019882	20019883	rs2764743	8e-07	IgG glycosylation
chr15	89358800	89358801	rs4932217	8e-07	Height
chr16	19393322	19393323	rs4780805	8e-07	Sleep duration
chr14	97057407	97057408	rs724210	8e-07	DNA methylation (variation)
chr16	11281008	11281009	rs737008	8e-07	Obesity-related traits
chr16	11281008	11281009	rs737008	8e-07	Obesity-related traits
chr16	16636870	16636871	rs9937036	8e-07	Obesity-related traits
chr5	15618071	15618072	rs12659622	9.000000000000001e-07	Obesity-related traits
chr3	842167	842168	rs4684585	9.000000000000001e-07	Response to statin therapy
chr4	122408206	122408207	rs17388568	9.000000000000001e-07	Ulcerative colitis
chr4	13100726	13100727	rs13122273	9.000000000000001e-07	Inflammatory biomarkers
chr4	141788569	141788570	rs17007695	9.000000000000001e-07	Response to treatment for acute lymphoblastic leukemia
chr4	16016700	16016701	rs2531154	9.000000000000001e-07	Dental caries
chr4	179766846	179766847	rs6844851	9.000000000000001e-07	Bipolar disorder
chr4	181783397	181783398	rs6855088	9.000000000000001e-07	Obesity-related traits
chr4	56955142	56955143	rs708547	9.000000000000001e-07	Bleomycin sensitivity
chr5	22812154	22812155	rs780179	9.000000000000001e-07	Multiple myeloma (IgH translocation)
chr4	86911447	86911448	rs3113494	9.000000000000001e-07	Amyotrophic lateral sclerosis
chr5	110672512	110672513	rs17132261	9.000000000000001e-07	Cardiac structure and function
chr5	119099431	119099432	rs116348108	9.000000000000001e-07	Alzheimer's disease (cognitive decline)
chr3	6214309	6214310	rs6774280	9.000000000000001e-07	Response to tocilizumab in rheumatoid arthritis
chr4	53464699	53464700	rs2412488	9.000000000000001e-07	DNA methylation (variation)
chr4	75491176	75491177	rs13137105	9.000000000000001e-07	Response to tocilizumab in rheumatoid arthritis
chr3	103612638	103612639	rs9820695	9.000000000000001e-07	Economic and political preferences (environmentalism)
chr3	2804631	2804632	rs975334	9.000000000000001e-07	Gallbladder cancer
chr2	139390261	139390262	rs1399645	9.000000000000001e-07	Male infertility
chr5	3558423	3558424	rs10512697	9.000000000000001e-07	Immune response to smallpox vaccine (IL-6)
chr21	40621780	40621781	rs3804024	9.000000000000001e-07	Obesity-related traits
chr2	200157230	200157231	rs1569175	9.000000000000001e-07	Response to treatment for acute lymphoblastic leukemia
chr22	32349928	32349929	rs5998432	9.000000000000001e-07	T-tau
chr23	110695976	110695977	rs5943057	9.000000000000001e-07	Coronary heart disease
chr3	2853999	2854000	rs11713158	9.000000000000001e-07	Intelligence
chr23	34874385	34874386	rs4271113	9.000000000000001e-07	Multiple sclerosis
chr2	75232541	75232542	rs765684	9.000000000000001e-07	Sexual dimorphism in anthropometric traits
chr3	157232789	157232790	rs9866141	9.000000000000001e-07	Diabetic retinopathy 
chr3	187008098	187008099	rs11710456	9.000000000000001e-07	IgG glycosylation
chr3	187008098	187008099	rs11710456	9.000000000000001e-07	IgG glycosylation
chr3	187696202	187696203	rs6764050	9.000000000000001e-07	Response to citalopram treatment
chr3	25496825	25496826	rs1997352	9.000000000000001e-07	Airflow obstruction 
chr2	60492834	60492835	rs766432	9.000000000000001e-07	Sickle cell anemia (haemolysis)
chr5	44186565	44186566	rs4296809	9.000000000000001e-07	Brain structure
chr8	132091042	132091043	rs2014357	9.000000000000001e-07	Common traits (Other)
chr5	56537691	56537692	rs30360	9.000000000000001e-07	Fasting insulin (interaction)
chr8	33707859	33707860	rs4469412	9.000000000000001e-07	Immune response to smallpox vaccine (IL-6)
chr8	33815492	33815493	rs11786194	9.000000000000001e-07	Immune response to smallpox vaccine (IL-6)
chr8	4356656	4356657	rs10503256	9.000000000000001e-07	Schizophrenia
chr8	54527507	54527508	rs10104997	9.000000000000001e-07	Dengue shock syndrome 
chr8	61141903	61141904	rs12681792	9.000000000000001e-07	Migraine
chr8	62346357	62346358	rs142014203	9.000000000000001e-07	Bulimia nervosa
chr8	20224378	20224379	rs1390943	9.000000000000001e-07	Circulating myeloperoxidase levels (serum) 
chr9	11402318	11402319	rs10809457 	9.000000000000001e-07	Palmitic acid (16:0) plasma levels
chr9	16385133	16385134	rs9406636	9.000000000000001e-07	Metabolite levels (Dihydroxy docosatrienoic acid)
chr9	6253570	6253571	rs10975519	9.000000000000001e-07	Endometriosis
chr9	68614262	68614263	rs7864204	9.000000000000001e-07	Body mass index (interaction)
chr9	88196266	88196267	rs2814828	9.000000000000001e-07	Height
chr9	90801253	90801254	rs290986	9.000000000000001e-07	Multiple sclerosis
chr21	36112763	36112764	rs4817775	9.000000000000001e-07	Bone mineral density
chr9	115662707	115662708	rs12006166	9.000000000000001e-07	Migraine
chr5	54606508	54606509	rs2548621	9.000000000000001e-07	Immune response to smallpox vaccine (IL-6)
chr8	17943259	17943260	rs2299587	9.000000000000001e-07	Economic and political preferences
chr7	131603230	131603231	rs12534221	9.000000000000001e-07	AB1-42
chr5	6767198	6767199	rs12520016	9.000000000000001e-07	Eye color
chr6	109277760	109277761	rs13210693	9.000000000000001e-07	Ankylosing spondylitis
chr6	154405853	154405854	rs2275336	9.000000000000001e-07	Parkinson's disease
chr6	156807122	156807123	rs11967485	9.000000000000001e-07	Calcium levels
chr6	30814224	30814225	rs886424	9.000000000000001e-07	Bipolar disorder and schizophrenia
chr6	32415272	32415273	rs4959027	9.000000000000001e-07	Pubertal anthropometrics
chr7	21567733	21567734	rs12670798	9.000000000000001e-07	Cholesterol, total
chr6	36824280	36824281	rs236373	9.000000000000001e-07	Heart rate
chr6	71067267	71067268	rs11968814	9.000000000000001e-07	F-cell distribution
chr6	97571203	97571204	rs9320598	9.000000000000001e-07	Multiple sclerosis (OCB status)
chr7	103764367	103764368	rs7341475	9.000000000000001e-07	Schizophrenia
chr9	9924723	9924724	rs7849581	9.000000000000001e-07	Myopia (pathological)
chr7	126684536	126684537	rs17691394	9.000000000000001e-07	Carotid atherosclerosis in HIV infection
chr7	128775140	128775141	rs1799922	9.000000000000001e-07	Primary tooth development (time to first tooth eruption)
chr6	61285854	61285855	rs2342002	9.000000000000001e-07	Esophageal adenocarcinoma
chr2	119388078	119388079	rs1374313	9.000000000000001e-07	Obesity-related traits
chr7	108908602	108908603	rs848353	9.000000000000001e-07	Smoking behavior
chr20	45495882	45495883	rs11696501	9.000000000000001e-07	Brain structure
chr11	94538496	94538497	rs11020821	9.000000000000001e-07	Response to angiotensin II receptor blocker therapy
chr11	94579156	94579157	rs2212361	9.000000000000001e-07	Attention deficit hyperactivity disorder symptoms (interaction)
chr1	206453481	206453482	rs2483058	9.000000000000001e-07	Cholesterol and Triglycerides
chr12	102332559	102332560	rs1520223	9.000000000000001e-07	Height
chr12	108349042	108349043	rs17040430	9.000000000000001e-07	Bipolar disorder
chr12	114942587	114942588	rs10850408	9.000000000000001e-07	Alzheimer's disease
chr11	92917835	92917836	rs7950811	9.000000000000001e-07	Conduct disorder (case status)
chr12	123915002	123915003	rs1316952	9.000000000000001e-07	Visceral adipose tissue/subcutaneous adipose tissue ratio
chr1	22247448	22247449	rs909814	9.000000000000001e-07	Testosterone levels
chr1	22371953	22371954	rs7524102	9.000000000000001e-07	Bone mineral density
chr12	2620465	2620466	rs216013	9.000000000000001e-07	Warfarin maintenance dose
chr12	51870171	51870172	rs17126180	9.000000000000001e-07	Response to antipsychotic treatment in schizophrenia (reasoning)
chr12	53647407	53647408	rs11170631	9.000000000000001e-07	Height
chr12	65389597	65389598	rs10506525	9.000000000000001e-07	Primary tooth development (number of teeth)
chr12	13774961	13774962	rs6488619	9.000000000000001e-07	Ovarian reserve
chr12	7182620	7182621	rs12828421	9.000000000000001e-07	IgG glycosylation
chr1	192462867	192462868	rs12067906	9.000000000000001e-07	Blood pressure
chr11	65582284	65582285	rs6591182	9.000000000000001e-07	Non-alcoholic fatty liver disease histology (lobular)
chr20	57063480	57063481	rs331615	9.000000000000001e-07	White blood cell types
chr10	103887336	103887337	rs3814219	9.000000000000001e-07	Endothelial function traits
chr10	116727588	116727589	rs1665650	9.000000000000001e-07	Colorectal cancer
chr10	121521143	121521144	rs3135753	9.000000000000001e-07	Gout
chr10	129702675	129702676	rs11016883	9.000000000000001e-07	Waist-to-hip circumference ratio (interaction)
chr10	37693168	37693169	rs7474896	9.000000000000001e-07	Obesity (extreme)
chr1	171588460	171588461	rs2421847	9.000000000000001e-07	Alzheimer's disease (cognitive decline)
chr10	50250947	50250948	rs10508921	9.000000000000001e-07	Thiazide-induced adverse metabolic effects in hypertensive patients
chr10	96880088	96880089	rs17112190	9.000000000000001e-07	Multiple myeloma (IgH translocation)
chr10	99397680	99397681	rs76850691	9.000000000000001e-07	Liver enzyme levels (aspartate transaminase)
chr11	113120895	113120896	rs1436109	9.000000000000001e-07	Cardiac muscle measurement
chr11	113553835	113553836	rs7952106	9.000000000000001e-07	Systolic blood pressure in sickle cell anemia
chr11	114516379	114516380	rs4466877	9.000000000000001e-07	IgG glycosylation
chr11	125591813	125591814	rs548181	9.000000000000001e-07	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr10	57964642	57964643	rs7088591	9.000000000000001e-07	Blood pressure
chr13	110308595	110308596	rs3809346	9.000000000000001e-07	Coronary artery calcification
chr11	39306408	39306409	rs12808199	9.000000000000001e-07	Osteoporosis
chr14	38551300	38551301	rs10498345	9.000000000000001e-07	Coronary spasm
chr17	39884509	39884510	rs2872507	9.000000000000001e-07	Rheumatoid arthritis
chr17	44148178	44148179	rs227584	9.000000000000001e-07	Bone mineral density (hip)
chr17	56046611	56046612	rs2060070	9.000000000000001e-07	IgG glycosylation
chr17	56115161	56115162	rs1431318	9.000000000000001e-07	Cannabis dependence
chr1	82846151	82846152	rs11163585	9.000000000000001e-07	Response to antipsychotic treatment
chr18	69475620	69475621	rs17184557	9.000000000000001e-07	Osteoporosis
chr17	28274106	28274107	rs2006933	9.000000000000001e-07	Amyotrophic lateral sclerosis
chr19	10727809	10727810	rs11671653	9.000000000000001e-07	Coronary heart disease
chr19	44466712	44466713	rs644148	9.000000000000001e-07	Personality dimensions
chr19	45351660	45351661	rs13181	9.000000000000001e-07	Lung Cancer (DNA repair capacity)
chr19	51293044	51293045	rs10414689 	9.000000000000001e-07	Palmitic acid (16:0) plasma levels
chr19	54404499	54404500	rs11084337	9.000000000000001e-07	Blood trace element (Se levels)
chr13	94300577	94300578	rs9301951	9.000000000000001e-07	Disc degeneration (lumbar)
chr20	17848635	17848636	rs2745851	9.000000000000001e-07	IgG glycosylation
chr19	15566898	15566899	rs1273516	9.000000000000001e-07	Response to tocilizumab in rheumatoid arthritis
chr16	9120022	9120023	rs3743832	9.000000000000001e-07	Behavioural disinhibition (generation interaction)
chr1	89559959	89559960	rs922106	9.000000000000001e-07	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel)
chr16	82293199	82293200	rs11863065	9.000000000000001e-07	Obesity-related traits
chr14	75347324	75347325	rs11621969	9.000000000000001e-07	Periodontal microbiota
chr16	89659626	89659627	rs154663	9.000000000000001e-07	Height
chr15	55657883	55657884	rs11071200	9.000000000000001e-07	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin)
chr15	68304788	68304789	rs7174755	9.000000000000001e-07	Major depressive disorder
chr15	80708936	80708937	rs12148329	9.000000000000001e-07	Immune response to smallpox vaccine (IL-6)
chr15	83854002	83854003	rs1383484	9.000000000000001e-07	Height
chr16	11128380	11128381	rs78394940	9.000000000000001e-07	Obesity-related traits
chr15	83647131	83647132	rs2554380	9.000000000000001e-07	Height
chr16	11983774	11983775	rs12922317	9.000000000000001e-07	Schizophrenia
chr16	15788109	15788110	rs17213965	9.000000000000001e-07	Waist-hip ratio
chr16	53796552	53796553	rs9930506	9.000000000000001e-07	Obesity-related traits
chr16	53796552	53796553	rs9930506	9.000000000000001e-07	Obesity-related traits
chr16	61089242	61089243	rs2639889	9.000000000000001e-07	Morbidity-free survival
chr16	79373020	79373021	rs17797882	9.000000000000001e-07	Type 2 diabetes
chr14	63486803	63486804	rs11158493	9.000000000000001e-07	Response to antineoplastic agents
chr4	46966032	46966033	rs2055942	1e-06	Type 2 diabetes
chr4	186417180	186417181	rs11935103	1e-06	Response to citalopram treatment
chr4	21204866	21204867	rs1023721	1e-06	IgG glycosylation
chr4	21204866	21204867	rs1023721	1e-06	IgG glycosylation
chr4	180308046	180308047	rs17834666	1e-06	Metabolite levels (HVA/MHPG ratio)
chr4	25401643	25401644	rs16877106	1e-06	Weight
chr4	38159442	38159443	rs115426111	1e-06	Serum dimethylarginine levels (symmetric)
chr4	181563615	181563616	rs1439283	1e-06	Obesity-related traits
chr4	81009659	81009660	rs1960445	1e-06	Refractive error
chr4	71738581	71738582	rs222054	1e-06	Non-alcoholic fatty liver disease histology (other)
chr4	72917686	72917687	rs6816344	1e-06	Dialysis-related mortality
chr4	75968234	75968235	rs2273	1e-06	Longevity
chr4	76499630	76499631	rs1986734	1e-06	Eosinophilic esophagitis (pediatric)
chr4	99792607	99792608	rs11735070	1e-06	Response to antipsychotic treatment
chr5	100966101	100966102	rs17161553	1e-06	IgG glycosylation
chr4	166534340	166534341	rs11941399	1e-06	Capecitabine sensitivity
chr5	102523612	102523613	rs1502844	1e-06	Schizophrenia
chr4	71261171	71261172	rs2579330	1e-06	QT interval
chr4	165951383	165951384	rs6812849	1e-06	Post-traumatic stress disorder
chr4	109976428	109976429	rs11568995	1e-06	IgG glycosylation
chr4	150180519	150180520	rs11947645	1e-06	Social autistic-like traits
chr5	10463994	10463995	rs2967951	1e-06	Body mass index
chr3	99873751	99873752	rs813218	1e-06	Orofacial clefts
chr4	102881007	102881008	rs78640361	1e-06	Serum dimethylarginine levels (asymmetric)
chr4	108296772	108296773	rs13144621	1e-06	Airflow obstruction 
chr4	108801969	108801970	rs4956211	1e-06	Systemic lupus erythematosus
chr4	112390633	112390634	rs4833407	1e-06	Obesity
chr4	113027633	113027634	rs10014072	1e-06	Blood trace element (Cu levels)
chr4	116012922	116012923	rs7676999	1e-06	Age-related macular degeneration
chr4	116954104	116954105	rs1440306	1e-06	Bronchopulmonary dysplasia
chr4	120941345	120941346	rs10018902	1e-06	Obesity-related traits
chr4	122451977	122451978	rs2069772	1e-06	IgE grass sensitization
chr4	13120910	13120911	rs573332	1e-06	Response to antidepressant treatment
chr4	136739227	136739228	rs6813479	1e-06	Longevity
chr4	1371338	1371339	rs13118159	1e-06	Longevity
chr4	137213426	137213427	rs10519410	1e-06	Adverse response to radiation therapy
chr4	140466283	140466284	rs17532515	1e-06	Select biomarker traits
chr4	148390575	148390576	rs11725509	1e-06	Subcutaneous adipose tissue
chr4	149804059	149804060	rs10030601	1e-06	Epilepsy (generalized)
chr4	149980604	149980605	rs11930273	1e-06	Visceral adipose tissue adjusted for BMI
chr4	155724360	155724361	rs13139571	1e-06	Systolic blood pressure
chr5	104872311	104872312	rs10074959	1e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors)
chr5	56537691	56537692	rs30360	1e-06	Homeostasis model assessment of insulin resistance (interaction)
chr5	108065749	108065750	rs11242661	1e-06	Response to amphetamines
chr5	32748530	32748531	rs10061804	1e-06	Ovarian reserve
chr5	35037009	35037010	rs37369	1e-06	Metabolite levels
chr5	38051490	38051491	rs270545	1e-06	Major depressive disorder
chr5	40237271	40237272	rs36019094	1e-06	Obesity-related traits
chr5	40410481	40410482	rs11742570	1e-06	Crohn's disease
chr5	4720471	4720472	rs7727102	1e-06	Bipolar disorder and schizophrenia
chr5	51339043	51339044	rs6449586	1e-06	Barrett's esophagus
chr5	52509907	52509908	rs7702276	1e-06	Alzheimer's disease biomarkers
chr5	3092077	3092078	rs6873793	1e-06	QT interval
chr3	7487867	7487868	rs9870680	1e-06	Major depressive disorder (broad)
chr5	618470	618471	rs7726839	1e-06	Obesity-related traits
chr5	63522072	63522073	rs255414	1e-06	Body mass index
chr5	65121850	65121851	rs7729539	1e-06	QT interval
chr5	65137572	65137573	rs17206232	1e-06	Schizophrenia
chr5	66443610	66443611	rs10514995	1e-06	RR interval (heart rate)
chr5	7227933	7227934	rs7729273	1e-06	Cognitive performance
chr5	73919411	73919412	rs16871023	1e-06	D-dimer levels
chr5	73981077	73981078	rs6894385	1e-06	QT interval
chr5	5897580	5897581	rs7728043	1e-06	QT interval
chr5	30899409	30899410	rs6871087	1e-06	Response to angiotensin II receptor blocker therapy
chr5	29040013	29040014	rs488884	1e-06	Migraine without aura
chr5	177415472	177415473	rs2731672	1e-06	Platelet function and related traits
chr5	111099791	111099792	rs2416257	1e-06	Eosinophil counts
chr5	112357673	112357674	rs379440	1e-06	vWF and FVIII levels
chr5	113387869	113387870	rs1318772	1e-06	F-cell distribution
chr5	116639959	116639960	rs6898653	1e-06	Allergic rhinitis
chr5	125907326	125907327	rs1119582	1e-06	Select biomarker traits
chr5	132335968	132335969	rs10479002	1e-06	Fibrinogen
chr5	132660271	132660272	rs20541	1e-06	Self-reported allergy
chr5	13798449	13798450	rs795544	1e-06	Corneal astigmatism
chr5	141320921	141320922	rs10875595	1e-06	Pulmonary function decline
chr5	157181988	157181989	rs411174	1e-06	Personality dimensions
chr5	157515276	157515277	rs11740562	1e-06	Bipolar disorder and schizophrenia
chr5	160545013	160545014	rs1592749	1e-06	Response to anti-TNF alpha therapy in inflammatory bowel disease
chr5	163571508	163571509	rs294588	1e-06	Aging
chr5	166891184	166891185	rs3853240	1e-06	Adverse response to lamotrigine and phenytoin
chr5	166962487	166962488	rs17404956	1e-06	Diabetic retinopathy 
chr5	168216539	168216540	rs6885116	1e-06	Periodontal microbiota
chr5	169647051	169647052	rs169082	1e-06	Protein quantitative trait loci
chr5	175184336	175184337	rs4336372	1e-06	Response to anti-TNF treatment in rheumatoid arthritis
chr5	175817030	175817031	rs7448069	1e-06	Attention deficit hyperactivity disorder (inattention symptoms)
chr5	108064803	108064804	rs288139	1e-06	Eye color
chr3	67093413	67093414	rs4392363	1e-06	Migraine - clinic-based
chr3	12881697	12881698	rs2569991	1e-06	Periodontitis (DPAL)
chr3	62051049	62051050	rs10490775	1e-06	Fuchs's corneal dystrophy
chr23	145059798	145059799	rs6627057	1e-06	Bipolar disorder and schizophrenia
chr23	30101659	30101660	rs6628506	1e-06	Metabolite levels (HVA/MHPG ratio)
chr23	3492627	3492628	rs7059886	1e-06	Antineutrophil cytoplasmic antibody-associated vasculitis 
chr23	38140398	38140399	rs56156506	1e-06	Anorexia nervosa
chr2	34868225	34868226	rs7600259	1e-06	Response to amphetamines
chr2	36448386	36448387	rs848512	1e-06	IgE levels in asthmatics
chr23	86936999	86937000	rs2710057	1e-06	Bone mineral density (hip)
chr2	44478475	44478476	rs698813	1e-06	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel)
chr23	134188573	134188574	rs765132	1e-06	Response to anti-TNF alpha therapy in inflammatory bowel disease
chr2	46323629	46323630	rs7582701	1e-06	IgG glycosylation
chr2	50504179	50504180	rs6754640	1e-06	Temperament
chr2	52284655	52284656	rs17042688	1e-06	Estradiol plasma levels (breast cancer)
chr2	53010181	53010182	rs1160297	1e-06	Hemostatic factors and hematological phenotypes
chr2	54929492	54929493	rs6726292	1e-06	Obesity (extreme)
chr2	55781768	55781769	rs7577894	1e-06	Amyotrophic lateral sclerosis
chr2	60232670	60232671	rs359268	1e-06	Hypersomnia (HLA-DQB1*06:02 negative)
chr2	60839530	60839531	rs1432295	1e-06	Hodgkin's lymphoma
chr2	70537555	70537556	rs432203	1e-06	Longevity
chr2	50288879	50288880	rs1356888	1e-06	Longevity
chr23	117088294	117088295	rs6646773	1e-06	Response to citalopram treatment
chr2	30303913	30303914	rs6708166	1e-06	vWF and FVIII levels
chr2	27375229	27375230	rs4665972	1e-06	Breast size
chr2	212432528	212432529	rs1505368	1e-06	Serum dimethylarginine levels (symmetric)
chr2	213683812	213683813	rs6707387	1e-06	Homeostasis model assessment of insulin resistance (interaction)
chr2	214052677	214052678	rs1510552	1e-06	Contrast sensitivity
chr2	216343847	216343848	rs6756590	1e-06	Migraine
chr2	218891660	218891661	rs7349332	1e-06	Hair morphology
chr2	219069625	219069626	rs1052483	1e-06	Height
chr2	221207457	221207458	rs17348202	1e-06	Paclitaxel-induced neuropathy
chr22	22158021	22158022	rs987710	1e-06	Iron deficiency
chr22	22158021	22158022	rs987710	1e-06	Iron status biomarkers
chr2	231931899	231931900	rs749052	1e-06	Height
chr2	234394165	234394166	rs11887188	1e-06	Blood pressure measurement (high sodium and potassium intervention)
chr22	37155566	37155567	rs743777	1e-06	Rheumatoid arthritis
chr22	37217268	37217269	rs13053175	1e-06	Longevity
chr22	38172998	38172999	rs738322	1e-06	Cutaneous nevi
chr22	41822851	41822852	rs7364180	1e-06	Alzheimer's disease biomarkers
chr22	47136752	47136753	rs5766691	1e-06	Longevity
chr22	50223439	50223440	rs5771242	1e-06	Lung function (forced expiratory flow between 25% and 75% of forced vital capacity)
chr22	50237829	50237830	rs7511006	1e-06	Obesity-related traits
chr22	50666251	50666252	rs9616906	1e-06	Longevity
chr2	71731349	71731350	rs2900976	1e-06	Protein quantitative trait loci
chr2	74744953	74744954	rs205611	1e-06	Iris characteristics
chr2	8390125	8390126	rs13008689	1e-06	Longevity
chr2	98623467	98623468	rs12618769	1e-06	Bipolar disorder
chr3	175385824	175385825	rs62287976	1e-06	Metabolite levels (MHPG)
chr3	178048675	178048676	rs7634528	1e-06	Myopia (pathological)
chr3	178137843	178137844	rs9883878	1e-06	Asthma (childhood onset)
chr3	178623793	178623794	rs2054399	1e-06	Bipolar disorder and schizophrenia
chr3	182133495	182133496	rs16832889	1e-06	Estradiol plasma levels (breast cancer)
chr3	184125346	184125347	rs6806377	1e-06	Obesity-related traits
chr3	184796824	184796825	rs4686760	1e-06	vWF and FVIII levels
chr3	185793898	185793899	rs4402960	1e-06	Type 2 diabetes
chr3	25070679	25070680	rs993804	1e-06	Bipolar disorder and schizophrenia
chr3	3088536	3088537	rs334809 	1e-06	Oleic acid (18:1n-9) plasma levels
chr3	3088960	3088961	rs3804795	1e-06	Immune response to smallpox vaccine (IL-6)
chr3	355869	355870	rs892295	1e-06	Obesity-related traits
chr3	37193097	37193098	rs7631605	1e-06	P-tau181p
chr3	42406978	42406979	rs2286720	1e-06	Response to antipsychotic treatment in schizophrenia (reasoning)
chr3	48445933	48445934	rs9876781	1e-06	Longevity
chr3	5663364	5663365	rs11710433	1e-06	Bipolar disorder (mood-incongruent)
chr3	56764466	56764467	rs13100723	1e-06	Obesity-related traits
chr3	57409038	57409039	rs1916284	1e-06	Prostate cancer (gene x gene interaction)
chr3	58120048	58120049	rs13077017	1e-06	Eating disorders (purging via substances) 
chr3	175175984	175175985	rs17531088	1e-06	Kawasaki disease
chr3	63827977	63827978	rs7614311	1e-06	Lung function (forced vital capacity)
chr3	1700080	1700081	rs73001827	1e-06	Response to amphetamines
chr3	162964206	162964207	rs1425609	1e-06	Aging (time to death)
chr3	103526247	103526248	rs1397924	1e-06	Economic and political preferences (environmentalism)
chr3	103573381	103573382	rs4856162	1e-06	Economic and political preferences (environmentalism)
chr3	103681237	103681238	rs7628767	1e-06	Economic and political preferences (environmentalism)
chr3	103720029	103720030	rs4493441	1e-06	Economic and political preferences (environmentalism)
chr3	106570102	106570103	rs12491921	1e-06	Cannabis dependence
chr3	109810702	109810703	rs679711	1e-06	Sleep depth
chr3	118443775	118443776	rs10511378	1e-06	Obesity-related traits
chr3	120706483	120706484	rs13077101	1e-06	Obesity-related traits
chr3	122649499	122649500	rs2650951	1e-06	QT interval
chr5	75359900	75359901	rs3846663	1e-06	Quantitative traits
chr3	133680857	133680858	rs2718812	1e-06	Iron status biomarkers
chr3	135506406	135506407	rs11712655	1e-06	Visceral adipose tissue/subcutaneous adipose tissue ratio
chr3	141386727	141386728	rs724016	1e-06	Height
chr3	14439269	14439270	rs6790433 	1e-06	Response to taxane treatment (docetaxel)
chr3	149259526	149259527	rs7617219	1e-06	Subcutaneous adipose tissue
chr3	153760633	153760634	rs6794649	1e-06	IgG glycosylation
chr3	157079819	157079820	rs17451107	1e-06	Adiposity in newborns
chr3	159926507	159926508	rs6799788	1e-06	Major depressive disorder
chr3	160623107	160623108	rs4679904	1e-06	Primary biliary cirrhosis
chr3	168007560	168007561	rs7632500	1e-06	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined)
chr5	79533425	79533426	rs7713917	1e-06	Major depressive disorder
chr6	31936026	31936027	rs9332739	1e-06	Age-related macular degeneration (GA)
chr5	81423305	81423306	rs7732320	1e-06	Glioblastoma
chr8	31176758	31176759	rs11774682	1e-06	IgG glycosylation
chr8	34187742	34187743	rs9297216	1e-06	Asthma (childhood onset)
chr8	37238540	37238541	rs1015003	1e-06	Heart rate
chr8	53206653	53206654	rs1425902	1e-06	IgE levels in asthmatics (D.p. specific) 
chr8	69500214	69500215	rs6982250	1e-06	Height
chr8	72720792	72720793	rs2247572	1e-06	Cognitive performance
chr8	80395914	80395915	rs7000782	1e-06	Atopic dermatitis
chr8	80557884	80557885	rs272594	1e-06	Neutrophil count
chr8	31176758	31176759	rs11774682	1e-06	IgG glycosylation
chr8	81074717	81074718	rs5003154	1e-06	Bladder cancer
chr8	91348167	91348168	rs921231	1e-06	Fat distribution (HIV)
chr8	9327635	9327636	rs2126259	1e-06	HDL cholesterol
chr8	96784502	96784503	rs3763558	1e-06	DNA methylation (variation)
chr8	99822953	99822954	rs959695	1e-06	Hippocampal atrophy
chr9	101775327	101775328	rs4523321	1e-06	Obesity-related traits
chr9	104561918	104561919	rs13287980	1e-06	Gout
chr9	109037282	109037283	rs643410	1e-06	Schizophrenia (negative symptoms)
chr9	110368882	110368883	rs1327533	1e-06	Longevity
chr8	82991578	82991579	rs7015622	1e-06	Response to antidepressant treatment
chr8	22786193	22786194	rs12155789	1e-06	Serum dimethylarginine levels (asymmetric)
chr8	1935185	1935186	rs13279485	1e-06	Multiple sclerosis
chr8	1798783	1798784	rs11986414	1e-06	Gaucher disease severity
chr7	8137766	8137767	rs17143586	1e-06	Obesity-related traits
chr7	82102129	82102130	rs258671 	1e-06	Response to taxane treatment (docetaxel)
chr7	82820718	82820719	rs2715148	1e-06	Major depressive disorder
chr7	87192663	87192664	rs11773103	1e-06	Bipolar disorder and major depressive disorder (combined)
chr7	9027189	9027190	rs10952132	1e-06	Response to fenofibrate
chr7	9226757	9226758	rs1285407	1e-06	Protein quantitative trait loci
chr7	96001883	96001884	rs1488515	1e-06	Obesity-related traits
chr7	96733031	96733032	rs1464807	1e-06	Attention deficit hyperactivity disorder
chr7	98391898	98391899	rs9649213	1e-06	Prostate cancer (gene x gene interaction)
chr7	999366	999367	rs10256972	1e-06	Longevity
chr8	102963760	102963761	rs6468852	1e-06	Alzheimer's disease (late onset)
chr8	104945311	104945312	rs16872085	1e-06	Sudden cardiac arrest
chr8	107777587	107777588	rs4534106	1e-06	Brain structure
chr8	111963911	111963912	rs12549576	1e-06	Bilirubin levels
chr8	11261527	11261528	rs2251301	1e-06	Response to antipsychotic therapy (extrapyramidal side effects)
chr8	11780734	11780735	rs6601606	1e-06	Neutrophil count
chr8	11841237	11841238	rs1296028	1e-06	Parkinson's disease
chr8	131318468	131318469	rs10108033	1e-06	IgG glycosylation
chr8	14256306	14256307	rs9886428	1e-06	IgG glycosylation
chr9	110657478	110657479	rs10980508	1e-06	Type 2 diabetes (dietary heme iron intake interaction)
chr7	8118256	8118257	rs6463768	1e-06	Metabolite levels (Pyroglutamine)
chr9	114842789	114842790	rs11554257	1e-06	Ulcerative colitis
chr9	119297430	119297431	rs4837628	1e-06	Parkinson's disease
chr9	4981601	4981602	rs10758669	1e-06	Ulcerative colitis
chr9	5213686	5213687	rs10975003	1e-06	Ulcerative colitis
chr9	70479618	70479619	rs963265	1e-06	Migraine with aura
chr9	71169347	71169348	rs4745062	1e-06	Longevity
chr9	7274695	7274696	rs1887867	1e-06	Obesity-related traits
chr9	76226484	76226485	rs10746997	1e-06	Response to fenofibrate (adiponectin levels)
chr9	79695982	79695983	rs914715	1e-06	Bipolar disorder
chr9	81757825	81757826	rs11139399	1e-06	Hippocampal atrophy
chr9	4834393	4834394	rs457287	1e-06	Platelet counts
chr9	82800065	82800066	rs1998303	1e-06	Select biomarker traits
chr9	87620878	87620879	rs11141915	1e-06	Response to gemcitabine in pancreatic cancer 
chr9	90793456	90793457	rs290258	1e-06	Prostate cancer (gene x gene interaction)
chr9	93125037	93125038	rs2275848	1e-06	Obesity (early onset extreme)
chr9	97933920	97933921	rs755109	1e-06	Quantitative traits
chr9	9910122	9910123	rs10759102	1e-06	Airflow obstruction 
chr9	99275687	99275688	rs10819643	1e-06	Lung function (forced expiratory flow between 25% and 75% of forced vital capacity)
chr17	1422002	1422003	rs1083 2417	1e-06	Blood pressure measurement (high sodium intervention)
chr2	204118830	204118831	rs16840760	1e-06	Obesity-related traits
chr9	87416753	87416754	rs1806864	1e-06	Bipolar disorder and schizophrenia
chr9	4267208	4267209	rs1571583	1e-06	Thyroid hormone levels
chr9	36099401	36099402	rs4878639	1e-06	IgG glycosylation
chr9	33283583	33283584	rs12336160	1e-06	Erectile dysfunction and prostate cancer treatment
chr9	120099018	120099019	rs16909449	1e-06	Response to statin therapy
chr9	127857357	127857358	rs7865146	1e-06	Metabolic syndrome
chr9	12914396	12914397	rs1953021	1e-06	Periodontitis (CDC/AAP)
chr9	133263861	133263862	rs657152	1e-06	Thyroid hormone levels
chr9	133813957	133813958	rs756777	1e-06	IgG glycosylation
chr9	133970220	133970221	rs3780792	1e-06	Multiple sclerosis
chr9	134812935	134812936	rs7874142	1e-06	Longevity
chr9	135136830	135136831	rs3849221	1e-06	Obesity-related traits
chr9	135137854	135137855	rs10776934	1e-06	Response to hepatitis C treatment
chr9	136374885	136374886	rs10781500	1e-06	Ankylosing spondylitis
chr9	14441678	14441679	rs59677118	1e-06	Alcohol consumption
chr9	15335915	15335916	rs16933006	1e-06	Obesity-related traits
chr9	21499624	21499625	rs7849420	1e-06	Lipid traits
chr9	22029547	22029548	rs564398	1e-06	Type 2 diabetes
chr9	26614848	26614849	rs10812428	1e-06	Drug-induced liver injury (flucloxacillin)
chr9	2696554	2696555	rs930811	1e-06	Obesity-related traits
chr9	31450667	31450668	rs148359873	1e-06	Serum dimethylarginine levels (symmetric)
chr9	31546473	31546474	rs4576506	1e-06	Alzheimer's disease
chr9	33139454	33139455	rs3780486	1e-06	IgG glycosylation
chr9	116372516	116372517	rs7869550	1e-06	Height
chr5	79803174	79803175	rs259067	1e-06	Obesity
chr7	73441938	73441939	rs2240466	1e-06	Caffeine consumption
chr7	50597224	50597225	rs12540874	1e-06	Systemic sclerosis
chr6	152417618	152417619	rs17082664	1e-06	Bipolar disorder and major depressive disorder (combined)
chr6	159716654	159716655	rs4516970	1e-06	Iron status biomarkers
chr6	16255811	16255812	rs10484358	1e-06	Major depressive disorder
chr6	165601942	165601943	rs7762160	1e-06	Conduct disorder (symptom count)
chr6	166292680	166292681	rs6915183	1e-06	Longevity
chr6	18791491	18791492	rs41441749	1e-06	Hyperactive-impulsive symptoms
chr6	20751083	20751084	rs7747724	1e-06	Bladder cancer
chr6	31218248	31218249	rs9263963	1e-06	IgG glycosylation
chr6	150841978	150841979	rs17427389	1e-06	Alcohol and nictotine co-dependence
chr6	31834687	31834688	rs4711279	1e-06	IgG glycosylation
chr6	32195970	32195971	rs13215567	1e-06	Obesity-related traits
chr6	32706959	32706960	rs1794265	1e-06	IgG glycosylation
chr6	32717772	32717773	rs3916765	1e-06	Type 2 diabetes
chr6	3294589	3294590	rs9378357	1e-06	Obesity-related traits
chr6	33093044	33093045	rs6928954	1e-06	Bilirubin levels
chr6	33118471	33118472	rs3117035	1e-06	RR interval (heart rate)
chr6	33518954	33518955	rs6457730	1e-06	Self-reported allergy
chr6	33656955	33656956	rs999943	1e-06	Obesity (extreme)
chr6	32159699	32159700	rs3134950 	1e-06	Oleic acid (18:1n-9) plasma levels
chr6	148466869	148466870	rs6930337	1e-06	Protein quantitative trait loci
chr6	147379996	147379997	rs9373523	1e-06	Tuberculosis
chr6	147228160	147228161	rs556493	1e-06	Bronchopulmonary dysplasia
chr5	84203824	84203825	rs347344	1e-06	Chemerin levels
chr5	85922050	85922051	rs1583686	1e-06	Obesity-related traits
chr5	91979495	91979496	rs421379	1e-06	Breast cancer (prognosis)
chr5	95926808	95926809	rs11738945	1e-06	IgG glycosylation
chr5	95937705	95937706	rs7700895	1e-06	IgG glycosylation
chr5	95965758	95965759	rs918629	1e-06	IgG glycosylation
chr5	96520974	96520975	rs2570467	1e-06	Waist circumference
chr5	9756216	9756217	rs7725217	1e-06	Hypersomnia (HLA-DQB1*06:02 negative)
chr5	98553031	98553032	rs4703129	1e-06	Asperger disorder
chr6	100308810	100308811	rs2841307	1e-06	Bipolar disorder and schizophrenia
chr6	105881179	105881180	rs9386485	1e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel)
chr6	106381661	106381662	rs6568433	1e-06	Longevity
chr6	108002554	108002555	rs17069122	1e-06	Bipolar disorder and schizophrenia
chr6	124835302	124835303	rs11154271	1e-06	Subcutaneous adipose tissue
chr6	12509894	12509895	rs12198798	1e-06	Obesity-related traits
chr6	131125650	131125651	rs602848	1e-06	Migraine - clinic-based
chr6	132321977	132321978	rs589756	1e-06	Obesity-related traits
chr6	133539206	133539207	rs9402515	1e-06	Protein quantitative trait loci
chr6	14598588	14598589	rs7770731	1e-06	Response to antipsychotic treatment in schizophrenia (working memory)
chr6	3836963	3836964	rs17318866	1e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin)
chr7	7219638	7219639	rs12702595	1e-06	Serum dimethylarginine levels (symmetric)
chr6	43304449	43304450	rs4149178	1e-06	Urate levels
chr6	4512744	4512745	rs6942328	1e-06	Uric acid levels
chr7	134565569	134565570	rs4732038	1e-06	Longevity
chr7	148203923	148203924	rs4549702	1e-06	Body mass index (interaction)
chr7	148203923	148203924	rs4549702	1e-06	Body mass index (interaction)
chr7	151423861	151423862	rs13232179	1e-06	Coronary heart disease
chr7	153852210	153852211	rs2192271	1e-06	Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms)
chr7	153855978	153855979	rs6947495	1e-06	Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms)
chr7	153861863	153861864	rs12671878	1e-06	Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms)
chr7	1872585	1872586	rs4721135	1e-06	Longevity
chr7	123736505	123736506	rs9649465	1e-06	Migraine
chr7	21544469	21544470	rs2285947	1e-06	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)
chr7	31864412	31864413	rs2270221	1e-06	Endometriosis
chr7	32337135	32337136	rs10237735 	1e-06	Palmitic acid (16:0) plasma levels
chr7	32421111	32421112	rs62458065	1e-06	Metabolite levels (HVA/MHPG ratio)
chr7	36506460	36506461	rs7777593	1e-06	Obesity-related traits
chr7	37325591	37325592	rs2392492	1e-06	Alzheimer's disease (cognitive decline)
chr7	3875931	3875932	rs6462411	1e-06	Quantitative traits
chr7	43337676	43337677	rs17172199	1e-06	Alzheimer's disease (cognitive decline)
chr7	48778368	48778369	rs11767191	1e-06	Response to amphetamines
chr7	25568788	25568789	rs17151904	1e-06	Carotid atherosclerosis in HIV infection
chr7	123119925	123119926	rs4727963	1e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel)
chr7	117427767	117427768	rs7808424	1e-06	Coronary heart disease
chr7	107862995	107862996	rs4598195	1e-06	Ulcerative colitis
chr6	45729050	45729051	rs1932040	1e-06	Periodontal microbiota
chr6	67176025	67176026	rs9342616	1e-06	QT interval
chr6	6738518	6738519	rs1294410	1e-06	Waist-hip ratio
chr6	68432115	68432116	rs9363918	1e-06	Pancreatic cancer
chr6	7118756	7118757	rs11755724	1e-06	Age-related macular degeneration
chr6	71429868	71429869	rs1727638	1e-06	AB1-42
chr6	76556470	76556471	rs4235898	1e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)
chr6	79756406	79756407	rs6925255	1e-06	Aging
chr6	88403097	88403098	rs10485165	1e-06	Select biomarker traits
chr6	88584025	88584026	rs12527253	1e-06	Response to statin therapy
chr6	90247743	90247744	rs3757247	1e-06	Type 1 diabetes
chr6	92487581	92487582	rs13207034	1e-06	Metabolite levels (HVA-5-HIAA Factor score)
chr6	93138165	93138166	rs594442	1e-06	Dialysis-related mortality
chr6	93142533	93142534	rs1408282	1e-06	C-reactive protein
chr6	99224137	99224138	rs2132683	1e-06	Brain structure
chr6	9993503	9993504	rs116201121	1e-06	Serum dimethylarginine levels (asymmetric/symetric ratio)
chr7	102878583	102878584	rs17135875	1e-06	Blood pressure measurement (cold pressor test)
chr7	10325095	10325096	rs2882834	1e-06	Capecitabine sensitivity
chr7	105640740	105640741	rs11983798	1e-06	Alzheimer's disease (late onset)
chr6	4379276	4379277	rs17138114	1e-06	Obesity-related traits
chr2	200285316	200285317	rs295137	1e-06	Asthma (bronchodilator response)
chr5	157983269	157983270	rs11958404	1e-06	IgG glycosylation
chr2	184932500	184932501	rs6755404	1e-06	Malaria
chr12	38349705	38349706	rs6582630	1e-06	Drug-induced liver injury (flucloxacillin)
chr12	39959193	39959194	rs10877840	1e-06	Parkinson's disease
chr1	241592264	241592265	rs1053221	1e-06	Obesity-related traits
chr12	42766941	42766942	rs12316797	1e-06	Visceral adipose tissue/subcutaneous adipose tissue ratio
chr1	242792260	242792261	rs12751297	1e-06	Obesity-related traits
chr12	42859611	42859612	rs1520832	1e-06	Heart failure
chr12	43536192	43536193	rs275380	1e-06	Adverse response to lamotrigine and phenytoin
chr1	244004498	244004499	rs12127679	1e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr1	233203464	233203465	rs4649444	1e-06	Homeostasis model assessment of beta-cell function (interaction)
chr12	4414289	4414290	rs10849061	1e-06	Migraine - clinic-based
chr12	47529232	47529233	rs7307902	1e-06	Obesity-related traits
chr12	48417316	48417317	rs4489787	1e-06	Prostate cancer (gene x gene interaction)
chr12	48824387	48824388	rs2070615	1e-06	Bipolar disorder
chr12	56045424	56045425	rs12580100	1e-06	Psoriasis
chr12	56810375	56810376	rs12367822	1e-06	Platelet aggregation
chr12	57133499	57133500	rs11172113	1e-06	Migraine - clinic-based
chr1	2622184	2622185	rs3890745	1e-06	Rheumatoid arthritis
chr12	74192429	74192430	rs10506701	1e-06	Bone mineral density
chr1	244227261	244227262	rs10429924	1e-06	Schizophrenia
chr12	32384553	32384554	rs11051970	1e-06	Response to tocilizumab in rheumatoid arthritis
chr1	232383403	232383404	rs669408	1e-06	Immunoglobulin A 
chr1	232110280	232110281	rs10746514	1e-06	Response to statin therapy
chr12	115774057	115774058	rs17719439	1e-06	IgG glycosylation
chr12	119380703	119380704	rs11064768	1e-06	Schizophrenia
chr12	120442630	120442631	rs17431357	1e-06	Insulin resistance/response
chr12	120925920	120925921	rs6489785	1e-06	Longevity
chr12	120965920	120965921	rs7953249	1e-06	Chronic obstructive pulmonary disease-related biomarkers
chr12	128610526	128610527	rs7296262	1e-06	Suicide attempts in bipolar disorder
chr12	128840392	128840393	rs10744391	1e-06	Renal sinus fat 
chr12	131040507	131040508	rs3847687	1e-06	Longevity
chr12	131455374	131455375	rs10466868	1e-06	Protein quantitative trait loci
chr12	131600650	131600651	rs7315621	1e-06	Longevity
chr1	2138241	2138242	rs3753242	1e-06	Response to antipsychotic treatment in schizophrenia (reasoning)
chr1	214088006	214088007	rs1440620	1e-06	Dietary macronutrient intake
chr1	219500485	219500486	rs1417066	1e-06	Osteoarthritis
chr12	20378821	20378822	rs1348582	1e-06	QT interval
chr1	222650186	222650187	rs17465637	1e-06	Coronary heart disease
chr1	22371953	22371954	rs7524102	1e-06	Bone mineral density
chr12	28075633	28075634	rs522958	1e-06	Attention deficit hyperactivity disorder
chr1	229582253	229582254	rs12049351	1e-06	Circulating myeloperoxidase levels (plasma)
chr12	31944425	31944426	rs1151008	1e-06	Corneal astigmatism
chr12	76083175	76083176	rs1368578	1e-06	Obesity-related traits
chr1	211527315	211527316	rs7526425	1e-06	Coronary heart disease
chr12	9218735	9218736	rs6487679	1e-06	Non-alcoholic fatty liver disease histology (AST)
chr1	29964420	29964421	rs6694545	1e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr14	48968727	48968728	rs2352908	1e-06	Social communication problems
chr14	51766557	51766558	rs11626056	1e-06	Hippocampal atrophy
chr14	54881399	54881400	rs3783637	1e-06	Obesity-related traits
chr14	57652477	57652478	rs10134944	1e-06	Bipolar disorder
chr14	64774230	64774231	rs11158559	1e-06	Obesity-related traits
chr1	46713637	46713638	rs10789491	1e-06	Response to hepatitis C treatment
chr14	70783084	70783085	rs17108533	1e-06	Response to antipsychotic treatment in schizophrenia (reasoning)
chr14	71727683	71727684	rs17100926	1e-06	Obesity-related traits
chr14	48095752	48095753	rs7151223	1e-06	Cognitive performance
chr14	71965431	71965432	rs4902960	1e-06	Economic and political preferences (environmentalism)
chr14	76237007	76237008	rs7156960	1e-06	Acute lymphoblastic leukemia (childhood)
chr14	77047500	77047501	rs1986116	1e-06	Sleep quality
chr14	85270824	85270825	rs1867082	1e-06	QRS duration
chr14	90292546	90292547	rs2282032	1e-06	Longevity
chr14	93738998	93738999	rs6575353	1e-06	Insomnia (caffeine-induced)
chr14	94491376	94491377	rs1998207	1e-06	Obesity-related traits
chr14	94944191	94944192	rs10133840	1e-06	Body mass index (interaction)
chr15	100188457	100188458	rs2086452	1e-06	Osteosarcoma
chr14	76033959	76033960	rs9323624	1e-06	Acute urticaria and angiodema (non-steroidal anti-inflammatory drug-induced)
chr14	28552721	28552722	rs7493138	1e-06	Longevity
chr14	24802313	24802314	rs854384	1e-06	MRI atrophy measures
chr14	20556459	20556460	rs1243647	1e-06	Prostate cancer (gene x gene interaction)
chr13	108016198	108016199	rs12871532	1e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr13	108163876	108163877	rs10492664	1e-06	Attention deficit hyperactivity disorder and conduct disorder
chr13	22135530	22135531	rs7318731	1e-06	RR interval (heart rate)
chr13	27484266	27484267	rs7336332	1e-06	Weight
chr13	28794568	28794569	rs954108	1e-06	Obesity-related traits
chr13	30740317	30740318	rs3885907	1e-06	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU)
chr13	31551177	31551178	rs1902272	1e-06	Metabolite levels (HVA/MHPG ratio)
chr1	33782462	33782463	rs476463	1e-06	Brain structure
chr13	44919745	44919746	rs17648246 	1e-06	Oleic acid (18:1n-9) plasma levels
chr13	61104777	61104778	rs3106598	1e-06	Longevity
chr13	71309081	71309082	rs9592783	1e-06	Longevity
chr13	77305240	77305241	rs7322722	1e-06	Preeclampsia
chr13	89970200	89970201	rs2882281	1e-06	Longevity
chr13	92436397	92436398	rs4771859	1e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)
chr13	92679632	92679633	rs9523762	1e-06	Multiple sclerosis
chr13	95028030	95028031	rs4148546	1e-06	Longevity
chr13	98314062	98314063	rs688872	1e-06	Brain structure
chr13	98474048	98474049	rs9517320	1e-06	Longevity
chr13	99986137	99986138	rs13542	1e-06	Orofacial clefts
chr12	95633982	95633983	rs17356907	1e-06	Breast size
chr15	100711513	100711514	rs184234 	1e-06	Response to taxane treatment (placlitaxel)
chr12	114267780	114267781	rs1920592	1e-06	Schizophrenia
chr12	113053978	113053979	rs7956193	1e-06	Visceral adipose tissue adjusted for BMI
chr10	66465127	66465128	rs2441727	1e-06	Interstitial lung disease 
chr10	71007651	71007652	rs10509328	1e-06	Multiple myeloma (IgH translocation)
chr10	72018508	72018509	rs1245582	1e-06	Disc degeneration (lumbar)
chr10	80151968	80151969	rs1953600	1e-06	Sarcoidosis
chr10	80939734	80939735	rs1484170	1e-06	Cardiac hypertrophy
chr10	88967576	88967577	rs1926203	1e-06	Lung cancer
chr10	90203705	90203706	rs2250149	1e-06	Economic and political preferences (feminism/equality)
chr10	95038790	95038791	rs1934951	1e-06	Osteonecrosis of the jaw
chr10	65983895	65983896	rs72791417	1e-06	Bronchopulmonary dysplasia
chr1	108875056	108875057	rs7523050	1e-06	Fat distribution (HIV)
chr11	102284742	102284743	rs2852894	1e-06	MRI atrophy measures
chr11	102757320	102757321	rs7924357	1e-06	Multiple sclerosis
chr11	102862431	102862432	rs12808148	1e-06	Alzheimer's disease
chr11	10647680	10647681	rs7940646	1e-06	Platelet aggregation
chr1	110695062	110695063	rs12061304	1e-06	Panic disorder
chr11	10718818	10718819	rs2018368	1e-06	Bipolar disorder and schizophrenia
chr11	116427649	116427650	rs490592	1e-06	Brain structure
chr1	111894721	111894722	rs2798334	1e-06	Visceral adipose tissue adjusted for BMI
chr1	109577109	109577110	rs6537837	1e-06	Major depressive disorder
chr10	61935288	61935289	rs6479779	1e-06	IgG glycosylation
chr10	6057081	6057082	rs2104286	1e-06	Rheumatoid arthritis
chr10	54631542	54631543	rs1937395	1e-06	Pulmonary function decline
chr2	191099906	191099907	rs7574865	1e-06	Primary biliary cirrhosis
chr10	103179457	103179458	rs11191593	1e-06	Blood pressure
chr10	112994328	112994329	rs7901695	1e-06	Coronary heart disease
chr10	113755360	113755361	rs3981351	1e-06	Obesity-related traits
chr10	12396783	12396784	rs10906142	1e-06	Obesity-related traits
chr10	12396783	12396784	rs10906142	1e-06	Obesity-related traits
chr10	124737578	124737579	rs2629540	1e-06	Cocaine dependence
chr10	128135191	128135192	rs2387326	1e-06	Select biomarker traits
chr10	13713543	13713544	rs1541010	1e-06	RR interval (heart rate)
chr10	17088693	17088694	rs11254363	1e-06	Folate pathway vitamin levels
chr10	18108317	18108318	rs17661538	1e-06	Response to antipsychotic treatment
chr10	18441438	18441439	rs7069923	1e-06	Quantitative traits
chr10	18493950	18493951	rs8181477	1e-06	Obesity-related traits
chr10	21278635	21278636	rs3847375	1e-06	Schizophrenia
chr10	3473912	3473913	rs2165468	1e-06	Bone mineral density
chr10	4007810	4007811	rs2031577	1e-06	Longevity
chr10	4613372	4613373	rs10458787	1e-06	Body mass index
chr10	49021592	49021593	rs2137920	1e-06	Migraine with aura
chr10	49368587	49368588	rs12220898	1e-06	Inflammatory biomarkers
chr11	125302696	125302697	rs750338	1e-06	Alcohol dependence
chr12	11394597	11394598	rs2900174	1e-06	Response to gemcitabine in pancreatic cancer 
chr11	125591813	125591814	rs548181	1e-06	Schizophrenia
chr11	126939808	126939809	rs1939992	1e-06	Protein quantitative trait loci
chr1	167749261	167749262	rs4145462	1e-06	Alzheimer's disease (late onset)
chr1	170664754	170664755	rs659580	1e-06	Response to angiotensin II receptor blocker therapy
chr11	71134157	71134158	rs35198051	1e-06	Obesity-related traits
chr11	73325435	73325436	rs2027760   	1e-06	Pulmonary function (interaction)
chr1	174583672	174583673	rs17301853	1e-06	Migraine without aura
chr1	177753771	177753772	rs12140439	1e-06	Schizophrenia
chr1	183389269	183389270	rs2078087	1e-06	Obesity-related traits
chr11	8462541	8462542	rs10769908	1e-06	Body mass index
chr1	167451187	167451188	rs2056626	1e-06	Systemic sclerosis
chr11	89008491	89008492	rs5016282	1e-06	Attention deficit hyperactivity disorder
chr11	92367189	92367190	rs7129229	1e-06	Homeostasis model assessment of beta-cell function (interaction)
chr11	98852485	98852486	rs11217223	1e-06	Obesity-related traits
chr1	200908433	200908434	rs7554511	1e-06	Ulcerative colitis
chr1	202422614	202422615	rs12739262	1e-06	Obesity-related traits
chr1	203403356	203403357	rs1539143	1e-06	Obesity-related traits
chr12	103640540	103640541	rs1650123	1e-06	IgG glycosylation
chr12	111241409	111241410	rs886126	1e-06	Coronary heart disease
chr12	111774028	111774029	rs2238151	1e-06	Stroke (ischemic)
chr1	191970657	191970658	rs17403780	1e-06	IgG glycosylation
chr11	66567836	66567837	rs2242663	1e-06	Bipolar disorder
chr11	64566641	64566642	rs2078267	1e-06	Urate levels
chr11	64212170	64212171	rs12575642	1e-06	Attention deficit hyperactivity disorder
chr11	131937276	131937277	rs12098973	1e-06	Cardiac Troponin-T levels
chr11	132959966	132959967	rs1567127	1e-06	Visceral adipose tissue/subcutaneous adipose tissue ratio
chr11	133930323	133930324	rs1682859	1e-06	Obesity-related traits
chr11	14076934	14076935	rs17556665	1e-06	Inflammatory biomarkers
chr1	11676542	11676543	rs2336030	1e-06	Visceral adipose tissue adjusted for BMI
chr11	16895671	16895672	rs11024074	1e-06	Diastolic blood pressure
chr1	117208742	117208743	rs12046117	1e-06	Arthritis (juvenile idiopathic)
chr11	18244251	18244252	rs12282742	1e-06	Bipolar disorder and schizophrenia
chr11	2745051	2745052	rs2237878	1e-06	Protein quantitative trait loci
chr11	3015093	3015094	rs739401	1e-06	Longevity
chr11	42294335	42294336	rs7394570	1e-06	Immune response to smallpox vaccine (IL-6)
chr11	48093536	48093537	rs3942852	1e-06	Acute lymphoblastic leukemia (childhood)
chr11	5242622	5242623	rs16912210	1e-06	Obesity-related traits
chr11	5242622	5242623	rs16912210	1e-06	Obesity-related traits
chr1	152565477	152565478	rs10888501	1e-06	Response to antipsychotic treatment
chr1	155957960	155957961	rs2364403	1e-06	Amyotrophic lateral sclerosis (age of onset)
chr11	5666793	5666794	rs11820502	1e-06	IgG glycosylation
chr1	159032431	159032432	rs861318	1e-06	Obesity-related traits
chr1	159226974	159226975	rs10489849	1e-06	Select biomarker traits
chr11	126160719	126160720	rs10501858	1e-06	Estradiol plasma levels (breast cancer)
chr15	24833639	24833640	rs3867498	1e-06	Pulmonary function
chr11	16228636	16228637	rs1401454	1e-06	Blood pressure
chr1	53115997	53115998	rs3820201	1e-06	Hippocampal atrophy
chr19	28375688	28375689	rs995834	1e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin)
chr19	33223021	33223022	rs8106493	1e-06	Visceral adipose tissue adjusted for BMI
chr19	33843008	33843009	rs166988	1e-06	Obesity-related traits
chr19	37834895	37834896	rs16975963	1e-06	Longevity
chr19	406933	406934	rs12978500	1e-06	Obesity-related traits
chr1	94145743	94145744	rs2774920	1e-06	D-dimer levels
chr1	94209169	94209170	rs2274788	1e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr19	44642802	44642803	rs7255066	1e-06	Multiple sclerosis
chr19	22431319	22431320	rs931608	1e-06	Dental caries
chr19	44888996	44888997	rs6857	1e-06	Age-related macular degeneration
chr19	44892008	44892009	rs157580	1e-06	Alzheimer's disease biomarkers
chr19	44892361	44892362	rs2075650	1e-06	Age-related macular degeneration
chr19	44892361	44892362	rs2075650	1e-06	Alzheimer's disease biomarkers
chr19	44908683	44908684	rs429358	1e-06	Alzheimer's disease biomarkers
chr19	44911193	44911194	rs439401	1e-06	Alzheimer's disease biomarkers
chr19	45692497	45692498	rs7245708	1e-06	Subcutaneous adipose tissue
chr1	96478437	96478438	rs1973993	1e-06	Weight
chr19	8607114	8607115	rs7249094	1e-06	Height
chr19	44888996	44888997	rs6857	1e-06	Age-related macular degeneration
chr19	18357075	18357076	rs7248363	1e-06	Bipolar disorder and schizophrenia
chr1	91745462	91745463	rs17131547	1e-06	Bone mineral density
chr19	17309479	17309480	rs2303745	1e-06	Systemic lupus erythematosus
chr18	55527729	55527730	rs17512836	1e-06	Schizophrenia
chr18	55997050	55997051	rs1978503	1e-06	Breast cancer
chr18	5762618	5762619	rs11662748	1e-06	Obesity-related traits
chr18	62414859	62414860	rs3018362	1e-06	Bone mineral density (hip)
chr18	6567182	6567183	rs948426	1e-06	Hypothyroidism
chr18	70475177	70475178	rs8092443	1e-06	Response to antipsychotic treatment
chr18	75185205	75185206	rs9948784	1e-06	IgG glycosylation
chr18	76389984	76389985	rs4891159	1e-06	Longevity
chr18	77275675	77275676	rs2717128	1e-06	RR interval (heart rate)
chr18	77893442	77893443	rs9961113	1e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine)
chr18	77941566	77941567	rs11661856	1e-06	Inflammatory biomarkers
chr1	88159952	88159953	rs12032672	1e-06	Periodontal microbiota
chr1	88336328	88336329	rs2179965	1e-06	Cognitive test performance
chr18	8966145	8966146	rs10502386	1e-06	Obesity-related traits
chr1	90478349	90478350	rs2390582	1e-06	Coronary artery calcification
chr19	10409387	10409388	rs8112449	1e-06	Multiple sclerosis
chr19	12035554	12035555	rs3745672	1e-06	Multiple sclerosis
chr19	1423199	1423200	rs4807927	1e-06	Reading and spelling
chr19	14240761	14240762	rs4528684	1e-06	Mortality in heart failure
chr1	98883279	98883280	rs11166135	1e-06	Dental caries
chr1	85306325	85306326	rs233100	1e-06	Multiple sclerosis
chr20	11176362	11176363	rs6040399	1e-06	Response to citalopram treatment
chr20	17848635	17848636	rs2745851	1e-06	IgG glycosylation
chr2	126573376	126573377	rs1550404	1e-06	Intelligence
chr2	127094444	127094445	rs10207628	1e-06	Alzheimer's disease
chr2	130787618	130787619	rs13395546	1e-06	Metabolite levels (Dihydroxy docosatrienoic acid)
chr21	32796262	32796263	rs2154427	1e-06	Bilirubin levels
chr2	135749356	135749357	rs6430585	1e-06	Corneal structure
chr21	40331019	40331020	rs727333	1e-06	Estradiol plasma levels (breast cancer)
chr21	40803033	40803034	rs2837828	1e-06	Neutrophil count
chr21	41672040	41672041	rs2838088	1e-06	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel)
chr2	122533445	122533446	rs1527243	1e-06	Erectile dysfunction and prostate cancer treatment
chr21	42023388	42023389	rs2839440	1e-06	Preeclampsia
chr21	45704263	45704264	rs4819143	1e-06	Insulin resistance/response
chr2	148800290	148800291	rs2121433	1e-06	Alzheimer's disease biomarkers
chr2	148810826	148810827	rs4499362	1e-06	Alzheimer's disease biomarkers
chr2	158813936	158813937	rs16843372	1e-06	Obesity-related traits
chr2	159213244	159213245	rs13022357	1e-06	Sudden cardiac arrest
chr2	170965955	170965956	rs4668356	1e-06	Cognitive performance
chr2	180212021	180212022	rs13418455	1e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr15	26766993	26766994	rs3212335	1e-06	Longevity
chr21	43348681	43348682	rs643608	1e-06	Non-alcoholic fatty liver disease histology (other)
chr21	21537794	21537795	rs2826891	1e-06	Longevity
chr2	12072318	12072319	rs16858228	1e-06	Obesity-related traits
chr21	18159124	18159125	rs77600076	1e-06	Bulimia nervosa
chr20	19232245	19232246	rs6081541	1e-06	Psychosis (atypical)
chr20	20653461	20653462	rs6132333	1e-06	IgG glycosylation
chr20	20653461	20653462	rs6132333	1e-06	IgG glycosylation
chr20	23117242	23117243	rs1320561	1e-06	Obesity-related traits
chr20	25226017	25226018	rs1044573	1e-06	Allergic rhinitis
chr20	34977951	34977952	rs11906160	1e-06	Anticoagulant levels
chr20	37841291	37841292	rs4811196	1e-06	Bone mineral density
chr20	3795527	3795528	rs3761218	1e-06	Bipolar disorder
chr20	38329434	38329435	rs6024905	1e-06	Bipolar disorder and schizophrenia
chr20	40849892	40849893	rs6102185	1e-06	IgG glycosylation
chr20	57063693	57063694	rs6127921	1e-06	Response to citalopram treatment
chr20	58589798	58589799	rs127430	1e-06	Cardiovascular disease risk factors
chr20	60320787	60320788	rs11698685	1e-06	Type 1 diabetes nephropathy
chr20	61353180	61353181	rs4468878	1e-06	Longevity
chr20	61637437	61637438	rs2024714	1e-06	Longevity
chr20	8723904	8723905	rs6077414	1e-06	Estradiol plasma levels (breast cancer)
chr2	101413183	101413184	rs12620464	1e-06	Estradiol plasma levels (breast cancer)
chr2	105998817	105998818	rs1669539	1e-06	Systolic blood pressure in sickle cell anemia
chr21	16295398	16295399	rs2823743	1e-06	Chronic obstructive pulmonary disease-related biomarkers
chr20	12893936	12893937	rs2073233	1e-06	Brain structure
chr18	51164248	51164249	rs7230711	1e-06	Immune response to anthrax vaccine 
chr20	6770441	6770442	rs2273074	1e-06	Obesity-related traits
chr1	83789051	83789052	rs7539409	1e-06	Alzheimer's disease
chr1	58292242	58292243	rs527409	1e-06	Kawasaki disease
chr15	90350435	90350436	rs6496667	1e-06	Rheumatoid arthritis
chr15	90907210	90907211	rs2677744	1e-06	Attention deficit hyperactivity disorder
chr15	92114142	92114143	rs207954	1e-06	Acute lymphoblastic leukemia (childhood)
chr15	93095171	93095172	rs7168353	1e-06	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy)
chr15	97975561	97975562	rs4965121	1e-06	Neuroticism
chr10	102836091	102836092	rs3824755	1e-06	Blood pressure
chr16	11065027	11065028	rs887864	1e-06	Allergic rhinitis
chr16	11281008	11281009	rs737008	1e-06	Obesity-related traits
chr16	12503077	12503078	rs117147010	1e-06	Serum dimethylarginine levels (symmetric)
chr16	2047156	2047157	rs2516739	1e-06	Longevity
chr16	23055938	23055939	rs8049603	1e-06	Multiple sclerosis
chr16	23754452	23754453	rs4968031	1e-06	Platelet counts
chr16	29895224	29895225	rs4787484 	1e-06	Response to taxane treatment (placlitaxel)
chr16	4053869	4053870	rs2601828	1e-06	Partial epilepsies
chr1	65049849	65049850	rs478665	1e-06	Estradiol plasma levels (breast cancer)
chr16	50722862	50722863	rs5743289	1e-06	Crohn's disease
chr16	52797549	52797550	rs6499100	1e-06	Tetralogy of Fallot
chr16	53039875	53039876	rs10852453	1e-06	IgG glycosylation
chr15	82683529	82683530	rs11638815	1e-06	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy
chr16	55570215	55570216	rs6499766	1e-06	Thyroid hormone levels
chr15	78490934	78490935	rs11858836	1e-06	Chronic obstructive pulmonary disease
chr15	74256431	74256432	rs9783698	1e-06	Obesity-related traits
chr15	31537503	31537504	rs2125623	1e-06	Mortality in heart failure
chr1	84156829	84156830	rs903263	1e-06	Breast cancer (male) 
chr15	32758221	32758222	rs1258763	1e-06	Orofacial clefts
chr15	37367847	37367848	rs587847	1e-06	Intraocular pressure
chr15	38694166	38694167	rs12912251	1e-06	Bipolar disorder and major depressive disorder (combined)
chr15	39023156	39023157	rs12907914	1e-06	Cardiac hypertrophy
chr15	39251744	39251745	rs17691453	1e-06	Metabolite levels (Dihydroxy docosatrienoic acid)
chr15	40240666	40240667	rs4924439	1e-06	Obesity-related traits
chr15	43267032	43267033	rs748404	1e-06	Lung cancer
chr15	53513627	53513628	rs7168365	1e-06	Longevity
chr15	54049267	54049268	rs1897031	1e-06	Cognitive performance
chr15	54388433	54388434	rs10518765	1e-06	Select biomarker traits
chr15	57470594	57470595	rs2934442	1e-06	Bipolar disorder (age of onset and psychomotor symptoms)
chr15	57617965	57617966	rs937254	1e-06	Coronary heart disease
chr15	57788418	57788419	rs1559777	1e-06	Myopia (pathological)
chr15	62104189	62104190	rs7172432	1e-06	Type 2 diabetes
chr15	63623586	63623587	rs11630290	1e-06	Iris characteristics
chr15	68426647	68426648	rs16952065	1e-06	IgG glycosylation
chr15	70283798	70283799	rs1971791	1e-06	Amyotrophic lateral sclerosis
chr15	75157332	75157333	rs4886670	1e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs)
chr16	55827881	55827882	rs8192935	1e-06	Response to dabigatran etexilate treatment
chr15	61708932	61708933	rs10519131	1e-06	Parkinson's disease
chr16	59856793	59856794	rs8056650	1e-06	Brain structure (hippocampal volume)
chr17	48334137	48334138	rs9303542	1e-06	Ovarian cancer
chr17	48672428	48672429	rs8074700	1e-06	Body mass index (non-asthmatics)
chr17	50211708	50211709	rs2586502 	1e-06	Response to taxane treatment (docetaxel)
chr17	58236542	58236543	rs8067912	1e-06	IgG glycosylation
chr17	64330938	64330939	rs6504218	1e-06	Coronary heart disease
chr1	76433778	76433779	rs4949718	1e-06	Liver enzyme levels (aspartate transaminase)
chr17	65646423	65646424	rs8074751	1e-06	Attention deficit hyperactivity disorder
chr17	66102426	66102427	rs2319125	1e-06	&beta;2-Glycoprotein I (&beta;2-GPI) plasma levels
chr17	66240199	66240200	rs10048158	1e-06	&beta;2-Glycoprotein I (&beta;2-GPI) plasma levels
chr17	71112611	71112612	rs1859962	1e-06	Prostate cancer
chr17	74272068	74272069	rs7219585	1e-06	Information processing speed
chr17	78223863	78223864	rs17879146	1e-06	Periodontitis (Mean PAL)
chr17	81288008	81288009	rs10445407	1e-06	Longevity
chr1	78772329	78772330	rs4650608	1e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr18	10899029	10899030	rs11080466	1e-06	Non-small cell lung cancer
chr18	31209761	31209762	rs2920001	1e-06	Multiple sclerosis
chr16	58533333	58533334	rs37062	1e-06	Electrocardiographic traits
chr18	3522007	3522008	rs8083633	1e-06	Economic and political preferences (time)
chr18	31693165	31693166	rs10438933	1e-06	Amyotrophic lateral sclerosis
chr17	46788072	46788073	rs2074404	1e-06	Celiac disease
chr17	46751564	46751565	rs199533	1e-06	Parkinson's disease
chr17	73004800	73004801	rs4969049	1e-06	Body mass index (interaction)
chr17	3126259	3126260	rs12449465	1e-06	Endometriosis
chr16	69796424	69796425	rs6499255	1e-06	IgE levels 
chr16	68566447	68566448	rs17689437	1e-06	Response to antipsychotic treatment in schizophrenia (reasoning)
chr16	64601499	64601500	rs16967753	1e-06	Metabolite levels (Pyroglutamine)
chr17	44253360	44253361	rs5023	1e-06	Obesity-related traits
chr1	67236842	67236843	rs11465804	1e-06	Crohn's disease
chr16	73467636	73467637	rs12446956	1e-06	Major depressive disorder
chr16	78536059	78536060	rs17706989	1e-06	Response to antipsychotic treatment in schizophrenia (reasoning)
chr16	78597896	78597897	rs2859631	1e-06	Radiation response
chr16	80158707	80158708	rs8060581	1e-06	Presence of antiphospholipid antibodies
chr16	82293199	82293200	rs11863065	1e-06	Obesity-related traits
chr16	74042352	74042353	rs2716601	1e-06	Treatment response for severe sepsis 
chr16	83453865	83453866	rs17216786	1e-06	Response to antipsychotic treatment
chr16	86430088	86430089	rs2178146	1e-06	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined)
chr16	89675087	89675088	rs12443954	1e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr1	72372722	72372723	rs10789336	1e-06	Body mass index
chr16	9581388	9581389	rs12325410	1e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr17	21020763	21020764	rs7226229	1e-06	Blood trace element (Se levels)
chr1	7053051	7053052	rs11120822 	1e-06	Stearic acid (18:0) plasma levels
chr16	82659206	82659207	rs8057927	1e-06	Schizophrenia
chr4	130869345	130869346	rs1478091	2e-06	Multiple sclerosis (severity)
chr4	1297324	1297325	rs13108904	2e-06	Obesity-related traits
chr4	125072346	125072347	rs1986655	2e-06	Bilirubin levels
chr4	105530153	105530154	rs12499086	2e-06	Economic and political preferences (time)
chr4	116928292	116928293	rs2389339	2e-06	IgG glycosylation
chr4	116003027	116003028	rs17586843	2e-06	Age-related macular degeneration
chr4	113079799	113079800	rs7694725	2e-06	Prostate cancer (gene x gene interaction)
chr4	111781478	111781479	rs1585471	2e-06	Myopia (pathological)
chr4	105542555	105542556	rs11730243	2e-06	Economic and political preferences (time)
chr4	13115137	13115138	rs491376	2e-06	Response to antidepressant treatment
chr4	108125803	108125804	rs956237	2e-06	Systemic lupus erythematosus
chr4	122277279	122277280	rs6534347	2e-06	Type 1 diabetes
chr4	137306454	137306455	rs987360	2e-06	Temperament
chr4	173633680	173633681	rs11944332	2e-06	Cocaine dependence
chr4	145983151	145983152	rs11100904	2e-06	Dental caries
chr4	15735724	15735725	rs4698412	2e-06	Parkinson's disease
chr4	16020916	16020917	rs2677780	2e-06	Smooth-surface caries 
chr4	161681056	161681057	rs17638464	2e-06	Height
chr4	17133719	17133720	rs4698169	2e-06	Temperament (bipolar disorder)
chr4	173633680	173633681	rs11944332	2e-06	Cocaine dependence
chr4	175740935	175740936	rs17599018	2e-06	Temperament (bipolar disorder)
chr4	179743499	179743500	rs2383393	2e-06	Body mass index
chr4	179783764	179783765	rs11495908	2e-06	Obesity-related traits
chr4	181688711	181688712	rs12641856	2e-06	Preeclampsia
chr4	182900508	182900509	rs13114435	2e-06	Obesity-related traits
chr4	10322535	10322536	rs9291683	2e-06	Bone mineral density
chr4	182339447	182339448	rs10520528	2e-06	Systolic blood pressure in sickle cell anemia
chr4	182829875	182829876	rs4862110	2e-06	Wegener's granulomatosis
chr4	145847921	145847922	rs1027841	2e-06	Behavioural disinhibition (generation interaction)
chr3	99547492	99547493	rs13070584	2e-06	Chronic kidney disease and serum creatinine levels
chr3	59935293	59935294	rs4502542	2e-06	Response to citalopram treatment
chr3	96963417	96963418	rs7650621	2e-06	Obesity-related traits
chr3	3106296	3106297	rs17879755	2e-06	QT interval
chr3	32306331	32306332	rs4627791	2e-06	Bipolar disorder
chr4	185691520	185691521	rs4376189	2e-06	Visceral adipose tissue/subcutaneous adipose tissue ratio
chr3	36814538	36814539	rs9834970	2e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr3	37954985	37954986	rs9311171	2e-06	Prostate cancer
chr3	38553481	38553482	rs7638909	2e-06	Electrocardiographic conduction measures
chr3	47347456	47347457	rs8180040	2e-06	Colorectal cancer
chr3	4972190	4972191	rs6442925	2e-06	Corneal structure
chr3	52684263	52684264	rs10865974	2e-06	Bipolar disorder (mood-incongruent)
chr3	52801337	52801338	rs736408	2e-06	Bipolar disorder
chr3	56932217	56932218	rs2062583	2e-06	Rheumatoid arthritis
chr3	59368431	59368432	rs6771019	2e-06	Capecitabine sensitivity
chr3	60522606	60522607	rs80171647	2e-06	Response to amphetamines
chr3	60777522	60777523	rs11919041	2e-06	Breast size
chr3	62079094	62079095	rs11130874	2e-06	Schizophrenia
chr3	64550971	64550972	rs80311637	2e-06	Liver enzyme levels (aspartate transaminase)
chr3	64732581	64732582	rs2371767	2e-06	Sexual dimorphism in anthropometric traits
chr3	64900434	64900435	rs1036797	2e-06	White matter integrity (interaction)
chr3	67323552	67323553	rs977102	2e-06	Response to amphetamines
chr3	6861609	6861610	rs3749380	2e-06	Panic disorder
chr3	69124223	69124224	rs7638995	2e-06	Alzheimer's disease (late onset)
chr3	69393485	69393486	rs922948	2e-06	Hip geometry
chr3	70577208	70577209	rs7628219	2e-06	Insomnia (caffeine-induced)
chr3	70879778	70879779	rs2687201	2e-06	Barrett's esophagus
chr3	71251415	71251416	rs17008402	2e-06	Subcutaneous adipose tissue
chr3	86109734	86109735	rs2324999	2e-06	Subcutaneous adipose tissue
chr3	86919358	86919359	rs17023661	2e-06	Obesity-related traits
chr3	8766828	8766829	rs237899	2e-06	Depression and alcohol dependence
chr3	88928746	88928747	rs12497795	2e-06	Periodontitis (Mean PAL)
chr3	99448262	99448263	rs2670321	2e-06	RR interval (heart rate)
chr4	186417180	186417181	rs11935103	2e-06	Response to citalopram treatment
chr5	132660150	132660151	rs1295686	2e-06	Atopic dermatitis
chr4	24374209	24374210	rs17650401	2e-06	Molar-incisor hypomineralization
chr5	123349433	123349434	rs2115172	2e-06	Weight
chr5	123439090	123439091	rs7705033	2e-06	Visceral adipose tissue/subcutaneous adipose tissue ratio
chr5	124496958	124496959	rs12513663	2e-06	Major depressive disorder
chr5	126697271	126697272	rs1546498	2e-06	QT interval
chr5	128186850	128186851	rs10089	2e-06	Ileal carcinoids
chr5	131078287	131078288	rs6867265	2e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr5	132386056	132386057	rs7731390	2e-06	IgG glycosylation
chr5	132461229	132461230	rs11745587	2e-06	Asthma
chr5	13505321	13505322	rs4463179	2e-06	Prostate cancer (gene x gene interaction)
chr5	141809601	141809602	rs248471	2e-06	Myopia (pathological)
chr5	142143434	142143435	rs1062158	2e-06	Multiple sclerosis
chr5	146845680	146845681	rs609412	2e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr5	148425556	148425557	rs10043775	2e-06	Periodontal microbiota
chr5	15364374	15364375	rs1447276	2e-06	Obesity-related traits
chr5	159580769	159580770	rs10065906	2e-06	Major depressive disorder
chr5	159580769	159580770	rs10065906	2e-06	Major depressive disorder
chr5	160452970	160452971	rs2431697	2e-06	Systemic lupus erythematosus
chr5	167799973	167799974	rs1549309	2e-06	Dietary macronutrient intake
chr5	16913745	16913746	rs17614462	2e-06	Obesity-related traits
chr5	173925759	173925760	rs1106693	2e-06	Obesity-related traits
chr5	177307646	177307647	rs72813183	2e-06	Obesity-related traits
chr5	177307646	177307647	rs72813183	2e-06	Obesity-related traits
chr5	180385667	180385668	rs10479469	2e-06	Fat distribution (HIV)
chr5	181168137	181168138	rs1279750	2e-06	Platelet counts
chr5	19440058	19440059	rs349475	2e-06	Depression (quantitative trait)
chr5	21779044	21779045	rs4701252	2e-06	Waist circumference
chr5	25692863	25692864	rs193741	2e-06	&beta;2-Glycoprotein I (&beta;2-GPI) plasma levels
chr3	27496417	27496418	rs13082711	2e-06	Systolic blood pressure
chr5	26389152	26389153	rs969088	2e-06	Response to platinum-based chemotherapy in non-small-cell lung cancer
chr5	123279829	123279830	rs6881280	2e-06	Self-reported allergy
chr4	18864545	18864546	rs6845621	2e-06	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU)
chr5	119020719	119020720	rs111649495	2e-06	Response to amphetamines
chr5	113379676	113379677	rs6594713	2e-06	Brain cytoarchitecture
chr4	33078032	33078033	rs1448284	2e-06	Brain structure (temporal lobe volume)
chr4	35409008	35409009	rs1533317	2e-06	QT interval
chr4	37643766	37643767	rs4832928	2e-06	IgG glycosylation
chr4	41637498	41637499	rs4345220	2e-06	Migraine with aura
chr4	52545962	52545963	rs346923	2e-06	Biochemical measures
chr4	52890832	52890833	rs2898681	2e-06	Optic disc size (cup)
chr4	54221413	54221414	rs17084051	2e-06	Corneal astigmatism
chr4	55432026	55432027	rs6832769	2e-06	Personality dimensions
chr4	5757141	5757142	rs735172	2e-06	Prostate cancer (gene x gene interaction)
chr4	6056769	6056770	rs16838131	2e-06	Response to angiotensin II receptor blocker therapy
chr4	61100554	61100555	rs4599440	2e-06	Biochemical measures
chr4	62558370	62558371	rs11944965	2e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin)
chr4	66868138	66868139	rs1155865	2e-06	Cognitive test performance
chr4	67581530	67581531	rs2242330	2e-06	Parkinson's disease
chr4	72551806	72551807	rs1383934	2e-06	Dental caries
chr4	81228676	81228677	rs710841	2e-06	Height
chr4	86552622	86552623	rs4478147	2e-06	Migraine - clinic-based
chr4	90480459	90480460	rs187200046	2e-06	Metabolite levels (HVA)
chr4	91996063	91996064	rs6853847	2e-06	IgG glycosylation
chr4	94912882	94912883	rs1859156	2e-06	Attention deficit hyperactivity disorder
chr4	970570	970571	rs11248060	2e-06	Parkinson's disease
chr5	10159428	10159429	rs2009501	2e-06	Metabolite levels (HVA/MHPG ratio)
chr5	101612840	101612841	rs13188771	2e-06	Conduct disorder (interaction)
chr5	10467589	10467590	rs1092913	2e-06	Breast cancer
chr5	107388886	107388887	rs252817	2e-06	Bipolar disorder and schizophrenia
chr5	10797773	10797774	rs6882716	2e-06	Alcohol consumption (maxi-drinks)
chr5	111166730	111166731	rs17132883	2e-06	Periodontitis (PAL4Q3)
chr5	111383488	111383489	rs77636885	2e-06	Alzheimer's disease (cognitive decline)
chr5	111436705	111436706	rs10491334	2e-06	Longevity
chr5	117177908	117177909	rs12153048	2e-06	Periodontitis (DPAL)
chr3	23152436	23152437	rs4619807	2e-06	Psychosis (atypical)
chr22	50463960	50463961	rs5771040	2e-06	IgG glycosylation
chr3	22251078	22251079	rs1388551	2e-06	Waist-to-hip circumference ratio (interaction)
chr22	40480229	40480230	rs6001930	2e-06	Breast cancer
chr22	43239566	43239567	rs5751452	2e-06	Response to fenofibrate (adiponectin levels)
chr22	44165406	44165407	rs5764106	2e-06	IgG glycosylation
chr22	44754778	44754779	rs5765956	2e-06	Orofacial clefts
chr22	48234371	48234372	rs13054085	2e-06	Obesity-related traits
chr22	48256184	48256185	rs1004689	2e-06	DNA methylation (variation)
chr22	48345985	48345986	rs4407	2e-06	Endometrial cancer
chr2	24880238	24880239	rs2033654	2e-06	Body mass index (non-asthmatics)
chr2	25410372	25410373	rs10180663	2e-06	Multiple myeloma (IgH translocation)
chr2	26005337	26005338	rs112288323	2e-06	Metabolite levels (HVA/MHPG ratio)
chr2	26027029	26027030	rs68184094	2e-06	Metabolite levels (HVA)
chr2	26444261	26444262	rs3795958	2e-06	Metabolite levels (HVA)
chr2	26559752	26559753	rs1011108	2e-06	Periodontal microbiota
chr2	239496965	239496966	rs6743931	2e-06	Response to antipsychotic therapy (extrapyramidal side effects)
chr2	29057894	29057895	rs882632	2e-06	Major depressive disorder
chr23	117954092	117954093	rs2430212	2e-06	Iron status biomarkers
chr23	133991763	133991764	rs7883190	2e-06	Relative hand skill
chr23	140231899	140231900	rs5955415	2e-06	Bipolar disorder and schizophrenia
chr2	32640453	32640454	rs1031261	2e-06	Hippocampal atrophy
chr23	31997258	31997259	rs16990008	2e-06	Response to antidepressant treatment
chr2	35437730	35437731	rs13402855	2e-06	Metabolite levels (5-HIAA)
chr2	3701380	3701381	rs6730148	2e-06	Obesity-related traits
chr2	37523836	37523837	rs4352210	2e-06	RR interval (heart rate)
chr2	37713398	37713399	rs4670766	2e-06	Total ventricular volume
chr2	39712395	39712396	rs17024218	2e-06	Obesity-related traits
chr2	39720580	39720581	rs2716734	2e-06	Erectile dysfunction and prostate cancer treatment
chr2	41853483	41853484	rs4305317	2e-06	Rheumatoid arthritis
chr2	42049780	42049781	rs4952590	2e-06	Atopy
chr23	116170938	116170939	rs1403543	2e-06	Cystic fibrosis severity
chr22	39463163	39463164	rs909674	2e-06	IgG glycosylation
chr22	38149611	38149612	rs6001027	2e-06	Melanoma
chr22	37586004	37586005	rs12157904	2e-06	Response to antidepressant treatment
chr5	30661465	30661466	rs9292394	2e-06	Emphysema-related traits
chr2	192877446	192877447	rs10174573	2e-06	Major depressive disorder
chr2	198097518	198097519	rs7595412	2e-06	Hip bone size
chr2	198737200	198737201	rs11893063	2e-06	Brain cytoarchitecture
chr2	20061923	20061924	rs7565124	2e-06	Major depressive disorder
chr2	203300447	203300448	rs11888559	2e-06	Height
chr2	205000108	205000109	rs2335704	2e-06	Tuberculosis
chr2	206853058	206853059	rs6755560	2e-06	QT interval (interaction)
chr2	208713875	208713876	rs13383928	2e-06	Lung cancer-asbestos exposure interaction
chr2	214323894	214323895	rs16851771	2e-06	Obesity-related traits
chr2	217865141	217865142	rs3791950	2e-06	Height
chr22	17965346	17965347	rs1978968	2e-06	Presence of antiphospholipid antibodies
chr2	218219809	218219810	rs6733051	2e-06	Obesity-related traits
chr2	218265790	218265791	rs1079204	2e-06	Smooth-surface caries 
chr2	218976168	218976169	rs359965	2e-06	Immune response to smallpox vaccine (IL-6)
chr22	20241018	20241019	rs701428	2e-06	Obesity-related traits
chr22	21585385	21585386	rs5754217	2e-06	Systemic lupus erythematosus
chr22	26007632	26007633	rs1001021	2e-06	Schizophrenia, bipolar disorder and depression (combined)
chr2	227532849	227532850	rs6731443	2e-06	Airway hyperresponsiveness
chr2	227805858	227805859	rs10175070	2e-06	Eating disorders (purging via substances) 
chr22	29451732	29451733	rs13053817	2e-06	Carotid atherosclerosis in HIV infection
chr22	31042374	31042375	rs111383589	2e-06	Bulimia nervosa
chr2	233944047	233944048	rs12472151	2e-06	Alcohol consumption
chr22	34427836	34427837	rs1034394	2e-06	Major depressive disorder
chr22	36812104	36812105	rs739031	2e-06	Obesity-related traits
chr22	36813251	36813252	rs4820255	2e-06	Sexual dysfunction (female)
chr22	37066895	37066896	rs855791	2e-06	Mean corpuscular hemoglobin
chr22	37155566	37155567	rs743777	2e-06	Rheumatoid arthritis
chr22	37155566	37155567	rs743777	2e-06	Type 1 diabetes autoantibodies
chr2	42758662	42758663	rs6719977	2e-06	Hyperactive-impulsive symptoms
chr2	46323629	46323630	rs7582701	2e-06	IgG glycosylation
chr2	46415109	46415110	rs2346177	2e-06	Coronary heart disease
chr2	47002699	47002700	rs17540621	2e-06	Response to statin therapy
chr3	133691816	133691817	rs1867504	2e-06	Iron status biomarkers
chr3	13695500	13695501	rs4450798	2e-06	Bipolar disorder (mood-incongruent)
chr3	139185142	139185143	rs7638110	2e-06	Obesity and blood pressure
chr3	140456517	140456518	rs11708189	2e-06	Sudden cardiac arrest
chr3	141359345	141359346	rs9857275	2e-06	Prion diseases
chr3	143286186	143286187	rs17636071	2e-06	Response to cholinesterase inhibitors in Alzheimer's disease
chr3	153004185	153004186	rs9883654	2e-06	Response to antineoplastic agents
chr3	153760633	153760634	rs6794649	2e-06	IgG glycosylation
chr3	15606496	15606497	rs7651039	2e-06	Coronary heart disease
chr3	156908301	156908302	rs12638253	2e-06	Multiple sclerosis (severity)
chr3	158735489	158735490	rs7646881	2e-06	Tetralogy of Fallot
chr3	161102735	161102736	rs4557202	2e-06	Menarche (age at onset)
chr3	162351220	162351221	rs12493123	2e-06	Reading and spelling
chr3	167631049	167631050	rs7627289	2e-06	Visceral fat
chr3	169759717	169759718	rs12638862	2e-06	Multiple myeloma (IgH translocation)
chr3	171840553	171840554	rs6794092	2e-06	Body mass index
chr3	174476452	174476453	rs10936797	2e-06	Obesity-related traits
chr3	176704863	176704864	rs1490075	2e-06	Response to amphetamines
chr3	179064232	179064233	rs4955793	2e-06	Post-traumatic stress disorder (asjusted for relatedness)
chr3	185228060	185228061	rs7374394	2e-06	Cognitive performance
chr3	187008098	187008099	rs11710456	2e-06	IgG glycosylation
chr3	187014890	187014891	rs17776120	2e-06	IgG glycosylation
chr3	187014890	187014891	rs17776120	2e-06	IgG glycosylation
chr3	187988098	187988099	rs184662298	2e-06	Serum dimethylarginine levels (symmetric)
chr3	188724691	188724692	rs9290877	2e-06	IgE levels 
chr3	190279606	190279607	rs16865258	2e-06	Response to antipsychotic treatment in schizophrenia (working memory)
chr3	194004540	194004541	rs724767	2e-06	Estradiol plasma levels (breast cancer)
chr3	20179219	20179220	rs6767049	2e-06	Temperament (bipolar disorder)
chr3	21913705	21913706	rs11719664	2e-06	Attention deficit hyperactivity disorder
chr3	132974743	132974744	rs2369955	2e-06	Alcoholism (heaviness of drinking)
chr3	23052082	23052083	rs9310709	2e-06	Chronic kidney disease and serum creatinine levels
chr3	130793	130794	rs6795349	2e-06	Response to antidepressant treatment
chr3	126185321	126185322	rs1107366	2e-06	Metabolite levels
chr2	47658336	47658337	rs2969775	2e-06	Alzheimer's disease
chr2	58974893	58974894	rs111835151	2e-06	Serum dimethylarginine levels (asymmetric/symetric ratio)
chr2	64122067	64122068	rs7604693	2e-06	Kawasaki disease
chr2	65531390	65531391	rs3845817	2e-06	Bipolar disorder
chr2	663482	663483	rs12999373	2e-06	Uric acid levels
chr2	79405220	79405221	rs2100290	2e-06	Alcohol consumption
chr2	84482090	84482091	rs7581224	2e-06	Coronary artery calcification
chr2	86633507	86633508	rs114532231	2e-06	Serum dimethylarginine levels (asymmetric)
chr2	88089018	88089019	rs2919856	2e-06	IgG glycosylation
chr2	96745211	96745212	rs6746896	2e-06	Bipolar disorder
chr3	1004353	1004354	rs6764623	2e-06	Venous thromboembolism
chr3	100872080	100872081	rs9833094	2e-06	Acute urticaria and angiodema (non-steroidal anti-inflammatory drug-induced)
chr3	102129716	102129717	rs10212363	2e-06	Waist-to-hip circumference ratio (interaction)
chr3	102484200	102484201	rs2063640	2e-06	Sensory disturbances after bilateral sagittal split ramus osteotomy
chr3	103588797	103588798	rs7612581	2e-06	Economic and political preferences (environmentalism)
chr3	103678924	103678925	rs12485744	2e-06	Economic and political preferences (environmentalism)
chr3	103684669	103684670	rs10511217	2e-06	Economic and political preferences (environmentalism)
chr3	109743552	109743553	rs1164064	2e-06	Corneal astigmatism
chr3	112550439	112550440	rs2705520	2e-06	Asthma (childhood onset)
chr3	113276226	113276227	rs775227	2e-06	Dental caries
chr3	113571620	113571621	rs13092825	2e-06	Dental caries
chr3	11583939	11583940	rs6802119	2e-06	Metabolite levels (HVA)
chr3	117588719	117588720	rs1875517	2e-06	Waist circumference
chr3	121435345	121435346	rs6800901	2e-06	Multiple myeloma (IgH translocation)
chr3	123284450	123284451	rs13317079	2e-06	Obesity-related traits
chr3	12351625	12351626	rs1801282	2e-06	Type 2 diabetes
chr3	12351625	12351626	rs1801282	2e-06	Type 2 diabetes
chr3	12351625	12351626	rs1801282	2e-06	Type 2 diabetes
chr3	12510307	12510308	rs6766510	2e-06	Prostate cancer (gene x gene interaction)
chr3	130252257	130252258	rs9813712	2e-06	Response to amphetamines
chr5	33636488	33636489	rs6868223	2e-06	Mortality in heart failure
chr8	134626388	134626389	rs733254	2e-06	Height
chr5	35874472	35874473	rs6897932	2e-06	Multiple sclerosis
chr8	117077273	117077274	rs7815720	2e-06	Intraocular pressure
chr8	11786405	11786406	rs804292	2e-06	Alcohol dependence
chr8	117897020	117897021	rs7459527	2e-06	Obesity-related traits
chr8	121896263	121896264	rs7844723	2e-06	Hemostatic factors and hematological phenotypes
chr8	121950975	121950976	rs907121	2e-06	Weight
chr8	122693915	122693916	rs4871297	2e-06	Type 1 diabetes nephropathy
chr8	128059914	128059915	rs2648875	2e-06	End-stage renal disease
chr8	130080166	130080167	rs6984045	2e-06	Multiple sclerosis
chr8	130605603	130605604	rs16904316	2e-06	Methotrexate phramacokinetics (acute lymphoblastic leukemia)
chr8	130799786	130799787	rs263238	2e-06	Total ventricular volume
chr8	133184605	133184606	rs4527850	2e-06	Type 2 diabetes
chr8	133656433	133656434	rs2860223	2e-06	Schizophrenia (negative symptoms)
chr2	191099906	191099907	rs7574865	2e-06	Rheumatoid arthritis
chr8	116544031	116544032	rs4876662	2e-06	Aortic root size
chr8	135700893	135700894	rs4243849	2e-06	Non-alcoholic fatty liver disease histology (other)
chr8	138243674	138243675	rs4909764	2e-06	Inflammatory biomarkers
chr8	141150964	141150965	rs3816063	2e-06	Obesity-related traits
chr8	142040309	142040310	rs4917300	2e-06	Amyotrophic lateral sclerosis
chr8	14256306	14256307	rs9886428	2e-06	IgG glycosylation
chr8	14256306	14256307	rs9886428	2e-06	IgG glycosylation
chr8	143720285	143720286	rs35925379	2e-06	Obesity-related traits
chr8	14692646	14692647	rs11989868	2e-06	Obesity-related traits
chr8	15808102	15808103	rs240657	2e-06	Intelligence
chr8	17286320	17286321	rs3793427	2e-06	Tonometry
chr8	18376072	18376073	rs7006687	2e-06	QT interval (interaction)
chr8	19793649	19793650	rs920590	2e-06	Acute lymphoblastic leukemia (childhood)
chr8	19929379	19929380	rs7816032	2e-06	Hyperactive-impulsive symptoms
chr8	20389246	20389247	rs17412740	2e-06	Preeclampsia
chr8	137893052	137893053	rs9657451	2e-06	Cognitive performance
chr8	114566077	114566078	rs7014900	2e-06	Post-traumatic stress disorder (asjusted for relatedness)
chr8	114108797	114108798	rs9942773	2e-06	Periodontal microbiota
chr8	112061866	112061867	rs1996720	2e-06	Temperament
chr7	30043404	30043405	rs10488084	2e-06	Estradiol levels
chr7	35361836	35361837	rs2392362	2e-06	Information processing speed
chr7	37037248	37037249	rs10488031	2e-06	QT interval
chr7	41703695	41703696	rs2877098	2e-06	Migraine without aura
chr7	41997237	41997238	rs846271	2e-06	IgG glycosylation
chr7	42225079	42225080	rs4724100	2e-06	Allergic rhinitis
chr7	46236129	46236130	rs1486139	2e-06	Select biomarker traits
chr7	5840745	5840746	rs308097	2e-06	IgG glycosylation
chr7	71008018	71008019	rs1525293	2e-06	Major depressive disorder
chr7	71551173	71551174	rs4719147	2e-06	Response to angiotensin II receptor blocker therapy
chr7	71923864	71923865	rs11766496	2e-06	Airflow obstruction 
chr7	72286330	72286331	rs12699131	2e-06	Schizophrenia
chr7	73573023	73573024	rs2286276	2e-06	Hypertriglyceridemia
chr7	77010553	77010554	rs6955651	2e-06	Body mass index
chr7	77967494	77967495	rs848452	2e-06	Dental caries
chr7	7809280	7809281	rs10259199	2e-06	Obesity-related traits
chr7	7825119	7825120	rs12702661	2e-06	Obesity-related traits
chr7	7825119	7825120	rs12702661	2e-06	Obesity-related traits
chr7	80970040	80970041	rs4236644	2e-06	Bilirubin levels
chr7	88967070	88967071	rs6959888	2e-06	Anorexia nervosa
chr7	94084208	94084209	rs10487245	2e-06	Obesity-related traits
chr7	94424687	94424688	rs441051	2e-06	Mean forced vital capacity from 2 exams
chr7	95301078	95301079	rs854555	2e-06	Response to TNF antagonist treatment
chr7	96001883	96001884	rs1488515	2e-06	Obesity-related traits
chr7	96785742	96785743	rs12669076	2e-06	Immunoglobulin A 
chr7	97793613	97793614	rs1229542	2e-06	Myopia (pathological)
chr7	97991378	97991379	rs13438327	2e-06	Sudden cardiac arrest
chr8	101215694	101215695	rs1264202	2e-06	Response to antipsychotic treatment in schizophrenia (reasoning)
chr8	102627712	102627713	rs6998277	2e-06	Migraine
chr8	20479061	20479062	rs10111661	2e-06	Dental caries
chr8	29137504	29137505	rs13251954	2e-06	Metabolite levels (HVA-5-HIAA Factor score)
chr8	34269429	34269430	rs6990255	2e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr8	36601935	36601936	rs7814403	2e-06	Obesity-related traits
chr9	123933490	123933491	rs10818894	2e-06	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU)
chr9	124565483	124565484	rs10114038	2e-06	Follicule stimulating hormone
chr9	128214277	128214278	rs2502731	2e-06	Attention deficit hyperactivity disorder
chr9	14064741	14064742	rs7039300	2e-06	Alzheimer's disease biomarkers
chr9	14898162	14898163	rs10961780	2e-06	Height
chr9	15309929	15309930	rs2245641	2e-06	Bipolar disorder
chr9	16000236	16000237	rs79156074	2e-06	Metabolite levels (5-HIAA/ MHPG Ratio)
chr9	17979579	17979580	rs1755271	2e-06	Obesity-related traits
chr9	2203937	2203938	rs6475600	2e-06	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU)
chr9	22842202	22842203	rs12554707	2e-06	Response to amphetamines
chr9	25449123	25449124	rs12552736	2e-06	RR interval (heart rate)
chr9	26694889	26694890	rs13294589	2e-06	Gallbladder cancer
chr9	26935997	26935998	rs7045881	2e-06	Schizophrenia
chr9	28359783	28359784	rs16912725	2e-06	Obesity-related traits
chr9	32914590	32914591	rs12377462	2e-06	Vitamin B12 levels
chr9	33125805	33125806	rs10758189	2e-06	IgG glycosylation
chr9	34071542	34071543	rs7871764	2e-06	Height
chr9	38675467	38675468	rs7039377	2e-06	Obesity-related traits
chr9	7195407	7195408	rs2820914	2e-06	Obesity-related traits
chr9	73542783	73542784	rs12555078	2e-06	Obesity-related traits
chr9	8012417	8012418	rs12682851	2e-06	Prostate cancer (gene x gene interaction)
chr9	82696231	82696232	rs668853	2e-06	Ulcerative colitis
chr9	84126545	84126546	rs13288553	2e-06	Molar-incisor hypomineralization
chr9	86912542	86912543	rs11141597	2e-06	Asthma (childhood onset)
chr9	90419248	90419249	rs883924	2e-06	Hepatitis C induced liver fibrosis
chr9	92797222	92797223	rs10992471	2e-06	Visceral adipose tissue/subcutaneous adipose tissue ratio
chr9	94096128	94096129	rs6479527	2e-06	Esophageal adenocarcinoma
chr9	96776855	96776856	rs10816533	2e-06	Height
chr9	98490943	98490944	rs2779551	2e-06	Post-traumatic stress disorder (asjusted for relatedness)
chr9	121787362	121787363	rs10985375	2e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr7	28392856	28392857	rs7799265	2e-06	Airflow obstruction 
chr9	118268750	118268751	rs876347	2e-06	Response to antipsychotic therapy (extrapyramidal side effects)
chr9	115440436	115440437	rs9409154	2e-06	Visceral adipose tissue adjusted for BMI
chr8	37094395	37094396	rs2407103	2e-06	Insulin resistance/response
chr8	3970615	3970616	rs1529316	2e-06	Multiple sclerosis
chr8	40196085	40196086	rs10958605	2e-06	Parkinson's disease (motor and cognition)
chr8	50472426	50472427	rs13272236	2e-06	IgG glycosylation
chr8	53497647	53497648	rs10958369	2e-06	Response to antineoplastic agents
chr8	53642639	53642640	rs11773966	2e-06	Bipolar disorder (mood-incongruent)
chr8	5516017	5516018	rs62494762	2e-06	Metabolite levels (HVA/MHPG ratio)
chr8	566478	566479	rs722782	2e-06	Age-related macular degeneration (GA)
chr8	59266161	59266162	rs10089517	2e-06	Visceral adipose tissue/subcutaneous adipose tissue ratio
chr8	60091337	60091338	rs6995588	2e-06	Cardiac hypertrophy
chr8	60963484	60963485	rs10104895	2e-06	Pulmonary function decline
chr8	67887141	67887142	rs6990917	2e-06	Adverse response to lamotrigine and phenytoin
chr8	70632512	70632513	rs13272623	2e-06	IgG glycosylation
chr8	70632512	70632513	rs13272623	2e-06	IgG glycosylation
chr8	71535182	71535183	rs13263568	2e-06	Migraine
chr8	73361955	73361956	rs12679254	2e-06	Inattentive symptoms
chr8	77768113	77768114	rs3864663	2e-06	Sudden cardiac arrest
chr8	91348167	91348168	rs921231	2e-06	Fat distribution (HIV)
chr8	96251189	96251190	rs7814319	2e-06	Lung function (forced vital capacity)
chr8	97142212	97142213	rs17737465	2e-06	Sleep duration
chr8	98009780	98009781	rs2444896	2e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel)
chr9	100214258	100214259	rs10989019	2e-06	Preeclampsia
chr9	101775327	101775328	rs4523321	2e-06	Obesity-related traits
chr9	105869668	105869669	rs9969729	2e-06	Alzheimer's disease (late onset)
chr9	106204806	106204807	rs2090409	2e-06	Pubertal anthropometrics
chr9	106914611	106914612	rs1858231	2e-06	Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule)
chr9	109091965	109091966	rs523340	2e-06	Information processing speed
chr9	111541398	111541399	rs7873730	2e-06	Menarche (age at onset)
chr9	115288134	115288135	rs7853844	2e-06	Pancreatic cancer
chr9	117077048	117077049	rs16934284	2e-06	Obesity-related traits
chr7	27936943	27936944	rs10486567	2e-06	Prostate cancer
chr7	25094229	25094230	rs39453	2e-06	Colorectal cancer
chr7	23440847	23440848	rs11763760	2e-06	IgG glycosylation
chr6	116222683	116222684	rs1204798	2e-06	Dental caries
chr6	117522908	117522909	rs210648	2e-06	Economic and political preferences
chr6	118467488	118467489	rs11752626	2e-06	QT interval
chr6	12048593	12048594	rs1570989	2e-06	Alcohol and nictotine co-dependence
chr6	121018032	121018033	rs1343075	2e-06	Cognitive performance
chr6	121581722	121581723	rs4541776	2e-06	Protein quantitative trait loci
chr6	12196979	12196980	rs1040994	2e-06	Response to antipsychotic treatment
chr6	124084009	124084010	rs13204086	2e-06	Periodontitis (Mean PAL)
chr6	125701455	125701456	rs1777220	2e-06	Endometrial cancer
chr6	127070698	127070699	rs972275	2e-06	Iron status biomarkers
chr6	128171036	128171037	rs10499138	2e-06	Hearing impairment
chr6	12903724	12903725	rs9349379	2e-06	Migraine - clinic-based
chr6	130228917	130228918	rs10447419	2e-06	PR interval
chr6	131034723	131034724	rs6908917	2e-06	IgG glycosylation
chr6	132321977	132321978	rs589756	2e-06	Obesity-related traits
chr6	132321977	132321978	rs589756	2e-06	Obesity-related traits
chr6	132825656	132825657	rs7769051	2e-06	Type 2 diabetes nephropathy
chr6	134223594	134223595	rs1763500	2e-06	Body mass index (interaction)
chr6	135173736	135173737	rs9321490	2e-06	Multiple sclerosis
chr6	136183897	136183898	rs560713	2e-06	Intraocular pressure
chr6	137874928	137874929	rs2230926	2e-06	Rheumatoid arthritis
chr6	138104894	138104895	rs1556640	2e-06	Bulimia nervosa
chr6	139952509	139952510	rs642858	2e-06	Type 2 diabetes
chr6	14596133	14596134	rs6914079	2e-06	Cognitive test performance
chr6	14597750	14597751	rs9296949	2e-06	Metabolite levels (HVA/MHPG ratio)
chr6	147438397	147438398	rs9403856	2e-06	IgG glycosylation
chr6	150781693	150781694	rs75253868	2e-06	Alzheimer's disease (cognitive decline)
chr6	150804114	150804115	rs10046456	2e-06	Obesity-related traits
chr6	151586612	151586613	rs4869742	2e-06	Chronic myeloid leukemia
chr6	114270821	114270822	rs9488363	2e-06	Optic disc size (rim)
chr6	151974477	151974478	rs9383951	2e-06	Breast cancer
chr6	113158132	113158133	rs2473967	2e-06	Asthma (childhood onset)
chr6	104959786	104959787	rs314277	2e-06	Digit length ratio
chr5	39058253	39058254	rs13160161	2e-06	Obesity-related traits
chr5	40134674	40134675	rs2548145	2e-06	Alcoholism (alcohol use disorder factor score)
chr5	51940491	51940492	rs16879308	2e-06	Migraine without aura
chr5	52724561	52724562	rs830884	2e-06	Response to platinum-based agents
chr5	52899202	52899203	rs1551943	2e-06	Pulmonary function
chr5	54084724	54084725	rs273218	2e-06	Migraine
chr5	56027066	56027067	rs17348299	2e-06	IgG glycosylation
chr5	56027066	56027067	rs17348299	2e-06	IgG glycosylation
chr5	56028974	56028975	rs16884711	2e-06	IgG glycosylation
chr5	57514310	57514311	rs6892553	2e-06	Orthostatic hypotension
chr5	58025126	58025127	rs1844437	2e-06	Hoarding
chr5	59546947	59546948	rs702543	2e-06	Neuroticism
chr5	59801096	59801097	rs2963826	2e-06	Obesity-related traits
chr5	67156346	67156347	rs1697137	2e-06	Carotid atherosclerosis in HIV infection
chr5	68011633	68011634	rs10067755	2e-06	Waist-to-hip circumference ratio (interaction)
chr5	72114528	72114529	rs2199161	2e-06	Attention deficit hyperactivity disorder
chr5	73136208	73136209	rs17663555	2e-06	Renal function-related traits (BUN)
chr5	77222616	77222617	rs4704397	2e-06	Hypothyroidism
chr5	78335029	78335030	rs6881634	2e-06	Hippocampal atrophy
chr5	82643498	82643499	rs1032757	2e-06	Eosinophilic esophagitis (pediatric)
chr5	83664914	83664915	rs3846635	2e-06	Visceral fat
chr5	85287950	85287951	rs12153606	2e-06	Blood trace element (Cu levels)
chr5	87136799	87136800	rs2032794	2e-06	Personality dimensions
chr5	92818871	92818872	rs17668565	2e-06	Obesity-related traits
chr5	93128709	93128710	rs12519773	2e-06	Migraine
chr5	96092979	96092980	rs7734985	2e-06	IgG glycosylation
chr6	100509467	100509468	rs240768	2e-06	Economic and political preferences (immigration/crime)
chr6	101907991	101907992	rs12207601	2e-06	Biochemical measures
chr6	104145991	104145992	rs9377619	2e-06	Bipolar disorder and schizophrenia
chr6	106451350	106451351	rs1417352	2e-06	Select biomarker traits
chr5	35799891	35799892	rs3822735	2e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin)
chr6	160038158	160038159	rs78797168	2e-06	Periodontitis (CDC/AAP)
chr6	165521932	165521933	rs519595	2e-06	Response to fenofibrate
chr6	90212020	90212021	rs370409	2e-06	Graves' disease
chr6	93004086	93004087	rs652520	2e-06	Chronic obstructive pulmonary disease-related biomarkers
chr6	99335002	99335003	rs17059400	2e-06	Illicit drug use
chr7	101238121	101238122	rs3757458	2e-06	QT interval
chr7	102166570	102166571	rs365836	2e-06	Response to antidepressants
chr7	103985429	103985430	rs4298437	2e-06	Alzheimer's disease
chr7	105902133	105902134	rs13438712	2e-06	Obesity-related traits
chr7	107951752	107951753	rs2072209	2e-06	IgG glycosylation
chr7	108908602	108908603	rs848353	2e-06	Smoking behavior
chr7	110407413	110407414	rs6968385	2e-06	Attention deficit hyperactivity disorder (time to onset)
chr7	112454687	112454688	rs6956741	2e-06	Amyotrophic lateral sclerosis (age of onset)
chr7	114101049	114101050	rs6466479	2e-06	IgG glycosylation
chr7	114101049	114101050	rs6466479	2e-06	IgG glycosylation
chr7	121393066	121393067	rs7776725	2e-06	Biomedical quantitative traits
chr7	129353914	129353915	rs11979476	2e-06	Inflammatory biomarkers
chr7	129716365	129716366	rs9641855	2e-06	Obesity-related traits
chr7	131768905	131768906	rs1106684	2e-06	Body mass index
chr7	132504929	132504930	rs10808265	2e-06	Pulmonary function decline
chr7	140002793	140002794	rs17837497	2e-06	Acute lymphoblastic leukemia (childhood)
chr7	151849503	151849504	rs7795096	2e-06	Bipolar disorder (age of onset and psychomotor symptoms)
chr7	153181247	153181248	rs4285401	2e-06	Nicotine use
chr7	154717613	154717614	rs12666280	2e-06	QT interval
chr7	1846898	1846899	rs6952808	2e-06	Bipolar disorder and schizophrenia
chr7	18760789	18760790	rs11764116	2e-06	Ulcerative colitis
chr7	1881189	1881190	rs10275045	2e-06	Schizophrenia or bipolar disorder
chr7	2001796	2001797	rs1107592	2e-06	Bipolar disorder and schizophrenia
chr7	20047358	20047359	rs6954796	2e-06	Non-word repetition
chr7	20752374	20752375	rs2108258	2e-06	Dental caries
chr7	21703355	21703356	rs368331	2e-06	Total ventricular volume
chr6	88008047	88008048	rs366676	2e-06	Echocardiographic traits
chr6	160402995	160402996	rs2504916	2e-06	Response to hepatitis C treatment
chr6	79823469	79823470	rs1321847	2e-06	Body mass index
chr6	74448549	74448550	rs72960926	2e-06	Metabolite levels (MHPG)
chr6	19443703	19443704	rs16882214	2e-06	Breast cancer
chr6	20109360	20109361	rs2457335	2e-06	Obesity-related traits
chr6	24544738	24544739	rs16889440	2e-06	Radiation response
chr6	26092912	26092913	rs1800562	2e-06	Hematology traits
chr6	26107234	26107235	rs198846	2e-06	Mean corpuscular volume
chr6	28948474	28948475	rs4947339	2e-06	Platelet aggregation
chr6	29734732	29734733	rs2523395	2e-06	Prostate cancer (gene x gene interaction)
chr6	29966385	29966386	rs6935053	2e-06	Ulcerative colitis
chr6	30698891	30698892	rs9468811	2e-06	IgG glycosylation
chr6	30769708	30769709	rs3094117	2e-06	Migraine without aura
chr6	31409809	31409810	rs12175489	2e-06	Visceral adipose tissue adjusted for BMI
chr6	31531825	31531826	rs3853601	2e-06	Atopic dermatitis
chr6	31915901	31915902	rs9267673	2e-06	Hepatocellular carcinoma
chr6	32351859	32351860	rs9268301	2e-06	Obesity-related traits
chr6	32690532	32690533	rs9469220	2e-06	Crohn's disease
chr6	32700558	32700559	rs2647046	2e-06	Lymphoma
chr6	32948073	32948074	rs16871226	2e-06	IgG glycosylation
chr6	32985502	32985503	rs3097645	2e-06	IgG glycosylation
chr6	3307628	3307629	rs9391988	2e-06	Fasting insulin (interaction)
chr6	3307628	3307629	rs9391988	2e-06	Homeostasis model assessment of insulin resistance (interaction)
chr6	39149921	39149922	rs2115200	2e-06	Eating disorders
chr6	39571430	39571431	rs4714261	2e-06	Attention deficit hyperactivity disorder symptoms (interaction)
chr6	396320	396321	rs12203592	2e-06	Sunburns
chr6	40568388	40568389	rs2494938	2e-06	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)
chr6	41336066	41336067	rs9471576	2e-06	Total ventricular volume
chr6	44772211	44772212	rs1342371	2e-06	Obesity-related traits
chr6	66538516	66538517	rs9445732	2e-06	Corneal astigmatism
chr6	70031316	70031317	rs3793039	2e-06	IgG glycosylation
chr6	78846448	78846449	rs16890334	2e-06	Blood pressure measurement (high sodium intervention)
chr2	189778922	189778923	rs7606224	2e-06	Bilirubin levels
chr2	27684605	27684606	rs17006206	2e-06	Alzheimer's disease
chr2	180649001	180649002	rs918959	2e-06	Systemic lupus erythematosus
chr12	2236128	2236129	rs1006737	2e-06	Schizophrenia or bipolar disorder
chr12	2240417	2240418	rs4765905	2e-06	Schizophrenia
chr12	24125886	24125887	rs7979575	2e-06	Response to statin therapy
chr12	24241437	24241438	rs1522232	2e-06	AIDS
chr1	225713303	225713304	rs10915864	2e-06	Obesity-related traits
chr12	2773377	2773378	rs10848704	2e-06	Quantitative traits
chr12	28662858	28662859	rs1606355	2e-06	Metabolite levels (Pyroglutamine)
chr1	228744367	228744368	rs6426514	2e-06	Type 2 diabetes
chr1	237103302	237103303	rs7554607	2e-06	Acute lymphoblastic leukemia (childhood)
chr1	237186437	237186438	rs6683225	2e-06	Obesity-related traits
chr1	237940200	237940201	rs2499604	2e-06	Non-alcoholic fatty liver disease histology (AST)
chr1	238506475	238506476	rs6692700	2e-06	Serum selenium levels
chr12	38859305	38859306	rs11169838	2e-06	IgG glycosylation
chr1	22159377	22159378	rs16826658	2e-06	Endometriosis
chr1	238912413	238912414	rs1915279	2e-06	Treatment response for severe sepsis 
chr12	39960441	39960442	rs11174478	2e-06	Insomnia
chr1	240282295	240282296	rs17672135	2e-06	Coronary heart disease
chr12	41572058	41572059	rs1458175	2e-06	Multiple sclerosis
chr1	241715244	241715245	rs12569163	2e-06	Radiation response
chr1	243779781	243779782	rs4132509	2e-06	RR interval (heart rate)
chr1	244010569	244010570	rs10927101	2e-06	Diabetic retinopathy 
chr12	4414289	4414290	rs10849061	2e-06	Migraine without aura
chr12	46978486	46978487	rs2711721	2e-06	Prostate cancer (gene x gene interaction)
chr1	247051575	247051576	rs4925540 	2e-06	Response to taxane treatment (docetaxel)
chr12	47421188	47421189	rs1881744	2e-06	Metabolite levels (HVA/5-HIAA ratio)
chr1	24866663	24866664	rs3131513	2e-06	Alcohol dependence
chr12	51310049	51310050	rs766903	2e-06	Aging (time to death)
chr12	53160498	53160499	rs2272306	2e-06	Obesity-related traits
chr1	23974358	23974359	rs6667686	2e-06	Obesity-related traits
chr12	21298460	21298461	rs16923647	2e-06	Methotrexate phramacokinetics (acute lymphoblastic leukemia)
chr1	220938437	220938438	rs7542375	2e-06	Obesity-related traits
chr1	220836862	220836863	rs12073837	2e-06	F-cell distribution
chr11	97088524	97088525	rs11224899	2e-06	Formal thought disorder in schizophrenia
chr11	98595537	98595538	rs4237591	2e-06	Non-alcoholic fatty liver disease histology (lobular)
chr1	200991178	200991179	rs2297909	2e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr1	206859405	206859406	rs574773	2e-06	Economic and political preferences
chr1	209553911	209553912	rs12130212	2e-06	Obesity (extreme)
chr1	209815924	209815925	rs642961	2e-06	Orofacial clefts
chr12	102731911	102731912	rs2172873	2e-06	Uterine fibroids
chr12	105065018	105065019	rs10861342	2e-06	IgG glycosylation
chr12	108448085	108448086	rs11113894	2e-06	Obesity-related traits
chr1	210995416	210995417	rs1501550	2e-06	Circulating vasoactive peptide levels 
chr12	111803961	111803962	rs671	2e-06	Triglycerides
chr12	11702689	11702690	rs2187642	2e-06	Height
chr12	120536706	120536707	rs614226	2e-06	Type 1 diabetes nephropathy
chr12	121500381	121500382	rs10849893	2e-06	Fasting glucose-related traits (interaction with BMI)
chr12	122973071	122973072	rs7296418	2e-06	Platelet counts
chr12	123890662	123890663	rs10773046	2e-06	Osteoarthritis (hip)
chr12	124035298	124035299	rs1716403	2e-06	Response to fenofibrate (adiponectin levels)
chr12	127819872	127819873	rs11059374	2e-06	Response to amphetamines
chr12	129162026	129162027	rs12580240	2e-06	IgG glycosylation
chr12	129745861	129745862	rs7979367	2e-06	Illicit drug use
chr12	131378357	131378358	rs7965445	2e-06	Mortality in heart failure
chr12	13634911	13634912	rs2160519	2e-06	Cognitive performance
chr1	214283665	214283666	rs9308433	2e-06	IgG glycosylation
chr1	216542977	216542978	rs12145418	2e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)
chr12	17220804	17220805	rs9971637	2e-06	Amyotrophic lateral sclerosis
chr1	219477790	219477791	rs12022722	2e-06	Visceral adipose tissue/subcutaneous adipose tissue ratio
chr12	19626858	19626859	rs10841287	2e-06	Obesity-related traits
chr12	20605678	20605679	rs11611208	2e-06	Height
chr12	20687904	20687905	rs11045392	2e-06	Response to TNF-alpha inhibitors in rheumatoid arthritis
chr12	53765492	53765493	rs7969151	2e-06	Tanning
chr12	57109991	57109992	rs167769	2e-06	Eosinophilic esophagitis (pediatric)
chr12	60403921	60403922	rs10506410	2e-06	Cardiac hypertrophy
chr12	64858337	64858338	rs939876	2e-06	Cognitive performance
chr1	3734844	3734845	rs10910018	2e-06	Visceral fat
chr13	78807965	78807966	rs9574309	2e-06	IgG glycosylation
chr13	79594868	79594869	rs9601248	2e-06	Major depressive disorder
chr13	80049210	80049211	rs7981942	2e-06	Fasting insulin-related traits (interaction with BMI)
chr13	83556096	83556097	rs6563353	2e-06	Response to citalopram treatment
chr13	84458191	84458192	rs17371334	2e-06	Temperament (bipolar disorder)
chr13	84480130	84480131	rs9546711	2e-06	Coronary heart disease
chr13	86590601	86590602	rs4773460	2e-06	Hippocampal atrophy
chr13	93238416	93238417	rs6492654	2e-06	Tonometry
chr13	94735862	94735863	rs184488877	2e-06	Serum dimethylarginine levels (asymmetric/symetric ratio)
chr13	95222701	95222702	rs1926657	2e-06	Breast cancer
chr13	97364161	97364162	rs9556711	2e-06	Alcoholism (alcohol use disorder factor score)
chr13	98341775	98341776	rs9584805	2e-06	Non-alcoholic fatty liver disease histology (lobular)
chr14	100217854	100217855	rs2766692	2e-06	Electroencephalographic traits in alcoholism
chr14	100785651	100785652	rs1884537	2e-06	Optic disc size (disc)
chr14	104042738	104042739	rs11622475	2e-06	Bipolar disorder
chr14	21257494	21257495	rs17197037	2e-06	Bipolar disorder
chr14	27330970	27330971	rs2877832	2e-06	Diabetes related insulin traits
chr14	28663670	28663671	rs1956388	2e-06	Ulcerative colitis
chr14	28780142	28780143	rs2038256	2e-06	Multiple sclerosis--Brain Glutamate Levels
chr14	30045905	30045906	rs11847697	2e-06	Body mass index
chr14	31624341	31624342	rs7142881	2e-06	Response to iloperidone treatment (QT prolongation)
chr1	43179739	43179740	rs621559	2e-06	Telomere length
chr14	31964651	31964652	rs915071	2e-06	Bipolar disorder and schizophrenia
chr14	33117356	33117357	rs17460823	2e-06	Inflammatory biomarkers
chr14	34665979	34665980	rs7141276	2e-06	Response to anti-TNF treatment in rheumatoid arthritis
chr14	48903597	48903598	rs2352904	2e-06	Cognitive test performance
chr14	48957638	48957639	rs7158872	2e-06	Post-traumatic stress disorder (asjusted for relatedness)
chr14	54185760	54185761	rs1953743	2e-06	Dental caries
chr1	3734844	3734845	rs10910018	2e-06	Visceral fat
chr11	96290049	96290050	rs485842	2e-06	Corneal astigmatism
chr1	3734466	3734467	rs12562437	2e-06	Visceral adipose tissue/subcutaneous adipose tissue ratio
chr13	69449552	69449553	rs352236	2e-06	Obesity-related traits
chr12	65448477	65448478	rs1494508	2e-06	Temperament
chr12	69661129	69661130	rs1373453	2e-06	Orofacial clefts
chr12	71183320	71183321	rs1495377	2e-06	Creutzfeldt-Jakob disease (variant)
chr1	27405146	27405147	rs11548323	2e-06	Estradiol plasma levels (breast cancer)
chr1	27935897	27935898	rs4409675	2e-06	Corneal astigmatism
chr12	82591099	82591100	rs12425131	2e-06	Immune response to smallpox vaccine (IL-6)
chr12	84793731	84793732	rs4761097	2e-06	Behavioural disinhibition (generation interaction)
chr12	91911493	91911494	rs17019682	2e-06	Heart failure
chr12	9228262	9228263	rs10771431	2e-06	Breast size
chr12	95302643	95302644	rs3596	2e-06	Endometriosis
chr12	99104408	99104409	rs10860392	2e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr12	99567570	99567571	rs2373011	2e-06	Waist circumference
chr13	103275656	103275657	rs1529276	2e-06	Prostate cancer
chr13	103317140	103317141	rs4771450	2e-06	Uric acid levels
chr13	108728377	108728378	rs10492418	2e-06	Presence of antiphospholipid antibodies
chr13	111128712	111128713	rs12853515	2e-06	Homeostasis model assessment of insulin resistance (interaction)
chr13	111921289	111921290	rs9577381	2e-06	Axial length
chr13	112182340	112182341	rs9324268	2e-06	Renal transplant outcome
chr13	21340974	21340975	rs17356983	2e-06	Obesity-related traits
chr13	24406810	24406811	rs1816752	2e-06	Obesity-related traits
chr13	28857200	28857201	rs1161463	2e-06	Attention deficit hyperactivity disorder symptoms (interaction)
chr13	29884599	29884600	rs9314986	2e-06	Biliary atresia
chr1	3363688	3363689	rs6658356	2e-06	Response to statin therapy
chr13	39776774	39776775	rs7993214	2e-06	Psoriasis
chr13	40233345	40233346	rs10492681	2e-06	Select biomarker traits
chr13	54059237	54059238	rs9596905	2e-06	DNA methylation (variation)
chr13	55410860	55410861	rs2315885	2e-06	Blood pressure
chr13	59379331	59379332	rs12585963	2e-06	Breast size
chr13	69345266	69345267	rs2593525	2e-06	Obesity-related traits
chr13	71600220	71600221	rs9919839	2e-06	Adverse response to lamotrigine and phenytoin
chr11	96258964	96258965	rs11021499	2e-06	Waist-to-hip circumference ratio (interaction)
chr1	196073531	196073532	rs7512769	2e-06	Bipolar disorder and schizophrenia
chr1	195945142	195945143	rs7517337	2e-06	Total ventricular volume
chr10	6081531	6081532	rs12251307	2e-06	Type 1 diabetes
chr10	61876771	61876772	rs2675609	2e-06	Serum total protein level
chr2	181143072	181143073	rs1018326	2e-06	Ankylosing spondylitis
chr10	62685803	62685804	rs10761659	2e-06	Crohn's disease
chr10	63267097	63267098	rs10995485	2e-06	Response to fenofibrate
chr10	63267849	63267850	rs10761731	2e-06	Platelet counts
chr10	6351297	6351298	rs4750316	2e-06	Rheumatoid arthritis
chr10	6904300	6904301	rs6602217	2e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr10	71362187	71362188	rs1084004	2e-06	Obesity-related traits
chr10	76571559	76571560	rs2637266	2e-06	Pulmonary function
chr10	7694940	7694941	rs11255291	2e-06	Ovarian reserve
chr10	79276249	79276250	rs1250540	2e-06	Multiple sclerosis
chr10	82059368	82059369	rs4933824	2e-06	Response to iloperidone treatment (QT prolongation)
chr10	85934534	85934535	rs76765968	2e-06	Anorexia nervosa
chr10	90202912	90202913	rs2250245	2e-06	Economic and political preferences (feminism/equality)
chr10	9526946	9526947	rs17515642	2e-06	IgG glycosylation
chr10	96375747	96375748	rs10786284	2e-06	Attention deficit hyperactivity disorder
chr10	97148975	97148976	rs7072055	2e-06	IgG glycosylation
chr10	98886423	98886424	rs11189853	2e-06	Migraine without aura
chr10	99530543	99530544	rs6584283	2e-06	Ulcerative colitis
chr10	99605555	99605556	rs11190179	2e-06	&beta;2-Glycoprotein I (&beta;2-GPI) plasma levels
chr1	101086369	101086370	rs17410015	2e-06	Response to antipsychotic treatment
chr1	104056318	104056319	rs3934285	2e-06	Obesity-related traits
chr1	104056318	104056319	rs3934285	2e-06	Obesity-related traits
chr1	104056318	104056319	rs3934285	2e-06	Obesity-related traits
chr1	104310115	104310116	rs10881542	2e-06	Glaucoma (primary open-angle)
chr1	105887664	105887665	rs11184708	2e-06	Waist-to-hip circumference ratio (interaction)
chr1	110102704	110102705	rs17025426	2e-06	Visceral adipose tissue/subcutaneous adipose tissue ratio
chr11	102138548	102138549	rs11225148	2e-06	Pubertal anthropometrics
chr10	58444841	58444842	rs7085387	2e-06	Migraine without aura
chr11	103076735	103076736	rs7947821	2e-06	Tuberculosis
chr10	53535113	53535114	rs583012	2e-06	Select biomarker traits
chr10	48901177	48901178	rs3849150	2e-06	Subclinical atherosclerosis traits (other)
chr10	100306427	100306428	rs17112901	2e-06	Obesity-related traits
chr10	100496439	100496440	rs9420790	2e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr10	111282334	111282335	rs10885122	2e-06	Fasting glucose-related traits
chr10	112442767	112442768	rs12355831	2e-06	Migraine
chr10	113996370	113996371	rs82625	2e-06	Gaucher disease severity
chr10	115753076	115753077	rs10490919	2e-06	Information processing speed
chr10	119206826	119206827	rs1397615	2e-06	Obesity-related traits
chr10	120283976	120283977	rs11199254	2e-06	IgG glycosylation
chr10	121579460	121579461	rs1078806	2e-06	Breast cancer
chr10	121865674	121865675	rs10510102	2e-06	Breast cancer
chr10	122406098	122406099	rs6585827	2e-06	Height
chr10	125447268	125447269	rs989507	2e-06	Obesity-related traits
chr10	126579070	126579071	rs11245052	2e-06	Metabolite levels (MHPG)
chr10	128584973	128584974	rs193189882	2e-06	Serum dimethylarginine levels (asymmetric)
chr10	13321045	13321046	rs10508459	2e-06	IgG glycosylation
chr10	1634335	1634336	rs6560749	2e-06	Quantitative traits
chr10	16592299	16592300	rs7068341	2e-06	Migraine
chr10	16706610	16706611	rs7916663	2e-06	Obesity-related traits
chr10	20610678	20610679	rs2359536	2e-06	Peripheral artery disease
chr10	23014323	23014324	rs1054052	2e-06	IgG glycosylation
chr10	28094003	28094004	rs927675	2e-06	MRI atrophy measures
chr10	29047919	29047920	rs788076 	2e-06	Palmitoleic acid (16:1n-7) plasma levels
chr10	3112980	3112981	rs7896691	2e-06	Disc degeneration (lumbar)
chr10	32346043	32346044	rs2370759	2e-06	Sexual dysfunction (female)
chr10	3366754	3366755	rs17135159	2e-06	Reading and spelling
chr10	36596992	36596993	rs1360573	2e-06	Periodontal microbiota
chr10	43260305	43260306	rs28461806	2e-06	Obesity-related traits
chr10	44665660	44665661	rs1480597	2e-06	Parkinson's disease
chr10	48527517	48527518	rs10776612	2e-06	Conduct disorder (case status)
chr10	52815235	52815236	rs6480975	2e-06	Age-related macular degeneration
chr14	54409465	54409466	rs4251631	2e-06	Dental caries
chr11	103109864	103109865	rs12283022	2e-06	Tuberculosis
chr11	114750746	114750747	rs1712790	2e-06	Urinary albumin excretion
chr11	46357891	46357892	rs11038871	2e-06	Immunoglobulin A 
chr1	147089016	147089017	rs11239930	2e-06	AIDS progression
chr1	150989392	150989393	rs1722784	2e-06	Melanoma
chr1	152345684	152345685	rs3120667	2e-06	Eating disorders
chr11	5666793	5666794	rs11820502	2e-06	IgG glycosylation
chr1	15744514	15744515	rs59905655	2e-06	Obesity-related traits
chr11	59866019	59866020	rs526934	2e-06	Folate pathway vitamin levels
chr1	160452125	160452126	rs16832015	2e-06	Cognitive performance
chr1	160546517	160546518	rs6427528	2e-06	Response to anti-TNF treatment in rheumatoid arthritis
chr11	65376420	65376421	rs34400381	2e-06	Serum dimethylarginine levels (asymmetric/symetric ratio)
chr1	165862411	165862412	rs4657482	2e-06	Testicular germ cell tumor
chr1	167439432	167439433	rs840016	2e-06	Rheumatoid arthritis
chr1	169165888	169165889	rs16861990	2e-06	D-dimer levels
chr11	69419725	69419726	rs4980785	2e-06	Renal cell carcinoma
chr11	69642524	69642525	rs1352075	2e-06	Multiple myeloma (hyperdiploidy)
chr1	170159466	170159467	rs495524	2e-06	Methotrexate phramacokinetics (acute lymphoblastic leukemia)
chr1	171292053	171292054	rs6660565	2e-06	Sudden cardiac arrest
chr1	172741859	172741860	rs859637	2e-06	Celiac disease
chr1	17967992	17967993	rs16861326	2e-06	Erectile dysfunction and prostate cancer treatment
chr1	185044869	185044870	rs3753573	2e-06	Obesity-related traits
chr11	86344858	86344859	rs6592284	2e-06	Cognitive performance
chr11	86477109	86477110	rs1870323	2e-06	Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule)
chr1	186663184	186663185	rs10911902	2e-06	Schizophrenia
chr1	18705777	18705778	rs2236824	2e-06	Response to amphetamines
chr11	88086258	88086259	rs1386330	2e-06	Multiple sclerosis (age of onset)
chr11	89277877	89277878	rs1393350	2e-06	Skin sensitivity to sun
chr11	93187235	93187236	rs12296063	2e-06	Obesity-related traits
chr11	94398972	94398973	rs3758785	2e-06	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy)
chr11	94934798	94934799	rs10831284	2e-06	Attention deficit hyperactivity disorder and conduct disorder
chr11	45925912	45925913	rs10838532	2e-06	Axial length
chr11	11206826	11206827	rs2722769	2e-06	Type 2 diabetes
chr11	4495345	4495346	rs10160399	2e-06	Obesity-related traits
chr11	42852451	42852452	rs4129601	2e-06	Methotrexate phramacokinetics (acute lymphoblastic leukemia)
chr11	116736720	116736721	rs1558861	2e-06	LDL cholesterol
chr11	117103212	117103213	rs12269901	2e-06	Coronary heart disease
chr11	118371279	118371280	rs502514	2e-06	Fat distribution (HIV)
chr11	119364693	119364694	rs2195525	2e-06	Urate levels
chr11	12138113	12138114	rs1994318	2e-06	PR interval
chr11	124146785	124146786	rs4936894	2e-06	Aging (time to death)
chr11	125300742	125300743	rs1426153	2e-06	Alcohol and nictotine co-dependence
chr11	125371149	125371150	rs12273350	2e-06	Creutzfeldt-Jakob disease (variant)
chr11	125407597	125407598	rs7112365	2e-06	Obesity-related traits
chr11	126737684	126737685	rs7114000	2e-06	Menarche (age at onset)
chr11	127240287	127240288	rs2514895	2e-06	IgG glycosylation
chr11	131455351	131455352	rs11601906	2e-06	Obesity-related traits
chr11	134612571	134612572	rs1944866	2e-06	Myopia (pathological)
chr1	113901971	113901972	rs12079716	2e-06	Obesity-related traits
chr1	114064741	114064742	rs79079833	2e-06	Obesity-related traits
chr11	16018628	16018629	rs16932455	2e-06	Capecitabine sensitivity
chr1	118274105	118274106	rs7527203	2e-06	Obesity-related traits
chr11	19030324	19030325	rs7111562	2e-06	IgG glycosylation
chr11	22808210	22808211	rs7111546	2e-06	Dialysis-related mortality
chr11	2464889	2464890	rs16928297	2e-06	QT interval
chr11	24828019	24828020	rs10500991	2e-06	Iron status biomarkers
chr11	2731378	2731379	rs231906	2e-06	QT interval
chr11	27987915	27987916	rs1568889	2e-06	Bipolar disorder
chr11	3238578	3238579	rs11026091	2e-06	Multiple sclerosis
chr11	35517720	35517721	rs650950	2e-06	Bronchopulmonary dysplasia
chr11	37849430	37849431	rs16930685	2e-06	Cutaneous nevi
chr11	38257399	38257400	rs5004866	2e-06	Metabolite levels (MHPG)
chr11	41831113	41831114	rs1484948	2e-06	RR interval (heart rate)
chr11	44356605	44356606	rs11037965	2e-06	Blood pressure measurement (high sodium intervention)
chr14	54881399	54881400	rs3783637	2e-06	Rheumatoid arthritis
chr10	61935288	61935289	rs6479779	2e-06	IgG glycosylation
chr14	56058850	56058851	rs398652	2e-06	Telomere length
chr19	31667557	31667558	rs16966122	2e-06	Narcolepsy with cataplexy
chr19	32426548	32426549	rs2111504	2e-06	Bipolar disorder
chr19	38697471	38697472	rs11083475	2e-06	Heart rate
chr19	39738768	39738769	rs12611334	2e-06	Schizophrenia
chr1	94067457	94067458	rs1931575 	2e-06	Palmitoleic acid (16:1n-7) plasma levels
chr19	42016955	42016956	rs8099939	2e-06	Bipolar disorder
chr19	44110054	44110055	rs2061333	2e-06	Alzheimer's disease
chr19	44738849	44738850	rs2927438	2e-06	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined)
chr19	44919688	44919689	rs4420638	2e-06	Quantitative traits
chr19	45192479	45192480	rs2159324	2e-06	Quantitative traits
chr19	45692497	45692498	rs7245708	2e-06	Subcutaneous adipose tissue
chr19	47072458	47072459	rs3745618	2e-06	Obesity-related traits
chr19	47845105	47845106	rs11668505	2e-06	Lung function (forced vital capacity)
chr19	29588696	29588697	rs10403021	2e-06	Diabetic retinopathy 
chr19	48024324	48024325	rs3936340	2e-06	Intelligence
chr19	48711212	48711213	rs281380	2e-06	Multiple sclerosis
chr19	50916289	50916290	rs1701930	2e-06	Obesity-related traits
chr19	50927339	50927340	rs7245858	2e-06	Alzheimer's disease (cognitive decline)
chr1	95226753	95226754	rs1414896	2e-06	Non-alcoholic fatty liver disease histology (AST)
chr1	95680411	95680412	rs6693882	2e-06	Pain
chr19	6080470	6080471	rs11880706	2e-06	Bipolar disorder and schizophrenia
chr19	7223836	7223837	rs4804416	2e-06	Thyroid hormone levels
chr1	98920736	98920737	rs1571500	2e-06	Dental caries
chr20	10202868	10202869	rs6039763	2e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide)
chr20	17848635	17848636	rs2745851	2e-06	IgG glycosylation
chr20	18098486	18098487	rs17725255	2e-06	Anorexia nervosa
chr20	18905093	18905094	rs742731	2e-06	Fasting insulin (interaction)
chr20	2594722	2594723	rs6050469	2e-06	Obesity-related traits
chr19	48702914	48702915	rs516246	2e-06	Obesity-related traits
chr19	22332448	22332449	rs1975174	2e-06	Telomere length
chr1	92088725	92088726	rs34856868	2e-06	Obesity-related traits
chr19	1811603	1811604	rs7250872	2e-06	Bipolar disorder
chr17	80763486	80763487	rs7215564	2e-06	Myopia (pathological)
chr17	81244913	81244914	rs2659005	2e-06	IgG glycosylation
chr1	78711182	78711183	rs4650376	2e-06	IgG glycosylation
chr1	79043423	79043424	rs6687262	2e-06	IgG glycosylation
chr1	79534962	79534963	rs3000140	2e-06	Obesity-related traits
chr18	10321349	10321350	rs206626	2e-06	Metabolite levels (Pyroglutamine)
chr18	25813139	25813140	rs7231041	2e-06	Obesity-related traits
chr1	82589115	82589116	rs10874322 	2e-06	Response to taxane treatment (docetaxel)
chr18	26034738	26034739	rs12960119	2e-06	Rhegmatogenous retinal detachment
chr18	28479147	28479148	rs4131805	2e-06	Hip geometry
chr18	42357543	42357544	rs9304270	2e-06	Obesity-related traits
chr18	42361000	42361001	rs346452	2e-06	Periodontitis (PAL4Q3)
chr18	42522675	42522676	rs1346987	2e-06	Economic and political preferences (immigration/crime)
chr18	43900561	43900562	rs1380836	2e-06	Obesity-related traits
chr18	4539084	4539085	rs7228133	2e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs)
chr1	84760615	84760616	rs1750491	2e-06	Dental caries
chr1	84845508	84845509	rs1983853	2e-06	Type 1 diabetes
chr18	48810330	48810331	rs7227892	2e-06	Migraine with aura
chr18	48927092	48927093	rs4939827	2e-06	Colorectal cancer
chr18	60205755	60205756	rs12955983	2e-06	Urate levels
chr18	70486383	70486384	rs11663206	2e-06	Response to antipsychotic treatment
chr18	71712153	71712154	rs2887004	2e-06	IgG glycosylation
chr18	74211281	74211282	rs9951925	2e-06	Chronic obstructive pulmonary disease-related biomarkers
chr18	75185205	75185206	rs9948784	2e-06	IgG glycosylation
chr18	75824755	75824756	rs9956878	2e-06	Obesity-related traits
chr18	76776323	76776324	rs2406342	2e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin)
chr18	77926066	77926067	rs12455580	2e-06	IgG glycosylation
chr1	90074205	90074206	rs2813746	2e-06	Brain structure (hippocampal volume)
chr19	12580370	12580371	rs7247513	2e-06	Bipolar disorder
chr20	35176750	35176751	rs867186	2e-06	Hemostatic factors and hematological phenotypes
chr20	35509523	35509524	rs2236164	2e-06	Height
chr20	37137933	37137934	rs8115854	2e-06	Hippocampal atrophy
chr20	38349232	38349233	rs11536940	2e-06	Periodontitis (DPAL)
chr21	25630064	25630065	rs17001239	2e-06	Cognitive performance
chr2	127225068	127225069	rs7567389	2e-06	Self-rated health
chr21	27372036	27372037	rs1452093	2e-06	Dialysis-related mortality
chr2	127638591	127638592	rs78022502	2e-06	Alzheimer's disease (cognitive decline)
chr21	28768698	28768699	rs2832077	2e-06	Cognitive test performance
chr2	128785192	128785193	rs11690256	2e-06	Serum dimethylarginine levels (symmetric)
chr21	32008726	32008727	rs2833607	2e-06	Vitiligo
chr2	136258420	136258421	rs4452212	2e-06	Telomere length
chr21	36437078	36437079	rs9984974	2e-06	Myopia (pathological)
chr21	39008322	39008323	rs2836823	2e-06	Nicotine dependence
chr2	139869161	139869162	rs16842994	2e-06	Methotrexate phramacokinetics (acute lymphoblastic leukemia)
chr2	141038050	141038051	rs10210358	2e-06	Erectile dysfunction and prostate cancer treatment
chr21	41139990	41139991	rs2837960	2e-06	Rheumatoid arthritis
chr21	41421863	41421864	rs459482	2e-06	IgG glycosylation
chr2	149840633	149840634	rs11889862	2e-06	Menopause (age at onset)
chr2	154214053	154214054	rs958672	2e-06	Aging traits
chr2	156696347	156696348	rs7601713	2e-06	QT interval
chr2	15821474	15821475	rs7586898	2e-06	Hair morphology
chr2	160900617	160900618	rs10208407	2e-06	Obesity-related traits
chr2	167785459	167785460	rs1004368	2e-06	Obesity-related traits
chr2	168906637	168906638	rs560887	2e-06	Fasting plasma glucose
chr2	170400086	170400087	rs7561268	2e-06	Obesity-related traits
chr2	172628349	172628350	rs836589	2e-06	Erectile dysfunction
chr2	173640195	173640196	rs13028485	2e-06	Multiple myeloma (IgH translocation)
chr2	177044866	177044867	rs1529093	2e-06	Non-alcoholic fatty liver disease histology (other)
chr2	178777247	178777248	rs12476289	2e-06	QT interval
chr2	180497651	180497652	rs16867321	2e-06	Obesity
chr2	18053179	18053180	rs16984239	2e-06	Amyotrophic lateral sclerosis
chr14	55866794	55866795	rs7350721	2e-06	Body mass index (interaction)
chr21	25454201	25454202	rs8127977	2e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs)
chr17	80086943	80086944	rs1467979	2e-06	IgG glycosylation
chr2	12500614	12500615	rs1534422	2e-06	Type 1 diabetes
chr2	119755556	119755557	rs13401620	2e-06	Breast size
chr20	40849892	40849893	rs6102185	2e-06	IgG glycosylation
chr20	43362960	43362961	rs2010809	2e-06	Smooth-surface caries 
chr20	4406486	4406487	rs586446	2e-06	IgG glycosylation
chr20	4631230	4631231	rs6052699	2e-06	Platelet aggregation
chr20	46831683	46831684	rs6066084	2e-06	Quantitative traits
chr20	47579860	47579861	rs6125048	2e-06	Response to treatment for acute lymphoblastic leukemia
chr20	48460485	48460486	rs910191	2e-06	Attention deficit hyperactivity disorder (combined symptoms)
chr20	48460485	48460486	rs910191	2e-06	Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms)
chr20	48726521	48726522	rs6063312	2e-06	Tonometry
chr20	48763273	48763274	rs2426087	2e-06	Narcolepsy with cataplexy
chr20	57454547	57454548	rs328506	2e-06	Type 2 diabetes
chr20	57615577	57615578	rs2073145	2e-06	Hippocampal atrophy
chr20	59176061	59176062	rs6015450	2e-06	Blood pressure
chr20	5968887	5968888	rs4815879	2e-06	Preeclampsia
chr20	6054581	6054582	rs2326679	2e-06	Menopause (age at onset)
chr20	61668354	61668355	rs944260	2e-06	Sudden cardiac arrest
chr20	61806742	61806743	rs4925295	2e-06	&beta;2-Glycoprotein I (&beta;2-GPI) plasma levels
chr20	6629229	6629230	rs6107853	2e-06	Body mass index
chr20	8856123	8856124	rs6056209	2e-06	Cognitive performance
chr2	100219271	100219272	rs10865035	2e-06	Rheumatoid arthritis
chr2	103153779	103153780	rs6735786	2e-06	Bone mineral density (hip)
chr2	10763285	10763286	rs1198872	2e-06	Cardiac Troponin-T levels
chr21	10510445	10510446	rs240444	2e-06	Bipolar disorder and schizophrenia
chr21	10540505	10540506	rs10439884	2e-06	Celiac disease
chr2	11080435	11080436	rs6739054	2e-06	Cognitive performance
chr2	111712577	111712578	rs11122895	2e-06	Allergic sensitization
chr2	113132795	113132796	rs4252023	2e-06	Obesity-related traits
chr2	114223389	114223390	rs3105491	2e-06	Systolic blood pressure in sickle cell anemia
chr2	115483609	115483610	rs1375144	2e-06	Bipolar disorder
chr21	20512989	20512990	rs2826340	2e-06	Attention deficit hyperactivity disorder and conduct disorder
chr17	78874498	78874499	rs2009196	2e-06	Periodontitis (CDC/AAP)
chr21	40845028	40845029	rs2837857	2e-06	Tuberculosis
chr17	72830264	72830265	rs12943829	2e-06	Visceral adipose tissue adjusted for BMI
chr15	60608763	60608764	rs980000	2e-06	Menarche (age at onset)
chr15	60645202	60645203	rs339978	2e-06	Menarche (age at onset)
chr15	60871999	60872000	rs1902618	2e-06	Pulmonary function decline
chr15	61547903	61547904	rs4775413	2e-06	Schizophrenia
chr15	67410568	67410569	rs7359257	2e-06	Menarche (age at onset)
chr15	69054605	69054606	rs311904	2e-06	Obesity-related traits
chr15	69054605	69054606	rs311904	2e-06	Obesity-related traits
chr15	69105685	69105686	rs1392635	2e-06	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy
chr15	69703004	69703005	rs17374222	2e-06	Rheumatoid arthritis
chr15	71282459	71282460	rs9806183	2e-06	Periodontitis (PAL4Q3)
chr1	57160258	57160259	rs17541203	2e-06	Pubertal anthropometrics
chr15	71877124	71877125	rs12050794	2e-06	Metabolite levels (HVA/MHPG ratio)
chr1	57854155	57854156	rs985795	2e-06	Bulimia nervosa
chr15	78981703	78981704	rs3743200	2e-06	RR interval (heart rate)
chr15	79241029	79241030	rs4779031	2e-06	IgG glycosylation
chr15	84644013	84644014	rs34069323	2e-06	Periodontitis (CDC/AAP)
chr15	85524074	85524075	rs6496044	2e-06	Interstitial lung disease 
chr15	86117488	86117489	rs12914656	2e-06	Fasting insulin (interaction)
chr15	86117488	86117489	rs12914656	2e-06	Homeostasis model assessment of insulin resistance (interaction)
chr15	86441008	86441009	rs16977195	2e-06	Schizophrenia
chr15	86510614	86510615	rs2011905	2e-06	Cytomegalovirus antibody response
chr15	91902642	91902643	rs3924426	2e-06	Response to iloperidone treatment (QT prolongation)
chr1	59296795	59296796	rs835367	2e-06	Obesity-related traits
chr15	96459422	96459423	rs11637980	2e-06	Prostate cancer (gene x gene interaction)
chr1	60593586	60593587	rs2989476	2e-06	Bipolar disorder
chr16	11128380	11128381	rs78394940	2e-06	Obesity-related traits
chr16	11293102	11293103	rs117096873	2e-06	Bulimia nervosa
chr16	13160098	13160099	rs153091	2e-06	Response to antipsychotic treatment
chr16	13563027	13563028	rs2903308	2e-06	Response to citalopram treatment
chr15	58438439	58438440	rs17301739	2e-06	Alzheimer's disease (cognitive decline)
chr16	13951541	13951542	rs4781563	2e-06	Bilirubin levels
chr15	58343383	58343384	rs4775031	2e-06	Cognitive performance
chr15	52480825	52480826	rs2222656	2e-06	Metabolite levels (Pyroglutamine)
chr14	60216711	60216712	rs216518	2e-06	Allergic rhinitis
chr17	77948567	77948568	rs16970672	2e-06	Alzheimer's disease
chr14	62710425	62710426	rs869834	2e-06	Subcutaneous adipose tissue
chr14	65291923	65291924	rs7159888	2e-06	IgG glycosylation
chr14	65308976	65308977	rs11847263	2e-06	IgG glycosylation
chr14	71520347	71520348	rs11158907	2e-06	Response to alcohol consumption (flushing response)
chr1	47632733	47632734	rs2506991	2e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide)
chr14	80939577	80939578	rs12587252 	2e-06	Palmitoleic acid (16:1n-7) plasma levels
chr14	84308864	84308865	rs11159647	2e-06	Alzheimer's disease
chr14	87274680	87274681	rs1756650	2e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel)
chr14	89831930	89831931	rs8021963	2e-06	Metabolite levels (HVA/MHPG ratio)
chr14	95544251	95544252	rs7120	2e-06	Obesity-related traits
chr14	98033120	98033121	rs10144042	2e-06	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy
chr14	98374105	98374106	rs1459148	2e-06	Response to antipsychotic therapy (extrapyramidal side effects)
chr1	51393569	51393570	rs6673480	2e-06	IgE grass sensitization
chr15	24888838	24888839	rs2030062	2e-06	Obesity-related traits
chr15	26727938	26727939	rs8043440	2e-06	Cognitive performance
chr15	28947613	28947614	rs17680945	2e-06	Temperament
chr15	31171174	31171175	rs7169523	2e-06	Myasthenia gravis 
chr15	32758221	32758222	rs1258763	2e-06	Orofacial clefts
chr15	36001403	36001404	rs4923705	2e-06	Attention deficit hyperactivity disorder
chr15	39746231	39746232	rs8033957	2e-06	Obesity-related traits
chr15	40042374	40042375	rs2412475	2e-06	Obesity-related traits
chr15	40121914	40121915	rs8023845	2e-06	Chronic lymphocytic leukemia
chr1	54641345	54641346	rs1368882	2e-06	Non-substance related behavioral disinhibition
chr15	48700699	48700700	rs2725544	2e-06	Insomnia
chr15	48900593	48900594	rs8023445	2e-06	Major depressive disorder
chr15	50581146	50581147	rs2414059	2e-06	QT interval
chr15	51677470	51677471	rs17525472	2e-06	Asthma
chr15	52911103	52911104	rs2414208	2e-06	Obesity-related traits
chr16	17645834	17645835	rs12445126	2e-06	Corneal astigmatism
chr14	92170368	92170369	rs1009170	2e-06	Dialysis-related mortality
chr16	20339908	20339909	rs11859916	2e-06	Femoral neck bone geometry
chr17	13159477	13159478	rs9900808	2e-06	Cannabis use (initiation)
chr17	14986607	14986608	rs8066099	2e-06	Obesity-related traits
chr1	71605445	71605446	rs10493485	2e-06	Hemostatic factors and hematological phenotypes
chr17	1730809	1730810	rs12150338	2e-06	Calcium levels
chr17	3284717	3284718	rs2005290	2e-06	Cocaine dependence
chr17	33410402	33410403	rs1354492	2e-06	vWF and FVIII levels
chr17	34645709	34645710	rs4990638	2e-06	Personality dimensions
chr17	35516492	35516493	rs8070473	2e-06	Depression (quantitative trait)
chr17	36949011	36949012	rs2306658	2e-06	Obesity-related traits
chr17	37538239	37538240	rs2074409	2e-06	Response to angiotensin II receptor blocker therapy
chr17	37738048	37738049	rs4430796	2e-06	Type 2 diabetes
chr17	37741164	37741165	rs7501939	2e-06	Prostate cancer
chr17	39176709	39176710	rs626657	2e-06	IgG glycosylation
chr17	39884509	39884510	rs2872507	2e-06	Type 1 diabetes autoantibodies
chr17	44960840	44960841	rs1007190	2e-06	DNA methylation (variation)
chr17	45135595	45135596	rs2291447	2e-06	Economic and political preferences
chr17	48279757	48279758	rs2084881	2e-06	Ovarian cancer
chr17	48643202	48643203	rs2326017	2e-06	Body mass index (non-asthmatics)
chr1	75448140	75448141	rs1857353	2e-06	MRI atrophy measures
chr17	56046611	56046612	rs2060070	2e-06	IgG glycosylation
chr17	56046611	56046612	rs2060070	2e-06	IgG glycosylation
chr17	56352793	56352794	rs12449568	2e-06	Height
chr17	57031372	57031373	rs6503782	2e-06	Age-related macular degeneration
chr17	57933598	57933599	rs8074980	2e-06	Multiple sclerosis--Brain Glutamate Levels
chr1	76011521	76011522	rs12122440	2e-06	Pubertal anthropometrics
chr17	70882345	70882346	rs1015657	2e-06	Formal thought disorder in schizophrenia
chr17	7215002	7215003	rs507506	2e-06	Adiponectin levels
chr16	20115651	20115652	rs12919130	2e-06	Attention deficit hyperactivity disorder (inattention symptoms)
chr17	71493931	71493932	rs9907236	2e-06	Coronary artery calcification
chr17	11439290	11439291	rs1877644	2e-06	Obesity-related traits
chr17	11346901	11346902	rs8076431	2e-06	IgG glycosylation
chr17	56125998	56125999	rs8065311	2e-06	Cannabis dependence
chr17	10127772	10127773	rs12150284	2e-06	Intraocular pressure
chr17	11197347	11197348	rs8076220	2e-06	Obesity-related traits
chr16	29874125	29874126	rs4787483	2e-06	Anthropometric traits
chr16	23629145	23629146	rs249954	2e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr1	63125457	63125458	rs10493340	2e-06	Blood pressure
chr16	31322914	31322915	rs11150610	2e-06	Systemic lupus erythematosus
chr16	49108594	49108595	rs16946931	2e-06	Social autistic-like traits
chr16	27423605	27423606	rs8057551	2e-06	Bone mineral density
chr16	51576035	51576036	rs2030114	2e-06	Blood pressure measurement (high sodium and potassium intervention)
chr16	52878386	52878387	rs1344484	2e-06	Bipolar disorder
chr1	65813441	65813442	rs4384209	2e-06	Economic and political preferences (feminism/equality)
chr16	6098028	6098029	rs4786816	2e-06	Obesity-related traits
chr16	6106324	6106325	rs7403856	2e-06	Obesity-related traits
chr16	62764947	62764948	rs2962462	2e-06	Relative hand skill in reading disability
chr16	68349143	68349144	rs7197653	2e-06	Magnesium levels
chr16	71619733	71619734	rs2334880	2e-06	Malaria
chr16	4953072	4953073	rs34924084	2e-06	Metabolite levels (HVA/MHPG ratio)
chr16	86451524	86451525	rs11644988	2e-06	Corneal astigmatism
chr16	7177120	7177121	rs9302841	2e-06	Response to antipsychotic therapy (extrapyramidal side effects)
chr16	9305866	9305867	rs631208	2e-06	IgE grass sensitization
chr16	89404837	89404838	rs2086824	2e-06	Multiple myeloma (IgH translocation)
chr16	9650237	9650238	rs17550532	2e-06	Sudden cardiac arrest
chr16	85985026	85985027	rs2280381	2e-06	Rheumatoid arthritis
chr16	84013109	84013110	rs11864146	2e-06	Non-alcoholic fatty liver disease histology (other)
chr16	8279324	8279325	rs2034588	2e-06	Response to antidepressant treatment
chr1	70421415	70421416	rs672203	2e-06	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU)
chr16	82783985	82783986	rs12386026	2e-06	Tuberculosis
chr16	82753447	82753448	rs8056064	2e-06	Multiple myeloma (IgH translocation)
chr16	77295743	77295744	rs7192208	2e-06	White matter integrity
chr16	76812368	76812369	rs113716969	2e-06	Serum dimethylarginine levels (asymmetric/symetric ratio)
chr16	72975124	72975125	rs7199343	2e-06	Kawasaki disease
chr4	189720015	189720016	rs11132733	3e-06	Testosterone levels
chr4	186336421	186336422	rs13148903	3e-06	Response to statin therapy
chr4	179746493	179746494	rs17090640	3e-06	Multiple sclerosis
chr4	173626005	173626006	rs4129566	3e-06	Cocaine dependence
chr4	168609106	168609107	rs17054392	3e-06	Response to iloperidone treatment (QT prolongation)
chr4	154733268	154733269	rs727153	3e-06	Alzheimer's disease
chr4	167218228	167218229	rs9312517	3e-06	Obesity-related traits
chr4	160107664	160107665	rs17261688	3e-06	DNA methylation (variation)
chr4	146438978	146438979	rs191493117	3e-06	Serum dimethylarginine levels (asymmetric/symetric ratio)
chr4	148400193	148400194	rs1490453	3e-06	Biochemical measures
chr4	173626005	173626006	rs4129566	3e-06	Cocaine dependence
chr4	6696038	6696039	rs3822262	3e-06	Obesity-related traits
chr4	4702286	4702287	rs4476553	3e-06	Response to amphetamines
chr4	34923441	34923442	rs1317830	3e-06	Body mass index (non-asthmatics)
chr4	35981488	35981489	rs6834483	3e-06	Obesity-related traits
chr4	43535582	43535583	rs13130255	3e-06	Anticoagulant levels
chr4	5219810	5219811	rs2008242	3e-06	Electrocardiographic conduction measures
chr4	5928305	5928306	rs4333127	3e-06	Blood trace element (Zn levels)
chr4	61587490	61587491	rs2172802	3e-06	Partial epilepsies
chr4	63027559	63027560	rs145379083	3e-06	Bulimia nervosa
chr4	64408121	64408122	rs6836944	3e-06	Axial length
chr4	66491735	66491736	rs17730929	3e-06	Colorectal cancer
chr4	68301952	68301953	rs939207	3e-06	Obesity-related traits
chr4	21475366	21475367	rs358592	3e-06	Suicidal ideation
chr4	124344157	124344158	rs2125000	3e-06	Major depressive disorder
chr3	74578551	74578552	rs13073838	3e-06	Economic and political preferences
chr4	117171980	117171981	rs10433903	3e-06	Obesity (extreme)
chr3	29234154	29234155	rs4680719	3e-06	Metabolite levels (HVA)
chr3	28887368	28887369	rs2221154	3e-06	Alzheimer's disease
chr3	29533971	29533972	rs1530057	3e-06	Lung cancer
chr4	7157974	7157975	rs3894944	3e-06	Coronary artery calcification
chr3	29811911	29811912	rs10510628	3e-06	Bone mineral density
chr3	34170673	34170674	rs6781182	3e-06	Visceral adipose tissue adjusted for BMI
chr3	3608554	3608555	rs9837561	3e-06	Response to amphetamines
chr3	53646096	53646097	rs1401492	3e-06	Insulin resistance/response
chr3	55279371	55279372	rs358806	3e-06	Type 2 diabetes
chr3	59943124	59943125	rs931317	3e-06	Myopia (pathological)
chr3	61141531	61141532	rs9877396	3e-06	Bronchopulmonary dysplasia
chr3	6336007	6336008	rs271066	3e-06	Alzheimer's disease (age of onset)
chr3	6439937	6439938	rs17216035	3e-06	Visceral adipose tissue adjusted for BMI
chr3	64941349	64941350	rs704454	3e-06	Alzheimer's disease (age of onset)
chr3	76212668	76212669	rs1516459	3e-06	Eating disorders (purging via substances) 
chr3	76673614	76673615	rs264537	3e-06	Periodontitis (PAL4Q3)
chr3	85453694	85453695	rs13323436	3e-06	Visceral fat
chr3	99677427	99677428	rs13095226	3e-06	Age-related macular degeneration
chr4	109878940	109878941	rs6847149	3e-06	Exercise treadmill test traits
chr4	110043205	110043206	rs10012953	3e-06	Obesity-related traits
chr4	112406921	112406922	rs6838440	3e-06	Epirubicin-induced leukopenia 
chr4	113940143	113940144	rs4460079b	3e-06	Blood pressure measurement (high sodium and potassium intervention)
chr4	11501979	11501980	rs1390096	3e-06	Nonalcoholic fatty liver disease
chr4	11673036	11673037	rs7671189	3e-06	Obesity-related traits
chr4	116928292	116928293	rs2389339	3e-06	IgG glycosylation
chr4	122408206	122408207	rs17388568	3e-06	Type 1 diabetes
chr4	7422023	7422024	rs7694661	3e-06	Obesity-related traits
chr5	56515264	56515265	rs456867	3e-06	Urate levels
chr4	99329261	99329262	rs1789891	3e-06	Conduct disorder (interaction)
chr5	59417853	59417854	rs2547917	3e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine)
chr5	6599108	6599109	rs6876835	3e-06	Visceral fat
chr5	67537428	67537429	rs7717572	3e-06	Prostate cancer (gene x gene interaction)
chr5	6813823	6813824	rs275456	3e-06	Paclitaxel-induced neuropathy
chr5	6834053	6834054	rs11134178	3e-06	Attention deficit hyperactivity disorder
chr5	6879864	6879865	rs275437	3e-06	Obesity-related traits
chr5	79460954	79460955	rs10078095	3e-06	Height
chr5	81359146	81359147	rs4703516	3e-06	Orofacial clefts
chr5	83689919	83689920	rs4466137	3e-06	Prostate cancer
chr5	88792621	88792622	rs770189	3e-06	Tonometry
chr5	94812832	94812833	rs469339	3e-06	Anorexia nervosa
chr5	96151235	96151236	rs4869266	3e-06	IgG glycosylation
chr5	98594261	98594262	rs461409	3e-06	Acute urticaria and angiodema (non-steroidal anti-inflammatory drug-induced)
chr6	103984289	103984290	rs4520040	3e-06	Cardiac hypertrophy
chr6	103997491	103997492	rs9499708	3e-06	Obsessive-compulsive disorder
chr6	105881179	105881180	rs9386485	3e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)
chr6	10921297	10921298	rs190994806	3e-06	Serum dimethylarginine levels (symmetric)
chr6	11617933	11617934	rs479526	3e-06	Reading and spelling
chr6	116765214	116765215	rs654128	3e-06	Telomere length
chr6	117284827	117284828	rs13201929	3e-06	Myopia (pathological)
chr6	117498193	117498194	rs2057314	3e-06	Colorectal cancer
chr6	120777310	120777311	rs2817937	3e-06	Primary tooth development (number of teeth)
chr3	28664272	28664273	rs7617877	3e-06	Parkinson's disease
chr6	122961795	122961796	rs13192613	3e-06	Prostate cancer (gene x gene interaction)
chr6	124629916	124629917	rs504008	3e-06	QRS duration
chr5	56558325	56558326	rs6867983	3e-06	Triglycerides
chr4	91082745	91082746	rs6532271	3e-06	Response to amphetamines
chr5	56028974	56028975	rs16884711	3e-06	IgG glycosylation
chr5	42288490	42288491	rs11748684 	3e-06	Response to taxane treatment (docetaxel)
chr5	10670927	10670928	rs4702718	3e-06	Obesity-related traits
chr5	110161258	110161259	rs4460176	3e-06	Hemostatic factors and hematological phenotypes
chr5	115803050	115803051	rs13174348	3e-06	IgG glycosylation
chr5	115803050	115803051	rs13174348	3e-06	IgG glycosylation
chr5	123783870	123783871	rs11241713	3e-06	Amyotrophic lateral sclerosis
chr5	132386056	132386057	rs7731390	3e-06	IgG glycosylation
chr5	132406535	132406536	rs6596075	3e-06	Crohn's disease
chr5	134985855	134985856	rs299362	3e-06	Bulimia nervosa
chr5	135878987	135878988	rs7734448	3e-06	Obesity-related traits
chr5	13740866	13740867	rs6554809	3e-06	IgE grass sensitization
chr5	140992636	140992637	rs31872	3e-06	Visceral adipose tissue adjusted for BMI
chr5	146941259	146941260	rs1864982	3e-06	Alcohol dependence
chr5	147035652	147035653	rs9325032	3e-06	Cognitive test performance
chr5	151078584	151078585	rs10036748	3e-06	Systemic lupus erythematosus
chr5	157037230	157037231	rs2036402	3e-06	Hypertriglyceridemia
chr5	166530080	166530081	rs2122554	3e-06	Conduct disorder (symptom count)
chr5	174350516	174350517	rs12659144	3e-06	Multiple myeloma (hyperdiploidy)
chr5	175184336	175184337	rs4336372	3e-06	Response to anti-TNF treatment in rheumatoid arthritis
chr5	179605486	179605487	rs6894268	3e-06	Eating disorders
chr5	180367207	180367208	rs10464059	3e-06	Parkinson's disease
chr5	25902232	25902233	rs10038113	3e-06	Autism
chr5	26139028	26139029	rs4701523	3e-06	Visceral fat
chr5	26389152	26389153	rs969088	3e-06	Response to platinum-based chemotherapy in non-small-cell lung cancer
chr5	33879686	33879687	rs1364044	3e-06	Stroke (pediatric)
chr5	38452791	38452792	rs7715172	3e-06	Response to citalopram treatment
chr5	4831487	4831488	rs816475	3e-06	Heart rate
chr3	23101555	23101556	rs4591517	3e-06	Colorectal cancer
chr2	2515740	2515741	rs10199521	3e-06	Diabetic retinopathy 
chr3	191949987	191949988	rs7635839	3e-06	Response to antipsychotic treatment
chr2	229105081	229105082	rs6436839	3e-06	Response to antipsychotic treatment in schizophrenia (reasoning)
chr22	29397651	29397652	rs2267138	3e-06	Myopia (pathological)
chr22	31279198	31279199	rs4141404	3e-06	Paclitaxel-induced neuropathy
chr22	32387916	32387917	rs12530	3e-06	IgG glycosylation
chr2	233274721	233274722	rs2241880	3e-06	Crohn's disease
chr2	23369273	23369274	rs2577704	3e-06	IgG glycosylation
chr22	35381624	35381625	rs2071748	3e-06	Obesity-related traits
chr2	236613198	236613199	rs7607316	3e-06	Airflow obstruction 
chr2	23931321	23931322	rs11674248	3e-06	Obesity-related traits
chr22	40258271	40258272	rs12628051	3e-06	Prostate cancer (gene x gene interaction)
chr2	241073313	241073314	rs6721345	3e-06	Sex hormone-binding globulin levels
chr2	228777705	228777706	rs11679180	3e-06	Endometrial cancer
chr2	241431685	241431686	rs757978	3e-06	Chronic lymphocytic leukemia
chr2	24298896	24298897	rs6707600	3e-06	Response to antipsychotic treatment in schizophrenia (working memory)
chr22	44615880	44615881	rs4823246	3e-06	Economic and political preferences (feminism/equality)
chr22	44787133	44787134	rs16992796	3e-06	Electroencephalographic traits in alcoholism
chr22	47888764	47888765	rs9627183	3e-06	Attention deficit hyperactivity disorder
chr22	48345985	48345986	rs4407	3e-06	Endometrial cancer
chr2	24874774	24874775	rs13407913	3e-06	Body mass index (non-asthmatics)
chr2	25082886	25082887	rs1530016	3e-06	Body mass index (non-asthmatics)
chr2	27519735	27519736	rs780093 	3e-06	Palmitic acid (16:0) plasma levels
chr23	130065836	130065837	rs3788848	3e-06	Dental caries
chr23	153741040	153741041	rs11156606	3e-06	Bipolar disorder and schizophrenia
chr23	22142874	22142875	rs12559632	3e-06	F-cell distribution
chr22	41940167	41940168	rs5758511	3e-06	Birth weight
chr22	27039857	27039858	rs742004	3e-06	Metabolite levels (HVA/MHPG ratio)
chr22	26645318	26645319	rs16982515	3e-06	IgG glycosylation
chr2	226136269	226136270	rs6758183	3e-06	Corneal astigmatism
chr2	163461365	163461366	rs12476047	3e-06	Response to antipsychotic treatment
chr6	131907628	131907629	rs6907728	3e-06	Obesity-related traits
chr2	164893879	164893880	rs13424957	3e-06	Coronary heart disease
chr2	168286524	168286525	rs9917256	3e-06	Parkinson's disease
chr2	170604621	170604622	rs6749331	3e-06	Obesity-related traits
chr2	170876714	170876715	rs4668338	3e-06	Uric acid levels
chr2	175375120	175375121	rs4972755	3e-06	Bipolar disorder and major depressive disorder (combined)
chr2	178383692	178383693	rs7580640	3e-06	QT interval
chr2	180176558	180176559	rs16867225	3e-06	Prostate cancer (gene x gene interaction)
chr2	18062267	18062268	rs4075511	3e-06	Temperament (bipolar disorder)
chr2	181591266	181591267	rs993648	3e-06	Response to iloperidone treatment (QT prolongation)
chr2	181647128	181647129	rs1441147	3e-06	Lung function (forced expiratory volume in 1 second)
chr2	20135947	20135948	rs4666360	3e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel)
chr2	201942472	201942473	rs17385675	3e-06	Response to antipsychotic treatment
chr2	202472277	202472278	rs12468226	3e-06	Urate levels
chr2	203225006	203225007	rs16839626	3e-06	Obesity-related traits
chr2	20488757	20488758	rs13021401	3e-06	Systemic sclerosis
chr2	210704997	210704998	rs2371030	3e-06	Non-small cell lung cancer
chr2	215995826	215995827	rs3770549	3e-06	Blood trace element (Se levels)
chr2	218216573	218216574	rs13403276	3e-06	Obesity-related traits
chr2	219999932	219999933	rs10198756	3e-06	IgG glycosylation
chr2	221936979	221936980	rs824931	3e-06	Body mass index
chr2	223053264	223053265	rs12621643	3e-06	Acute lymphoblastic leukemia (childhood)
chr22	23423077	23423078	rs4822410	3e-06	Pulmonary function decline
chr2	223594964	223594965	rs16864968	3e-06	Response to hepatitis C treatment
chr23	22873959	22873960	rs5925696	3e-06	Erectile dysfunction and prostate cancer treatment
chr3	22129804	22129805	rs6797769	3e-06	IgG glycosylation
chr23	4678096	4678097	rs5916687	3e-06	Amyotrophic lateral sclerosis
chr2	3793829	3793830	rs11677370	3e-06	Type 2 diabetes
chr3	127231282	127231283	rs4234284	3e-06	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel)
chr3	133009058	133009059	rs7617456	3e-06	IgE grass sensitization
chr3	135516515	135516516	rs1502172	3e-06	Visceral adipose tissue adjusted for BMI
chr3	140504951	140504952	rs9862730	3e-06	Fasting insulin (interaction)
chr3	140821875	140821876	rs908821	3e-06	Multiple sclerosis
chr3	143175568	143175569	rs894177	3e-06	Non-alcoholic fatty liver disease histology (other)
chr3	143705979	143705980	rs2800	3e-06	Non-alcoholic fatty liver disease histology (other)
chr3	143785690	143785691	rs2166775	3e-06	Response to angiotensin II receptor blocker therapy
chr3	144621362	144621363	rs800082	3e-06	Smoking behavior
chr3	14489212	14489213	rs9036	3e-06	Cognitive performance
chr3	146914376	146914377	rs12629805	3e-06	Subcutaneous adipose tissue
chr3	122637603	122637604	rs78411303	3e-06	Periodontitis (CDC/AAP)
chr3	147098923	147098924	rs4681346	3e-06	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia
chr3	151862084	151862085	rs6798928	3e-06	Immunoglobulin A 
chr3	15253856	15253857	rs1318937	3e-06	Alcohol dependence
chr3	157119116	157119117	rs7624327	3e-06	Eating disorders
chr3	168968887	168968888	rs16852912	3e-06	Aging (time to event)
chr3	175337969	175337970	rs2042126	3e-06	Sleep duration
chr3	1798008	1798009	rs10510217	3e-06	Total ventricular volume
chr3	187008098	187008099	rs11710456	3e-06	IgG glycosylation
chr3	187014936	187014937	rs3821819	3e-06	IgG glycosylation
chr3	187988098	187988099	rs184662298	3e-06	Serum dimethylarginine levels (asymmetric/symetric ratio)
chr3	188045609	188045610	rs6789987	3e-06	Visceral adipose tissue/subcutaneous adipose tissue ratio
chr3	188703108	188703109	rs1152846	3e-06	Body mass index
chr3	149532801	149532802	rs17787940	3e-06	Preeclampsia
chr3	112779032	112779033	rs1002979	3e-06	Prostate cancer (gene x gene interaction)
chr3	109485565	109485566	rs769554	3e-06	Cardiac hypertrophy
chr3	108302	108303	rs12485321	3e-06	Prostate cancer (gene x gene interaction)
chr23	79393695	79393696	rs1474563	3e-06	Height
chr23	83699481	83699482	rs5968205	3e-06	Depression and alcohol dependence
chr2	39731919	39731920	rs2540226	3e-06	Personality dimensions
chr2	40435405	40435406	rs4629203	3e-06	Obesity-related traits
chr2	41046490	41046491	rs17027130	3e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin)
chr2	46407505	46407506	rs12623288	3e-06	Hair morphology
chr2	58809780	58809781	rs6719884	3e-06	Myasthenia gravis 
chr2	58809780	58809781	rs6719884	3e-06	Myasthenia gravis 
chr2	65635243	65635244	rs1457451	3e-06	Iron status biomarkers
chr2	663482	663483	rs12999373	3e-06	Response to fenofibrate (adiponectin levels)
chr2	68806450	68806451	rs115522963	3e-06	Serum dimethylarginine levels (asymmetric/symetric ratio)
chr2	74018649	74018650	rs6546886	3e-06	Dialysis-related mortality
chr2	74236438	74236439	rs13006863	3e-06	Post-traumatic stress disorder (asjusted for relatedness)
chr2	74847839	74847840	rs681900	3e-06	Femoral neck bone geometry
chr2	78312539	78312540	rs2037723	3e-06	Lung function (forced expiratory volume in 1 second to forced vital capacity ratio)
chr2	79312861	79312862	rs13409348	3e-06	Bipolar disorder
chr2	84123792	84123793	rs1534238	3e-06	Response to antipsychotic treatment
chr2	86133449	86133450	rs2241437	3e-06	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)
chr2	9119468	9119469	rs9636252	3e-06	IgG glycosylation
chr2	9505502	9505503	rs55794209	3e-06	Serum dimethylarginine levels (asymmetric/symetric ratio)
chr2	96747750	96747751	rs2314398	3e-06	Bipolar disorder
chr2	98766428	98766429	rs7578035	3e-06	Bipolar disorder
chr2	98849038	98849039	rs6733011	3e-06	Bipolar disorder
chr3	101693133	101693134	rs112553552	3e-06	Response to amphetamines
chr3	102484200	102484201	rs2063640	3e-06	Type 2 diabetes
chr23	6302432	6302433	rs7885458	3e-06	Biochemical measures
chr6	13215825	13215826	rs4715166	3e-06	Hip geometry
chr8	11786405	11786406	rs804292	3e-06	Nicotine use
chr6	135097879	135097880	rs9399137	3e-06	Hematology traits
chr8	136837767	136837768	rs16906415	3e-06	IgG glycosylation
chr8	138065484	138065485	rs984440	3e-06	Obesity-related traits
chr8	139985032	139985033	rs1870805	3e-06	Obesity-related traits
chr8	141349450	141349451	rs7386474	3e-06	Bipolar disorder and schizophrenia
chr8	14256306	14256307	rs9886428	3e-06	IgG glycosylation
chr8	143611668	143611669	rs2045084	3e-06	Rhegmatogenous retinal detachment
chr8	2003133	2003134	rs13263558	3e-06	Obesity-related traits
chr8	20130191	20130192	rs10503672	3e-06	Amyotrophic lateral sclerosis (age of onset)
chr8	23244106	23244107	rs7463256	3e-06	Attention deficit hyperactivity disorder
chr8	24521227	24521228	rs11781622	3e-06	White matter integrity
chr8	27882899	27882900	rs11774576	3e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin)
chr8	135859495	135859496	rs12680546	3e-06	Amyotrophic lateral sclerosis
chr8	28065870	28065871	rs4732812	3e-06	Suicidal ideation
chr8	29486944	29486945	rs12548021	3e-06	Colorectal cancer
chr8	31176758	31176759	rs11774682	3e-06	IgG glycosylation
chr8	3219436	3219437	rs28455997	3e-06	Periodontitis (CDC/AAP)
chr8	34379473	34379474	rs2609653	3e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr8	37823907	37823908	rs12676965	3e-06	Axial length
chr8	4120607	4120608	rs4875284	3e-06	Serum selenium levels
chr8	5569008	5569009	rs11777345	3e-06	Waist-hip ratio
chr8	56188231	56188232	rs13273123	3e-06	Height
chr8	59633104	59633105	rs4737547	3e-06	Multiple myeloma (IgH translocation)
chr8	71351720	71351721	rs2218488	3e-06	Sleepiness
chr8	72194680	72194681	rs1963982	3e-06	Blood pressure
chr8	29248541	29248542	rs2954793	3e-06	Metabolite levels (HVA)
chr8	134866915	134866916	rs4909801	3e-06	Response to alcohol consumption (flushing response)
chr8	134857732	134857733	rs12541063	3e-06	Blood pressure
chr8	133462833	133462834	rs2736871	3e-06	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia
chr7	91643028	91643029	rs1476442	3e-06	Obesity-related traits
chr7	983091	983092	rs12701220	3e-06	Bronchopulmonary dysplasia
chr8	10129144	10129145	rs1484642	3e-06	Bipolar disorder and schizophrenia
chr8	101583981	101583982	rs6988306	3e-06	Bronchopulmonary dysplasia
chr8	103561560	103561561	rs75686122	3e-06	Cocaine dependence
chr8	10477270	10477271	rs11782819	3e-06	Alzheimer's disease
chr8	105601092	105601093	rs17217757	3e-06	Tuberculosis
chr8	10605295	10605296	rs4841398	3e-06	Obesity-related traits
chr8	107028123	107028124	rs7004587	3e-06	Obesity-related traits
chr8	107269198	107269199	rs6993449	3e-06	IgG glycosylation
chr8	109205036	109205037	rs7823896	3e-06	Myopia (pathological)
chr8	109466592	109466593	rs73313124	3e-06	Obesity-related traits
chr8	117172543	117172544	rs13266634	3e-06	Type 2 diabetes
chr8	11826953	11826954	rs2645424	3e-06	Non-alcoholic fatty liver disease histology (lobular)
chr8	118818440	118818441	rs903614	3e-06	Chronic obstructive pulmonary disease-related biomarkers
chr8	121198649	121198650	rs7819988	3e-06	Periodontitis (CDC/AAP)
chr8	125492483	125492484	rs6987702	3e-06	LDL cholesterol
chr8	125522428	125522429	rs921720	3e-06	Obesity-related traits
chr8	126080637	126080638	rs1906493	3e-06	Crohn's disease
chr8	127175773	127175774	rs2466024	3e-06	Chronic lymphocytic leukemia
chr8	127519891	127519892	rs10090154	3e-06	Prostate cancer
chr8	127907950	127907951	rs16902460	3e-06	Psychosis (atypical)
chr8	131318468	131318469	rs10108033	3e-06	IgG glycosylation
chr8	131341487	131341488	rs4596632	3e-06	Eye color
chr8	133258304	133258305	rs2272651	3e-06	Post-traumatic stress disorder (asjusted for relatedness)
chr8	72451753	72451754	rs2116078	3e-06	Multiple sclerosis (age of onset)
chr7	84281954	84281955	rs488333	3e-06	Prion diseases
chr8	75124208	75124209	rs1531590	3e-06	IgG glycosylation
chr8	82756884	82756885	rs6473383	3e-06	Heart failure
chr9	2551653	2551654	rs12237653	3e-06	Gambling
chr9	27561050	27561051	rs774359	3e-06	Amyotrophic lateral sclerosis
chr9	2777383	2777384	rs10812641	3e-06	Blood trace element (Se levels)
chr9	289060	289061	rs6476030	3e-06	Obesity-related traits
chr9	33128022	33128023	rs10813951	3e-06	IgG glycosylation
chr9	35269821	35269822	rs10121009	3e-06	Parkinson's disease
chr9	4292082	4292083	rs10758593	3e-06	Type 1 diabetes
chr9	5410722	5410723	rs1535454	3e-06	Obesity-related traits
chr9	6486307	6486308	rs16924631	3e-06	Periodontal microbiota
chr9	678836	678837	rs12352279	3e-06	Migraine - clinic-based
chr9	73149648	73149649	rs3758354	3e-06	Schizophrenia, bipolar disorder and depression (combined)
chr9	24111281	24111282	rs2225614	3e-06	Quantitative traits
chr9	75661758	75661759	rs10512049	3e-06	Total ventricular volume
chr9	79274442	79274443	rs2769967	3e-06	Inattentive symptoms
chr9	81400121	81400122	rs10867752	3e-06	Hippocampal atrophy
chr9	81607702	81607703	rs815847	3e-06	Visceral fat
chr9	82520999	82521000	rs7043482	3e-06	Insulin resistance/response
chr9	841151	841152	rs912062	3e-06	Obesity-related traits
chr9	90124948	90124949	rs2081670	3e-06	Protein quantitative trait loci
chr9	93868851	93868852	rs10114408	3e-06	Colorectal cancer
chr9	94552458	94552459	rs16910061	3e-06	Height
chr9	97829180	97829181	rs7045138	3e-06	Thyroid hormone levels
chr9	99356807	99356808	rs12551906	3e-06	Callous-unemotional behaviour
chr2	161029591	161029592	rs2357982	3e-06	Presence of antiphospholipid antibodies
chr9	77705448	77705449	rs4745661	3e-06	IgG glycosylation
chr9	22132076	22132077	rs2383208	3e-06	Type 2 diabetes
chr9	18215281	18215282	rs1944766	3e-06	Fat distribution (HIV)
chr9	17938352	17938353	rs1755289	3e-06	Multiple sclerosis
chr8	8719868	8719869	rs13256369	3e-06	Obesity-related traits
chr8	88981258	88981259	rs10429371	3e-06	Smooth-surface caries 
chr8	89198870	89198871	rs2046315	3e-06	Dental caries
chr8	89329956	89329957	rs4397449	3e-06	Cognitive performance
chr8	9032587	9032588	rs1045529	3e-06	Myopia (pathological)
chr8	93345869	93345870	rs7387468	3e-06	Temperament
chr8	93903874	93903875	rs35820208	3e-06	Response to amphetamines
chr8	9956900	9956901	rs656319	3e-06	Myopia (pathological)
chr9	100046402	100046403	rs7028939	3e-06	Preeclampsia
chr9	104769674	104769675	rs2472476	3e-06	Obesity-related traits
chr9	105664780	105664781	rs1463984	3e-06	Cognitive performance
chr9	109764008	109764009	rs1327796	3e-06	Type 2 diabetes
chr9	110183124	110183125	rs7032940	3e-06	Height
chr9	111531353	111531354	rs10980926	3e-06	Pubertal anthropometrics
chr9	112060840	112060841	rs4979078	3e-06	Venous thromboembolism
chr9	118033711	118033712	rs2416604	3e-06	Obesity-related traits
chr9	119496298	119496299	rs10984561	3e-06	Pulmonary function decline
chr9	12108915	12108916	rs12351590	3e-06	Reading and spelling
chr9	124163827	124163828	rs2807580	3e-06	Cognitive performance
chr9	127345684	127345685	rs4130590	3e-06	Bipolar disorder
chr9	129125836	129125837	rs10988217	3e-06	Hypersomnia (HLA-DQB1*06:02 negative)
chr9	129608080	129608081	rs10988449	3e-06	Response to antidepressant treatment
chr9	13007129	13007130	rs1360517	3e-06	AIDS
chr9	132221379	132221380	rs11243676	3e-06	Systemic lupus erythematosus
chr9	133810891	133810892	rs7021663	3e-06	IgG glycosylation
chr8	80072799	80072800	rs181166265	3e-06	Metabolite levels (HVA/MHPG ratio)
chr6	134398928	134398929	rs9402592	3e-06	Dental caries
chr7	84027483	84027484	rs10235789	3e-06	Iris characteristics
chr7	80629493	80629494	rs10499859	3e-06	Left ventricular mass
chr6	30711850	30711851	rs3094093	3e-06	IgG glycosylation
chr6	30768373	30768374	rs12526186	3e-06	Response to antipsychotic treatment
chr6	30827393	30827394	rs7772131	3e-06	Response to angiotensin II receptor blocker therapy
chr6	31008441	31008442	rs28360974	3e-06	Preeclampsia
chr6	31607498	31607499	rs9348876	3e-06	Crohn's disease
chr6	31876146	31876147	rs2736428	3e-06	Telomere length
chr6	32108721	32108722	rs2269426	3e-06	Eosinophil counts
chr6	32255480	32255481	rs3130320	3e-06	Systemic lupus erythematosus
chr6	32357593	32357594	rs13196329	3e-06	Visceral fat
chr6	32390492	32390493	rs3117099	3e-06	Bipolar disorder and schizophrenia
chr6	32396066	32396067	rs9268480	3e-06	Ulcerative colitis
chr6	30698891	30698892	rs9468811	3e-06	IgG glycosylation
chr6	32443868	32443869	rs7192	3e-06	Non-obstructive azoospermia
chr6	32614111	32614112	rs4530903	3e-06	Lymphoma
chr6	32985502	32985503	rs3097645	3e-06	IgG glycosylation
chr6	33572431	33572432	rs210134	3e-06	Chronic lymphocytic leukemia
chr6	35354985	35354986	rs7744392	3e-06	Cataracts in type 2 diabetes
chr6	40472760	40472761	rs9296335	3e-06	Obesity-related traits
chr6	41682997	41682998	rs2842643	3e-06	Attention deficit hyperactivity disorder
chr6	42527539	42527540	rs16895812	3e-06	Obesity-related traits
chr6	44457062	44457063	rs543844	3e-06	Migraine
chr6	475488	475489	rs12210050	3e-06	Schizophrenia
chr6	51295196	51295197	rs1555967	3e-06	Waist circumference
chr6	51801832	51801833	rs10498792	3e-06	Prostate cancer
chr6	32461865	32461866	rs9268853	3e-06	Ulcerative colitis
chr6	30698891	30698892	rs9468811	3e-06	IgG glycosylation
chr6	29553099	29553100	rs16895057	3e-06	Height
chr6	29384006	29384007	rs9378134	3e-06	Retinopathy in non-diabetics
chr6	135105434	135105435	rs4895441	3e-06	Mean corpuscular hemoglobin concentration
chr6	135105434	135105435	rs4895441	3e-06	Red blood cell traits
chr6	139510042	139510043	rs679582	3e-06	Blood trace element (Se levels)
chr6	139514551	139514552	rs668459	3e-06	Adiponectin levels
chr6	141712588	141712589	rs17071124	3e-06	Sleep quality
chr6	14173196	14173197	rs853356	3e-06	Height
chr6	142432200	142432201	rs1329705	3e-06	Airflow obstruction 
chr6	149113974	149113975	rs7772697	3e-06	Diabetic retinopathy 
chr6	150804114	150804115	rs10046456	3e-06	Obesity-related traits
chr6	150804114	150804115	rs10046456	3e-06	Obesity-related traits
chr6	151592977	151592978	rs3757318	3e-06	Breast cancer
chr6	151759696	151759697	rs60945108	3e-06	Obesity-related traits
chr6	152944074	152944075	rs13218732	3e-06	Migraine
chr6	153756057	153756058	rs1937579	3e-06	Coronary artery calcification
chr6	156688246	156688247	rs9384488	3e-06	Alzheimer's disease biomarkers
chr6	157119915	157119916	rs9478751	3e-06	Uric acid levels
chr6	157620250	157620251	rs2163287	3e-06	Response to antidepressant treatment
chr6	160912904	160912905	rs1247318	3e-06	Aging
chr6	165052861	165052862	rs227458	3e-06	Visceral adipose tissue adjusted for BMI
chr6	167143545	167143546	rs11575088	3e-06	Social autistic-like traits
chr6	168356430	168356431	rs6915443	3e-06	Sexual dimorphism in anthropometric traits
chr6	170110296	170110297	rs10946292	3e-06	Obesity-related traits
chr6	17632829	17632830	rs2274136	3e-06	Obesity-related traits
chr6	24234704	24234705	rs793834	3e-06	Information processing speed
chr6	25812921	25812922	rs1165196	3e-06	Serum uric acid levels
chr6	5260702	5260703	rs2224391	3e-06	Height
chr7	82708542	82708543	rs2371208	3e-06	Aging traits
chr6	566740	566741	rs2476842	3e-06	Dental caries
chr6	65468586	65468587	rs4710520	3e-06	IgG glycosylation
chr7	157297601	157297602	rs2527866	3e-06	Quantitative traits
chr7	158344293	158344294	rs4909189	3e-06	Response to amphetamines
chr7	21544469	21544470	rs2285947	3e-06	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)
chr7	26442183	26442184	rs10951138	3e-06	Visceral adipose tissue/subcutaneous adipose tissue ratio
chr7	29178542	29178543	rs245914	3e-06	Obesity-related traits
chr7	32149927	32149928	rs11975235	3e-06	Presence of antiphospholipid antibodies
chr7	36172139	36172140	rs9648428	3e-06	Obesity-related traits
chr7	37226746	37226747	rs4723619	3e-06	Response to treatment for acute lymphoblastic leukemia
chr7	39081899	39081900	rs10464366	3e-06	IgG glycosylation
chr7	40925527	40925528	rs7789197	3e-06	Prostate cancer (gene x gene interaction)
chr7	41439009	41439010	rs10486715	3e-06	Quantitative traits
chr7	154513712	154513713	rs10260404	3e-06	Amyotrophic lateral sclerosis
chr7	46713892	46713893	rs700750	3e-06	Obesity-related traits
chr7	47740370	47740371	rs7800244	3e-06	Hepatitis C induced liver fibrosis
chr7	50273755	50273756	rs10276619	3e-06	Hippocampal atrophy
chr7	50686981	50686982	rs2282930	3e-06	Bone mineral density
chr7	67594279	67594280	rs10263639	3e-06	Breast cancer
chr7	67723800	67723801	rs7807441	3e-06	Menarche (age at onset)
chr7	72664688	72664689	rs13238203	3e-06	Triglycerides
chr7	73450538	73450539	rs714052	3e-06	Hypertriglyceridemia
chr7	75430049	75430050	rs236670	3e-06	Obesity-related traits
chr7	78413973	78413974	rs17150687	3e-06	Response to antidepressant treatment
chr7	78529154	78529155	rs12666870	3e-06	Obesity-related traits
chr7	78546659	78546660	rs11525066	3e-06	Hippocampal atrophy
chr7	4683902	4683903	rs9791644	3e-06	Lung function (forced vital capacity)
chr7	154513712	154513713	rs10260404	3e-06	Amyotrophic lateral sclerosis
chr7	150972887	150972888	rs3778872	3e-06	QT interval
chr7	150940774	150940775	rs4725982	3e-06	Electrocardiographic traits
chr6	66943385	66943386	rs28631020	3e-06	Bulimia nervosa
chr6	7118756	7118757	rs11755724	3e-06	Multiple sclerosis
chr6	73749013	73749014	rs9447004	3e-06	Calcium levels
chr6	8000883	8000884	rs9328448	3e-06	Coronary artery calcification
chr6	81483391	81483392	rs17530068	3e-06	Breast cancer
chr6	8228708	8228709	rs6929568	3e-06	Coronary artery calcification
chr6	85982221	85982222	rs1577917	3e-06	Response to antipsychotic treatment
chr6	86756773	86756774	rs493187	3e-06	Bipolar disorder and schizophrenia
chr6	89971746	89971747	rs6917758	3e-06	Obesity-related traits
chr7	10110348	10110349	rs7778619	3e-06	Select biomarker traits
chr7	101472712	101472713	rs17135437	3e-06	Response to citalopram treatment
chr7	102878583	102878584	rs17135875	3e-06	Blood pressure measurement (cold pressor test)
chr7	103987588	103987589	rs17157903	3e-06	Multiple sclerosis (age of onset)
chr7	106769005	106769006	rs17398575	3e-06	Carotid intima media thickness
chr7	110407906	110407907	rs4730430	3e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr7	110827164	110827165	rs10279573	3e-06	Cognitive performance
chr7	112519122	112519123	rs5009270	3e-06	Osteoarthritis (hip)
chr7	113009358	113009359	rs6969802	3e-06	IgG glycosylation
chr7	114101049	114101050	rs6466479	3e-06	IgG glycosylation
chr7	12673444	12673445	rs10488226	3e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil)
chr7	131215361	131215362	rs10265216	3e-06	Major depressive disorder (broad)
chr7	132168841	132168842	rs12386622	3e-06	Homeostasis model assessment of beta-cell function (interaction)
chr7	135794824	135794825	rs12707249	3e-06	Obesity-related traits
chr7	14406291	14406292	rs6971925	3e-06	Response to treatment for acute lymphoblastic leukemia
chr7	148005599	148005600	rs2214681	3e-06	Bone mineral density
chr6	62450241	62450242	rs682238	3e-06	Calcium levels
chr2	1554154	1554155	rs10206020	3e-06	IgG glycosylation
chr18	30561721	30561722	rs2729409	3e-06	Protein quantitative trait loci
chr21	41807558	41807559	rs7279297	3e-06	Tanning
chr12	118725273	118725274	rs11069062	3e-06	Obesity-related traits
chr12	121838348	121838349	rs4298948	3e-06	Obesity-related traits
chr12	123091194	123091195	rs1727307	3e-06	Platelet counts
chr12	123600954	123600955	rs786425	3e-06	Pubertal anthropometrics
chr12	128701644	128701645	rs10773568	3e-06	Height
chr1	213682244	213682245	rs17706439	3e-06	RR interval (heart rate)
chr12	13770393	13770394	rs11055612	3e-06	Brain structure (temporal lobe volume)
chr12	13911526	13911527	rs4764039	3e-06	Total ventricular volume
chr12	1747786	1747787	rs12230440	3e-06	Adverse response to lamotrigine and phenytoin
chr12	18355317	18355318	rs11044045	3e-06	Gray matter volume (schizophrenia interaction)
chr1	220741577	220741578	rs337161	3e-06	Response to antipsychotic therapy (extrapyramidal side effects)
chr12	116857527	116857528	rs17429217	3e-06	Alzheimer's disease (age of onset)
chr1	221378196	221378197	rs12733856	3e-06	Mortality in heart failure
chr12	26483452	26483453	rs2306677	3e-06	Amyotrophic lateral sclerosis
chr1	2274141	2274142	rs12045693	3e-06	IgG glycosylation
chr12	29951208	29951209	rs2046383	3e-06	Heart failure
chr1	230159168	230159169	rs2144300	3e-06	Circulating myeloperoxidase levels (serum) 
chr12	32864108	32864109	rs1454933	3e-06	Obesity-related traits
chr12	32864108	32864109	rs1454933	3e-06	Obesity-related traits
chr1	236748756	236748757	rs12048046	3e-06	Periodontitis (CDC/AAP)
chr1	239438668	239438669	rs6677208	3e-06	Platelet counts
chr12	39947282	39947283	rs1005956	3e-06	Sleep quality
chr1	241730783	241730784	rs10926554	3e-06	Illicit drug use
chr12	41778179	41778180	rs871392	3e-06	Biochemical measures
chr12	23486982	23486983	rs2120771	3e-06	Economic and political preferences (feminism/equality)
chr12	114199617	114199618	rs7294372	3e-06	Visceral fat
chr12	111803961	111803962	rs671	3e-06	Intracranial aneurysm
chr12	109403134	109403135	rs9943753	3e-06	HDL cholesterol
chr11	78948099	78948100	rs11826937	3e-06	Retinopathy in non-diabetics
chr1	17918212	17918213	rs6686929	3e-06	Obesity-related traits
chr11	7993229	7993230	rs12420464	3e-06	Depression (quantitative trait)
chr11	831882	831883	rs35694355	3e-06	Obesity-related traits
chr1	183867897	183867898	rs4651156	3e-06	Response to antidepressants
chr11	85453706	85453707	rs10898392	3e-06	Height
chr1	186755870	186755871	rs4140564	3e-06	Knee osteoarthritis
chr1	188414184	188414185	rs12142669	3e-06	Obesity-related traits
chr11	89611856	89611857	rs1488902	3e-06	Amyotrophic lateral sclerosis
chr1	193765769	193765770	rs2025934	3e-06	Subcutaneous adipose tissue
chr1	193952417	193952418	rs606149	3e-06	Major depressive disorder
chr1	194561783	194561784	rs3001167	3e-06	Obesity-related traits
chr11	95689702	95689703	rs1939875	3e-06	Eosinophilic esophagitis (pediatric)
chr11	97703983	97703984	rs11212364	3e-06	Information processing speed
chr11	97811563	97811564	rs2405657	3e-06	Amyotrophic lateral sclerosis
chr1	201915823	201915824	rs2819348	3e-06	Breast size
chr1	204305390	204305391	rs7534537 	3e-06	Palmitoleic acid (16:1n-7) plasma levels
chr1	204814889	204814890	rs7552806	3e-06	Dental caries
chr1	204814889	204814890	rs7552806	3e-06	Dental caries
chr12	101293264	101293265	rs2290720	3e-06	Brain structure (hippocampal volume)
chr12	102571550	102571551	rs7964748	3e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr12	103745255	103745256	rs7306642	3e-06	vWF and FVIII levels
chr12	104424413	104424414	rs11112046	3e-06	Obesity-related traits
chr12	106556916	106556917	rs3891355	3e-06	Cognitive test performance
chr12	108631650	108631651	rs8179116	3e-06	Conduct disorder (symptom count)
chr1	243127339	243127340	rs55716084	3e-06	Bronchopulmonary dysplasia
chr11	77443593	77443594	rs527589	3e-06	Orofacial clefts
chr12	54515359	54515360	rs1629826	3e-06	Obesity-related traits
chr12	5872186	5872187	rs7307889	3e-06	Obesity-related traits
chr13	37188499	37188500	rs2323397 	3e-06	Palmitoleic acid (16:1n-7) plasma levels
chr13	37461051	37461052	rs1590305	3e-06	Hip geometry
chr13	38942489	38942490	rs9315632	3e-06	Metabolic syndrome
chr13	44480954	44480955	rs17065868	3e-06	Antineutrophil cytoplasmic antibody-associated vasculitis 
chr13	46129006	46129007	rs7324845	3e-06	Non-alcoholic fatty liver disease histology (other)
chr13	47813586	47813587	rs8001976	3e-06	Aging (time to event)
chr13	53393955	53393956	rs10507577	3e-06	Select biomarker traits
chr13	61391169	61391170	rs2323266	3e-06	Schizophrenia
chr13	63567779	63567780	rs1000589	3e-06	Pancreatic cancer
chr13	67122012	67122013	rs2875517	3e-06	Dental caries
chr13	73859669	73859670	rs4883955	3e-06	Bronchopulmonary dysplasia
chr13	35777628	35777629	rs7328278	3e-06	Asthma (childhood onset)
chr1	3752791	3752792	rs76597070	3e-06	Obesity-related traits
chr13	78836438	78836439	rs11838918	3e-06	Conduct disorder (case status)
chr13	78976798	78976799	rs7319358	3e-06	Ulcerative colitis
chr1	38255990	38255991	rs11802770	3e-06	Waist-to-hip circumference ratio (interaction)
chr13	84677576	84677577	rs9319064	3e-06	Obesity-related traits
chr13	86116391	86116392	rs7984869	3e-06	Economic and political preferences (fairness)
chr13	90213291	90213292	rs16944141	3e-06	Prostate cancer (gene x gene interaction)
chr13	91080515	91080516	rs61970269	3e-06	Metabolite levels (5-HIAA)
chr13	91363722	91363723	rs8002779	3e-06	Height
chr13	92929537	92929538	rs9523848	3e-06	Breast size
chr13	97551472	97551473	rs349114	3e-06	Obesity-related traits
chr14	101223707	101223708	rs8008758	3e-06	Body mass index (interaction)
chr13	78785288	78785289	rs17070284	3e-06	Cognitive performance
chr13	34331917	34331918	rs627871	3e-06	Obesity-related traits
chr13	34328954	34328955	rs571411	3e-06	Obesity-related traits
chr13	33224124	33224125	rs2555603	3e-06	Body mass index (asthmatics)
chr12	6471415	6471416	rs10492096	3e-06	Hip geometry
chr12	68976975	68976976	rs9943849	3e-06	Major depressive disorder
chr12	69434900	69434901	rs11177669	3e-06	Height
chr12	72020782	72020783	rs10879357	3e-06	Colorectal cancer
chr12	75670747	75670748	rs12582659	3e-06	Blood trace element (Cu levels)
chr12	79381467	79381468	rs11114027	3e-06	Obesity-related traits
chr12	82625408	82625409	rs11115322	3e-06	Immune response to smallpox vaccine (IL-6)
chr12	83614495	83614496	rs2403106	3e-06	Neonatal lupus
chr12	89666808	89666809	rs17249754	3e-06	Biomedical quantitative traits
chr12	93156524	93156525	rs1836127	3e-06	Non-alcoholic fatty liver disease histology (other)
chr12	96085488	96085489	rs2660869	3e-06	Height
chr12	99510761	99510762	rs1961649	3e-06	Metabolite levels (HVA/5-HIAA ratio)
chr1	29958712	29958713	rs1009080	3e-06	Schizophrenia
chr1	30052866	30052867	rs2860031	3e-06	Bipolar disorder (mood-incongruent)
chr1	30094748	30094749	rs910696	3e-06	Smoking behavior
chr13	101407724	101407725	rs1572591	3e-06	Psychosis (atypical)
chr13	103439194	103439195	rs583464	3e-06	Response to amphetamines
chr13	105182818	105182819	rs16966085	3e-06	Obesity-related traits
chr13	105944369	105944370	rs488248	3e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel)
chr13	107839243	107839244	rs1509091	3e-06	Metabolite levels (Pyroglutamine)
chr13	108803486	108803487	rs984300	3e-06	Obesity-related traits
chr13	113004793	113004794	rs4907479	3e-06	Bladder cancer
chr13	20635372	20635373	rs7326068	3e-06	Schizophrenia, bipolar disorder and depression (combined)
chr13	26841535	26841536	rs9319321	3e-06	Asthma (toluene diisocyanate-induced)
chr13	30383550	30383551	rs7335631	3e-06	Fat distribution (HIV)
chr12	56983562	56983563	rs4759042	3e-06	Migraine
chr14	101260769	101260770	rs2400997	3e-06	Prostate cancer (gene x gene interaction)
chr11	76621165	76621166	rs11236809	3e-06	Atopic dermatitis
chr1	17508245	17508246	rs2254135	3e-06	Response to hepatitis C treatment
chr10	44331748	44331749	rs10900020	3e-06	Schizophrenia
chr10	44627930	44627931	rs11239177	3e-06	Bipolar disorder and schizophrenia
chr10	48728290	48728291	rs11101442	3e-06	Systemic lupus erythematosus
chr10	51502872	51502873	rs1952138	3e-06	IgG glycosylation
chr10	51922033	51922034	rs11000137	3e-06	Migraine
chr10	52815235	52815236	rs6480975	3e-06	Age-related macular degeneration
chr10	58559136	58559137	rs1658442	3e-06	Corneal astigmatism
chr10	6025724	6025725	rs2025345	3e-06	Self-reported allergy
chr10	60788631	60788632	rs3213056	3e-06	Reading and spelling
chr10	60792131	60792132	rs2456778	3e-06	Cocaine dependence
chr10	62896152	62896153	rs10995356	3e-06	Temperament
chr10	36359111	36359112	rs1779876	3e-06	Protein quantitative trait loci
chr10	63107151	63107152	rs10995439	3e-06	IgG glycosylation
chr10	71036119	71036120	rs1891159	3e-06	Obesity-related traits
chr10	71356184	71356185	rs2252996	3e-06	Systemic lupus erythematosus
chr10	75538850	75538851	rs2043090	3e-06	Anorexia nervosa
chr10	79425557	79425558	rs181715218	3e-06	Serum dimethylarginine levels (asymmetric/symetric ratio)
chr10	85980995	85980996	rs10788473	3e-06	Pancreatic cancer
chr10	87992453	87992454	rs149784093	3e-06	Periodontitis (Mean PAL)
chr10	92409039	92409040	rs2263638	3e-06	Airflow obstruction 
chr10	92703124	92703125	rs1111875	3e-06	Type 2 diabetes
chr10	95032444	95032445	rs1934954	3e-06	Tuberculosis
chr10	95362483	95362484	rs4918918	3e-06	Suicide risk
chr10	95541246	95541247	rs11188352	3e-06	IgG glycosylation
chr10	6904789	6904790	rs2501677	3e-06	Fasting insulin-related traits (interaction with BMI)
chr10	33968683	33968684	rs1780436	3e-06	Major depressive disorder
chr10	33214250	33214251	rs2506155	3e-06	Migraine
chr10	31126176	31126177	rs793108	3e-06	Multiple sclerosis
chr21	45209674	45209675	rs2838815	3e-06	Pulmonary function
chr10	10346231	10346232	rs7092703	3e-06	Corneal astigmatism
chr10	104124357	104124358	rs10883969	3e-06	Preeclampsia
chr10	110277216	110277217	rs11195062	3e-06	Multiple myeloma
chr10	111118042	111118043	rs2065779	3e-06	Insomnia (caffeine-induced)
chr10	112998589	112998590	rs7903146	3e-06	Fasting insulin-related traits (interaction with BMI)
chr10	113479004	113479005	rs17770015	3e-06	Migraine without aura
chr10	116214084	116214085	rs12413355	3e-06	Migraine with aura
chr10	117658592	117658593	rs2184898	3e-06	Conduct disorder (case status)
chr10	120062025	120062026	rs17621444	3e-06	IgG glycosylation
chr10	1200942	1200943	rs4880487	3e-06	Migraine
chr10	120283976	120283977	rs11199254	3e-06	IgG glycosylation
chr10	122092311	122092312	rs11200392	3e-06	Obesity-related traits
chr10	122970359	122970360	rs7069346	3e-06	Migraine without aura
chr10	123492158	123492159	rs705162	3e-06	Migraine
chr10	133538648	133538649	rs2249694	3e-06	Obesity-related traits
chr10	17100526	17100527	rs6602175	3e-06	MRI atrophy measures
chr10	18236240	18236241	rs2482109	3e-06	Metabolite levels (HVA/MHPG ratio)
chr10	20145850	20145851	rs4634985	3e-06	Bronchopulmonary dysplasia
chr10	23080491	23080492	rs722258	3e-06	Sleep time
chr10	23145814	23145815	rs7893600	3e-06	Obesity-related traits
chr10	24822980	24822981	rs11014249	3e-06	Obesity-related traits
chr10	28463176	28463177	rs2153299	3e-06	Obesity-related traits
chr10	29000101	29000102	rs11007350	3e-06	Cannabis dependence
chr10	29807698	29807699	rs2986971	3e-06	Non-alcoholic fatty liver disease histology (lobular)
chr10	98820365	98820366	rs17470570	3e-06	Migraine without aura
chr1	17593321	17593322	rs6693036	3e-06	Obesity-related traits
chr10	9955026	9955027	rs12263766	3e-06	Obesity-related traits
chr1	102668352	102668353	rs10874639	3e-06	Protein quantitative trait loci
chr11	29140588	29140589	rs1602565	3e-06	Schizophrenia
chr11	32342640	32342641	rs2057178	3e-06	Tuberculosis
chr11	34583887	34583888	rs5028798	3e-06	Volumetric brain MRI
chr11	35134184	35134185	rs2785173	3e-06	Response to Vitamin E supplementation
chr1	152515440	152515441	rs73004856	3e-06	Obesity-related traits
chr1	153876519	153876520	rs7414227	3e-06	Lentiform nucleus volume 
chr11	5604372	5604373	rs7108470	3e-06	IgG glycosylation
chr11	5666793	5666794	rs11820502	3e-06	IgG glycosylation
chr1	15753675	15753676	rs12725198	3e-06	Cardiac Troponin-T levels
chr1	157699487	157699488	rs3761959	3e-06	Multiple sclerosis
chr1	159178722	159178723	rs1474747	3e-06	Select biomarker traits
chr11	27561581	27561582	rs7481311	3e-06	Weight
chr11	5938526	5938527	rs3858526	3e-06	DNA methylation (variation)
chr1	161493796	161493797	rs7535475	3e-06	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia
chr11	61842277	61842278	rs174583	3e-06	Response to statin therapy
chr11	61944658	61944659	rs2727261	3e-06	Estradiol levels
chr11	63406211	63406212	rs7101446	3e-06	Economic and political preferences
chr11	64545818	64545819	rs7124676	3e-06	Obesity-related traits
chr1	164769933	164769934	rs6670655	3e-06	Height
chr1	167451187	167451188	rs2056626	3e-06	Systemic sclerosis
chr1	169529736	169529737	rs6030	3e-06	Uric acid levels
chr11	69781754	69781755	rs4084127	3e-06	Type 1 diabetes
chr11	70660100	70660101	rs525304	3e-06	Response to fenofibrate (adiponectin levels)
chr11	72564864	72564865	rs183778342	3e-06	Serum dimethylarginine levels (asymmetric)
chr1	159740726	159740727	rs11265263	3e-06	Vaccine-related adverse events 
chr11	2301598	2301599	rs11022157	3e-06	Chronic lymphocytic leukemia
chr11	22092546	22092547	rs11026412	3e-06	Parkinson's disease
chr11	2116908	2116909	rs6578985	3e-06	Femoral neck bone geometry and menarche (age at onset)
chr1	109862648	109862649	rs6537883	3e-06	Sensory disturbances after bilateral sagittal split ramus osteotomy
chr11	100535908	100535909	rs12800752	3e-06	Menarche (age at onset)
chr11	103937423	103937424	rs10895547	3e-06	Coronary heart disease
chr11	106459434	106459435	rs10895959	3e-06	Inattentive symptoms
chr11	109002391	109002392	rs10890920	3e-06	QT interval (interaction)
chr11	113425896	113425897	rs1079596	3e-06	Select biomarker traits
chr11	114320293	114320294	rs2847476	3e-06	Volumetric brain MRI
chr11	117518216	117518217	rs11216435	3e-06	Menarche (age at onset)
chr11	122083948	122083949	rs7121446	3e-06	Cardiovascular disease risk factors
chr1	112313947	112313948	rs7555668	3e-06	Cognitive performance
chr11	123777624	123777625	rs17744026	3e-06	IgE levels in asthmatics (D.p. specific) 
chr11	123881120	123881121	rs12280105 	3e-06	Oleic acid (18:1n-9) plasma levels
chr11	125443702	125443703	rs7930295	3e-06	Schizophrenia
chr11	126035362	126035363	rs472926	3e-06	Alzheimer's disease (late onset)
chr11	126158821	126158822	rs563519	3e-06	Heart failure
chr11	126989260	126989261	rs620875	3e-06	Response to antipsychotic treatment
chr1	112770940	112770941	rs11590090	3e-06	Hyperactive-impulsive symptoms
chr11	130659323	130659324	rs12792526	3e-06	Periodontitis (Mean PAL)
chr11	130960852	130960853	rs10894294	3e-06	Schizophrenia
chr11	131450175	131450176	rs1550976	3e-06	Asperger disorder
chr11	134396072	134396073	rs7928758	3e-06	Alcohol consumption (maxi-drinks)
chr1	114172961	114172962	rs2774292	3e-06	Bipolar disorder and schizophrenia
chr11	20334897	20334898	rs7128099	3e-06	Obesity-related traits
chr11	203787	203788	rs2280543	3e-06	Intracranial aneurysm
chr11	20677382	20677383	rs1793004	3e-06	Crohn's disease
chr1	101075442	101075443	rs17450029	3e-06	QT interval (interaction)
chr14	101894407	101894408	rs7142002	3e-06	Autism
chr10	23014323	23014324	rs1054052	3e-06	IgG glycosylation
chr1	41374149	41374150	rs4660531	3e-06	Bipolar disorder
chr1	84295664	84295665	rs1085093	3e-06	Metabolic syndrome
chr18	47333892	47333893	rs9947662	3e-06	Migraine
chr18	48701072	48701073	rs16949825	3e-06	IgG glycosylation
chr18	55195876	55195877	rs1970671	3e-06	Diabetic retinopathy 
chr18	57787144	57787145	rs10503019	3e-06	Vitiligo
chr18	58143500	58143501	rs549476	3e-06	Response to amphetamines
chr18	59647574	59647575	rs11152166	3e-06	Major depressive disorder
chr18	68625021	68625022	rs17232800	3e-06	Attention deficit hyperactivity disorder
chr18	68877517	68877518	rs1539893	3e-06	Liver enzyme levels (alanine transaminase)
chr1	87147674	87147675	rs7553864	3e-06	Smoking behavior
chr18	905123	905124	rs1893154	3e-06	Obesity-related traits
chr18	42495990	42495991	rs8090196	3e-06	Economic and political preferences (immigration/crime)
chr1	89557236	89557237	rs922107	3e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin)
chr19	17479471	17479472	rs11666579	3e-06	Response to antidepressants
chr19	19678718	19678719	rs2304130	3e-06	LDL cholesterol
chr19	19678718	19678719	rs2304130	3e-06	Triglycerides
chr19	22425571	22425572	rs10404998	3e-06	Dental caries
chr19	24172690	24172691	rs11668609 	3e-06	Response to taxane treatment (docetaxel)
chr1	92838045	92838046	rs6604026	3e-06	Multiple sclerosis
chr19	29417199	29417200	rs10425935	3e-06	Obesity-related traits
chr19	30446935	30446936	rs33428	3e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs)
chr19	33034012	33034013	rs73039434	3e-06	Obesity-related traits
chr19	348742	348743	rs6510725	3e-06	Non-small cell lung cancer
chr19	3927772	3927773	rs10412199	3e-06	Aging (time to event)
chr19	10199715	10199716	rs2116940	3e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr18	41648345	41648346	rs9958032	3e-06	Blood trace element (Zn levels)
chr1	8387661	8387662	rs2120461	3e-06	Bone mineral density
chr18	37634042	37634043	rs2162440	3e-06	Telomere length
chr17	67491904	67491905	rs2017854	3e-06	Pulmonary function
chr17	69806210	69806211	rs11870477	3e-06	Response to TNF-alpha inhibitors in rheumatoid arthritis
chr17	72598489	72598490	rs11077614	3e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr17	73811573	73811574	rs12451840	3e-06	IgG glycosylation
chr17	77008130	77008131	rs11653989	3e-06	Cardiac repolarization
chr17	78114436	78114437	rs2613514	3e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr17	80086943	80086944	rs1467979	3e-06	IgG glycosylation
chr17	80350458	80350459	rs12051723	3e-06	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy
chr17	928426	928427	rs2360111	3e-06	Economic and political preferences
chr18	10923809	10923810	rs264272	3e-06	Major depressive disorder
chr18	11494199	11494200	rs1455244	3e-06	Schizophrenia
chr1	81781562	81781563	rs11163372	3e-06	Temperament
chr18	23155443	23155444	rs4369779	3e-06	Height
chr18	25813139	25813140	rs7231041	3e-06	Obesity-related traits
chr18	27107406	27107407	rs9953270	3e-06	Bronchopulmonary dysplasia
chr18	28193051	28193052	rs4800843	3e-06	Response to amphetamines
chr18	29096707	29096708	rs4145170	3e-06	Cognitive performance
chr18	30376476	30376477	rs6508673	3e-06	Obesity-related traits
chr10	102448041	102448042	rs927821	3e-06	Social autistic-like traits
chr18	322521	322522	rs621636	3e-06	Obesity-related traits
chr18	3328747	3328748	rs1623523	3e-06	Antineutrophil cytoplasmic antibody-associated vasculitis 
chr18	35517995	35517996	rs9953852	3e-06	Capecitabine sensitivity
chr1	8362615	8362616	rs2252865	3e-06	Schizophrenia
chr18	37348675	37348676	rs4799915	3e-06	Response to iloperidone treatment (QT prolongation)
chr18	37618332	37618333	rs10502675	3e-06	Response to amphetamines
chr19	48725014	48725015	rs2287921	3e-06	Bipolar disorder
chr17	66521194	66521195	rs11651708	3e-06	Coronary artery calcification
chr19	49496751	49496752	rs2280401	3e-06	Serum total protein level
chr19	54109320	54109321	rs254262	3e-06	Obesity-related traits
chr20	61683794	61683795	rs16985437	3e-06	Axial length
chr20	63037683	63037684	rs6089829	3e-06	Prostate cancer (gene x gene interaction)
chr20	63666448	63666449	rs6011002	3e-06	Dental caries
chr20	7314255	7314256	rs6054906	3e-06	Response to amphetamines
chr20	7771718	7771719	rs6077251	3e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin)
chr2	102047166	102047167	rs2310173	3e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr2	104051279	104051280	rs6758152	3e-06	Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms)
chr2	104366808	104366809	rs7570682	3e-06	Bipolar disorder
chr2	112771605	112771606	rs6542095	3e-06	Endometriosis
chr2	114829361	114829362	rs6732028	3e-06	Obesity-related traits
chr2	11897365	11897366	rs4027132	3e-06	Bipolar disorder
chr20	57108939	57108940	rs11699237	3e-06	Schizophrenia
chr2	119266115	119266116	rs72840936	3e-06	Cocaine dependence
chr2	126905320	126905321	rs13418717	3e-06	Heart failure
chr2	127762222	127762223	rs13013415	3e-06	Lung function (forced expiratory volume in 1 second to forced vital capacity ratio)
chr2	128746776	128746777	rs7561966 	3e-06	Palmitic acid (16:0) plasma levels
chr21	31445193	31445194	rs580140	3e-06	Renal sinus fat 
chr2	133282946	133282947	rs7577925	3e-06	Attention deficit hyperactivity disorder
chr2	133680387	133680388	rs1901440	3e-06	Response to gemcitabine in pancreatic cancer 
chr2	136733550	136733551	rs1582861	3e-06	Subcutaneous adipose tissue
chr21	38349841	38349842	rs2836326	3e-06	Metabolite levels (HVA)
chr21	38942779	38942780	rs2836770	3e-06	Immune response to smallpox vaccine (IL-6)
chr21	40621780	40621781	rs3804024	3e-06	Obesity-related traits
chr14	101988595	101988596	rs4906172	3e-06	Menopause (age at onset)
chr2	124240786	124240787	rs1367248	3e-06	Tonometry
chr20	57063693	57063694	rs6127921	3e-06	Response to citalopram treatment
chr20	55184589	55184590	rs6092078	3e-06	Response to antipsychotic treatment
chr20	50758704	50758705	rs6122972	3e-06	Bipolar disorder
chr19	55368503	55368504	rs1126757	3e-06	Response to antidepressants
chr19	55754297	55754298	rs17634917	3e-06	Major depressive disorder
chr19	7196553	7196554	rs2115386	3e-06	Diabetic retinopathy 
chr19	7669624	7669625	rs3745367	3e-06	Resistin levels 
chr20	12749394	12749395	rs1413020	3e-06	Body mass index (interaction)
chr20	17611654	17611655	rs12480819	3e-06	Migraine - clinic-based
chr20	17844498	17844499	rs2077147	3e-06	IgG glycosylation
chr20	19383334	19383335	rs2424234	3e-06	Pulmonary function decline
chr20	20653461	20653462	rs6132333	3e-06	IgG glycosylation
chr20	22906618	22906619	rs6075982	3e-06	Obesity-related traits
chr20	23866371	23866372	rs6138150	3e-06	Response to TNF antagonist treatment
chr20	33968970	33968971	rs6059594	3e-06	IgG glycosylation
chr20	40056899	40056900	rs2870137	3e-06	Cytomegalovirus antibody response
chr20	42365453	42365454	rs6030171	3e-06	IgG glycosylation
chr20	45145095	45145096	rs7361168	3e-06	IgG glycosylation
chr20	48150491	48150492	rs11086243	3e-06	Nephrotic syndrome (acquired)
chr20	48459907	48459908	rs13043694	3e-06	Attention deficit hyperactivity disorder (combined symptoms)
chr20	48459907	48459908	rs13043694	3e-06	Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms)
chr20	48459953	48459954	rs4810796	3e-06	Attention deficit hyperactivity disorder (combined symptoms)
chr20	48459953	48459954	rs4810796	3e-06	Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms)
chr20	48461278	48461279	rs4402823	3e-06	Attention deficit hyperactivity disorder (combined symptoms)
chr20	48461278	48461279	rs4402823	3e-06	Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms)
chr20	48461290	48461291	rs4458264	3e-06	Attention deficit hyperactivity disorder (combined symptoms)
chr20	48461290	48461291	rs4458264	3e-06	Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms)
chr20	5057127	5057128	rs261360	3e-06	Hair morphology
chr19	51224705	51224706	rs3865444	3e-06	Alzheimer's disease (late onset)
chr17	66137607	66137608	rs7209395	3e-06	Weight
chr2	124499158	124499159	rs11899928	3e-06	IgG glycosylation
chr17	61419287	61419288	rs2079795	3e-06	Height
chr14	94505904	94505905	rs11627075	3e-06	Obesity-related traits
chr15	27752100	27752101	rs17565841	3e-06	Parkinson's disease (age of onset)
chr15	30606128	30606129	rs143536437	3e-06	Epilepsy (remission after treatment)
chr15	31042158	31042159	rs17815774	3e-06	Response to antipsychotic treatment
chr15	31501726	31501727	rs7164569	3e-06	Venous thromboembolism
chr15	38694166	38694167	rs12912251	3e-06	Bipolar disorder
chr15	40303425	40303426	rs1869901	3e-06	Schizophrenia
chr15	40904185	40904186	rs8036080	3e-06	Visceral adipose tissue/subcutaneous adipose tissue ratio
chr15	45207848	45207849	rs765787	3e-06	Uric acid levels
chr15	48340955	48340956	rs11637235	3e-06	Protein quantitative trait loci
chr15	54088002	54088003	rs11071033	3e-06	Menarche (age at onset)
chr14	94491376	94491377	rs1998207	3e-06	Obesity-related traits
chr15	57921215	57921216	rs1550576	3e-06	Hypertension
chr15	60618350	60618351	rs3784609	3e-06	Total ventricular volume
chr15	69357713	69357714	rs11072089	3e-06	Bipolar disorder and schizophrenia
chr15	70342369	70342370	rs11072158	3e-06	Migraine with aura
chr15	73936723	73936724	rs893817	3e-06	Aortic root size
chr15	74256431	74256432	rs9783698	3e-06	Obesity-related traits
chr15	74741058	74741059	rs2472299	3e-06	Coronary heart disease
chr15	75426327	75426328	rs8028182	3e-06	Sudden cardiac arrest
chr15	85155975	85155976	rs8040855	3e-06	Bulimia nervosa
chr15	85919620	85919621	rs4262906	3e-06	Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule)
chr15	89831024	89831025	rs2028299	3e-06	Type 2 diabetes
chr15	90571143	90571144	rs12915189	3e-06	Information processing speed
chr15	58420003	58420004	rs11857380	3e-06	Obesity-related traits
chr14	94096846	94096847	rs7157940	3e-06	Anthropometric traits
chr14	93178033	93178034	rs1268843	3e-06	Endometriosis
chr14	93129245	93129246	rs11624776	3e-06	Thyroid hormone levels
chr14	26937685	26937686	rs17111920	3e-06	Bipolar disorder and schizophrenia
chr17	6190630	6190631	rs3744728	3e-06	Bipolar disorder (mood-incongruent)
chr14	27330970	27330971	rs2877832	3e-06	Diabetes related insulin traits
chr1	4384478	4384479	rs239339	3e-06	Obesity-related traits
chr14	42186071	42186072	rs2154294	3e-06	Alcoholism (12-month weekly alcohol consumption)
chr14	48957638	48957639	rs7158872	3e-06	Post-traumatic stress disorder (asjusted for relatedness)
chr14	51453103	51453104	rs7153703	3e-06	Total ventricular volume
chr14	53824111	53824112	rs12431733	3e-06	Parkinson's disease
chr14	54390567	54390568	rs4293296	3e-06	Response to antipsychotic treatment in schizophrenia (working memory)
chr14	54656199	54656200	rs17127713	3e-06	Obesity-related traits
chr14	58722642	58722643	rs17094983	3e-06	Colorectal cancer
chr14	61267921	61267922	rs7141238	3e-06	Obesity-related traits
chr14	61428326	61428327	rs11158345	3e-06	Word reading
chr14	62051629	62051630	rs6573416	3e-06	Self-rated health
chr14	62187979	62187980	rs973968	3e-06	Iron status biomarkers
chr14	62211584	62211585	rs1514928	3e-06	Attention deficit hyperactivity disorder
chr14	66987140	66987141	rs8020095	3e-06	Depression (quantitative trait)
chr1	47544324	47544325	rs11582540	3e-06	Response to amphetamines
chr14	76147334	76147335	rs935334	3e-06	Blood pressure
chr14	76237007	76237008	rs7156960	3e-06	Acute lymphoblastic leukemia (childhood)
chr14	86350751	86350752	rs10484100	3e-06	Blood trace element (Zn levels)
chr14	88360137	88360138	rs17772222	3e-06	Coronary artery calcification
chr14	88360337	88360338	rs17124581	3e-06	Information processing speed
chr14	89568627	89568628	rs8004664	3e-06	Fasting glucose-related traits (interaction with BMI)
chr14	92236251	92236252	rs1741439	3e-06	Obesity-related traits
chr15	92008798	92008799	rs7495052	3e-06	Inattentive symptoms
chr15	92588401	92588402	rs2173063	3e-06	Subcutaneous adipose tissue
chr14	53370766	53370767	rs12434047	3e-06	Economic and political preferences (fairness)
chr15	94968607	94968608	rs6496074	3e-06	Cognitive performance
chr16	65861460	65861461	rs1126179	3e-06	Molar-incisor hypomineralization
chr16	74944719	74944720	rs2042415	3e-06	Obesity-related traits
chr16	77882293	77882294	rs435746	3e-06	Bipolar disorder and schizophrenia
chr16	78224912	78224913	rs2059238	3e-06	Cardiac structure and function
chr16	81924692	81924693	rs7192724	3e-06	Breast cancer (menopausal hormone therapy interaction)
chr16	82293199	82293200	rs11863065	3e-06	Obesity-related traits
chr16	82346347	82346348	rs4082514	3e-06	Cognitive performance
chr1	68319529	68319530	rs11209261	3e-06	Airflow obstruction 
chr16	83723722	83723723	rs3784962	3e-06	Cognitive performance
chr16	8467742	8467743	rs11861787	3e-06	Epilepsy (remission after treatment)
chr16	86331964	86331965	rs2696835	3e-06	Diabetic retinopathy 
chr16	6063659	6063660	rs6500744	3e-06	Conduct disorder (interaction)
chr16	86647424	86647425	rs1867485	3e-06	Obesity-related traits
chr17	13655762	13655763	rs10521233	3e-06	Asthma (childhood onset)
chr17	13805543	13805544	rs7215286	3e-06	IgG glycosylation
chr17	2241898	2241899	rs11078884	3e-06	Metabolite levels (5-HIAA)
chr17	2868217	2868218	rs12603284	3e-06	Sudden cardiac arrest
chr17	34662518	34662519	rs11654964	3e-06	Lobular breast cancer (menopausal hormone therapy interaction)
chr17	45325638	45325639	rs4792814	3e-06	Multiple sclerosis
chr17	47753581	47753582	rs12950390	3e-06	IgG glycosylation
chr17	59946962	59946963	rs1051424	3e-06	Obesity-related traits
chr15	94622350	94622351	rs1014922	3e-06	Sudden cardiac arrest
chr17	54470763	54470764	rs6504909	3e-06	Obesity-related traits
chr17	55442482	55442483	rs11653011	3e-06	Obesity-related traits
chr17	11900143	11900144	rs4792192	3e-06	Myopia (pathological)
chr16	58725427	58725428	rs12600277	3e-06	Aortic root size
chr17	37490446	37490447	rs712039	3e-06	Tuberculosis
chr16	57024669	57024670	rs821470	3e-06	Bipolar disorder and schizophrenia
chr1	59618843	59618844	rs12727131	3e-06	Neutrophil count
chr16	57269281	57269282	rs11640439	3e-06	Sleep duration
chr15	96301497	96301498	rs7181753	3e-06	Electroencephalographic traits in alcoholism
chr15	99759033	99759034	rs6598266	3e-06	Major depressive disorder
chr15	96266552	96266553	rs1437588	3e-06	Migraine
chr1	60593586	60593587	rs2989476	3e-06	Bipolar disorder
chr16	10881453	10881454	rs4781011	3e-06	Ulcerative colitis
chr16	11270221	11270222	rs416603	3e-06	Type 1 diabetes
chr16	11547323	11547324	rs7203193	3e-06	Coronary heart disease
chr16	12503077	12503078	rs117147010	3e-06	Serum dimethylarginine levels (asymmetric/symetric ratio)
chr16	13882498	13882499	rs2113334	3e-06	Metabolic syndrome
chr1	61914625	61914626	rs1056513	3e-06	Obesity-related traits
chr15	99817229	99817230	rs1823874	3e-06	IgG glycosylation
chr16	20046338	20046339	rs1902813	3e-06	Attention deficit hyperactivity disorder (inattention symptoms)
chr16	20045670	20045671	rs12596252	3e-06	Attention deficit hyperactivity disorder (inattention symptoms)
chr16	56961323	56961324	rs1800775	3e-06	Triglycerides
chr16	56691260	56691261	rs8064100	3e-06	Gambling
chr16	53723827	53723828	rs1421084	3e-06	Subcutaneous adipose tissue
chr16	56935235	56935236	rs2217332	3e-06	Metabolic syndrome
chr16	49716878	49716879	rs17281813	3e-06	Inattentive symptoms
chr16	50109032	50109033	rs8046148	3e-06	Testicular germ cell tumor
chr15	95789631	95789632	rs2567426	3e-06	Information processing speed
chr16	35853759	35853760	rs12599426 	3e-06	Palmitoleic acid (16:1n-7) plasma levels
chr16	3459055	3459056	rs40363	3e-06	Tuberculosis
chr16	20668883	20668884	rs433598	3e-06	Schizophrenia
chr16	20048354	20048355	rs12926725	3e-06	Attention deficit hyperactivity disorder (inattention symptoms)
chr3	34218599	34218600	rs145744974	4e-06	Periodontitis (Mean PAL)
chr3	355869	355870	rs892295	4e-06	Obesity-related traits
chr3	3587296	3587297	rs10865864	4e-06	Callous-unemotional behaviour
chr3	32887622	32887623	rs9310995	4e-06	Pulmonary function
chr3	36638606	36638607	rs950146	4e-06	Erectile dysfunction
chr3	38400998	38400999	rs2070488	4e-06	Electrocardiographic conduction measures
chr3	39512296	39512297	rs816488	4e-06	Cognitive performance
chr3	3314489	3314490	rs9874556	4e-06	Pancreatic cancer
chr3	39708101	39708102	rs9832461	4e-06	Brain structure (temporal lobe volume)
chr3	58041469	58041470	rs1623879	4e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin)
chr3	54598519	54598520	rs13064588	4e-06	Bipolar disorder and schizophrenia
chr3	55154245	55154246	rs11706236	4e-06	Insomnia (caffeine-induced)
chr3	55529315	55529316	rs1875110	4e-06	Periodontitis (Mean PAL)
chr3	60304112	60304113	rs10510837	4e-06	Asperger disorder
chr3	61428139	61428140	rs10514718	4e-06	Major depressive disorder
chr3	62747690	62747691	rs580384	4e-06	Breast size
chr3	66475538	66475539	rs3845905	4e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs)
chr3	71974548	71974549	rs2135319	4e-06	Bilirubin levels
chr3	72112081	72112082	rs6549438	4e-06	Migraine - clinic-based
chr3	73491466	73491467	rs4557101	4e-06	QT interval
chr3	44291831	44291832	rs13323323	4e-06	IgG glycosylation
chr3	32800608	32800609	rs9845475	4e-06	Attention deficit hyperactivity disorder (time to onset)
chr3	177511190	177511191	rs1353899	4e-06	Alcohol consumption
chr3	28165385	28165386	rs9310862	4e-06	Behavioural disinhibition (generation interaction)
chr3	12447382	12447383	rs4684854	4e-06	Sexual dimorphism in anthropometric traits
chr3	127274255	127274256	rs9871760	4e-06	MRI atrophy measures
chr3	13919659	13919660	rs9875589	4e-06	Ovarian reserve
chr3	77995537	77995538	rs9836484	4e-06	Brain imaging in schizophrenia (interaction)
chr3	140504951	140504952	rs9862730	4e-06	Homeostasis model assessment of insulin resistance (interaction)
chr3	143337624	143337625	rs7632299	4e-06	Non-alcoholic fatty liver disease histology (lobular)
chr3	143531227	143531228	rs1371924	4e-06	Tonometry
chr3	1470902	1470903	rs6763848	4e-06	Prostate cancer (gene x gene interaction)
chr3	150369220	150369221	rs1012583	4e-06	IgG glycosylation
chr3	151324675	151324676	rs12107539	4e-06	Lung function (forced expiratory flow between 25% and 75% of forced vital capacity)
chr3	16929445	16929446	rs9821630	4e-06	Multiple sclerosis
chr3	169582430	169582431	rs1344555	4e-06	Pulmonary function (interaction)
chr3	171116769	171116770	rs11920719	4e-06	Coronary heart disease
chr3	177377283	177377284	rs12629106	4e-06	Systemic lupus erythematosus
chr3	177879200	177879201	rs7612209	4e-06	Cognitive performance
chr3	178075318	178075319	rs1982821	4e-06	Uric acid levels
chr3	190534845	190534846	rs9290936	4e-06	Waist circumference
chr3	19334298	19334299	rs2053506	4e-06	Hip geometry
chr3	196460736	196460737	rs2342371	4e-06	Fat distribution (HIV)
chr3	25302123	25302124	rs322668	4e-06	IgG glycosylation
chr3	25518739	25518740	rs1435703	4e-06	Obesity (extreme)
chr3	25880793	25880794	rs7644516	4e-06	DNA methylation (variation)
chr3	2613006	2613007	rs4370013	4e-06	Blood pressure
chr3	32288004	32288005	rs4380451	4e-06	Bipolar disorder
chr3	78449846	78449847	rs9834373	4e-06	Protein quantitative trait loci
chr4	26135396	26135397	rs907499	4e-06	Obesity-related traits
chr3	87734825	87734826	rs9860340	4e-06	Electroencephalographic traits in alcoholism
chr4	37936896	37936897	rs10010758	4e-06	Periodontal microbiota
chr4	54616650	54616651	rs2537859	4e-06	Bipolar disorder
chr4	58142245	58142246	rs10517437	4e-06	Cognitive performance
chr4	6181456	6181457	rs10937705	4e-06	IgG glycosylation
chr4	67198721	67198722	rs10518025	4e-06	Multiple sclerosis (severity)
chr4	76497527	76497528	rs13106227	4e-06	Eosinophilic esophagitis (pediatric)
chr4	80614238	80614239	rs1385890	4e-06	Obesity-related traits
chr4	87154976	87154977	rs115694618	4e-06	Bulimia nervosa
chr4	87478957	87478958	rs4610302	4e-06	Esophageal adenocarcinoma
chr4	90480459	90480460	rs187200046	4e-06	Metabolite levels (HVA-5-HIAA Factor score)
chr4	37649532	37649533	rs2292298	4e-06	IgG glycosylation
chr4	94224983	94224984	rs11097407	4e-06	Bipolar disorder and schizophrenia
chr4	9789087	9789088	rs1850744	4e-06	Economic and political preferences
chr5	10372505	10372506	rs2607292	4e-06	Body mass index
chr5	111436705	111436706	rs10491334	4e-06	Blood pressure
chr5	120880341	120880342	rs78975256	4e-06	Bronchopulmonary dysplasia
chr5	122929040	122929041	rs2447820	4e-06	Migraine
chr5	123821727	123821728	rs257016	4e-06	Alzheimer's disease
chr5	125030273	125030274	rs6862844	4e-06	Erectile dysfunction and prostate cancer treatment
chr3	122295718	122295719	rs13083990	4e-06	Cardiac Troponin-T levels
chr5	127803923	127803924	rs1515641	4e-06	Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms)
chr5	128305168	128305169	rs27855	4e-06	Height
chr4	96959257	96959258	rs7694207	4e-06	Response to mTOR inhibitor (everolimus)
chr4	35370475	35370476	rs437943	4e-06	Response to TNF antagonist treatment
chr4	33201517	33201518	rs10517270	4e-06	Alzheimer's disease (age of onset)
chr4	29901429	29901430	rs7442317	4e-06	Attention deficit hyperactivity disorder motor coordination
chr4	101116561	101116562	rs2659546	4e-06	Corneal structure
chr4	101668125	101668126	rs7700191	4e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr4	1045426	1045427	rs62296075	4e-06	Obesity-related traits
chr4	107194064	107194065	rs10516541	4e-06	Mean forced vital capacity from 2 exams
chr4	109737910	109737911	rs10033900	4e-06	Age-related macular degeneration (GA)
chr4	113458222	113458223	rs1880529	4e-06	White matter integrity (interaction)
chr4	128775065	128775066	rs1974942	4e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr4	130091984	130091985	rs11933661	4e-06	Alcohol dependence
chr4	134601584	134601585	rs10026364	4e-06	Coronary heart disease
chr4	141196269	141196270	rs1550057	4e-06	Conduct disorder (case status)
chr4	144653691	144653692	rs1812175	4e-06	Height
chr4	146578185	146578186	rs10213084	4e-06	Heart rate
chr4	148649527	148649528	rs2358462	4e-06	Non-alcoholic fatty liver disease histology (other)
chr4	153232847	153232848	rs12644284	4e-06	Multiple sclerosis
chr4	162816968	162816969	rs6840361	4e-06	Hair morphology
chr4	169959731	169959732	rs11723530	4e-06	Myopia (pathological)
chr4	173594530	173594531	rs12646107	4e-06	Response to amphetamines
chr4	174150450	174150451	rs12507634	4e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr4	175087066	175087067	rs72698613	4e-06	Epilepsy (remission after treatment)
chr4	175937874	175937875	rs7687921	4e-06	Mortality in heart failure
chr4	179783764	179783765	rs11495908	4e-06	Obesity-related traits
chr4	18127017	18127018	rs1503874	4e-06	Illicit drug use
chr4	288709	288710	rs11723261	4e-06	Immune response to smallpox vaccine (IL-6)
chr3	86109734	86109735	rs2324999	4e-06	Subcutaneous adipose tissue
chr3	118957644	118957645	rs4687833	4e-06	Lung function (forced expiratory flow between 25% and 75% of forced vital capacity)
chr2	231327592	231327593	rs1669070	4e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr3	113103474	113103475	rs9811423	4e-06	Alzheimer's disease
chr2	194007458	194007459	rs2176528	4e-06	Bipolar disorder
chr2	198046441	198046442	rs67031482	4e-06	Alcohol consumption
chr2	198304371	198304372	rs13398206	4e-06	Prostate cancer (gene x gene interaction)
chr2	199773785	199773786	rs12615435	4e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs)
chr2	204503734	204503735	rs4673301	4e-06	Lung function (forced expiratory volume in 1 second)
chr2	207012740	207012741	rs1453160	4e-06	Subcutaneous adipose tissue
chr2	212003898	212003899	rs1879637	4e-06	Personality dimensions
chr2	217449529	217449530	rs11689435	4e-06	Metabolite levels (MHPG)
chr22	22490915	22490916	rs5751168	4e-06	Prostate cancer (gene x gene interaction)
chr2	223072019	223072020	rs1440072	4e-06	Body mass index
chr2	192090778	192090779	rs13007495	4e-06	Sudden cardiac arrest
chr2	223409903	223409904	rs16864755	4e-06	Osteoporosis-related phenotypes
chr2	224078967	224078968	rs6740660	4e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil)
chr2	224693324	224693325	rs1843834	4e-06	IgE levels in asthmatics (D.p. specific) 
chr22	25998757	25998758	rs8139900	4e-06	Uric acid levels
chr2	226228868	226228869	rs2943640	4e-06	Visceral adipose tissue/subcutaneous adipose tissue ratio
chr22	26293668	26293669	rs688034	4e-06	Coronary heart disease
chr22	27456221	27456222	rs6005451	4e-06	Prostate cancer (gene x gene interaction)
chr2	22901685	22901686	rs10189050	4e-06	Obesity-related traits
chr22	30196079	30196080	rs2412980	4e-06	Dialysis-related mortality
chr22	30757288	30757289	rs9609078	4e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine)
chr22	31249772	31249773	rs2106294	4e-06	Type 2 diabetes nephropathy
chr22	23828808	23828809	rs2186369	4e-06	IgG glycosylation
chr2	233031787	233031788	rs2233375	4e-06	Contrast sensitivity
chr2	184571534	184571535	rs17430279	4e-06	Obesity-related traits
chr2	168996709	168996710	rs11568377	4e-06	Systolic blood pressure in sickle cell anemia
chr2	12428869	12428870	rs10929808	4e-06	Bipolar disorder and schizophrenia
chr5	128363681	128363682	rs374748	4e-06	Obesity (extreme)
chr21	26344334	26344335	rs9975851	4e-06	Airflow obstruction 
chr21	27362677	27362678	rs9977499	4e-06	Dialysis-related mortality
chr21	29678496	29678497	rs363512	4e-06	Hyperactive-impulsive symptoms
chr21	30688171	30688172	rs13046373	4e-06	HDL cholesterol
chr21	32012872	32012873	rs2833610	4e-06	Type 2 diabetes
chr21	32180199	32180200	rs2833693	4e-06	Temperament
chr2	137115776	137115777	rs892877	4e-06	Liver enzyme levels (aspartate transaminase)
chr21	39197852	39197853	rs2150410	4e-06	Temperament (bipolar disorder)
chr2	175853012	175853013	rs9287989	4e-06	Periodontal microbiota
chr21	40043116	40043117	rs9981861	4e-06	Non-small cell lung cancer (survival)
chr21	43067293	43067294	rs2851391	4e-06	Obesity-related traits
chr2	143671038	143671039	rs10928195	4e-06	Quantitative traits
chr2	145286483	145286484	rs1822881	4e-06	Attention deficit hyperactivity disorder (inattention symptoms)
chr2	145287996	145287997	rs11687420	4e-06	Attention deficit hyperactivity disorder (inattention symptoms)
chr2	148630398	148630399	rs10191411	4e-06	Protein quantitative trait loci
chr2	149601109	149601110	rs10170236	4e-06	Acute lymphoblastic leukemia (childhood)
chr2	154377805	154377806	rs12621256	4e-06	Liver enzyme levels (alanine transaminase)
chr2	1554154	1554155	rs10206020	4e-06	IgG glycosylation
chr2	166086766	166086767	rs11890028	4e-06	Epilepsy (generalized)
chr2	168532580	168532581	rs13393173	4e-06	Response to TNF antagonist treatment
chr21	42416076	42416077	rs11203203	4e-06	Rheumatoid arthritis
chr3	116726476	116726477	rs1432364	4e-06	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)
chr2	233595451	233595452	rs2602397	4e-06	Brain lesion load
chr2	235630662	235630663	rs6431393	4e-06	Menarche (age at onset)
chr2	39616056	39616057	rs7587205	4e-06	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy)
chr2	4271385	4271386	rs11686135	4e-06	Pulmonary function decline
chr2	46323629	46323630	rs7582701	4e-06	IgG glycosylation
chr2	46323629	46323630	rs7582701	4e-06	IgG glycosylation
chr2	50533364	50533365	rs6750634	4e-06	Metabolite levels (HVA/MHPG ratio)
chr2	54457419	54457420	rs11898505	4e-06	Bone mineral density (spine)
chr2	55884173	55884174	rs3791675	4e-06	Height
chr2	58845833	58845834	rs17552189	4e-06	Cannabis dependence
chr2	59562569	59562570	rs10203166	4e-06	IgG glycosylation
chr2	60054472	60054473	rs6712720	4e-06	Monocyte early outgrowth colony forming units
chr23	83280160	83280161	rs1410530	4e-06	Bipolar disorder and schizophrenia
chr2	64276760	64276761	rs2698530	4e-06	Iron status biomarkers
chr2	68423864	68423865	rs6759808	4e-06	Obesity-related traits
chr2	68836776	68836777	rs10496166	4e-06	RR interval (heart rate)
chr2	69955672	69955673	rs7583236	4e-06	Obesity-related traits
chr2	74712048	74712049	rs1137	4e-06	Myopia (pathological)
chr2	7896128	7896129	rs2193071	4e-06	Obesity-related traits
chr2	84019461	84019462	rs1447537	4e-06	RR interval (heart rate)
chr2	84217761	84217762	rs6547537	4e-06	IgG glycosylation
chr2	96562301	96562302	rs4907240	4e-06	Event-related brain oscillations
chr2	9784257	9784258	rs2357266	4e-06	Self-rated health
chr3	10733073	10733074	rs1682825	4e-06	Economic and political preferences (feminism/equality)
chr2	67374838	67374839	rs6739392	4e-06	Waist-hip ratio
chr2	233675677	233675678	rs2602381	4e-06	Attention deficit hyperactivity disorder
chr2	38050688	38050689	rs6741148	4e-06	Erectile dysfunction and prostate cancer treatment
chr2	34255007	34255008	rs6733379	4e-06	Attention deficit hyperactivity disorder and conduct disorder
chr2	237763781	237763782	rs11680012	4e-06	Adiposity
chr22	40040968	40040969	rs11704416	4e-06	Prostate cancer
chr22	40279086	40279087	rs4821941	4e-06	Prostate cancer (gene x gene interaction)
chr2	240369087	240369088	rs1574192	4e-06	Brain imaging in schizophrenia (interaction)
chr22	40424146	40424147	rs5757949	4e-06	Height
chr22	40600362	40600363	rs17002034	4e-06	Bipolar disorder and schizophrenia
chr22	41265149	41265150	rs2235852	4e-06	Self-reported allergy
chr2	24469939	24469940	rs2165738	4e-06	Type 1 diabetes
chr2	24935411	24935412	rs713587	4e-06	Body mass index (non-asthmatics)
chr2	26027029	26027030	rs68184094	4e-06	Metabolite levels (HVA-5-HIAA Factor score)
chr2	37817200	37817201	rs4670779	4e-06	Bone mineral density (spine)
chr2	26303550	26303551	rs6753473	4e-06	Non-small cell lung cancer
chr2	27364856	27364857	rs1058065	4e-06	IgG glycosylation
chr2	27508072	27508073	rs1260326	4e-06	Serum total protein level
chr23	10263650	10263651	rs12388359	4e-06	Alcohol dependence
chr2	31241518	31241519	rs649729	4e-06	Mean platelet volume
chr23	13596998	13596999	rs5978649	4e-06	Multiple sclerosis
chr2	31367918	31367919	rs761926	4e-06	Obesity-related traits
chr23	149485919	149485920	rs530501	4e-06	Cognitive performance
chr23	26351781	26351782	rs6526555	4e-06	Metabolite levels (HVA/MHPG ratio)
chr23	33765945	33765946	rs5928363	4e-06	Tuberculosis
chr2	33476822	33476823	rs13385731	4e-06	Systemic lupus erythematosus
chr2	26444261	26444262	rs3795958	4e-06	Metabolite levels (HVA/MHPG ratio)
chr5	130456440	130456441	rs6894216	4e-06	Response to amphetamines
chr7	147880444	147880445	rs2708240	4e-06	QT interval (interaction)
chr5	135227466	135227467	rs634308	4e-06	Immune response to anthrax vaccine 
chr7	8512983	8512984	rs765855	4e-06	Breast Cancer in BRCA1 mutation carriers
chr7	91286038	91286039	rs2888830	4e-06	Dental caries
chr7	92617429	92617430	rs42041	4e-06	Rheumatoid arthritis
chr7	97388482	97388483	rs10255878	4e-06	Adverse response to radiation therapy
chr7	99610252	99610253	rs7792939	4e-06	Anthropometric traits
chr8	100829317	100829318	rs3108919	4e-06	AIDS
chr8	10165427	10165428	rs7017212	4e-06	Schizophrenia
chr8	10214109	10214110	rs11775334	4e-06	Hypertension
chr8	10494797	10494798	rs4281086	4e-06	Obesity-related traits
chr8	106896780	106896781	rs4269515	4e-06	Dental caries
chr7	84143098	84143099	rs447	4e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr8	114566077	114566078	rs7014900	4e-06	Post-traumatic stress disorder (asjusted for relatedness)
chr8	123702481	123702482	rs13258681	4e-06	Prostate cancer (gene x gene interaction)
chr8	123753461	123753462	rs10088262	4e-06	Pancreatic cancer
chr8	127082910	127082911	rs13252298	4e-06	Prostate cancer
chr8	128234168	128234169	rs10492294	4e-06	Immunoglobulin A 
chr8	13318897	13318898	rs1671400	4e-06	Obesity-related traits
chr8	133603506	133603507	rs2945733	4e-06	Intraocular pressure
chr8	14996271	14996272	rs4427170	4e-06	Methamphetamine dependence
chr8	18523724	18523725	rs10090117	4e-06	Paclitaxel-induced neuropathy
chr8	18924536	18924537	rs4921617	4e-06	Neutrophil count
chr8	20208537	20208538	rs1106634	4e-06	Bipolar disorder and schizophrenia
chr8	11755188	11755189	rs804280	4e-06	Myopia (pathological)
chr8	23778767	23778768	rs218869	4e-06	Response to mTOR inhibitor (everolimus)
chr7	7262661	7262662	rs1299548	4e-06	Visceral adipose tissue adjusted for BMI
chr7	69773171	69773172	rs11765886	4e-06	IgG glycosylation
chr7	12892423	12892424	rs732577	4e-06	Sudden cardiac arrest
chr7	131336339	131336340	rs7807274	4e-06	Asthma (childhood onset)
chr7	136899615	136899616	rs1364402	4e-06	Migraine with aura
chr7	140531329	140531330	rs10237118	4e-06	Optic disc size (cup)
chr7	140892426	140892427	rs17623382	4e-06	Response to Vitamin E supplementation
chr7	148560955	148560956	rs7807268	4e-06	Crohn's disease
chr7	152690783	152690784	rs10234749 	4e-06	Palmitic acid (16:0) plasma levels
chr7	157502243	157502244	rs10227331	4e-06	Inattentive symptoms
chr7	16797829	16797830	rs2280655	4e-06	IgG glycosylation
chr7	17278687	17278688	rs13236243	4e-06	Sensory disturbances after bilateral sagittal split ramus osteotomy
chr7	7228799	7228800	rs10259085	4e-06	Multiple sclerosis (severity)
chr7	19009764	19009765	rs2107595	4e-06	Stroke (ischemic)
chr7	21703355	21703356	rs368331	4e-06	MRI atrophy measures
chr7	22474433	22474434	rs17364464	4e-06	Dialysis-related mortality
chr7	2408857	2408858	rs6952809	4e-06	Multiple sclerosis
chr7	37027789	37027790	rs10488029	4e-06	IgG glycosylation
chr7	37717953	37717954	rs6951258	4e-06	Obesity-related traits
chr7	4434500	4434501	rs314590	4e-06	Obesity-related traits
chr7	54114238	54114239	rs6593122	4e-06	Vaccine-related adverse events 
chr7	5485173	5485174	rs10216189	4e-06	Relative hand skill in reading disability
chr7	66152607	66152608	rs875971	4e-06	Aortic root size
chr7	66565624	66565625	rs801193	4e-06	Aortic root size
chr7	19765856	19765857	rs6977660	4e-06	Thyroid stimulating hormone
chr8	28048370	28048371	rs6983473	4e-06	Cardiac Troponin-T levels
chr8	30405269	30405270	rs2979481	4e-06	Heart rate variability traits
chr8	37084023	37084024	rs4739466	4e-06	Bipolar disorder
chr9	24720233	24720234	rs10491833	4e-06	Serum dimethylarginine levels (symmetric)
chr9	25452813	25452814	rs13300284	4e-06	RR interval (heart rate)
chr9	27075716	27075717	rs1577330	4e-06	IgG glycosylation
chr9	2742770	2742771	rs2034764	4e-06	Alzheimer's disease (age of onset)
chr9	28181086	28181087	rs1319535	4e-06	IgG glycosylation
chr9	29545876	29545877	rs13290799	4e-06	Obesity-related traits
chr9	32433527	32433528	rs10970976	4e-06	Asthma
chr9	33799371	33799372	rs216345	4e-06	Bipolar disorder
chr9	35648952	35648953	rs3138083	4e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel)
chr9	69251015	69251016	rs2282335	4e-06	Renal sinus fat 
chr9	22026077	22026078	rs615552	4e-06	Migraine without aura
chr9	76995711	76995712	rs79460104	4e-06	Response to amphetamines
chr9	84329509	84329510	rs12000457	4e-06	Obesity-related traits
chr9	85315129	85315130	rs2841498	4e-06	Partial epilepsies
chr9	86958167	86958168	rs9792548	4e-06	Insulin resistance/response
chr9	88645646	88645647	rs17054265	4e-06	Obesity-related traits
chr9	94681755	94681756	rs10125337	4e-06	Obesity-related traits
chr9	94978991	94978992	rs3802458	4e-06	Erectile dysfunction and prostate cancer treatment
chr9	955793	955794	rs364477	4e-06	Major depressive disorder
chr9	95614416	95614417	rs10988802	4e-06	Chemerin levels
chr9	96054201	96054202	rs1547201	4e-06	IgG glycosylation
chr2	122368902	122368903	rs10496584	4e-06	Lentiform nucleus volume 
chr9	78325659	78325660	rs1411916	4e-06	Visceral fat
chr9	19664082	19664083	rs4258076	4e-06	Cognitive performance
chr9	17895106	17895107	rs10810865	4e-06	Cognitive performance
chr9	15335915	15335916	rs16933006	4e-06	Obesity-related traits
chr8	38146906	38146907	rs16887217	4e-06	Orthostatic hypotension
chr8	4427867	4427868	rs1154053	4e-06	Disc degeneration (lumbar)
chr8	4625618	4625619	rs2616984	4e-06	Cognitive performance
chr8	47036077	47036078	rs2287654	4e-06	Visceral adipose tissue adjusted for BMI
chr8	5017649	5017650	rs10112481	4e-06	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU)
chr8	5369579	5369580	rs77265424	4e-06	Metabolite levels (5-HIAA)
chr8	59217736	59217737	rs3110127	4e-06	RR interval (heart rate)
chr8	60281610	60281611	rs10957125	4e-06	Response to amphetamines
chr8	64817649	64817650	rs6472155	4e-06	Retinopathy in non-diabetics
chr8	70632512	70632513	rs13272623	4e-06	IgG glycosylation
chr8	75235718	75235719	rs16939046	4e-06	Information processing speed
chr8	80316590	80316591	rs11987678	4e-06	Sleep duration
chr8	80526184	80526185	rs1051920	4e-06	Hypothyroidism
chr8	82161593	82161594	rs13264970	4e-06	Prostate cancer (gene x gene interaction)
chr8	95492243	95492244	rs77742018	4e-06	Anorexia nervosa
chr8	95583507	95583508	rs3104964	4e-06	Colorectal cancer
chr8	98305510	98305511	rs11785622	4e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr9	105678260	105678261	rs10120372	4e-06	Visceral adipose tissue/subcutaneous adipose tissue ratio
chr9	112035756	112035757	rs10125054	4e-06	Obesity-related traits
chr9	115068532	115068533	rs7847271	4e-06	Prostate cancer (gene x gene interaction)
chr9	118584138	118584139	rs1572299	4e-06	Schizophrenia
chr9	136372043	136372044	rs4077515	4e-06	Crohn's disease
chr9	1456796	1456797	rs1412259 	4e-06	Response to taxane treatment (docetaxel)
chr7	12153805	12153806	rs114945094	4e-06	Anorexia nervosa
chr5	1320606	1320607	rs402710	4e-06	Lung cancer
chr7	120665094	120665095	rs728115	4e-06	Alcohol and nictotine co-dependence
chr7	117383480	117383481	rs4730779	4e-06	Waist circumference
chr5	57834990	57834991	rs10940579	4e-06	Prostate cancer (gene x gene interaction)
chr5	75006832	75006833	rs4555772 	4e-06	Stearic acid (18:0) plasma levels
chr5	7816531	7816532	rs326155	4e-06	Visceral fat
chr5	81110746	81110747	rs138206701	4e-06	Eating disorders
chr5	81115401	81115402	rs4703822	4e-06	Orofacial clefts
chr5	87738534	87738535	rs1673101	4e-06	Major depressive disorder
chr5	93231832	93231833	rs4869419	4e-06	Natriuretic peptide levels
chr5	95911055	95911056	rs3777193	4e-06	IgG glycosylation
chr5	99380063	99380064	rs11745890	4e-06	IgG glycosylation
chr6	100947530	100947531	rs11969893	4e-06	Economic and political preferences (immigration/crime)
chr5	57370672	57370673	rs10052004	4e-06	Schizophrenia
chr6	106135044	106135045	rs742108	4e-06	Systemic lupus erythematosus
chr6	114748552	114748553	rs6928844	4e-06	IgG glycosylation
chr6	118297817	118297818	rs166881	4e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr6	123668595	123668596	rs9490860	4e-06	IgG glycosylation
chr6	124021517	124021518	rs6917824L	4e-06	Schizophrenia
chr6	129687299	129687300	rs12660691	4e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel)
chr6	132567799	132567800	rs9399032	4e-06	Migraine without aura
chr6	134817851	134817852	rs2049953	4e-06	Non-alcoholic fatty liver disease histology (AST)
chr6	135097777	135097778	rs7776054	4e-06	Red blood cell traits
chr6	14199915	14199916	rs7758616	4e-06	Obesity-related traits
chr6	142501079	142501080	rs9496398	4e-06	Neutrophil count
chr6	109420811	109420812	rs9487094	4e-06	Height
chr6	143758716	143758717	rs6931865	4e-06	Erectile dysfunction
chr5	56808480	56808481	rs10461617	4e-06	Type 2 diabetes
chr5	5407700	5407701	rs2964475	4e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin)
chr5	142066414	142066415	rs6867913	4e-06	Asthma
chr5	142484038	142484039	rs17577085	4e-06	Coronary heart disease
chr5	14393511	14393512	rs10065203	4e-06	Paclitaxel-induced neuropathy
chr5	146369971	146369972	rs7718446	4e-06	Migraine without aura
chr5	149657412	149657413	rs17710780	4e-06	Major depressive disorder
chr5	149831284	149831285	rs32579	4e-06	Tanning
chr5	151964996	151964997	rs170020	4e-06	Interstitial lung disease 
chr5	154431929	154431930	rs10037670	4e-06	Behavioural disinhibition (generation interaction)
chr5	156712557	156712558	rs157350	4e-06	Anthropometric traits
chr5	158256516	158256517	rs11957368	4e-06	Metabolite levels (Dihydroxy docosatrienoic acid)
chr5	56027066	56027067	rs17348299	4e-06	IgG glycosylation
chr5	158748660	158748661	rs13170526	4e-06	Obesity-related traits
chr5	178186542	178186543	rs2961663	4e-06	Rheumatoid arthritis
chr5	18483541	18483542	rs4866334	4e-06	IgG glycosylation
chr5	25087615	25087616	rs2047267	4e-06	Uric acid levels
chr5	31927210	31927211	rs7719829	4e-06	Obesity-related traits
chr5	3939361	3939362	rs492478	4e-06	Cognitive performance
chr5	39902262	39902263	rs11954519	4e-06	Urate levels
chr5	42375140	42375141	rs979233	4e-06	Systemic lupus erythematosus
chr5	428120	428121	rs12188164	4e-06	Cystic fibrosis severity
chr5	50730630	50730631	rs282544	4e-06	Myopia (pathological)
chr5	51877489	51877490	rs17835853	4e-06	IgG glycosylation
chr5	17002975	17002976	rs6870564	4e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr6	150059747	150059748	rs78546022	4e-06	Metabolite levels (HVA/5-HIAA ratio)
chr6	150249730	150249731	rs3734729	4e-06	Pulmonary function
chr6	152417618	152417619	rs17082664	4e-06	Bipolar disorder
chr6	35007637	35007638	rs2140418	4e-06	Alcoholism (alcohol use disorder factor score)
chr6	38068643	38068644	rs17589516	4e-06	Insulin resistance/response
chr6	42763376	42763377	rs6458307	4e-06	Bipolar disorder
chr6	43844024	43844025	rs9472138	4e-06	Type 2 diabetes
chr6	475488	475489	rs12210050	4e-06	Schizophrenia
chr6	53258319	53258320	rs735860	4e-06	Glaucoma
chr6	66219154	66219155	rs3857536	4e-06	Blood trace element (Cu levels)
chr6	69364339	69364340	rs3757057	4e-06	Response to statin therapy
chr6	7106082	7106083	rs2842895	4e-06	Visceral adipose tissue adjusted for BMI
chr6	7106082	7106083	rs2842895	4e-06	Visceral adipose tissue adjusted for BMI
chr6	35007637	35007638	rs2140418	4e-06	Alcoholism (alcohol dependence factor score)
chr6	71772754	71772755	rs10455248	4e-06	Cognitive performance
chr6	87667330	87667331	rs28381552	4e-06	Obesity-related traits
chr6	88543929	88543930	rs2610739	4e-06	IgG glycosylation
chr6	89589490	89589491	rs6939321	4e-06	Metabolite levels (Pyroglutamine)
chr6	9030102	9030103	rs438259	4e-06	Attention deficit hyperactivity disorder
chr6	92487581	92487582	rs13207034	4e-06	Metabolite levels (HVA)
chr6	95519535	95519536	rs2380220	4e-06	Behavioural disinhibition (generation interaction)
chr6	9853685	9853686	rs4716055	4e-06	Adiponectin levels
chr7	109363516	109363517	rs10277209	4e-06	Prostate cancer (gene x gene interaction)
chr7	114101049	114101050	rs6466479	4e-06	IgG glycosylation
chr7	114989230	114989231	rs7784447	4e-06	Obesity
chr6	87620223	87620224	rs13213285	4e-06	Obesity-related traits
chr6	32146737	32146738	rs9296009	4e-06	IgG glycosylation
chr6	32146737	32146738	rs9296009	4e-06	IgG glycosylation
chr6	31962663	31962664	rs592229	4e-06	IgG glycosylation
chr6	153683835	153683836	rs2186141	4e-06	Migraine - clinic-based
chr6	158014539	158014540	rs9365723	4e-06	Colorectal cancer
chr6	166157954	166157955	rs1056053	4e-06	Visceral adipose tissue/subcutaneous adipose tissue ratio
chr6	16741801	16741802	rs697739	4e-06	Amyotrophic lateral sclerosis
chr6	20382368	20382369	rs1570155	4e-06	Obesity-related traits
chr6	21384381	21384382	rs9466056	4e-06	Bone mineral density
chr6	22246374	22246375	rs4236016	4e-06	Cardiac hypertrophy
chr6	22303974	22303975	rs1341239	4e-06	Paget's disease
chr6	2355440	2355441	rs2505675	4e-06	Tuberculosis
chr6	23840903	23840904	rs9466930	4e-06	Major depressive disorder
chr6	24062559	24062560	rs146696563	4e-06	Periodontitis (Mean PAL)
chr6	24106864	24106865	rs6922632	4e-06	Information processing speed
chr6	252144	252145	rs6927090	4e-06	Hematology traits
chr6	25997229	25997230	rs12216125	4e-06	Iron status biomarkers
chr6	26092912	26092913	rs1800562	4e-06	Red blood cell traits
chr6	30831621	30831622	rs9501030	4e-06	Ulcerative colitis
chr6	31303938	31303939	rs9461688	4e-06	Protein quantitative trait loci
chr6	31392477	31392478	rs7751505	4e-06	Pubertal anthropometrics
chr6	31605178	31605179	rs2844479	4e-06	IgG glycosylation
chr6	31605178	31605179	rs2844479	4e-06	IgG glycosylation
chr6	31623120	31623121	rs2736172	4e-06	Psychosis (atypical)
chr6	31635189	31635190	rs1046089	4e-06	Schizophrenia
chr6	31834687	31834688	rs4711279	4e-06	IgG glycosylation
chr7	12055339	12055340	rs1035147	4e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors)
chr21	20448095	20448096	rs1735884	4e-06	Obesity-related traits
chr20	17848635	17848636	rs2745851	4e-06	IgG glycosylation
chr2	114292240	114292241	rs4513299	4e-06	Inflammatory biomarkers
chr1	229150110	229150111	rs9793739	4e-06	Dental caries
chr1	230539079	230539080	rs701157	4e-06	Attention deficit hyperactivity disorder and conduct disorder
chr12	32227566	32227567	rs10844154	4e-06	Weight
chr12	32323792	32323793	rs261902	4e-06	Normalized brain volume
chr1	233584237	233584238	rs11800854	4e-06	Periodontal microbiota
chr1	234590609	234590610	rs11581667	4e-06	IgG glycosylation
chr12	3705071	3705072	rs10848911	4e-06	Male infertility
chr1	237747703	237747704	rs2819770	4e-06	Exercise treadmill test traits
chr1	240120435	240120436	rs11810574	4e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr1	24105465	24105466	rs3934861	4e-06	Bipolar disorder (mood-incongruent)
chr12	2674805	2674806	rs2302729	4e-06	Sleep quality
chr1	242368351	242368352	rs1439523	4e-06	IgG glycosylation
chr12	4290803	4290804	rs3217869	4e-06	QT interval (interaction)
chr1	244413414	244413415	rs3102460	4e-06	Obesity-related traits
chr1	246497933	246497934	rs11800820	4e-06	Obesity-related traits
chr1	246497933	246497934	rs11800820	4e-06	Obesity-related traits
chr1	247184886	247184887	rs3738443	4e-06	Alcohol dependence
chr12	53925942	53925943	rs894734	4e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs)
chr12	57668883	57668884	rs10876993	4e-06	Celiac disease and Rheumatoid arthritis
chr12	58356896	58356897	rs1795708	4e-06	Obesity-related traits
chr12	59046450	59046451	rs17121944	4e-06	Temperament (bipolar disorder)
chr12	6199356	6199357	rs3181157	4e-06	Paclitaxel-induced neuropathy
chr12	42767022	42767023	rs2731006	4e-06	Panic disorder
chr1	2622184	2622185	rs3890745	4e-06	Rheumatoid arthritis
chr1	225405224	225405225	rs16844846	4e-06	IgG glycosylation
chr1	224351237	224351238	rs11579964	4e-06	Major depressive disorder
chr1	205514466	205514467	rs12127944	4e-06	IgG glycosylation
chr1	209160871	209160872	rs4382726	4e-06	Response to amphetamines
chr12	105714940	105714941	rs10219670	4e-06	Alzheimer's disease biomarkers
chr12	106835926	106835927	rs10444533	4e-06	Social autistic-like traits
chr12	114914925	114914926	rs2384550	4e-06	Blood pressure
chr1	211518363	211518364	rs7553035	4e-06	Retinopathy in non-diabetics
chr12	11809638	11809639	rs7314811	4e-06	IgG glycosylation
chr12	120125169	120125170	rs11065028	4e-06	Obesity-related traits
chr12	121184500	121184501	rs3751143	4e-06	Chronic obstructive pulmonary disease-related biomarkers
chr12	122690195	122690196	rs601339	4e-06	Adiponectin levels
chr1	225402972	225402973	rs16844841	4e-06	IgG glycosylation
chr12	12576381	12576382	rs12302103	4e-06	Homeostasis model assessment of beta-cell function (interaction)
chr12	130868016	130868017	rs7304057	4e-06	Response to amphetamines
chr1	214283665	214283666	rs9308433	4e-06	IgG glycosylation
chr1	214781595	214781596	rs6695352	4e-06	Migraine without aura
chr12	15236702	15236703	rs12311304	4e-06	Behavioural disinhibition (generation interaction)
chr1	217353681	217353682	rs1497828	4e-06	Dialysis-related mortality
chr12	1825414	1825415	rs2887631	4e-06	Behavioural disinhibition (generation interaction)
chr12	20707158	20707159	rs3794271	4e-06	Response to TNF-alpha inhibitors in rheumatoid arthritis
chr12	22212900	22212901	rs2216228	4e-06	Non-alcoholic fatty liver disease histology (lobular)
chr12	22413494	22413495	rs11046430	4e-06	Coronary artery calcification
chr1	222750008	222750009	rs6683071	4e-06	Cognitive performance
chr12	130146389	130146390	rs11060736	4e-06	Gambling
chr1	195562292	195562293	rs1890645	4e-06	Neonatal lupus
chr12	62787035	62787036	rs549433	4e-06	Obesity-related traits
chr12	65723777	65723778	rs2358944	4e-06	Type 2 diabetes nephropathy
chr13	42378008	42378009	rs9594738	4e-06	Bone mineral density
chr13	44053651	44053652	rs17065323	4e-06	Uric acid levels
chr13	44063268	44063269	rs9567349	4e-06	Prostate cancer (gene x gene interaction)
chr13	44234037	44234038	rs9533799	4e-06	Amyotrophic lateral sclerosis
chr13	58330178	58330179	rs10492604	4e-06	Sleep duration
chr13	62356166	62356167	rs9563960	4e-06	IgG glycosylation
chr1	36439118	36439119	rs6702784	4e-06	Diabetic retinopathy 
chr13	65782208	65782209	rs17077331	4e-06	Pulmonary function decline
chr13	67997904	67997905	rs7318913	4e-06	Serum dimethylarginine levels (symmetric)
chr1	37493211	37493212	rs9253	4e-06	Hemostatic factors and hematological phenotypes
chr13	41565108	41565109	rs17594362	4e-06	Multiple sclerosis
chr13	75674966	75674967	rs11841001	4e-06	Corneal astigmatism
chr13	98479039	98479040	rs912330	4e-06	Alzheimer's disease
chr13	99544697	99544698	rs9513627	4e-06	Obesity-related traits
chr1	40773838	40773839	rs4660456	4e-06	Platelet counts
chr14	102129287	102129288	rs1190596	4e-06	Behavioural disinhibition (generation interaction)
chr14	22468663	22468664	rs12589282	4e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs)
chr14	22487721	22487722	rs227869	4e-06	Relative hand skill in reading disability
chr14	33007059	33007060	rs4982029	4e-06	Schizophrenia, bipolar disorder and depression (combined)
chr14	34375169	34375170	rs1958589	4e-06	Celiac disease
chr14	36384930	36384931	rs12590640	4e-06	Malaria
chr1	43651334	43651335	rs660899	4e-06	Hypertension risk in short sleep duration
chr13	93286452	93286453	rs11839514	4e-06	Visceral fat
chr1	26293157	26293158	rs6598955	4e-06	Obesity-related traits
chr13	30311085	30311086	rs185694	4e-06	Antineutrophil cytoplasmic antibody-associated vasculitis 
chr13	23329651	23329652	rs4770433	4e-06	Protein quantitative trait loci
chr12	65970728	65970729	rs12424086	4e-06	Primary tooth development (number of teeth)
chr12	6829707	6829708	rs3741920	4e-06	Response to Vitamin E supplementation
chr12	71241013	71241014	rs4760790	4e-06	Type 2 diabetes
chr12	72913801	72913802	rs10879517	4e-06	Cognitive performance
chr12	74660812	74660813	rs7311660	4e-06	Obesity-related traits
chr12	77344224	77344225	rs6538140	4e-06	Tuberculosis
chr12	79668449	79668450	rs7297018	4e-06	Attention deficit hyperactivity disorder and conduct disorder
chr12	80069303	80069304	rs10778699	4e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr12	81150756	81150757	rs10492002	4e-06	Response to antidepressant treatment (citalopram)
chr12	81449348	81449349	rs12426725	4e-06	Schizophrenia
chr13	29387194	29387195	rs2388082	4e-06	Insomnia (caffeine-induced)
chr12	82770776	82770777	rs12317459	4e-06	Prostate cancer (gene x gene interaction)
chr12	9394365	9394366	rs7397814	4e-06	IgG glycosylation
chr12	95663407	95663408	rs2367563	4e-06	Allergic dermatitis (nickel)
chr12	96414138	96414139	rs11108495	4e-06	Weight
chr13	105596959	105596960	rs1549059	4e-06	Obesity-related traits
chr13	110378230	110378231	rs7319311	4e-06	Bipolar disorder and schizophrenia
chr13	111128712	111128713	rs12853515	4e-06	Fasting insulin (interaction)
chr13	20162076	20162077	rs6490525	4e-06	Capecitabine sensitivity
chr13	20705894	20705895	rs735539	4e-06	Dental caries
chr13	21241729	21241730	rs17064136	4e-06	Obesity-related traits
chr13	21301956	21301957	rs9788333	4e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr12	93589777	93589778	rs7953508	4e-06	Pubertal anthropometrics
chr11	94538496	94538497	rs11020821	4e-06	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy)
chr11	93970882	93970883	rs11825709	4e-06	Obesity-related traits
chr11	93433564	93433565	rs2658782	4e-06	Pulmonary function decline
chr10	66405508	66405509	rs2441755	4e-06	Dental caries
chr10	68254472	68254473	rs10998035	4e-06	Eating disorders (purging via substances) 
chr10	68866672	68866673	rs10998466	4e-06	Disc degeneration (lumbar)
chr10	71223227	71223228	rs16928529	4e-06	Attention deficit hyperactivity disorder
chr10	75049001	75049002	rs7919006	4e-06	Weight
chr10	77781076	77781077	rs12261589	4e-06	Obesity-related traits
chr10	82659653	82659654	rs2219937	4e-06	IgG glycosylation
chr10	85875166	85875167	rs1970525	4e-06	Periodontal microbiota
chr10	87683552	87683553	rs10887741	4e-06	Exercise (leisure time)
chr10	94774505	94774506	rs6583954	4e-06	Migraine
chr10	66204614	66204615	rs1471384	4e-06	Lung function (forced vital capacity)
chr10	95470004	95470005	rs579342	4e-06	Obesity-related traits
chr1	108875056	108875057	rs7523050	4e-06	Fat distribution (HIV)
chr1	109275907	109275908	rs646776	4e-06	Response to statin therapy
chr11	100172687	100172688	rs12803066	4e-06	Myopia (pathological)
chr11	107885824	107885825	rs2186903	4e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr11	111540882	111540883	rs11213935	4e-06	Obesity-related traits
chr11	115893326	115893327	rs638882	4e-06	Hip geometry
chr11	118246302	118246303	rs11216831	4e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr11	120156039	120156040	rs2084898	4e-06	Stroke (pediatric)
chr11	12049117	12049118	rs16910421	4e-06	Visceral fat
chr11	122318756	122318757	rs565229	4e-06	Hemostatic factors and hematological phenotypes
chr10	98531418	98531419	rs577969	4e-06	Migraine
chr11	124085758	124085759	rs1893767	4e-06	Obesity-related traits
chr10	6351297	6351298	rs4750316	4e-06	Rheumatoid arthritis
chr10	31207044	31207045	rs1250307	4e-06	Disc degeneration (lumbar)
chr10	101938947	101938948	rs34014631	4e-06	Coronary artery calcification
chr10	102959338	102959339	rs12413409	4e-06	Coronary heart disease
chr10	104206645	104206646	rs515910	4e-06	Attention deficit hyperactivity disorder
chr10	107810091	107810092	rs12570947	4e-06	Prion diseases
chr10	10932292	10932293	rs10905868	4e-06	Obesity-related traits
chr10	114054632	114054633	rs10885531	4e-06	Adiponectin levels
chr10	114379269	114379270	rs4751674	4e-06	Cognitive performance
chr10	114567790	114567791	rs10885582	4e-06	Prostate cancer (gene x gene interaction)
chr10	116065376	116065377	rs2302105	4e-06	IgG glycosylation
chr10	121141108	121141109	rs2901286	4e-06	Response to treatment for acute lymphoblastic leukemia
chr10	31226202	31226203	rs2484990	4e-06	Disc degeneration (lumbar)
chr10	12396783	12396784	rs10906142	4e-06	Obesity-related traits
chr10	12833207	12833208	rs10906233	4e-06	Eating disorders
chr10	130748996	130748997	rs4750829	4e-06	Obesity-related traits
chr21	20448095	20448096	rs1735884	4e-06	Obesity-related traits
chr10	133492653	133492654	rs1536827	4e-06	Visceral adipose tissue/subcutaneous adipose tissue ratio
chr10	19640583	19640584	rs1326986	4e-06	Ankylosing spondylitis
chr10	23376508	23376509	rs1398024	4e-06	Crohn's disease and sarcoidosis (combined)
chr10	24935532	24935533	rs11014306	4e-06	Metabolite levels (Pyroglutamine)
chr10	26005898	26005899	rs16926523	4e-06	PR interval
chr10	29075767	29075768	rs10826566	4e-06	Migraine with aura
chr10	29198435	29198436	rs4387258	4e-06	Methotrexate phramacokinetics (acute lymphoblastic leukemia)
chr10	127880409	127880410	rs6482992	4e-06	Parkinson's disease (motor and cognition)
chr11	130659323	130659324	rs12792526	4e-06	Periodontitis (Mean PAL)
chr11	131466179	131466180	rs992564	4e-06	Bipolar disorder and schizophrenia
chr11	15333699	15333700	rs11605083	4e-06	Prostate cancer (gene x gene interaction)
chr1	164720524	164720525	rs1387389	4e-06	Breast cancer (prognosis)
chr1	165439857	165439858	rs10800098	4e-06	AIDS
chr11	65493174	65493175	rs600231	4e-06	Bone mineral density
chr1	167187262	167187263	rs9803659	4e-06	Liver enzyme levels
chr11	68789313	68789314	rs2924679	4e-06	Obesity-related traits
chr1	16889835	16889836	rs6586513	4e-06	Allergic rhinitis
chr1	169707344	169707345	rs3177980	4e-06	Amyotrophic lateral sclerosis
chr1	173332376	173332377	rs1342038	4e-06	Diabetic retinopathy 
chr11	73765999	73766000	rs1723838	4e-06	Obesity-related traits
chr1	175327311	175327312	rs3766680	4e-06	Tonometry
chr11	64224328	64224329	rs1059440	4e-06	Attention deficit hyperactivity disorder
chr11	77589002	77589003	rs7129556	4e-06	Weight loss (gastric bypass surgery)
chr11	79372575	79372576	rs12290811	4e-06	Bipolar disorder
chr11	81524107	81524108	rs2032381	4e-06	Smooth-surface caries 
chr1	183201812	183201813	rs1028771	4e-06	Coronary heart disease
chr1	184792230	184792231	rs682331	4e-06	Obesity-related traits
chr1	188410296	188410297	rs12125250	4e-06	Economic and political preferences
chr11	89180494	89180495	rs621313	4e-06	Age-related macular degeneration
chr1	19060090	19060091	rs12123383	4e-06	Response to amphetamines
chr1	190872542	190872543	rs2053302	4e-06	Response to statin therapy
chr1	192837110	192837111	rs7550636	4e-06	Coronary artery calcification
chr11	93359970	93359971	rs12098946	4e-06	Obesity-related traits
chr11	79354055	79354056	rs530965	4e-06	Cognitive test performance
chr11	64196474	64196475	rs11607165	4e-06	Attention deficit hyperactivity disorder
chr1	163172764	163172765	rs12035879	4e-06	Liver enzyme levels (alanine transaminase)
chr1	163083498	163083499	rs2063142	4e-06	Response to mTOR inhibitor (rapamycin)
chr1	11728506	11728507	rs4846033	4e-06	Schizophrenia
chr11	18800489	18800490	rs4627050	4e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin)
chr11	19548015	19548016	rs874426	4e-06	Attention deficit hyperactivity disorder (time to onset)
chr11	21599401	21599402	rs1573535	4e-06	Cannabis use (initiation)
chr11	25468935	25468936	rs10834691	4e-06	IgG glycosylation
chr11	26583783	26583784	rs12295638	4e-06	Obesity (extreme)
chr11	2818520	2818521	rs2237892	4e-06	Type 2 diabetes
chr11	31863372	31863373	rs11031492	4e-06	Metabolite levels (HVA/5-HIAA ratio)
chr11	33566663	33566664	rs10437629	4e-06	Suicide attempts in bipolar disorder
chr11	33785275	33785276	rs11825259	4e-06	Coronary artery calcification
chr11	34641413	34641414	rs286905	4e-06	Obesity-related traits
chr11	34742931	34742932	rs1355223	4e-06	Systemic lupus erythematosus and Systemic sclerosis
chr11	4541987	4541988	rs12416860	4e-06	Obesity-related traits
chr11	48518670	48518671	rs11039798	4e-06	Axial length
chr1	149942457	149942458	rs1061955	4e-06	Obesity-related traits
chr1	152065038	152065039	rs3124314	4e-06	Hair morphology
chr1	152344113	152344114	rs3120665	4e-06	Personality dimensions
chr1	152482114	152482115	rs908922	4e-06	Hair morphology
chr1	153668350	153668351	rs7536700	4e-06	Multiple myeloma (IgH translocation)
chr1	153966653	153966654	rs11264736	4e-06	Lentiform nucleus volume 
chr11	56672759	56672760	rs11228719	4e-06	Orofacial clefts
chr11	589563	589564	rs4963128	4e-06	Systemic lupus erythematosus
chr11	61829739	61829740	rs174570	4e-06	HDL cholesterol
chr14	49067706	49067707	rs8013477	4e-06	Visceral adipose tissue/subcutaneous adipose tissue ratio
chr14	50411264	50411265	rs1265879	4e-06	Cognitive performance
chr10	132144256	132144257	rs954820	4e-06	Chronic obstructive pulmonary disease-related biomarkers
chr14	61718576	61718577	rs8005745	4e-06	Select biomarker traits
chr18	6668050	6668051	rs11662297	4e-06	Obesity-related traits
chr18	67349862	67349863	rs2124349	4e-06	Cognitive performance
chr18	6941108	6941109	rs4398173	4e-06	Response to citalopram treatment
chr18	71581358	71581359	rs1539909	4e-06	Response to TNF-alpha inhibitors in rheumatoid arthritis
chr18	75075089	75075090	rs17056274	4e-06	Estradiol levels
chr18	76606652	76606653	rs13381277	4e-06	Dental caries
chr18	78152921	78152922	rs4798896	4e-06	Schizophrenia
chr18	78655449	78655450	rs66591657	4e-06	Response to amphetamines
chr18	8209270	8209271	rs8098064	4e-06	Dialysis-related mortality
chr18	849176	849177	rs1291183	4e-06	Pulmonary function in asthmatics
chr1	86585517	86585518	rs1953652	4e-06	IgG glycosylation
chr1	88875724	88875725	rs17130643	4e-06	Obesity-related traits
chr19	13135153	13135154	rs10408126	4e-06	Obesity-related traits
chr19	16356947	16356948	rs875622	4e-06	White matter integrity
chr19	17278894	17278895	rs8170	4e-06	Ovarian cancer
chr1	91728764	91728765	rs11165354	4e-06	Type 2 diabetes
chr19	18636794	18636795	rs3764628	4e-06	Orofacial clefts
chr19	19610912	19610913	rs12610185	4e-06	Obesity-related traits
chr19	22873543	22873544	rs7246967	4e-06	Bronchopulmonary dysplasia
chr19	29412769	29412770	rs12986207	4e-06	Bulimia nervosa
chr19	31420222	31420223	rs11880316	4e-06	Estradiol levels
chr19	3318511	3318512	rs11669592	4e-06	Non-alcoholic fatty liver disease histology (other)
chr18	9288457	9288458	rs2864527	4e-06	Dental caries
chr1	9351409	9351410	rs11121382	4e-06	Immune response to anthrax vaccine 
chr18	5978931	5978932	rs1539808	4e-06	Sleep time
chr18	57085082	57085083	rs1557351	4e-06	Multiple sclerosis (age of onset)
chr1	78762270	78762271	rs1937020	4e-06	Anorexia nervosa
chr1	78798119	78798120	rs10873998	4e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr1	79668437	79668438	rs7533906	4e-06	Bipolar disorder and schizophrenia
chr1	80268895	80268896	rs11162963	4e-06	Aging (time to event)
chr18	10923809	10923810	rs264272	4e-06	Major depressive disorder
chr18	120295	120296	rs57440971	4e-06	Periodontitis (Mean PAL)
chr18	1206982	1206983	rs1826508	4e-06	Metabolite levels (Dihydroxy docosatrienoic acid)
chr18	26205683	26205684	rs8097810	4e-06	Periodontitis (Mean PAL)
chr18	278795	278796	rs7226677	4e-06	Bipolar disorder and major depressive disorder (combined)
chr18	31458159	31458160	rs1941184	4e-06	Parkinson's disease (age of onset)
chr18	58546157	58546158	rs12456021	4e-06	Multiple sclerosis
chr18	33347810	33347811	rs6507016	4e-06	Prostate cancer (gene x gene interaction)
chr18	355943	355944	rs644435	4e-06	Obesity-related traits
chr18	42443340	42443341	rs346221	4e-06	Periodontitis (PAL4Q3)
chr18	42478916	42478917	rs7235528	4e-06	Economic and political preferences (immigration/crime)
chr18	42479655	42479656	rs16976171	4e-06	Coronary artery calcification
chr1	84327289	84327290	rs315553	4e-06	Obesity-related traits
chr1	84802559	84802560	rs10782529	4e-06	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy
chr18	48289045	48289046	rs1944582	4e-06	Response to taxane treatment (docetaxel)
chr18	49053599	49053600	rs357894	4e-06	Dental caries
chr18	54000197	54000198	rs1995138	4e-06	Periodontitis (Mean PAL)
chr18	55359125	55359126	rs1631486	4e-06	Obesity (early onset extreme)
chr18	33840045	33840046	rs1013696	4e-06	Response to antidepressants
chr17	80092817	80092818	rs2361701	4e-06	IgG glycosylation
chr19	38683691	38683692	rs973009	4e-06	Migraine with aura
chr19	44428796	44428797	rs1434579	4e-06	Tuberculosis
chr20	35261375	35261376	rs1555322	4e-06	Attention deficit hyperactivity disorder
chr20	36277317	36277318	rs8115222	4e-06	Obesity-related traits
chr20	37439986	37439987	rs17194885	4e-06	Retinopathy in non-diabetics
chr20	43858563	43858564	rs6103489	4e-06	Response to amphetamines
chr20	46869083	46869084	rs6124878	4e-06	Visceral adipose tissue/subcutaneous adipose tissue ratio
chr20	47051862	47051863	rs878131	4e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr20	49727773	49727774	rs1980946 	4e-06	Palmitic acid (16:0) plasma levels
chr20	51123322	51123323	rs230014	4e-06	QT interval (interaction)
chr20	57469127	57469128	rs6070116	4e-06	Response to statin therapy
chr20	58088217	58088218	rs6070346	4e-06	Pulmonary function decline
chr20	35176750	35176751	rs867186	4e-06	D-dimer levels
chr20	61718506	61718507	rs16985493	4e-06	Migraine - clinic-based
chr20	63786983	63786984	rs2315656	4e-06	Obesity-related traits
chr2	101305707	101305708	rs6711606	4e-06	Pancreatic cancer
chr2	103956546	103956547	rs2119507	4e-06	Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms)
chr2	103964044	103964045	rs12613775	4e-06	Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms)
chr2	103970892	103970893	rs10193430	4e-06	Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms)
chr2	103972679	103972680	rs11903187	4e-06	Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms)
chr2	105261412	105261413	rs17636747	4e-06	Preeclampsia
chr2	110949827	110949828	rs3789119	4e-06	Economic and political preferences (immigration/crime)
chr2	111039953	111039954	rs3789080	4e-06	Prostate cancer (gene x gene interaction)
chr14	57355497	57355498	rs7144649	4e-06	Alcohol consumption
chr20	61933123	61933124	rs6061910	4e-06	Obesity-related traits
chr1	94256103	94256104	rs12750249	4e-06	IgG glycosylation
chr20	33968970	33968971	rs6059594	4e-06	IgG glycosylation
chr20	32849800	32849801	rs7270085	4e-06	Attention deficit hyperactivity disorder (combined symptoms)
chr19	44823510	44823511	rs1871045	4e-06	Waist-to-hip circumference ratio (interaction)
chr19	44912382	44912383	rs445925	4e-06	Carotid intima media thickness
chr19	45531299	45531300	rs8111589	4e-06	Depression and alcohol dependence
chr19	45804147	45804148	rs8111071	4e-06	Sudden cardiac arrest
chr1	94868630	94868631	rs17520351	4e-06	Metabolite levels (Dihydroxy docosatrienoic acid)
chr19	49720008	49720009	rs3810265	4e-06	Panic disorder
chr19	53178788	53178789	rs16984547	4e-06	Asthma
chr19	55599708	55599709	rs140900046	4e-06	Periodontitis (Mean PAL)
chr19	55802161	55802162	rs299175	4e-06	Multiple sclerosis (severity)
chr1	96571526	96571527	rs10783050	4e-06	Body mass index
chr20	33130846	33130847	rs6059101	4e-06	Ulcerative colitis
chr1	99123822	99123823	rs303386	4e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors)
chr20	11228873	11228874	rs6040449	4e-06	Relative hand skill
chr20	12101993	12101994	rs11907106	4e-06	Obesity-related traits
chr20	13167504	13167505	rs2144134	4e-06	Body mass index (interaction)
chr20	15140097	15140098	rs11087123	4e-06	Eating disorders
chr20	16760179	16760180	rs4491792	4e-06	Post-traumatic stress disorder (asjusted for relatedness)
chr20	32789188	32789189	rs6119285	4e-06	Attention deficit hyperactivity disorder (combined symptoms)
chr20	32797073	32797074	rs6057648	4e-06	Attention deficit hyperactivity disorder (combined symptoms)
chr20	32807670	32807671	rs6119286	4e-06	Attention deficit hyperactivity disorder (combined symptoms)
chr20	32822530	32822531	rs6057651	4e-06	Attention deficit hyperactivity disorder (combined symptoms)
chr20	32832002	32832003	rs6057652	4e-06	Attention deficit hyperactivity disorder (combined symptoms)
chr1	99123822	99123823	rs303386	4e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin)
chr17	796779	796780	rs623323	4e-06	Type 2 diabetes
chr2	103962074	103962075	rs1036736	4e-06	Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms)
chr17	56533929	56533930	rs17760268	4e-06	Celiac disease
chr1	55642930	55642931	rs1165472	4e-06	Paclitaxel-induced neuropathy
chr15	56444279	56444280	rs6493858	4e-06	Relative hand skill in reading disability
chr15	61044242	61044243	rs7172342	4e-06	Schizophrenia
chr15	61410579	61410580	rs3884558	4e-06	Breast cancer (prognosis)
chr15	62020640	62020641	rs4143844	4e-06	Bipolar disorder and schizophrenia
chr15	73457266	73457267	rs11635553	4e-06	IgG glycosylation
chr15	74839977	74839978	rs936229	4e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin)
chr15	79900632	79900633	rs36035742	4e-06	Periodontitis (Mean PAL)
chr15	81241353	81241354	rs7172689	4e-06	Inattentive symptoms
chr15	84872154	84872155	rs12900463	4e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine)
chr15	46277267	46277268	rs6493206	4e-06	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)
chr15	86520857	86520858	rs12591257	4e-06	Psychosis (methamphetamine induced)
chr15	92507735	92507736	rs1455782	4e-06	Pulmonary function
chr15	93021741	93021742	rs7179432	4e-06	IgG glycosylation
chr15	94396278	94396279	rs4984390	4e-06	Drug-induced liver injury (flucloxacillin)
chr15	94775537	94775538	rs16949516 	4e-06	Stearic acid (18:0) plasma levels
chr15	96719196	96719197	rs4533251	4e-06	Attention deficit hyperactivity disorder and conduct disorder
chr15	99757457	99757458	rs1993293	4e-06	Coronary artery calcification
chr1	60225915	60225916	rs17120400	4e-06	Periodontitis (PAL4Q3)
chr16	10094202	10094203	rs7203315	4e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr16	11155471	11155472	rs6498169	4e-06	Multiple sclerosis
chr16	12091952	12091953	rs8048589	4e-06	Fasting insulin (interaction)
chr15	87434244	87434245	rs2679073	4e-06	Coronary artery calcification
chr16	12091952	12091953	rs8048589	4e-06	Homeostasis model assessment of insulin resistance (interaction)
chr15	38546062	38546063	rs8035957	4e-06	Type 1 diabetes
chr15	38219781	38219782	rs16966460	4e-06	Bipolar disorder
chr14	62855628	62855629	rs8012941	4e-06	Major depressive disorder
chr1	76306642	76306643	rs10873876	4e-06	Acute lymphoblastic leukemia (childhood)
chr14	65178531	65178532	rs7158173	4e-06	Anthropometric traits
chr14	65281040	65281041	rs1256531	4e-06	Conduct disorder (symptom count)
chr14	70177451	70177452	rs7146198	4e-06	Corneal curvature
chr14	72417165	72417166	rs7159300	4e-06	Smoking cessation
chr14	78068562	78068563	rs3850370	4e-06	Response to platinum-based chemotherapy in non-small-cell lung cancer
chr14	81056783	81056784	rs17111394	4e-06	Optic disc size (rim)
chr14	82788860	82788861	rs746630	4e-06	Obesity-related traits
chr14	82875977	82875978	rs10130259	4e-06	Obesity-related traits
chr15	38441645	38441646	rs8029989	4e-06	Psychosis (atypical)
chr14	87829255	87829256	rs4322600	4e-06	Breast cancer
chr14	89834690	89834691	rs12100561	4e-06	Hepatocellular carcinoma
chr14	90149168	90149169	rs4900022	4e-06	Coronary artery calcification
chr1	50472175	50472176	rs3827730	4e-06	Depression and alcohol dependence
chr15	23572573	23572574	rs2900	4e-06	IgG glycosylation
chr15	25357802	25357803	rs8025093	4e-06	Obesity-related traits
chr1	53163912	53163913	rs6695567	4e-06	Systemic lupus erythematosus
chr15	34776107	34776108	rs543686	4e-06	Prostate cancer (gene x gene interaction)
chr15	35757290	35757291	rs2947253	4e-06	Paclitaxel-induced neuropathy
chr15	37050400	37050401	rs8041675	4e-06	Hyperactive-impulsive symptoms
chr15	37157417	37157418	rs17439560	4e-06	Response to amphetamines
chr14	88093647	88093648	rs6574988	4e-06	Bipolar disorder
chr16	12614350	12614351	rs1560104	4e-06	Obesity-related traits
chr14	70928886	70928887	rs2810114	4e-06	Alcohol dependence
chr16	22877864	22877865	rs2519974	4e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide)
chr16	89382254	89382255	rs3096299	4e-06	Multiple myeloma (IgH translocation)
chr16	9120022	9120023	rs3743832	4e-06	Non-substance related behavioral disinhibition
chr1	69688757	69688758	rs1417437	4e-06	Orofacial clefts
chr1	69890297	69890298	rs12037173	4e-06	Attention deficit hyperactivity disorder
chr17	12734053	12734054	rs9905820	4e-06	Testosterone levels
chr17	13636486	13636487	rs10521232	4e-06	Tonometry
chr17	14726428	14726429	rs9899891	4e-06	Visceral adipose tissue/subcutaneous adipose tissue ratio
chr17	16913228	16913229	rs4792793	4e-06	Metabolite levels (Pyroglutamine)
chr17	18161415	18161416	rs8077577	4e-06	Obesity-related traits
chr17	189132	189133	rs7217319	4e-06	AIDS progression
chr16	86430088	86430089	rs2178146	4e-06	Esophageal adenocarcinoma
chr1	72358029	72358030	rs990871	4e-06	Subcutaneous adipose tissue
chr17	33066683	33066684	rs17808461	4e-06	Obesity-related traits
chr1	73588376	73588377	rs2341260	4e-06	Cardiac Troponin-T levels
chr17	37738048	37738049	rs4430796	4e-06	Type 2 diabetes
chr17	38945126	38945127	rs9906595	4e-06	Obesity-related traits
chr17	39175091	39175092	rs523516	4e-06	IgG glycosylation
chr17	41094386	41094387	rs4006360	4e-06	Bipolar disorder and schizophrenia
chr17	45727827	45727828	rs9303521	4e-06	Bone mineral density (hip)
chr17	45718066	45718067	rs11655470	4e-06	Head circumference (infant)
chr17	49213432	49213433	rs627386	4e-06	IgG glycosylation
chr16	19144693	19144694	rs8062326	4e-06	Alcohol dependence
chr17	26993862	26993863	rs73317122	4e-06	Response to amphetamines
chr16	84651902	84651903	rs11647936	4e-06	Waist circumference
chr17	44115816	44115817	rs228769	4e-06	Bone mineral density (spine)
chr16	83737890	83737891	rs444881	4e-06	IgG glycosylation
chr1	68461829	68461830	rs435066	4e-06	IgG glycosylation
chr1	63015058	63015059	rs17124318	4e-06	Weight
chr16	4951378	4951379	rs9635542	4e-06	Lung cancer-asbestos exposure interaction
chr16	49609654	49609655	rs2080501	4e-06	IgG glycosylation
chr16	49618867	49618868	rs16944158	4e-06	IgG glycosylation
chr16	50403616	50403617	rs9941219	4e-06	Liver enzyme levels (alanine transaminase)
chr16	51211575	51211576	rs7185923	4e-06	Weight loss (gastric bypass surgery)
chr16	51296619	51296620	rs4131099	4e-06	Personality dimensions
chr16	53805222	53805223	rs8044769	4e-06	Osteoarthritis
chr1	6571370	6571371	rs11587438	4e-06	White blood cell types
chr16	580664	580665	rs1981483	4e-06	Disc degeneration (lumbar)
chr16	35447821	35447822	rs62057608	4e-06	Obesity-related traits
chr16	611334	611335	rs7204439	4e-06	Disc degeneration (lumbar)
chr16	82485622	82485623	rs1991867	4e-06	D-dimer levels
chr16	6058428	6058429	rs1906060	4e-06	Intraocular pressure
chr16	81927352	81927353	rs3813009	4e-06	IgG glycosylation
chr16	81440043	81440044	rs310008	4e-06	Menarche (age at onset)
chr16	79618643	79618644	rs386965	4e-06	Multiple sclerosis
chr16	23877518	23877519	rs7404928	4e-06	Rheumatoid arthritis
chr16	73795370	73795371	rs427576	4e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr16	7114217	7114218	rs1478693	4e-06	Sleep time
chr16	69101145	69101146	rs8047014	4e-06	Attention deficit hyperactivity disorder
chr16	77294997	77294998	rs12935229	4e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)
chr16	67659893	67659894	rs7204371	4e-06	Obesity-related traits
chr4	109806403	109806404	rs4698790	5e-06	Homeostasis model assessment of insulin resistance (interaction)
chr3	46386698	46386699	rs6441975	5e-06	AIDS progression
chr3	52699089	52699090	rs6765687	5e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr3	53646096	53646097	rs1401492	5e-06	Insulin resistance/response
chr3	55001846	55001847	rs4955826	5e-06	Immune response to smallpox vaccine (IL-6)
chr3	57794108	57794109	rs6768930	5e-06	Obesity-related traits
chr3	60016098	60016099	rs9311745	5e-06	Pit-and-Fissure caries 
chr3	62126466	62126467	rs35593266	5e-06	Metabolite levels (HVA/5-HIAA ratio)
chr3	67366680	67366681	rs2363709	5e-06	IgE levels 
chr3	67480963	67480964	rs6792584	5e-06	Corneal astigmatism
chr3	80319312	80319313	rs10511112	5e-06	Migraine
chr3	85825325	85825326	rs12494658	5e-06	Temperament
chr3	86845327	86845328	rs9757252	5e-06	Prostate cancer (gene x gene interaction)
chr3	94524868	94524869	rs13067306	5e-06	Blood pressure measurement (high sodium intervention)
chr4	10048516	10048517	rs733175	5e-06	Alzheimer's disease
chr4	100885374	100885375	rs13107740	5e-06	Response to angiotensin II receptor blocker therapy
chr4	10103045	10103046	rs717615	5e-06	Uric acid levels
chr4	101794730	101794731	rs4522865	5e-06	Systemic lupus erythematosus
chr3	30330560	30330561	rs7634533	5e-06	Dental caries
chr4	109976428	109976429	rs11568995	5e-06	IgG glycosylation
chr3	71006010	71006011	rs13093086	5e-06	Intraocular pressure
chr3	96681754	96681755	rs6793516	5e-06	Blood trace element (Zn levels)
chr3	192195080	192195081	rs9836672	5e-06	Sleep quality
chr3	21677753	21677754	rs1490157	5e-06	Partial epilepsies
chr3	16366981	16366982	rs12635698	5e-06	Obesity (extreme)
chr3	164044175	164044176	rs7427021	5e-06	Bipolar disorder
chr3	170999731	170999732	rs11920090	5e-06	Fasting glucose-related traits
chr3	173125486	173125487	rs11720607	5e-06	Prostate cancer (gene x gene interaction)
chr3	177573908	177573909	rs644695	5e-06	Major depressive disorder (broad)
chr3	183152029	183152030	rs683395	5e-06	Bipolar disorder
chr3	184158723	184158724	rs1969253	5e-06	Major depressive disorder
chr3	185158994	185158995	rs7647854	5e-06	Major depressive disorder
chr3	185811291	185811292	rs1470579	5e-06	Type 2 diabetes
chr3	30305476	30305477	rs10510634	5e-06	Fasting plasma glucose
chr3	186966575	186966576	rs6778436	5e-06	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)
chr3	187008098	187008099	rs11710456	5e-06	IgG glycosylation
chr3	195870035	195870036	rs2278034	5e-06	Bronchopulmonary dysplasia
chr3	196826995	196826996	rs2084385	5e-06	Total ventricular volume
chr3	20067053	20067054	rs1124376	5e-06	Bipolar disorder and schizophrenia
chr3	20916317	20916318	rs6787231	5e-06	IgG glycosylation
chr3	20916317	20916318	rs6787231	5e-06	IgG glycosylation
chr3	21207149	21207150	rs11720452	5e-06	Bipolar disorder
chr3	21664876	21664877	rs3821396	5e-06	Bipolar disorder
chr3	21677348	21677349	rs9816269 	5e-06	Palmitic acid (16:0) plasma levels
chr3	187008098	187008099	rs11710456	5e-06	IgG glycosylation
chr4	120880634	120880635	rs180730	5e-06	Fasting plasma glucose
chr4	75556519	75556520	rs17000647	5e-06	Parkinson's disease (motor and cognition)
chr4	12767607	12767608	rs11945798	5e-06	Word reading
chr4	95546351	95546352	rs11097470	5e-06	Obesity-related traits
chr4	99242715	99242716	rs2201728	5e-06	Cardiac Troponin-T levels
chr4	99401287	99401288	rs991316	5e-06	Hypertension
chr4	99618738	99618739	rs1032355	5e-06	Celiac disease
chr5	100006342	100006343	rs10067427	5e-06	Non-alcoholic fatty liver disease histology (lobular)
chr5	102067881	102067882	rs6861497	5e-06	QRS duration
chr5	104863358	104863359	rs1632744	5e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors)
chr5	10701401	10701402	rs3756407	5e-06	Metabolite levels (Pyroglutamine)
chr5	10811361	10811362	rs17176973	5e-06	Bipolar disorder and schizophrenia
chr4	91996063	91996064	rs6853847	5e-06	IgG glycosylation
chr5	111072303	111072304	rs1898671	5e-06	Allergic rhinitis
chr5	125011394	125011395	rs3936060	5e-06	Body mass index
chr5	126846169	126846170	rs959573	5e-06	Parkinson's disease (motor and cognition)
chr5	127774793	127774794	rs10463832	5e-06	Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms)
chr5	127786619	127786620	rs10463833	5e-06	Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms)
chr5	127790069	127790070	rs7722425	5e-06	Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms)
chr5	133293191	133293192	rs17166496	5e-06	Type 1 diabetes
chr5	135828928	135828929	rs13178541	5e-06	IgG glycosylation
chr3	162413619	162413620	rs12636148	5e-06	Visceral adipose tissue/subcutaneous adipose tissue ratio
chr5	13764309	13764310	rs2896103	5e-06	Subclinical atherosclerosis traits (other)
chr5	114513596	114513597	rs400028	5e-06	Obesity-related traits
chr4	88131170	88131171	rs2231142	5e-06	Uric acid levels
chr4	87997953	87997954	rs2725236	5e-06	Caffeine consumption
chr4	85794158	85794159	rs7687906	5e-06	Obesity-related traits
chr4	137233657	137233658	rs10004839	5e-06	Retinopathy in non-diabetics
chr4	13792791	13792792	rs10489087	5e-06	Hemostatic factors and hematological phenotypes
chr4	153782443	153782444	rs17030434	5e-06	Electrocardiographic conduction measures
chr4	16512784	16512785	rs955943	5e-06	Rhegmatogenous retinal detachment
chr4	165909211	165909212	rs12513380	5e-06	Multiple sclerosis
chr4	17219609	17219610	rs12643440	5e-06	Metabolite levels (Pyroglutamine)
chr4	175349733	175349734	rs2333163	5e-06	Obesity-related traits
chr4	175727180	175727181	rs9284954	5e-06	IgG glycosylation
chr4	181861391	181861392	rs10520514	5e-06	Fasting insulin (interaction)
chr4	181861391	181861392	rs10520514	5e-06	Homeostasis model assessment of insulin resistance (interaction)
chr4	187270151	187270152	rs4478239	5e-06	Major depressive disorder
chr4	188940096	188940097	rs11731175	5e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr4	20493511	20493512	rs666088	5e-06	Echocardiographic traits
chr4	23586838	23586839	rs1511453	5e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr4	30466543	30466544	rs6856768	5e-06	Alzheimer's disease
chr4	45362896	45362897	rs10517133	5e-06	Adiponectin levels
chr4	47406691	47406692	rs6289	5e-06	Obesity-related traits
chr4	56467945	56467946	rs12505749	5e-06	Airflow obstruction 
chr4	66435083	66435084	rs2009314	5e-06	Obesity-related traits
chr4	6734637	6734638	rs7661864	5e-06	IgG glycosylation
chr4	70463772	70463773	rs1109501	5e-06	Alcoholism (heaviness of drinking)
chr4	127545544	127545545	rs2090104	5e-06	IgG glycosylation
chr3	161674787	161674788	rs6808138	5e-06	Hyperactive-impulsive symptoms
chr22	37675035	37675036	rs4820294	5e-06	Fat distribution (HIV)
chr3	15399048	15399049	rs6442522	5e-06	Uric acid levels
chr2	189813818	189813819	rs5743030	5e-06	Subcutaneous adipose tissue
chr2	199425635	199425636	rs1992950	5e-06	Ulcerative colitis
chr2	201994893	201994894	rs6754521	5e-06	Response to amphetamines
chr2	204263297	204263298	rs6738181	5e-06	Alzheimer's disease (late onset)
chr2	205198573	205198574	rs11681930	5e-06	Attention deficit hyperactivity disorder (combined symptoms)
chr2	206769511	206769512	rs2277912	5e-06	Height
chr2	214477165	214477166	rs7604827	5e-06	PR interval
chr22	15473563	15473564	rs4911642	5e-06	Celiac disease
chr2	216028913	216028914	rs1344694	5e-06	Alcohol dependence
chr2	171271409	171271410	rs4667682	5e-06	Hippocampal atrophy
chr2	219084461	219084462	rs16859517	5e-06	Height
chr22	26257395	26257396	rs1207393	5e-06	Airflow obstruction 
chr22	26646141	26646142	rs744016	5e-06	RR interval (heart rate)
chr2	226908749	226908750	rs3820928	5e-06	Pulmonary function
chr22	27020861	27020862	rs4417	5e-06	Fat distribution (HIV)
chr2	230365455	230365456	rs6712333	5e-06	Nicotine use
chr2	231311827	231311828	rs7580717	5e-06	Multiple myeloma
chr2	232871533	232871534	rs2675968	5e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr2	23369273	23369274	rs2577704	5e-06	IgG glycosylation
chr22	34463800	34463801	rs130575	5e-06	Attention deficit hyperactivity disorder
chr22	21585385	21585386	rs5754217	5e-06	Systemic lupus erythematosus
chr22	34975258	34975259	rs9619497	5e-06	Metabolite levels (HVA-5-HIAA Factor score)
chr2	165287903	165287904	rs16850317	5e-06	Periodontitis (DPAL)
chr2	153712243	153712244	rs10931753	5e-06	Blood trace element (Zn levels)
chr5	141831187	141831188	rs166040	5e-06	Major depressive disorder
chr21	29116978	29116979	rs2832191	5e-06	Dental caries
chr21	29640838	29640839	rs363598	5e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr2	132386818	132386819	rs16831128	5e-06	Conduct disorder (symptom count)
chr21	32890378	32890379	rs2833991	5e-06	IgG glycosylation
chr21	33408743	33408744	rs2268241	5e-06	Obesity-related traits
chr21	34326089	34326090	rs1013063	5e-06	Body mass index (interaction)
chr21	34835764	34835765	rs9976946	5e-06	Preeclampsia
chr21	35641322	35641323	rs12483148	5e-06	Obesity-related traits
chr2	156031987	156031988	rs1918172	5e-06	Attention deficit hyperactivity disorder
chr21	36563370	36563371	rs9984896	5e-06	QT interval
chr21	38684498	38684499	rs743446	5e-06	Neonatal lupus
chr2	140468739	140468740	rs72899866	5e-06	Periodontitis (CDC/AAP)
chr21	41099700	41099701	rs16998084	5e-06	Economic and political preferences (immigration/crime)
chr21	41866242	41866243	rs2839398	5e-06	Parkinson's disease
chr21	43058386	43058387	rs6586282	5e-06	Blood trace element (Se levels)
chr2	149652817	149652818	rs16827293	5e-06	Waist-to-hip circumference ratio (interaction)
chr2	151397403	151397404	rs10197940	5e-06	Lung cancer
chr2	152580055	152580056	rs11675841	5e-06	IgG glycosylation
chr2	152892853	152892854	rs78683678	5e-06	Serum dimethylarginine levels (asymmetric)
chr21	37445509	37445510	rs11700462	5e-06	IgG glycosylation
chr22	37074183	37074184	rs2413450	5e-06	Hematological and biochemical traits
chr22	43228758	43228759	rs139014	5e-06	IgG glycosylation
chr22	44165406	44165407	rs5764106	5e-06	IgG glycosylation
chr2	61545121	61545122	rs6545883	5e-06	Tuberculosis
chr2	64800489	64800490	rs11683197	5e-06	Visceral fat
chr2	67715347	67715348	rs724568	5e-06	Major depressive disorder (broad)
chr2	68425447	68425448	rs11126185	5e-06	Obesity-related traits
chr2	68971255	68971256	rs4254535	5e-06	Lung cancer
chr2	69758302	69758303	rs7597155 	5e-06	Palmitoleic acid (16:1n-7) plasma levels
chr2	70509086	70509087	rs454305	5e-06	Neutrophil count
chr2	75563362	75563363	rs17011455	5e-06	Presence of antiphospholipid antibodies
chr2	773277	773278	rs4380275	5e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin)
chr2	60696884	60696885	rs7589998	5e-06	Obesity-related traits
chr2	7913465	7913466	rs4669226	5e-06	Multiple sclerosis
chr3	108524703	108524704	rs2603127	5e-06	Hemostatic factors and hematological phenotypes
chr3	110208528	110208529	rs13323983	5e-06	Neutrophil count
chr3	111704281	111704282	rs4450776	5e-06	Cognitive performance
chr3	117524948	117524949	rs72951640	5e-06	Serum dimethylarginine levels (asymmetric)
chr3	119365483	119365484	rs17203055	5e-06	Schizophrenia
chr3	119542527	119542528	rs7648642	5e-06	Lobular breast cancer (menopausal hormone therapy interaction)
chr3	133756877	133756878	rs1799852	5e-06	Iron status biomarkers
chr3	145456000	145456001	rs345013	5e-06	Prostate cancer
chr3	153632326	153632327	rs7623788	5e-06	IgG glycosylation
chr2	84018043	84018044	rs13398848	5e-06	Conduct disorder (case status)
chr2	59272211	59272212	rs10490113	5e-06	Breast cancer
chr2	5912618	5912619	rs7586540	5e-06	Coronary artery calcification
chr2	55746596	55746597	rs2163237	5e-06	IgG glycosylation
chr2	26860400	26860401	rs11887277	5e-06	Obesity-related traits
chr2	27508072	27508073	rs1260326	5e-06	Lipoprotein-associated phospholipase A2 activity and mass
chr2	27518369	27518370	rs780094	5e-06	Urate levels
chr2	27519735	27519736	rs780093	5e-06	Breast size
chr23	129970757	129970758	rs2361405	5e-06	Periodontitis (Mean PAL)
chr23	136973135	136973136	rs1190739	5e-06	Coronary heart disease
chr23	140084523	140084524	rs5907577	5e-06	Bipolar disorder and schizophrenia
chr23	148242735	148242736	rs5936441	5e-06	Response to acetaminophen (hepatotoxicity)
chr2	315214	315215	rs4643574	5e-06	Cognitive performance
chr23	26351781	26351782	rs6526555	5e-06	Metabolite levels (5-HIAA/ MHPG Ratio)
chr23	32207137	32207138	rs1456737	5e-06	Bipolar disorder and schizophrenia
chr23	83616186	83616187	rs5922838	5e-06	Depression and alcohol dependence
chr2	38689827	38689828	rs6741892	5e-06	5-HTT brain serotonin transporter levels
chr23	90033227	90033228	rs5941436	5e-06	Cognitive performance
chr2	41777856	41777857	rs719593	5e-06	Conduct disorder (interaction)
chr2	44927768	44927769	rs528301	5e-06	Alcohol and nictotine co-dependence
chr2	46126026	46126027	rs10495928	5e-06	Hematological and biochemical traits
chr2	48950461	48950462	rs7591064	5e-06	Radiation response
chr2	52486668	52486669	rs1526687	5e-06	Cardiac Troponin-T levels
chr2	52722179	52722180	rs1349882	5e-06	Serum dimethylarginine levels (asymmetric)
chr2	53529403	53529404	rs56148675	5e-06	Bulimia nervosa
chr3	156618765	156618766	rs7651778	5e-06	Corneal astigmatism
chr5	149833892	149833893	rs32576	5e-06	Obesity-related traits
chr7	37522764	37522765	rs1425132	5e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin)
chr5	15581895	15581896	rs1978633	5e-06	Economic and political preferences (feminism/equality)
chr8	126320411	126320412	rs11986011	5e-06	Age-related macular degeneration
chr8	129664392	129664393	rs9918807	5e-06	Retinopathy in non-diabetics
chr8	133059587	133059588	rs2741200	5e-06	Temperament
chr8	13403026	13403027	rs289585	5e-06	Bipolar disorder
chr8	134581481	134581482	rs6577655	5e-06	Visceral adipose tissue/subcutaneous adipose tissue ratio
chr8	138492026	138492027	rs11166827	5e-06	Cognitive performance
chr8	141530824	141530825	rs7837045	5e-06	Breast size
chr8	14256306	14256307	rs9886428	5e-06	IgG glycosylation
chr8	14531971	14531972	rs1903595	5e-06	Platelet aggregation
chr8	126320411	126320412	rs11986011	5e-06	Age-related macular degeneration
chr8	18850360	18850361	rs7833787	5e-06	Obesity-related traits
chr8	22027032	22027033	rs11776272	5e-06	Obesity-related traits
chr8	22120858	22120859	rs76547188	5e-06	Obesity-related traits
chr8	23668949	23668950	rs1512268	5e-06	Prostate cancer
chr8	2962286	2962287	rs4875857	5e-06	IgG glycosylation
chr8	38611784	38611785	rs7832232	5e-06	Pancreatic cancer
chr8	41757619	41757620	rs7006290	5e-06	Pulmonary function decline
chr8	50500030	50500031	rs310558	5e-06	Pulmonary function
chr8	56266460	56266461	rs7815788	5e-06	Height
chr8	58596020	58596021	rs11994937	5e-06	IgG glycosylation
chr8	20007663	20007664	rs2083637	5e-06	Waist circumference and related phenotypes
chr8	5907419	5907420	rs2840445	5e-06	Dietary macronutrient intake
chr8	121609668	121609669	rs11995252	5e-06	Obesity-related traits
chr8	11419032	11419033	rs2002030	5e-06	Cognitive performance
chr7	29001573	29001574	rs2252521	5e-06	Cognitive performance
chr7	29881907	29881908	rs740145	5e-06	Corneal curvature
chr7	36152089	36152090	rs4302748	5e-06	Platelet counts
chr7	43247239	43247240	rs17172185	5e-06	Esophageal adenocarcinoma
chr7	50214300	50214301	rs17664743	5e-06	Self-reported allergy
chr7	52404753	52404754	rs1012036	5e-06	Emphysema-related traits
chr7	53059865	53059866	rs1174864	5e-06	IgG glycosylation
chr7	55656751	55656752	rs9656709	5e-06	Behavioural disinhibition (generation interaction)
chr7	57639444	57639445	rs4870684	5e-06	Bipolar disorder and schizophrenia
chr8	11502128	11502129	rs1600249	5e-06	Rheumatoid arthritis
chr7	69773171	69773172	rs11765886	5e-06	IgG glycosylation
chr7	77133633	77133634	rs12540771	5e-06	Response to amphetamines
chr7	78335470	78335471	rs2691543	5e-06	Height
chr7	78702148	78702149	rs1496766	5e-06	Acute lymphoblastic leukemia (childhood)
chr7	82156903	82156904	rs2367911	5e-06	Bipolar disorder and schizophrenia
chr7	89065755	89065756	rs10236237	5e-06	IgG glycosylation
chr7	99610252	99610253	rs7792939	5e-06	Anthropometric traits
chr8	100907092	100907093	rs931812	5e-06	Attention deficit hyperactivity disorder and conduct disorder
chr8	101932634	101932635	rs517811	5e-06	Cognitive performance
chr8	106832218	106832219	rs2981205	5e-06	Intelligence (childhood)
chr7	70580954	70580955	rs10237317	5e-06	Bipolar disorder
chr8	60192639	60192640	rs10098647	5e-06	Obesity-related traits
chr8	65087727	65087728	rs2980003	5e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr8	68818483	68818484	rs16935110	5e-06	Obesity-related traits
chr9	27630563	27630564	rs12555345	5e-06	Total ventricular volume
chr9	31450667	31450668	rs148359873	5e-06	Serum dimethylarginine levels (asymmetric/symetric ratio)
chr9	32422691	32422692	rs7032871	5e-06	IgG glycosylation
chr9	36969207	36969208	rs16933812	5e-06	Obesity and blood pressure
chr9	37916410	37916411	rs3747547	5e-06	Metabolite levels (Dihydroxy docosatrienoic acid)
chr9	4426630	4426631	rs10974531	5e-06	Pancreatic cancer
chr9	4985878	4985879	rs2274471	5e-06	Crohn's disease
chr9	6849316	6849317	rs4742269	5e-06	Radiation response
chr9	27533985	27533986	rs10812610	5e-06	Heart failure
chr9	69328085	69328086	rs3750552	5e-06	Bipolar disorder
chr9	75811008	75811009	rs12344488	5e-06	Non-alcoholic fatty liver disease histology (AST)
chr9	76050859	76050860	rs7047865	5e-06	Metabolite levels (5-HIAA)
chr9	76291233	76291234	rs2842483	5e-06	Multiple sclerosis (age of onset)
chr9	81907833	81907834	rs13295552	5e-06	IgG glycosylation
chr9	90870957	90870958	rs10993738	5e-06	Type 2 diabetes
chr9	93953745	93953746	rs11789015	5e-06	Barrett's esophagus
chr9	97553947	97553948	rs1475545	5e-06	Obesity-related traits
chr9	97977841	97977842	rs4743150	5e-06	Coronary heart disease
chr9	99472040	99472041	rs649057	5e-06	Dental caries
chr9	7043454	7043455	rs16925187	5e-06	Response to fenofibrate (adiponectin levels)
chr9	22670715	22670716	rs613391	5e-06	Quantitative traits
chr9	22134094	22134095	rs10811661	5e-06	Type 2 diabetes
chr8	71357846	71357847	rs7006821	5e-06	Chronic obstructive pulmonary disease-related biomarkers
chr8	72866406	72866407	rs10504543	5e-06	Echocardiographic traits
chr8	73153943	73153944	rs2383876	5e-06	Corneal curvature
chr8	76699389	76699390	rs4735738	5e-06	Menarche (age at onset)
chr8	86012783	86012784	rs285406	5e-06	Adverse response to lamotrigine and phenytoin
chr8	91063414	91063415	rs4493873	5e-06	Migraine - clinic-based
chr8	96357405	96357406	rs2640806	5e-06	Obesity-related traits
chr9	10043013	10043014	rs291272	5e-06	Temperament
chr9	102740215	102740216	rs10990268	5e-06	Tourette syndrome
chr9	1056958	1056959	rs17641078	5e-06	Hyperactive-impulsive symptoms
chr9	12108915	12108916	rs12351590	5e-06	Word reading
chr9	122810750	122810751	rs16912238	5e-06	Obesity-related traits
chr9	12582564	12582565	rs1325154	5e-06	Attention deficit hyperactivity disorder (time to onset)
chr9	126095571	126095572	rs10987149	5e-06	Response to mTOR inhibitor (everolimus)
chr9	127348131	127348132	rs7029536	5e-06	Metabolite levels (HVA)
chr9	127741790	127741791	rs514024	5e-06	Eating disorders (purging via substances) 
chr9	132771633	132771634	rs10901212	5e-06	Obesity-related traits
chr9	134924612	134924613	rs2094962	5e-06	IgG glycosylation
chr9	136371143	136371144	rs34971035	5e-06	Obesity-related traits
chr9	15104562	15104563	rs10756650	5e-06	Metabolite levels (Pyroglutamine)
chr9	15283098	15283099	rs12003180	5e-06	Bipolar disorder and schizophrenia
chr7	2875743	2875744	rs6977940	5e-06	White matter integrity
chr5	152188537	152188538	rs294958	5e-06	Periodontitis (PAL4Q3)
chr7	28723345	28723346	rs2237349	5e-06	Attention deficit hyperactivity disorder
chr7	23381147	23381148	rs375092	5e-06	Personality dimensions
chr6	107339441	107339442	rs2430457	5e-06	IgG glycosylation
chr6	108946846	108946847	rs2798641	5e-06	Pulmonary function
chr6	113344124	113344125	rs7765175	5e-06	Coronary artery calcification
chr6	113695930	113695931	rs9488238	5e-06	Disc degeneration (lumbar)
chr6	118486683	118486684	rs25422	5e-06	Renal cell carcinoma
chr6	127873327	127873328	rs12194062	5e-06	QRS duration
chr2	128721267	128721268	rs4662834	5e-06	Bleomycin sensitivity
chr6	130565291	130565292	rs9492645	5e-06	IgG glycosylation
chr6	130961069	130961070	rs6941712	5e-06	Lentiform nucleus volume 
chr6	102523370	102523371	rs17430337	5e-06	Obesity-related traits
chr6	131125650	131125651	rs602848	5e-06	Migraine with aura
chr6	132321977	132321978	rs589756	5e-06	Obesity-related traits
chr6	147209944	147209945	rs2786189	5e-06	Bronchopulmonary dysplasia
chr6	148602652	148602653	rs13196614	5e-06	Migraine
chr6	1535762	1535763	rs11242704	5e-06	Response to hepatitis C treatment
chr6	154093427	154093428	rs675026	5e-06	Coronary heart disease
chr6	154665529	154665530	rs9397738	5e-06	Renal function-related traits (eGRFcrea)
chr6	155608666	155608667	rs35229355	5e-06	Response to treatment for acute lymphoblastic leukemia
chr6	1573377	1573378	rs2338	5e-06	Response to platinum-based agents
chr6	161512902	161512903	rs16892673	5e-06	Aging
chr6	131737806	131737807	rs12199015	5e-06	Response to fenofibrate (adiponectin levels)
chr6	161893888	161893889	rs12207186	5e-06	IgG glycosylation
chr5	95905517	95905518	rs10069748	5e-06	IgG glycosylation
chr5	86881955	86881956	rs2471042	5e-06	Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule)
chr5	157388754	157388755	rs871012	5e-06	IgG glycosylation
chr5	168073454	168073455	rs13358864	5e-06	Uric acid levels
chr5	169472982	169472983	rs13156607	5e-06	Waist circumference
chr5	171293728	171293729	rs2278255	5e-06	Visceral fat
chr5	17215334	17215335	rs2962370	5e-06	Bipolar disorder (mood-incongruent)
chr5	172865302	172865303	rs6890783	5e-06	Periodontitis (CDC/AAP)
chr5	175355115	175355116	rs251925	5e-06	Obesity-related traits
chr5	177264277	177264278	rs10037055	5e-06	Migraine without aura
chr5	177370341	177370342	rs4074995	5e-06	Calcium levels
chr5	90485153	90485154	rs2562519	5e-06	Nevirapine-induced rash
chr5	180799672	180799673	rs655601	5e-06	Quantitative traits
chr5	41233943	41233944	rs7443270	5e-06	Response to fenofibrate (adiponectin levels)
chr5	4488131	4488132	rs10462794	5e-06	DNA methylation (variation)
chr5	50937364	50937365	rs151997	5e-06	Callous-unemotional behaviour
chr5	51922016	51922017	rs10042348	5e-06	Bipolar disorder and schizophrenia
chr5	61654383	61654384	rs11738335	5e-06	Alzheimer's disease
chr5	7155498	7155499	rs4702435	5e-06	Obesity-related traits
chr5	76928345	76928346	rs2460504	5e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr5	78814708	78814709	rs6453417	5e-06	Attention deficit hyperactivity disorder
chr5	79549887	79549888	rs13358260	5e-06	Adiponectin levels
chr5	2335466	2335467	rs17586674	5e-06	Cognitive performance
chr6	16342824	16342825	rs9383153	5e-06	Gambling
chr6	165521932	165521933	rs519595	5e-06	Response to fenofibrate
chr6	169327505	169327506	rs12190007	5e-06	Obesity-related traits
chr7	100892455	100892456	rs7636	5e-06	Type 2 diabetes
chr7	107802940	107802941	rs4730268	5e-06	IgG glycosylation
chr7	107839073	107839074	rs4730273	5e-06	Ulcerative colitis
chr7	108904403	108904404	rs1404697	5e-06	Smoking behavior
chr7	112988317	112988318	rs10229603	5e-06	Attention deficit hyperactivity disorder and conduct disorder
chr7	113009358	113009359	rs6969802	5e-06	IgG glycosylation
chr7	118519494	118519495	rs2106595	5e-06	Smoking behavior
chr7	12179908	12179909	rs17594709	5e-06	IgG glycosylation
chr7	12897629	12897630	rs17166499	5e-06	Bipolar disorder and schizophrenia
chr6	98489269	98489270	rs2213553	5e-06	Response to amphetamines
chr7	132640549	132640550	rs4731889 	5e-06	Oleic acid (18:1n-9) plasma levels
chr7	138174019	138174020	rs10255295	5e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr7	138174019	138174020	rs10255295	5e-06	Bipolar disorder (mood-incongruent)
chr7	154374934	154374935	rs6977820	5e-06	Tardive dyskinesia 
chr7	17045696	17045697	rs6961860	5e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)
chr7	19208654	19208655	rs17140875	5e-06	Obesity-related traits
chr7	2001796	2001797	rs1107592	5e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr7	21108058	21108059	rs11974269	5e-06	Obesity-related traits
chr7	21984421	21984422	rs1175000	5e-06	Height
chr7	2238590	2238591	rs7799006	5e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr7	13504103	13504104	rs13307587	5e-06	Reading and spelling
chr6	98048075	98048076	rs2505059	5e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs)
chr6	89948063	89948064	rs404256	5e-06	IgG glycosylation
chr6	89601246	89601247	rs6454764	5e-06	vWF and FVIII levels
chr6	17632829	17632830	rs2274136	5e-06	Obesity-related traits
chr6	17813593	17813594	rs10456809	5e-06	Prostate cancer (gene x gene interaction)
chr6	25488354	25488355	rs2274089	5e-06	Iron status biomarkers
chr6	28053041	28053042	rs172166	5e-06	Cardiac Troponin-T levels
chr6	32614111	32614112	rs4530903	5e-06	Schizophrenia
chr6	32762234	32762235	rs7453920	5e-06	Lymphoma
chr6	32985502	32985503	rs3097645	5e-06	IgG glycosylation
chr6	33883395	33883396	rs16869652	5e-06	Schizophrenia
chr6	41994932	41994933	rs9357377	5e-06	Metabolite levels (5-HIAA/ MHPG Ratio)
chr6	43844024	43844025	rs9472138	5e-06	Thyroid hormone levels
chr6	44869618	44869619	rs3799977	5e-06	Attention deficit hyperactivity disorder
chr6	47262878	47262879	rs2103868	5e-06	Panic disorder
chr6	51020054	51020055	rs190759	5e-06	Sudden cardiac arrest
chr6	57982676	57982677	rs9500256	5e-06	Eosinophilic esophagitis (pediatric)
chr6	63093282	63093283	rs789942	5e-06	Obesity-related traits
chr6	65468586	65468587	rs4710520	5e-06	IgG glycosylation
chr6	68584592	68584593	rs9351730	5e-06	Prostate cancer (gene x gene interaction)
chr6	71016835	71016836	rs1158058	5e-06	Metabolite levels (MHPG)
chr6	72197049	72197050	rs2249625	5e-06	Acute urticaria and angiodema (non-steroidal anti-inflammatory drug-induced)
chr6	7736509	7736510	rs2068361	5e-06	Orofacial clefts
chr6	81805597	81805598	rs16893526	5e-06	Coronary heart disease
chr7	2542817	2542818	rs6972204	5e-06	Obesity-related traits
chr21	27293027	27293028	rs2830840	5e-06	Response to citalopram treatment
chr13	20519464	20519465	rs4770049	5e-06	Obesity-related traits
chr21	25272768	25272769	rs9977253	5e-06	Non-alcoholic fatty liver disease histology (other)
chr1	228860874	228860875	rs801112	5e-06	Endometriosis
chr1	228883400	228883401	rs11585386	5e-06	Aging
chr12	31997308	31997309	rs4931594	5e-06	Obesity-related traits
chr1	234527143	234527144	rs271738	5e-06	Bipolar disorder
chr1	234590265	234590266	rs744487	5e-06	Coronary heart disease
chr12	3640961	3640962	rs4766152	5e-06	Cytomegalovirus antibody response
chr12	40373559	40373560	rs10467147	5e-06	Obesity-related traits
chr12	40959946	40959947	rs13328933	5e-06	IgG glycosylation
chr12	43040478	43040479	rs1167125	5e-06	Obesity-related traits
chr1	224068645	224068646	rs10916248	5e-06	QT interval (interaction)
chr1	243671883	243671884	rs320320	5e-06	Menarche (age at onset)
chr1	25076132	25076133	rs10903027	5e-06	IgG glycosylation
chr1	2521539	2521540	rs12073504	5e-06	Obesity-related traits
chr12	53522930	53522931	rs12321906	5e-06	Height
chr12	55522995	55522996	rs12230513	5e-06	Contrast sensitivity
chr12	5642175	5642176	rs2110166	5e-06	IgG glycosylation
chr12	61841051	61841052	rs2198776	5e-06	Obesity-related traits
chr12	62610802	62610803	rs7302017	5e-06	Waist circumference
chr12	63051311	63051312	rs10506458	5e-06	Hemostatic factors and hematological phenotypes
chr1	26324058	26324059	rs11247915	5e-06	Obesity-related traits
chr12	47793470	47793471	rs75365750	5e-06	Obesity-related traits
chr12	6333476	6333477	rs4149584	5e-06	Multiple sclerosis
chr12	23793211	23793212	rs11047102	5e-06	Systemic sclerosis
chr1	22164230	22164231	rs7521902	5e-06	Ovarian cancer
chr1	204134489	204134490	rs2293335	5e-06	Periodontitis (CDC/AAP)
chr1	204602942	204602943	rs12143943	5e-06	Cognitive performance
chr1	205211281	205211282	rs76872152	5e-06	Obesity-related traits
chr1	205743401	205743402	rs188212039	5e-06	Serum dimethylarginine levels (symmetric)
chr1	207866125	207866126	rs1967689	5e-06	Age-related macular degeneration
chr1	207866125	207866126	rs1967689	5e-06	Age-related macular degeneration
chr12	10018127	10018128	rs11053548	5e-06	Systolic blood pressure in sickle cell anemia
chr12	103799045	103799046	rs4964805	5e-06	Attention deficit hyperactivity disorder
chr12	113541850	113541851	rs11066587	5e-06	Quantitative traits
chr12	21843110	21843111	rs11046207	5e-06	Obesity-related traits
chr12	117835065	117835066	rs2723279	5e-06	Migraine
chr12	120798454	120798455	rs1039302	5e-06	Quantitative traits
chr12	123915002	123915003	rs1316952	5e-06	Visceral adipose tissue adjusted for BMI
chr12	128251976	128251977	rs12297524 	5e-06	Palmitic acid (16:0) plasma levels
chr1	213661299	213661300	rs4655303	5e-06	Metabolite levels (5-HIAA)
chr1	213985912	213985913	rs340874	5e-06	Fasting glucose-related traits
chr1	214657273	214657274	rs438034	5e-06	Response to antineoplastic agents
chr12	16253755	16253756	rs10772915	5e-06	Visceral fat
chr12	16456103	16456104	rs10772939	5e-06	Economic and political preferences
chr1	218532471	218532472	rs1018040	5e-06	Attention deficit hyperactivity disorder
chr12	118016863	118016864	rs5745796	5e-06	Obesity-related traits
chr12	67235050	67235051	rs1082714	5e-06	Hippocampal atrophy
chr12	68138296	68138297	rs12321565	5e-06	Bipolar disorder and schizophrenia
chr12	70296304	70296305	rs2904524	5e-06	Amyotrophic lateral sclerosis (age of onset)
chr13	32136382	32136383	rs7331540	5e-06	IgG glycosylation
chr13	32813107	32813108	rs990324	5e-06	Total ventricular volume
chr13	35866961	35866962	rs12428086	5e-06	Obesity-related traits
chr13	39329105	39329106	rs6563695	5e-06	Preeclampsia
chr13	41931537	41931538	rs1900442	5e-06	Tuberculosis
chr13	42382484	42382485	rs17638544	5e-06	Bone mineral density
chr13	44128732	44128733	rs9525916	5e-06	Homeostasis model assessment of insulin resistance (interaction)
chr13	46259581	46259582	rs958546	5e-06	Atrial fibrillation
chr13	47862789	47862790	rs11620399	5e-06	Visceral adipose tissue adjusted for BMI
chr13	28355573	28355574	rs17086609	5e-06	Cognitive performance
chr13	47862789	47862790	rs11620399	5e-06	Visceral adipose tissue/subcutaneous adipose tissue ratio
chr13	50519977	50519978	rs9316500	5e-06	Pulmonary function decline
chr13	50532651	50532652	rs3118906	5e-06	Pubertal anthropometrics
chr13	51150527	51150528	rs7325564	5e-06	IgG glycosylation
chr13	53716197	53716198	rs2806731	5e-06	Obesity-related traits
chr13	70236090	70236091	rs1928007	5e-06	Word reading
chr13	72114635	72114636	rs9652236	5e-06	Obsessive-compulsive disorder
chr1	37731168	37731169	rs731174	5e-06	Prostate cancer (gene x gene interaction)
chr13	78806680	78806681	rs2184180	5e-06	IgG glycosylation
chr13	78881696	78881697	rs1218282	5e-06	Response to statin therapy
chr13	49506710	49506711	rs2031532	5e-06	Cardiac hypertrophy
chr13	27786349	27786350	rs1923834	5e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin)
chr13	27503006	27503007	rs9512730	5e-06	Schizophrenia
chr13	27012735	27012736	rs12020569	5e-06	Alcohol dependence
chr12	71677264	71677265	rs10748180	5e-06	Economic and political preferences (time)
chr12	73694027	73694028	rs7964120	5e-06	Obesity-related traits
chr12	76615279	76615280	rs2669010	5e-06	Systemic lupus erythematosus
chr12	77335604	77335605	rs1402279	5e-06	Smoking behavior
chr12	78092213	78092214	rs300489	5e-06	Self-rated health
chr12	90215239	90215240	rs10745527	5e-06	vWF and FVIII levels
chr12	91586596	91586597	rs10777317	5e-06	Sudden cardiac arrest
chr12	91770524	91770525	rs10777332	5e-06	Biochemical measures
chr12	92496743	92496744	rs10219495	5e-06	Sudden cardiac arrest
chr1	29712814	29712815	rs1866967	5e-06	Prostate cancer (gene x gene interaction)
chr12	97295989	97295990	rs10777845	5e-06	Sudden cardiac arrest
chr13	107127967	107127968	rs1927745	5e-06	Depression (quantitative trait)
chr13	108858710	108858711	rs814141	5e-06	Lung function (forced expiratory flow between 25% and 75% of forced vital capacity)
chr13	110796767	110796768	rs167890	5e-06	Obesity-related traits
chr13	20476435	20476436	rs7989332	5e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin)
chr13	20557071	20557072	rs9506514	5e-06	Coronary artery calcification
chr13	23468370	23468371	rs10162002	5e-06	Hypothyroidism
chr13	24024244	24024245	rs17079773	5e-06	Inattentive symptoms
chr13	24959692	24959693	rs2483374	5e-06	Obesity-related traits
chr13	25463821	25463822	rs4770837	5e-06	Bipolar disorder and schizophrenia
chr13	26150189	26150190	rs17511627	5e-06	Alzheimer's disease
chr1	200703777	200703778	rs7512898	5e-06	Electrocardiographic conduction measures
chr13	80070482	80070483	rs12431307	5e-06	Obesity-related traits
chr1	193026082	193026083	rs9427573	5e-06	Cannabis dependence
chr1	18468760	18468761	rs3007729	5e-06	Diabetic retinopathy 
chr10	59386823	59386824	rs11006464 	5e-06	Oleic acid (18:1n-9) plasma levels
chr10	60586879	60586880	rs16915157	5e-06	Schizophrenia
chr10	60792131	60792132	rs2456778	5e-06	Cocaine dependence
chr10	62685803	62685804	rs10761659	5e-06	Crohn's disease
chr10	6882481	6882482	rs11816922	5e-06	Migraine
chr10	70572683	70572684	rs10999409	5e-06	Obesity (extreme)
chr10	70703237	70703238	rs17600642	5e-06	Bipolar disorder
chr10	70741006	70741007	rs10823607	5e-06	Sleep duration
chr10	79193378	79193379	rs703970	5e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr10	55031208	55031209	rs10740609	5e-06	Weight
chr10	8282925	8282926	rs11255615	5e-06	Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule)
chr10	89058619	89058620	rs7920888	5e-06	Obesity-related traits
chr10	90873141	90873142	rs4586057	5e-06	Economic and political preferences (time)
chr10	92705801	92705802	rs5015480	5e-06	Type 2 diabetes
chr10	95535831	95535832	rs12772243	5e-06	IgG glycosylation
chr10	95541246	95541247	rs11188352	5e-06	IgG glycosylation
chr10	96658172	96658173	rs7098785	5e-06	Orthostatic hypotension
chr10	96672945	96672946	rs7895244	5e-06	IgG glycosylation
chr1	10739519	10739520	rs12046278	5e-06	Systolic blood pressure
chr1	108875056	108875057	rs7523050	5e-06	Fat distribution (HIV)
chr10	85848702	85848703	rs7076096	5e-06	Post-traumatic stress disorder (asjusted for relatedness)
chr1	109540263	109540264	rs7550711 	5e-06	Stearic acid (18:0) plasma levels
chr10	52370992	52370993	rs112125027	5e-06	Periodontitis (Mean PAL)
chr10	49292413	49292414	rs17774576 	5e-06	Oleic acid (18:1n-9) plasma levels
chr21	27285629	27285630	rs457603	5e-06	Liver enzyme levels (aspartate transaminase)
chr10	10559896	10559897	rs11256676	5e-06	Dental caries
chr10	117422359	117422360	rs181500	5e-06	Bipolar disorder and schizophrenia
chr10	117577234	117577235	rs384627	5e-06	Obesity-related traits
chr10	117845426	117845427	rs1925265	5e-06	Metabolite levels (MHPG)
chr10	120831860	120831861	rs2919009	5e-06	Obesity-related traits
chr10	124605597	124605598	rs3740540	5e-06	Obesity-related traits
chr10	128200107	128200108	rs1329189	5e-06	Orofacial clefts
chr10	1300821	1300822	rs11599315	5e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr10	50359536	50359537	rs2574975	5e-06	Response to amphetamines
chr10	131149698	131149699	rs10741243	5e-06	Type 2 diabetes
chr10	15519543	15519544	rs7077361	5e-06	Parkinson's disease
chr10	16706610	16706611	rs7916663	5e-06	Obesity-related traits
chr10	26144436	26144437	rs2096176	5e-06	Obesity-related traits
chr10	27404375	27404376	rs1334893	5e-06	Fasting insulin-related traits (interaction with BMI)
chr10	29888958	29888959	rs3006564	5e-06	Orofacial clefts
chr10	32020076	32020077	rs1775715	5e-06	Bipolar disorder (mood-incongruent)
chr10	33005846	33005847	rs11009175	5e-06	Depression (quantitative trait)
chr10	46046325	46046326	rs10993994	5e-06	Prostate cancer
chr10	49016720	49016721	rs2244967	5e-06	Uric acid levels
chr10	15087402	15087403	rs11259474	5e-06	Obesity-related traits
chr11	105101790	105101791	rs11226613	5e-06	Bronchopulmonary dysplasia
chr11	107476550	107476551	rs11212260	5e-06	IgG glycosylation
chr1	110875292	110875293	rs2885805	5e-06	Cytomegalovirus antibody response
chr1	155126428	155126429	rs11264330	5e-06	Obesity-related traits
chr1	156371702	156371703	rs7525133	5e-06	Visceral adipose tissue adjusted for BMI
chr1	162349733	162349734	rs11577628	5e-06	Word reading
chr11	63003915	63003916	rs11231299	5e-06	Visceral fat
chr11	63899471	63899472	rs12099085	5e-06	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)
chr1	163987265	163987266	rs424950	5e-06	Sex hormone-binding globulin levels
chr11	64816758	64816759	rs470763	5e-06	Economic and political preferences (fairness)
chr11	6501573	6501574	rs2555155	5e-06	DNA methylation (variation)
chr11	67947556	67947557	rs308309	5e-06	QRS duration
chr1	15465930	15465931	rs2901964	5e-06	Erectile dysfunction and prostate cancer treatment
chr11	69328515	69328516	rs7102705	5e-06	Breast size
chr11	72539078	72539079	rs12418204	5e-06	Optic disc size (cup)
chr11	74457365	74457366	rs2270676	5e-06	Corneal astigmatism
chr11	7687049	7687050	rs7932813	5e-06	Waist circumference
chr1	177599663	177599664	rs16851585	5e-06	Age-related macular degeneration
chr1	178502086	178502087	rs12760731	5e-06	Obesity-related traits
chr1	179102620	179102621	rs1325195	5e-06	IgE grass sensitization
chr11	80600626	80600627	rs2140930	5e-06	IgG glycosylation
chr1	183211124	183211125	rs16860537	5e-06	Systemic lupus erythematosus and Systemic sclerosis
chr1	183297046	183297047	rs4652795	5e-06	Obesity-related traits
chr11	70819415	70819416	rs3017493	5e-06	Renal transplant outcome
chr1	153941293	153941294	rs2252508	5e-06	Lentiform nucleus volume 
chr1	153796923	153796924	rs9426935	5e-06	Lentiform nucleus volume 
chr1	150305957	150305958	rs12403795	5e-06	Illicit drug use
chr11	110125218	110125219	rs746463	5e-06	Exercise treadmill test traits
chr11	115269832	115269833	rs7950069	5e-06	Orofacial clefts
chr11	116958936	116958937	rs7120173	5e-06	Visceral adipose tissue adjusted for BMI
chr11	118470933	118470934	rs7948661	5e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr11	126412001	126412002	rs4937126	5e-06	Coronary heart disease
chr11	126749294	126749295	rs1557488	5e-06	Attention deficit hyperactivity disorder and conduct disorder
chr11	127211695	127211696	rs4529888	5e-06	Amyotrophic lateral sclerosis
chr11	13309678	13309679	rs4757144	5e-06	Schizophrenia
chr1	115333023	115333024	rs4332358	5e-06	Bipolar disorder and schizophrenia
chr11	15930747	15930748	rs11023787	5e-06	Bone mineral density (wrist)
chr1	116587088	116587089	rs17036023	5e-06	Asthma (childhood onset)
chr11	18668105	18668106	rs12295403	5e-06	Ovarian reserve
chr11	20540972	20540973	rs7128311	5e-06	Response to treatment for acute lymphoblastic leukemia
chr11	21037184	21037185	rs4569005	5e-06	Adverse response to lamotrigine and phenytoin
chr11	21655795	21655796	rs2051457	5e-06	Obesity-related traits
chr11	2287531	2287532	rs2521263	5e-06	Obesity-related traits
chr11	25186157	25186158	rs12794435	5e-06	Ovarian cancer
chr11	2932492	2932493	rs3847646	5e-06	Calcium levels
chr11	41204403	41204404	rs980952	5e-06	IgG glycosylation
chr11	43064543	43064544	rs10501293	5e-06	Cognitive performance
chr11	45506565	45506566	rs1488665	5e-06	Obesity-related traits
chr11	92986514	92986515	rs10830964	5e-06	Insomnia (caffeine-induced)
chr13	91849409	91849410	rs7328464	5e-06	Obesity-related traits
chr10	31223168	31223169	rs2484992	5e-06	Disc degeneration (lumbar)
chr13	98443779	98443780	rs9517302	5e-06	Obesity-related traits
chr18	53379660	53379661	rs11876941	5e-06	Body mass index (interaction)
chr18	5857091	5857092	rs11662763	5e-06	Immunoglobulin A 
chr18	65363999	65364000	rs470490	5e-06	Atrioventricular conduction
chr1	86585517	86585518	rs1953652	5e-06	IgG glycosylation
chr18	67284975	67284976	rs8099213	5e-06	Multiple myeloma (IgH translocation)
chr18	73914270	73914271	rs2278331	5e-06	Sleep duration
chr18	75480490	75480491	rs1865721	5e-06	Intelligence
chr1	87666696	87666697	rs983332	5e-06	Response to TNF antagonist treatment
chr18	8966145	8966146	rs10502386	5e-06	Obesity-related traits
chr18	51878593	51878594	rs1351435	5e-06	Obesity-related traits
chr1	90822572	90822573	rs3843306	5e-06	Pulmonary function decline
chr19	2160529	2160530	rs3803915	5e-06	Body mass index
chr19	28522013	28522014	rs8113142	5e-06	Femoral neck bone geometry and menarche (age at onset)
chr19	29245434	29245435	rs11083866	5e-06	Lentiform nucleus volume 
chr19	30452769	30452770	rs33436	5e-06	Obesity-related traits
chr19	3251220	3251221	rs17764205	5e-06	Bipolar disorder and schizophrenia
chr19	33223021	33223022	rs8106493	5e-06	Visceral adipose tissue/subcutaneous adipose tissue ratio
chr19	33830352	33830353	rs398426	5e-06	Major depressive disorder
chr19	37194063	37194064	rs11673344	5e-06	Obesity-related traits
chr19	38422123	38422124	rs892055	5e-06	Asperger disorder
chr19	11223618	11223619	rs4804155	5e-06	Coronary heart disease
chr1	93997212	93997213	rs17110736	5e-06	Dialysis-related mortality
chr18	49583322	49583323	rs9951026	5e-06	Testicular germ cell tumor
chr18	45145696	45145697	rs998124	5e-06	Prostate cancer (gene x gene interaction)
chr17	72588125	72588126	rs718073	5e-06	Relative hand skill in reading disability
chr17	7281161	7281162	rs5415	5e-06	Birth weight
chr17	77001814	77001815	rs4789400	5e-06	Cannabis use (initiation)
chr17	78308428	78308429	rs8081523	5e-06	Blood trace element (Se levels)
chr17	81715020	81715021	rs3204270	5e-06	Dental caries
chr1	78789076	78789077	rs12730292	5e-06	Bipolar disorder
chr1	80012194	80012195	rs10493631	5e-06	Obesity-related traits
chr18	23141008	23141009	rs11082304	5e-06	Platelet counts
chr18	25813139	25813140	rs7231041	5e-06	Obesity-related traits
chr18	4721358	4721359	rs1557305	5e-06	Eating disorders
chr18	25825223	25825224	rs9966832	5e-06	Periodontitis (Mean PAL)
chr18	27107359	27107360	rs9961915	5e-06	Dental caries
chr18	27490390	27490391	rs4800279	5e-06	White matter integrity
chr18	27587980	27587981	rs1420956	5e-06	Obesity-related traits
chr18	28544723	28544724	rs879500	5e-06	Lung function (forced vital capacity)
chr18	29026682	29026683	rs2155929	5e-06	Temperament (bipolar disorder)
chr18	3415832	3415833	rs12457997	5e-06	Periodontitis (DPAL)
chr18	36791897	36791898	rs7226408	5e-06	Obesity-related traits
chr18	42443816	42443817	rs12606301	5e-06	Economic and political preferences (immigration/crime)
chr18	43011118	43011119	rs9958208	5e-06	Acute lymphoblastic leukemia (childhood)
chr18	26184270	26184271	rs11877878	5e-06	Periodontitis (Mean PAL)
chr19	40848627	40848628	rs1801272	5e-06	Smoking behavior
chr19	44919688	44919689	rs4420638	5e-06	Quantitative traits
chr1	94615888	94615889	rs4474258	5e-06	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU)
chr20	51054897	51054898	rs4811117	5e-06	Molar-incisor hypomineralization
chr20	52021120	52021121	rs6013355	5e-06	Subcutaneous adipose tissue
chr20	52086093	52086094	rs6013382	5e-06	Amyotrophic lateral sclerosis
chr20	54227259	54227260	rs2585417	5e-06	Obesity-related traits
chr20	54794479	54794480	rs13037755	5e-06	Relative hand skill
chr20	54797999	54798000	rs157640	5e-06	Celiac disease
chr20	569273	569274	rs6084946	5e-06	IgG glycosylation
chr20	57483298	57483299	rs59972978	5e-06	Alcohol consumption
chr20	60321656	60321657	rs6027506	5e-06	Type 1 diabetes nephropathy
chr20	49365590	49365591	rs237450	5e-06	QT interval
chr2	100208904	100208905	rs9653442	5e-06	Type 1 diabetes
chr2	102772134	102772135	rs12465996	5e-06	IgG glycosylation
chr2	102772134	102772135	rs12465996	5e-06	IgG glycosylation
chr2	112933826	112933827	rs12467847	5e-06	Response to amphetamines
chr2	120943712	120943713	rs11122834	5e-06	Erectile dysfunction and prostate cancer treatment
chr2	12112223	12112224	rs17551536	5e-06	Bronchopulmonary dysplasia
chr2	122370212	122370213	rs2037892	5e-06	Lentiform nucleus volume 
chr2	122379313	122379314	rs1919922	5e-06	Lentiform nucleus volume 
chr21	23417235	23417236	rs3819055	5e-06	Visceral fat
chr13	94853007	94853008	rs11070098	5e-06	Obesity-related traits
chr2	102259126	102259127	rs1345301	5e-06	Waist circumference
chr20	46292991	46292992	rs6065945	5e-06	IgG glycosylation
chr20	46111556	46111557	rs6074022	5e-06	Multiple sclerosis
chr20	4406486	4406487	rs586446	5e-06	IgG glycosylation
chr19	50217816	50217817	rs4802666	5e-06	Disc degeneration (lumbar)
chr19	51270547	51270548	rs1878047	5e-06	Body mass index
chr19	52880931	52880932	rs6509701	5e-06	Alzheimer's disease
chr19	55579965	55579966	rs149546760	5e-06	Periodontitis (Mean PAL)
chr19	7223836	7223837	rs4804416	5e-06	Hypothyroidism
chr1	99317400	99317401	rs12743824	5e-06	Non-alcoholic fatty liver disease histology (other)
chr20	13316264	13316265	rs1223271	5e-06	Parkinson's disease
chr20	15355107	15355108	rs6110577	5e-06	Obesity (extreme)
chr20	17376927	17376928	rs4814615	5e-06	Dialysis-related mortality
chr20	18905093	18905094	rs742731	5e-06	Homeostasis model assessment of insulin resistance (interaction)
chr20	1948895	1948896	rs6035126	5e-06	Liver enzyme levels (alanine transaminase)
chr20	19821543	19821544	rs6046346	5e-06	Obesity-related traits
chr20	20653461	20653462	rs6132333	5e-06	IgG glycosylation
chr20	25259552	25259553	rs2281558	5e-06	Calcium levels
chr20	32857340	32857341	rs6057659	5e-06	Attention deficit hyperactivity disorder (combined symptoms)
chr20	32859051	32859052	rs8123073	5e-06	Attention deficit hyperactivity disorder (combined symptoms)
chr20	32859561	32859562	rs17123726	5e-06	Attention deficit hyperactivity disorder (combined symptoms)
chr20	33968970	33968971	rs6059594	5e-06	IgG glycosylation
chr20	38349566	38349567	rs1739654	5e-06	IgG glycosylation
chr20	39216833	39216834	rs6028335	5e-06	Alcohol and nictotine co-dependence
chr20	40849892	40849893	rs6102185	5e-06	IgG glycosylation
chr17	70637923	70637924	rs16975985	5e-06	Obesity-related traits
chr17	70112275	70112276	rs12936361	5e-06	Periodontitis (DPAL)
chr2	102718981	102718982	rs33993717	5e-06	Response to amphetamines
chr17	66451046	66451047	rs7207499	5e-06	Post-traumatic stress disorder (asjusted for relatedness)
chr1	47855548	47855549	rs946836	5e-06	White matter integrity
chr14	81312299	81312300	rs6574644	5e-06	Obesity-related traits
chr14	82911658	82911659	rs12050412	5e-06	Word reading
chr14	89127950	89127951	rs7158359	5e-06	Weight loss (gastric bypass surgery)
chr14	94628059	94628060	rs8005845	5e-06	Body mass index
chr14	96927347	96927348	rs8016620	5e-06	Obesity-related traits
chr1	5110651	5110652	rs7513590	5e-06	Anthropometric traits
chr15	23817767	23817768	rs7164923	5e-06	Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms)
chr15	29439239	29439240	rs11856574	5e-06	Life threatening arrhythmia
chr14	77218498	77218499	rs2287375	5e-06	Bipolar disorder
chr1	53492929	53492930	rs1298637	5e-06	Nicotine use
chr1	53854663	53854664	rs11206226	5e-06	Nonalcoholic fatty liver disease
chr15	45508836	45508837	rs950027	5e-06	Response to fenofibrate (adiponectin levels)
chr15	45692872	45692873	rs12594515	5e-06	Weight
chr15	48755930	48755931	rs16961557	5e-06	Obesity-related traits
chr1	55277163	55277164	rs12239436	5e-06	Coronary heart disease
chr1	5600948	5600949	rs7528859	5e-06	Migraine with aura
chr15	61410579	61410580	rs3884558	5e-06	Response to amphetamines
chr15	62998445	62998446	rs12595433	5e-06	Obesity-related traits
chr1	5647755	5647756	rs4845812	5e-06	Metabolite levels (MHPG)
chr15	35566381	35566382	rs6495785	5e-06	Menopause (age at onset)
chr14	77031631	77031632	rs183266	5e-06	Adverse response to lamotrigine and phenytoin
chr14	76184420	76184421	rs2121070	5e-06	Blood pressure
chr14	74856090	74856091	rs8014204	5e-06	Caffeine consumption
chr13	99122392	99122393	rs11069349	5e-06	Self-reported allergy
chr17	6703698	6703699	rs218676	5e-06	Economic and political preferences (time)
chr13	99840905	99840906	rs9513675	5e-06	Obesity-related traits
chr13	99902783	99902784	rs7992643	5e-06	Attention deficit hyperactivity disorder
chr14	101073046	101073047	rs7147503	5e-06	Corneal astigmatism
chr14	102910983	102910984	rs10133111	5e-06	Brain imaging in schizophrenia (interaction)
chr14	23912305	23912306	rs12436436	5e-06	Bipolar disorder
chr14	26790836	26790837	rs1951082	5e-06	Attention deficit hyperactivity disorder and conduct disorder
chr14	33011715	33011716	rs8015959	5e-06	Bipolar disorder
chr1	43539608	43539609	rs2819332	5e-06	Amyotrophic lateral sclerosis (age of onset)
chr14	35928473	35928474	rs1168987	5e-06	Response to antineoplastic agents
chr1	43664107	43664108	rs669446	5e-06	Amyotrophic lateral sclerosis (age of onset)
chr14	41233394	41233395	rs1612141	5e-06	QT interval (interaction)
chr14	49484631	49484632	rs1530947	5e-06	Visceral fat
chr14	50857023	50857024	rs8019546	5e-06	Dietary macronutrient intake
chr14	65398906	65398907	rs7147624	5e-06	Chronic obstructive pulmonary disease-related biomarkers
chr14	68519439	68519440	rs11624164	5e-06	Obesity-related traits
chr14	70153924	70153925	rs4899329	5e-06	IgG glycosylation
chr14	70885930	70885931	rs36563	5e-06	Alcohol dependence
chr14	72225784	72225785	rs699363	5e-06	Obesity (extreme)
chr14	72552527	72552528	rs4903031	5e-06	C-reactive protein
chr15	67906572	67906573	rs448720	5e-06	Cognitive performance
chr15	71280614	71280615	rs76917273	5e-06	Serum dimethylarginine levels (symmetric)
chr14	22139541	22139542	rs1474476	5e-06	Obesity-related traits
chr1	58859953	58859954	rs4601609	5e-06	Cognitive performance
chr16	72897185	72897186	rs16971384	5e-06	Coronary heart disease
chr16	74944719	74944720	rs2042415	5e-06	Obesity-related traits
chr16	76284644	76284645	rs7193230	5e-06	Response to amphetamines
chr16	7703701	7703702	rs12444931	5e-06	Bipolar disorder and schizophrenia
chr16	79397955	79397956	rs4888966	5e-06	Dental caries
chr16	79551123	79551124	rs7498403	5e-06	Height
chr1	68168240	68168241	rs1367448	5e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs)
chr16	82293199	82293200	rs11863065	5e-06	Obesity-related traits
chr16	82929157	82929158	rs17675602	5e-06	Migraine - clinic-based
chr16	7089171	7089172	rs11866781	5e-06	Periodontitis (PAL4Q3)
chr16	83250732	83250733	rs10514585	5e-06	Depression (quantitative trait)
chr16	87428362	87428363	rs9646303	5e-06	Major depressive disorder
chr1	69219313	69219314	rs4650135	5e-06	Inattentive symptoms
chr17	12144226	12144227	rs1870584	5e-06	Response to amphetamines
chr17	32569436	32569437	rs225212	5e-06	Hypertension risk in short sleep duration
chr1	7461524	7461525	rs1616122	5e-06	Periodontal microbiota
chr17	47232326	47232327	rs11079764	5e-06	IgG glycosylation
chr17	58770583	58770584	rs9303401	5e-06	Cognitive test performance
chr15	81066795	81066796	rs2663905	5e-06	QT interval (interaction)
chr17	57746190	57746191	rs8077059	5e-06	Sex hormone-binding globulin levels
chr1	68461829	68461830	rs435066	5e-06	IgG glycosylation
chr1	66580442	66580443	rs1867631	5e-06	Menopause (age at onset)
chr17	4104299	4104300	rs7221595	5e-06	Functional impairment in major depressive disorder, bipolar disorder and schizophrenia
chr16	625679	625680	rs763014	5e-06	Height
chr1	66303416	66303417	rs6683977	5e-06	Acute lymphoblastic leukemia (childhood)
chr15	92263060	92263061	rs4304977	5e-06	DNA methylation (variation)
chr15	93170436	93170437	rs6497031	5e-06	Periodontitis (CDC/AAP)
chr15	93271899	93271900	rs17612678	5e-06	Obesity-related traits
chr1	59387646	59387647	rs7534016	5e-06	Obesity-related traits
chr15	94775356	94775357	rs17664713	5e-06	Response to mTOR inhibitor (rapamycin)
chr15	96165061	96165062	rs8023580	5e-06	Sex hormone-binding globulin levels
chr15	98332799	98332800	rs970843	5e-06	Obesity (extreme)
chr16	10569769	10569770	rs2221433	5e-06	Eating disorders
chr16	19948997	19948998	rs4527026	5e-06	Obesity-related traits
chr15	92161800	92161801	rs2238341	5e-06	Serum dimethylarginine levels (symmetric)
chr16	24799359	24799360	rs17177078	5e-06	Type 2 diabetes (dietary heme iron intake interaction)
chr16	2057111	2057112	rs45502703	5e-06	Obesity-related traits
chr16	55211124	55211125	rs17291845	5e-06	Information processing speed
chr16	49609654	49609655	rs2080501	5e-06	IgG glycosylation
chr16	57529758	57529759	rs8052123	5e-06	Cataracts in type 2 diabetes
chr16	4207311	4207312	rs75825892	5e-06	Obesity-related traits
chr16	49360364	49360365	rs8057939	5e-06	Prostate cancer (gene x gene interaction)
chr15	88705907	88705908	rs8027587	5e-06	Obesity-related traits
chr16	3719579	3719580	rs56240109	5e-06	Metabolite levels (HVA/5-HIAA ratio)
chr16	32469602	32469603	rs13380637	5e-06	Response to amphetamines
chr16	31336426	31336427	rs3925075	5e-06	IgA nephropathy
chr3	66475538	66475539	rs3845905	6e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin)
chr3	70414178	70414179	rs1024889	6e-06	Body mass index
chr3	65393618	65393619	rs1016553	6e-06	Homeostasis model assessment of beta-cell function (interaction)
chr3	70971338	70971339	rs17651978	6e-06	Attention deficit hyperactivity disorder
chr3	71066599	71066600	rs7616330	6e-06	QT interval
chr3	71364893	71364894	rs13072512	6e-06	IgG glycosylation
chr3	65413222	65413223	rs7649739	6e-06	IgG glycosylation
chr3	72460119	72460120	rs11128271	6e-06	IgG glycosylation
chr4	110306659	110306660	rs13148252	6e-06	IgG glycosylation
chr3	76676751	76676752	rs10511052	6e-06	IgG glycosylation
chr3	79554913	79554914	rs7617400	6e-06	Liver enzyme levels (aspartate transaminase)
chr4	106079304	106079305	rs11097912	6e-06	Airflow obstruction 
chr4	112002080	112002081	rs17589290	6e-06	Coronary heart disease
chr4	120592059	120592060	rs10017284	6e-06	F-cell distribution
chr3	65341206	65341207	rs6764388	6e-06	Corneal astigmatism
chr4	122408206	122408207	rs17388568	6e-06	Type 1 diabetes autoantibodies
chr4	12498596	12498597	rs62295889	6e-06	Obesity-related traits
chr3	76435031	76435032	rs3849491	6e-06	Sex hormone-binding globulin levels
chr4	120880634	120880635	rs180730	6e-06	Fasting plasma glucose
chr3	270665	270666	rs6764363	6e-06	Sudden cardiac arrest
chr3	62492518	62492519	rs13325751	6e-06	Economic and political preferences (environmentalism)
chr3	171253501	171253502	rs2088885	6e-06	Brain imaging in schizophrenia (interaction)
chr3	173462842	173462843	rs11709498	6e-06	Periodontitis (DPAL)
chr3	178712150	178712151	rs9290663	6e-06	Acute lymphoblastic leukemia (childhood)
chr4	125505539	125505540	rs12639834	6e-06	Cognitive performance
chr3	18540355	18540356	rs7633075	6e-06	Serum dimethylarginine levels (symmetric)
chr3	187738920	187738921	rs3733017	6e-06	PR interval
chr3	188227135	188227136	rs1975991	6e-06	White matter integrity (interaction)
chr3	188703108	188703109	rs1152846	6e-06	Weight
chr3	192100852	192100853	rs4585146	6e-06	Major depressive disorder
chr3	195037280	195037281	rs3892715	6e-06	Attention deficit hyperactivity disorder (time to onset)
chr3	20311273	20311274	rs9871864	6e-06	Behavioural disinhibition (generation interaction)
chr3	22432237	22432238	rs17011371	6e-06	Periodontitis (PAL4Q3)
chr3	3157950	3157951	rs1669338	6e-06	White matter integrity
chr3	3190153	3190154	rs1672743	6e-06	IgG glycosylation
chr3	34921176	34921177	rs10514688	6e-06	Tonometry
chr3	36368108	36368109	rs2605393	6e-06	Celiac disease
chr3	42766578	42766579	rs339665	6e-06	Periodontitis (DPAL)
chr3	48466175	48466176	rs3135940	6e-06	Obesity-related traits
chr3	55537731	55537732	rs1795648	6e-06	Bipolar disorder and schizophrenia
chr3	63827977	63827978	rs7614311	6e-06	Lung function (forced expiratory volume in 1 second)
chr4	134026645	134026646	rs1494978	6e-06	Lung function (forced expiratory volume in 1 second)
chr4	75407764	75407765	rs2903698	6e-06	Prion diseases
chr4	154560136	154560137	rs4508864	6e-06	Chronic obstructive pulmonary disease-related biomarkers
chr4	89057648	89057649	rs16996151	6e-06	Response to antipsychotic therapy (extrapyramidal side effects)
chr4	94722805	94722806	rs10027628	6e-06	QT interval
chr4	98416729	98416730	rs10516430	6e-06	Biochemical measures
chr4	99216336	99216337	rs6820368	6e-06	QRS duration
chr5	100655943	100655944	rs4702982	6e-06	Panic disorder
chr5	100966101	100966102	rs17161553	6e-06	IgG glycosylation
chr5	10512584	10512585	rs111426949	6e-06	Metabolite levels (HVA/MHPG ratio)
chr5	11111658	11111659	rs6884431	6e-06	Pulmonary function decline
chr4	86762561	86762562	rs181519890	6e-06	Serum dimethylarginine levels (symmetric)
chr5	117177908	117177909	rs12153048	6e-06	Periodontitis (DPAL)
chr5	135132009	135132010	rs477687	6e-06	AIDS progression
chr5	135236538	135236539	rs606854	6e-06	Obesity-related traits
chr5	13769864	13769865	rs7715811	6e-06	Subclinical atherosclerosis traits (other)
chr5	139471319	139471320	rs13181561	6e-06	Chronic obstructive pulmonary disease-related biomarkers
chr5	143520235	143520236	rs12153243	6e-06	Migraine
chr3	165562420	165562421	rs1523288	6e-06	Heart failure
chr5	147845950	147845951	rs891992	6e-06	Obesity-related traits
chr5	153125368	153125369	rs1438949	6e-06	Response to amphetamines
chr5	127726278	127726279	rs12523164	6e-06	Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms)
chr4	81541442	81541443	rs1822818	6e-06	Major depressive disorder
chr4	78158602	78158603	rs17002988	6e-06	Uric acid levels
chr4	77420505	77420506	rs7677281	6e-06	Lung function (forced expiratory volume in 1 second to forced vital capacity ratio)
chr4	15543786	15543787	rs9918079	6e-06	Obesity-related traits
chr4	159361565	159361566	rs6536413	6e-06	Intelligence (childhood)
chr4	15963239	15963240	rs4698433	6e-06	QT interval
chr4	162321900	162321901	rs4440177	6e-06	Alcohol dependence
chr4	16906380	16906381	rs6819013	6e-06	QT interval
chr4	174379627	174379628	rs6852435	6e-06	Response to acetaminophen (hepatotoxicity)
chr4	182216244	182216245	rs2726807	6e-06	Schizophrenia
chr4	184086239	184086240	rs4862307	6e-06	Serum dimethylarginine levels (asymmetric/symetric ratio)
chr4	188663198	188663199	rs7686384	6e-06	Obesity-related traits
chr4	2101368	2101369	rs1923775	6e-06	Alzheimer's disease
chr4	21453633	21453634	rs11942476	6e-06	IgG glycosylation
chr4	22019876	22019877	rs16872248	6e-06	Obesity-related traits
chr4	30066590	30066591	rs6818288	6e-06	Obesity-related traits
chr4	31154555	31154556	rs74879986	6e-06	Bulimia nervosa
chr4	35981488	35981489	rs6834483	6e-06	Obesity-related traits
chr4	36025124	36025125	rs1567482	6e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil)
chr4	54375413	54375414	rs9312648	6e-06	Response to amphetamines
chr4	68726063	68726064	rs293428	6e-06	Sex hormone-binding globulin levels
chr4	741361	741362	rs4234853	6e-06	Hemostatic factors and hematological phenotypes
chr4	14142583	14142584	rs6844339	6e-06	Obesity-related traits
chr3	165407370	165407371	rs9878522	6e-06	Response to amphetamines
chr2	24024643	24024644	rs7561273	6e-06	Quantitative traits
chr3	1581708	1581709	rs402675	6e-06	Estradiol levels
chr2	198720831	198720832	rs16830366	6e-06	Waist circumference
chr2	199149759	199149760	rs12471454	6e-06	Insomnia
chr2	205195912	205195913	rs10153620	6e-06	Attention deficit hyperactivity disorder (combined symptoms)
chr2	205285869	205285870	rs1207421	6e-06	Knee osteoarthritis
chr22	19577733	19577734	rs2106139	6e-06	IgG glycosylation
chr22	20443001	20443002	rs5763911	6e-06	Retinopathy in non-diabetics
chr2	221034723	221034724	rs10498091	6e-06	Echocardiographic traits
chr22	21953146	21953147	rs412050	6e-06	Attention deficit hyperactivity disorder
chr2	198123210	198123211	rs988583	6e-06	Neutrophil count
chr22	23250863	23250864	rs5751614	6e-06	Height
chr22	27633570	27633571	rs16985179	6e-06	Alcohol consumption
chr2	230171028	230171029	rs13010639	6e-06	Obesity-related traits
chr22	33170600	33170601	rs4821132	6e-06	Visceral adipose tissue adjusted for BMI
chr2	234706552	234706553	rs6736997	6e-06	Pancreatic cancer
chr2	235886698	235886699	rs13025591	6e-06	Schizophrenia
chr22	36862460	36862461	rs4821544	6e-06	Atopic dermatitis
chr22	37073550	37073551	rs4820268	6e-06	Iron status biomarkers
chr2	238397626	238397627	rs3739070	6e-06	Iris characteristics
chr22	26301228	26301229	rs591044	6e-06	Insulin resistance/response
chr2	239765594	239765595	rs10207060	6e-06	Obesity-related traits
chr2	195007094	195007095	rs10172965	6e-06	Temperament
chr2	188854235	188854236	rs2675399	6e-06	Obesity-related traits
chr21	43028607	43028608	rs2839627	6e-06	Information processing speed
chr5	154130035	154130036	rs2033195	6e-06	Body mass index
chr2	152580055	152580056	rs11675841	6e-06	IgG glycosylation
chr2	152580055	152580056	rs11675841	6e-06	IgG glycosylation
chr2	154146333	154146334	rs16836124	6e-06	Obesity-related traits
chr2	154370164	154370165	rs707040	6e-06	Sudden cardiac arrest
chr2	154370164	154370165	rs707040	6e-06	Sudden cardiac arrest
chr2	160928657	160928658	rs1829975	6e-06	Treatment response for severe sepsis 
chr2	189742426	189742427	rs12053254	6e-06	Obesity-related traits
chr2	164720653	164720654	rs10221833	6e-06	Response to statin therapy
chr2	169767710	169767711	rs2114646	6e-06	Obesity-related traits
chr2	173462116	173462117	rs10930597	6e-06	Blood pressure measurement (high sodium and potassium intervention)
chr2	173497620	173497621	rs7590983	6e-06	Anthropometric traits
chr2	178239570	178239571	rs34479159	6e-06	Breast size
chr2	179352003	179352004	rs13403289	6e-06	Presence of antiphospholipid antibodies
chr2	181397141	181397142	rs7602460	6e-06	Atrioventricular conduction
chr2	185160007	185160008	rs11678036	6e-06	IgG glycosylation
chr2	185319302	185319303	rs1364477	6e-06	IgG glycosylation
chr2	166085629	166085630	rs11904006	6e-06	Response to amphetamines
chr2	240582849	240582850	rs2953174	6e-06	Bipolar disorder
chr22	43122268	43122269	rs742134	6e-06	Prostate cancer
chr22	43808438	43808439	rs8140172	6e-06	IgG glycosylation
chr2	69586325	69586326	rs12987661	6e-06	Metabolite levels (Dihydroxy docosatrienoic acid)
chr2	70141790	70141791	rs6708331	6e-06	Obesity-related traits
chr2	75565016	75565017	rs17011478	6e-06	Obesity-related traits
chr2	76996811	76996812	rs1470506	6e-06	IgG glycosylation
chr2	96835062	96835063	rs9948	6e-06	Erectile dysfunction and prostate cancer treatment
chr3	103644216	103644217	rs10937544	6e-06	Economic and political preferences (environmentalism)
chr3	10998752	10998753	rs9990174	6e-06	Conduct disorder (interaction)
chr3	11033327	11033328	rs2675163	6e-06	Response to Vitamin E supplementation
chr2	64268492	64268493	rs1529102	6e-06	Breast size
chr3	112962737	112962738	rs1488193	6e-06	Economic and political preferences
chr3	121625292	121625293	rs3772130	6e-06	Cognitive performance
chr3	122610312	122610313	rs2173763	6e-06	Major depressive disorder
chr3	122670145	122670146	rs790123	6e-06	Response to angiotensin II receptor blocker therapy
chr3	127242304	127242305	rs13075436	6e-06	Response to angiotensin II receptor blocker therapy
chr3	128563853	128563854	rs6806253	6e-06	Pit-and-Fissure caries 
chr3	128933709	128933710	rs9810890	6e-06	Dental caries
chr3	133542029	133542030	rs11708304	6e-06	Bulimia nervosa
chr3	143264056	143264057	rs9810857	6e-06	Attention deficit hyperactivity disorder
chr3	114123165	114123166	rs2087017	6e-06	Personality dimensions
chr2	63369700	63369701	rs11683229	6e-06	Protein quantitative trait loci
chr2	60864814	60864815	rs842636	6e-06	Psoriasis
chr2	60307063	60307064	rs6545803	6e-06	Nevirapine-induced rash
chr22	49448639	49448640	rs9627735	6e-06	Serum dimethylarginine levels (symmetric)
chr2	25390276	25390277	rs7577599	6e-06	Multiple myeloma (IgH translocation)
chr2	25664688	25664689	rs11684202	6e-06	Coronary heart disease
chr23	111912004	111912005	rs7050529	6e-06	Smoking behavior
chr23	143759023	143759024	rs139956886	6e-06	Tuberculosis
chr23	22116539	22116540	rs5951698	6e-06	Tourette syndrome
chr2	3388303	3388304	rs10865541	6e-06	Obesity-related traits
chr23	44540939	44540940	rs6610953	6e-06	Personality dimensions
chr2	35301851	35301852	rs6750486	6e-06	Conduct disorder (symptom count)
chr23	63405318	63405319	rs10127000	6e-06	Periodontitis (Mean PAL)
chr23	66386850	66386851	rs5965182	6e-06	Erectile dysfunction and prostate cancer treatment
chr23	83456933	83456934	rs213443	6e-06	Bipolar disorder and schizophrenia
chr23	95824870	95824871	rs5990417	6e-06	Major depressive disorder (broad)
chr2	42754098	42754099	rs930421	6e-06	Attention deficit hyperactivity disorder
chr2	43411698	43411699	rs13429458	6e-06	Response to amphetamines
chr2	47820195	47820196	rs4381823	6e-06	Schizophrenia
chr2	53038990	53038991	rs2357013	6e-06	Hemostatic factors and hematological phenotypes
chr2	54854238	54854239	rs12713280	6e-06	Economic and political preferences
chr2	59899175	59899176	rs145433814	6e-06	Eating disorders (purging via substances) 
chr3	159981156	159981157	rs4680534	6e-06	Multiple sclerosis
chr5	156712557	156712558	rs157350	6e-06	Anthropometric traits
chr7	78523354	78523355	rs62468577	6e-06	Bronchopulmonary dysplasia
chr5	165950693	165950694	rs9313296	6e-06	Waist circumference
chr8	129968225	129968226	rs10092658	6e-06	Protein quantitative trait loci
chr8	136756648	136756649	rs16906293	6e-06	Bilirubin levels
chr8	136837767	136837768	rs16906415	6e-06	IgG glycosylation
chr8	137906701	137906702	rs2705293	6e-06	Neuroticism
chr8	141546704	141546705	rs1566080	6e-06	Obesity-related traits
chr8	27219080	27219081	rs1446682	6e-06	Bipolar disorder and schizophrenia
chr8	28933641	28933642	rs2221894	6e-06	Obesity-related traits
chr8	31078839	31078840	rs2553268	6e-06	Exercise treadmill test traits
chr8	12834361	12834362	rs17120471	6e-06	IgG glycosylation
chr8	31317313	31317314	rs2575029	6e-06	Obesity-related traits
chr8	34269429	34269430	rs6990255	6e-06	Bipolar disorder
chr8	4252509	4252510	rs13259289	6e-06	Illicit drug use
chr8	4306490	4306491	rs4875320	6e-06	Coronary heart disease
chr8	5213889	5213890	rs7816936	6e-06	Endometriosis
chr8	55687217	55687218	rs4738393	6e-06	Migraine - clinic-based
chr8	58795749	58795750	rs960089	6e-06	Cognitive performance
chr8	60433637	60433638	rs9650199	6e-06	Response to amphetamines
chr8	61496868	61496869	rs903027	6e-06	MRI atrophy measures
chr8	3298697	3298698	rs142816172	6e-06	Eating disorders (purging via substances) 
chr8	6964094	6964095	rs2738058	6e-06	Periodontitis (PAL4Q3)
chr8	124709124	124709125	rs11781525	6e-06	IgG glycosylation
chr8	119635688	119635689	rs7007970	6e-06	Height
chr7	7359772	7359773	rs10486158	6e-06	Bipolar disorder and schizophrenia
chr7	76321912	76321913	rs7789940	6e-06	Multiple sclerosis
chr7	76348911	76348912	rs17149161	6e-06	Multiple sclerosis
chr7	77920588	77920589	rs12234571	6e-06	Obesity-related traits
chr7	7898964	7898965	rs10486201	6e-06	Obesity-related traits
chr7	82138855	82138856	rs117576300	6e-06	Serum dimethylarginine levels (asymmetric)
chr7	82210236	82210237	rs11978472	6e-06	Crohn's disease (need for surgery)
chr7	86719682	86719683	rs2189812	6e-06	IgG glycosylation
chr8	121610259	121610260	rs17232789	6e-06	Dialysis-related mortality
chr7	89065755	89065756	rs10236237	6e-06	IgG glycosylation
chr7	99610252	99610253	rs7792939	6e-06	Anthropometric traits
chr8	104688451	104688452	rs4734806	6e-06	Periodontitis (DPAL)
chr8	105497746	105497747	rs2622633	6e-06	Coronary artery calcification
chr8	113861150	113861151	rs1912816	6e-06	Bronchopulmonary dysplasia
chr8	11622947	11622948	rs2243407	6e-06	Periodontitis (CDC/AAP)
chr8	11622947	11622948	rs2243407	6e-06	Periodontitis (CDC/AAP)
chr8	117815599	117815600	rs11989122	6e-06	Height
chr8	118753954	118753955	rs11988997	6e-06	Pancreatitis
chr7	90134549	90134550	rs10266254	6e-06	Coronary artery calcification
chr8	70227094	70227095	rs72663955	6e-06	Metabolite levels (HVA-5-HIAA Factor score)
chr8	8859496	8859497	rs332034	6e-06	Conduct disorder (interaction)
chr8	95093808	95093809	rs4590408	6e-06	Metabolite levels (HVA)
chr9	17458873	17458874	rs10810790	6e-06	Response to amphetamines
chr9	24092073	24092074	rs4246856	6e-06	D-dimer levels
chr9	26208858	26208859	rs4978053	6e-06	Visceral adipose tissue/subcutaneous adipose tissue ratio
chr9	26789941	26789942	rs1889899	6e-06	Smoking behavior
chr9	27309660	27309661	rs10967875	6e-06	Obesity-related traits
chr9	29783990	29783991	rs10969375	6e-06	Obesity-related traits
chr9	36099401	36099402	rs4878639	6e-06	IgG glycosylation
chr9	7274695	7274696	rs1887867	6e-06	Obesity-related traits
chr9	15986717	15986718	rs1927702	6e-06	Body mass index
chr9	7518655	7518656	rs2381628	6e-06	IgG glycosylation
chr9	78468980	78468981	rs10125737	6e-06	Obesity-related traits
chr9	8235632	8235633	rs10815798	6e-06	Attention deficit hyperactivity disorder and conduct disorder
chr9	84307120	84307121	rs10123041	6e-06	Response to statin therapy
chr9	89634668	89634669	rs10908907	6e-06	Alcoholism (heaviness of drinking)
chr9	91213188	91213189	rs773506	6e-06	Type 2 diabetes nephropathy
chr9	93800280	93800281	rs7027203	6e-06	DNA methylation (variation)
chr9	96369761	96369762	rs10820447	6e-06	Migraine with aura
chr21	42736658	42736659	rs9979235	6e-06	Pulmonary function decline
chr9	75413429	75413430	rs489332	6e-06	Schizophrenia
chr9	15157978	15157979	rs1780159	6e-06	Calcium levels
chr9	135383929	135383930	rs10858396	6e-06	Attention deficit hyperactivity disorder
chr9	134614731	134614732	rs11103429	6e-06	Crohn's disease (need for surgery)
chr8	95093808	95093809	rs4590408	6e-06	Metabolite levels (HVA-5-HIAA Factor score)
chr8	98076352	98076353	rs13278732	6e-06	Eosinophilic esophagitis (pediatric)
chr9	101860585	101860586	rs10989661	6e-06	Smoking behavior
chr9	10430601	10430602	rs649891	6e-06	Type 2 diabetes
chr9	108110026	108110027	rs7042864	6e-06	Tonometry
chr9	108693294	108693295	rs10512385	6e-06	Paclitaxel-induced neuropathy
chr9	110434982	110434983	rs7042161	6e-06	Bipolar disorder
chr9	112087909	112087910	rs2782931	6e-06	Amyotrophic lateral sclerosis
chr9	112925454	112925455	rs10817408	6e-06	IgG glycosylation
chr9	112925454	112925455	rs10817408	6e-06	IgG glycosylation
chr9	117162815	117162816	rs6478282	6e-06	Immune response to anthrax vaccine 
chr9	117375478	117375479	rs2226006	6e-06	Economic and political preferences (fairness)
chr9	120294358	120294359	rs4837752	6e-06	Response to antipsychotic therapy (extrapyramidal side effects)
chr9	121336256	121336257	rs767770	6e-06	Bipolar disorder and schizophrenia
chr9	122144443	122144444	rs3818638	6e-06	Obesity-related traits
chr9	128640941	128640942	rs12380424	6e-06	Axial length
chr9	128713303	128713304	rs72758841	6e-06	Obesity-related traits
chr9	132900646	132900647	rs1076160	6e-06	Psoriasis
chr9	132969647	132969648	rs2905072	6e-06	Bipolar disorder
chr7	73580145	73580146	rs12666883	6e-06	Obesity-related traits
chr5	160422578	160422579	rs1895320	6e-06	Insulin-related traits
chr7	63117391	63117392	rs6956675	6e-06	Obesity-related traits
chr7	50555013	50555014	rs1451375	6e-06	Malaria
chr6	129895364	129895365	rs9375674	6e-06	Renal sinus fat 
chr6	130037282	130037283	rs6899976	6e-06	Height
chr6	131242436	131242437	rs4629710	6e-06	Multiple myeloma (IgH translocation)
chr6	133342450	133342451	rs11753937	6e-06	Response to angiotensin II receptor blocker therapy
chr6	139818677	139818678	rs12664111	6e-06	IgG glycosylation
chr6	142798694	142798695	rs12211360	6e-06	Adiponectin levels
chr6	149204469	149204470	rs636864	6e-06	Hemostatic factors and hematological phenotypes
chr6	15088919	15088920	rs6941421	6e-06	Multiple sclerosis (severity)
chr6	11943292	11943293	rs1205863	6e-06	Disc degeneration (lumbar)
chr6	166121253	166121254	rs6456042	6e-06	Asthma
chr6	168089887	168089888	rs9364220	6e-06	Attention deficit hyperactivity disorder (inattention symptoms)
chr6	2235398	2235399	rs9378688	6e-06	Caudate nucleus volume
chr6	22709509	22709510	rs4712709	6e-06	Metabolite levels (Pyroglutamine)
chr6	30112591	30112592	rs34704616	6e-06	Cognitive performance
chr6	31440487	31440488	rs2524276	6e-06	Capecitabine sensitivity
chr6	31899475	31899476	rs9267663	6e-06	Economic and political preferences (environmentalism)
chr6	32700132	32700133	rs2647044	6e-06	Pulmonary function
chr6	32713499	32713500	rs2858331	6e-06	IgE levels 
chr6	167988247	167988248	rs2843012	6e-06	Metabolite levels (5-HIAA)
chr6	32713898	32713899	rs3104402	6e-06	Immune response to anthrax vaccine 
chr6	108532289	108532290	rs17041	6e-06	Obesity-related traits
chr6	10175802	10175803	rs12210761	6e-06	Major depressive disorder
chr5	171649222	171649223	rs254893	6e-06	Quantitative traits
chr5	176529269	176529270	rs890835	6e-06	Menopause (age at onset)
chr5	178381673	178381674	rs2910124	6e-06	Bulimia nervosa
chr5	178413380	178413381	rs10070303	6e-06	Obesity-related traits
chr5	180743818	180743819	rs12517906	6e-06	Body mass index
chr5	23243915	23243916	rs17376026	6e-06	Economic and political preferences (immigration/crime)
chr5	40626650	40626651	rs11955175	6e-06	Bipolar disorder and schizophrenia
chr5	51877489	51877490	rs17835853	6e-06	IgG glycosylation
chr6	105805123	105805124	rs1355023	6e-06	Age-related macular degeneration
chr5	52411071	52411072	rs6889746	6e-06	Presence of antiphospholipid antibodies
chr5	65238813	65238814	rs13183791	6e-06	Bipolar disorder and schizophrenia
chr5	75184462	75184463	rs4704187	6e-06	Response to amphetamines
chr5	75359900	75359901	rs3846663	6e-06	Quantitative traits
chr5	76206584	76206585	rs4704296	6e-06	Migraine - clinic-based
chr5	79803640	79803641	rs7735699	6e-06	Bipolar disorder and schizophrenia
chr5	91466930	91466931	rs933688	6e-06	Smoking behavior
chr5	93151836	93151837	rs13173682	6e-06	Obesity-related traits
chr5	99445398	99445399	rs1829883	6e-06	Hemostatic factors and hematological phenotypes
chr5	63088871	63088872	rs71627250	6e-06	Bronchopulmonary dysplasia
chr6	32985502	32985503	rs3097645	6e-06	IgG glycosylation
chr6	32985502	32985503	rs3097645	6e-06	IgG glycosylation
chr6	33794464	33794465	rs2274459	6e-06	Obesity (extreme)
chr7	121635174	121635175	rs10253361	6e-06	Alcoholism (alcohol dependence factor score)
chr7	12351692	12351693	rs6967385	6e-06	Response to taxane treatment (placlitaxel)
chr7	126999549	126999550	rs17864092	6e-06	Depression (quantitative trait)
chr7	130969091	130969092	rs2048672	6e-06	Breast cancer
chr7	13520595	13520596	rs1357978	6e-06	Word reading
chr7	138726679	138726680	rs3800569	6e-06	F-cell distribution
chr7	153838603	153838604	rs2110267	6e-06	Attention deficit hyperactivity disorder (combined symptoms)
chr7	155492439	155492440	rs1861960	6e-06	Migraine
chr7	12020179	12020180	rs769111	6e-06	Tourette syndrome
chr7	15703160	15703161	rs10486776	6e-06	Stroke
chr7	21464808	21464809	rs17144465	6e-06	Major depressive disorder
chr7	22954566	22954567	rs73082373	6e-06	Periodontitis (Mean PAL)
chr7	29178542	29178543	rs245914	6e-06	Obesity-related traits
chr7	38201306	38201307	rs4723738	6e-06	Treatment response for severe sepsis 
chr7	38795434	38795435	rs11984145	6e-06	Cognitive performance
chr7	43118877	43118878	rs2024125	6e-06	Obesity-related traits
chr7	4799633	4799634	rs2306921	6e-06	Obesity-related traits
chr7	50273755	50273756	rs10276619	6e-06	Systemic lupus erythematosus
chr7	16850187	16850188	rs1525739	6e-06	Type 2 diabetes (dietary heme iron intake interaction)
chr7	116706548	116706549	rs10243024	6e-06	Multiple sclerosis (severity)
chr7	114101049	114101050	rs6466479	6e-06	IgG glycosylation
chr7	112002590	112002591	rs61159171	6e-06	Breast size
chr6	34956086	34956087	rs847845	6e-06	Non-small cell lung cancer
chr6	36954907	36954908	rs1405069	6e-06	Chemerin levels
chr6	39394077	39394078	rs9296295	6e-06	Obesity-related traits
chr6	51234457	51234458	rs7762246	6e-06	Obesity-related traits
chr6	53442895	53442896	rs9395865	6e-06	Electroencephalographic traits in alcoholism
chr6	53650147	53650148	rs9474614	6e-06	Obesity-related traits
chr6	577819	577820	rs9504361	6e-06	Pit-and-Fissure caries 
chr6	58438252	58438253	rs4513829	6e-06	Serum dimethylarginine levels (symmetric)
chr6	65468586	65468587	rs4710520	6e-06	IgG glycosylation
chr6	68275037	68275038	rs10455657	6e-06	Cannabis use (initiation)
chr6	71696615	71696616	rs4707930	6e-06	Response to anti-TNF alpha therapy in inflammatory bowel disease
chr6	77080090	77080091	rs7738636	6e-06	Acute lymphoblastic leukemia (childhood)
chr6	92905731	92905732	rs2506933	6e-06	Cognitive performance
chr6	96971721	96971722	rs974417	6e-06	Body mass index
chr6	98140877	98140878	rs9375225	6e-06	QT interval (interaction)
chr7	100342683	100342684	rs13228694	6e-06	Obesity-related traits
chr7	104826516	104826517	rs4073894	6e-06	Educational attainment
chr7	106030820	106030821	rs10270308	6e-06	Warfarin maintenance dose
chr7	107021637	107021638	rs7798500	6e-06	Adverse response to lamotrigine and phenytoin
chr7	54607179	54607180	rs679830	6e-06	Obesity-related traits
chr21	39649824	39649825	rs10854398	6e-06	Suicide risk
chr20	53733352	53733353	rs6091737	6e-06	Calcium levels
chr21	31068220	31068221	rs1475591	6e-06	Coronary heart disease
chr12	120017959	120017960	rs11064994	6e-06	Cognitive performance
chr12	12223530	12223531	rs11054731	6e-06	Coronary artery calcification
chr12	129745861	129745862	rs7979367	6e-06	Behavioural disinhibition (generation interaction)
chr1	21328241	21328242	rs213032	6e-06	Obesity-related traits
chr12	13962547	13962548	rs4764043	6e-06	Aging (time to event)
chr1	21549422	21549423	rs885814	6e-06	Response to TNF-alpha inhibitors in rheumatoid arthritis
chr1	216330926	216330927	rs7532570	6e-06	IgG glycosylation
chr1	216459605	216459606	rs10495024	6e-06	Testosterone levels
chr12	118455442	118455443	rs11613092	6e-06	Hemostatic factors and hematological phenotypes
chr12	17509300	17509301	rs1706631	6e-06	Major depressive disorder
chr1	220756013	220756014	rs1494373	6e-06	Response to antipsychotic therapy (extrapyramidal side effects)
chr1	221443733	221443734	rs12032381	6e-06	Dupuytren's disease
chr1	222071915	222071916	rs10863681	6e-06	Metabolite levels (HVA-5-HIAA Factor score)
chr12	25331258	25331259	rs7965364	6e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr1	225405224	225405225	rs16844846	6e-06	IgG glycosylation
chr1	226668187	226668188	rs10916025	6e-06	Subcutaneous adipose tissue
chr12	27855835	27855836	rs258401	6e-06	Retinopathy in non-diabetics
chr12	28040055	28040056	rs7964407	6e-06	IgG glycosylation
chr1	217544789	217544790	rs2059397	6e-06	Visceral adipose tissue adjusted for BMI
chr1	233508109	233508110	rs10910200	6e-06	Diabetic retinopathy 
chr12	117916065	117916066	rs10444502	6e-06	Biochemical measures
chr12	115453597	115453598	rs7315438	6e-06	Colorectal cancer
chr1	190097255	190097256	rs1935881	6e-06	Echocardiographic traits
chr1	191970657	191970658	rs17403780	6e-06	IgG glycosylation
chr1	197051527	197051528	rs2990510	6e-06	Erectile dysfunction
chr1	198500031	198500032	rs10922438	6e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide)
chr11	98852485	98852486	rs11217223	6e-06	Obesity-related traits
chr11	99715004	99715005	rs952700	6e-06	Volumetric brain MRI
chr1	201625536	201625537	rs2068824	6e-06	Celiac disease
chr1	205514466	205514467	rs12127944	6e-06	IgG glycosylation
chr12	11789785	11789786	rs2856329	6e-06	Lung function (forced expiratory volume in 1 second)
chr1	208584240	208584241	rs17259784	6e-06	Cardiac hypertrophy
chr12	10318450	10318451	rs12303914	6e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr12	103640540	103640541	rs1650123	6e-06	IgG glycosylation
chr12	10368789	10368790	rs10743889	6e-06	Obesity-related traits
chr12	106391775	106391776	rs6539267	6e-06	Tourette syndrome
chr12	110821	110822	rs2011738	6e-06	Response to angiotensin II receptor blocker therapy
chr12	111446803	111446804	rs3184504	6e-06	Coronary heart disease
chr12	111446803	111446804	rs3184504	6e-06	Rheumatoid arthritis
chr12	112971370	112971371	rs2072134	6e-06	HDL cholesterol
chr12	10017561	10017562	rs1054611	6e-06	Sensory disturbances after bilateral sagittal split ramus osteotomy
chr1	234447871	234447872	rs10489896	6e-06	Cognitive test performance
chr1	234680807	234680808	rs482329	6e-06	Life threatening arrhythmia
chr1	235557597	235557598	rs291353	6e-06	Aging traits
chr13	29046516	29046517	rs2479768	6e-06	Methotrexate phramacokinetics (acute lymphoblastic leukemia)
chr13	32398488	32398489	rs11571833	6e-06	Breast cancer
chr13	35957410	35957411	rs34065801	6e-06	Breast size
chr13	36196879	36196880	rs7327064	6e-06	Economic and political preferences
chr13	37491308	37491309	rs9646096	6e-06	Age-related macular degeneration
chr13	37491308	37491309	rs9646096	6e-06	Age-related macular degeneration
chr13	40983973	40983974	rs7329174	6e-06	Systemic lupus erythematosus
chr1	34523635	34523636	rs10914967	6e-06	Visceral adipose tissue adjusted for BMI
chr13	24080088	24080089	rs17079928	6e-06	Orofacial clefts
chr13	46999480	46999481	rs12583882	6e-06	Subcutaneous adipose tissue
chr13	50411981	50411982	rs201789	6e-06	Anthropometric traits
chr1	35222213	35222214	rs673604	6e-06	Endometrial cancer
chr13	54006951	54006952	rs9536591	6e-06	Stroke
chr13	56198561	56198562	rs1512651	6e-06	Warfarin maintenance dose
chr1	3732997	3732998	rs9662633	6e-06	Visceral adipose tissue adjusted for BMI
chr13	91792974	91792975	rs2352028	6e-06	Lung cancer
chr13	94218510	94218511	rs1572050	6e-06	Renal sinus fat 
chr13	97401537	97401538	rs4771996	6e-06	Obesity-related traits
chr13	47624580	47624581	rs1575891	6e-06	Cardiac hypertrophy
chr13	23930815	23930816	rs2765086	6e-06	Weight
chr13	23180987	23180988	rs4770403	6e-06	Alcohol dependence
chr13	103534568	103534569	rs16962638	6e-06	Insulin resistance/response
chr1	237457938	237457939	rs1478912 	6e-06	Response to taxane treatment (docetaxel)
chr1	238745052	238745053	rs2689154	6e-06	Pancreatic cancer
chr12	4009150	4009151	rs4238010	6e-06	Major depressive disorder
chr1	24257999	24258000	rs6670533	6e-06	Fasting insulin-related traits (interaction with BMI)
chr1	243852690	243852691	rs4430311	6e-06	Post-traumatic stress disorder (asjusted for relatedness)
chr1	244347873	244347874	rs4658627	6e-06	Asthma (childhood onset)
chr1	246059817	246059818	rs6693295	6e-06	Migraine with aura
chr12	47779568	47779569	rs4760636	6e-06	Urate levels
chr12	51333811	51333812	rs3951439	6e-06	Obesity-related traits
chr12	5642175	5642176	rs2110166	6e-06	IgG glycosylation
chr12	60341391	60341392	rs7974425	6e-06	Obesity-related traits
chr12	60341391	60341392	rs7974425	6e-06	Obesity-related traits
chr12	6574120	6574121	rs1057510	6e-06	Myopia (pathological)
chr12	69130142	69130143	rs10784762	6e-06	QRS duration
chr12	69187441	69187442	rs12367448	6e-06	IgG glycosylation
chr12	72330253	72330254	rs12831974	6e-06	Rheumatoid arthritis
chr12	82068446	82068447	rs7137515	6e-06	IgG glycosylation
chr12	90049704	90049705	rs10858945	6e-06	Optic disc size (cup)
chr13	102196914	102196915	rs544434	6e-06	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)
chr1	189892273	189892274	rs1400544	6e-06	Subclinical atherosclerosis traits (other)
chr13	98179340	98179341	rs9556893	6e-06	Response to amphetamines
chr11	86127765	86127766	rs10792830	6e-06	Alzheimer's disease
chr1	183647748	183647749	rs10911390	6e-06	Systemic lupus erythematosus
chr10	26195224	26195225	rs12764197	6e-06	Obesity-related traits
chr10	28738293	28738294	rs1248993	6e-06	Preeclampsia
chr10	31701694	31701695	rs7081678	6e-06	Waist-hip ratio
chr10	33799124	33799125	rs1412115	6e-06	Schizophrenia
chr10	37270651	37270652	rs1200821	6e-06	Hemostatic factors and hematological phenotypes
chr10	43963265	43963266	rs898549	6e-06	Obesity-related traits
chr10	44824205	44824206	rs7911712	6e-06	Emphysema-related traits
chr10	4967566	4967567	rs2904804	6e-06	Economic and political preferences (immigration/crime)
chr10	23014323	23014324	rs1054052	6e-06	IgG glycosylation
chr10	58451029	58451030	rs10509091	6e-06	Height
chr10	6365774	6365775	rs11258317	6e-06	Bipolar disorder and schizophrenia
chr10	66328749	66328750	rs10762058	6e-06	Asthma (toluene diisocyanate-induced)
chr10	66881192	66881193	rs4142041	6e-06	Nicotine dependence
chr10	67120044	67120045	rs10997517	6e-06	Migraine without aura
chr10	69778535	69778536	rs4746003	6e-06	Alzheimer's disease
chr10	70767760	70767761	rs12761224	6e-06	Prion diseases
chr10	71767289	71767290	rs1867982	6e-06	Pulmonary function decline
chr10	74943247	74943248	rs10466033	6e-06	Breast size
chr10	5876468	5876469	rs17145612	6e-06	Obesity-related traits
chr10	78341103	78341104	rs2395528	6e-06	Conduct disorder (interaction)
chr10	1855783	1855784	rs12360000	6e-06	Metabolite levels (Dihydroxy docosatrienoic acid)
chr10	16955891	16955892	rs10508517	6e-06	Quantitative traits
chr10	100741813	100741814	rs4509693	6e-06	Alzheimer's disease
chr10	10254155	10254156	rs7097577	6e-06	Obesity-related traits
chr10	107614625	107614626	rs11193561	6e-06	Endometriosis
chr10	109211676	109211677	rs17783561	6e-06	IgG glycosylation
chr10	113118107	113118108	rs74157220	6e-06	Serum dimethylarginine levels (asymmetric/symetric ratio)
chr10	114439415	114439416	rs941853	6e-06	Obesity-related traits
chr10	117450863	117450864	rs6585436	6e-06	Cardiac repolarization
chr21	37560475	37560476	rs2835810	6e-06	Metabolic syndrome
chr10	18470699	18470700	rs7076247	6e-06	Protein quantitative trait loci
chr10	126011366	126011367	rs10901513	6e-06	Visceral fat
chr10	12660569	12660570	rs75263140	6e-06	Anorexia nervosa
chr10	128435543	128435544	rs10764775	6e-06	IgG glycosylation
chr10	129875721	129875722	rs9804200	6e-06	Sleep time
chr10	130839041	130839042	rs7094308	6e-06	Serum dimethylarginine levels (asymmetric/symetric ratio)
chr10	1364168	1364169	rs11250464	6e-06	Radiation response
chr10	15677621	15677622	rs7895372	6e-06	Quantitative traits
chr10	1588625	1588626	rs2999399	6e-06	Emphysema-related traits
chr10	16702523	16702524	rs11254160	6e-06	Obesity-related traits
chr10	12633061	12633062	rs10906189	6e-06	QT interval (interaction)
chr10	79295868	79295869	rs12355688	6e-06	Breast cancer
chr10	84829145	84829146	rs11201253	6e-06	Obesity-related traits
chr10	84961424	84961425	rs12266096	6e-06	Lung function (forced expiratory flow between 25% and 75% of forced vital capacity)
chr11	2116908	2116909	rs6578985	6e-06	Femoral neck bone geometry and menarche (age at onset)
chr11	22291019	22291020	rs11827962	6e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr11	22821608	22821609	rs712022	6e-06	Dialysis-related mortality
chr11	39887111	39887112	rs11035577	6e-06	Temperament (bipolar disorder)
chr1	145789474	145789475	rs12744221	6e-06	Epilepsy (remission after treatment)
chr1	152520082	152520083	rs4845783	6e-06	Asthma
chr1	153507521	153507522	rs4845552	6e-06	Hippocampal atrophy
chr1	159492590	159492591	rs4325129	6e-06	Obesity-related traits
chr11	15599039	15599040	rs17439299	6e-06	Obesity-related traits
chr1	159678197	159678198	rs12093699	6e-06	Protein quantitative trait loci
chr1	165862411	165862412	rs4657482	6e-06	Testicular germ cell tumor
chr11	69787643	69787644	rs10796849	6e-06	IgG glycosylation
chr11	69787643	69787644	rs10796849	6e-06	IgG glycosylation
chr11	75260512	75260513	rs17133858	6e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr11	7680271	7680272	rs11041530	6e-06	Blood pressure
chr1	178522743	178522744	rs12023718	6e-06	Obesity-related traits
chr1	179500178	179500179	rs12047808	6e-06	Multiple sclerosis (age of onset)
chr11	82938725	82938726	rs10792665	6e-06	Obesity-related traits
chr1	16066861	16066862	rs9442235	6e-06	Cognitive performance
chr1	114135325	114135326	rs529989	6e-06	Illicit drug use
chr1	113683520	113683521	rs61742849	6e-06	Bulimia nervosa
chr11	134218787	134218788	rs1031381	6e-06	Cognitive test performance
chr10	86356721	86356722	rs7904985	6e-06	Barrett's esophagus
chr10	89012071	89012072	rs2234978	6e-06	Immunoglobulin A 
chr10	95541246	95541247	rs11188352	6e-06	IgG glycosylation
chr10	97040341	97040342	rs3824789	6e-06	Obesity-related traits
chr10	99514607	99514608	rs7078219	6e-06	Dental caries
chr10	99732645	99732646	rs2281636	6e-06	Obesity-related traits
chr1	101472920	101472921	rs1948368	6e-06	Bipolar disorder
chr1	107288235	107288236	rs10494067	6e-06	Anorexia nervosa
chr1	109488565	109488566	rs12049330	6e-06	Major depressive disorder
chr11	106652497	106652498	rs12364992	6e-06	Obesity-related traits
chr11	115431151	115431152	rs220836	6e-06	Obesity-related traits
chr11	116728675	116728676	rs180358	6e-06	Multiple sclerosis (severity)
chr11	117980336	117980337	rs58603829	6e-06	Obesity-related traits
chr11	121333891	121333892	rs4936613 	6e-06	Response to taxane treatment (placlitaxel)
chr11	124668098	124668099	rs544368	6e-06	Bipolar disorder
chr11	126003206	126003207	rs7104745	6e-06	Breast size
chr11	130759226	130759227	rs10894239	6e-06	Obesity-related traits
chr11	131481073	131481074	rs12421680	6e-06	Sunburns
chr11	133251041	133251042	rs2078454	6e-06	Smooth-surface caries 
chr1	184708329	184708330	rs3736757	6e-06	Obesity-related traits
chr14	22313944	22313945	rs11845134	6e-06	Obesity-related traits
chr10	121179859	121179860	rs7085142	6e-06	Visceral fat
chr14	25010335	25010336	rs11850957	6e-06	Subcutaneous adipose tissue
chr18	68646834	68646835	rs1704734	6e-06	Bipolar disorder and schizophrenia
chr18	71175006	71175007	rs17083844	6e-06	Systemic lupus erythematosus
chr18	71712153	71712154	rs2887004	6e-06	IgG glycosylation
chr1	87239347	87239348	rs6576878	6e-06	White blood cell types
chr18	73808897	73808898	rs17088339	6e-06	Coronary artery calcification
chr18	75795613	75795614	rs12326088	6e-06	Obesity-related traits
chr18	75815680	75815681	rs1017745	6e-06	Response to amphetamines
chr18	78649596	78649597	rs2002842	6e-06	Rheumatoid arthritis
chr18	65331538	65331539	rs8083346	6e-06	D-dimer levels
chr18	8966145	8966146	rs10502386	6e-06	Obesity-related traits
chr19	11544194	11544195	rs11880637	6e-06	IgG glycosylation
chr19	11544194	11544195	rs11880637	6e-06	IgG glycosylation
chr19	11544194	11544195	rs11880637	6e-06	IgG glycosylation
chr19	1423199	1423200	rs4807927	6e-06	Word reading
chr19	17641879	17641880	rs12608932	6e-06	Amyotrophic lateral sclerosis (sporadic)
chr19	18456228	18456229	rs731945	6e-06	Self-reported allergy
chr19	19925366	19925367	rs10411195	6e-06	Smoking behavior
chr19	22372051	22372052	rs1865075	6e-06	Dental caries
chr1	91104131	91104132	rs164898	6e-06	Metabolic syndrome
chr19	24039983	24039984	rs7260598 	6e-06	Response to taxane treatment (placlitaxel)
chr18	65217681	65217682	rs605920	6e-06	Cardiac Troponin-T levels
chr18	60441956	60441957	rs4257308	6e-06	Tuberculosis
chr17	4998686	4998687	rs11658587	6e-06	Obesity-related traits
chr17	52216277	52216278	rs16951120	6e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr17	70294991	70294992	rs6501384	6e-06	Eosinophilic esophagitis (pediatric)
chr17	73065794	73065795	rs903107	6e-06	Liver enzyme levels (alanine transaminase)
chr1	79777315	79777316	rs12024204	6e-06	Endometriosis
chr17	9971887	9971888	rs3786094	6e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel)
chr1	81609166	81609167	rs11809789	6e-06	Bilirubin levels
chr18	23141008	23141009	rs11082304	6e-06	Smoking behavior
chr18	61599137	61599138	rs2032366	6e-06	Obesity-related traits
chr18	24526811	24526812	rs7235440	6e-06	Obesity-related traits
chr18	27989093	27989094	rs2298574	6e-06	vWF and FVIII levels
chr18	42525691	42525692	rs7231412	6e-06	Economic and political preferences (immigration/crime)
chr18	43292307	43292308	rs12457996	6e-06	Major depressive disorder
chr18	48790716	48790717	rs12455557	6e-06	Lung function (forced vital capacity)
chr18	57766969	57766970	rs7236632	6e-06	Attention deficit hyperactivity disorder and conduct disorder
chr18	57829072	57829073	rs62094879	6e-06	Metabolite levels (MHPG)
chr18	58442626	58442627	rs8099014	6e-06	Platelet counts
chr18	60295883	60295884	rs17773430	6e-06	Obesity and blood pressure
chr18	25151395	25151396	rs8083432	6e-06	Adverse response to lamotrigine and phenytoin
chr19	31310223	31310224	rs1078373	6e-06	Cognitive performance
chr19	3159770	3159771	rs11880198	6e-06	Heart failure
chr19	3613473	3613474	rs12977510	6e-06	Obesity-related traits
chr20	58900135	58900136	rs13831	6e-06	Event-related brain oscillations
chr20	60693651	60693652	rs6027755	6e-06	Non-alcoholic fatty liver disease histology (other)
chr20	6641037	6641038	rs2145270	6e-06	Body mass index
chr20	7199408	7199409	rs6085920	6e-06	Uric acid levels
chr20	7571856	7571857	rs6108011	6e-06	Hemostatic factors and hematological phenotypes
chr20	8297295	8297296	rs2745761	6e-06	Response to irinotecan in non-small-cell lung cancer
chr2	102895833	102895834	rs13402330	6e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr2	105221140	105221141	rs6712932	6e-06	Type 2 diabetes
chr20	58221727	58221728	rs4811971	6e-06	Height
chr2	105294055	105294056	rs1030877	6e-06	Obesity-related traits
chr21	14472730	14472731	rs1006899	6e-06	Bone mineral density (spine)
chr2	122383968	122383969	rs4848768	6e-06	Lentiform nucleus volume 
chr2	124225478	124225479	rs1170612	6e-06	Schizophrenia
chr2	127745010	127745011	rs17015535	6e-06	Coronary artery calcification
chr21	29341276	29341277	rs17744121	6e-06	Visceral fat
chr21	29728477	29728478	rs933117	6e-06	Body mass index
chr14	23370823	23370824	rs10137082	6e-06	Type 1 diabetes
chr21	29805193	29805194	rs458685	6e-06	Breast cancer
chr2	11115213	11115214	rs12692432	6e-06	Metabolite levels (HVA/MHPG ratio)
chr20	56534247	56534248	rs6024938	6e-06	Obesity-related traits
chr20	54846435	54846436	rs1512060	6e-06	Axial length
chr20	53652455	53652456	rs2041278	6e-06	Obesity-related traits
chr19	39359148	39359149	rs562638	6e-06	Obesity-related traits
chr19	3944241	3944242	rs10406174	6e-06	Age-related macular degeneration
chr19	41015732	41015733	rs7260329	6e-06	Smoking behavior
chr1	94604484	94604485	rs7542900	6e-06	Type 2 diabetes
chr19	5022592	5022593	rs263063	6e-06	Periodontitis (CDC/AAP)
chr19	50406507	50406508	rs2230245	6e-06	Obesity-related traits
chr19	5080635	5080636	rs11673509	6e-06	Periodontitis (CDC/AAP)
chr19	50873906	50873907	rs2664156	6e-06	Celiac disease
chr19	51223356	51223357	rs3826656	6e-06	Alzheimer's disease
chr19	55754297	55754298	rs17634917	6e-06	Major depressive disorder
chr20	17585423	17585424	rs17791782	6e-06	Presence of antiphospholipid antibodies
chr20	23161017	23161018	rs844917	6e-06	Liver enzyme levels (alanine transaminase)
chr20	23287999	23288000	rs4815191	6e-06	Obesity-related traits
chr20	37181379	37181380	rs6031882	6e-06	Hippocampal atrophy
chr20	40015915	40015916	rs8120917	6e-06	Obesity-related traits
chr20	40810842	40810843	rs4812466	6e-06	Metabolite levels (HVA-5-HIAA Factor score)
chr20	4188431	4188432	rs16989303	6e-06	Panic disorder
chr20	43945181	43945182	rs6031252	6e-06	Conduct disorder (symptom count)
chr20	44225493	44225494	rs6017291	6e-06	Cognitive performance
chr17	48680212	48680213	rs3096644	6e-06	Metabolite levels (Dihydroxy docosatrienoic acid)
chr17	47970289	47970290	rs2597167	6e-06	Metabolite levels (Pyroglutamine)
chr2	124570372	124570373	rs2901331	6e-06	Response to statin therapy
chr17	4490202	4490203	rs333119	6e-06	Obesity-related traits
chr1	50141356	50141357	rs12092053	6e-06	Obesity-related traits
chr15	24679515	24679516	rs12902137	6e-06	Periodontitis (DPAL)
chr15	24777840	24777841	rs8030136	6e-06	Periodontitis (DPAL)
chr15	29046298	29046299	rs1873283	6e-06	Response to mTOR inhibitor (rapamycin)
chr1	5294783	5294784	rs912988	6e-06	Major depressive disorder
chr15	30923731	30923732	rs7178375	6e-06	Hypertriglyceridemia
chr1	53311958	53311959	rs2788032	6e-06	Body mass index (interaction)
chr15	33201019	33201020	rs6494964	6e-06	IgG glycosylation
chr14	98176234	98176235	rs10484128	6e-06	Hemostatic factors and hematological phenotypes
chr15	38711561	38711562	rs2643217	6e-06	Bipolar disorder and schizophrenia
chr15	45830737	45830738	rs35053544	6e-06	Serum dimethylarginine levels (symmetric)
chr15	48608388	48608389	rs1876206	6e-06	Breast cancer
chr15	48929393	48929394	rs10519201	6e-06	Eating disorders
chr15	68426647	68426648	rs16952065	6e-06	IgG glycosylation
chr15	70506219	70506220	rs8034004	6e-06	Self-reported allergy
chr15	71131669	71131670	rs12904863	6e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr15	73457266	73457267	rs11635553	6e-06	IgG glycosylation
chr15	79171504	79171505	rs1474256	6e-06	Bronchopulmonary dysplasia
chr15	40030350	40030351	rs2250402	6e-06	Corneal curvature
chr15	79927250	79927251	rs75598935	6e-06	Periodontitis (Mean PAL)
chr14	92089710	92089711	rs17807815	6e-06	Orofacial clefts
chr14	86435709	86435710	rs12882718	6e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)
chr14	31884043	31884044	rs2039485	6e-06	Brain lesion load
chr1	74527378	74527379	rs1514174	6e-06	Pubertal anthropometrics
chr14	32813263	32813264	rs2383378	6e-06	Anorexia nervosa
chr14	47584955	47584956	rs4143912	6e-06	IgG glycosylation
chr14	52052092	52052093	rs730532	6e-06	Pulmonary function
chr14	56419967	56419968	rs17832777	6e-06	Chronic obstructive pulmonary disease-related biomarkers
chr14	58867409	58867410	rs4901869	6e-06	Panic disorder
chr14	61432120	61432121	rs17098356	6e-06	Reading and spelling
chr14	89930229	89930230	rs7147996	6e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr14	64774230	64774231	rs11158559	6e-06	Obesity-related traits
chr14	68285925	68285926	rs8008961	6e-06	Acute urticaria and angiodema (non-steroidal anti-inflammatory drug-induced)
chr14	71040883	71040884	rs11848070	6e-06	Alzheimer's disease (late onset)
chr14	73289590	73289591	rs10483853	6e-06	Coronary artery calcification
chr14	78319815	78319816	rs6574433	6e-06	Cognitive performance
chr14	79535752	79535753	rs7147705	6e-06	Amyotrophic lateral sclerosis (age of onset)
chr14	80120797	80120798	rs10220309	6e-06	Lung function (forced expiratory volume in 1 second)
chr14	81109109	81109110	rs8017455	6e-06	Hair morphology
chr14	84131040	84131041	rs7152554	6e-06	Obesity-related traits
chr14	65308976	65308977	rs11847263	6e-06	IgG glycosylation
chr15	80402579	80402580	rs2278702	6e-06	Bipolar disorder
chr14	33448831	33448832	rs11845867	6e-06	Self-reported allergy
chr15	87166834	87166835	rs8024343	6e-06	Bulimia nervosa
chr16	7786294	7786295	rs3112740	6e-06	Smoking behavior
chr16	7853606	7853607	rs12446289	6e-06	Metabolite levels (MHPG)
chr16	79329916	79329917	rs7191820	6e-06	Obesity-related traits
chr16	82451645	82451646	rs8053728	6e-06	Response to fenofibrate (adiponectin levels)
chr16	83178792	83178793	rs8055236	6e-06	Coronary heart disease
chr16	83605729	83605730	rs6563943	6e-06	Height
chr16	83723722	83723723	rs3784962	6e-06	Cognitive performance
chr16	84240798	84240799	rs746080	6e-06	Visceral adipose tissue adjusted for BMI
chr16	84762996	84762997	rs12932018	6e-06	Response to mTOR inhibitor (everolimus)
chr16	86478308	86478309	rs7187365	6e-06	Obesity (early onset extreme)
chr16	89784624	89784625	rs16966142	6e-06	Caffeine consumption
chr1	69113568	69113569	rs4147141	6e-06	Attention deficit hyperactivity disorder
chr16	9249489	9249490	rs1397142	6e-06	Obesity-related traits
chr1	69938856	69938857	rs1023008	6e-06	Obesity-related traits
chr17	17057663	17057664	rs6502557	6e-06	IgG glycosylation
chr17	32208836	32208837	rs17780304	6e-06	Obesity-related traits
chr15	86316244	86316245	rs12901001	6e-06	Barrett's esophagus
chr17	32550639	32550640	rs225190	6e-06	Pancreatic cancer
chr17	33960429	33960430	rs11650066	6e-06	Coronary heart disease
chr16	73547158	73547159	rs7191888	6e-06	Multiple sclerosis (severity)
chr16	73405455	73405456	rs9934948	6e-06	Breast cancer (survival)
chr14	32381818	32381819	rs1951681	6e-06	Economic and political preferences (environmentalism)
chr16	70471455	70471456	rs11861805	6e-06	Obesity-related traits
chr15	88180480	88180481	rs1104918	6e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr15	92501108	92501109	rs8040009	6e-06	Bipolar I disorder
chr15	94146423	94146424	rs2388436	6e-06	Hoarding
chr15	96287320	96287321	rs2398162	6e-06	Hypertension
chr16	10536919	10536920	rs6498068	6e-06	Metabolite levels (MHPG)
chr16	11116557	11116558	rs9923856	6e-06	Atopic dermatitis
chr16	12967753	12967754	rs7192086	6e-06	Schizophrenia
chr16	13944316	13944317	rs3136202	6e-06	Conduct disorder (symptom count)
chr16	19017226	19017227	rs4265793	6e-06	Response to angiotensin II receptor blocker therapy
chr15	95829399	95829400	rs744738	6e-06	Obesity-related traits
chr16	20049507	20049508	rs12931939	6e-06	Attention deficit hyperactivity disorder (inattention symptoms)
chr16	20110967	20110968	rs2608200	6e-06	Attention deficit hyperactivity disorder (inattention symptoms)
chr16	20112192	20112193	rs6497436	6e-06	Attention deficit hyperactivity disorder (inattention symptoms)
chr16	20663169	20663170	rs151222	6e-06	Schizophrenia
chr16	2973603	2973604	rs886427	6e-06	Metabolic syndrome
chr16	63921542	63921543	rs1381102	6e-06	Attention deficit hyperactivity disorder and conduct disorder
chr16	53782362	53782363	rs8050136	6e-06	Type 2 diabetes
chr16	59906283	59906284	rs16961543	6e-06	Obesity-related traits
chr1	61914625	61914626	rs1056513	6e-06	Obesity-related traits
chr3	5146560	5146561	rs11918654	7.000000000000001e-06	Disc degeneration (lumbar)
chr3	53344217	53344218	rs2029213	7.000000000000001e-06	Heart rate
chr3	59995798	59995799	rs212016	7.000000000000001e-06	Orofacial clefts
chr3	64092332	64092333	rs153734	7.000000000000001e-06	Folate pathway vitamin levels
chr3	64550971	64550972	rs80311637	7.000000000000001e-06	Liver enzyme levels (alanine transaminase)
chr3	77603590	77603591	rs73114594	7.000000000000001e-06	Metabolite levels (5-HIAA/ MHPG Ratio)
chr3	84153051	84153052	rs4522784	7.000000000000001e-06	Obesity-related traits
chr4	120041229	120041230	rs1845344	7.000000000000001e-06	F-cell distribution
chr4	104923115	104923116	rs10005603	7.000000000000001e-06	Tuberculosis
chr4	124494378	124494379	rs6534441	7.000000000000001e-06	Major depressive disorder
chr4	126012136	126012137	rs1320267	7.000000000000001e-06	Subclinical atherosclerosis traits (other)
chr4	132405239	132405240	rs7690467	7.000000000000001e-06	Eating disorders
chr4	141221574	141221575	rs17007017	7.000000000000001e-06	Conduct disorder (case status)
chr4	148713872	148713873	rs10519980	7.000000000000001e-06	Hypothyroidism
chr4	16892269	16892270	rs1483012	7.000000000000001e-06	QT interval
chr4	173680896	173680897	rs11727767	7.000000000000001e-06	Obesity-related traits
chr4	102428582	102428583	rs6533014	7.000000000000001e-06	Homeostasis model assessment of beta-cell function (interaction)
chr3	48445643	48445644	rs730566	7.000000000000001e-06	Prion diseases
chr3	193054505	193054506	rs13068101	7.000000000000001e-06	Sleep time
chr3	3617155	3617156	rs1601875	7.000000000000001e-06	Bipolar disorder
chr3	152045911	152045912	rs1351267	7.000000000000001e-06	Schizophrenia
chr3	152954989	152954990	rs6785504	7.000000000000001e-06	Response to antineoplastic agents
chr3	156679959	156679960	rs2665390	7.000000000000001e-06	Ovarian cancer in BRCA1 mutation carriers 
chr3	159991863	159991864	rs2243123	7.000000000000001e-06	Multiple sclerosis
chr3	163116512	163116513	rs9824150	7.000000000000001e-06	Capecitabine sensitivity
chr3	164137280	164137281	rs78661745	7.000000000000001e-06	Bulimia nervosa
chr3	167790273	167790274	rs13090836	7.000000000000001e-06	Heart rate
chr3	168119959	168119960	rs4345115	7.000000000000001e-06	Height
chr3	179943529	179943530	rs7630877	7.000000000000001e-06	Type 2 diabetes
chr3	180833425	180833426	rs1879248	7.000000000000001e-06	Schizophrenia
chr3	187999097	187999098	rs1553091	7.000000000000001e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin)
chr3	192179428	192179429	rs975121	7.000000000000001e-06	Ileal carcinoids
chr3	193865920	193865921	rs604222	7.000000000000001e-06	Major depressive disorder
chr3	195017143	195017144	rs2676917	7.000000000000001e-06	Metabolite levels (Pyroglutamine)
chr3	196351555	196351556	rs6774852	7.000000000000001e-06	Obesity-related traits
chr3	20095466	20095467	rs12636856	7.000000000000001e-06	Response to mTOR inhibitor (rapamycin)
chr3	2583253	2583254	rs2619566	7.000000000000001e-06	Amyotrophic lateral sclerosis
chr3	38802155	38802156	rs11717455	7.000000000000001e-06	Systemic lupus erythematosus
chr4	175705120	175705121	rs12640626	7.000000000000001e-06	Educational attainment
chr4	37062708	37062709	rs13117816	7.000000000000001e-06	Multiple sclerosis--Brain Glutamate Levels
chr4	178480278	178480279	rs2702449	7.000000000000001e-06	Response to mTOR inhibitor (everolimus)
chr5	11298110	11298111	rs2530215	7.000000000000001e-06	Bipolar disorder and schizophrenia
chr5	113244592	113244593	rs17323670	7.000000000000001e-06	Bipolar disorder and schizophrenia
chr5	116398107	116398108	rs7734156	7.000000000000001e-06	IgG glycosylation
chr5	127718585	127718586	rs4835929	7.000000000000001e-06	Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms)
chr5	127724249	127724250	rs12513840	7.000000000000001e-06	Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms)
chr5	130607625	130607626	rs7731657	7.000000000000001e-06	Fasting plasma glucose
chr5	13242861	13242862	rs10066447	7.000000000000001e-06	Visceral fat
chr5	141303323	141303324	rs3749779	7.000000000000001e-06	Obesity-related traits
chr5	14752740	14752741	rs17250963	7.000000000000001e-06	Homeostasis model assessment of insulin resistance (interaction)
chr5	151206305	151206306	rs7724774	7.000000000000001e-06	Bulimia nervosa
chr5	15285304	15285305	rs745978	7.000000000000001e-06	Visceral fat
chr5	152908892	152908893	rs4262150	7.000000000000001e-06	Bipolar disorder and schizophrenia
chr5	153260116	153260117	rs3112530	7.000000000000001e-06	Aging (time to event)
chr5	156073981	156073982	rs4704970	7.000000000000001e-06	Multiple sclerosis (age of onset)
chr5	158817074	158817075	rs1432679	7.000000000000001e-06	Breast cancer
chr3	144059865	144059866	rs16854884	7.000000000000001e-06	Economic and political preferences (feminism/equality)
chr5	159940963	159940964	rs11750092	7.000000000000001e-06	Migraine
chr5	111771417	111771418	rs173896	7.000000000000001e-06	Bipolar disorder and schizophrenia
chr5	108498545	108498546	rs4571457	7.000000000000001e-06	Ulcerative colitis
chr5	108396256	108396257	rs1001579	7.000000000000001e-06	IgG glycosylation
chr5	105532234	105532235	rs7447447	7.000000000000001e-06	Caffeine consumption
chr4	179462157	179462158	rs2716816	7.000000000000001e-06	Breast size
chr4	182766635	182766636	rs10017238	7.000000000000001e-06	Response to amphetamines
chr4	186757711	186757712	rs925642	7.000000000000001e-06	Obesity
chr4	22089760	22089761	rs6448119	7.000000000000001e-06	Rheumatoid arthritis
chr4	24739334	24739335	rs12500612	7.000000000000001e-06	Major depressive disorder
chr4	25808473	25808474	rs959903	7.000000000000001e-06	Non-alcoholic fatty liver disease histology (other)
chr5	170115595	170115596	rs1895302	7.000000000000001e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs)
chr4	38159442	38159443	rs115426111	7.000000000000001e-06	Serum dimethylarginine levels (asymmetric/symetric ratio)
chr4	177397036	177397037	rs1395479	7.000000000000001e-06	Heart rate variability traits
chr4	43050168	43050169	rs9997524	7.000000000000001e-06	Obesity-related traits
chr4	64526493	64526494	rs1425392	7.000000000000001e-06	Post-traumatic stress disorder (asjusted for relatedness)
chr4	76850191	76850192	rs17002253	7.000000000000001e-06	Adverse response to lamotrigine and phenytoin
chr4	79643353	79643354	rs10518224	7.000000000000001e-06	Quantitative traits
chr4	85208462	85208463	rs7691216	7.000000000000001e-06	IgG glycosylation
chr4	88282517	88282518	rs893971	7.000000000000001e-06	Conduct disorder (interaction)
chr4	88299791	88299792	rs9995093	7.000000000000001e-06	Bipolar disorder
chr4	94232197	94232198	rs3106136	7.000000000000001e-06	Capecitabine sensitivity
chr5	103423956	103423957	rs17155315	7.000000000000001e-06	QT interval
chr4	5108412	5108413	rs6833812	7.000000000000001e-06	Sensory disturbances after bilateral sagittal split ramus osteotomy
chr4	94935529	94935530	rs10021303	7.000000000000001e-06	Hypertension
chr22	27694208	27694209	rs5762311	7.000000000000001e-06	Sudden cardiac arrest
chr3	139197550	139197551	rs11706018	7.000000000000001e-06	IgG glycosylation
chr2	145314284	145314285	rs10180522	7.000000000000001e-06	Attention deficit hyperactivity disorder (inattention symptoms)
chr21	46025876	46025877	rs4293630	7.000000000000001e-06	Alcoholism (alcohol dependence factor score)
chr2	14661376	14661377	rs7602441	7.000000000000001e-06	Visceral adipose tissue adjusted for BMI
chr2	166320848	166320849	rs4438497	7.000000000000001e-06	Dental caries
chr2	166521467	166521468	rs13015447	7.000000000000001e-06	Amyotrophic lateral sclerosis
chr2	170509378	170509379	rs10176755	7.000000000000001e-06	Visceral fat
chr2	170684312	170684313	rs2080401	7.000000000000001e-06	Coronary heart disease
chr2	173462116	173462117	rs10930597	7.000000000000001e-06	Blood pressure measurement (low sodium intervention)
chr2	175790009	175790010	rs7566934	7.000000000000001e-06	Information processing speed
chr2	17807390	17807391	rs214034	7.000000000000001e-06	Response to amphetamines
chr2	179281547	179281548	rs6733818	7.000000000000001e-06	Migraine without aura
chr2	195501165	195501166	rs4591358	7.000000000000001e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)
chr2	203869763	203869764	rs231779	7.000000000000001e-06	Hypothyroidism
chr2	21354870	21354871	rs219553	7.000000000000001e-06	Erectile dysfunction and prostate cancer treatment
chr2	215420651	215420652	rs17458018	7.000000000000001e-06	Coronary heart disease
chr2	218216573	218216574	rs13403276	7.000000000000001e-06	Obesity-related traits
chr2	218414373	218414374	rs7607369	7.000000000000001e-06	Amyotrophic lateral sclerosis
chr21	41855385	41855386	rs915832 	7.000000000000001e-06	Response to taxane treatment (placlitaxel)
chr2	140511872	140511873	rs183373550	7.000000000000001e-06	Serum dimethylarginine levels (symmetric)
chr2	137384593	137384594	rs13405020	7.000000000000001e-06	Non-small cell lung cancer
chr2	136797653	136797654	rs1427593	7.000000000000001e-06	Pancreatic cancer
chr20	59215380	59215381	rs12625057	7.000000000000001e-06	Response to antipsychotic therapy (extrapyramidal side effects)
chr5	173932327	173932328	rs17763373	7.000000000000001e-06	Prion diseases
chr20	61939167	61939168	rs4925325	7.000000000000001e-06	Obesity-related traits
chr20	6718947	6718948	rs4813802	7.000000000000001e-06	Colorectal cancer
chr20	778671	778672	rs6117615	7.000000000000001e-06	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel)
chr20	8134056	8134057	rs6118083	7.000000000000001e-06	Cognitive performance
chr20	839018	839019	rs6108038	7.000000000000001e-06	Obesity-related traits
chr2	102475080	102475081	rs17027258	7.000000000000001e-06	White blood cell types
chr2	218964483	218964484	rs359980	7.000000000000001e-06	Obesity-related traits
chr2	104762498	104762499	rs12615966	7.000000000000001e-06	Pancreatic cancer
chr2	112926297	112926298	rs10864907	7.000000000000001e-06	Pulmonary function
chr2	113074734	113074735	rs6761276	7.000000000000001e-06	Protein quantitative trait loci
chr2	118638114	118638115	rs651477	7.000000000000001e-06	Multiple sclerosis
chr21	20448095	20448096	rs1735884	7.000000000000001e-06	Obesity-related traits
chr2	120544334	120544335	rs6721654	7.000000000000001e-06	Age-related macular degeneration
chr21	29872160	29872161	rs457352	7.000000000000001e-06	Periodontitis (DPAL)
chr2	133472645	133472646	rs1821625	7.000000000000001e-06	Multiple sclerosis
chr2	134385715	134385716	rs12467609	7.000000000000001e-06	Subcutaneous adipose tissue
chr2	105281282	105281283	rs1020064	7.000000000000001e-06	AIDS
chr3	139887951	139887952	rs2554152	7.000000000000001e-06	Visceral adipose tissue adjusted for BMI
chr2	219804016	219804017	rs3815854	7.000000000000001e-06	Orofacial clefts
chr22	26655334	26655335	rs739310	7.000000000000001e-06	Obesity-related traits
chr2	37730336	37730337	rs13012266	7.000000000000001e-06	Metabolite levels (HVA/MHPG ratio)
chr2	46105029	46105030	rs12712969	7.000000000000001e-06	Pulmonary function decline
chr2	47617365	47617366	rs6544997	7.000000000000001e-06	Vitiligo
chr2	48422565	48422566	rs7565792	7.000000000000001e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr2	49487882	49487883	rs12987465	7.000000000000001e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide)
chr2	60535366	60535367	rs2556378	7.000000000000001e-06	Attention deficit hyperactivity disorder
chr2	64137497	64137498	rs6733160	7.000000000000001e-06	Allergic dermatitis (nickel)
chr2	77848117	77848118	rs7595103	7.000000000000001e-06	Attention deficit hyperactivity disorder and conduct disorder
chr2	81645797	81645798	rs12052359	7.000000000000001e-06	Bilirubin levels
chr2	85472626	85472627	rs7577642	7.000000000000001e-06	Protein quantitative trait loci
chr2	98467428	98467429	rs12617721	7.000000000000001e-06	Bipolar disorder (mood-incongruent)
chr3	100237711	100237712	rs12486865	7.000000000000001e-06	Visceral adipose tissue/subcutaneous adipose tissue ratio
chr3	103794591	103794592	rs1673866	7.000000000000001e-06	IgG glycosylation
chr3	113962103	113962104	rs1386478	7.000000000000001e-06	Crohn's disease and psoriasis
chr3	120517481	120517482	rs9289146	7.000000000000001e-06	Obesity-related traits
chr3	125874013	125874014	rs71327718	7.000000000000001e-06	Metabolite levels (HVA/5-HIAA ratio)
chr3	131994721	131994722	rs1320900	7.000000000000001e-06	Amyotrophic lateral sclerosis
chr23	43747785	43747786	rs3027409	7.000000000000001e-06	Smoking behavior
chr2	33302231	33302232	rs41464348	7.000000000000001e-06	Height
chr23	25835496	25835497	rs5944185	7.000000000000001e-06	Erectile dysfunction and prostate cancer treatment
chr23	148299500	148299501	rs2159767	7.000000000000001e-06	Schizophrenia
chr2	231294498	231294499	rs745962	7.000000000000001e-06	Hormone measurements
chr2	23191779	23191780	rs1449984	7.000000000000001e-06	Depression (quantitative trait)
chr2	233133770	233133771	rs10933436	7.000000000000001e-06	Coronary heart disease
chr22	34206198	34206199	rs5754891	7.000000000000001e-06	Coronary artery calcification
chr22	34455672	34455673	rs55794228	7.000000000000001e-06	Serum dimethylarginine levels (symmetric)
chr2	235220306	235220307	rs1991705	7.000000000000001e-06	Obesity-related traits
chr22	36803761	36803762	rs2022068	7.000000000000001e-06	Pit-and-Fissure caries 
chr22	38782369	38782370	rs738144	7.000000000000001e-06	IgG glycosylation
chr2	222488726	222488727	rs17496827	7.000000000000001e-06	Anorexia nervosa
chr2	240576178	240576179	rs2953145	7.000000000000001e-06	Bipolar disorder
chr22	44572649	44572650	rs138597	7.000000000000001e-06	Economic and political preferences (time)
chr22	48057773	48057774	rs117294	7.000000000000001e-06	Economic and political preferences (fairness)
chr22	49692724	49692725	rs6009824	7.000000000000001e-06	Natriuretic peptide levels
chr2	2586608	2586609	rs2598592	7.000000000000001e-06	White matter integrity
chr2	27519735	27519736	rs780093	7.000000000000001e-06	Calcium levels
chr2	2922240	2922241	rs17491951	7.000000000000001e-06	White matter integrity (interaction)
chr23	112403235	112403236	rs5982533	7.000000000000001e-06	Biochemical measures
chr23	117735950	117735951	rs5910235	7.000000000000001e-06	Metabolite levels (5-HIAA/ MHPG Ratio)
chr22	42274958	42274959	rs134882	7.000000000000001e-06	Bipolar disorder and schizophrenia
chr5	174198150	174198151	rs6863418	7.000000000000001e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine)
chr7	4371577	4371578	rs10488360	7.000000000000001e-06	Factor VII
chr5	25419979	25419980	rs1904173	7.000000000000001e-06	IgG glycosylation
chr8	125495146	125495147	rs2954038	7.000000000000001e-06	Response to statin therapy
chr8	128268702	128268703	rs11775199	7.000000000000001e-06	Metabolite levels (Dihydroxy docosatrienoic acid)
chr8	140140069	140140070	rs6992848	7.000000000000001e-06	Response to amphetamines
chr8	17472317	17472318	rs2720508	7.000000000000001e-06	Conduct disorder (case status)
chr8	21804932	21804933	rs17581368	7.000000000000001e-06	Entorhinal cortical thickness
chr8	22230918	22230919	rs12541335	7.000000000000001e-06	Hypertriglyceridemia
chr8	22762037	22762038	rs11998649	7.000000000000001e-06	Visceral fat
chr8	23726712	23726713	rs13273073	7.000000000000001e-06	Treatment response for severe sepsis 
chr8	26861362	26861363	rs4732957	7.000000000000001e-06	Response to amphetamines
chr8	32554840	32554841	rs2439312	7.000000000000001e-06	Dialysis-related mortality
chr8	3332373	3332374	rs2551043	7.000000000000001e-06	Obesity-related traits
chr8	34379473	34379474	rs2609653	7.000000000000001e-06	Bipolar disorder
chr8	3459463	3459464	rs17394429	7.000000000000001e-06	Obesity-related traits
chr8	34666484	34666485	rs6987004	7.000000000000001e-06	Pulmonary function decline
chr8	4247624	4247625	rs1714746	7.000000000000001e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin)
chr8	48140604	48140605	rs11778329	7.000000000000001e-06	Attention deficit hyperactivity disorder
chr8	616206	616207	rs17666538	7.000000000000001e-06	IgG glycosylation
chr8	121694050	121694051	rs279612	7.000000000000001e-06	Metabolite levels (5-HIAA)
chr8	62709009	62709010	rs2882926	7.000000000000001e-06	Periodontitis (PAL4Q3)
chr8	120682409	120682410	rs11989782	7.000000000000001e-06	Eosinophilic esophagitis (pediatric)
chr8	116629370	116629371	rs11987235	7.000000000000001e-06	Corneal curvature
chr7	50315610	50315611	rs6421315	7.000000000000001e-06	IgG glycosylation
chr7	67961335	67961336	rs6961611	7.000000000000001e-06	Information processing speed
chr7	72841238	72841239	rs2058059	7.000000000000001e-06	Subcutaneous adipose tissue
chr7	75582097	75582098	rs237238	7.000000000000001e-06	Alcoholism (12-month weekly alcohol consumption)
chr7	82218334	82218335	rs10954668	7.000000000000001e-06	Non-alcoholic fatty liver disease histology (lobular)
chr7	82485923	82485924	rs10262537	7.000000000000001e-06	Metabolite levels (Dihydroxy docosatrienoic acid)
chr7	8678449	8678450	rs2349775	7.000000000000001e-06	Neuroticism
chr7	87067397	87067398	rs1476587	7.000000000000001e-06	Brachial circumference
chr7	88852127	88852128	rs10248351	7.000000000000001e-06	Hypothyroidism
chr7	89065755	89065756	rs10236237	7.000000000000001e-06	IgG glycosylation
chr7	89431418	89431419	rs6973392	7.000000000000001e-06	Dental caries
chr7	9027189	9027190	rs10952132	7.000000000000001e-06	Response to fenofibrate
chr7	91286038	91286039	rs2888830	7.000000000000001e-06	Dental caries
chr7	9149910	9149911	rs1371737	7.000000000000001e-06	Obesity-related traits
chr7	93908982	93908983	rs180273	7.000000000000001e-06	Pulmonary function decline
chr8	100795001	100795002	rs36061340	7.000000000000001e-06	Alcohol consumption
chr8	115098495	115098496	rs218361	7.000000000000001e-06	Eating disorders
chr8	117172543	117172544	rs13266634	7.000000000000001e-06	Type 2 diabetes
chr8	6295397	6295398	rs6559140	7.000000000000001e-06	Metabolite levels (5-HIAA)
chr8	6964094	6964095	rs2738058	7.000000000000001e-06	Periodontitis (PAL4Q3)
chr8	69897025	69897026	rs12680109	7.000000000000001e-06	Attention deficit hyperactivity disorder
chr9	19579428	19579429	rs3780215	7.000000000000001e-06	Body mass index (asthmatics)
chr9	20098712	20098713	rs16937883	7.000000000000001e-06	Asthma (toluene diisocyanate-induced)
chr9	2194226	2194227	rs4741652	7.000000000000001e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr9	22134094	22134095	rs10811661	7.000000000000001e-06	Fasting glucose-related traits (interaction with BMI)
chr9	22362104	22362105	rs961831	7.000000000000001e-06	Personality dimensions
chr9	23426272	23426273	rs12000445	7.000000000000001e-06	Response to platinum-based chemotherapy in non-small-cell lung cancer
chr9	28402044	28402045	rs10968562	7.000000000000001e-06	Obesity-related traits
chr9	33122646	33122647	rs10113903	7.000000000000001e-06	IgG glycosylation
chr9	33153528	33153529	rs10813957	7.000000000000001e-06	IgG glycosylation
chr9	38750581	38750582	rs184891496	7.000000000000001e-06	Metabolite levels (HVA/MHPG ratio)
chr9	6784725	6784726	rs10815468	7.000000000000001e-06	Bipolar disorder and schizophrenia
chr9	72272786	72272787	rs11143230	7.000000000000001e-06	Suicidal ideation
chr9	76050859	76050860	rs7047865	7.000000000000001e-06	Amyotrophic lateral sclerosis (age of onset)
chr9	76423253	76423254	rs6560517	7.000000000000001e-06	Dialysis-related mortality
chr9	78695763	78695764	rs1757948	7.000000000000001e-06	vWF and FVIII levels
chr9	96054201	96054202	rs1547201	7.000000000000001e-06	IgG glycosylation
chr20	59012715	59012716	rs4812048	7.000000000000001e-06	Mean platelet volume
chr9	14562315	14562316	rs10961577	7.000000000000001e-06	Visceral adipose tissue adjusted for BMI
chr9	14470834	14470835	rs10961534	7.000000000000001e-06	Hypothyroidism
chr9	137194177	137194178	rs28417902	7.000000000000001e-06	Obesity-related traits
chr9	136374885	136374886	rs10781500	7.000000000000001e-06	Ulcerative colitis
chr8	70255758	70255759	rs2926702	7.000000000000001e-06	Non-small cell lung cancer
chr8	72158499	72158500	rs11994034	7.000000000000001e-06	Attention deficit hyperactivity disorder (combined symptoms)
chr8	76595377	76595378	rs7846606	7.000000000000001e-06	Orofacial clefts
chr8	8864867	8864868	rs10108954	7.000000000000001e-06	Prion diseases
chr8	93073309	93073310	rs1027730	7.000000000000001e-06	Attention deficit hyperactivity disorder
chr8	95503659	95503660	rs1909881	7.000000000000001e-06	Obesity-related traits
chr8	9744188	9744189	rs12545912	7.000000000000001e-06	Multiple myeloma (hyperdiploidy)
chr9	10139579	10139580	rs294845	7.000000000000001e-06	Obesity-related traits
chr7	50310670	50310671	rs6583437	7.000000000000001e-06	IgG glycosylation
chr9	102105555	102105556	rs10989824	7.000000000000001e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr9	103261937	103261938	rs16922670	7.000000000000001e-06	Alzheimer's disease
chr9	104915007	104915008	rs4149263	7.000000000000001e-06	Periodontitis (Mean PAL)
chr9	107363529	107363530	rs817858	7.000000000000001e-06	Body mass index
chr9	112925454	112925455	rs10817408	7.000000000000001e-06	IgG glycosylation
chr9	128322348	128322349	rs11539570	7.000000000000001e-06	Obesity-related traits
chr9	129587317	129587318	rs73628692	7.000000000000001e-06	Metabolite levels (HVA/5-HIAA ratio)
chr9	131574685	131574686	rs11243437	7.000000000000001e-06	Response to amphetamines
chr9	133261661	133261662	rs687621	7.000000000000001e-06	D-dimer levels
chr9	102679834	102679835	rs2210533	7.000000000000001e-06	Obesity-related traits
chr7	43871282	43871283	rs10232743	7.000000000000001e-06	Obesity-related traits
chr7	41772309	41772310	rs10486722	7.000000000000001e-06	Pit-and-Fissure caries 
chr7	40914881	40914882	rs29880	7.000000000000001e-06	Iron status biomarkers
chr6	109686443	109686444	rs9400317	7.000000000000001e-06	Response to hepatitis C treatment
chr6	114748552	114748553	rs6928844	7.000000000000001e-06	IgG glycosylation
chr6	121495732	121495733	rs9490306	7.000000000000001e-06	Migraine
chr6	130565291	130565292	rs9492645	7.000000000000001e-06	IgG glycosylation
chr6	13332234	13332235	rs499818	7.000000000000001e-06	Major CVD
chr6	134773133	134773134	rs11760067	7.000000000000001e-06	Coronary artery calcification
chr6	143622176	143622177	rs9390123	7.000000000000001e-06	Lung Cancer (DNA repair capacity)
chr6	149977705	149977706	rs1853665	7.000000000000001e-06	Radiation response
chr6	156336707	156336708	rs12213468	7.000000000000001e-06	IgG glycosylation
chr6	157968708	157968709	rs9458975	7.000000000000001e-06	Cannabis use (initiation)
chr6	159981672	159981673	rs6917747	7.000000000000001e-06	Brain lesion load
chr6	161815042	161815043	rs3016539	7.000000000000001e-06	Pancreatic cancer
chr6	168083404	168083405	rs4708431	7.000000000000001e-06	Attention deficit hyperactivity disorder (combined symptoms)
chr6	168089887	168089888	rs9364220	7.000000000000001e-06	Attention deficit hyperactivity disorder (combined symptoms)
chr6	169420285	169420286	rs438465	7.000000000000001e-06	Corneal astigmatism
chr6	21454921	21454922	rs9460635	7.000000000000001e-06	Metabolite levels (HVA-5-HIAA Factor score)
chr6	31106252	31106253	rs6457327	7.000000000000001e-06	Follicular lymphoma
chr6	108595369	108595370	rs9480865	7.000000000000001e-06	Normalized brain volume
chr6	105812252	105812253	rs7750345	7.000000000000001e-06	Age-related macular degeneration
chr6	104784357	104784358	rs9322817	7.000000000000001e-06	Thyroid stimulating hormone
chr6	104215902	104215903	rs2744203	7.000000000000001e-06	IgG glycosylation
chr5	25841503	25841504	rs396045	7.000000000000001e-06	Obesity-related traits
chr5	36137517	36137518	rs267759	7.000000000000001e-06	Response to treatment for acute lymphoblastic leukemia
chr5	36900740	36900741	rs293748	7.000000000000001e-06	Obesity-related traits
chr5	437986	437987	rs10078	7.000000000000001e-06	Fat distribution (HIV)
chr5	51868280	51868281	rs12186641	7.000000000000001e-06	Congenital heart disease
chr5	54015671	54015672	rs255758	7.000000000000001e-06	Rheumatoid arthritis
chr5	73952686	73952687	rs283610	7.000000000000001e-06	Obesity-related traits
chr5	78964064	78964065	rs337847	7.000000000000001e-06	Hippocampal atrophy
chr6	31605178	31605179	rs2844479	7.000000000000001e-06	IgG glycosylation
chr5	81791714	81791715	rs410644	7.000000000000001e-06	Anorexia nervosa
chr5	85310709	85310710	rs4920799	7.000000000000001e-06	Echocardiographic traits
chr5	89725760	89725761	rs10514310	7.000000000000001e-06	Obesity-related traits
chr5	92818871	92818872	rs17668565	7.000000000000001e-06	Obesity-related traits
chr5	94474502	94474503	rs6869388	7.000000000000001e-06	Gallbladder cancer
chr5	96766239	96766240	rs27524	7.000000000000001e-06	Hodgkin's lymphoma
chr5	96775666	96775667	rs13160562	7.000000000000001e-06	Alcohol dependence
chr5	99244259	99244260	rs17736767	7.000000000000001e-06	Renal sinus fat 
chr6	10163734	10163735	rs13195786	7.000000000000001e-06	Calcium levels
chr5	83594090	83594091	rs310501	7.000000000000001e-06	Major depressive disorder
chr5	174268774	174268775	rs11952171	7.000000000000001e-06	Subcutaneous adipose tissue
chr6	32985502	32985503	rs3097645	7.000000000000001e-06	IgG glycosylation
chr6	34227233	34227234	rs1776897	7.000000000000001e-06	Height
chr7	13514382	13514383	rs13227425	7.000000000000001e-06	Word reading
chr7	144044486	144044487	rs11976180	7.000000000000001e-06	Obesity-related traits
chr7	15093501	15093502	rs12699683	7.000000000000001e-06	Paclitaxel-induced neuropathy
chr7	151217984	151217985	rs1122979	7.000000000000001e-06	IgG glycosylation
chr7	153574791	153574792	rs11771429	7.000000000000001e-06	Barrett's esophagus
chr7	153881330	153881331	rs38989	7.000000000000001e-06	IgG glycosylation
chr7	155178758	155178759	rs10263087	7.000000000000001e-06	Formal thought disorder in schizophrenia
chr7	155217002	155217003	rs1561176	7.000000000000001e-06	Personality dimensions
chr7	18940643	18940644	rs2853552	7.000000000000001e-06	Obesity-related traits
chr7	1911172	1911173	rs4332037	7.000000000000001e-06	Bipolar disorder
chr7	20607391	20607392	rs10950821	7.000000000000001e-06	Response to statin therapy
chr7	21123735	21123736	rs10950840	7.000000000000001e-06	Obesity-related traits
chr7	21183170	21183171	rs6971109	7.000000000000001e-06	Capecitabine sensitivity
chr7	2258591	2258592	rs2398668	7.000000000000001e-06	Bipolar disorder and schizophrenia
chr7	27290436	27290437	rs13225783	7.000000000000001e-06	Heart failure
chr7	28351522	28351523	rs11765845	7.000000000000001e-06	Diabetic retinopathy 
chr7	34657527	34657528	rs2530545	7.000000000000001e-06	IgG glycosylation
chr7	132144368	132144369	rs1399090	7.000000000000001e-06	Economic and political preferences
chr7	125751590	125751591	rs1419607	7.000000000000001e-06	Obesity-related traits
chr7	12233525	12233526	rs14978	7.000000000000001e-06	Response to amphetamines
chr7	114717487	114717488	rs1869839	7.000000000000001e-06	Crohn's disease
chr6	35088665	35088666	rs2005	7.000000000000001e-06	Obesity-related traits
chr6	37206968	37206969	rs1680005	7.000000000000001e-06	Bipolar disorder (mood-incongruent)
chr6	37483919	37483920	rs904251	7.000000000000001e-06	Cognitive performance
chr6	37519267	37519268	rs1757171	7.000000000000001e-06	Cognitive performance
chr6	37564326	37564327	rs9394438	7.000000000000001e-06	IgG glycosylation
chr6	39234380	39234381	rs9366999	7.000000000000001e-06	Obesity-related traits
chr6	56345965	56345966	rs16887812	7.000000000000001e-06	Allergic sensitization
chr6	61285854	61285855	rs2342002	7.000000000000001e-06	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined)
chr6	33857580	33857581	rs2104362	7.000000000000001e-06	Alzheimer's disease (age of onset)
chr6	6612233	6612234	rs2326810	7.000000000000001e-06	Major depressive disorder (broad)
chr6	79446541	79446542	rs12204683	7.000000000000001e-06	Presence of antiphospholipid antibodies
chr6	80593087	80593088	rs10943724	7.000000000000001e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr6	80771636	80771637	rs6902257	7.000000000000001e-06	Obesity-related traits
chr6	87942861	87942862	rs2509458	7.000000000000001e-06	Blood pressure
chr6	92659936	92659937	rs6918777	7.000000000000001e-06	Amyotrophic lateral sclerosis
chr6	93201400	93201401	rs12527818	7.000000000000001e-06	Response to hepatitis C treatment
chr7	107940393	107940394	rs2158836	7.000000000000001e-06	Ulcerative colitis
chr7	114101049	114101050	rs6466479	7.000000000000001e-06	IgG glycosylation
chr6	70950407	70950408	rs6922893	7.000000000000001e-06	Obesity-related traits
chr20	57926922	57926923	rs6099847	7.000000000000001e-06	Obesity-related traits
chr3	24226944	24226945	rs826221	7.000000000000001e-06	Systolic blood pressure in sickle cell anemia
chr20	53993956	53993957	rs2276498	7.000000000000001e-06	Bipolar disorder and schizophrenia
chr1	207478830	207478831	rs17045328	7.000000000000001e-06	Type 2 diabetes
chr12	101360175	101360176	rs10507130	7.000000000000001e-06	Coronary artery calcification
chr12	109930395	109930396	rs2292354	7.000000000000001e-06	Metabolic syndrome
chr12	112735688	112735689	rs3803064	7.000000000000001e-06	Platelet counts
chr12	11495483	11495484	rs2908835	7.000000000000001e-06	Information processing speed
chr12	116761608	116761609	rs12322695	7.000000000000001e-06	Obesity-related traits
chr12	117668388	117668389	rs10431397	7.000000000000001e-06	Endometriosis
chr12	122146361	122146362	rs1043763	7.000000000000001e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)
chr12	122903374	122903375	rs10847980	7.000000000000001e-06	Adiponectin levels
chr12	122929801	122929802	rs2270788	7.000000000000001e-06	IgG glycosylation
chr12	123832328	123832329	rs7978454	7.000000000000001e-06	IgG glycosylation
chr12	124014994	124014995	rs1048497	7.000000000000001e-06	Visceral adipose tissue/subcutaneous adipose tissue ratio
chr12	124549386	124549387	rs12423712	7.000000000000001e-06	Cognitive performance
chr12	130906208	130906209	rs7299940	7.000000000000001e-06	Panic disorder
chr12	14257550	14257551	rs17221259	7.000000000000001e-06	Breast cancer
chr12	14507249	14507250	rs3827886	7.000000000000001e-06	Response to amphetamines
chr1	216565445	216565446	rs7553212	7.000000000000001e-06	Alcohol consumption
chr1	204143855	204143856	rs3795578	7.000000000000001e-06	Response to acetaminophen (hepatotoxicity)
chr1	216885136	216885137	rs1436900	7.000000000000001e-06	Optic disc size (cup)
chr1	20128726	20128727	rs12722987	7.000000000000001e-06	Obesity-related traits
chr1	191970657	191970658	rs17403780	7.000000000000001e-06	IgG glycosylation
chr11	63825148	63825149	rs10897449	7.000000000000001e-06	Electroencephalographic traits in alcoholism
chr11	64362249	64362250	rs538147	7.000000000000001e-06	Leprosy
chr1	165647350	165647351	rs6686643	7.000000000000001e-06	Total ventricular volume
chr1	173315059	173315060	rs4916321	7.000000000000001e-06	Multiple sclerosis
chr11	7443140	7443141	rs4076555	7.000000000000001e-06	IgG glycosylation
chr1	174583672	174583673	rs17301853	7.000000000000001e-06	Migraine - clinic-based
chr1	175746469	175746470	rs17312292	7.000000000000001e-06	Corneal astigmatism
chr11	77112437	77112438	rs3781684	7.000000000000001e-06	Cognitive performance
chr11	81274504	81274505	rs1458095	7.000000000000001e-06	Body mass index
chr1	181686615	181686616	rs3845441	7.000000000000001e-06	IgG glycosylation
chr11	83165227	83165228	rs1943345	7.000000000000001e-06	Obesity-related traits
chr1	184033739	184033740	rs756199	7.000000000000001e-06	Height
chr11	84706802	84706803	rs10501570	7.000000000000001e-06	Parkinson's disease
chr11	86703239	86703240	rs2512987	7.000000000000001e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin)
chr1	187442909	187442910	rs2244067	7.000000000000001e-06	Metabolite levels (5-HIAA)
chr1	187933849	187933850	rs655167	7.000000000000001e-06	Hypothyroidism
chr1	189754492	189754493	rs10737562	7.000000000000001e-06	Systemic lupus erythematosus
chr1	196875462	196875463	rs6428370	7.000000000000001e-06	Acute lymphoblastic leukemia (childhood)
chr12	17209881	17209882	rs1513049	7.000000000000001e-06	Word reading
chr1	220428280	220428281	rs7512221	7.000000000000001e-06	Fat distribution (HIV)
chr1	220855165	220855166	rs11118620	7.000000000000001e-06	Heart failure
chr12	69938046	69938047	rs789560	7.000000000000001e-06	Attention deficit hyperactivity disorder and conduct disorder
chr12	71183320	71183321	rs1495377	7.000000000000001e-06	Type 2 diabetes
chr12	92593431	92593432	rs11829373	7.000000000000001e-06	Periodontitis (Mean PAL)
chr12	94135048	94135049	rs3847794	7.000000000000001e-06	Behavioural disinhibition (generation interaction)
chr1	29792804	29792805	rs6691847	7.000000000000001e-06	Non-alcoholic fatty liver disease
chr12	98940750	98940751	rs483610	7.000000000000001e-06	Obesity-related traits
chr13	105415570	105415571	rs17655948	7.000000000000001e-06	Periodontitis (DPAL)
chr13	107047869	107047870	rs9558942	7.000000000000001e-06	Obesity-related traits
chr13	107482560	107482561	rs9520462	7.000000000000001e-06	Reading and spelling
chr13	107832105	107832106	rs2036707	7.000000000000001e-06	Obesity-related traits
chr13	108850500	108850501	rs17485138	7.000000000000001e-06	Dental caries
chr13	24084216	24084217	rs9805786	7.000000000000001e-06	Depression and alcohol dependence
chr13	27623298	27623299	rs7097	7.000000000000001e-06	Large B-cell lymphoma
chr13	30539241	30539242	rs11618202	7.000000000000001e-06	MRI atrophy measures
chr13	30740542	30740543	rs3922435	7.000000000000001e-06	Non-word repetition
chr13	35880055	35880056	rs2051090	7.000000000000001e-06	Non-alcoholic fatty liver disease
chr13	38796457	38796458	rs9594293	7.000000000000001e-06	Cytomegalovirus antibody response
chr12	6332834	6332835	rs4149639	7.000000000000001e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs)
chr12	63052181	63052182	rs10877945	7.000000000000001e-06	Obesity-related traits
chr1	26293157	26293158	rs6598955	7.000000000000001e-06	Obesity-related traits
chr12	62217078	62217079	rs11615916	7.000000000000001e-06	Pulmonary function decline
chr12	21168435	21168436	rs10841753	7.000000000000001e-06	Methotrexate phramacokinetics (acute lymphoblastic leukemia)
chr1	22247448	22247449	rs909814	7.000000000000001e-06	IgG glycosylation
chr12	29719384	29719385	rs16934812	7.000000000000001e-06	Schizophrenia
chr1	230787204	230787205	rs12038826	7.000000000000001e-06	Myopia (pathological)
chr12	32108304	32108305	rs1144713	7.000000000000001e-06	Obesity-related traits
chr1	235103811	235103812	rs11577354	7.000000000000001e-06	Obesity-related traits
chr1	238561440	238561441	rs10754644	7.000000000000001e-06	Economic and political preferences (feminism/equality)
chr1	239233803	239233804	rs1339738	7.000000000000001e-06	IgG glycosylation
chr11	61830499	61830500	rs1535	7.000000000000001e-06	Response to statin therapy
chr1	240682823	240682824	rs4659996	7.000000000000001e-06	Ankle-brachial index 
chr1	242358739	242358740	rs2919024	7.000000000000001e-06	IgG glycosylation
chr1	245570305	245570306	rs10924245	7.000000000000001e-06	Schizophrenia
chr1	247526229	247526230	rs1881797	7.000000000000001e-06	Acute lymphoblastic leukemia (childhood)
chr1	24970251	24970252	rs10751776	7.000000000000001e-06	IgG glycosylation
chr12	50963758	50963759	rs12304921	7.000000000000001e-06	Type 2 diabetes
chr12	53601292	53601293	rs1485395	7.000000000000001e-06	Migraine without aura
chr12	55031131	55031132	rs1386809	7.000000000000001e-06	IgG glycosylation
chr12	57095925	57095926	rs1059513	7.000000000000001e-06	Sensory disturbances after bilateral sagittal split ramus osteotomy
chr1	242111605	242111606	rs10803016	7.000000000000001e-06	Coronary artery calcification
chr1	159711077	159711078	rs2808630	7.000000000000001e-06	Lung cancer
chr1	159372648	159372649	rs6687840	7.000000000000001e-06	Chemerin levels
chr1	155898833	155898834	rs2282301	7.000000000000001e-06	Conduct disorder (interaction)
chr10	3616726	3616727	rs705469	7.000000000000001e-06	Capecitabine sensitivity
chr10	3625533	3625534	rs705471	7.000000000000001e-06	Capecitabine sensitivity
chr10	3959704	3959705	rs2031573	7.000000000000001e-06	Word reading
chr10	4108928	4108929	rs10795130	7.000000000000001e-06	Sex hormone-binding globulin levels
chr10	4677603	4677604	rs1391511	7.000000000000001e-06	Neonatal lupus
chr10	48555120	48555121	rs10776614	7.000000000000001e-06	Self-employment
chr10	51482942	51482943	rs293314	7.000000000000001e-06	Obesity-related traits
chr10	57964627	57964628	rs7070038	7.000000000000001e-06	Coronary artery calcification
chr10	58795817	58795818	rs11006263	7.000000000000001e-06	Obesity-related traits
chr10	6057081	6057082	rs2104286	7.000000000000001e-06	Multiple sclerosis
chr10	61432655	61432656	rs7088627	7.000000000000001e-06	Serum dimethylarginine levels (asymmetric)
chr10	61602228	61602229	rs2814021	7.000000000000001e-06	Obesity-related traits
chr10	6530262	6530263	rs11259403	7.000000000000001e-06	Body mass index (asthmatics)
chr10	69823441	69823442	rs7077164	7.000000000000001e-06	Non-alcoholic fatty liver disease histology (lobular)
chr10	713327	713328	rs7916968	7.000000000000001e-06	Migraine
chr10	76151273	76151274	rs10740455	7.000000000000001e-06	Methotrexate phramacokinetics (acute lymphoblastic leukemia)
chr10	77684994	77684995	rs4979906	7.000000000000001e-06	Mortality in heart failure
chr10	3375931	3375932	rs1570854	7.000000000000001e-06	Economic and political preferences (environmentalism)
chr10	29002968	29002969	rs1612122	7.000000000000001e-06	Major depressive disorder (broad)
chr10	28328705	28328706	rs1148186	7.000000000000001e-06	Pulmonary function decline
chr10	28099220	28099221	rs10763642	7.000000000000001e-06	Obesity-related traits
chr20	54084753	54084754	rs6064045	7.000000000000001e-06	IgG glycosylation
chr10	103538012	103538013	rs7069733	7.000000000000001e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr10	106494705	106494706	rs2039964	7.000000000000001e-06	Metabolite levels (MHPG)
chr10	106738319	106738320	rs2486152	7.000000000000001e-06	Metabolite levels (Pyroglutamine)
chr10	120961460	120961461	rs4752485	7.000000000000001e-06	Pulmonary function decline
chr10	124456269	124456270	rs908366	7.000000000000001e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin)
chr10	124587344	124587345	rs12773846	7.000000000000001e-06	Subcutaneous adipose tissue
chr10	125607575	125607576	rs10510146	7.000000000000001e-06	Non-alcoholic fatty liver disease histology (other)
chr10	7845657	7845658	rs11255400	7.000000000000001e-06	IgG glycosylation
chr10	127939366	127939367	rs12049671	7.000000000000001e-06	Response to amphetamines
chr10	130193980	130193981	rs4751178	7.000000000000001e-06	Speech perception in dyslexia
chr10	131531762	131531763	rs11018023	7.000000000000001e-06	Temperament
chr10	13268070	13268071	rs10796051	7.000000000000001e-06	Self-reported allergy
chr10	13488216	13488217	rs17153352	7.000000000000001e-06	IgG glycosylation
chr10	13625730	13625731	rs7089227	7.000000000000001e-06	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU)
chr10	20385723	20385724	rs12772794	7.000000000000001e-06	Neutrophil count
chr10	25591529	25591530	rs17558301	7.000000000000001e-06	IgG glycosylation
chr10	25713318	25713319	rs2504183	7.000000000000001e-06	IgG glycosylation
chr10	128450661	128450662	rs9804317	7.000000000000001e-06	Cognitive performance
chr13	40167769	40167770	rs9315762	7.000000000000001e-06	Presence of antiphospholipid antibodies
chr10	80617833	80617834	rs6586111	7.000000000000001e-06	Capecitabine sensitivity
chr10	89058619	89058620	rs7920888	7.000000000000001e-06	Obesity-related traits
chr11	134269885	134269886	rs478881	7.000000000000001e-06	Obesity-related traits
chr11	14762563	14762564	rs11023332	7.000000000000001e-06	Adiponectin levels
chr1	115378733	115378734	rs7552722	7.000000000000001e-06	Non-alcoholic fatty liver disease
chr11	16880720	16880721	rs381815	7.000000000000001e-06	Blood pressure
chr11	19562954	19562955	rs10500856	7.000000000000001e-06	Obesity-related traits
chr11	2027257	2027258	rs4930144	7.000000000000001e-06	Celiac disease
chr11	20356577	20356578	rs11025523	7.000000000000001e-06	Obesity-related traits
chr11	21647746	21647747	rs10833583	7.000000000000001e-06	Obesity-related traits
chr11	24230981	24230982	rs16912285	7.000000000000001e-06	Visceral adipose tissue/subcutaneous adipose tissue ratio
chr11	2529499	2529500	rs179429	7.000000000000001e-06	Platelet aggregation
chr11	3701073	3701074	rs685782	7.000000000000001e-06	Metabolite levels (Dihydroxy docosatrienoic acid)
chr11	44581777	44581778	rs730129	7.000000000000001e-06	Hemostatic factors and hematological phenotypes
chr11	4475615	4475616	rs2278170	7.000000000000001e-06	Amyotrophic lateral sclerosis
chr1	150351807	150351808	rs11587682	7.000000000000001e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr1	154453787	154453788	rs4129267	7.000000000000001e-06	Pulmonary function
chr1	154781717	154781718	rs6691316	7.000000000000001e-06	Obesity-related traits
chr11	55368742	55368743	rs7927370	7.000000000000001e-06	Systemic lupus erythematosus
chr11	134269885	134269886	rs478881	7.000000000000001e-06	Obesity-related traits
chr11	132714223	132714224	rs1793257	7.000000000000001e-06	Alcohol dependence
chr11	129828960	129828961	rs10894147	7.000000000000001e-06	Obesity-related traits
chr11	128319205	128319206	rs4937314	7.000000000000001e-06	Alzheimer's disease (late onset)
chr10	89058619	89058620	rs7920888	7.000000000000001e-06	Obesity-related traits
chr10	92588072	92588073	rs6583826	7.000000000000001e-06	Type 2 diabetes
chr10	95092932	95092933	rs72820627	7.000000000000001e-06	Response to amphetamines
chr10	95437220	95437221	rs2274491	7.000000000000001e-06	Migraine - clinic-based
chr10	97535039	97535040	rs12767760	7.000000000000001e-06	Obesity-related traits
chr1	103477008	103477009	rs7524694	7.000000000000001e-06	Obesity-related traits
chr1	10578546	10578547	rs12741973	7.000000000000001e-06	Optic disc size (rim)
chr1	106921020	106921021	rs12125971	7.000000000000001e-06	Intelligence
chr10	83110319	83110320	rs7915137	7.000000000000001e-06	Obesity-related traits
chr11	107476550	107476551	rs11212260	7.000000000000001e-06	IgG glycosylation
chr1	111565046	111565047	rs10776733	7.000000000000001e-06	Obesity-related traits
chr1	111565046	111565047	rs10776733	7.000000000000001e-06	Obesity-related traits
chr1	111565046	111565047	rs10776733	7.000000000000001e-06	Obesity-related traits
chr11	116072534	116072535	rs1426391	7.000000000000001e-06	Hypertriglyceridemia
chr11	12050955	12050956	rs923175 	7.000000000000001e-06	Response to taxane treatment (docetaxel)
chr11	120649919	120649920	rs4245040	7.000000000000001e-06	Attention deficit hyperactivity disorder
chr11	123002367	123002368	rs2126200	7.000000000000001e-06	IgG glycosylation
chr11	12447849	12447850	rs7120489	7.000000000000001e-06	Mortality in heart failure
chr11	109022639	109022640	rs7101378	7.000000000000001e-06	IgG glycosylation
chr13	40374013	40374014	rs913246	7.000000000000001e-06	Bipolar disorder and schizophrenia
chr1	159730248	159730249	rs11265260	7.000000000000001e-06	C-reactive protein
chr13	44128732	44128733	rs9525916	7.000000000000001e-06	Fasting insulin (interaction)
chr17	61245681	61245682	rs17513268	7.000000000000001e-06	Obesity-related traits
chr17	67902692	67902693	rs7216064	7.000000000000001e-06	Lung cancer
chr17	72367253	72367254	rs12941150	7.000000000000001e-06	Pulmonary function decline
chr17	79414776	79414777	rs1316453	7.000000000000001e-06	Self-reported allergy
chr18	1595019	1595020	rs8097348	7.000000000000001e-06	Exercise (leisure time)
chr1	82299368	82299369	rs1770678	7.000000000000001e-06	Obesity-related traits
chr1	8278294	8278295	rs438895	7.000000000000001e-06	Economic and political preferences
chr18	278795	278796	rs7226677	7.000000000000001e-06	Bipolar disorder
chr18	3041398	3041399	rs78192384	7.000000000000001e-06	Serum dimethylarginine levels (symmetric)
chr18	31059581	31059582	rs1126214	7.000000000000001e-06	Bronchopulmonary dysplasia
chr18	31322358	31322359	rs7236477	7.000000000000001e-06	Eosinophilic esophagitis (pediatric)
chr18	33686776	33686777	rs4799710	7.000000000000001e-06	Pulmonary function
chr1	83767064	83767065	rs17129289	7.000000000000001e-06	Obesity-related traits
chr18	3879738	3879739	rs76205593	7.000000000000001e-06	Obesity-related traits
chr18	43228832	43228833	rs17664267	7.000000000000001e-06	Conduct disorder (interaction)
chr1	84399546	84399547	rs12144715	7.000000000000001e-06	Response to hepatitis C treatment
chr18	48701072	48701073	rs16949825	7.000000000000001e-06	IgG glycosylation
chr17	57042632	57042633	rs8073390	7.000000000000001e-06	Response to amphetamines
chr17	56538255	56538256	rs17760296	7.000000000000001e-06	Orofacial clefts
chr1	75304939	75304940	rs1249675	7.000000000000001e-06	Capecitabine sensitivity
chr1	74833097	74833098	rs11161851	7.000000000000001e-06	Visceral fat
chr16	80271653	80271654	rs11859036	7.000000000000001e-06	Corneal astigmatism
chr16	81122916	81122917	rs4889240	7.000000000000001e-06	Attention deficit hyperactivity disorder and conduct disorder
chr16	82713331	82713332	rs11646411	7.000000000000001e-06	Attention deficit hyperactivity disorder
chr16	83521919	83521920	rs4074373	7.000000000000001e-06	Homeostasis model assessment of beta-cell function (interaction)
chr16	84276792	84276793	rs138642423	7.000000000000001e-06	Serum dimethylarginine levels (asymmetric)
chr1	68461829	68461830	rs435066	7.000000000000001e-06	IgG glycosylation
chr1	68461829	68461830	rs435066	7.000000000000001e-06	IgG glycosylation
chr16	85873009	85873010	rs11648716	7.000000000000001e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr18	49594945	49594946	rs17798991	7.000000000000001e-06	Obesity-related traits
chr16	85927955	85927956	rs17444745	7.000000000000001e-06	QRS duration
chr1	70977466	70977467	rs909848	7.000000000000001e-06	IgG glycosylation
chr17	17030089	17030090	rs11867934	7.000000000000001e-06	Diabetic retinopathy 
chr1	71808789	71808790	rs12141391	7.000000000000001e-06	Systemic lupus erythematosus
chr17	34137134	34137135	rs9901756	7.000000000000001e-06	Hypothyroidism
chr17	37666304	37666305	rs6607284	7.000000000000001e-06	Bipolar disorder and schizophrenia
chr17	3883612	3883613	rs758642	7.000000000000001e-06	Smoking behavior
chr17	39820215	39820216	rs9303277	7.000000000000001e-06	Systemic lupus erythematosus and Systemic sclerosis
chr17	46257340	46257341	rs2458179	7.000000000000001e-06	Response to amphetamines
chr16	9817528	9817529	rs8058295	7.000000000000001e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr16	79152988	79152989	rs8050187	7.000000000000001e-06	Anorexia nervosa
chr18	50851863	50851864	rs732528	7.000000000000001e-06	Entorhinal cortical thickness
chr18	58243290	58243291	rs158856	7.000000000000001e-06	Insomnia (caffeine-induced)
chr19	51869722	51869723	rs10411161	7.000000000000001e-06	Breast cancer
chr19	57248649	57248650	rs2014572	7.000000000000001e-06	Hyperactive-impulsive symptoms
chr1	99870420	99870421	rs17121403	7.000000000000001e-06	Pulmonary function decline
chr20	13715481	13715482	rs6042314	7.000000000000001e-06	Intelligence (childhood)
chr20	14347252	14347253	rs6079395	7.000000000000001e-06	Non-alcoholic fatty liver disease histology (other)
chr20	16022760	16022761	rs6080100	7.000000000000001e-06	Presence of antiphospholipid antibodies
chr20	24736448	24736449	rs2424635	7.000000000000001e-06	Bipolar disorder and schizophrenia
chr20	2820154	2820155	rs7360412	7.000000000000001e-06	White matter integrity
chr20	32822530	32822531	rs6057651	7.000000000000001e-06	Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms)
chr20	32832002	32832003	rs6057652	7.000000000000001e-06	Attention deficit hyperactivity disorder (hyperactivity-impulsivity symptoms)
chr20	33968970	33968971	rs6059594	7.000000000000001e-06	IgG glycosylation
chr20	35795711	35795712	rs11906854	7.000000000000001e-06	Migraine - clinic-based
chr20	3775949	3775950	rs13043330	7.000000000000001e-06	Visceral adipose tissue adjusted for BMI
chr20	3795527	3795528	rs3761218	7.000000000000001e-06	Bipolar disorder
chr20	4371456	4371457	rs159788	7.000000000000001e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr13	42057582	42057583	rs6561030	7.000000000000001e-06	Height
chr20	47771968	47771969	rs4810685	7.000000000000001e-06	Attention deficit hyperactivity disorder (time to onset)
chr19	3944241	3944242	rs10406174	7.000000000000001e-06	Age-related macular degeneration
chr19	37256205	37256206	rs7246657	7.000000000000001e-06	Coronary artery calcification
chr19	34275682	34275683	rs10407640	7.000000000000001e-06	Functional MRI
chr19	30544778	30544779	rs10418356	7.000000000000001e-06	Serum dimethylarginine levels (asymmetric)
chr18	60083781	60083782	rs12957347	7.000000000000001e-06	Metabolic syndrome
chr18	63192087	63192088	rs899967	7.000000000000001e-06	Cardiac Troponin-T levels
chr18	64503490	64503491	rs4553720	7.000000000000001e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel)
chr18	65231429	65231430	rs637644	7.000000000000001e-06	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU)
chr18	7042911	7042912	rs16951095	7.000000000000001e-06	Non-small cell lung cancer
chr18	72559785	72559786	rs17086172	7.000000000000001e-06	Airflow obstruction 
chr18	77240801	77240802	rs8084125	7.000000000000001e-06	Obesity-related traits
chr18	77926066	77926067	rs12455580	7.000000000000001e-06	IgG glycosylation
chr18	57960607	57960608	rs11875185	7.000000000000001e-06	Antineutrophil cytoplasmic antibody-associated vasculitis 
chr18	78831634	78831635	rs12967884	7.000000000000001e-06	Subcutaneous adipose tissue
chr19	10688227	10688228	rs2569507	7.000000000000001e-06	Obesity-related traits
chr19	11127796	11127797	rs2738459	7.000000000000001e-06	LDL cholesterol
chr19	12114556	12114557	rs17638629	7.000000000000001e-06	Cognitive performance
chr19	14602680	14602681	rs7254215	7.000000000000001e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr19	17007622	17007623	rs11666377	7.000000000000001e-06	Brain lesion load
chr19	1803582	1803583	rs7253430	7.000000000000001e-06	Obesity-related traits
chr19	18376856	18376857	rs78015699	7.000000000000001e-06	Periodontitis (Mean PAL)
chr19	20663464	20663465	rs4808260	7.000000000000001e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr18	8966145	8966146	rs10502386	7.000000000000001e-06	Obesity-related traits
chr16	77749682	77749683	rs4888671	7.000000000000001e-06	Obesity-related traits
chr18	45573983	45573984	rs10502868	7.000000000000001e-06	Biochemical measures
chr13	69880827	69880828	rs11843309	7.000000000000001e-06	Bilirubin levels
chr14	77218326	77218327	rs4467006	7.000000000000001e-06	Bipolar disorder
chr14	85216708	85216709	rs1550584	7.000000000000001e-06	IgG glycosylation
chr14	90213565	90213566	rs8017423	7.000000000000001e-06	Mortality in heart failure
chr14	94491376	94491377	rs1998207	7.000000000000001e-06	Obesity-related traits
chr14	97521519	97521520	rs8022296	7.000000000000001e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)
chr14	99141142	99141143	rs2693676	7.000000000000001e-06	Corneal curvature
chr14	99279936	99279937	rs2614463	7.000000000000001e-06	IgG glycosylation
chr15	101181686	101181687	rs12593811	7.000000000000001e-06	Corneal astigmatism
chr15	24496143	24496144	rs35600665	7.000000000000001e-06	Obesity-related traits
chr15	26043246	26043247	rs6576507	7.000000000000001e-06	Insulin resistance/response
chr15	28243741	28243742	rs8028689	7.000000000000001e-06	Multiple myeloma (IgH translocation)
chr15	29132551	29132552	rs2636061	7.000000000000001e-06	Obesity-related traits
chr15	33304874	33304875	rs2676071	7.000000000000001e-06	Periodontitis (Mean PAL)
chr15	36021763	36021764	rs10520045	7.000000000000001e-06	Major depressive disorder
chr15	45692872	45692873	rs12594515	7.000000000000001e-06	Waist circumference
chr15	47713272	47713273	rs8028579	7.000000000000001e-06	Coronary artery calcification
chr15	54088002	54088003	rs11071033	7.000000000000001e-06	Menarche (age at onset)
chr14	75449760	75449761	rs84044	7.000000000000001e-06	Obesity-related traits
chr14	74899025	74899026	rs732765	7.000000000000001e-06	Non-small cell lung cancer
chr14	68941979	68941980	rs2268983	7.000000000000001e-06	Smoking behavior
chr14	62265945	62265946	rs10146615	7.000000000000001e-06	Economic and political preferences (immigration/crime)
chr13	62356166	62356167	rs9563960	7.000000000000001e-06	IgG glycosylation
chr16	71931292	71931293	rs16973500	7.000000000000001e-06	Attention deficit hyperactivity disorder and conduct disorder
chr13	75562511	75562512	rs9543976	7.000000000000001e-06	Diabetic retinopathy 
chr13	78234778	78234779	rs9574199	7.000000000000001e-06	Total ventricular volume
chr13	79725586	79725587	rs2039553	7.000000000000001e-06	Pancreatic cancer
chr13	80783535	80783536	rs11149178	7.000000000000001e-06	Major depressive disorder
chr13	93556395	93556396	rs190494527	7.000000000000001e-06	Serum dimethylarginine levels (asymmetric/symetric ratio)
chr13	98174780	98174781	rs285098	7.000000000000001e-06	Migraine
chr15	55164311	55164312	rs16976033	7.000000000000001e-06	Neutrophil count
chr13	98308507	98308508	rs4318070	7.000000000000001e-06	Total ventricular volume
chr14	106767969	106767970	rs10129255	7.000000000000001e-06	Kawasaki disease
chr14	22995272	22995273	rs997154	7.000000000000001e-06	Primary tooth development (time to first tooth eruption)
chr14	36520213	36520214	rs2076751	7.000000000000001e-06	Menarche (age at onset)
chr14	37597369	37597370	rs12587630	7.000000000000001e-06	Periodontitis (CDC/AAP)
chr14	41054256	41054257	rs1959947	7.000000000000001e-06	Hemostatic factors and hematological phenotypes
chr14	47584955	47584956	rs4143912	7.000000000000001e-06	IgG glycosylation
chr14	57652477	57652478	rs10134944	7.000000000000001e-06	Bipolar disorder
chr14	57931197	57931198	rs808225	7.000000000000001e-06	Pulmonary function
chr14	104880569	104880570	rs2841233	7.000000000000001e-06	IgG glycosylation
chr15	58882339	58882340	rs7179456	7.000000000000001e-06	Asperger disorder
chr14	85187674	85187675	rs12436689	7.000000000000001e-06	Pulmonary function decline
chr15	62606960	62606961	rs12913538	7.000000000000001e-06	Sleep depth
chr1	61914625	61914626	rs1056513	7.000000000000001e-06	Obesity-related traits
chr1	61914625	61914626	rs1056513	7.000000000000001e-06	Obesity-related traits
chr16	20082731	20082732	rs7201408	7.000000000000001e-06	Attention deficit hyperactivity disorder (inattention symptoms)
chr16	20083223	20083224	rs12924103	7.000000000000001e-06	Attention deficit hyperactivity disorder (inattention symptoms)
chr16	20083563	20083564	rs7185264	7.000000000000001e-06	Attention deficit hyperactivity disorder (inattention symptoms)
chr16	20084305	20084306	rs11647507	7.000000000000001e-06	Attention deficit hyperactivity disorder (inattention symptoms)
chr16	20089047	20089048	rs12926729	7.000000000000001e-06	Attention deficit hyperactivity disorder (inattention symptoms)
chr16	20098330	20098331	rs11642377	7.000000000000001e-06	Attention deficit hyperactivity disorder (inattention symptoms)
chr1	61914625	61914626	rs1056513	7.000000000000001e-06	Obesity-related traits
chr16	259155	259156	rs1122794	7.000000000000001e-06	Red blood cell traits
chr16	28041641	28041642	rs205391	7.000000000000001e-06	Obesity-related traits
chr16	29871168	29871169	rs12917712	7.000000000000001e-06	Systemic lupus erythematosus
chr16	31287617	31287618	rs9937837	7.000000000000001e-06	Systemic lupus erythematosus
chr16	53782362	53782363	rs8050136	7.000000000000001e-06	Type 2 diabetes
chr1	65845181	65845182	rs10493389	7.000000000000001e-06	Echocardiographic traits
chr16	62343248	62343249	rs11645366	7.000000000000001e-06	Cystic fibrosis severity
chr15	59532787	59532788	rs17302400	7.000000000000001e-06	Visceral adipose tissue adjusted for BMI
chr16	71013580	71013581	rs195656	7.000000000000001e-06	Celiac disease
chr16	26159618	26159619	rs9933429	7.000000000000001e-06	Obesity-related traits
chr16	17968278	17968279	rs7194356	7.000000000000001e-06	IgG glycosylation
chr1	66657373	66657374	rs6681460	7.000000000000001e-06	Presence of antiphospholipid antibodies
chr16	15038116	15038117	rs1136001	7.000000000000001e-06	Height
chr16	16162909	16162910	rs3213473	7.000000000000001e-06	IgG glycosylation
chr15	71284415	71284416	rs1442779	7.000000000000001e-06	Periodontitis (Mean PAL)
chr15	71284415	71284416	rs1442779	7.000000000000001e-06	Periodontitis (PAL4Q3)
chr15	75157332	75157333	rs4886670	7.000000000000001e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel)
chr15	77559192	77559193	rs2137111	7.000000000000001e-06	Anticoagulant levels
chr15	78238597	78238598	rs1533665	7.000000000000001e-06	Personality dimensions
chr15	78796768	78796769	rs3825807	7.000000000000001e-06	Coronary artery calcification
chr15	82059858	82059859	rs12324805	7.000000000000001e-06	Body mass index
chr15	83057426	83057427	rs1568657	7.000000000000001e-06	Kawasaki disease
chr15	70188274	70188275	rs6494849	7.000000000000001e-06	Bipolar disorder
chr15	88118507	88118508	rs9806762	7.000000000000001e-06	Gaucher disease severity
chr15	89073849	89073850	rs420017	7.000000000000001e-06	Height
chr1	59333488	59333489	rs17119280	7.000000000000001e-06	Response to antipsychotic therapy (extrapyramidal side effects)
chr15	95509512	95509513	rs933769	7.000000000000001e-06	Alcoholism (alcohol dependence factor score)
chr15	95613138	95613139	rs4321143	7.000000000000001e-06	Conduct disorder (interaction)
chr15	96475502	96475503	rs113154706	7.000000000000001e-06	Response to amphetamines
chr15	97207104	97207105	rs1513859	7.000000000000001e-06	Obesity-related traits
chr15	85826198	85826199	rs7176093	7.000000000000001e-06	Aging traits
chr4	125438300	125438301	rs1395241	8e-06	Bipolar disorder and major depressive disorder (combined)
chr4	12578221	12578222	rs10002492	8e-06	IgG glycosylation
chr4	127420964	127420965	rs724950	8e-06	Obesity-related traits
chr4	12772369	12772370	rs16887552	8e-06	Response to mTOR inhibitor (everolimus)
chr4	135272184	135272185	rs17639207	8e-06	Sexual dimorphism in anthropometric traits
chr4	137771095	137771096	rs2313132	8e-06	Systemic lupus erythematosus
chr4	139501979	139501980	rs17050782	8e-06	Smoking behavior
chr4	147401234	147401235	rs1429107	8e-06	Obesity-related traits
chr4	15480735	15480736	rs1861050	8e-06	Conduct disorder (case status)
chr4	152975007	152975008	rs77708442	8e-06	Obesity-related traits
chr3	4181931	4181932	rs2587949	8e-06	Periodontitis (DPAL)
chr4	161252327	161252328	rs7676384	8e-06	Response to amphetamines
chr4	166422786	166422787	rs17635075	8e-06	Obesity-related traits
chr4	168417368	168417369	rs1963569	8e-06	Obesity-related traits
chr4	179127207	179127208	rs17067123	8e-06	Response to hepatitis C treatment
chr4	118942320	118942321	rs1472066	8e-06	IgE levels in asthmatics
chr4	18016106	18016107	rs6830062	8e-06	Height
chr4	151987016	151987017	rs360932	8e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr4	117730667	117730668	rs4422476	8e-06	Neutrophil count
chr3	65500712	65500713	rs1524976	8e-06	PR interval
chr4	110105770	110105771	rs10011926	8e-06	Attention deficit hyperactivity disorder
chr4	180308046	180308047	rs17834666	8e-06	Metabolite levels (HVA)
chr3	42051929	42051930	rs1498095	8e-06	Visceral adipose tissue/subcutaneous adipose tissue ratio
chr3	4591807	4591808	rs2322734	8e-06	Airflow obstruction 
chr3	53813034	53813035	rs893363	8e-06	Axial length
chr3	54983721	54983722	rs3773582	8e-06	Endometrial cancer
chr3	55150185	55150186	rs6782380	8e-06	Coronary artery calcification
chr3	59917074	59917075	rs1825630	8e-06	Aortic root size
chr3	60785374	60785375	rs6791644	8e-06	Attention deficit hyperactivity disorder
chr3	62796792	62796793	rs304172	8e-06	IgG glycosylation
chr3	64043706	64043707	rs831574	8e-06	Metabolite levels (Dihydroxy docosatrienoic acid)
chr3	64744215	64744216	rs7638389	8e-06	Visceral adipose tissue adjusted for BMI
chr3	7496514	7496515	rs1450100	8e-06	Orofacial clefts
chr3	78304440	78304441	rs9831754	8e-06	Calcium levels
chr3	8209102	8209103	rs9866825	8e-06	QT interval
chr3	856977	856978	rs35964523	8e-06	Response to statin therapy
chr3	96609982	96609983	rs6796026	8e-06	Obesity-related traits
chr4	101511544	101511545	rs890448	8e-06	Acute urticaria and angiodema (non-steroidal anti-inflammatory drug-induced)
chr4	117158750	117158751	rs10516635	8e-06	Visceral adipose tissue adjusted for BMI
chr4	181301573	181301574	rs17183114	8e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr5	165636878	165636879	rs958994	8e-06	Carotid atherosclerosis in HIV infection
chr4	184000145	184000146	rs12498735	8e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr5	112907270	112907271	rs469727	8e-06	Attention deficit hyperactivity disorder
chr5	113660956	113660957	rs17135859	8e-06	F-cell distribution
chr5	116233059	116233060	rs253959	8e-06	Bipolar disorder and schizophrenia
chr5	116392140	116392141	rs7702057	8e-06	Amyotrophic lateral sclerosis
chr5	122100900	122100901	rs890749	8e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr5	125513212	125513213	rs17468244	8e-06	Obesity-related traits
chr5	127816283	127816284	rs1421746	8e-06	Amyotrophic lateral sclerosis (age of onset)
chr5	133867904	133867905	rs1644305	8e-06	Attention deficit hyperactivity disorder and conduct disorder
chr5	135036994	135036995	rs31198	8e-06	Height
chr5	143062228	143062229	rs3776331	8e-06	Uric acid levels
chr5	150446306	150446307	rs13177918	8e-06	Visceral adipose tissue/subcutaneous adipose tissue ratio
chr5	152354547	152354548	rs1010254	8e-06	Optic disc size (cup)
chr5	153560844	153560845	rs10065813	8e-06	Obesity-related traits
chr5	155775517	155775518	rs11134474	8e-06	Smoking behavior
chr5	157983269	157983270	rs11958404	8e-06	IgG glycosylation
chr5	16037992	16037993	rs1039443	8e-06	IgG glycosylation
chr3	39433850	39433851	rs17038828	8e-06	IgG glycosylation
chr5	11169832	11169833	rs6885224	8e-06	Myopia (pathological)
chr5	111623084	111623085	rs11241130	8e-06	Obesity-related traits
chr5	105961827	105961828	rs13189969	8e-06	Obesity-related traits
chr5	103428346	103428347	rs2099077	8e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr4	188665924	188665925	rs7659062	8e-06	Cognitive performance
chr4	188669704	188669705	rs7662358	8e-06	Cognitive performance
chr4	26999372	26999373	rs6822297	8e-06	Obesity-related traits
chr4	27192448	27192449	rs13149020	8e-06	QT interval
chr4	38463849	38463850	rs4615179	8e-06	Obesity-related traits
chr4	40971509	40971510	rs4466078	8e-06	Dental caries
chr4	49060874	49060875	rs11725957	8e-06	Response to hepatitis C treatment
chr4	5160661	5160662	rs13128441	8e-06	Celiac disease
chr4	181478541	181478542	rs7672826	8e-06	Multiple sclerosis
chr4	57073696	57073697	rs10049992	8e-06	IgG glycosylation
chr4	62476551	62476552	rs6819266	8e-06	Age-related macular degeneration
chr4	7016457	7016458	rs16839553	8e-06	IgG glycosylation
chr4	74358872	74358873	rs1350666	8e-06	Attention deficit hyperactivity disorder
chr4	75105710	75105711	rs1426063	8e-06	QT interval
chr4	86833265	86833266	rs10050311	8e-06	Insulin-related traits
chr4	92399875	92399876	rs7666831	8e-06	Obesity-related traits
chr4	99474256	99474257	rs148915469	8e-06	Eating disorders
chr4	99523526	99523527	rs13126513	8e-06	Metabolite levels (MHPG)
chr4	58637560	58637561	rs282708	8e-06	Acute lymphoblastic leukemia (childhood)
chr3	38844921	38844922	rs3923518	8e-06	Migraine
chr2	175869869	175869870	rs4972489	8e-06	Obesity-related traits
chr3	32223498	32223499	rs4376071	8e-06	IgG glycosylation
chr2	234692419	234692420	rs4663476	8e-06	Response to angiotensin II receptor blocker therapy
chr22	36121883	36121884	rs1476029	8e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin)
chr2	237362250	237362251	rs10202497	8e-06	Aging (time to event)
chr2	237590800	237590801	rs2292873	8e-06	Obesity-related traits
chr2	237913688	237913689	rs10185142	8e-06	Obesity-related traits
chr2	239191275	239191276	rs3791556	8e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr22	39352848	39352849	rs137699	8e-06	IgG glycosylation
chr22	39559867	39559868	rs9611198	8e-06	Schizophrenia
chr2	239824023	239824024	rs4852140	8e-06	Obesity-related traits
chr2	239904220	239904221	rs12618573	8e-06	Response to amphetamines
chr2	242106608	242106609	rs12478296	8e-06	Obesity-related traits
chr22	47792503	47792504	rs5767992	8e-06	Obesity-related traits
chr22	49957322	49957323	rs28372448	8e-06	Cannabis dependence
chr2	2541961	2541962	rs181867028	8e-06	Serum dimethylarginine levels (asymmetric/symetric ratio)
chr2	26049732	26049733	rs13388915	8e-06	Immune response to smallpox vaccine (IL-6)
chr2	27636449	27636450	rs111571364	8e-06	Periodontitis (CDC/AAP)
chr23	28214935	28214936	rs5971305	8e-06	Erectile dysfunction and prostate cancer treatment
chr22	33350539	33350540	rs2267193	8e-06	Visceral fat
chr2	23325742	23325743	rs2577720	8e-06	F-cell distribution
chr22	32436886	32436887	rs2076054	8e-06	Migraine with aura
chr2	230555685	230555686	rs17275498	8e-06	Cognitive performance
chr5	17148801	17148802	rs682748	8e-06	Hippocampal atrophy
chr2	176147849	176147850	rs4972806	8e-06	IgG glycosylation
chr2	184668852	184668853	rs7597593	8e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr2	191099906	191099907	rs7574865	8e-06	Systemic lupus erythematosus
chr2	1922220	1922221	rs2241685	8e-06	Attention deficit hyperactivity disorder
chr2	200293398	200293399	rs12612420	8e-06	Exercise (leisure time)
chr2	202085127	202085128	rs1521882	8e-06	Attention deficit hyperactivity disorder and conduct disorder
chr2	205971887	205971888	rs7603514	8e-06	Obesity (extreme)
chr23	33793723	33793724	rs113065570	8e-06	Periodontitis (Mean PAL)
chr2	208129320	208129321	rs2242073	8e-06	Attention deficit hyperactivity disorder
chr2	213973788	213973789	rs9789347	8e-06	Obesity-related traits
chr22	22152175	22152176	rs11089937	8e-06	Periodontitis (PAL4Q3)
chr22	23302606	23302607	rs9608102	8e-06	Immune response to smallpox vaccine (IL-6)
chr2	22353227	22353228	rs1605834	8e-06	Bipolar disorder and schizophrenia
chr22	23580795	23580796	rs140174	8e-06	Migraine
chr2	227720181	227720182	rs11691652	8e-06	Obesity-related traits
chr2	229485272	229485273	rs11890081	8e-06	IgG glycosylation
chr2	23016070	23016071	rs41458646	8e-06	Alzheimer's disease (late onset)
chr2	21072102	21072103	rs541041	8e-06	Response to statin therapy
chr2	36299292	36299293	rs1863080	8e-06	Anthropometric traits
chr2	37504521	37504522	rs960902	8e-06	Response to TNF-alpha inhibitors in rheumatoid arthritis
chr2	37749873	37749874	rs604381	8e-06	Conduct disorder (interaction)
chr3	141657297	141657298	rs11921014	8e-06	Coronary artery calcification
chr3	144053404	144053405	rs13068298	8e-06	Economic and political preferences (feminism/equality)
chr3	146684383	146684384	rs1912785	8e-06	Barrett's esophagus
chr3	148038898	148038899	rs1841770	8e-06	Multiple sclerosis
chr3	150979420	150979421	rs16863118	8e-06	IgG glycosylation
chr3	156384944	156384945	rs3772255	8e-06	Aging traits
chr3	161674787	161674788	rs6808138	8e-06	Hyperactive-impulsive symptoms
chr3	172667902	172667903	rs11712263	8e-06	Obesity-related traits
chr3	141260568	141260569	rs16851254	8e-06	Cognitive performance
chr3	172758628	172758629	rs7646507	8e-06	Obesity-related traits
chr3	176209662	176209663	rs11923600	8e-06	Height
chr3	184498341	184498342	rs3930234	8e-06	Alcoholism (alcohol use disorder factor score)
chr3	185968951	185968952	rs10049246	8e-06	Attention deficit hyperactivity disorder symptoms (interaction)
chr3	190632671	190632672	rs7626795	8e-06	Lung cancer
chr3	191478802	191478803	rs16822582	8e-06	Bipolar disorder and schizophrenia
chr3	1992670	1992671	rs2729313	8e-06	Serum dimethylarginine levels (asymmetric)
chr3	30999010	30999011	rs1506203	8e-06	Eating disorders (purging via substances) 
chr3	32198626	32198627	rs9825310	8e-06	Alcohol dependence
chr3	175243597	175243598	rs1463525	8e-06	Systemic lupus erythematosus
chr3	37813622	37813623	rs11129773	8e-06	Illicit drug use
chr3	139354168	139354169	rs1044826	8e-06	Obesity-related traits
chr3	138306553	138306554	rs9846480	8e-06	MRI atrophy measures
chr23	8426211	8426212	rs7892812	8e-06	Cognitive performance
chr2	38882416	38882417	rs3099950	8e-06	Amyotrophic lateral sclerosis
chr2	45949822	45949823	rs6751349	8e-06	QT interval
chr2	52476451	52476452	rs12619788	8e-06	Economic and political preferences (immigration/crime)
chr2	53275636	53275637	rs996712	8e-06	Obesity-related traits
chr2	6556955	6556956	rs962528	8e-06	Visceral fat
chr2	67070276	67070277	rs1833219	8e-06	Periodontitis (CDC/AAP)
chr2	679178	679179	rs1320333	8e-06	Obesity-related traits
chr3	139324393	139324394	rs4894410	8e-06	Kawasaki disease
chr2	70470534	70470535	rs3771514	8e-06	Obesity-related traits
chr2	81629401	81629402	rs12615721	8e-06	Pulmonary function decline
chr2	96176054	96176055	rs11886999	8e-06	Cardiac Troponin-T levels
chr3	11191092	11191093	rs4684059	8e-06	IgG glycosylation
chr3	11583939	11583940	rs6802119	8e-06	Metabolite levels (HVA-5-HIAA Factor score)
chr3	120324988	120324989	rs10511400	8e-06	Economic and political preferences (feminism/equality)
chr3	128939648	128939649	rs2933343	8e-06	IgG glycosylation
chr3	133765184	133765185	rs3811647	8e-06	Iron status biomarkers
chr3	135868968	135868969	rs1401543	8e-06	Anticoagulant levels
chr2	77019204	77019205	rs6547115	8e-06	IgG glycosylation
chr5	172844003	172844004	rs792975	8e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel)
chr9	90647074	90647075	rs1831521	8e-06	Cognitive test performance
chr5	176422987	176422988	rs2913737	8e-06	Obesity-related traits
chr8	115621471	115621472	rs2721937	8e-06	Major depressive disorder
chr8	117138753	117138754	rs11989843	8e-06	Obesity-related traits
chr8	118379169	118379170	rs17749211	8e-06	Multiple sclerosis
chr8	121170069	121170070	rs1604897	8e-06	IgG glycosylation
chr8	126899350	126899351	rs2220321	8e-06	Obesity-related traits
chr8	128207826	128207827	rs11995854	8e-06	Obesity-related traits
chr8	129807792	129807793	rs2128382	8e-06	Colorectal cancer
chr8	132356846	132356847	rs978152	8e-06	Coronary artery calcification
chr8	140564094	140564095	rs2944755	8e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr8	141456720	141456721	rs11777747	8e-06	Coronary artery calcification
chr8	15339907	15339908	rs12676170	8e-06	Corneal astigmatism
chr8	17072125	17072126	rs10090288	8e-06	Depression and alcohol dependence
chr8	17424901	17424902	rs13271465	8e-06	Obesity-related traits
chr8	20443925	20443926	rs4922199	8e-06	Dental caries
chr8	2092275	2092276	rs2235121	8e-06	Bipolar disorder and schizophrenia
chr8	290577	290578	rs55680580	8e-06	Serum dimethylarginine levels (symmetric)
chr8	30641341	30641342	rs2978263	8e-06	Cognitive performance
chr8	103106337	103106338	rs6983777	8e-06	Attention deficit hyperactivity disorder (combined symptoms)
chr8	10228900	10228901	rs6999631	8e-06	Bulimia nervosa
chr7	98295241	98295242	rs77443149	8e-06	Obesity-related traits
chr7	9499648	9499649	rs9918508	8e-06	Hippocampal atrophy
chr7	22069840	22069841	rs10499559	8e-06	Thyroid stimulating hormone
chr7	22945390	22945391	rs2286492	8e-06	Bipolar disorder
chr7	25573040	25573041	rs975369	8e-06	Preeclampsia
chr7	26517998	26517999	rs886716	8e-06	Smoking behavior
chr7	29144872	29144873	rs10486607	8e-06	Diabetes related insulin traits
chr7	36878389	36878390	rs741301	8e-06	Type 2 diabetes nephropathy
chr7	36912415	36912416	rs10488023	8e-06	Breast size
chr7	36921714	36921715	rs13230047	8e-06	Anticoagulant levels
chr8	3234061	3234062	rs1442407	8e-06	Systolic blood pressure in sickle cell anemia
chr7	41582931	41582932	rs4724055	8e-06	Non-substance related behavioral disinhibition
chr7	64272952	64272953	rs10266483	8e-06	Response to statin therapy
chr7	76323979	76323980	rs758944	8e-06	Multiple sclerosis
chr7	76346268	76346269	rs7779014	8e-06	Multiple sclerosis
chr7	82228576	82228577	rs929351	8e-06	Ulcerative colitis
chr7	83979722	83979723	rs797820	8e-06	Attention deficit hyperactivity disorder
chr7	8602723	8602724	rs10245124	8e-06	Obesity-related traits
chr7	8602723	8602724	rs10245124	8e-06	Obesity-related traits
chr7	91610981	91610982	rs2540552	8e-06	IgG glycosylation
chr7	49594205	49594206	rs4492324	8e-06	Obesity-related traits
chr7	18389297	18389298	rs12155400	8e-06	Retinopathy in non-diabetics
chr8	4220830	4220831	rs2407314	8e-06	Insulin resistance/response
chr8	5068942	5068943	rs1454292	8e-06	Hair morphology
chr9	18761100	18761101	rs1978746	8e-06	QT interval (interaction)
chr9	22488678	22488679	rs586716	8e-06	Tuberculosis
chr9	22819576	22819577	rs7849973	8e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr9	25414052	25414053	rs7021404	8e-06	Metabolite levels (Dihydroxy docosatrienoic acid)
chr9	25551358	25551359	rs17774966	8e-06	Entorhinal cortical thickness
chr9	27126416	27126417	rs1334809	8e-06	IgG glycosylation
chr9	2978376	2978377	rs7045640	8e-06	Systolic blood pressure in sickle cell anemia
chr9	32755029	32755030	rs10758161	8e-06	Immune response to anthrax vaccine 
chr9	33217267	33217268	rs830407	8e-06	Bipolar disorder and schizophrenia
chr9	35700839	35700840	rs4879926	8e-06	IgE levels in asthmatics
chr9	38456367	38456368	rs1110183	8e-06	Hypertension
chr9	4555304	4555305	rs7856675	8e-06	Coronary artery calcification
chr9	7558260	7558261	rs4400445	8e-06	Obesity-related traits
chr9	82994865	82994866	rs10867921	8e-06	Obesity-related traits
chr9	9020222	9020223	rs378363	8e-06	Migraine - clinic-based
chr2	175869869	175869870	rs4972489	8e-06	Obesity-related traits
chr9	99472040	99472041	rs649057	8e-06	Smooth-surface caries 
chr9	17899607	17899608	rs4284125	8e-06	Cognitive performance
chr9	133858397	133858398	rs12344583	8e-06	vWF and FVIII levels
chr9	133273812	133273813	rs505922	8e-06	Graves' disease
chr9	132757105	132757106	rs12552369	8e-06	Major depressive disorder
chr8	51304201	51304202	rs7821565	8e-06	Tuberculosis
chr8	6493730	6493731	rs17077154	8e-06	Cytomegalovirus antibody response
chr8	65551242	65551243	rs6981992	8e-06	Obesity-related traits
chr8	65711996	65711997	rs10504390	8e-06	IgG glycosylation
chr8	77413648	77413649	rs13259667	8e-06	Behavioural disinhibition (generation interaction)
chr8	83078995	83078996	rs1375785	8e-06	Information processing speed
chr8	89644759	89644760	rs160441	8e-06	Tuberculosis
chr8	91406399	91406400	rs10504906	8e-06	Fat distribution (HIV)
chr8	43840090	43840091	rs58810682	8e-06	Response to amphetamines
chr8	91547686	91547687	rs2657195	8e-06	Disc degeneration (lumbar)
chr8	95107843	95107844	rs4392868	8e-06	Radiation response
chr8	9538021	9538022	rs6601327	8e-06	Multiple myeloma (hyperdiploidy)
chr9	104828990	104828991	rs7031748	8e-06	Myopia (pathological)
chr9	109834630	109834631	rs2025875	8e-06	Obesity-related traits
chr9	113234968	113234969	rs6477998	8e-06	Hematology traits
chr9	119222274	119222275	rs10984447	8e-06	Multiple sclerosis
chr9	129576790	129576791	rs10988428	8e-06	Metabolite levels (Pyroglutamine)
chr9	130872695	130872696	rs2070997	8e-06	Response to amphetamines
chr8	93157120	93157121	rs278567	8e-06	Bipolar disorder and schizophrenia
chr7	18335621	18335622	rs12666612	8e-06	Obesity-related traits
chr7	158430413	158430414	rs7786808	8e-06	Obesity-related traits
chr7	157717502	157717503	rs6459804	8e-06	Bipolar disorder and schizophrenia
chr5	9332168	9332169	rs7702187	8e-06	Parkinson's disease
chr5	95318168	95318169	rs255982	8e-06	IgG glycosylation
chr6	105164344	105164345	rs11962089	8e-06	Multiple sclerosis
chr6	109768845	109768846	rs4947019	8e-06	Hematological parameters
chr6	117409655	117409656	rs2273601	8e-06	QT interval (interaction)
chr6	135219241	135219242	rs210937	8e-06	Obesity-related traits
chr6	137945547	137945548	rs9321637	8e-06	Cardiac Troponin-T levels
chr6	143673061	143673062	rs9403521	8e-06	Obesity-related traits
chr6	147613810	147613811	rs9377063	8e-06	Obesity-related traits
chr6	148102234	148102235	rs9390537	8e-06	Alzheimer's disease
chr6	149272783	149272784	rs727979	8e-06	Hemostatic factors and hematological phenotypes
chr6	150688752	150688753	rs4869931	8e-06	Systolic blood pressure in sickle cell anemia
chr6	151836745	151836746	rs6902771	8e-06	Alcohol dependence
chr6	1524334	1524335	rs2569872	8e-06	Metabolite levels (HVA/MHPG ratio)
chr6	152626817	152626818	rs1322512	8e-06	Tonometry
chr6	165715149	165715150	rs9364813	8e-06	Economic and political preferences (immigration/crime)
chr6	166922662	166922663	rs9459805	8e-06	Endometrial cancer
chr5	91685569	91685570	rs13153333	8e-06	Subcutaneous adipose tissue
chr5	8983608	8983609	rs11134338	8e-06	Obesity-related traits
chr5	81207083	81207084	rs17228156	8e-06	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)
chr5	79647824	79647825	rs6859704	8e-06	IgG glycosylation
chr5	177592260	177592261	rs57960711	8e-06	Obesity-related traits
chr5	179143912	179143913	rs10039254	8e-06	Attention deficit hyperactivity disorder (time to onset)
chr5	179236406	179236407	rs469568	8e-06	Stroke (pediatric)
chr5	180778937	180778938	rs6859974	8e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr5	2109786	2109787	rs6879627	8e-06	Pancreatic cancer
chr5	25760569	25760570	rs7727656	8e-06	Hippocampal atrophy
chr5	26723673	26723674	rs4479806	8e-06	Anorexia nervosa
chr5	26927957	26927958	rs10057565	8e-06	Coronary artery calcification
chr6	167341486	167341487	rs12528714	8e-06	IgG glycosylation
chr5	2724247	2724248	rs2173226	8e-06	Obesity-related traits
chr5	35874472	35874473	rs6897932	8e-06	Type 1 diabetes
chr5	35910426	35910427	rs1445898	8e-06	Type 1 diabetes
chr5	36473134	36473135	rs2937550	8e-06	Height
chr5	42473452	42473453	rs13188386	8e-06	Iron status biomarkers
chr5	56027066	56027067	rs17348299	8e-06	IgG glycosylation
chr5	76326988	76326989	rs3733860	8e-06	Venous thromboembolism
chr5	78691700	78691701	rs784420	8e-06	Economic and political preferences
chr5	78977118	78977119	rs2052550	8e-06	Iron status biomarkers
chr5	35461097	35461098	rs284737	8e-06	Metabolite levels (HVA/5-HIAA ratio)
chr6	169713147	169713148	rs7762018	8e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr6	20567309	20567310	rs9460521	8e-06	Obesity-related traits
chr6	20694652	20694653	rs2206734	8e-06	Ileal carcinoids
chr6	88473860	88473861	rs11757661	8e-06	Subcutaneous adipose tissue
chr6	95731127	95731128	rs143247165	8e-06	Serum dimethylarginine levels (symmetric)
chr6	98291897	98291898	rs6909430	8e-06	Quantitative traits
chr6	9937126	9937127	rs149747749	8e-06	Serum dimethylarginine levels (asymmetric)
chr7	103534996	103534997	rs1008126	8e-06	Metabolite levels (Pyroglutamine)
chr7	105902133	105902134	rs13438712	8e-06	Obesity-related traits
chr7	107951752	107951753	rs2072209	8e-06	IgG glycosylation
chr7	108904403	108904404	rs1404697	8e-06	Smoking behavior
chr6	86897123	86897124	rs1853639	8e-06	IgG glycosylation
chr7	116937069	116937070	rs7782376	8e-06	Cognitive performance
chr7	133650422	133650423	rs10488172	8e-06	Tonometry
chr7	135803872	135803873	rs6946494	8e-06	Visceral adipose tissue adjusted for BMI
chr7	136461787	136461788	rs10250997	8e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr7	139892060	139892061	rs7810727	8e-06	Migraine without aura
chr7	147918547	147918548	rs2538958	8e-06	IgG glycosylation
chr7	153574791	153574792	rs11771429	8e-06	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined)
chr7	155976054	155976055	rs10267337	8e-06	Obesity-related traits
chr7	15718374	15718375	rs2159222	8e-06	Migraine with aura
chr7	124744272	124744273	rs7802263	8e-06	Reading and spelling
chr5	175334091	175334092	rs12652255	8e-06	Treatment response for severe sepsis 
chr6	76581081	76581082	rs12198063	8e-06	Capecitabine sensitivity
chr6	67617136	67617137	rs875033	8e-06	Response to amphetamines
chr6	22752817	22752818	rs7356884	8e-06	Obesity-related traits
chr6	23077082	23077083	rs9393366	8e-06	Tourette syndrome
chr6	24862846	24862847	rs4256430	8e-06	Electroencephalographic traits in alcoholism
chr6	30711850	30711851	rs3094093	8e-06	IgG glycosylation
chr6	30711850	30711851	rs3094093	8e-06	IgG glycosylation
chr6	30830213	30830214	rs7749924	8e-06	IgG glycosylation
chr6	32222250	32222251	rs3132946	8e-06	Interstitial lung disease 
chr6	32400309	32400310	rs3817963	8e-06	Multiple sclerosis (OCB status)
chr6	72483448	72483449	rs1334346	8e-06	Response to mTOR inhibitor (rapamycin)
chr6	32696680	32696681	rs2647012	8e-06	Systemic lupus erythematosus
chr6	33772247	33772248	rs2296743	8e-06	Obesity-related traits
chr6	40472760	40472761	rs9296335	8e-06	Obesity-related traits
chr6	41957565	41957566	rs11968166	8e-06	Neutrophil count
chr6	44999752	44999753	rs10948197	8e-06	Height
chr6	45127425	45127426	rs9395066	8e-06	Height
chr6	45917323	45917324	rs4714888	8e-06	Age-related macular degeneration
chr6	64926029	64926030	rs11754641	8e-06	Disc degeneration (lumbar)
chr6	64952727	64952728	rs7767572	8e-06	Metabolite levels (Dihydroxy docosatrienoic acid)
chr6	32706959	32706960	rs1794265	8e-06	IgG glycosylation
chr2	175424590	175424591	rs2461751	8e-06	Electrocardiographic conduction measures
chr4	46821616	46821617	rs11726563	8e-06	Migraine - clinic-based
chr2	15524631	15524632	rs7581919	8e-06	Conduct disorder (case status)
chr1	213944746	213944747	rs340849	8e-06	Alzheimer's disease
chr1	215883005	215883006	rs17025548	8e-06	IgG glycosylation
chr1	218532471	218532472	rs1018040	8e-06	Hyperactive-impulsive symptoms
chr12	18899245	18899246	rs1873386	8e-06	Personality dimensions
chr12	1947196	1947197	rs10505725	8e-06	Obesity-related traits
chr12	19648660	19648661	rs6486986	8e-06	Cognitive performance
chr12	19713194	19713195	rs4762767	8e-06	Pulmonary function
chr12	1982090	1982091	rs11062040	8e-06	Response to gemcitabine in pancreatic cancer 
chr12	28002146	28002147	rs10771399	8e-06	Breast Cancer in BRCA1 mutation carriers
chr12	28591707	28591708	rs10843215	8e-06	Obesity-related traits
chr1	230253242	230253243	rs3761944	8e-06	Hematology traits
chr12	3178112	3178113	rs878962	8e-06	Temporomandibular joint disorders
chr1	232019404	232019405	rs16856202	8e-06	Amyotrophic lateral sclerosis
chr12	33548230	33548231	rs9300212	8e-06	Cognitive test performance
chr1	237192684	237192685	rs268786	8e-06	Obesity-related traits
chr12	3759001	3759002	rs10744625	8e-06	Fasting insulin (interaction)
chr12	3804260	3804261	rs2058350	8e-06	Cognitive performance
chr12	13488771	13488772	rs1457614	8e-06	Major depressive disorder
chr12	13367061	13367062	rs11055387	8e-06	Major depressive disorder
chr12	131529660	131529661	rs10773920	8e-06	Obesity-related traits
chr12	130537464	130537465	rs1464108	8e-06	Alzheimer's disease
chr11	83744663	83744664	rs3885683	8e-06	Protein quantitative trait loci
chr1	18663756	18663757	rs2236835	8e-06	Body mass index
chr11	89379481	89379482	rs10830265	8e-06	Obesity-related traits
chr11	89769207	89769208	rs2130017 	8e-06	Response to taxane treatment (docetaxel)
chr11	91223045	91223046	rs4491175	8e-06	Response to angiotensin II receptor blocker therapy
chr1	19392329	19392330	rs7667	8e-06	Crohn's disease and psoriasis
chr11	96266935	96266936	rs7115578	8e-06	Response to treatment for acute lymphoblastic leukemia
chr1	201661826	201661827	rs586688	8e-06	Obesity-related traits
chr12	38859305	38859306	rs11169838	8e-06	IgG glycosylation
chr12	102119752	102119753	rs2292303	8e-06	Height
chr1	210724920	210724921	rs1934620	8e-06	Smooth-surface caries 
chr12	107310927	107310928	rs1820460	8e-06	Cognitive performance
chr12	108209192	108209193	rs7313402	8e-06	Temperament (bipolar disorder)
chr12	108483763	108483764	rs918304	8e-06	IgG glycosylation
chr12	117313619	117313620	rs478597	8e-06	Inattentive symptoms
chr12	117732103	117732104	rs4304868	8e-06	Visceral adipose tissue adjusted for BMI
chr12	118086620	118086621	rs7957470	8e-06	Obesity-related traits
chr12	129162055	129162056	rs12580533	8e-06	IgG glycosylation
chr12	104623385	104623386	rs12811699	8e-06	Cannabis dependence
chr11	83545824	83545825	rs2116483	8e-06	Obesity-related traits
chr1	239480870	239480871	rs13373941	8e-06	Obesity-related traits
chr12	46092054	46092055	rs1373549	8e-06	Hippocampal atrophy
chr13	23722722	23722723	rs7324557	8e-06	Visceral adipose tissue adjusted for BMI
chr13	26957129	26957130	rs17085007	8e-06	Ulcerative colitis
chr13	27305388	27305389	rs10507380	8e-06	Electrocardiographic traits
chr13	28590645	28590646	rs9579199	8e-06	Breast cancer (menopausal hormone therapy interaction)
chr13	29324645	29324646	rs61999321	8e-06	Obesity-related traits
chr13	29773697	29773698	rs2892463	8e-06	Non-word repetition
chr13	33106716	33106717	rs642899	8e-06	Behavioural disinhibition (generation interaction)
chr1	33517418	33517419	rs10798959	8e-06	Metabolite levels (HVA/MHPG ratio)
chr13	36089164	36089165	rs9315385	8e-06	Heart rate variability traits
chr13	48892794	48892795	rs1449572	8e-06	Multiple myeloma (IgH translocation)
chr13	49717705	49717706	rs9535307	8e-06	Obesity-related traits
chr13	50492486	50492487	rs1262778	8e-06	Bipolar disorder and major depressive disorder (combined)
chr13	50532418	50532419	rs1239947	8e-06	Height
chr13	52943748	52943749	rs732949	8e-06	Immune response to anthrax vaccine 
chr13	58554391	58554392	rs4886088	8e-06	Subcutaneous adipose tissue
chr13	63064195	63064196	rs3119939	8e-06	Asthma
chr13	65546651	65546652	rs1333026	8e-06	Body mass index
chr13	23170239	23170240	rs9507041	8e-06	Cannabis dependence
chr13	22179953	22179954	rs9580312	8e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs)
chr13	113804265	113804266	rs9329350	8e-06	IgG glycosylation
chr13	111166484	111166485	rs4773330	8e-06	Bilirubin levels
chr1	247420374	247420375	rs10925015	8e-06	Word reading
chr12	5022386	5022387	rs16932667	8e-06	Intelligence (childhood)
chr12	5031317	5031318	rs12302829	8e-06	Conduct disorder (symptom count)
chr12	56544598	56544599	rs2657888	8e-06	Adiponectin levels
chr12	57133499	57133500	rs11172113	8e-06	Pulmonary function (interaction)
chr12	60416870	60416871	rs2655898	8e-06	Obesity-related traits
chr12	61155299	61155300	rs17124610	8e-06	IgG glycosylation
chr12	62492342	62492343	rs7301016	8e-06	IgG glycosylation
chr1	241728932	241728933	rs9782914	8e-06	Behavioural disinhibition (generation interaction)
chr12	65970728	65970729	rs12424086	8e-06	Primary tooth development (time to first tooth eruption)
chr12	75324642	75324643	rs12318506	8e-06	Coronary artery calcification
chr12	90683730	90683731	rs1847461	8e-06	Smoking behavior
chr12	97134361	97134362	rs7953959	8e-06	IgG glycosylation
chr12	98796593	98796594	rs2036225	8e-06	Amyotrophic lateral sclerosis (age of onset)
chr13	101900897	101900898	rs9557754	8e-06	QT interval
chr13	103214753	103214754	rs912969	8e-06	Smoking behavior
chr13	107604871	107604872	rs957788	8e-06	Anorexia nervosa
chr13	109919862	109919863	rs7323507	8e-06	Lung function (forced vital capacity)
chr12	71731504	71731505	rs11178918	8e-06	Economic and political preferences (time)
chr11	83110339	83110340	rs4293143	8e-06	Age-related macular degeneration
chr1	181457773	181457774	rs2332267	8e-06	Coronary artery calcification
chr11	80851694	80851695	rs11232369	8e-06	Cognitive performance
chr10	520438	520439	rs11252926	8e-06	Alzheimer's disease
chr10	55789535	55789536	rs16907840	8e-06	Post-traumatic stress disorder (asjusted for relatedness)
chr10	5762567	5762568	rs2797501	8e-06	Osteosarcoma
chr10	58225909	58225910	rs2790232	8e-06	Obesity-related traits
chr10	60325578	60325579	rs10761482	8e-06	Schizophrenia
chr10	63898983	63898984	rs938036	8e-06	Tooth agenesis (mandibular third molar)
chr10	64688714	64688715	rs7900909	8e-06	Response to statin therapy
chr10	66614325	66614326	rs7909235	8e-06	Obesity-related traits
chr10	70281048	70281049	rs41322152	8e-06	Acute lymphoblastic leukemia (childhood)
chr10	7047053	7047054	rs10905099	8e-06	Orofacial clefts
chr10	70723253	70723254	rs1816002	8e-06	Weight
chr10	70928613	70928614	rs1466576	8e-06	Obesity-related traits
chr10	79195309	79195310	rs703965	8e-06	Bipolar disorder
chr10	8108749	8108750	rs10508343	8e-06	Response to treatment for acute lymphoblastic leukemia
chr10	81393489	81393490	rs588517	8e-06	Carotid atherosclerosis in HIV infection
chr10	81429196	81429197	rs1329201	8e-06	Retinopathy in non-diabetics
chr10	8591897	8591898	rs4749791	8e-06	Obesity-related traits
chr10	4634003	4634004	rs7086888	8e-06	Multiple myeloma (IgH translocation)
chr10	33116158	33116159	rs7902627	8e-06	IgG glycosylation
chr10	32336089	32336090	rs143713361	8e-06	Serum dimethylarginine levels (asymmetric/symetric ratio)
chr10	29719733	29719734	rs1927457	8e-06	Normalized brain volume
chr2	167709182	167709183	rs13408808	8e-06	Obesity-related traits
chr10	10031580	10031581	rs10905651	8e-06	Dental caries
chr10	10042602	10042603	rs17147135	8e-06	Obesity-related traits
chr10	1032841	1032842	rs12762955	8e-06	Response to angiotensin II receptor blocker therapy
chr10	110246727	110246728	rs716595	8e-06	Normalized brain volume
chr10	112628512	112628513	rs17267338	8e-06	Multiple sclerosis
chr10	11677010	11677011	rs12265836	8e-06	Obesity-related traits
chr10	124749449	124749450	rs10510138	8e-06	Obesity-related traits
chr10	89204856	89204857	rs11203032	8e-06	Heart failure
chr10	126134581	126134582	rs1278329	8e-06	Metabolite levels (5-HIAA/ MHPG Ratio)
chr10	13748264	13748265	rs10906466	8e-06	Migraine
chr10	1634335	1634336	rs6560749	8e-06	Quantitative traits
chr10	16702523	16702524	rs11254160	8e-06	Obesity-related traits
chr10	18871099	18871100	rs16917919	8e-06	Brain structure (hippocampal volume)
chr10	19116601	19116602	rs16918253	8e-06	Obesity-related traits
chr10	20503404	20503405	rs7897194	8e-06	Bipolar disorder
chr10	2489826	2489827	rs729397	8e-06	Response to statin therapy
chr10	27862005	27862006	rs11006747	8e-06	Obesity-related traits
chr10	126158099	126158100	rs12778749	8e-06	Endometrial cancer
chr1	107760299	107760300	rs12142335	8e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin)
chr11	106625311	106625312	rs1791581	8e-06	Visceral adipose tissue/subcutaneous adipose tissue ratio
chr11	110525133	110525134	rs12785341	8e-06	Renal sinus fat 
chr11	41203882	41203883	rs2862035	8e-06	IgG glycosylation
chr11	45062979	45062980	rs7951911	8e-06	IgG glycosylation
chr11	46871556	46871557	rs2306029	8e-06	D-dimer levels
chr11	48360918	48360919	rs1351696	8e-06	D-dimer levels
chr1	15013463	15013464	rs6429703	8e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin)
chr1	15021143	15021144	rs6667220	8e-06	Chronic obstructive pulmonary disease-related biomarkers
chr1	153801799	153801800	rs4434872	8e-06	Conduct disorder (symptom count)
chr1	157160774	157160775	rs6427356	8e-06	Attention deficit hyperactivity disorder and conduct disorder
chr11	38263950	38263951	rs10836945	8e-06	Bronchopulmonary dysplasia
chr1	157467719	157467720	rs6686423	8e-06	Renal sinus fat 
chr1	159387893	159387894	rs4446959	8e-06	Chemerin levels
chr11	601784	601785	rs2396545	8e-06	Systemic lupus erythematosus and Systemic sclerosis
chr1	161302650	161302651	rs4657015	8e-06	Visceral adipose tissue adjusted for BMI
chr1	161856824	161856825	rs3767633	8e-06	IgG glycosylation
chr1	161945710	161945711	rs10918270	8e-06	Parkinson's disease (age of onset)
chr11	73183227	73183228	rs11603160	8e-06	Body mass index (asthmatics)
chr11	73183802	73183803	rs1791933	8e-06	Insomnia (caffeine-induced)
chr11	80666007	80666008	rs17140547	8e-06	Lentiform nucleus volume 
chr1	158088318	158088319	rs6427419	8e-06	Obesity-related traits
chr13	69881528	69881529	rs7984606	8e-06	Cognitive performance
chr11	35679687	35679688	rs7928794	8e-06	Response to antipsychotic therapy (extrapyramidal side effects)
chr11	32500460	32500461	rs10767942	8e-06	Attention deficit hyperactivity disorder
chr11	116529664	116529665	rs7941534	8e-06	Bipolar disorder and schizophrenia
chr11	116742943	116742944	rs12280753	8e-06	Cardiovascular disease risk factors
chr1	111921753	111921754	rs17029069	8e-06	Cardiac repolarization
chr11	11962337	11962338	rs1472189	8e-06	Metabolite levels (Dihydroxy docosatrienoic acid)
chr11	120938750	120938751	rs12797755	8e-06	Cognitive performance
chr11	125308506	125308507	rs10893366	8e-06	Alcohol dependence
chr1	112648184	112648185	rs17030613	8e-06	Blood pressure
chr1	112673920	112673921	rs2932538	8e-06	Blood pressure
chr11	33847060	33847061	rs11032423	8e-06	Cognitive performance
chr11	128567057	128567058	rs7117932	8e-06	Obesity-related traits
chr11	132140222	132140223	rs4468361	8e-06	Chronic obstructive pulmonary disease-related biomarkers
chr11	134868375	134868376	rs906628	8e-06	Tooth agenesis (mandibular third molar)
chr1	114128346	114128347	rs2774307	8e-06	Breast cancer (prognosis)
chr11	20601476	20601477	rs2241941	8e-06	Obesity-related traits
chr1	12681228	12681229	rs2489260	8e-06	Obesity-related traits
chr11	27561581	27561582	rs7481311	8e-06	Body mass index
chr11	29173589	29173590	rs1491818	8e-06	Amyotrophic lateral sclerosis (age of onset)
chr11	30445952	30445953	rs11031093	8e-06	Dental caries
chr11	13069394	13069395	rs2727405	8e-06	Obesity-related traits
chr13	72194570	72194571	rs4083578	8e-06	Cognitive performance
chr10	30201774	30201775	rs2462021	8e-06	Suicide risk
chr1	37781480	37781481	rs12117544	8e-06	Cognitive performance
chr18	7755772	7755773	rs7243299	8e-06	Dialysis-related mortality
chr19	11220265	11220266	rs17699030	8e-06	Bipolar disorder and schizophrenia
chr19	1207238	1207239	rs3764640	8e-06	Alzheimer's disease
chr19	17652080	17652081	rs10416963	8e-06	Obesity-related traits
chr19	20218301	20218302	rs1654260	8e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs)
chr19	2275079	2275080	rs2523178	8e-06	Height
chr19	2410485	2410486	rs4806846	8e-06	Neuroticism
chr1	92838045	92838046	rs6604026	8e-06	Multiple sclerosis
chr19	29421386	29421387	rs892073	8e-06	Obesity-related traits
chr19	35482386	35482387	rs6510489	8e-06	Bipolar disorder
chr19	39679412	39679413	rs8103033	8e-06	Obesity-related traits
chr19	41167942	41167943	rs8105815	8e-06	Prion diseases
chr19	44466712	44466713	rs644148	8e-06	Personality dimensions
chr19	54109320	54109321	rs254262	8e-06	Obesity-related traits
chr19	54109320	54109321	rs254262	8e-06	Obesity-related traits
chr19	55986593	55986594	rs16986856	8e-06	Obesity-related traits
chr19	56620869	56620870	rs10404342	8e-06	IgE levels in asthmatics
chr18	75824755	75824756	rs9956878	8e-06	Obesity-related traits
chr18	70960841	70960842	rs2660917	8e-06	Iron status biomarkers
chr18	59084821	59084822	rs1037757	8e-06	Alzheimer's disease (age of onset)
chr18	56730390	56730391	rs17750015	8e-06	Depression and alcohol dependence
chr17	72699963	72699964	rs8066857	8e-06	Amyotrophic lateral sclerosis
chr17	75063977	75063978	rs11077773	8e-06	Information processing speed
chr17	78223509	78223510	rs2071214	8e-06	Behavioural disinhibition (generation interaction)
chr17	78872531	78872532	rs9900972	8e-06	Obesity-related traits
chr17	9186906	9186907	rs3785982	8e-06	Breast cancer (prognosis)
chr18	10766426	10766427	rs2865126	8e-06	Metabolite levels (5-HIAA/ MHPG Ratio)
chr18	11759432	11759433	rs9947295	8e-06	QT interval (interaction)
chr18	23664072	23664073	rs1788776	8e-06	Amyotrophic lateral sclerosis (sporadic)
chr19	58259516	58259517	rs260461	8e-06	Attention deficit hyperactivity disorder
chr18	24556604	24556605	rs12954803 	8e-06	Response to taxane treatment (docetaxel)
chr18	28346094	28346095	rs11083271	8e-06	Non-alcoholic fatty liver disease histology (lobular)
chr1	83921948	83921949	rs10465746	8e-06	Obesity-related traits
chr18	39585340	39585341	rs7226835	8e-06	Obesity-related traits
chr18	42708327	42708328	rs8085804	8e-06	Cognitive performance
chr1	84403277	84403278	rs604708	8e-06	IgG glycosylation
chr18	44510701	44510702	rs2048485	8e-06	Schizophrenia
chr18	48714339	48714340	rs9947954	8e-06	IgG glycosylation
chr18	52759027	52759028	rs768048	8e-06	Alcoholism (alcohol use disorder factor score)
chr18	28120826	28120827	rs11564386	8e-06	Obesity-related traits
chr19	6475601	6475602	rs3745571	8e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide)
chr20	15196933	15196934	rs199307	8e-06	Obesity-related traits
chr20	17387896	17387897	rs6044777	8e-06	Biochemical measures
chr2	129276752	129276753	rs7567687	8e-06	Periodontitis (PAL4Q3)
chr21	30013924	30013925	rs9305406	8e-06	Response to statin therapy
chr21	31923800	31923801	rs11910494	8e-06	IgG glycosylation
chr2	132989056	132989057	rs1437898	8e-06	Multiple sclerosis (age of onset)
chr21	35316229	35316230	rs2834902	8e-06	Corneal curvature
chr21	36429135	36429136	rs2835345	8e-06	Pulmonary function
chr2	137011131	137011132	rs979976	8e-06	Corneal astigmatism
chr2	138641783	138641784	rs58938945	8e-06	Metabolite levels (MHPG)
chr2	129276438	129276439	rs837841	8e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel)
chr2	138914384	138914385	rs9636231	8e-06	Alcohol dependence
chr21	43016066	43016067	rs2839619	8e-06	Biochemical measures
chr2	143932549	143932550	rs1011397	8e-06	Obesity-related traits
chr2	145335187	145335188	rs13407123	8e-06	Attention deficit hyperactivity disorder (inattention symptoms)
chr2	145347685	145347686	rs10445672	8e-06	Obesity-related traits
chr2	149008735	149008736	rs6435387	8e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr2	149540703	149540704	rs7578361	8e-06	Acute lymphoblastic leukemia (childhood)
chr13	74156254	74156255	rs8000245	8e-06	Optic disc size (rim)
chr2	152580055	152580056	rs11675841	8e-06	IgG glycosylation
chr21	43016066	43016067	rs2839619	8e-06	Biochemical measures
chr17	61590591	61590592	rs17610181	8e-06	Osteoarthritis (hip)
chr21	29222210	29222211	rs2832270	8e-06	Response to mTOR inhibitor (everolimus)
chr2	124534259	124534260	rs13021885	8e-06	IgG glycosylation
chr20	20653461	20653462	rs6132333	8e-06	IgG glycosylation
chr20	24077770	24077771	rs6049375	8e-06	Erectile dysfunction and prostate cancer treatment
chr20	25286263	25286264	rs139672965	8e-06	Serum dimethylarginine levels (asymmetric)
chr20	2537918	2537919	rs6049839	8e-06	Systemic lupus erythematosus
chr20	3846661	3846662	rs4815617	8e-06	Asthma
chr20	41435918	41435919	rs13037749	8e-06	Hippocampal atrophy
chr20	44413723	44413724	rs1800961	8e-06	C-reactive protein
chr20	49403280	49403281	rs6063399	8e-06	Obesity-related traits
chr21	28102876	28102877	rs9305354	8e-06	Urinary albumin excretion
chr20	52967443	52967444	rs10485813	8e-06	Attention deficit hyperactivity disorder
chr20	5859892	5859893	rs4815868	8e-06	Information processing speed
chr20	9798080	9798081	rs6056891	8e-06	Obesity-related traits
chr2	104542179	104542180	rs17624523 	8e-06	Response to taxane treatment (docetaxel)
chr2	111618385	111618386	rs1448190	8e-06	Obesity-related traits
chr21	19164330	19164331	rs2825388	8e-06	Attention deficit hyperactivity disorder symptoms (interaction)
chr21	22259355	22259356	rs2827312	8e-06	Alcoholism (heaviness of drinking)
chr21	22826493	22826494	rs7279441	8e-06	Self-rated health
chr2	124499158	124499159	rs11899928	8e-06	IgG glycosylation
chr20	55551450	55551451	rs11696973	8e-06	Migraine without aura
chr1	76018328	76018329	rs12753569	8e-06	Personality dimensions
chr2	137118304	137118305	rs1469622	8e-06	Tooth agenesis (third molar)
chr17	58506843	58506844	rs2302189	8e-06	Dental caries
chr14	78308962	78308963	rs7155434	8e-06	Brain structure (temporal lobe volume)
chr14	92505817	92505818	rs4904947	8e-06	Dialysis-related mortality
chr14	92757644	92757645	rs7160685	8e-06	IgG glycosylation
chr14	95381956	95381957	rs12432260	8e-06	Obesity-related traits
chr14	95560815	95560816	rs8005962	8e-06	Tuberculosis
chr14	96879468	96879469	rs4905558	8e-06	Neutrophil count
chr14	98773978	98773979	rs11623713	8e-06	Obesity-related traits
chr15	29596191	29596192	rs1471225	8e-06	Inattentive symptoms
chr15	33201019	33201020	rs6494964	8e-06	IgG glycosylation
chr15	33212865	33212866	rs974379	8e-06	Major depressive disorder
chr1	53512445	53512446	rs6588480	8e-06	Response to statin therapy
chr15	39284358	39284359	rs746265	8e-06	PR interval
chr15	45642670	45642671	rs607541	8e-06	Obesity-related traits
chr15	47600100	47600101	rs1898111	8e-06	Eating disorders
chr15	48305316	48305317	rs964611	8e-06	Metabolite levels (Pyroglutamine)
chr15	51221531	51221532	rs6493487	8e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr15	58382469	58382470	rs539901	8e-06	Non-small cell lung cancer
chr14	76346147	76346148	rs2360997	8e-06	Attention deficit hyperactivity disorder symptoms (interaction)
chr14	74860739	74860740	rs722599	8e-06	IgG glycosylation
chr14	71199579	71199580	rs17767225	8e-06	Alzheimer's disease (late onset)
chr14	70050465	70050466	rs12883884	8e-06	Cystic fibrosis severity
chr13	85091743	85091744	rs17079247	8e-06	Bipolar disorder (mania)
chr17	6004122	6004123	rs9303196	8e-06	Non-small cell lung cancer
chr1	38136400	38136401	rs7547921	8e-06	Visceral adipose tissue/subcutaneous adipose tissue ratio
chr13	94853007	94853008	rs11070098	8e-06	Obesity-related traits
chr1	39667122	39667123	rs873917	8e-06	Amyotrophic lateral sclerosis
chr14	100676552	100676553	rs730570	8e-06	Type 2 diabetes
chr14	101212917	101212918	rs6575836	8e-06	Tuberculosis
chr14	104883050	104883051	rs2028414	8e-06	IgG glycosylation
chr15	61037588	61037589	rs809736	8e-06	Response to citalopram treatment
chr14	21767649	21767650	rs718433	8e-06	Intraocular pressure
chr14	29618931	29618932	rs12431702	8e-06	IgG glycosylation
chr14	36530843	36530844	rs17104630	8e-06	Height
chr14	51610370	51610371	rs1006973	8e-06	Anticoagulant levels
chr14	55951400	55951401	rs10151037	8e-06	Obesity-related traits
chr14	57734006	57734007	rs1092015	8e-06	Bipolar disorder and schizophrenia
chr14	57918646	57918647	rs1335515	8e-06	Attention deficit hyperactivity disorder (time to onset)
chr14	65821191	65821192	rs7494064	8e-06	Obesity-related traits
chr1	46819250	46819251	rs12059860	8e-06	Testosterone levels
chr1	4255143	4255144	rs966321	8e-06	Factor VII
chr15	62121814	62121815	rs1436953	8e-06	Type 2 diabetes
chr14	104042738	104042739	rs11622475	8e-06	Bipolar disorder
chr15	74424267	74424268	rs8036030	8e-06	Airflow obstruction 
chr16	86347577	86347578	rs11641231	8e-06	Response to statin therapy
chr16	87078023	87078024	rs12933233	8e-06	Alzheimer's disease (age of onset)
chr16	88462371	88462372	rs904790	8e-06	Follicule stimulating hormone
chr16	88901028	88901029	rs533581	8e-06	Social autistic-like traits
chr1	69113568	69113569	rs4147141	8e-06	Inattentive symptoms
chr17	10664165	10664166	rs169313	8e-06	Relative hand skill in reading disability
chr17	13830488	13830489	rs12949531	8e-06	Systemic lupus erythematosus
chr17	15428199	15428200	rs2906966	8e-06	Pulmonary function
chr1	68461829	68461830	rs435066	8e-06	IgG glycosylation
chr17	18850556	18850557	rs4924935	8e-06	Pancreatic cancer
chr1	73873483	73873484	rs11210359	8e-06	Bipolar disorder and schizophrenia
chr17	39766005	39766006	rs907092	8e-06	Primary biliary cirrhosis
chr17	57670054	57670055	rs11079321	8e-06	Coronary artery calcification
chr17	47757911	47757912	rs11651000	8e-06	IgG glycosylation
chr17	47757911	47757912	rs11651000	8e-06	IgG glycosylation
chr17	58370935	58370936	rs2257205	8e-06	Pancreatic cancer
chr17	53160579	53160580	rs8073783	8e-06	Conduct disorder (interaction)
chr15	69714533	69714534	rs4776472	8e-06	Atrial fibrillation
chr17	37738048	37738049	rs4430796	8e-06	Prostate cancer
chr16	83325170	83325171	rs6563898	8e-06	IgE levels in asthmatics (D.f. specific) 
chr17	40890628	40890629	rs2315504	8e-06	Height
chr15	96104563	96104564	rs4984499	8e-06	Migraine
chr15	92142547	92142548	rs2238355	8e-06	Obesity-related traits
chr15	89073849	89073850	rs420017	8e-06	Obesity-related traits
chr1	58570952	58570953	rs638065	8e-06	Word reading
chr1	61914625	61914626	rs1056513	8e-06	Obesity-related traits
chr16	20078431	20078432	rs10521114	8e-06	Attention deficit hyperactivity disorder (inattention symptoms)
chr16	20079322	20079323	rs10521115	8e-06	Attention deficit hyperactivity disorder (inattention symptoms)
chr1	62652524	62652525	rs10889353	8e-06	LDL cholesterol
chr16	61744190	61744191	rs8048207	8e-06	Non-small cell lung cancer
chr16	67877613	67877614	rs8060686	8e-06	Coronary heart disease
chr16	56990404	56990405	rs17290922	8e-06	Schizophrenia
chr16	70471455	70471456	rs11861805	8e-06	Obesity-related traits
chr16	70880080	70880081	rs12149070	8e-06	Chronic obstructive pulmonary disease-related biomarkers
chr16	74944719	74944720	rs2042415	8e-06	Obesity-related traits
chr16	74944719	74944720	rs2042415	8e-06	Obesity-related traits
chr16	75957547	75957548	rs1948632	8e-06	Tuberculosis
chr16	79039523	79039524	rs17713676	8e-06	Response to amphetamines
chr16	82609045	82609046	rs11646213	8e-06	Hypertension
chr16	82631227	82631228	rs139419280	8e-06	Serum dimethylarginine levels (symmetric)
chr16	83292453	83292454	rs11644424	8e-06	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU)
chr4	119266455	119266456	rs11098499	9e-06	Corneal astigmatism
chr3	7941139	7941140	rs4591494	9e-06	Factor VII
chr4	105347436	105347437	rs2647264	9e-06	Immune response to anthrax vaccine 
chr4	109806403	109806404	rs4698790	9e-06	Fasting insulin (interaction)
chr4	109904477	109904478	rs17316633	9e-06	Hair morphology
chr3	72468888	72468889	rs9832314	9e-06	IgG glycosylation
chr3	169198451	169198452	rs9864370	9e-06	Multiple myeloma (hyperdiploidy)
chr4	125510763	125510764	rs950063	9e-06	Smoking behavior
chr4	127399752	127399753	rs1443170	9e-06	Obesity-related traits
chr4	130105332	130105333	rs114646238	9e-06	Metabolite levels (HVA/MHPG ratio)
chr4	13912748	13912749	rs10805321	9e-06	Response to antipsychotic therapy (extrapyramidal side effects)
chr4	147691336	147691337	rs11731298	9e-06	Obesity-related traits
chr4	151986547	151986548	rs360929	9e-06	Volumetric brain MRI
chr4	152972201	152972202	rs11099864	9e-06	Amyotrophic lateral sclerosis
chr4	153453831	153453832	rs6817170	9e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs)
chr4	121744358	121744359	rs7659604	9e-06	Type 2 diabetes
chr3	71415183	71415184	rs13063872	9e-06	Migraine - clinic-based
chr3	36801131	36801132	rs13072940	9e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr3	64188224	64188225	rs1035275	9e-06	IgG glycosylation
chr3	174311254	174311255	rs13074924	9e-06	Major depressive disorder
chr3	185424068	185424069	rs7629245	9e-06	Airflow obstruction 
chr3	185904040	185904041	rs6444087	9e-06	Smoking behavior
chr3	188045609	188045610	rs6789987	9e-06	Visceral adipose tissue adjusted for BMI
chr3	188571908	188571909	rs10937355	9e-06	Obesity-related traits
chr3	191283018	191283019	rs10937470	9e-06	Total ventricular volume
chr3	6968393	6968394	rs480409	9e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors)
chr3	20573780	20573781	rs1395103	9e-06	Bipolar disorder and schizophrenia
chr3	33971712	33971713	rs7620363	9e-06	Non-substance related behavioral disinhibition
chr3	36822997	36822998	rs6550435	9e-06	Bipolar disorder
chr3	39967142	39967143	rs9985399	9e-06	Information processing speed
chr3	41082243	41082244	rs10490823	9e-06	Bone mineral density (hip)
chr3	43256196	43256197	rs6767019	9e-06	Obesity-related traits
chr3	46410188	46410189	rs1015164	9e-06	AIDS progression
chr3	29167659	29167660	rs6549915	9e-06	Breast size
chr4	154074310	154074311	rs2404916	9e-06	Obesity-related traits
chr4	66435323	66435324	rs1949200	9e-06	Sleep quality
chr4	163611648	163611649	rs3792615	9e-06	Type 2 diabetes
chr4	88499934	88499935	rs10516809	9e-06	Pulmonary function decline
chr4	94693126	94693127	rs17022027	9e-06	Visceral fat
chr4	99090019	99090020	rs13132688	9e-06	Obesity-related traits
chr5	106083811	106083812	rs6894797	9e-06	Obesity-related traits
chr5	125983762	125983763	rs1073203	9e-06	Diabetic retinopathy 
chr5	126002781	126002782	rs13169113	9e-06	Cognitive performance
chr5	127386160	127386161	rs10519937	9e-06	IgG glycosylation
chr5	128317329	128317330	rs10057405	9e-06	Temperament
chr5	128380873	128380874	rs17608902	9e-06	Migraine with aura
chr5	129387002	129387003	rs10077875	9e-06	Obesity-related traits
chr5	137567006	137567007	rs1541364	9e-06	Bronchopulmonary dysplasia
chr5	13779633	13779634	rs1502050	9e-06	Subclinical atherosclerosis traits (other)
chr3	16150635	16150636	rs6771632	9e-06	Lung function (forced expiratory flow between 25% and 75% of forced vital capacity)
chr5	148223503	148223504	rs1368304	9e-06	IgG glycosylation
chr5	149326735	149326736	rs10044242	9e-06	Obesity-related traits
chr4	83800660	83800661	rs4693646	9e-06	Obesity-related traits
chr4	77034051	77034052	rs17002342	9e-06	Waist-to-hip circumference ratio (interaction)
chr4	7422023	7422024	rs7694661	9e-06	Obesity-related traits
chr4	58438965	58438966	rs1869463	9e-06	Corneal curvature
chr4	164957182	164957183	rs3733418	9e-06	Obesity-related traits
chr4	173734762	173734763	rs4521323	9e-06	Multiple myeloma (IgH translocation)
chr4	179363659	179363660	rs6811556	9e-06	Ulcerative colitis
chr4	182379460	182379461	rs4862046	9e-06	IgG glycosylation
chr4	188665924	188665925	rs7659062	9e-06	Cognitive performance
chr4	188669704	188669705	rs7662358	9e-06	Cognitive performance
chr4	189202163	189202164	rs7665939	9e-06	Amyotrophic lateral sclerosis
chr4	16000664	16000665	rs17478107	9e-06	Self-rated health
chr4	21509759	21509760	rs16871289	9e-06	Obesity-related traits
chr4	2393569	2393570	rs959770	9e-06	Schizophrenia
chr4	25415621	25415622	rs3816587	9e-06	Rheumatoid arthritis
chr4	38790902	38790903	rs4543123	9e-06	Alcohol consumption
chr4	41282693	41282694	rs4861096	9e-06	Cognitive performance
chr4	43318489	43318490	rs2006970	9e-06	Metabolite levels (5-HIAA/ MHPG Ratio)
chr4	44210147	44210148	rs17641529	9e-06	Response to amphetamines
chr4	55601046	55601047	rs13434995	9e-06	Adiponectin levels
chr4	21569463	21569464	rs1604805	9e-06	Obesity-related traits
chr3	161059175	161059176	rs9290065	9e-06	Kawasaki disease
chr22	34545583	34545584	rs4821261	9e-06	Behavioural disinhibition (generation interaction)
chr3	142712157	142712158	rs3773506	9e-06	Type 2 diabetes
chr2	182820834	182820835	rs10931041	9e-06	Waist-to-hip circumference ratio (interaction)
chr2	18359377	18359378	rs7580332	9e-06	Amyotrophic lateral sclerosis
chr2	187478769	187478770	rs7586970	9e-06	Coronary heart disease
chr2	191253320	191253321	rs1823913	9e-06	Obesity-related traits
chr2	191600871	191600872	rs6706693	9e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (5-fluorouracil)
chr2	206257057	206257058	rs2058710	9e-06	Bipolar disorder and schizophrenia
chr2	206975607	206975608	rs4675644	9e-06	Pulmonary function decline
chr2	210630862	210630863	rs12468557	9e-06	Body mass index (asthmatics)
chr2	217041108	217041109	rs13387042	9e-06	Breast cancer
chr22	17800480	17800481	rs5992105	9e-06	Lung function (forced expiratory flow between 25% and 75% of forced vital capacity)
chr22	25479297	25479298	rs1930961	9e-06	Bipolar disorder (mood-incongruent)
chr22	26615455	26615456	rs4822752	9e-06	Bipolar disorder and schizophrenia
chr2	227227318	227227319	rs35212277	9e-06	Metabolite levels (5-HIAA/ MHPG Ratio)
chr22	30355637	30355638	rs4820834	9e-06	Coronary artery calcification
chr2	233364595	233364596	rs838705	9e-06	Calcium levels
chr2	181647128	181647129	rs1441147	9e-06	Lung function (forced vital capacity)
chr2	17427971	17427972	rs12185578	9e-06	Subcutaneous adipose tissue
chr2	17246317	17246318	rs11889338	9e-06	Alzheimer's disease
chr2	169276575	169276576	rs830998	9e-06	Anorexia nervosa
chr2	123757464	123757465	rs13006237	9e-06	Attention deficit hyperactivity disorder (inattention symptoms)
chr5	151215240	151215241	rs979455	9e-06	Obesity-related traits
chr2	124225478	124225479	rs1170612	9e-06	Schizophrenia
chr2	124499158	124499159	rs11899928	9e-06	IgG glycosylation
chr2	127418463	127418464	rs1799810	9e-06	Self-rated health
chr21	30843933	30843934	rs7283316	9e-06	Information processing speed
chr21	32997452	32997453	rs117124364	9e-06	Bulimia nervosa
chr2	233905413	233905414	rs10187654	9e-06	Pulmonary function decline
chr2	136581369	136581370	rs934299	9e-06	Cognitive test performance
chr2	140984020	140984021	rs4954683	9e-06	IgG glycosylation
chr21	42093369	42093370	rs1475911	9e-06	IgG glycosylation
chr21	46599954	46599955	rs881827	9e-06	Lymphocyte counts
chr2	150269888	150269889	rs6716455	9e-06	Alcoholism (alcohol dependence factor score)
chr2	156068773	156068774	rs16839962	9e-06	Response to statin therapy
chr2	15786043	15786044	rs2544527	9e-06	Pulmonary function
chr2	160524376	160524377	rs10192369	9e-06	Amyotrophic lateral sclerosis
chr21	39751373	39751374	rs1735151	9e-06	Coronary heart disease
chr3	155549650	155549651	rs3851357	9e-06	IgG glycosylation
chr2	234991526	234991527	rs11676855	9e-06	Dialysis-related mortality
chr22	36914003	36914004	rs2075726	9e-06	Ankylosing spondylitis
chr2	5297409	5297410	rs13004938	9e-06	Obesity-related traits
chr2	59055455	59055456	rs991964	9e-06	Uterine fibroids
chr2	69496577	69496578	rs7577851	9e-06	Parkinson's disease (age of onset)
chr2	70836811	70836812	rs4852708	9e-06	IgG glycosylation
chr2	76532448	76532449	rs74529274	9e-06	Response to amphetamines
chr2	9109908	9109909	rs1109670	9e-06	Multiple sclerosis
chr3	103731746	103731747	rs2677247	9e-06	IgG glycosylation
chr3	11634314	11634315	rs6782029	9e-06	Anorexia nervosa
chr3	11652992	11652993	rs4684792	9e-06	Relative hand skill in reading disability
chr3	117437407	117437408	rs9870146	9e-06	Obesity-related traits
chr3	119027088	119027089	rs2160050	9e-06	Response to amphetamines
chr3	1303740	1303741	rs9861887	9e-06	Visceral adipose tissue/subcutaneous adipose tissue ratio
chr3	13816471	13816472	rs1124480	9e-06	Chronic obstructive pulmonary disease-related biomarkers
chr3	139197550	139197551	rs11706018	9e-06	IgG glycosylation
chr3	139354168	139354169	rs1044826	9e-06	Obesity-related traits
chr2	50517635	50517636	rs10176705	9e-06	Personality dimensions
chr2	49728358	49728359	rs17039212	9e-06	Systemic lupus erythematosus
chr2	46093954	46093955	rs12373805	9e-06	Suicide risk
chr2	43908174	43908175	rs13387221	9e-06	Intelligence (childhood)
chr22	37074183	37074184	rs2413450	9e-06	Red blood cell traits
chr22	37185381	37185382	rs229526	9e-06	Hypothyroidism
chr22	39123190	39123191	rs139371	9e-06	Multiple myeloma (IgH translocation)
chr22	39463163	39463164	rs909674	9e-06	IgG glycosylation
chr22	39463163	39463164	rs909674	9e-06	IgG glycosylation
chr22	43852623	43852624	rs470089	9e-06	Type 2 diabetes (dietary heme iron intake interaction)
chr22	50118977	50118978	rs138229	9e-06	Behavioural disinhibition (generation interaction)
chr22	36283011	36283012	rs735854	9e-06	Optic disc size (rim)
chr22	50538324	50538325	rs131788	9e-06	Obesity-related traits
chr23	132890475	132890476	rs7892161	9e-06	Periodontitis (Mean PAL)
chr23	147241104	147241105	rs5904726	9e-06	Coronary heart disease
chr23	152487089	152487090	rs10856240	9e-06	Cognitive performance
chr23	37995473	37995474	rs872690	9e-06	Erectile dysfunction and prostate cancer treatment
chr2	37240120	37240121	rs2041840	9e-06	Chronic lymphocytic leukemia
chr2	38874066	38874067	rs12479213	9e-06	Obesity-related traits
chr2	38937	38938	rs11542478	9e-06	Information processing speed
chr23	122833505	122833506	rs4559365	9e-06	Metabolite levels (MHPG)
chr5	153599993	153599994	rs12658202	9e-06	Anthropometric traits
chr7	63886507	63886508	rs13437751	9e-06	QT interval (interaction)
chr5	156755036	156755037	rs11135380	9e-06	Lung function (forced expiratory flow between 25% and 75% of forced vital capacity)
chr8	135976960	135976961	rs16905439	9e-06	Insomnia (caffeine-induced)
chr8	138289134	138289135	rs10875423	9e-06	Periodontitis (PAL4Q3)
chr8	138872265	138872266	rs6988229	9e-06	Asthma (bronchodilator response)
chr8	141290215	141290216	rs7827290	9e-06	Bipolar disorder
chr8	141939369	141939370	rs7845056	9e-06	IgG glycosylation
chr8	142610476	142610477	rs7465272	9e-06	Bipolar disorder and schizophrenia
chr8	143575429	143575430	rs2290416	9e-06	Attention deficit hyperactivity disorder
chr8	19986710	19986711	rs12678919	9e-06	Hematological and biochemical traits
chr8	28324237	28324238	rs11779594	9e-06	IgG glycosylation
chr8	31936592	31936593	rs1462872	9e-06	Coronary artery calcification
chr8	3231240	3231241	rs1540507	9e-06	Periodontitis (CDC/AAP)
chr8	3737383	3737384	rs2623702	9e-06	Pulmonary function decline
chr8	40395181	40395182	rs11786458	9e-06	Inattentive symptoms
chr8	40626719	40626720	rs2722425	9e-06	Fasting plasma glucose
chr8	4425095	4425096	rs980238	9e-06	Disc degeneration (lumbar)
chr8	12953642	12953643	rs2946505	9e-06	Migraine
chr8	5604230	5604231	rs4875598	9e-06	Attention deficit hyperactivity disorder symptoms (interaction)
chr8	127401059	127401060	rs6983267	9e-06	Prostate cancer
chr8	121897447	121897448	rs956225	9e-06	Alzheimer's disease
chr7	29922907	29922908	rs17158483	9e-06	Obesity-related traits
chr7	35567622	35567623	rs6973609	9e-06	Obesity-related traits
chr7	42136682	42136683	rs2049622	9e-06	Age-related macular degeneration
chr7	45942860	45942861	rs2462686	9e-06	Major depressive disorder
chr7	50185794	50185795	rs7805803	9e-06	Total ventricular volume
chr7	84153522	84153523	rs17158675	9e-06	Obesity-related traits
chr7	88931563	88931564	rs1406503	9e-06	Body mass index
chr7	8959345	8959346	rs17157663	9e-06	Quantitative traits
chr7	96952498	96952499	rs17598306	9e-06	Radiation response
chr8	100317980	100317981	rs1371867	9e-06	Atrioventricular conduction
chr8	115318625	115318626	rs6983039	9e-06	IgG glycosylation
chr8	115381845	115381846	rs17658378	9e-06	Attention deficit hyperactivity disorder (time to onset)
chr8	11622947	11622948	rs2243407	9e-06	Periodontitis (CDC/AAP)
chr8	119212565	119212566	rs1364705	9e-06	Hippocampal atrophy
chr8	120623155	120623156	rs6986718	9e-06	Bipolar disorder and schizophrenia
chr8	123684626	123684627	rs2294015	9e-06	Event-related brain oscillations
chr8	56401346	56401347	rs12545109	9e-06	Obesity-related traits
chr8	59710788	59710789	rs12541902	9e-06	Obesity-related traits
chr8	68476981	68476982	rs1517114	9e-06	Response to irinotecan in non-small-cell lung cancer
chr9	25501298	25501299	rs2210430	9e-06	Sleep quality
chr9	27882654	27882655	rs7029145	9e-06	Immunoglobulin A 
chr9	28181086	28181087	rs1319535	9e-06	IgG glycosylation
chr9	2838469	2838470	rs10968457	9e-06	Obesity-related traits
chr9	28587995	28587996	rs2891316	9e-06	Endometrial cancer
chr9	32870069	32870070	rs10971170	9e-06	IgG glycosylation
chr9	35141707	35141708	rs10972341	9e-06	Weight
chr9	565916	565917	rs7027930	9e-06	Pulmonary function decline
chr9	74534920	74534921	rs7042950	9e-06	Visceral adipose tissue/subcutaneous adipose tissue ratio
chr9	7558260	7558261	rs4400445	9e-06	Obesity-related traits
chr9	7734249	7734250	rs10758892	9e-06	Myopia (pathological)
chr9	81598244	81598245	rs2777777	9e-06	Visceral adipose tissue adjusted for BMI
chr9	84571489	84571490	rs4877280	9e-06	Waist-to-hip circumference ratio (interaction)
chr9	96335244	96335245	rs6479272	9e-06	Non-small cell lung cancer
chr2	122884034	122884035	rs17367118	9e-06	Attention deficit hyperactivity disorder
chr9	21035307	21035308	rs7867456	9e-06	Axial length
chr9	19213635	19213636	rs141215807	9e-06	Metabolite levels (HVA)
chr9	18458069	18458070	rs1340043	9e-06	Obesity-related traits
chr9	18444139	18444140	rs6475216	9e-06	Obesity-related traits
chr8	73555268	73555269	rs4342585	9e-06	Axial length
chr8	80445466	80445467	rs400824	9e-06	Migraine - clinic-based
chr8	82016362	82016363	rs7820074	9e-06	Orofacial clefts
chr8	98117278	98117279	rs2071598	9e-06	Prion diseases
chr9	10260262	10260263	rs2475335	9e-06	Partial epilepsies
chr9	103607661	103607662	rs144649413	9e-06	Metabolite levels (MHPG)
chr9	104826495	104826496	rs4149311	9e-06	Myopia (pathological)
chr7	27964578	27964579	rs4722750	9e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr9	104894788	104894789	rs3905000	9e-06	MRI atrophy measures
chr9	121713733	121713734	rs35061590	9e-06	Heart rate
chr9	123589938	123589939	rs7852296	9e-06	Personality dimensions
chr9	126068817	126068818	rs4838320	9e-06	Economic and political preferences (immigration/crime)
chr9	132469019	132469020	rs569434	9e-06	Obesity-related traits
chr9	14446002	14446003	rs1556032	9e-06	AIDS
chr9	16970810	16970811	rs4961511	9e-06	Corneal astigmatism
chr9	17487946	17487947	rs2383024	9e-06	Pulmonary function decline
chr9	114498553	114498554	rs10982256	9e-06	Bipolar disorder
chr5	155875571	155875572	rs1432723	9e-06	Obesity-related traits
chr7	20954871	20954872	rs12155172	9e-06	Prostate cancer
chr7	20216081	20216082	rs3095008	9e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide)
chr5	92818871	92818872	rs17668565	9e-06	Obesity-related traits
chr5	93151836	93151837	rs13173682	9e-06	Obesity-related traits
chr5	99257748	99257749	rs1500251	9e-06	Periodontitis (Mean PAL)
chr5	9978971	9978972	rs553169	9e-06	Age-related macular degeneration (smoking status interaction)
chr6	106539494	106539495	rs783396	9e-06	Stroke
chr6	10921297	10921298	rs190994806	9e-06	Serum dimethylarginine levels (asymmetric/symetric ratio)
chr6	126446453	126446454	rs1361108	9e-06	Height
chr6	132321977	132321978	rs589756	9e-06	Obesity-related traits
chr6	133546663	133546664	rs9375969	9e-06	Visceral fat
chr6	137352164	137352165	rs6928289	9e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr6	139338874	139338875	rs11155053	9e-06	Obesity-related traits
chr6	149008130	149008131	rs2500535	9e-06	Response to antidepressants
chr6	152470338	152470339	rs7747960	9e-06	Bipolar disorder
chr6	164479564	164479565	rs4709845	9e-06	Major depressive disorder
chr6	1918027	1918028	rs3800131	9e-06	Obesity-related traits
chr5	90914006	90914007	rs10074525	9e-06	Obesity-related traits
chr6	20155942	20155943	rs1202199	9e-06	Hyperactive-impulsive symptoms
chr5	86878329	86878330	rs1493354	9e-06	Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule)
chr5	65051793	65051794	rs266590	9e-06	Obesity-related traits
chr5	159395636	159395637	rs6887695	9e-06	Crohn's disease
chr5	159477304	159477305	rs12657996 	9e-06	Response to taxane treatment (placlitaxel)
chr5	170034542	170034543	rs3763048	9e-06	IgG glycosylation
chr5	170523389	170523390	rs11957313	9e-06	Normalized brain volume
chr5	172132526	172132527	rs17570583	9e-06	Migraine - clinic-based
chr5	173507894	173507895	rs7722022	9e-06	Adiponectin levels
chr5	179272309	179272310	rs901254	9e-06	Visceral adipose tissue adjusted for BMI
chr5	34951044	34951045	rs37439	9e-06	Response to angiotensin II receptor blocker therapy
chr5	36473134	36473135	rs2937550	9e-06	IgG glycosylation
chr5	45197676	45197677	rs10941694	9e-06	Chronic kidney disease and serum creatinine levels
chr5	45285615	45285616	rs981782	9e-06	Breast cancer
chr5	51632975	51632976	rs4865673	9e-06	Dental caries
chr5	53256408	53256409	rs27323	9e-06	IgG glycosylation
chr5	58786895	58786896	rs10065350	9e-06	IgG glycosylation
chr5	61729254	61729255	rs4699982	9e-06	IgG glycosylation
chr5	71539064	71539065	rs35131626	9e-06	Obesity-related traits
chr6	20652485	20652486	rs9295474	9e-06	Type 2 diabetes
chr6	22743173	22743174	rs10498712	9e-06	Quantitative traits
chr6	24749184	24749185	rs17419851	9e-06	Neutrophil count
chr7	107843991	107843992	rs4730276	9e-06	Ulcerative colitis
chr7	109512653	109512654	rs10953615	9e-06	Gallbladder cancer
chr7	112446277	112446278	rs17159640	9e-06	Mortality in heart failure
chr7	126797842	126797843	rs11971186	9e-06	Chemerin levels
chr7	129383755	129383756	rs7787531	9e-06	Tuberculosis
chr7	132028600	132028601	rs17166082	9e-06	Self-employment
chr7	138364641	138364642	rs357394	9e-06	Pulmonary function
chr7	138472644	138472645	rs1874326	9e-06	Quantitative traits
chr7	139858147	139858148	rs194151	9e-06	Obesity-related traits
chr7	145144437	145144438	rs10487524	9e-06	Attention deficit hyperactivity disorder
chr7	146438845	146438846	rs1358075	9e-06	Obesity-related traits
chr7	147200310	147200311	rs10273775	9e-06	Alzheimer's disease
chr7	147529798	147529799	rs6464816	9e-06	Visceral adipose tissue/subcutaneous adipose tissue ratio
chr7	152972754	152972755	rs11981919	9e-06	Obesity-related traits
chr7	16460516	16460517	rs10270805	9e-06	Response to statin therapy
chr7	107695612	107695613	rs2188561	9e-06	Alcohol consumption
chr6	98580989	98580990	rs1383808	9e-06	Obesity-related traits
chr6	98563624	98563625	rs2086512	9e-06	Cytomegalovirus antibody response
chr6	98471387	98471388	rs9491640	9e-06	Brain imaging in schizophrenia (interaction)
chr6	2500585	2500586	rs4959677	9e-06	Orthostatic hypotension
chr6	25640971	25640972	rs932316	9e-06	Iron status biomarkers
chr6	29639268	29639269	rs3095267	9e-06	Migraine without aura
chr6	31605178	31605179	rs2844479	9e-06	IgG glycosylation
chr6	31962663	31962664	rs592229	9e-06	IgG glycosylation
chr6	33004626	33004627	rs3128935	9e-06	Periodontitis (CDC/AAP)
chr6	33522104	33522105	rs9469457	9e-06	Obesity-related traits
chr7	20845475	20845476	rs13245023	9e-06	IgG glycosylation
chr6	43186048	43186049	rs61743561	9e-06	Obesity-related traits
chr6	51091007	51091008	rs283566	9e-06	Electrocardiographic conduction measures
chr6	74161514	74161515	rs6912405	9e-06	Obesity-related traits
chr6	7652483	7652484	rs7739678	9e-06	Obesity-related traits
chr6	858969	858970	rs1572438	9e-06	Aging
chr6	88266257	88266258	rs16880441	9e-06	Conduct disorder (interaction)
chr6	89930771	89930772	rs2289577	9e-06	Cognitive performance
chr6	90305319	90305320	rs12529935	9e-06	Systemic lupus erythematosus
chr6	44097573	44097574	rs7742824	9e-06	Major depressive disorder
chr2	121054647	121054648	rs4848143	9e-06	Capecitabine sensitivity
chr13	105936791	105936792	rs7336109	9e-06	Visceral fat
chr21	18109035	18109036	rs2055011	9e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs)
chr12	124014994	124014995	rs1048497	9e-06	Visceral adipose tissue adjusted for BMI
chr12	124409637	124409638	rs12582168	9e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs)
chr12	127329195	127329196	rs10744304	9e-06	Depression (quantitative trait)
chr12	128991393	128991394	rs643473	9e-06	Aging
chr12	129152802	129152803	rs12824981	9e-06	Heart rate
chr12	13299845	13299846	rs899435	9e-06	Coronary artery calcification
chr12	13476446	13476447	rs1531228	9e-06	Barrett's esophagus
chr1	21511261	21511262	rs16825455	9e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs)
chr1	217027540	217027541	rs2377360	9e-06	Major depressive disorder
chr12	19911033	19911034	rs10841397	9e-06	Response to amphetamines
chr1	22173036	22173037	rs17360053	9e-06	Obesity-related traits
chr1	231708600	231708601	rs12044355	9e-06	Alzheimer's disease
chr1	231763957	231763958	rs2793086	9e-06	Response to antineoplastic agents
chr12	32864108	32864109	rs1454933	9e-06	Obesity-related traits
chr12	3759001	3759002	rs10744625	9e-06	Homeostasis model assessment of insulin resistance (interaction)
chr1	212218820	212218821	rs6540731	9e-06	Intelligence (childhood)
chr1	240824453	240824454	rs7544372	9e-06	Obesity-related traits
chr12	11405942	11405943	rs71455379	9e-06	Periodontitis (CDC/AAP)
chr12	108483763	108483764	rs918304	9e-06	IgG glycosylation
chr1	180161587	180161588	rs55946907	9e-06	Anorexia nervosa
chr1	180676304	180676305	rs7527074	9e-06	Asthma (childhood onset)
chr1	183883779	183883780	rs10797919	9e-06	Attention deficit hyperactivity disorder and conduct disorder
chr1	185825750	185825751	rs13375391	9e-06	QRS duration
chr11	86072695	86072696	rs621942	9e-06	Tourette syndrome
chr1	186900939	186900940	rs12720541	9e-06	Epilepsy (generalized)
chr1	18879839	18879840	rs28441017	9e-06	Anorexia nervosa
chr11	89157945	89157946	rs10830228	9e-06	Age-related macular degeneration
chr11	92218987	92218988	rs1350445	9e-06	Subclinical atherosclerosis traits (other)
chr1	195821527	195821528	rs6677435	9e-06	Cocaine dependence
chr1	199387387	199387388	rs16844716	9e-06	Dialysis-related mortality
chr11	99622441	99622442	rs10501920	9e-06	Atrial fibrillation
chr1	203523591	203523592	rs13303128	9e-06	Metabolite levels (MHPG)
chr1	205708997	205708998	rs16856186	9e-06	Pulmonary function decline
chr1	207764890	207764891	rs7545126	9e-06	Obesity-related traits
chr12	112721032	112721033	rs7312122	9e-06	Methotrexate phramacokinetics (acute lymphoblastic leukemia)
chr12	40853939	40853940	rs312273	9e-06	Bipolar disorder
chr12	4196716	4196717	rs12827476	9e-06	Obesity-related traits
chr12	4307137	4307138	rs4625554	9e-06	Major depressive disorder
chr13	101493208	101493209	rs1335587	9e-06	Obesity-related traits
chr13	23118838	23118839	rs4770394	9e-06	Bipolar disorder
chr13	27855600	27855601	rs9512900	9e-06	Attention deficit hyperactivity disorder and conduct disorder
chr13	28704312	28704313	rs1305088	9e-06	Non-alcoholic fatty liver disease histology (other)
chr13	35194651	35194652	rs17051917	9e-06	Migraine with aura
chr1	33708219	33708220	rs564148	9e-06	Response to amphetamines
chr13	37789312	37789313	rs9548050	9e-06	Obesity-related traits
chr13	37789312	37789313	rs9548050	9e-06	Obesity-related traits
chr13	37957443	37957444	rs9548119	9e-06	Self-rated health
chr13	43153712	43153713	rs1324015	9e-06	Cognitive performance
chr1	34823437	34823438	rs7526035	9e-06	Formal thought disorder in schizophrenia
chr13	50545000	50545001	rs1239954	9e-06	Obesity-related traits
chr13	50620268	50620269	rs573666	9e-06	Osteosarcoma
chr13	53861101	53861102	rs6561750	9e-06	Bipolar disorder and schizophrenia
chr13	65907682	65907683	rs1585440	9e-06	Pancreatic cancer
chr13	101398738	101398739	rs9557635	9e-06	Non-small cell lung cancer
chr1	30842745	30842746	rs4949316	9e-06	Metabolite levels (5-HIAA)
chr1	30154864	30154865	rs2180233	9e-06	Attention deficit hyperactivity disorder and conduct disorder
chr12	99567570	99567571	rs2373011	9e-06	Body mass index
chr12	4315955	4315956	rs10849033	9e-06	Acute lymphoblastic leukemia (childhood)
chr1	246059817	246059818	rs6693295	9e-06	Migraine - clinic-based
chr12	48009981	48009982	rs11168351	9e-06	Bipolar disorder and schizophrenia
chr1	24946708	24946709	rs7551188	9e-06	Crohn's disease
chr12	53876443	53876444	rs2120991	9e-06	Biliary atresia
chr12	60341391	60341392	rs7974425	9e-06	Obesity-related traits
chr1	26242050	26242051	rs10902723	9e-06	Obesity-related traits
chr11	76754736	76754737	rs147269019	9e-06	Serum dimethylarginine levels (symmetric)
chr12	62424700	62424701	rs10877839	9e-06	IgG glycosylation
chr12	70895775	70895776	rs4760854	9e-06	IgG glycosylation
chr12	72769370	72769371	rs10879490	9e-06	Metabolite levels (Dihydroxy docosatrienoic acid)
chr12	73435175	73435176	rs7963521	9e-06	Chemerin levels
chr12	80943678	80943679	rs1163656	9e-06	Dental caries
chr12	9311209	9311210	rs10771515	9e-06	Obesity-related traits
chr12	94471700	94471701	rs1520724	9e-06	Obesity-related traits
chr12	95633982	95633983	rs17356907	9e-06	Breast cancer
chr12	6326404	6326405	rs10849441	9e-06	Obesity-related traits
chr13	68956531	68956532	rs2066219	9e-06	Diabetes related insulin traits
chr1	165478919	165478920	rs10918196	9e-06	Lentiform nucleus volume 
chr1	162119527	162119528	rs76662883	9e-06	Obesity-related traits
chr10	35771380	35771381	rs11010290	9e-06	Antineutrophil cytoplasmic antibody-associated vasculitis 
chr10	3820349	3820350	rs6601764	9e-06	Crohn's disease
chr10	45058280	45058281	rs12358699	9e-06	Lung function (forced expiratory volume in 1 second to forced vital capacity ratio)
chr10	4674349	4674350	rs2165953	9e-06	Obesity-related traits
chr10	61547716	61547717	rs2787702 	9e-06	Response to taxane treatment (placlitaxel)
chr10	68952305	68952306	rs2017305	9e-06	Depression (quantitative trait)
chr10	78755323	78755324	rs7900239	9e-06	Migraine
chr10	83493924	83493925	rs1414874	9e-06	Self-reported allergy
chr10	83663097	83663098	rs2224865	9e-06	Eosinophilic esophagitis (pediatric)
chr10	89058619	89058620	rs7920888	9e-06	Obesity-related traits
chr10	92705801	92705802	rs5015480	9e-06	Type 2 diabetes
chr10	97877820	97877821	rs531676	9e-06	Metabolic syndrome
chr10	98824157	98824158	rs2801405	9e-06	Obesity-related traits
chr1	102993980	102993981	rs11809524	9e-06	Bone mineral density
chr1	106098320	106098321	rs12408810	9e-06	Obesity (early onset extreme)
chr10	34529059	34529060	rs563507	9e-06	Acute lymphoblastic leukemia (childhood)
chr1	10690374	10690375	rs516243	9e-06	Migraine - clinic-based
chr10	3241814	3241815	rs2764980	9e-06	Attention deficit hyperactivity disorder and conduct disorder
chr10	28216014	28216015	rs11006923	9e-06	Alzheimer's disease
chr10	103273257	103273258	rs1712517	9e-06	Migraine
chr10	11182701	11182702	rs596406	9e-06	Liver enzyme levels (alanine transaminase)
chr10	116816094	116816095	rs740363	9e-06	Heart failure
chr10	123127608	123127609	rs61862032	9e-06	Periodontitis (Mean PAL)
chr10	123447984	123447985	rs17666963	9e-06	Cardiac Troponin-T levels
chr10	124455609	124455610	rs2459210	9e-06	Hemostatic factors and hematological phenotypes
chr10	126140442	126140443	rs1551678	9e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr10	126158099	126158100	rs12778749	9e-06	Endometrial cancer
chr10	12830880	12830881	rs2431623	9e-06	Serum dimethylarginine levels (asymmetric)
chr10	130748996	130748997	rs4750829	9e-06	Obesity-related traits
chr10	132482310	132482311	rs73389468	9e-06	Periodontitis (CDC/AAP)
chr10	15558671	15558672	rs28643277	9e-06	Periodontitis (CDC/AAP)
chr10	18099504	18099505	rs10508558	9e-06	Bipolar disorder and schizophrenia
chr10	22558509	22558510	rs7094131	9e-06	Obesity-related traits
chr10	2382361	2382362	rs12571964	9e-06	Obesity-related traits
chr10	30545702	30545703	rs11008099	9e-06	QT interval
chr1	108850214	108850215	rs1277203	9e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin)
chr1	109499821	109499822	rs1043274	9e-06	Obesity-related traits
chr11	103655025	103655026	rs7118412	9e-06	Disc degeneration (lumbar)
chr11	30486560	30486561	rs545610	9e-06	Dental caries
chr11	35101503	35101504	rs1559759	9e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr11	35473892	35473893	rs1996369	9e-06	Relative hand skill in reading disability
chr11	43214510	43214511	rs12365397	9e-06	Migraine
chr11	45792029	45792030	rs12285276	9e-06	Visceral fat
chr11	47105601	47105602	rs7117404	9e-06	D-dimer levels
chr1	147754659	147754660	rs1891498	9e-06	Cognitive performance
chr11	48185706	48185707	rs11039571	9e-06	D-dimer levels
chr11	48310475	48310476	rs12282928	9e-06	Migraine - clinic-based
chr1	153668350	153668351	rs7536700	9e-06	Multiple myeloma (IgH translocation)
chr1	154781717	154781718	rs6691316	9e-06	Obesity-related traits
chr11	56252448	56252449	rs17150243	9e-06	Obesity-related traits
chr1	156386687	156386688	rs6686886	9e-06	Subcutaneous adipose tissue
chr11	57598249	57598250	rs28362944	9e-06	Obesity-related traits
chr1	159783392	159783393	rs4233356	9e-06	Interstitial lung disease 
chr11	28212220	28212221	rs11601602	9e-06	Obesity-related traits
chr11	21875333	21875334	rs11026318	9e-06	Multiple myeloma (hyperdiploidy)
chr11	20962658	20962659	rs61883261	9e-06	Response to amphetamines
chr11	18363390	18363391	rs9783347	9e-06	Pancreatic cancer
chr11	103655295	103655296	rs7103004	9e-06	Disc degeneration (lumbar)
chr11	103658903	103658904	rs12805875	9e-06	Disc degeneration (lumbar)
chr11	103659637	103659638	rs4554859	9e-06	Disc degeneration (lumbar)
chr11	107476550	107476551	rs11212260	9e-06	IgG glycosylation
chr1	110921001	110921002	rs12567355	9e-06	Obesity-related traits
chr11	113235732	113235733	rs12279261	9e-06	Entorhinal cortical thickness
chr11	114091039	114091040	rs17116334	9e-06	Conduct disorder (interaction)
chr1	162851500	162851501	rs1912453	9e-06	Colorectal cancer
chr11	116776890	116776891	rs2160669	9e-06	Obesity-related traits
chr11	121335739	121335740	rs116875324	9e-06	Serum dimethylarginine levels (symmetric)
chr11	124085758	124085759	rs1893767	9e-06	Obesity-related traits
chr11	128336514	128336515	rs6590322	9e-06	Hippocampal atrophy
chr11	134703915	134703916	rs11825685	9e-06	IgG glycosylation
chr11	13974607	13974608	rs1819084	9e-06	Tuberculosis
chr1	115191469	115191470	rs195204	9e-06	Alcoholism (heaviness of drinking)
chr11	15435920	15435921	rs7114467	9e-06	Menarche (age at onset)
chr11	118161270	118161271	rs11600901	9e-06	Preeclampsia
chr2	11897052	11897053	rs17605562	9e-06	Hair morphology
chr13	70272070	70272071	rs9572423	9e-06	Major depressive disorder
chr13	73357976	73357977	rs1886449	9e-06	Pancreatic cancer
chr18	11282319	11282320	rs7243066	9e-06	Dental caries
chr18	22504710	22504711	rs473518	9e-06	Migraine - clinic-based
chr18	2498054	2498055	rs1879352	9e-06	Acute lymphoblastic leukemia (childhood)
chr18	2948030	2948031	rs10460009	9e-06	Type 2 diabetes
chr18	32399611	32399612	rs58263042	9e-06	Breast size
chr18	34065414	34065415	rs7239368	9e-06	Response to citalopram treatment
chr18	3512217	3512218	rs17724172	9e-06	Cardiac Troponin-T levels
chr1	84824725	84824726	rs9728717	9e-06	Economic and political preferences (time)
chr18	52689041	52689042	rs1460196	9e-06	Response to mTOR inhibitor (everolimus)
chr18	63509032	63509033	rs2032224	9e-06	Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule)
chr1	86585517	86585518	rs1953652	9e-06	IgG glycosylation
chr18	67733187	67733188	rs13353224	9e-06	Hyperactive-impulsive symptoms
chr18	72107042	72107043	rs337718	9e-06	Multiple sclerosis (severity)
chr18	75838007	75838008	rs9959259	9e-06	Obesity-related traits
chr18	77023178	77023179	rs11663697	9e-06	QT interval
chr1	78521616	78521617	rs672561	9e-06	IgG glycosylation
chr18	78897778	78897779	rs9951602	9e-06	Obesity-related traits
chr17	8227548	8227549	rs3027247	9e-06	Parkinson's disease (motor and cognition)
chr17	81144772	81144773	rs7220048	9e-06	Obesity-related traits
chr17	13781599	13781600	rs4792394	9e-06	Conduct disorder (symptom count)
chr17	20119785	20119786	rs2013441	9e-06	Obesity-related traits
chr17	36949011	36949012	rs2306658	9e-06	Obesity-related traits
chr17	43987618	43987619	rs9895585 	9e-06	Response to taxane treatment (placlitaxel)
chr17	46871733	46871734	rs11079740	9e-06	Antineutrophil cytoplasmic antibody-associated vasculitis 
chr17	47757911	47757912	rs11651000	9e-06	IgG glycosylation
chr17	49486649	49486650	rs1035050	9e-06	Bipolar disorder
chr17	50513847	50513848	rs6504663	9e-06	Visceral fat
chr17	61820093	61820094	rs12453935	9e-06	Lung function (forced expiratory flow between 25% and 75% of forced vital capacity)
chr17	64604816	64604817	rs111854052	9e-06	Periodontitis (Mean PAL)
chr17	70831947	70831948	rs1990193	9e-06	Obesity-related traits
chr17	77317252	77317253	rs4788985	9e-06	Illicit drug use
chr17	77404017	77404018	rs892961	9e-06	Airflow obstruction 
chr17	77705614	77705615	rs9906155	9e-06	Body mass index
chr17	78315909	78315910	rs4789580	9e-06	IgG glycosylation
chr17	81244913	81244914	rs2659005	9e-06	IgG glycosylation
chr18	79813547	79813548	rs4799088	9e-06	Amyotrophic lateral sclerosis
chr1	9091265	9091266	rs12080794	9e-06	Response to antidepressant treatment (citalopram)
chr19	11571679	11571680	rs7253363	9e-06	Multiple sclerosis (severity)
chr20	4234909	4234910	rs1556832	9e-06	Preeclampsia
chr20	45092851	45092852	rs6124684	9e-06	Bipolar disorder
chr20	46132845	46132846	rs12480534	9e-06	Response to amphetamines
chr20	48172480	48172481	rs62202398	9e-06	Alcohol consumption
chr20	60323150	60323151	rs6027511	9e-06	Lentiform nucleus volume 
chr20	614135	614136	rs1533087	9e-06	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined)
chr20	62860141	62860142	rs17854409	9e-06	Obesity-related traits
chr20	6999987	6999988	rs6085820	9e-06	Alzheimer's disease (late onset)
chr2	104192253	104192254	rs11890236	9e-06	Obesity-related traits
chr2	107062031	107062032	rs1357692	9e-06	Alzheimer's disease
chr2	11117378	11117379	rs16857178	9e-06	Obesity-related traits
chr21	15696846	15696847	rs2823455	9e-06	Panic disorder
chr2	115898218	115898219	rs272000	9e-06	Attention deficit hyperactivity disorder
chr2	11618304	11618305	rs73175262	9e-06	Obesity-related traits
chr21	16673912	16673913	rs2823962	9e-06	Amyotrophic lateral sclerosis
chr20	42212138	42212139	rs7345986	9e-06	Periodontitis (Mean PAL)
chr20	33968970	33968971	rs6059594	9e-06	IgG glycosylation
chr20	32943737	32943738	rs13045180	9e-06	Type 1 diabetes nephropathy
chr20	25038462	25038463	rs6050267	9e-06	Cognitive performance
chr19	14029108	14029109	rs12327666	9e-06	Obesity-related traits
chr19	18021730	18021731	rs12984174	9e-06	Pulmonary function in asthmatics
chr19	19165549	19165550	rs7249142	9e-06	IgG glycosylation
chr19	28544648	28544649	rs4141232	9e-06	Femoral neck bone geometry and menarche (age at onset)
chr19	39090096	39090097	rs472265	9e-06	Type 2 diabetes
chr19	53276772	53276773	rs2965260	9e-06	IgG glycosylation
chr19	5582523	5582524	rs732505	9e-06	vWF and FVIII levels
chr17	12901232	12901233	rs7209847	9e-06	Economic and political preferences
chr19	56578466	56578467	rs34863160	9e-06	Obesity-related traits
chr1	97354110	97354111	rs11165846	9e-06	Platelet counts
chr1	98987730	98987731	rs10443196	9e-06	Obesity-related traits
chr1	99803434	99803435	rs6689305	9e-06	White matter integrity (interaction)
chr20	10869815	10869816	rs1884136	9e-06	Information processing speed
chr20	11194254	11194255	rs2207418	9e-06	Cardiac hypertrophy
chr20	17848635	17848636	rs2745851	9e-06	IgG glycosylation
chr20	17848635	17848636	rs2745851	9e-06	IgG glycosylation
chr19	57957647	57957648	rs8106858	9e-06	Obesity-related traits
chr13	71771372	71771373	rs584480	9e-06	Urate levels
chr1	69688757	69688758	rs1417437	9e-06	Orofacial clefts
chr16	83750222	83750223	rs149740259	9e-06	Periodontitis (Mean PAL)
chr1	47559390	47559391	rs685001	9e-06	Obesity-related traits
chr1	47789109	47789110	rs6588505	9e-06	Obesity-related traits
chr14	88906406	88906407	rs17124955	9e-06	Obesity-related traits
chr14	88971071	88971072	rs12589060	9e-06	Hormone measurements
chr14	90555840	90555841	rs17793829	9e-06	Cytomegalovirus antibody response
chr14	92070614	92070615	rs12588287	9e-06	Coronary artery calcification
chr14	95739732	95739733	rs2369304	9e-06	Neutrophil count
chr14	97836993	97836994	rs1471356	9e-06	Radiation response
chr14	99275849	99275850	rs2664299	9e-06	IgG glycosylation
chr15	27262625	27262626	rs17137734	9e-06	Corneal curvature
chr15	27960417	27960418	rs4778214	9e-06	Lung function (forced expiratory flow between 25% and 75% of forced vital capacity)
chr15	35054339	35054340	rs10162694	9e-06	Bronchopulmonary dysplasia
chr15	39281333	39281334	rs12595668	9e-06	PR interval
chr15	51060051	51060052	rs1124769	9e-06	Cognitive performance
chr1	55647100	55647101	rs10443215	9e-06	Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel)
chr14	65796244	65796245	rs8007846	9e-06	Multiple sclerosis--Brain Glutamate Levels
chr14	60606156	60606157	rs10483727	9e-06	Optic disc size (rim)
chr14	57202814	57202815	rs11851015	9e-06	Alcohol consumption
chr14	57140348	57140349	rs7144018	9e-06	Multiple myeloma (IgH translocation)
chr1	37814314	37814315	rs3748682	9e-06	Hypothyroidism
chr13	84975600	84975601	rs9531686	9e-06	Anorexia nervosa
chr13	88110090	88110091	rs969962	9e-06	Cognitive performance
chr13	93688842	93688843	rs9561428	9e-06	Bipolar disorder and schizophrenia
chr13	97548317	97548318	rs2770228	9e-06	Metabolite levels (Dihydroxy docosatrienoic acid)
chr1	39968098	39968099	rs3103778	9e-06	PR interval
chr1	41831452	41831453	rs349423	9e-06	Bronchopulmonary dysplasia
chr15	58454630	58454631	rs3825776	9e-06	Amyotrophic lateral sclerosis
chr14	24139937	24139938	rs8010715	9e-06	IgG glycosylation
chr14	32911891	32911892	rs12146962	9e-06	Ankylosing spondylitis
chr1	43750156	43750157	rs2367725	9e-06	Aging (time to event)
chr14	42934255	42934256	rs11157317	9e-06	Multiple myeloma (hyperdiploidy)
chr14	44637428	44637429	rs12884395	9e-06	Obesity-related traits
chr14	53606139	53606140	rs1380131	9e-06	Alcoholism (heaviness of drinking)
chr14	54709625	54709626	rs17657012	9e-06	Lung function (forced expiratory flow between 25% and 75% of forced vital capacity)
chr14	55765081	55765082	rs7494275	9e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors)
chr14	30020416	30020417	rs718545	9e-06	Obesity-related traits
chr16	8453219	8453220	rs8045405	9e-06	QT interval
chr15	59426969	59426970	rs28890483	9e-06	Bipolar disorder and schizophrenia
chr15	64861490	64861491	rs12595292	9e-06	Coronary heart disease
chr16	55221278	55221279	rs2001970	9e-06	Visceral fat
chr16	5535850	5535851	rs870288	9e-06	Subcutaneous adipose tissue
chr16	56972677	56972678	rs7499892	9e-06	Biochemical measures
chr16	587211	587212	rs2017567	9e-06	Disc degeneration (lumbar)
chr16	6106324	6106325	rs7403856	9e-06	Obesity-related traits
chr1	66296782	66296783	rs546784	9e-06	Acute lymphoblastic leukemia (childhood)
chr16	6860383	6860384	rs12921846	9e-06	Attention deficit hyperactivity disorder and conduct disorder
chr16	69508472	69508473	rs744972	9e-06	Homeostasis model assessment of beta-cell function (interaction)
chr16	72223799	72223800	rs17668704	9e-06	Thiazide-induced adverse metabolic effects in hypertensive patients
chr16	75133680	75133681	rs7195303	9e-06	Crohn's disease (time to surgery)
chr16	76844964	76844965	rs13330107	9e-06	Inattentive symptoms
chr16	76856228	76856229	rs17679567	9e-06	Response to TNF-alpha inhibitors in rheumatoid arthritis
chr16	78301146	78301147	rs78867184	9e-06	Metabolite levels (5-HIAA)
chr16	81741192	81741193	rs12446319	9e-06	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin)
chr16	82293199	82293200	rs11863065	9e-06	Obesity-related traits
chr16	54460511	54460512	rs9921518	9e-06	Dialysis-related mortality
chr15	62046597	62046598	rs1436958	9e-06	IgG glycosylation
chr16	53994058	53994059	rs12596210	9e-06	Sex hormone-binding globulin levels
chr16	3746145	3746146	rs129963	9e-06	QT interval (interaction)
chr15	66774224	66774225	rs11858577	9e-06	Subcutaneous adipose tissue
chr1	56803847	56803848	rs6662617	9e-06	Obesity-related traits
chr15	68443246	68443247	rs1445021	9e-06	Coronary heart disease
chr15	73457266	73457267	rs11635553	9e-06	IgG glycosylation
chr15	73720095	73720096	rs1038094	9e-06	Bipolar disorder
chr15	78406416	78406417	rs7163013	9e-06	Obesity-related traits
chr15	78932340	78932341	rs2289700	9e-06	Bipolar disorder
chr1	64402668	64402669	rs11208446	9e-06	Bilirubin levels
chr15	79721079	79721080	rs2692194	9e-06	IgG glycosylation
chr15	89624876	89624877	rs894157	9e-06	Obesity-related traits
chr15	93334195	93334196	rs4777845	9e-06	Adiponectin levels
chr16	13145039	13145040	rs150063	9e-06	Lung function (forced expiratory volume in 1 second to forced vital capacity ratio)
chr16	17930992	17930993	rs9922516	9e-06	Obesity-related traits
chr16	24567136	24567137	rs7195386	9e-06	Obesity-related traits
chr16	27203662	27203663	rs16976587	9e-06	Obesity-related traits
chr16	3728335	3728336	rs3751845	9e-06	Obesity-related traits
chr15	84887737	84887738	rs3743162	9e-06	Alzheimer's disease (age of onset)
chr14	68893913	68893914	rs12050161	4000000.0	Periodontitis (Mean PAL)
chr18	10382885	10382886	rs206548	90000000.0	Serum protein levels (sST2)
